

*ADVANCES IN*  
**IMMUNOLOGY**

VOLUME 67

*Cumulative Subject Index*

*Volumes 37-65*



ACADEMIC PRESS

*ADVANCES IN*  
**Immunology**

CUMULATIVE SUBJECT INDEX  
VOLUMES 37-65

This Page Intentionally Left Blank

*ADVANCES IN*  
**Immunology**

*CUMULATIVE SUBJECT INDEX*  
*VOLUMES 37–65*

*EDITED BY*

FRANK J. DIXON

*The Scripps Research Institute*  
*La Jolla, California*

ASSOCIATE EDITORS

Frederick Alt  
K. Frank Austen  
Tadamitsu Kishimoto  
Fritz Melchers  
Jonathan W. Uhr

VOLUME 67



**ACADEMIC PRESS**

San Diego London Boston  
New York Sydney Tokyo Toronto



This book is printed on acid-free paper. ∞

Copyright © 1998 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-1998 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters.  
0065-2776/98 \$25.00

### Academic Press

*a division of Harcourt Brace & Company*

525 B Street, Suite 1900, San Diego, California 92101-4495, USA

<http://www.apnet.com>

Academic Press Limited

24-28 Oval Road, London NW1 7DX, UK

<http://www.hbuk.co.uk/ap/>

International Standard Book Number: 0-12-022467-4

PRINTED IN THE UNITED STATES OF AMERICA

97 98 99 00 01 02 QW 9 8 7 6 5 4 3 2 1

## CONTENTS

CONTENTS OF VOLUMES 37-65	vii
CUMULATIVE SUBJECT INDEX	1
CONTRIBUTOR INDEX	321

This Page Intentionally Left Blank

## CONTENTS OF VOLUMES 37–65

### Volume 37

- Structure, Function, and Genetics of Human Class III Molecules** 1  
ROBERT C. GILES AND J. DONALD CAPRA
- The Complexity of Virus—Cell Interactions in Abelson Virus Infection of Lymphoid and Other Hematopoietic Cells** 73  
CHERYL A. WHITLOCK AND OWEN N. WITTE
- Epstein–Barr Virus Infection and Immunoregulation in Man** 99  
GIOVANNA TOSATO AND R. MICHAEL BLAESE
- The Classical Complement Pathway: Activation and Regulation of the First Complement Component** 151  
NEIL R. COOPER
- Membrane Complement Receptors Specific for Bound Fragments of C3** 217  
GORDON D. ROSS AND M. EDWARD MEDOF
- Murine Models of Systemic Lupus Erythematosus** 269  
ARGYRIOS N. THEOFILOPOULOS AND FRANK J. DIXON

### Volume 38

- The Antigen-Specific, Major Histocompatibility Complex-Restricted Receptor on T Cells** 1  
PHILIPPA MARRACK AND JOHN KAPPLER

<b>Immune Response (<i>Ir</i>) Genes of the Murine Major Histocompatibility Complex</b>	<b>31</b>
RONALD H. SCHWARTZ	
<b>The Molecular Genetics of Components of Complement</b>	<b>203</b>
R. D. CAMPBELL, M. C. CARROLL, AND R. R. PORTER	
<b>Molecular Genetics of Human B Cell Neoplasia</b>	<b>245</b>
CARLO M. CROCE AND PETER C. NOWELL	
<b>Human Lymphocyte Hybridomas and Monoclonal Antibodies</b>	<b>275</b>
DENNIS A. CARSON AND BRUCE D. FREIMARK	
<b>Maternally Transmitted Antigen</b>	<b>313</b>
JOHN R. RODGERS, ROGER SMITH III, MARILYN M. HUSTON, AND ROBERT R. RICH	
<b>Phagocytosis of Particulate Activators of the Alternative Complement Pathway: Effects of Fibronectin</b>	<b>361</b>
JOYCE K. CZOP	

### Volume 39

<b>Immunological Regulation of Hematopoietic/Lymphoid Stem Cell Differentiation by Interleukin 3</b>	<b>1</b>
JAMES N. IHLE AND YACOB WEINSTEIN	
<b>Antigen Presentation by B Cells and Its Significance in T-B Interactions</b>	<b>51</b>
ROBERT W. CHESNUT AND HOWARD M. GREY	
<b>Ligand-Receptor Dynamics and Signal Amplification in the Neutrophil</b>	<b>95</b>
LARRY A. SKLAR	
<b>Arachidonic Acid Metabolism by the 5-Lipoxygenase Pathway, and the Effects of Alternative Dietary Fatty Acids</b>	<b>145</b>
TAK H. LEE AND K. FRANK AUSTEN	
<b>The Eosinophilic Leukocyte: Structure and Function</b>	<b>177</b>
GERALD J. GLEICH AND CHERYL B. ADOLPHSON	

**Idiotypic Interactions in the Treatment of Human Diseases** 255

RAIF S. GEHA

**Neuroimmunology** 299

DONALD G. PAYAN, JOSEPH P. MCGILLIS, AND EDWARD J. GOETZL

**Volume 40****Regulation of Human B Lymphocyte Activation, Proliferation,  
and Differentiation** 1

DIANE F. JELINEK AND PETER E. LIPSKY

**Biological Activities Residing in the Fc Region of Immunoglobulin** 61

EDWARD L. MORGAN AND WILLIAM O. WEIGLE

**Immunoglobulin-Specific Suppressor T Cells** 135

RICHARD G. LYNCH

**Immunoglobulin A (IgA): Molecular and Cellular Interactions Involved in  
IgA Biosynthesis and Immune Response** 153

JIRI MESTECKY AND JERRY R. MCGHEE

**The Arrangement of Immunoglobulin and T-Cell Receptor Genes in  
Human Lymphoproliferative Disorders** 247

THOMAS A. WALDMANN

**Human Tumor Antigens** 323

RALPH A. REISFELD AND DAVID A. CHERESH

**Human Marrow Transplantation: An Immunological Perspective** 379PAUL J. MARTIN, JOHN A. HANSEN, RAINER STORB, AND  
E. DONNALL THOMAS**Volume 41****Cell Surface Molecules and Early Events Involved in Human T  
Lymphocyte Activation** 1

ARTHUR WEISS AND JOHN B. IMBODEN

<b>Function and Specificity of T Cell Subsets in the Mouse</b>	<b>39</b>
JONATHAN SPRENT AND SUSAN R. WEBB	
<b>Determinants on Major Histocompatibility Complex Class I Molecules Recognized by Cytotoxic T Lymphocytes</b>	<b>135</b>
JAMES FORMAN	
<b>Experimental Models for Understanding B Lymphocyte Formation</b>	<b>181</b>
PAUL W. KINCADE	
<b>Cellular and Humoral Mechanisms of Cytotoxicity: Structural and Functional Analogies</b>	<b>269</b>
JOHN DING-E YOUNG AND ZANVIL A. COHN	
<b>Biology and Genetics of Hybrid Resistance</b>	<b>333</b>
MICHAEL BENNETT	

### Volume 42

<b>The Clonotype Repertoire of B-Cell Subpopulations</b>	<b>1</b>
NORMAN R. KLINMAN AND PHYLLIS-JEAN LINTON	
<b>The Molecular Genetics of the Arsonate Idiotypic System of A/J Mice</b>	<b>95</b>
GARY RATHBUN, INAKI SANZ, KATHERYN MEEK, PHILIP TUCKER, AND J. DONALD CAPRA	
<b>The Interleukin 2 Receptor</b>	<b>165</b>
KENDALL A. SMITH	
<b>Characterization of Functional Surface Structures on Human Natural Killer Cells</b>	<b>181</b>
JEROME RITZ, REINHOLD E. SCHMIDT, JEAN MICHON, THIERRY HERCEND, AND STUART E. SCHLOSSMAN	
<b>The Common Mediator of Shock, Cachexia, and Tumor Necrosis</b>	<b>213</b>
B. BEUTLER AND A. CERAMI	
<b>Myasthenia Gravis</b>	<b>233</b>
JON LINDSTROM, DIANE SHELTON, AND YOSHITAKA FUJII	

<b>Alterations of the Immune System in Ulcerative Colitis and Crohn's Disease</b>	<b>285</b>
RICHARD P. MACDERMOTT AND WILLIAM F. STENSON	

### Volume 43

<b>The Chemistry and Mechanism of Antibody Binding to Protein Antigens</b>	<b>1</b>
ELIZABETH D. GETZOFF, JOHN A. TAINER, RICHARD A. LERNER, AND H. MARIO GEYSEN	
<b>Structure of Antibody–Antigen Complexes: Implications for Immune Recognition</b>	<b>99</b>
P. M. COLMAN	
<b>The <math>\gamma\delta</math> T-Cell Receptor</b>	<b>133</b>
MICHAEL B. BRENNER, JACK L. STROMINGER, AND MICHAEL S. KRANGEL	
<b>Specificity of the T-Cell Receptor for Antigen</b>	<b>193</b>
STEPHEN M. HEDRICK	
<b>Transcriptional Controlling Elements in the Immunoglobulin and T-Cell Receptor Loci</b>	<b>235</b>
KATHRYN CALAME AND SUZANNE EATON	
<b>Molecular Aspects of Receptors and Binding Factors for IgE</b>	<b>277</b>
HENRY METZGER	

### Volume 44

<b>Diversity of the Immunoglobulin Gene Superfamily</b>	<b>1</b>
TIM HUNKAPILLER AND LEROY HOOD	
<b>Genetically Engineered Antibody Molecules</b>	<b>65</b>
SHERIE L. MORRISON AND VERNON T. OT	
<b>Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology</b>	<b>93</b>
ENG M. TAN	



<b>Interleukin-1 and Its Biologically Related Cytokines</b>	<b>153</b>
CHARLES A. DINARELLO	
<b>Molecular and Cellular Events of T-Cell Development</b>	<b>207</b>
B. J. FOWLKES AND DREW M. PARDOLL	
<b>Molecular Biology and Function of CD4 and CD8</b>	<b>265</b>
JANE R. PARNES	
<b>Lymphocyte Homing</b>	<b>313</b>
TED A. YEDNOCK AND STEVEN D. ROSEN	

### Volume 45

<b>Cellular Interactions in the Humoral Immune Response</b>	<b>1</b>
ELLEN S. VITETTA, RAFAEL FERNANDEZ-BOTRAN, CHRISTOPHER D. MYERS, AND VIRGINIA M. SANDERS	
<b>MHC–Antigen Interaction: What Does the T-Cell Receptor See?</b>	<b>107</b>
PHILIPPE KOURILSKY AND JEAN-MICHEL CLAVERIE	
<b>Synthetic T- and B-Cell Recognition Sites: Implications for Vaccine Development</b>	<b>195</b>
DAVID R. MILICH	
<b>Rationale for the Development of an Engineered Sporozoite Malaria Vaccine</b>	<b>283</b>
VICTOR NUSSENZWEIG AND RUTH S. NUSSENZWEIG	
<b>Virus-Induced Immunosuppression: Infections with Measles Virus and Human Immunodeficiency Virus</b>	<b>335</b>
MICHAEL B. MCCHESENEY AND MICHAEL B. A. OLDSTONE	
<b>The Regulators of Complement Activation (RCA) Gene Cluster</b>	<b>381</b>
DENNIS HOURCADE, V. MICHAEL HOLERS, AND JOHN P. ATKINSON	
<b>Origin and Significance of Autoreactive T Cells</b>	<b>417</b>
MAURICE ZAUDERER	

**Volume 46**

- Physical Maps of the Mouse and Human Immunoglobulin-like Loci** 1  
ERIC LAI, RICHARD K. WILSON, AND LEROY E. HOOD
- Molecular Genetics of Murine Lupus Models** 61  
ARGYRIOS N. THEOFILOPOULOS, REINHARD KOFLER, PAUL A. SINGER, AND  
FRANK J. DIXON
- Heterogeneity of Cytokine Secretion Patterns and Functions  
of Helper T Cells** 111  
TIM R. MOSMANN AND ROBERT L. COFFMAN
- The Leukocyte Integrins** 149  
TAKASHI K. KISHIMOTO, RICHARD S. LARSON, ANGEL L. CORBI,  
MICHAEL L. DUSTIN, DONALD E. STAUNTON, AND TIMOTHY A. SPRINGER
- Structure and Function of the Complement Receptors, CR1 (CD35)  
and CR2 (CD21)** 183  
JOSEPH M. AHEARN AND DOUGLAS T. FEARON
- The Cellular and Subcellular Bases of Immunosenescence** 221  
MARILYN L. THOMAN AND WILLIAM O. WEIGLE
- Immune Mechanisms in Autoimmune Thyroiditis** 263  
JEANNINE CHARREIRE

**Volume 47**

- Regulation of Immunoglobulin E Biosynthesis** 1  
KIMISHIGE ISHIZAKA
- Control of the Immune Response at the Level of Antigen-Presenting  
Cells: A Comparison of the Function of Dendritic Cells and  
B Lymphocytes** 45  
JOSHUA P. METLAY, ELLEN PURÉ, AND RALPH M. STEINMAN
- The CD5 B Cell** 117  
THOMAS J. KIPPS

<b>Biology of Natural Killer Cells</b>	<b>187</b>
GIORGIO TRINCHIERI	
<b>The Immunopathogenesis of HIV Infection</b>	<b>377</b>
ZEDA F. ROSENBERG AND ANTHONY S. FAUCI	
<b>The Obese Strain of Chickens: An Animal Model with Spontaneous Autoimmune Thyroiditis</b>	<b>433</b>
GEORGE WICK, HANS PETER BREZINSCHKE, KAREL HÁLA, HERMANN DIETRICH, HUGO WOLF, AND GUIDO KROEMER	

### Volume 48

<b>Internal Movements in Immunoglobulin Molecules</b>	<b>1</b>
ROALD NEZLIN	
<b>Somatic Diversification of the Chicken Immunoglobulin Light-Chain Gene</b>	<b>41</b>
WAYNE T. MCCORMACK AND CRAIG B. THOMPSON	
<b>T Lymphocyte-Derived Colony-Stimulating Factors</b>	<b>69</b>
ANNE KELSO AND DONALD METCALF	
<b>The Molecular Basis of Human Leukocyte Antigen Class II Disease Associations</b>	<b>107</b>
DOMINIQUE CHARRON	
<b>Neuroimmunology</b>	<b>161</b>
E. J. GOETZL, D. C. ADELMAN, AND S. P. SREEDHARAN	
<b>Immune Privilege and Immune Regulation in the Eye</b>	<b>191</b>
JERRY Y. NIEDERKORN	
<b>Molecular Events Mediating T-Cell Activation</b>	<b>227</b>
AMNON ALTMAN, K. MARK COGGESHALL, AND TOMAS MUSTELIN	

### Volume 49

<b>Human Immunoglobulin Heavy-Chain Variable Region Genes: Organization, Polymorphism, and Expression</b>	<b>1</b>
VIRGINIA PASCUAL AND J. DONALD CAPRA	

<b>Surface Antigens of Human Leucocytes</b>	<b>75</b>
V. HOŘEJŠÍ	
<b>Expression, Structure, and Function of the CD23 Antigen</b>	<b>149</b>
G. DELESPESE, U. SUTER, D. MOSSALAYI, B. BETTLER, M. SARFATI, H. HOFSTETTER, E. KILCHERR, P. DEBRE, AND A. DALLLOUL	
<b>Immunology and Clinical Importance of Antiphospholipid Antibodies</b>	<b>193</b>
H. PATRICK McNEIL, COLIN N. CHESTERMAN, AND STEVEN A. KRILIS	
<b>Adoptive T-Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells</b>	<b>281</b>
PHILIP D. GREENBERG	
<b>The Development of Rational Strategies for Selective Immunotherapy against Autoimmune Demyelinating Disease</b>	<b>357</b>
LAWRENCE STEINMAN	
<b>The Biology of Bone Marrow Transplantation for Severe Combined Immune Deficiency</b>	<b>381</b>
ROBERTSON PARKMAN	

### Volume 50

<b>Selective Elements for the V<math>\beta</math> Region of the T Cell Receptor: MIs and the Bacterial Toxic Mitogens</b>	<b>1</b>
CHARLES A. JANEWAY, JR.	
<b>Programmed Cell Death in the Immune System</b>	<b>55</b>
J. JOHN COHEN	
<b>Avian T-Cell Ontogeny</b>	<b>87</b>
MAX D. COOPER, CHEN-LO H. CHEN, R. PAT BUCY, AND CRAIG B. THOMPSON	
<b>Structural and Functional Chimerism Results from Chromosomal Translocation in Lymphoid Tumors</b>	<b>119</b>
T. H. RABBITS AND T. BOEHM	
<b>Interleukin-2, Autotolerance, and Autoimmunity</b>	<b>147</b>
GUIDO KROEMER, JOSÉ LUIS ANDREU, JOSÉ ANGEL GONZALO, JOSÉ C. GUTIERREZ-RAMOS, AND CARLOS MARTÍNEZ-A.	

- Histamine Releasing Factors and Cytokine-Dependent Activation of Basophils and Mast Cells** 237  
ALLEN P. KAPLAN, SESHA REDDIGARI, MARIA BAEZA, AND PIOTR KUNA
- Immunologic Interactions of T Lymphocytes with Vascular Endothelium** 261  
JORDAN S. POBER AND RAMZI S. COTRAN
- Adoptive Transfer of Human Lymphoid Cells to Severely Immunodeficient Mice: Models for Normal Human Immune Function, Autoimmunity, Lymphomagenesis, and AIDS** 303  
DONALD E. MOSIER

### Volume 51

- Human Antibody Effector Function** 1  
DENNIS R. BURTON AND JENNY M. WOOF
- The Development of Functionally Responsive T Cells** 85  
ELLEN V. ROTHENBERG
- Role of Perforin in Lymphocyte-Mediated Cytolysis** 215  
HIDEO YAGITA, MOTOMI NAKATA, AKEMI KAWASAKI, YOICHI SHINKAI, AND KO OKUMURA
- The Central Role of Follicular Dendritic Cells in Lymphoid Tissues** 243  
FOLKE SCHRIEVER AND LEE MARSHALL NADLER
- The Murine Autoimmune Diabetes Model: NOD and Related Strains** 285  
HITOSHI KIKUTANI AND SUSUMU MAKINO
- The Pathobiology of Bronchial Asthma** 323  
JONATHAN P. ARM AND TAK H. LEE

### Volume 52

- Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes** 1  
JONATHAN W. YEWDELL AND JACK R. BENNINK
- Human B Lymphocytes: Phenotype, Proliferation, and Differentiation** 125  
JACQUES BANCHEREAU AND FRANÇOISE ROUSSET

<b>Cytokine Gene Regulation: Regulatory <i>cis</i>-Elements and DNA Binding Factors Involved in the Interferon System</b>	<b>263</b>
NOBUYUKI TANAKA AND TADATSUGU TANIGUCHI	
<b>Cellular and Molecular Mechanisms of B Lymphocyte Tolerance</b>	<b>283</b>
G. J. V. NOSSAL	
<b>Cell Surface Structures on Human Basophils and Mast Cells: Biochemical and Functional Characterization</b>	<b>333</b>
PETER VALENT AND PETER BETTELHEIM	
<b>Animal Models for Acquired Immunodeficiency Syndrome</b>	<b>425</b>
THOMAS J. KINDT, VANESSA M. HIRSCH, PHILIP B. JOHNSON, AND SANSANA SAWASDIKOSOL	

### Volume 53

<b>Lymphokine and Cytokine Production by Fc<math>\epsilon</math>RI<sup>+</sup> Cells</b>	<b>1</b>
WILLIAM E. PAUL, ROBERT A. SEDER, AND MARSHALL PLAUT	
<b>The Leukemia Inhibitory Factor and Its Receptor</b>	<b>31</b>
DAVID P. GEARING	
<b>The Role of CD4 and CD8 in T-Cell Activation and Differentiation</b>	<b>59</b>
M. CARRIE MICELI AND JANE R. PARNES	
<b>B Lymphopoiesis in the Mouse</b>	<b>123</b>
ANTONIUS ROLINK AND FRITZ MELCHERS	
<b>Compartmentalization of the Peripheral Immune System</b>	<b>157</b>
GUIDO KROEMER, EDUARDO CUENDE, AND CARLOS MARTINEZ-A.	
<b>Immunological Memory</b>	<b>217</b>
CHARLES R. MACKAY	
<b>Recognition of Bacterial Endotoxins by Receptor-Dependent Mechanisms</b>	<b>267</b>
RICHARD J. ULEVITCH	

**Cell Adhesion Molecules as Targets of Autoantibodies in Pemphigus and Pemphigoid, Bullous Diseases Due to Defective Epidermal Cell Adhesion** 291

JOHN R. STANLEY

**Volume 54**

**Interleukin-6 in Biology and Medicine** 1

SHIZUO AKIRA, TETSUYA TAGA, AND TADAMITSU KICHIMOTO

**Interleukin-9** 79

J.-C. RENAULD, F. HOUSSIAU, J. LOUAHED, A. VINK, J. VAN SNICK,  
AND C. UYTENHOVE

**Superantigens and Their Potential Role in Human Disease** 99

BRIAN KOTZIN, DONALD Y. M. LEUNG, JOHN KAPPLER,  
AND PHILIPPA MARRACK

**Interleukin-1 Receptor Antagonist** 167

WILLIAM P. AREND

**The Mechanism and Regulation of Immunoglobulin Isotype Switching** 229

ROBERT L. COFFMAN, DEBORAH A. LEBMAN, AND PAUL ROTHMAN

**CD44 and Its Interaction with Extracellular Matrix** 271

JAYNE LESLEY, ROBERT HYMAN, AND PAUL W. KINCADE

**Immunoglobulin Receptor-Associated Molecules** 337

NOBUO SAKAGUCHI, TATSUYA MATSUI, JUN NOMURA, KAZUHIKO  
KUWAHARA, HIDEYA IGARASHI, AND SEIJI INUI

**Analysis of B Cell Tolerance *in Vitro*** 393

DAVID W. SCOTT

**Volume 55**

**The kit Ligand, Stem Cell Factor** 1

STEPHEN J. GALLI, KRISZTINA M. ZSEBO, AND EDWIN N. GEISSLER

**Interleukin-8 and Related Chemotactic Cytokines—CXC and CC Chemokines** 97

MARCO BAGGIOLINI, BEATRICE DEWALD, AND BERNHARD MOSER

<b>Receptors for Transforming Growth Factor-<math>\beta</math></b>	<b>181</b>
KOHEI MIYAZONO, PETER TEN DIJKE, HIDENORI ICHIJO, AND CARL-HENRIK HELDIN	
<b>Biochemistry of B Lymphocyte Activation</b>	<b>221</b>
MICHAEL R. GOLD AND ANTHONY L. DEFranco	
<b>CD5 B Cells, a Fetal B-Cell Lineage</b>	<b>297</b>
RICHARD R. HARDY AND KYOKO HAYAKAWA	
<b>Human Natural Killer Cells: Origin, Clonality, Specificity, and Receptors</b>	<b>341</b>
LORENZO MORETTA, ERMANNO CICCONE, MARIA CRISTINA MINGARI, ROBERTO BIASSONI, AND ALESSANDRO MORETTA	
<b>MHC Class I-Deficient Mice</b>	<b>381</b>
DAVID H. RAULET	
<b>The Immune System of Mice Lacking Conventional MHC Class II Molecules</b>	<b>424</b>
SUSANNA CARDELL, MATTHIAS MERKENSCHLAGER, HELEN BODMER, SUSAN CHAN, DOMINIC COSGROVE, CHRISTOPHE BENOIST, AND DIANE MATHIS	

### Volume 56

<b>Properties and Functions of Interleukin-10</b>	<b>1</b>
TIM R. MOSMANN	
<b>The Mechanism of V(D)J Joining: Lessons from Molecular, Immunological, and Comparative Analyses</b>	<b>27</b>
SUSANNA M. LEWIS	
<b>Involvement of the Protein Tyrosine Kinase p56<sup>lck</sup> in T-Cell Signaling and Thymocyte Development</b>	<b>151</b>
STEVEN J. ANDERSON, STEVEN D. LEVIN, AND ROGER M. PERLMUTTER	
<b>Generating the Antibody Repertoire in Rabbit</b>	<b>179</b>
KATHERINE L. KNIGHT AND MARY A. CRANE	



<b>Immunotherapeutic Strategies Directed at the Trimolecular Complex</b>	<b>219</b>
AMITABH GAUR AND C. GARRISON FATHMAN	
<b>Therapeutic Regulation of the Complement System in Acute Injury States</b>	<b>267</b>
FRANCIS D. MOORE, JR.	
<b>Chemoimmunoconjugates for the Treatment of Cancer</b>	<b>301</b>
GEOFFREY A. PIETERSZ, APRIL ROWLAND, MARK J. SMYTH, AND IAN F. C. MCKENZIE	
<b>The Molecular Basis of Susceptibility to Rheumatoid Arthritis</b>	<b>389</b>
ROBERT WINCHESTER	
<b>Retrovirus-Induced B Cell Neoplasia in the Bursa of Fabricius</b>	<b>467</b>
PAUL E. NEIMAN	

### Volume 57

<b>Molecular Basis of Fc Receptor Function</b>	<b>1</b>
MARK D. HULETT AND P. MARK HOGARTH	
<b>Fas and Fas Ligand: A Death Factor and Its Receptor</b>	<b>129</b>
SHIGEKAZU NAGATA	
<b>Interleukin-5 and Its Receptor System: Implications in the Immune System and Inflammation</b>	<b>145</b>
KIYOSHI TAKATSU, SATOSHI TAKAKI, AND YASUMICHI HITOSHI	
<b>Human Antibodies from Combinatorial Libraries</b>	<b>191</b>
DENNIS R. BURTON AND CARLOS F. BARBAS III	
<b>Immune Response against Tumors</b>	<b>281</b>
CLAUDE ROTH, CHRISTOPH ROCHLITZ, AND PHILIPPE KOURILSKY	
<b>Formation of the Chicken B-Cell Repertoire: Ontogenesis, Regulation of Ig Gene Rearrangement, and Diversification by Gene Conversion</b>	<b>353</b>
CLAUDE-AGNÈS REYNAUD, BARBARA BERTOCCHI, AURIEL DAHAN, AND JEAN-CLAUDE WEILL	

**Volume 58**

<b>NF-<math>\kappa</math>B and Rel Proteins in Innate Immunity</b>	<b>1</b>
ELIZABETH B. KOPP AND SANKAR GHOSH	
<b>V(D)J Recombination and Double-Strand Break Repair</b>	<b>29</b>
DAVID T. WEAVER	
<b>Development and Selection of T Cells: Facts and Puzzles</b>	<b>87</b>
PAWEL KISIELOW AND HARALD VON BOEHMER	
<b>The Pharmacology of T-Cell Apoptosis</b>	<b>211</b>
GUIDO KROEMER	
<b>Intraepithelial Lymphocytes and the Immune System</b>	<b>297</b>
GEK-KEE SIM	
<b>Leukocyte Migration and Adhesion</b>	<b>345</b>
BEAT A. IMHOF AND DOMINIQUE DUNON	
<b>Gene Transfer as Cancer Therapy</b>	<b>417</b>
GLENN DRANOFF AND RICHARD C. MULLIGAN	

**Volume 59**

<b>The CD1 Family: A Third Lineage of Antigen-Presenting Molecules</b>	<b>1</b>
STEVEN A. PORCELLI	
<b>Positive Selection of Thymocytes</b>	<b>99</b>
PAMELA J. FINK AND MICHAEL J. BEVAN	
<b>Molecular and Cellular Aspects of X-Linked Agammaglobulinemia</b>	<b>135</b>
PASCHALIS SIDERAS AND C. I. EDVARD SMITH	
<b>The Common <math>\delta</math>-Chain for Multiple Cytokine Receptors</b>	<b>225</b>
KAZUO SUGAMURA, HIRONOBU ASAO, MOTONARI KONDO, NOBUYUKI TANAKA, NAOTO ISHII, MASATAKA NAKAMURA, AND TOSHIKAZU NAKAMURA	

<b>Self-Tolerance Checkpoints in B Lymphocyte Development</b>	<b>279</b>
CHRISTOPHER C. GOODNOW, JASON G. CYSTER, SUZANNE B. HARTLEY, SARAH E. BELL, MICHAEL P. COOKE, JAMES L. HEALY, SRINIVAS AKKARAJU, JEFFREY C. RATHMELL, SARAH L. POGUE, AND KEVAN P. SHOKAT	
<b>The Regulation of Pulmonary Immunity</b>	<b>369</b>
MARY F. LIPSCOMB, DAVID E. RICE, C. RICHARD LYONS, MARK R. SCHUYLER, AND DAVID WILKES	

### Volume 60

<b>The <i>Janus</i> Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling</b>	<b>1</b>
JAMES N. IHLE	
<b>X-Linked Agammaglobulinemia and Immunoglobulin Deficiency with Normal or Elevated IgM: Immunodeficiencies of B-Cell Development and Differentiation</b>	<b>37</b>
RAMSAY FULEIHAN, NARAYANASWAMY RAMESH, AND RAIF S. GEHA	
<b>Defective Glycosyl Phosphatidylinositol Anchor Synthesis and Paroxysmal Nocturnal Hemoglobinuria</b>	<b>57</b>
TAROH KINOSHITA, NORIMITSU INOUE, AND JUNJI TAKEDA	
<b>The Use of Multiple Antigen Peptides in the Analysis and Induction of Protective Immune Responses against Infectious Diseases</b>	<b>105</b>
ELIZABETH H. NARDIN, GIANE A. OLIVEIRA, J. MAURICIO CALVO-CALLE, AND RUTH S. NUSSENZWEIG	
<b>Eosinophils: Biology and Role in Disease</b>	<b>151</b>
ANDREW J. WARDLAW, REDWAN MOQBEL, AND A. BARRY KAY	
<b><i>In Situ</i> Studies of the Germinal Center Reaction</b>	<b>267</b>
GARNETT KELSOE	
<b>Cytotoxic T Lymphocytes: The Newly Identified Fas (CD95)-Mediated Killing Mechanism and a Novel Aspect of Their Biological Functions</b>	<b>289</b>
HAJIME TAKAYAMA, HIDEFUMI KOJIMA, AND NOBUKATA SHINOHARA	
<b>The Role of Nitric Oxide in Inflammation</b>	<b>323</b>
C. RICK LYONS	

**Volume 61**

<b>CD40–CD40 Ligand: A Multifunctional Receptor–Ligand Pair</b>	<b>1</b>
CEES VAN KOOTEN AND JACQUES BANCHEREAU	
<b>Antibody Class Switching</b>	<b>79</b>
JANET STAVNEZER	
<b>Interleukin-2 Receptor Signaling Mechanisms</b>	<b>147</b>
LARRY M. KARNITZ AND ROBERT T. ABRAHAM	
<b>Control of the Complement System</b>	<b>201</b>
M. KATHRYN LISZEWSKI, TIMOTHY C. FARRIES, DOUGLAS M. LUBLIN, ISABELLE A. ROONEY, AND JOHN P. ATKINSON	
<b>V(D)J Recombination Pathology</b>	<b>285</b>
KLAUS SCHWARZ AND CLAUS R. BARTRAM	
<b>Major Histocompatibility Complex Class II Deficiency: A Disease of Gene Regulation</b>	<b>327</b>
VIKTOR STEIMLE, WALTER REITH, AND BERNARD MACH	
<b>TH1–TH2 Cells in Allergic Responses: At the Limits of a Concept</b>	<b>341</b>
IWAN AEBISCHER AND BEDA M. STADLER	

**Volume 62**

<b>Organization of the Human Immunoglobulin Heavy-Chain Locus</b>	<b>1</b>
FUMIHIKO MATSUDA AND TASUKU HONJO	
<b>Analysis of Gene Function in Lymphocytes by RAG-2-Deficient Blastocyst Complementation</b>	<b>31</b>
JIANZHU CHEN	
<b>Interferon-<math>\gamma</math>: Biology and Role in Pathogenesis</b>	<b>61</b>
ALFONS BILLIAU	
<b>Role of the CD28-B7 Costimulatory Pathways in T-Cell-Dependent B-Cell Responses</b>	<b>131</b>
KAREN S. HATHCOCK AND RICHARD J. HODES	

<b>Prostaglandin Endoperoxide H Synthases-1 and -2</b>	<b>167</b>
WILLIAM L. SMITH AND DAVID L. DEWITT	
<b>Human Tumor Antigens Are Ready to Fly</b>	<b>217</b>
ROBERT A. HENDERSON AND OLIVERA J. FINN	
<b>Inflammatory Mediators, Cytokines, and Adhesion Molecules in Pulmonary Inflammation and Injury</b>	<b>257</b>
NICHOLAS W. LUKACS AND PETER A. WARD	

### Volume 63

<b>Surrogate Light Chain in B-Cell Development</b>	<b>1</b>
HAJIME KARASUYAMA, ANTONIUS ROLINK, AND FRITZ MELCHERS	
<b>CD40 and Its Ligand</b>	<b>43</b>
LISA B. CLARK, TERESA M. FOY, AND RANDOLPH J. NOELLE	
<b>Human Immunodeficiency Virus Infection of Human Cells Transplanted to Severe Combined Immunodeficient Mice</b>	<b>79</b>
DONALD E. MOSIER	
<b>Lessons from Immunological, Biochemical, and Molecular Pathways of the Activation Mediated by IL-2 and IL-4</b>	<b>127</b>
ANGELITA REBOLLO, JAVIER GÓMEZ, AND CARLOS MARTÍNEZ-A.	
<b>B Lymphocyte Development and Transcription Regulation <i>in Vivo</i></b>	<b>197</b>
DAVINA OPSTELTEN	
<b>Soluble Cytokine Receptors: Their Roles in Immunoregulation, Disease, and Therapy</b>	<b>269</b>
RAFAEL FERNANDEZ-BOTRAN, PAULA M. CHILTON, AND YUHE MA	
<b>Cytokine Expression and Cell Activation in Inflammatory Arthritis</b>	<b>337</b>
LIONEL B. IVASHKIV	
<b>Prolactin, Growth Hormone, and Insulin-like Growth Factor I in the Immune System</b>	<b>377</b>
RON KOIJMAN, ELISABETH L. HOOGHE-PETERS, AND ROBERT HOOGHE	

## Volume 64

- Proteasomes and Antigen Processing** 1  
 KEIJI TANAKA, NOBUYUKI TANAHASHI, CHIZUKO TSURUMI, KIN-YA YOKOTA,  
 AND NAOKI SHIMBARA
- Recent Advances in Understanding V(D)J Recombination** 39  
 MARTIN GELLERT
- The Role of Ets Transcription Factors in the Development and Function of  
 the Mammalian Immune System** 65  
 ALEXANDER G. BASSUK AND JEFFREY M. LEIDEN
- Mechanism of Class I Assembly with  $\beta^2$ Microglobulin and Loading  
 with Peptide** 105  
 TED H. HANSEN AND DAVID R. LEE
- How Do Lymphocytes Know Where to Go: Current Concepts and  
 Enigmas of Lymphocyte Homing** 139  
 MARKO SALMI AND SIRPA JALKANEN
- Plasma Cell Dyscrasias** 219  
 NORIHIRO NISHIMOTO, SACHIKO SUEMATSU, AND TADAMITSU KISHIMOTO
- Anti-Tumor Necrosis Factor- $\alpha$**  283  
 MARC FELDMANN, MICHAEL J. ELLIOTT, JAMES N. WOODY,  
 AND RAVINDER N. MAINI

## Volume 65

- NF-IL6 and NF- $\kappa$ B in Cytokine Gene Regulation** 1  
 SHIZUO AKIRA AND TADAMITSU KISHIMOTO
- Transporter Associated with Antigen Processing** 47  
 TIM ELLIOTT
- NF- $\kappa$ B as a Frequent Target for Immunosuppressive and Anti-  
 Inflammatory Molecules** 111  
 PATRICK A. BAEUERLE AND VIJAY R. BAICHWAL

<b>Mouse Mammary Tumor Virus: Immunological Interplays between Virus and Host</b>	<b>139</b>
SANJIV A. LUTHER AND HANS ACHA-ORBEA	
<b>IgA Deficiency</b>	<b>245</b>
PETER D. BURROWS AND MAX D. COOPER	
<b>Role of Cellular Immunity in Protection against HIV Infection</b>	<b>277</b>
SARAH ROWLAND-JONES, RUSUNG TAN, AND ANDREW McMICHAEL	
<b>High Endothelial Venules: Lymphocyte Traffic Control and Controlled Traffic</b>	<b>347</b>
GEORG KRAAL AND REINA E. MEBIUS	

## SUBJECT INDEX

**Boldface numerals indicate volume number**

### A

- Aarskog-Scott syndrome, **63**:149  
Ab2s, **42**:149-157  
ABC transporters, **65**:55, 56-57, 59  
Abelson disease  
  anti-A-MuLv antibodies in study of c-abl-  
    encoded protein, **37**:77-78  
  *c-abl* expression pattern, normal and  
    leukemic cells, **37**:78-79  
  complexity  
    genetics of susceptibility, **37**:88-89  
    helper virus role in neoplastic  
      transformation, **37**:87-88  
    proliferating cells as transformation  
      targets *in vitro*, **37**:88  
    transformation of cells from genetically  
      resistant mice, **37**:89-90  
    use of site-directed antibodies, **37**:90, 91  
    variations in disease process induced by  
      mutants, **37**:90  
  complexity of transformation *in vitro*  
    associated cellular changes, **37**:93-94  
    cultured B cell lines in study of,  
      **37**:94-95  
    early effects of *v-abl* expression, **37**:91  
    preneoplastic growth properties of  
      infected pre-B cells, **37**:91-92  
    tumorigenicity progression, **37**:92-93  
  history of, **37**:75-76  
  neoplastic transformation  
    NIH 3T3 fibroblasts, **37**:83-84  
    pre-B cells, **37**:79-80  
    rapid induction of thymomas, **37**:83  
    target cells in monocyte-macrophage  
      lineage, **37**:82-83  
    techniques for, mature B and plasma  
      cells, **37**:80-81  
    transformed cell lines with differentiation  
      potential, **37**:82  
  non-neoplastic changes induced, **37**:84-85  
  agar colony formation from fetal liver  
    erythroblasts, **37**:85  
  lethality, **37**:86-87  
  resistance of GM-CFC to leukemia-  
    associated inhibition activity, **37**:85  
  overview, **37**:74-75  
  properties of *v-abl* and tyrosine kinase  
    transforming protein, **37**:76  
Abelson-murine leukemia virus  
  fetal liver cell infection, **39**:40-41  
  IL-3-regulated growth and, **39**:40-41  
  helper T cell infection, **39**:41  
  IL-2-regulated growth and, **39**:41  
  plasmacytomagenesis, **64**:230  
  transfected cells, rearrangement by V(D)J  
    joining of antigen receptor genes,  
      **56**:48-49  
  transformed mast cell lines, lymphokine  
    production by, **53**:4-6  
Abelson virus  
  B cell formation and, **41**:195, 209, 217,  
    219, 225  
  hybrid resistance and, **41**:397  
*abl*, tumor antigens derived from,  
  **57**:296-297  
ABL-MYC retrovirus, plasmacytomagenesis,  
  **64**:231-238



- Accessibility model, **61:84, 86**  
 germline transcription, **54:241**
- Accessory cells  
 B cell formation and, **41:220**  
 hybrid resistance and, **41:350, 373**  
 immune reconstitution and, **40:416–417**  
 isotype-specific responses and, **40:219**  
 T cell activation and, **41:7–14, 21**  
 T cell subsets and, **41:63–66, 69**
- Accessory genes, HIV-1 disease, **63:85–86, 94, 105**
- Accessory molecules  
 CD4 or CD8, role in immune response, **54:124–125**  
 CD40-dependent B cell activation, **63:56–57**  
 cytotoxic T cells and, **41:150–152, 158, 168–170**  
 T cell receptor and, **45:108–110**
- Acetylcholine receptor, *see also* Experimental autoimmune myasthenia gravis;  
 Myasthenia gravis  
 antigenic structure of, **42:240–248**  
 discovery of, **42:233–236**  
 Ig heavy-chain variable region genes and, **49:31, 46, 50–51**  
 main immunogenic region, Abs to, **42:240–241, 246, 262**  
 muscle, **42:239**  
 autoantibody effects on, **42:260–263**  
 neuromuscular transmission and, **42:236–237**  
 neuronal, **42:239**  
 polypeptide chain, **42:238**  
 skeletal muscle, **42:238**  
 structure of, **42:237–240**  
 suppressor T cells and, **42:269**  
 T cell epitopes and, **42:241–245**
- Acetylcholinesterase  
 autoimmune thyroiditis and, **46:268**  
 human erythrocyte,  
 ethanolaninephosphates in, **60:62**
- N-Acetylcysteine  
 effect on apoptosis, **58:250, 262–263**  
 inhibition of HIV lymphocyte death, **58:279**
- N-Acetylglucosamine  
 and glucosamine, in GPI-anchored proteins, **60:60–72**  
 transfer to PI from UDP-GlcNAC, **60:64–70**
- Acetyltransferase, antinuclear antibodies and, **44:109, 110**
- AChR, *see* Acetylcholine receptor
- $\alpha$ 1-Acid glycoprotein, **65:22**
- Acid hydrolysis, hybrid resistance and, **41:398**
- Acid phosphatase  
 B cell formation and, **41:212, 213**  
 cytolysis and, **41:281**
- cis*-Aconitic anhydride, in  
 chemoiimmunoconjugation, **56:315–316**
- Acquired agammaglobulinemia, **59:138–139, 146**
- Acquired C1 esterase inhibitor deficiency, B cell lymphoma reaction to anti-Id antibodies, **39:288–291**  
 idiotypic network and, **39:289, 291**
- Acquired immune deficiency syndrome, *see* AIDS; AIDS, animal models
- Acromegaly, **63:409**
- ACTH, *see* Adrenocorticotrophic hormone
- Actin  
 cytolysis and, **41:275**  
 hybrid resistance and, **41:378**  
 immunosenescence and, **46:224**  
 leukocyte integrins and, **46:151, 169**  
 polymerization, **63:149**
- Activated partial thromboplastin time, aPL antibodies and, **49:200–202, 244**
- Activated protein C, aPL antibodies and, **49:253–254, 257**
- Activating peptide receptors, **52:366–375**  
 for formyl-methionine peptides and related compounds, **52:371–372**  
 for IL-8 and related integrins, **52:367–371**  
 for substance P and other neuropeptides, **52:372–375**
- Activation  
 antigen-dependent, **52:199**  
 antigen receptor-dependent, *see* Antigen receptor-dependent activation  
 complement components and, **38:214, 234**  
 contact, *see* Contact activation  
 maternally transmitted antigen gene, **38:342**  
 polyclonal, B cell, *see* Polyclonal B cell activation  
 SCID and, **49:386**  
 sequential, of Ig genes, **40:256–257**

- surface antigens of human leukocytes and, **49:125**  
 T cell, *see* T cell activation  
 T cell receptor  $\gamma\delta$  lymphocytes, **43:171–172**
- Activation antigen, **48:248–250**  
 accessory, **48:241–242**  
 glycosyl-phosphatidylinositol, **48:237–241**  
 surface antigens of human leukocytes and, **49:115, 117**
- Activation-induced death, hybridomas, **50:67**
- Active immunotherapy, **62:219**
- Activin type II receptors  
 amino acid sequences, **55:190–192**  
 cDNA cloning, **55:188–192**  
 structure, **55:190–193**
- Acute asthmatic response, and airway tone, **51:350–351**
- Acute lymphoblastic leukemia, **46:45; 63:244**  
 B-lineage, **61:11–12**
- Acute lymphocytic leukemia  
 CD1 proteins, **59:60**  
 with 4:11 chromosomal translocation, **40:293**  
 T and B cell lineage-specific genes and, **40:284–290**
- Acute myelomonocytic leukemia, **46:160**
- Acute negative selection, **59:106–107**
- Acute phase proteins, **65:6**  
 NF- $\kappa$ B-dependent, **58:9–10**  
 synthesis, **54:25–27, 216**
- Acute phase response factor, **65:19**
- Acute respiratory distress syndrome, **62:260–265, 267, 270, 271, 286**  
 IL-8, **66:140**  
 MIF, **66:214–215**
- Acyl salicylates, PGHS, **62:187**
- Adapter molecules, **63:134, 141–143**
- Adaptive immunity, NK cells and, **47:291–295**
- Addressin cell adhesion molecule-1, ligand for  $\alpha 4\beta 7$  receptor, **60:170–171**
- Addressins, **62:257**  
 lymphocyte–HEV interaction, **65:361–363, 377**  
 mucosal, MadCAM-1, **58:360**  
 mucosal vascular, lymphocyte–HEV interaction, **65:362–363**  
 PLN-specific vascular, *see* Peripheral node vascular addressins
- surface antigens of human leukocytes and, **49:88**  
 vascular, role of GlyCAM-1, **58:359**
- Adenocarcinoma, rat pancreatic, **54:324**
- Adenoma, pituitary hormones, **63:380**
- Adenosine deaminase, **64:69**
- Adenosine deaminase deficiency, **59:151, 246**  
 SCID and, **49:382–383, 390, 396**
- Adenosine receptors, **52:396–398**
- Adenovirus  
 cytotoxic T cells and, **65:279**  
 E3/19K glycoprotein, effects on antigen processing and presentation, **52:44–47**  
 hybrid resistance and, **41:368**
- Adenylate cyclase, immunosenescence and, **46:226**
- Adhesins, antigen-presenting cells and, **47:61**
- Adhesion, *see* Cell adhesion
- Adhesion molecules, *see* Cell adhesion molecules
- Adipocytes  
 B cell formation and, **41:210**  
 IFN- $\gamma$  and, **62:91**
- Adipose tissue, cachectin and, **42:215, 222–223**
- Adjuvant, *see also* Freund's complete adjuvant  
 antigen concentration and, **40:91–92**  
 Freund's, **60:111–112, 116–117, 131**  
 T cell subsets and, **41:70, 71**  
 incomplete Freund's, autoimmune thyroiditis and, **46:277**  
 lipopeptide moiety, **60:141**  
 liposome–lipid A/alum, **60:112**  
 MAP/alum, **60:117–118**  
 RIBI, **60:131–132**  
 type, and differential results, **60:132**
- Adjuvant arthritis, **64:289**
- Adoptive immunotherapy, **58:437–438**
- Adoptive T cell therapy, tumors, *see* Tumors, adoptive T cell therapy
- Adrenal corticosteroids, MG therapy and, **42:270–271**
- $\beta$ -Adrenergic mediator, **48:162**
- Adrenocorticotrophic hormone, **48:170–172; 54:26–27**  
*in vitro* IgE synthesis, **61:370–371**  
 NK cells and, **47:268, 269**  
 production by leukocytes, **39:315, 316**

- Adrenocorticotrophic hormone (*continued*)  
 spontaneous autoimmune thyroiditis and, **47:477, 479, 493**  
 thymic factor-induced release, **39:315**
- Adriamycin  
 antitumor activity, **56:333–334**  
 monoclonal antibody conjugation procedure, **56:334–336, 338**
- Adsorption  
 experiments, IL-2 and, **42:166**  
 hybrid resistance and, **41:363**  
 T cells, **38:155–157**
- Adult respiratory distress syndrome,  
 therapeutic regulation of complement system in  
 clinical studies, **56:278–279**  
 inhibition using soluble CR1, **56:284–286**
- Advanced glycosylation end products,  
**63:390–391**
- AES, *see* Anti-eosinophil serum
- Afferent blockade  
 anterior chamber, **48:203–204**  
 corneal graft survival, **48:195–196**
- Afferent lymph dendritic cells, CD1 protein expression, **59:63–64**
- Affinity chromatography, leukemia inhibitory factor, **53:32**
- Affinity maturation, memory B cells, **53:233–234**
- Affinity purification, aPL antibodies and, **49:228–231, 257, 259**  
 specificity, **49:242–243, 251**
- Affinity threshold  
 receptor-ligand interaction, **42:48–51**  
 tolerance induction B cells, **42:77–78**  
 variable region gene complexes and, **42:73**
- African swine fever virus, **65:127–128**
- Agammaglobulinemia, **38:291; 59:139–141**,  
*see also* X-linked agammaglobulinemia  
 congenital, **59:138–139**
- Agarose gel electrophoresis, complement components and, **38:207, 208**
- Age  
 antiidiotypic regulation and, **42:57–58**  
 associated replacement of V $\gamma$ 6 T cells by V $\gamma$ 4, **58:303–304**  
 and B cell genesis, **63:215–216**  
 CD5 B cells and, **47:122, 123**  
 related extrathymic expansion of V $\delta$ 2 T cells, **58:309**  
 V gene segment utilization and, **42:30–32**
- Agglutination  
 epitope, **48:23**  
 hybrid resistance and, **41:342, 359**  
 segmental flexibility, **48:23–24**
- Agglutination test, aPL antibodies and, **49:235**
- Agretopes  
 immune response genes and antigen binding, **38:107**  
 competitive inhibition, **38:108**  
 cytotoxic T cells, **38:165**  
 tolerance, **38:130**  
 synthetic T and B cell sites and, **45:201, 202, 210**
- T cell receptor and  
 antigen processing, **45:122, 123**  
 structure-function relationships, **45:135, 139**  
 T cell repertoire, **45:166**  
 T cell subsets and, **41:53, 54**
- AIDS, *see also* AIDS, animal models  
 anti-TNF- $\alpha$  therapy, **64:311**  
 aPL antibodies and, **49:210**  
 associated lymphopenia, and lymphocyte PCD, **58:214**  
 CD4 molecules and, **44:290**  
 CTL suppression in, **65:305**  
 epidemic, **52:425–426**  
 exacerbation, **58:16**  
 HIV-1, **63:87–89**  
 chronic infection, **63:89**  
 immunity, **63:95–98**  
 infection, **63:84**  
 neuropathology, **63:95**  
 pathogenesis, **63:90–95, 100**  
 primary infection, **63:88**  
 transmission, **63:88**  
 treatment, **63:94–95**  
 xenograft models, **63:79, 107**  
 deletion mutant studies, **63:94, 105**  
 hu-PBL-SCID model, **63:89–98**  
 pediatric infection, **63:95**  
 SCID-hu thy/liv model, **63:89–90, 99–107**
- HIV infection and, **47:377, 413, 414**  
 activation, **47:398, 400, 403**  
 etiological agent, **47:378, 379, 384**  
 immune response, **47:405–409**  
 immunopathogenic mechanism, **47:388–391, 394, 395, 397**

- neuropsychiatric manifestations,
  - 47:403–405
- HIV progression to, **65**:285, 299, 302, 304
- humoral immune response and, **45**:78
- hybrid resistance and, **41**:353
- and IL-6, **54**:37–39
  - HIV infection, **54**:37–38
  - Kaposi's sarcoma, **54**:38–39
  - membrane cofactor protein, **61**:219–220
  - NK cells and, **47**:285, 302, 303
  - synthetic T and B cell sites and, **45**:219, 264
  - virus-induced immunosuppression and,
    - 45**:335, 336, 351–357, 360, 363, 365
- AIDS, animal models, **52**:427
- animal infection with HIV-1, **52**:454–466
  - chimpanzee, infection of, **52**:455–461
    - model for testing HIV-1 vaccines, **52**:457–459
    - pathogenesis of HIV-1 infection in, **52**:455–457
    - use to test therapies based on CD4, **52**:459–461
  - conclusions, **52**:466
  - mouse, SCID-hu, **52**:463–466
  - rabbit, infection with HIV-1, **52**:461–463
- epidemic of AIDS, **52**:425–426
- feline immunodeficiency virus, **52**:437–441
  - use to study antiviral therapy and vaccines, **52**:440–441
- feline leukemia model, **52**:434–436
  - antiviral therapy, **52**:436–437
  - pathogenic mechanism of FeLV-FAIDS, **52**:436
- models using viruses distantly related to HIV-1, **52**:430–432
  - murine leukemia virus, **52**:432–434
  - ungulate lentiviruses, **52**:430–432
- murine retroviral models, **58**:233–237
- relationships among viruses used, **52**:426–430
- simian immunodeficiency virus
  - infection of macaques, **52**:442–452
  - pathogenesis of simian
    - genetic drift of SIV molecular clones *in vivo*, **52**:451–452
    - immunodeficiency virus infection of macaques, **52**:443–452
    - natural history of SIV infection of macaques, **52**:443–448
    - use of SIV molecular clones to define viral determinants of pathogenesis, **52**:448–451
    - phylogeny of nonhuman primate lentiviruses, **52**:442–443
  - SIV/macaque model for testing vaccines, **52**:452–454
- AIDS-dementia complex, **47**:377, 403
- AIDS-related complex
  - immune response, **47**:408
  - immunopathogenic mechanism, **47**:388, 395, 397, 403
  - neuropsychiatric manifestations, **47**:404
- Airway hyperresponsiveness, **51**:351–352
  - and leukotrienes, **51**:344–346
- Airway hypersensitivity, guinea pig, IL-5 role, **57**:173–174
- Airway inflammation, *see* Pulmonary inflammation
- Airway mucosa, in bronchial asthma, **51**:326
- Airway tone, and acute asthmatic response, **51**:350–351
- Alamethicin, cytolysis and, **41**:315
- AL-amyloidosis, **64**:220–221
- Alanine
  - antinuclear antibodies and, **44**:119
  - genetically engineered antibody molecules and, **44**:84
  - IL-1 and, **44**:158
- Albumin
  - hybrid resistance and, **41**:392, 394
  - IL-1 and, **44**:165, 170, 186
  - membrane attack complex of complement and, **41**:300
- ALDC, *see* Afferent lymph dendritic cells
- Algorithms, T cell epitope prediction, **66**:78–84
- Alkaline phosphatase
  - B cell formation and, **41**:186, 213
  - hybrid resistance and, **41**:380
- Alkylating agent–antibody conjugates, as cancer treatment
  - chlorambucil, **56**:328–330
  - cis*-platinum, **56**:329, 332
  - melfhalan, **56**:329–331
  - mitomycin C, **56**:329, 332–333
  - phenylenediamine mustard, **56**:329, 331
  - properties, **56**:328–329
  - structure, **56**:328–329
  - trenimon, **56**:329, 331–332

- Alleles  
 adoptive T cell therapy of tumors and, **49:297**  
 aPL antibodies and, **49:255**  
 complement receptor 1 and, **46:188, 189, 191**  
 complement receptor 2 and, **46:202**  
 Ig gene superfamily and, **44:27–30, 44, 46**  
 Ig heavy-chain variable region genes and, **49:9, 14, 22–28**  
 surface antigens of human leukocytes and, **49:81**
- Allele specificity, cytotoxic T cells and, **38:162, 165, 167**
- Allele-specific oligonucleotide, **48:118–119**  
 hybridization, **48:118**  
 polymerase chain reaction, **48:118**
- Allelic exclusion  
 B cell development, **63:2, 19–21**  
 chicken, **57:372–374**  
 T cell receptor  $\beta$ -chain, in control of thymocyte by p56<sup>lck</sup>, **56:164–166**
- Allergen challenge  
 in fiberoptic bronchoscopy studies, **60:218–219**  
 and increased bronchial hyperresponsiveness, **60:168–171**
- Allergens, **61:363–364**  
 antibodies from combinatorial libraries, **57:228**  
 CD23 antigen and, **49:152**
- Allergic asthma  
 CD23 antigen and, **49:160**  
 IL-4 storage by lung mast cells, **53:15**
- Allergic bronchopulmonary aspergillosis  
 complication of asthma, **60:216**  
 in pulmonary eosinophilia, **60:226**
- Allergic diseases, **60:215–216**  
 CD23 antigen and, **49:174**  
 contact activation in, **66:258–259**  
 IgE biosynthesis and, **47:1**  
 antibody response, **47:7, 29, 30, 38**  
 binding factors, **47:13**
- Allergic pulmonary inflammation, **62:283–285**
- Allergic response, **61:341, 374–375**  
 APCs, **61:361–364**  
 conditioning, **61:368–369**  
 hybrid resistance and, **41:351**  
 IgE  
 regulation, **61:369–374**  
 synthesis, **61:342–344, 370–374**
- IL-4, **63:310**  
 inflammation, *see* Inflammation, allergic mast cells, **61:360–361**  
 nervous system role, **61:364–368, 374**  
 neuroendocrine factors, **61:366–367, 369–374**  
 prostaglandin E<sub>2</sub>, **61:98**  
 psychological factors, **61:368–369, 374–375**  
 T cell regulatory potential, **61:344–360**  
 T helper responses, **61:344–347**  
 APCs, **61:361–363**  
 CD8<sup>+</sup>, **61:358–360**  
 cytokines, **61:347–355**  
 extrinsic factors, **61:357–358**  
 surface molecules, **61:355–357**
- Allergic rhinitis, **60:221**
- Allergic thyroiditis, murine lupus models and, **46:79**
- Allergy, human  
 anti-Id autoantibodies and, **39:275–276**  
 idiotypic network and, **39:275–276**
- Alloantibodies, hybrid resistance and, **41:356**
- Alloantigens  
 B cell formation and, **41:190, 193, 194, 197, 198**  
 cytotoxic T cells and, **41:135, 136, 169, 170**  
 $\beta$ 2-microglobulin, **41:156**  
 amino acid, **41:159, 163**  
 hybrid resistance and, **41:333**  
 antibodies, **41:376**  
 bone marrow cells, **41:336–340**  
 leukemia/lymphoma cells, **41:359, 361**  
 lymphoid cells, **41:354, 356**  
 immunosenescence and, **46:221, 245, 252**  
*Ir* genes and, **38:114, 115**  
 presentation by cultured endothelial cells, **50:266–267**  
 response to, EC costimulator in, **50:271–272**
- T cell subsets and  
 cell surface molecules, **41:44**  
 H-2 molecules in thymus, **41:99, 107–109**  
 H-2-restricting antigen recognition, **41:63, 70, 74**  
 T cell specificity, **41:111**
- Allogeneic cells, immunosenescence and, **46:250**

- Allogeneic inhibition, hybrid resistance and, **41:334, 358–361, 369**
- Allogeneic lymphocyte cytotoxicity, hybrid resistance and, **41:356, 357**
- Allografts
- autoimmune thyroiditis and, **46:286**
  - corneal, *see* Corneal allograft
  - cytotoxicity and, **41:270**
  - cytotoxic T cells and, **41:135**
  - hybrid resistance and
    - antibodies, **41:379**
    - antigen expression, **41:404, 405, 408–410**
    - bone marrow cells, **41:348, 350**
    - effector mechanisms, **41:370**
    - leukemia/lymphoma cells, **41:366**
    - lymphoid cells, **41:355**
    - macrophages, **41:371, 372**
    - marrow engraftment, **41:387**
    - marrow microenvironment, **41:391**
    - NK cells, **41:372–375, 377**
    - syngeneic stem cells, **41:389, 390**
    - T cells, **41:383**
  - rejection
    - CD28–B7 costimulation, **62:142**
    - IFN- $\gamma$  and, **62:101–103**
    - T cell subsets and, **41:43, 92–95**
    - tumor, *see* Tumor allografts
- Alloimmune effector, anterior chamber, **48:204**
- Alloimmunization, human
- anti-HLA antibodies and, **39:281–283**
  - idiotypic network and, **39:281–283**
- Allophenic mice, *Ir* genes and, **38:62, 63**
- Alloreactivity
- autoreactive T cells and, **45:420, 421, 425**
  - B cell formation and, **41:190**
  - cytotoxic T cells and, **41:135–137, 169, 170**
    - $\beta_2$ -microglobulin, **41:156**
    - amino acid, **41:159, 162, 163, 165**
    - carbohydrate moieties, **41:153**
    - exon shuffling 141, **41:142, 144–148**
    - monoclonal antibodies, **41:156–158**
    - somatic cell class I variants, **41:167**
  - hybrid resistance and, **41:357, 372, 380, 381**
  - Immoral immune response and, **45:40**
  - Ir* genes and, **38:121–123**
  - synthetic T and B cell sites and, **45:234**
  - T cell receptor and, **45:148–157**
    - homogeneity, **45:128, 130**
    - MHC molecules, **45:116**
    - peptides, **45:138**
    - polymorphic residues, **45:158, 159, 162**
    - structure-function relationships, **45:136, 140**
    - T cell repertoire, **45:165**
  - T cell subsets and, **41:40**
    - cell surface molecules, **41:44**
    - H-2 alloantigen recognition, **41:78–83**
    - H-2 molecules in thymus, **41:100–102**
    - H-2-restricted antigen recognition, **41:68**
- Allospecificities, NK-defined, genetic analysis, **55:348–349**
- Allotype
- complement receptor 1 and, **46:185, 187–190, 195, 196**
  - immunosenescence and, **46:248**
- $\alpha, \beta$  heterodimer receptor structure, **42:168**
- $\alpha$  chain, **43:282, 284–287**
- free, retention of, **52:63–64**
  - IgA, structure and function, **40:155–158**
  - IL-2
    - cell division and, **42:173**
    - growth signal, **42:172–173**
- $\alpha$  enhancer, T cell receptor gene, **43:268**
- Alpha helix, amphipathic, **43:204**
- Alternate antigen pathway, and trapping of immune complexes, **51:265–269**
- Alternative complement pathway
- antibodies as activators, **51:28–29**
  - particulate activators, **38:384–386, 392**
- Alum adjuvant
- adsorbed MAP, **60:141**
  - HIV V3 loop in, **60:131**
  - with liposome–lipid A, MAP in, **60:112**
  - (TIB)<sub>4</sub> MAP in, **60:117–118**
- Alum/*Bordetella pertussis* (ABP), **46:137**
- Alveolitis
- CD23 antigen and, **49:160**
  - extrinsic allergic, **62:267**
- Alzheimer's disease
- causes, **66:260–261**
  - and IL-6, **54:42–43**
- Amino acids
- antibody diversity and, **42:97**
  - antigenic equivalence, **43:68–72**
  - antigen-presenting cells and, **47:60, 66, 89**
  - antinuclear antibodies and, **44:106, 108, 125, 129–131**

Amino acids (*continued*)

- autoimmune demyelinating disease and,
  - 49:358, 363, 366, 368
- autoimmune thyroiditis and, 46:317
  - antigens, 46:268, 272
  - genetic control, 46:284
  - humoral responses, 46:302
  - prevention, 46:315, 316
- B cell formation and, 41:197, 198
- CD1 proteins, 59:11–22
- CD4 molecules and, 44:285, 286, 289, 292, 295, 296
- CD5 B cell and, 47:145, 146
- CD8 molecules and, 44:272–276, 278
- CD23 antigen and, 49:156, 162–166
- complement receptor 1 and, 46:184, 186, 187, 194
- complement receptor 2 and, 46:202, 205, 210
- conservation, 43:115, 221–222
- contact residue, 43:119
- critical residue, 43:67–68
- critical to binding energy, 43:24
- cytolysis and, 41:285
- cytotoxic T cells and, 41:135, 170
  - $\beta_2$ -microglobulin, 41:154
  - exon shuffling, 41:142, 147, 148
  - H-2 mutant strains, 41:158–163
  - HLA class I subtypes, 41:163–165
  - HLA subtypes, 41:163–165
  - monoclonal antibodies, 41:157
  - somatic cell class I variants, 41:166, 167
- energy penalty of voids, 43:72
- epitope, 43:65–67
- genetically engineered Abs and antigen-combining sites, 44:84
  - biological properties, 44:83
  - cloning, 44:73, 75
  - expression, 44:78, 79
  - production, 44:68
- HIV infection and, 47:386, 405–408
- human T cell activation and, 41:3, 5, 10, 13
- humoral immune response and, 45:18, 20
- hybrid resistance and, 41:394
- IgE biosynthesis and, 47:15–17, 20, 39
- Ig gene superfamily and
  - evolution, 44:49
  - homology unit, 44:3, 6, 7
  - nonimmune receptor members, 44:40
  - receptors, 44:11, 18, 21, 22
- Ig heavy-chain variable region genes and D segments, 49:28, 31
  - J<sub>H</sub> segments, 49:34
  - V<sub>H</sub> families, 49:7, 14, 18
  - V<sub>H</sub> gene expression, 49:35, 43, 51
- IL-1 and, 44:153, 154
  - biological effects, 44:167, 168
  - receptor, 44:179, 181, 182
  - structure, 44:155–158
  - TNF, 44:185, 188
- intrinsic hydrophilicity parameters, 43:49
- leukocyte integrins and, 46:154–156, 159, 174, 176
- lymphocyte homing and, 44:342, 355
- maps of Ig-like loci and, 46:2
  - structure, 46:7, 8, 10, 12, 13, 15, 21, 25
  - T cell receptor, 46:35, 38, 41
- membrane attack complex of complement and, 41:307
- MHC contact, 43:210
- murine lupus models and, 46:69
- pore formers and, 41:313–318
- propensity factors, sequential epitopes, 43:66–67
- regulators of complement activation and, 45:381, 411
  - genes, 45:405, 406
  - protein expression, 45:399, 400, 402
  - RCA-like protein utilization, 45:409, 410
  - short consensus repeat, 45:391, 392, 394
- replaceability, 43:69–71, 77
- sequential epitope role, 43:39
- sporozoite malaria vaccine and antibodies, 45:300
  - CS proteins, 45:292, 294–300
  - CS-specific T cells, 45:311–313
  - human trials, 45:315
  - Plasmodium vivax*, 45:317
- surface antigens of human leukocytes and, 49:81, 92
- synthetic T and B cell sites and, 45:196, 255, 256, 258, 262
  - antigens, 45:232, 233
  - bacterial antigens, 45:230, 231
  - candidate synthetic peptide vaccines, 45:253, 255, 256, 258
  - globular protein antigens, 45:210, 216
  - immunological considerations, 45:200
  - prediction, 45:251
  - viral antigens, 45:219–221, 227, 228

- T cell receptor, **43**:157–159
- T cell receptor and  
 alloreactivity, **45**:151–153  
 antigen processing, **45**:120–123  
 epitopes, **45**:143, 145, 148  
 peptides, **45**:138  
 polymorphic residues, **45**:159  
 T cell repertoire, **45**:165
- T cell subsets and, **41**:85  
 activated T cells and hybridomas,  
**41**:54, 56  
 cell surface molecules, **41**:46, 47  
 H-2 alloantigen recognition, **41**:83  
 virus-induced immunosuppression and,  
**45**:350, 362, 364
- VL and VH domains, **43**:109, 125
- Amino acid sequence, **48**:108
- activin type II receptor, **55**:190–192
- amino-terminal, peptides, **54**:350
- antibodies from combinatorial libraries  
 analysis, **57**:233–238  
 RGD, **57**:261–263
- Ars A response and, **42**:95, 97, 111–112  
 heavy chains and, **42**:99  
 $J_H$ 2 segment and, **42**:102–108  
 light chains and, **42**:139–141
- chemokine, **55**:98–99
- chemokine receptors, **55**:129, 132–133
- desmoglein, **53**:314
- ELR motif of CXC chemokines,  
**55**:136–138
- IL-8 receptor, **55**:129–131
- interferon regulatory factors 1 and 2,  
 mouse, **52**:268
- LIF, human, **53**:40
- oncostatin M, **53**:40
- PV antigen, **53**:314
- TCR  $\gamma$  genes, human  
 $C_\gamma$ , **43**:143  
 $J_\gamma$ , **43**:142  
 $V_\gamma$ , **43**:141
- TGF- $\beta$  receptor II, **55**:190–192
- V $\beta$ 1 and V $\beta$ 2 gene segments, chicken,  
**50**:110
- Aminoacylation, antinuclear antibodies and,  
**44**:94, 119, 127, 134, 135, 138
- 3-Aminobenzamide, effect on cytolysis,  
**58**:252–253
- Aminopterin, in cancer treatment, monoclonal  
 antibody conjugation procedure, **56**:342
- 5-Aminosalicylic acid, *see also* Sulfasalazine  
 prostaglandin synthesis and, **42**:312–313,  
 317, 318–329
- AML1, **65**:24–25
- Amoebas, pore-forming proteins of, **41**:312,  
 313
- Amphipathicity, T cell receptor, **43**:204
- Amphiphilic nature, C5b-9, membrane attack  
 complex of complement and, **41**:299–304
- Amyloidosis, **64**:219, 220–221
- Anaphylatoxins, **61**:204, 255
- Anaphylaxis, IFN- $\gamma$  and, **62**:103
- Anatomical sequestration, lens, **48**:220
- Anchor, GPI, defective synthesis, **60**:57–74
- Anchor residues, **62**:231
- Androgens, spontaneous autoimmune  
 thyroiditis and, **47**:480, 481
- Anemia, **59**:146–147, 343  
 aPL antibodies and, **49**:218, 225, 250–251,  
 255, 257  
 aplastic, PNH associated with, **60**:91  
 erythropoiesis and, **42**:224  
 hemolytic, in PNH, **60**:74–75
- Anemic cells, hybrid resistance and, **41**:346,  
 348, 388
- Anemic mouse, B cell formation and, **41**:224
- Anergy  
 B cells, **59**:321–322  
 $\gamma\delta$  T cells, **58**:313  
 and peripheral tolerance to cancer, **58**:421  
 resulting from tolerization processes,  
**58**:271–272  
 surviving T cells, **58**:260  
 T cell, cyclosporin A effect, **58**:262
- Angioedema, hereditary, **61**:206
- Angiogenesis, in rheumatoid arthritis, **64**:295
- Angioimmunoblastic lymphadenopathy, gene  
 rearrangement and, **40**:294
- Angiotensin II, synthetic T and B cell sites  
 and, **45**:232, 233
- Anhydrides  
*cis*-aconitic, in conjugation procedure for  
 chemoimmunoconjugates in cancer  
 treatment, **56**:318–319  
 mixed, in conjugation procedure for  
 chemoimmunoconjugates in cancer  
 treatment, **56**:319
- Anions, cytolysis and, **41**:282, 312
- ANK repeat, **65**:14
- Ankylosing spondylitis, HLA-B27 and, **65**:94



- Ankyrin repeats, interaction with NF- $\kappa$ B rel domain, **58:3–4**
- Anopheles*, sporozoite malaria vaccine and, **45:283, 284**
- Anorexia, cachectin and, **42:213, 219**
- Anterior chamber, **48:191, 192**  
 afferent blockade, **48:203–204**  
 alloimmune effector, **48:204**  
 alloimmunity down-regulation, **48:204**  
 antigen-processing cells, **48:206, 207**  
 DBA/2 mastocytoma cell, **48:204**  
 immunological privilege, **48:203–212**  
 intraocular HSV-1 infection, **48:210**  
 contralateral eye, **48:210**  
 DTH suppression, **48:210**  
 mastocytoma, **48:213–215**  
 physiochemical environment, **48:206, 207**  
 systemic cell-mediated immunity, **48:204**  
 tumor allograft, **48:204**  
 tumorigenesis, **48:213–215**  
 UV5C25, **48:213–215**
- Anterior chamber-associated immune deviation, **48:205–211, 206**  
 cytotoxic T cell, **48:208, 209**  
 DBA/2 mastocytoma model, **48:207**  
 delayed-type hypersensitivity, **48:219**  
 antigen-specific down-regulation, **48:208, 209**  
 antigen-specific suppression, **48:211**  
 anterior chamber, **48:211**  
 efferent mode, **48:211**  
 hapten model, **48:211**  
 suppressor T cell, **48:211**  
 intraocular tumor allograft, **48:208, 209**  
 effector mechanism, **48:211–212**  
 expression, **48:207–210**  
 eye, **48:206**  
 induction, **48:205–207**  
 ocular HSV infection, **48:208–210**  
 S antigen, **48:219**  
 spleen, **48:206, 211**  
 tumor allograft, intraocular, **48:207–208**  
 tumorigenesis, **48:213**  
 vascular route, **48:205**
- Anthracycline-antibody conjugates, as cancer treatment  
 direct conjugation  
 C-14 methyl group, **56:336**  
 hydroxyl group, **56:336–337**  
 keto group, **56:337**  
 sugar amino group, **56:334–336**  
 sugar moiety, **56:334**
- intermediary carriers  
 dextran, **56:337–338**  
 polyglutamic acid, **56:338**  
 properties, **56:333–334**  
 structure, **56:333–334**
- Antiadhesion therapy, **64:195–197**
- Antibodies, **48:16–18**  
 adoptive T cell therapy of tumors and, **49:331, 333**  
 mechanisms, **49:312–315**  
 principles, **49:289, 297**  
 affinity threshold of, **42:69, 70–71**  
 anti-BrMRBC/anti-PC, secreting CD5 B cells, **55:315–316**
- antidansyl  
 genetically engineered antibody molecules and, **44:78, 80, 81**  
 segmental flexibility, **48:13, 14**
- anti-DNA, **38:297, 298**
- antigen binding, **43:105**
- antigen-presenting cells and  
 antigen presentation, **47:68, 73, 75**  
 antigen processing, **47:92**  
 APC-T cell binding, **47:95, 97, 99**  
 cell surface, **47:57–59, 61, 62**  
 immunogeneity, **47:102, 103**  
 interaction with T cells, **47:93**  
 T cell-dependent antibody responses, **47:81–86**  
 T cell growth, **47:100, 101**  
 tissue distribution, **47:49, 50, 53, 57**
- anti-Ia, experimental autoimmune encephalomyelitis, **48:164, 166**
- anti-Id  
 autoimmune thyroiditis and, **46:318**  
 genetic control, **46:287**  
 humoral responses, **46:301, 304–309**  
 prevention, **46:308, 312, 314**
- Ig heavy-chain variable region genes and, **49:37, 40, 46**
- immunosenescence and, **46:247, 248, 252, 253**
- MG therapy and, **42:268, 272**  
 specific immunoregulation, **42:55–57**
- anti-Id, animal, as vaccines, protection from  
 bacterial antigens, **39:283**  
 parasite antigens, **39:284**  
 viral antigens, **39:283**

- anti-Id, human therapeutic  
 B cell tumors and, **39:285–291**  
 solid tumors and, **39:291–292**  
 T cell leukemias and, **39:288**
- anti-Id, rabbit  
 to human anti-TT antibodies  
 binding to B cells, **39:264–266**  
 binding to Id, **39:261–263**  
 binding to T cells, **39:265–267**  
 human immune responses and,  
**39:267–269**  
 production, **39:261**  
 to human IgM-RF, **39:263**
- anti-Ig, **52:185–188**  
 anti-TNF- $\alpha$  therapy, **64:323–325**  
*Branhamella catarrhalis* and others,  
**52:188**  
 induced proliferation of normal human B  
 cells, **54:363**  
 inhibitory effects, **52:186–187**  
 inhibitory effects of anti-Ig antibodies,  
**52:186–187**  
*Staphylococcus aureus* Strain Cowan,  
**52:187–188**  
 stimulatory effects, **52:185–186**  
 as surrogate antigens, differential effects  
 on mature and immature cells,  
**52:295–297**
- anti-IgE, **43:279–281**
- anti-IgM  
 growth arrest and apoptosis induced by,  
**54:410–411**  
 induced unresponsiveness in adult B  
 cells, **54:404–405**  
 role of apoptosis in neonatal B cell  
 tolerance, **54:403–404**  
 surrogate systems, **54:402–410**  
 tolerance in B cell subsets, **54:405–407**
- anti-IgM and anti-CD40, costimulatory  
 effect on B cell proliferation, **52:190**
- antinuclear, *see* Antinuclear antibodies
- antipeptide, **43:61**  
 binding, **43:118**  
 design, **43:59–65**  
 affinities of monoclonal anti-MHR  
 antibodies, **43:61–62**  
 local mobility and antigenicity, **43:61**
- antiphospholipid, *See* Antiphospholipid  
 antibodies
- antiprotein, binding, **43:42**
- antiprothrombin, **49:247, 256**
- antiporozoite, **60:112–124**
- antithrombin III, **49:256**
- autogeneic, *see* Autoantibodies
- autoimmune demyelinating disease and,  
**49:363, 368–374**
- autoimmune thyroiditis and, **46:263,**  
**317–319**  
 antigens, **46:272, 273**  
 cellular immune responses, **46:287, 289,**  
**290, 293–295**  
 experimental models, **46:276–278, 281,**  
**282**  
 genetic control, **46:283, 285–287**  
 humoral responses, **46:298–307, 309**  
 prevention, **46:308, 310, 312, 314, 315**  
 autoreactive T cells and, **45:427**
- B cell formation and, **41:182, 183**  
 B cell precursors, **41:189, 191, 192, 194,**  
**201, 202**  
 bone marrow cultures, **41:213**  
 Ig genes, **41:203, 204**  
 lymphohemopoietic tissue organization,  
**41:187**
- Clq interaction, **51:9–21**
- catalysis, **43:1–2**
- CD1, **59:39–43**
- CD2, role in T cell death, **58:226**
- CD3, IGF-I-R, **63:403**
- CD4 molecules and, **44:297, 300**
- CD5 B cell and, **47:161, 162**  
 Ig gene expression, **47:150–154, 157,**  
**158**  
 lineage, **47:129**  
 marker for activation, **47:127**  
 physiology, **47:130, 131, 133, 135–137,**  
**139, 140**  
 primordial immune network, **47:159–161**  
 surface antigen, **47:143, 144**
- CD23 antigen and, **49:149, 176**  
 biological activity, **49:168–169, 172**  
 cellular expression, **49:152–153, 155**  
 expression regulation, **49:159**  
 Fc $\epsilon$ RII, **49:165**
- CD40, **52:188–191**  
 and anti-IgM, costimulatory effect on B  
 cell proliferation, **52:190**
- CD59, in venous thrombosis, **60:91–92**
- cell mediation, **41:271, 272**

- Antibodies (*continued*)
- cold-reactive antilymphocyte, IgG levels in, **42:292**
  - combining site, structure variability, **43:14–15**
  - complement receptor 1 and, **46:193, 196, 200, 201**
  - complement receptor 2 and, **46:206**
  - complex with antigens, trapping by follicular dendritic cells, **60:274**
  - conformation, **43:17, 124–125**
  - crystallographic studies, I diversity, **43:133**
  - cytolysis, **41:275, 278, 283**
  - cytotoxic T cells and
    - $\beta_2$ -microglobulin, **41:156**
    - exon shuffling, **41:141, 144–146**
    - HLA class I antigens, **41:150, 151**
    - monoclonal antibodies, **41:156–158**
  - $\delta$  dextran
    - class switching, **61:91–92**
    - Ig production, **63:65**
  - Dob structure, **43:8**
  - to double-stranded cDNA, cA2 treatment, **64:325**
  - electrostatic recognition with antigen, **43:12–13**
  - enzymatic activity, **43:81**
  - F23.1, induction of thymic cell depletion, **58:274**
  - Fab Kol, crystal packing, **43:19–20**
  - Fab region, **43:8–9**
  - Fab structures, **43:17**
  - Fc region, **43:8–9**
  - genetically engineered, *see* Genetically engineered antibodies
  - glycoprotein, phase I clinical trials, **40:366–370**
  - helper T cell cytokines and
    - cross-regulation of differentiation, **46:131, 132**
    - differential induction, **46:127, 129, 130**
    - functions, **46:116, 118–120**
    - immune responses, **46:133, 137, 138**
    - precursors of differentiation states, **46:124**
  - HIV-1 immunity, **63:97–98**
  - HIV infection and
    - immune response, **47:405–410**
    - immunopathogenic mechanism, **47:388, 389, 393, 395, 398**
    - neuropsychiatric manifestations, **47:404**
  - human, from combinatorial libraries
    - affinity, strategy for improvement, **57:263–266**
  - allergens, **57:228**
  - amino acid sequences
    - analysis, **57:233–238**
    - RGD, **57:261–263**
  - bacteria, **57:228**
  - cloning strategies, **57:203–206**
  - design, **57:261–263**
  - Epstein–Barr virus-transformed cell line-derived, **57:229–230**
  - expression of antibody fragments, **57:207–208**
  - to Graves' ophthalmopathy self-antigens
    - from human donors, **57:245**
  - to HIV-1 self-antigens from human donors, **57:246–250**
  - HuSCID mouse-derived, **57:230–231**
  - hybridomas, **57:229–230**
  - immune donors, **57:208–242**
  - naive repertoire approach, **57:250–252**
  - overview, **57:191–192**
  - phage display
    - antibody fragments, **57:195–198**
    - vector systems, **57:199–203**
  - to primary biliary cirrhosis self-antigens
    - from human donors, **57:244–245**
  - primate-derived, **57:231–232**
  - principles of combinatorial approach, **57:192–195, 266–267**
  - selection strategies, **57:206–207, 261–263**
  - staphylococcal protein A, **57:229**
  - study of responses, **57:232–242**
  - synthetic repertoire approach, **57:250, 252–260**
  - to thyroid disease self-antigens from human donors, **57:242–244**
  - viruses, **57:209–228**
    - cytomegalovirus, **57:220–221**
    - hepatitis B virus, **57:220**
    - herpes simplex virus type 1, **57:222–227**
    - herpes simplex virus type 2, **57:222–227**
  - HIV-1, **57:211–217**
  - measles, **57:227–228**

- respiratory syncytial virus, **57:217–219**  
 varicella Zoster virus, **57:221–222**  
 whole antibody molecules, **57:208**
- human antichimeric, **64:323–324, 330**  
 human anti-mouse, **64:323**  
 immune response, chemotherapy limited  
 by, **56:304, 358–360**
- humoral immune response and, **45:1–6**  
 antigens, **45:10, 12**  
 cellular interactions *in vivo*, **45:78, 81–83, 85**  
 helper T cells, **45:24–30, 32**  
 interleukins, **45:62, 67, 72, 74**  
 physical interaction, **45:38, 40–54**
- hybrid resistance and  
 antigen expression, **41:400, 402–405**  
 bone marrow cells, **41:336, 338, 341, 349, 350**  
 effector mechanisms, **41:370, 376–380**  
 leukemia/lymphoma cells, **41:359, 365, 368**  
 lymphoid cells, **41:352, 356, 357**  
 macrophages, **41:371, 372**  
 marrow engraftment, **41:386, 387**  
 NK cells, **41:374**  
 T cells, **41:383**
- IBD and, **42:290–291, 294–295, 298**
- IFN- $\gamma$ , **62:63, 87–89**
- IgE biosynthesis and, **47:1**  
 binding factors, **47:12, 14, 15, 17, 19, 21–23, 25, 28**  
 response, **47:1–12**  
 response suppression, **47:28–39**
- Ig gene superfamily and, **44:4, 9, 38, 44**
- Ig heavy-chain variable region genes and, **49:1–3, 61**  
 D segments, **49:31–33**  
 J<sub>H</sub> segments, **49:34**  
 organization, **49:4, 6**  
 V<sub>H</sub> families, **49:9, 14, 16**  
 V<sub>H</sub> gene expression, **49:40–45**
- IL-1, **44:189, 190, 192; 66:140**  
 gene expression, **44:163**  
 immunocompetent cells, **44:173, 177, 178**  
 receptor, **44:182**  
 structure, **44:157, 158**  
 systemic effects, **44:169**  
 TNF, **44:187**
- IL-6, **66:132**  
 clinical applications, **54:50**  
 immunosenescence and, **46:221, 253**  
 lymphocyte activation, **46:222**  
 mucosal immunity, **46:252**  
 regulatory changes, **46:247, 248, 250, 251**  
 stem cells, **46:246**
- induced complementarity, **43:16–20**  
 immunological, biochemical and  
 crystallographic data, **43:16–18**  
 mobility data, **43:20**  
 variable domain structure superposition,  
**43:18–20**
- to Leu7, **42:191–192**
- leukocyte integrins and, **46:164**
- lung, **59:393–394, 411–412**
- lymphocyte homing and  
 high endothelial venules, **44:317, 318**  
 immune response, **44:330–332, 335**  
 molecules, **44:342–344, 346, 350, 352**  
 regional specificity, **44:326, 328, 338, 341**
- lymphotoxin and, **41:298**
- membrane attack complex of complement  
 and, **41:301, 302, 307, 309**
- MG and, **42:262**
- monoclonal, *see* Monoclonal antibodies
- murine lupus models and, **46:99**  
 Ig germline, **46:65, 66, 72, 74, 76, 77**  
 lupus strains, **46:64**  
 T cell antigen receptor, **46:79, 88, 90, 98**
- neutralizing, **48:95–96**  
 HIV infection and, **47:407, 408, 410, 413**
- NK cells and, **47:189**  
 adaptive immunity, **47:292–294**  
 alteration, **47:300**  
 antimicrobial activity, **47:286–288**  
 cell-mediated cytotoxicity, **47:190, 196**  
 congenital defects, **47:224**  
 cytotoxicity, **47:249–251, 254, 257–259, 261**  
 differentiation, **47:231, 233**  
 effector mechanisms, **47:235, 237, 238, 240, 241, 243–248**  
 hematopoiesis, **47:274, 275, 277, 281**  
 identification, **47:196, 198**  
 malignant expansion, **47:227–229**  
 surface phenotype, **47:201, 202, 204–213**  
 tissue distribution, **47:221**

Antibodies (*continued*)

- PGHS-1 or PGHS-2, **62:178**
- phosphorylcholine, **42:10**
- PM-1, reshaped, **64:261**
- polyclonal, phagocytosis and, **38:376**
- pore-forming protein, **41:291, 296**
- to rabbit molecules, **56:182–183**
- raised against native protein, **43:3**
- receptor structure, *see* Antibodies, structure
- regulators of complement activation and complement pathways, **45:381**
  - protein expression, **45:396, 397**
  - protein roles, **45:389, 390**
- reshaped, human PM-1, construction, **64:261**
- SCID and, **49:397, 401**
- secondary B cell lineage and, **42:69–71**
- secretory, **65:249, 250**
- sequence variation, **43:13–16**
- serum, **42:291–292**
- serum, IBD and, **42:291–292**
- SLE and, **42:291–292**
- spontaneous autoimmune thyroiditis and, **47:433, 492**
  - altered thyroid function, **47:460**
  - disturbed immunoregulation, **47:479**
  - histopathology, **47:442**
  - humoral immune reactions, **47:444, 445, 447, 479**
  - potential effector mechanisms, **47:468**
- sporozoite malaria vaccine and, **45:320, 321**
  - CS proteins, **45:292, 299, 300**
  - CS-specific T cells, **45:306–313**
  - endemic areas, **45:315–317**
  - human trials, **45:313–315**
  - immunity, **45:286–292**
  - interferon- $\gamma$ , **45:301, 304, 306**
  - Plasmodium vivax*, **45:317, 318**
  - role, **45:300, 301**
- structure
  - conformational changes, **43:113–114**
  - domain-domain interactions, **43:110**
  - domain structure, **43:107–109**
  - Fab fragments, **43:107**
  - H and L chain CDR, **43:108–109**
  - module structure, **43:110–113**
  - polypeptide loops, **43:107**
  - sheet-sheet interactions, **43:110**
  - V and C domains, **43:109**
  - variable domains, **43:109**
  - VL–VH interface, **43:110, 112, 124**
  - VL–VL pairing, **43:112**
  - V module interface, **43:111**
- surface antigens of human leukocytes and, **49:113, 117**
- synthetic T and B cell sites and, **45:196, 260–264**
  - antigens, **45:233, 236**
  - bacterial antigens, **45:231**
  - candidate synthetic peptidevaccines, **45:253, 255–259**
  - globular protein antigens, **45:215, 216**
  - immunological considerations, **45:197**
  - parasitic antigens, **45:228, 229**
  - peptides, **45:237–239**
  - prediction, **45:251**
  - viral antigens, **45:220–223, 225, 227**
- Tac, **42:167, 169, 171, 172**
- T cell activation and, **41:6, 7, 9, 11, 13**
- T cell development and, **44:207, 255**
  - ontogeny, **44:218, 221**
  - thymocyte subpopulation, **44:226, 237, 239, 241**
- T cell receptor and
  - accessory molecules, **45:108, 109**
  - alloreactivity, **45:152, 154**
  - homogeneity, **45:128, 130**
  - peptides, **45:138**
  - polymorphic residues, **45:158, 160**
  - structure-function relationships, **45:136, 140**
- T cell repertoire, **45:164**
- T cell subsets and, **41:39, 40**
  - activated T cells and hybridomas, **41:54, 56**
  - cell surface molecules, **41:49**
  - effector phase, **41:76**
  - H-2 alloantigen recognition, **41:83–86, 89–93**
  - H-2 molecules in thymus, **41:97, 98, 105**
  - H-2 restricted recognition of antigen, **41:50, 52**
  - T accessory molecules, **41:61, 62**
  - T cell receptor, **41:40**
  - unprimed and resting T cells, **41:64, 65, 70, 72**
- to TCR1, TCR2, and TCR3, embryonic treatment with, **50:103–105**
- TCR antibody, **48:90**
- TNF- $\alpha$ , *see* Anti-TNF- $\alpha$  therapy

- to TNF, treatment with, **66**:124, 132, 150  
 TNKTAR, **42**:201–202  
 trimolecular complex  
   anti- $\alpha/\beta$  T cell receptor antibody, **56**:228–229  
   anti-CD3 antibody, **56**:220–223  
   anti-CD4 antibody, **56**:223–228  
   anti-T cell receptor V $\beta$  antibody, **56**:229–233  
 virus-induced immunosuppression and  
   HIV, **45**:351–353, 356, 357, 363, 365, 368  
   measles, **45**:340, 341, 343, 345–347  
   X-ray analysis, **43**:121  
 Antibody–antigen interaction, **43**:99–128, *see*  
   *also* Antigen recognition  
 affinities to small molecules, **43**:82  
 analysis of structure, **43**:22  
 buried surface, **43**:82  
 chemistry and binding energy, **43**:72–84  
 concerted shifts, **43**:22  
 contact residue, **43**:26  
 criteria for systematic studies, **43**:5–8  
 critical residues, **43**:27  
 crystallographic approaches, **43**:4  
 degree of fidelity, **43**:60  
 dominant epitopes and collective response, **43**:46–49  
 electrostatic attraction, **43**:80  
 evaluation of predictive methods  
   criteria for assessing prediction success, **43**:50–59  
   sequence data, **43**:49–50  
 immunological cross-reactivity, **43**:64  
 interface adaptor hypothesis, **43**:125–128  
 local antibody conformation effect, **43**:17–18  
 lock-and-key fit, **43**:78, 128  
 MHR, **43**:42  
 mobile structural elements, **43**:80  
 nature of immune response, **43**:83  
 recognition and binding components, **43**:79  
 reconciling crystallographic and peptide mapping data, **43**:23–27  
 surface mobility role, **43**:16–17  
 synthesis of structural description, **43**:26  
 three-dimensional structures, **43**:119–120  
   complementarity, **43**:122  
   conformational changes, **43**:123–125  
   epitope and paratope size, **43**:120–121  
   epitope character, **43**:121–122  
   X-ray crystallography, **43**:8–11  
   X-ray structures, **43**:73  
 Antibody class switching, **61**:79–81  
   heavy chain isotype expression, **61**:82–84  
   problems in other studies, **61**:81–82  
   regulation of isotype specificity, **61**:84–89  
   switch recombination, **61**:99–130  
 Antibody complexes, crystallographic structures, **43**:4  
 Antibody-dependent cellular cytotoxicity, **41**:269, 273; **46**:114, 122; **58**:223  
 adoptive T cell therapy of tumors and, **49**:312–313  
 cytolysis and, **41**:275, 277–281, 283  
 eosinophil, for helminthic parasites, **60**:211–213  
 Fc $\gamma$ R-mediated, **60**:180  
 HIV infection and, **47**:384, 388, 405, 410, 413  
 hybrid resistance and  
   bone marrow cells, **41**:336, 338  
   effector mechanisms, **41**:376–378  
   lymphoid cells, **41**:351  
   macrophages, **41**:371  
   T cells, **41**:383  
 mechanisms  
   IBD and, **42**:294–295  
   NK cells and, **42**:191, 192, 203–204  
 membrane attack complex of complement, **41**:307  
 NK cells and, **47**:189, 190  
 antimicrobial activity, **47**:285  
 cytotoxicity, **47**:251, 253, 258  
 effector mechanisms, **47**:241–243  
 genetic control, **47**:222  
 malignant expansion, **47**:227, 228  
 reproduction, **47**:271, 272  
 surface phenotype, **47**:204, 212, 213  
 spontaneous autoimmune thyroiditis and, **47**:451, 452, 466, 469  
 Antibody diversity, *see* Arsonate idiotypic system, A/J mouse  
 Antibody effector function, human  
   bacterial Fc receptors, **51**:56–60  
   catabolism of antibodies, **51**:54–55  
   complement activation by, **51**:7–29  
   antibodies as activators of alternative pathway, **51**:28–29

- Antibody effector function (*continued*)
- C1 activation, **51:21–25**
  - C3 activation, **51:25–28**
  - C4 activation, **51:25–28**
  - cell lysis, **51:25–28**
  - interaction of C1q and antibody, **51:8–21**
  - conclusions, **51:62–64**
  - human leukocyte Fc Receptors, **51:29–54**
  - molecular explanation, **51:1–2**
  - structure, considerations, **51:2–7**
    - Fc, **51:2–4**
    - IgG, conformation and flexibility, **51:4–7**
    - other-antibody classes, **51:7**
- Antibody–hapten complexes, **43:119**
- Antibody isotype switching, **48:83–84**
- Antibody-mediated complement-dependent cytotoxicity, HIV infection and, **47:409, 410, 413**
- Antibody repertoire, generation in rabbit
- B cell development
    - B lymphopoiesis, **56:180–186**
    - immune response ontogeny, **56:186–187, 209**
  - development of repertoire
    - contributing factors, **56:194–195**
    - somatic gene conversion, **56:198–202**
    - somatic mutation, **56:201, 203**
    - V<sub>H</sub> allotype, **56:195**
    - V<sub>H</sub> usage, **56:195–198**
  - gut-associated lymphoid tissue
    - as bursal equivalent, **56:204**
    - follicular structure, **56:203**
    - germfree rabbits, **56:204–206**
    - model, **56:206–209**
  - Ig genes
    - C<sub>H</sub>, **56:191–193**
    - D, **56:189–191**
    - J<sub>H</sub>, **56:188–191**
    - κ light-chain, **56:193–194**
    - λ light-chain, **56:194**
    - organization, **56:187–188**
    - V<sub>H</sub>, **56:188–191, 195–198**
  - mechanism, **56:179–180, 209**
- Antibody response, **45:4**
- B cell proliferation and, **40:6–12**
  - Ir* genes and
    - gene dosage, **38:31, 80**
    - insulin, **38:142, 143**
    - T cell suppression, **38:135, 147**
    - T cell-T cell interactions, **38:154, 156, 157, 160**
    - tolerance, **38:128, 129**
    - model of, **40:1–2, 10, 45**
    - suppression by CTLs, **60:306–308**
    - T cell dependent, **40:3–4**
- Antibody secretion
- IBD and, **42:301–307**
  - inhibition by specific T cells, **40:139–140, 141**
- Anti-bromelaine-treated red blood cells, **46:72, 74**
- Anticardiolipin antibodies, **49:193, 259**
- affinity purification, **49:230–232**
  - antibody subsets, **49:233**
  - antimitochondrial antibodies, **49:249–250**
  - binding to cell membrane, **49:250–252**
  - clinical aspects, **49:203–212, 215–218, 220–224**
  - history, **49:199**
  - isotype, **49:224–227**
  - LA antibodies, **49:241, 243–247**
  - pathogenic potential, **49:254–255, 257**
  - reactivity, **49:248–249**
  - specificity, **49:234–240**
- Anticholinesterase drugs, MG and, **42:269–270, 271**
- Anticytokine therapy, **66:151**
- Anti-DNA transgenic model, **52:314–315**
- Antiendothelial antibodies, **49:252**
- Anti-eosinophil serum, parasite-infected animals and, **39:209**
- Antiergotypic T cell, **48:166**
- Antigen-antibody binding, first stage, **43:79**
- Antigen binding
- Ars A response and, **42:109, 139–141**
  - assay, *Ir* genes and, **38:35**
  - cachectin and, **42:225**
  - α chain, **42:168–172**
  - Ir* genes and
    - competitive inhibition, **38:108–110**
    - determinant selection, **38:98, 99**
    - Ia molecules, pigeon cytochrome c and, **38:99–104**
    - macrophages, **38:111–115**
    - T cell activation, **38:104–108**
    - T cell-T cell interactions, **38:155, 156, 160**

- Antigen-binding lymphocytes, **38:285, 286**
- Antigen bridging, T cell suppression and, **38:142, 143, 151**
- Antigen catabolism, *Ir* genes and, **38:95, 96**
- Antigen-dependent activation, **52:199**
- Antigenic determinants, *see* Epitopes
- Antigenicity
- chemistry, **43:2**
  - epitope prediction, **43:58**
  - flexibility, **43:105, 118**
  - relationship with local mobility, **43:61**
  - secondary structure, **43:76**
  - in terms of recognition frequency, **43:29–32**
  - value, **43:50**
- Antigenic microassemblies, **43:42**
- Antigenic peptide, KAVYNFATC, induced
- positive selection of thymocytes
  - Antigenic peptide, **59:126**
- Antigenic signaling, constraints to biochemical study of, **52:294–295**
- Antigen stimulation, **42:19–22**
- memory generation by, **53:221–223**
  - sensitivity of naive and memory T cells to, **53:228**
  - T cell differentiation after, **53:229–230**
- Antigenic variation, Delbrück model of, **38:340–344**
- Antigen-independent recruitment, T cells into tissues by endothelial cells, **50:274–287**
- expression of endothelial leukocyte adhesion molecules *in vivo*, **50:283–284**
  - extravasation of T cells, **50:285–287**
  - leukocyte adhesion molecules, **50:279–281**
  - migration of memory T cells to inflammatory sites, **50:278–284**
  - migration of naive T cells to lymph nodes, **50:275–278**
  - migration of pre-T cells to thymus, **50:275**
  - role of endothelial leukocyte adhesion molecules in lymphocyte binding *in vitro*, **50:281–283**
  - tissue-specific homing of lymphocytes, **50:284–285**
- Antigen-induced arthritis, **64:289**
- Antigen–MHC determinant, formation
- antigen competition, **43:208–211**
  - binding of antigen and MHC molecules in solution, **43:211–213**
  - immune response gene control, **43:206–208**
- Antigen–MHC interactions, **43:219**
- binding rate constants, **43:212**
  - correlation with immune-response phenotype, **43:212**
- Antigen pathway, alternate, and trapping of immune complexes, **51:265–269**
- Antigen polymerization, and B cell tolerance, **52:287–290**
- Felton's paralysis and other early results with polymers, **52:287–288**
  - polymeric antigens and IgE responses, **52:289–290**
  - size-fractionated polymers: Dintzis model, **52:288–289**
- Antigen presentation, *see also* Antigen processing and presentation
- by B cells, tolerance, **52:321–322**
  - Ir* genes and, **38:189**
  - antigen binding, **38:98–115**
  - antigen processing, **38:93–97**
  - blocking, **38:69–71**
  - complementation, **38:74–79**
  - cytotoxic T cells, **38:164, 165, 186**
  - expression, **38:55–60, 188**
  - gene dosage, **38:81**
  - H-Y antigen, **38:176, 177, 179**
  - Ia molecules, **38:83, 84**
  - I region mutations, **38:88–90**
  - MHC restriction, **38:64, 66**
  - T cells, **38:153, 157, 158, 160**
  - proliferation, inhibition of, **38:68, 69**
  - selection, **38:131, 133, 134**
  - suppression, **38:151, 152**
  - tolerance, **38:120, 122, 123, 125, 127, 128, 130**
- islet beta cell, **48:142**
- protein antigen, by cultured endothelial cells, **50:265–266**
- to T cells by
- B cell lymphomas, **39:54, 63–66, 86**
  - B cells, **39:52–54**
  - comparison with non-B cells, **39:85–86**
  - Ig role, **39:52–53, 55–56, 58–59**



- Antigen-presenting cells, **47:45–47**, **105**,  
**48:232**, **62:231**  
 adoptive T cell therapy of tumors and,  
**49:283**, **291**, **334**  
 expression, **49:324–325**, **328–329**, **331**  
 recognition, **49:319–321**, **323**  
 antigen presentation, **47:64**  
 allogeneic MHC products, **47:73–76**  
 H-Y antigens, **47:80**  
 MIs stimulation, **47:76–79**  
 protein, **47:65–73**  
 TNP-modified syngeneic cells, **47:79**, **80**  
 viral antigens, **47:80**, **81**  
 antigen processing  
 B cells, **47:89**, **90**  
 dendritic cells, **47:90**, **91**  
 MHC-peptide complexes, **47:87–89**  
 MHC products, **47:92**  
 for antitumor immunity, **58:436–437**  
 APC-T cell binding, **47:95–99**  
 autoimmune demyelinating disease and,  
**49:367**  
 autoimmune thyroiditis and, **46:266**, **317**  
 cellular immune responses, **46:289**,  
**294–297**  
 experimental models, **46:281**  
 autoimmunity, **47:104**, **105**  
 autoreactive T cells and  
 activation, **45:421–427**  
 origin, **45:419**  
 regulation, **45:432**  
 B cell formation and, **41:225**  
 CD23 antigen and, **49:167–168**  
 cell surface, **47:57**  
 CD5 leukocyte common antigen,  
**47:60**, **61**  
 integrins, **47:61**  
 MHC products, **47:57–60**  
 receptors, **47:62–64**  
 eosinophils as, **60:200**  
 helper T cell cytokines and, **46:112**,  
**128–130**  
 human T cell activation and, **41:1**, **30**  
 accessory molecules, **41:14**  
 cell surface molecules, **41:2**  
 T cell antigen receptor, **41:2**, **5**, **7**  
 humoral immune response and, **45:5–8**  
 B cells, **45:10–12**  
 cellular interactions *in vivo*, **45:79–**  
**81**, **84**  
 class II molecules, **45:18–20**  
 helper T cells, **45:24**, **30**, **31**  
 interleukins, **45:55**, **62–64**, **71**, **73**  
 physical interaction, **45:35**, **36**, **41**, **42**,  
**45**, **53**  
 processing, **45:8**, **9**, **12**, **13**  
 types, **45:9**, **10**  
*in vitro*, **45:21**  
*in vivo*, **45:21–24**  
 IgE biosynthesis and, **47:27**, **28**, **33**, **37**, **39**  
 immunogeneity, **47:101–104**  
 interaction with T cells, **47:92–94**  
 modification, **58:438**  
 SCID and, **49:384**, **387**, **393**  
 sporozoite malaria vaccine and, **45:287**,  
**305**, **307**, **316**  
 surface antigens of human leukocytes and,  
**49:77–78**, **80**, **82–83**, **87**  
 synthetic T and B cell sites and, **45:197**,  
**201**, **202**  
 antigens, **45:232**, **237**  
 globular protein antigens, **45:215**  
 prediction, **45:252**  
 viral antigens, **45:220**, **225**  
 T cell-dependent antibody responses  
 B cells, **47:81**, **82**, **84–86**  
 dendritic cells, **47:83**  
 helper T cell subsets, **47:83**, **84**  
 T cell growth, **47:99–101**  
 T cell receptor and, **45:107**  
 accessory molecules, **45:108**, **109**  
 alloreactivity, **45:153**  
 antigen processing, **45:118**, **120**, **123**,  
**124**, **127**  
 epitopes, **45:143**, **144**  
 homogeneity, **45:129**  
 MHC molecules, **45:116**  
 peptides, **45:132**, **138**  
 T cell repertoire, **45:165**  
 T cell subsets and  
 H-2 alloantigen recognition, **41:80**, **83**,  
**88**, **92**  
 H-2 molecules in thymus, **41:100–102**,  
**105**, **107**  
 H-2-restricted antigen recognition,  
**41:53**, **56**, **58**, **60–62**, **68**, **70**, **74**, **75**  
 T cell specificity, **41:110**, **111**  
 T cell triggering, **41:111**, **112**  
 T cell surface molecules in communication  
 with, **58:112–139**

- TH response, **61:361–364**
- tissue distribution
- circulation, **47:54–57**
  - delayed-type hypersensitivity, **47:57**
  - life span, **47:49, 50**
  - lymphoid organs, **47:50–52**
  - nonlymphoid organs, **47:52–54**
  - origin, **47:47–49**
- virus-induced immunosuppression and, **45:366**
- Antigen processing, **52:11–78; 64:1–3**
- by B cell lymphomas, **39:63–66**
  - by B cells, **39:63–66, 87**
  - entry of proteins into class I processing pathway, **52:13–14**
  - Ir* genes and, **38:93–97, 152, 172, 188**
  - by macrophages, **39:62–66**
  - MHC class I-associated peptides, generation, **64:16–31**
  - preliminaries, **52:11–13**
  - proteasome system, **64:8–32**
    - activator protein, **64:21–24**
    - cleavage properties, **64:24–26**
    - inhibitors, **64:11–12**
    - LMP and IFN- $\gamma$  regulation, **64:12–14**
    - molecular adaptation, **64:19–21**
    - structural and catalytic features, **64:8–11**
    - subunits X/Y and immunoproteasomes, **64:14–16**
    - subunits Z and MECL1, **64:16–18**
    - threonine residues, **64:18–19**
  - proteolytic degradation, **39:63–64, 66**
  - regulation of antigen processing, **52:76–78**
  - TAP system, **64:3–5, 30–31**
  - T cells, **43:196–197**
  - translocation, **52:35–42**
  - ubiquitin system, **64:3, 5–8**
  - unfolding, **52:22**
  - unfolding and proteolysis, **52:22–78**
    - assembly of class I molecules, **52:42–76**
    - control of class I export to cell surface, **52:62–76**
    - proteolysis, **52:22–35**
- Antigen processing and presentation
- class Ib molecules, **52:92–104**
    - characteristics of individual class Ib products, **52:94–104**
    - general aspects of structure and function, **52:92–94**
  - clinical relevance: immune, autoimmune and immunodeficiency states, **52:106–108**
  - autoimmunity, **52:107**
  - novel immunodeficiency states, **52:107–108**
  - tumor immunology, **52:104–106**
  - vaccines, **52:106–107**
- immune system evolution, **52:1–11**
- history of discovery of MHC restriction, **52:4–6**
  - overview of T cell recognition and function, **52:1–4**
- properties of cell surface class I molecules, **52:78–92**
- association with exogenous  $\beta$ 2m, **52:86–87**
  - interaction with exogenous peptides, **52:78–86**
  - internalization, **52:87–92**
    - evidence for internalization, **52:87–89**
    - internalization signals, **52:89–92**
- T<sub>CD8+</sub>, what it recognizes, **52:104–111**
- clinical relevance of antigen processing and presentation, **52:104–108**
- Antigen receptor
- genes, V(D)J joining, *see* V(D)J joining, antigen receptor genes
  - homology motif, signal transduction role, **57:81–83**
  - loci, V–D–J recombination, **61:304–306**
  - modulation, **59:322–324**
  - structure, **43:105–107**
- Antigen receptor-dependent activation
- cytokines and B cell differentiation, **52:204–206**
    - IL-2, **52:204–205**
    - IL-4, **52:205–206**
    - other stimulatory cytokines, **52:206**
  - cytokines and B cell growth, **52:195–200**
  - antigen-dependent activation, **52:199**
  - polyclonal activators, **52:195–199**
    - IL-2, **52:195–196**
    - IL-4, **52:196–198**
    - other stimulatory cytokines, **52:198–199**
    - transforming growth-factor,13, **52:199**
- Antigen recognition, **43:60, 223–225**
- altered self model, **43:202**
  - antigen dose-response curve, **43:202**

- Antigen recognition (*continued*)
- chemistry, **43:6**
    - amino acid residues, **43:27**
    - antigenicity in terms of recognition frequency, **43:29–32**
    - reactive site stereochemistry, **43:32–39**
    - systematic data base, **43:27–29**
  - class II MHC molecules, **43:203–205**
  - difference between T and B cells, **43:134**
  - dual recognition, **43:202**
  - hydrogen bonds and electrostatic forces, **43:83**
  - hypothesis for origin, **43:224**
  - mechanisms, **43:39**
    - critical residues, **43:39–42**
    - induced complementarity, **43:42–46**
  - MHC-restricted, **43:202–203**
  - T cell, **43:194**
  - T cell receptor As, **43:176**
- Antigens, **43:117–119**
- ABC transporters, **65:55, 56–57, 59**
  - adoptive T cell therapy of tumors and, **49:281–285, 334–335**
    - expression of antitumor responses, **49:324, 327, 329–332**
    - macrophages, **49:307–308, 311–312**
    - mechanisms, **49:299–301, 304, 313, 318**
    - principles, **49:287, 289–290, 295–296, 298**
    - recognition, **49:318–324**
  - and antigen recognition, **58:318–324**
  - antinuclear antibodies and, **44:93, 94, 120**
    - autoantibodies, **44:126, 127, 137, 138**
    - autoantigen, **44:127–131**
    - autoimmune response, **44:131–134, 136**
    - dermatomyositis, **44:118–120**
    - drug-induced autoimmunity, **44:109**
    - scleroderma, **44:114, 121–125**
    - Sjögren's syndrome, **44:111–113, 118**
    - SLE, **44:95, 100–107**
  - aPL antibodies and, **49:193–194, 256, 258–259**
    - affinity purification, **49:228**
    - clinical aspects, **49:200, 205**
    - history, **49:198–199**
    - LA antibodies, **49:241, 243**
    - specificity, **49:234–239, 248–251**
  - Ascaris*, inhalation challenge, **60:168–169**
  - autogeneic, *see* Autoantigens
  - autoimmune demyelinating disease and, **49:368–370, 372–374**
  - autoimmune thyroiditis and, **46:263, 265–273, 317–319**
    - cellular immune responses, **46:288, 289, 291, 293–295, 297, 298**
    - experimental models, **46:273, 276, 281**
    - genetic control, **46:284, 285**
    - humoral responses, **46:298, 299, 302–305, 307**
    - prevention, **46:310, 312, 314–316**
  - autoreactive T cells and, **45:417, 418, 433**
    - activation, **45:421–426**
    - origin, **45:418–421**
    - physiology, **45:427, 428, 430, 431**
    - regulation, **45:431, 432**
  - bacterial, IBD and, **42:290**
  - based vaccination strategies, **58:435–437**
  - B cell, **52:173–174, see also** B cell surface antigens
    - Bgp 95, **52:173**
    - CK226 antigen, **52:173**
    - IgM-binding protein (Fc $\mu$  receptor), **52:173**
  - B cell anergy, **59:321–322**
  - B cell elimination, **59:306–308**
  - B cell populations and assessment, **42:19–22**
    - secondary, **42:75**
  - binding by B cells, activation and, **39:71**
  - BrMRBC, autoantibodies, secretion by CD5 B cells, **55:315–316**
  - CD1-restricted, **59:78–87**
  - CD2, role in T cell death, **58:226**
  - CD3, expression during NK cell maturation, **55:346**
  - CD4 and CD8, **44:265–270, 299–302**
    - CD4 molecular biology, **44:293, 295**
    - CD8 molecular biology, **44:270, 272, 282, 284**
    - on IELs, **58:306–307**
  - CD4<sup>+</sup>CD8<sup>-</sup>, majority of  $\gamma\delta$  T cells as, **58:102**
  - CD4/CD8 coreceptor, role in negative selection, **58:171–172**
  - CD5 B cell and, **47:117, 118, 120, 161**
    - bone marrow transplantation, **47:129**
    - genetic influence, **47:148**
    - Ig gene expression, **47:150, 151, 155, 156, 158**

- lineage, **47:129**  
 malignancies, **47:123, 124**  
 marker for activation, **47:125, 126**  
 ontogeny, **47:122**  
 physiology, **47:131, 133–136, 138–143**  
 primordial immune network, **47:159–161**  
 surface, **47:143–147**
- CDw60, on CD4<sup>+</sup>8<sup>+</sup> T cells, **58:108–109**  
 changes in amino acid side chain, **43:24**  
 clustered, *see* Clustered antigens  
 competition, **43:208–211**  
 complementarity-determining regions, **43:9–10**  
 complementarity induced by, **43:20–23**  
 complement receptor 1 and, **46:200**  
 complement receptor 2 and, **46:205, 207–209, 211**  
 concentration, effect of Fc fragments and, **40:91**  
 conformational changes, **43:123–124**  
 conformational hierarchy levels, **43:74**  
 differentiation in avian T cells, **50:88–89**  
 electrostatic recognition with antibody, **43:12–13**  
 environmental, influences on GALT, **40:207–209**  
 eosinophil, recognition by antisera, **39:183–184**  
 epithelial, **62:238–239**  
 epitopes, *see* Epitopes  
 equivalence, **43:68–72**  
 evolution, **52:1–11**  
   history of discovery of MHC restriction, **52:4–6**  
   overview of T cell recognition and function, **52:1–4**  
   T<sub>CD8+</sub>, what it recognizes, **52:6–11**  
     nature of antigens bound to class I molecules, **52:8–10**  
     what T cell antigen receptor sees, **52:10–11**
- expression, hybrid resistance and  
   genetics of, **41:397–401**  
   hemopoietic cell grafts, **41:404–407**  
   Hh-1, **41:401–403**  
   marrow allograft reactivity, **41:408–410**  
   transplanted cells, **41:403, 404**
- Fas, **57:129–131**  
 flexibility, **43:118–119**  
 follicular dendritic cell expression of, **51:257–261**  
 foreign, CD5 B cell response, **55:318–319**  
 fragment properties, **43:204**  
 ganglioside, *see* Ganglioside antigens  
 genetically engineered Abs and, **44:65, 66, 89**  
   antigen-combining sites, **44:84, 85**  
   chimeric antibodies, **44:79, 80, 87, 88**  
   cloning, **44:75**  
   expression, **44:76–78**  
   fusion proteins, **44:85**  
   production, **44:66, 67**
- global structure, binding process, **43:22**  
 glycoprotein, *see* Glycoprotein antigens  
 heat-stable, for B and T cells, **53:235–236**  
 helper T cell cytokines and, **46:111**  
   cross-regulation of differentiation, **46:130–132**  
   differential induction, **46:128–130**  
   functions, **46:114, 115, 117–122**  
   immune responses, **46:138**  
   precursors of differentiation states, **46:122–127**  
   secretion patterns, **46:112, 113**
- HIV infection and  
 activation, **47:398, 400, 402**  
 etiological agent, **47:378, 380, 383, 384**  
 immune response, **47:408–410**  
 immunopathogenic mechanism, **47:388, 390–392, 394, 397**  
 neuropsychiatric manifestations, **47:404**
- homing of plasma cell precursors and, **40:205**
- humoral immune response and, **45:2, 5–7**  
 cell surface molecules, **45:41–46**  
 cellular interactions *in vivo*, **45:79, 80, 82–85**  
 helper T cells, **45:24–33, 35**  
 lymphokines, **45:46–54**  
 physical interaction, **45:35–41**  
 presentation, **45:9–12, 15–24**  
 processing, **45:8, 9, 12–15, 17, 18**
- Ia, *see* Ia molecules
- IBD and  
 Crohn's disease, **42:289**  
 cytotoxic effector cells, **42:297**  
 DR, **42:288, 292–294**  
 lymphocytes, **42:290**  
 somatic mutations and, **42:34**

Antigens (*continued*)IFN- $\gamma$  and, **62:80**IgE biosynthesis and, **47:1**antibody response, **47:3-6, 8, 10, 11**antibody response suppression, **47:28, 29, 31-39**binding factors, **47:12, 14, 15, 21, 23-28**Ig gene superfamily and, **44:1**evolution, **44:5, 462!!**homology unit, **44:4**MHC complex, **44:24-26, 28, 29**nonimmune receptor members, **44:29-31, 34-36, 38, 39, 41**receptors, **44:9-12, 17, 18, 20, 23, 24**Ig heavy-chain variable region genes and, **49:26, 28, 34, 54**V<sub>H</sub> gene expression, **49:36, 39, 41-43, 49, 51-52**IL-1 and, **44:154, 189, 192**biological effects, **44:166**immunocompetent cells, **44:173-175, 177**structure, **44:156**systemic effects, **44:169, 171**immunosenescence and, **46:253**lymphocyte activation, **46:222-224, 228, 231, 235**lymphocyte subsets, **46:237**mucosal immunity, **46:253**regulatory changes, **46:249-251**stem cells, **46:247**interaction energy, **43:23-24**intestinal, IBD and, **42:290***Ir* genes andblocking, **38:70, 71**competitive inhibition, **38:108-110**cytotoxic T cells, **38:161, 163-165, 170-174**

expression

in B cells, **38:57, 58**in lymphoid tissue, **38:162, 190**in T cells, **38:62, 190**gene dosage, **38:80**gene function, **38:92**genetic control, **38:34-36**H-Y, *see* H-Y antigenimmunodominance, **38:181, 184, 185**macrophages, **38:111-115**MHC, **38:44, 46, 188**MHC restriction, **38:64-67**mutations, I region, **38:84-90**pigeon cytochrome c, **38:77-79**positive T cell selection, **38:130-134**response to polypeptides, **38:46, 49**suppression, **38:134, 135, 137-142, 144, 148, 150, 152**T cells, **38:40, 41, 43, 154, 160**activation, **38:105-108**proliferation, inhibition of, **38:68**repertoire, **38:117, 118**tolerance, **38:120, 123, 125-129**leukocyte integrins and, **46:149, 153, 161-163, 169**lymphocyte homing and, **44:313, 314**carbohydrate, **44:360-362, 371**high endothelial venules, **44:321**inflammation, **44:340, 341**molecules, **44:342, 343, 345, 347-352**regional specificity, **44:326, 327, 330-338**lymphocyte hybridomas and, **38:275, 276**donor lymphocytes, **38:283**EB nuclear, **38:277**human-human, **38:297**human-murine, **38:290**maps of Ig-like loci and, **46:1, 7, 29, 31, 32, 34**MHC, *see* Major histocompatibility complex antigensmicrosomal, autoimmune thyroiditis and, **46:266, 273, 298, 299**multiple antigen peptides as, **60:137-139**murine lupus models and, **46:65, 99**Ig germline, **46:72, 74, 76-78**T cell antigen receptor, **46:81, 90, 91**mutants, **43:117-118**mycobacterial, recognition, **58:321-322**neuroimmunology and, **39:299-300**NK cell, *see* Natural killer cells, surface antigensNK cells and, **42:182, 183; 47:187-190**adaptive immunity, **47:292, 293, 295**alterations, **47:302**antimicrobial activity, **47:288, 289**CNS, **47:266**congenital defects, **47:226**differentiation, **47:232, 233**effector mechanisms, **47:235, 237-240, 247, 248**genetic control, **47:222**

- hematopoiesis, **47:273, 275, 281, 282**  
 lymphokine production, **47:264**  
 malignant expansion, **47:227**  
 regulation, **47:257, 259, 261**  
 reproduction, **47:271, 272**  
 surface phenotype, **47:200–212**  
 tissue distribution, **47:221**  
 nonclustered, B cell, *see* Nonclustered antigens, B cell  
 non-self, *see* Non-self antigens  
 nonspecific killing, **60:302**  
 parasitic, synthetic T and B cell sites and, **45:228–230**  
 peptide, *see* Peptide antigens  
 plasmacyte, **52:174**  
   other antigens of plasmocytes, **52:174**  
   PC-1, a plasma cell threonine-specific protein kinase, **52:174**  
 polymeric, and IgE responses, **52:289–290**  
 position-specific, leukocyte integrins and, **46:153**  
 pulmonary immunity, **59:387–388**  
 regulators of complement activation and, **45:381, 389**  
 replaceability, amino acids, **43:69–70**  
 residues, definition, **43:23**  
 responses to, enhancement by V $\beta$  selective elements, **50:36–37**  
 schistosome  
   Sm23, **60:126–127**  
   Sm28-GST, **60:127–128**  
   TPI, **60:125–126**  
 SCID and, **49:381–388**  
   graft-versus-host disease, **49:398**  
   lack of stem cell engraftment, **49:397**  
   posttransplant immunocompetence, **49:400, 402**  
   stem cell engraftment, **49:391**  
   tolerance, **49:398–399**  
   transplantation, **49:393–395**  
 self-, *see* Self-antigens  
 sites, hydrophilicity, **43:76**  
 specific activation, molecular basis, **54:337–338**  
 specific killing, CTL-mediated, **60:292–303**  
 sporozoite malaria vaccine and, **45:283, 319–322**  
   CS proteins, **45:299**  
   CS-specific T cells, **45:307–311**  
   endemic areas, **45:317**  
   human trials, **45:314**  
   immunity, **45:287, 291, 292**  
   interferon- $\gamma$ , **45:304–306**  
   *Plasmodium vivax*, **45:318**  
 staphylococcal protein A, antibodies to, **57:229**  
 structural characteristics, antibody-binding sites, **43:118**  
 superantigens, *see* Superantigens  
 surface  
   accessibility, **43:119**  
   NK cell, *see* Natural killer cells, surface antigens  
 surface, human leukocyte, **49:75–76, 116–126**  
   adhesion molecules, **49:82–89**  
   antigen-specific receptors, **49:76–80**  
   expression, **49:113, 116–117, 119–124**  
   membrane enzymes, **49:111–114**  
   MHC glycoproteins, **49:80–82**  
   receptors  
     chemotactic, **49:111**  
     for complement components, **49:91–94**  
     for growth factors, **49:99–101**  
     for Igs, **49:89–91**  
     for interleukins, **94, 49:98–99**  
     membrane proteins, **49:93–97**  
     for neurotransmitters, **49:101, 111**  
     T cell molecules, **49:101–110**  
   transport proteins, **49:114–116**  
 synthetic T and B cell sites and, **45:195, 197, 260–264**  
   bacterial antigens, **45:230–232**  
   candidate synthetic peptide vaccines, **45:253–259**  
   globular protein antigens, **45:203–216**  
   immunological considerations, **45:197–202**  
   parasitic antigens, **45:230**  
   peptides, **45:203, 232–250**  
   prediction, **45:251**  
   viral antigens, **45:216–228**  
 tac, **59:228**  
 tachyzoite, **65:208**  
 T and B cell sites and, **45:197, 263**  
   antigens, **45:209, 212–214, 234–236**  
   immunology, **45:198–200, 202**  
   prediction, **45:252**  
   viral antigens, **45:217, 218, 221, 225, 226**

Antigens (*continued*)

- T cell development and, **44:207, 208, 255**
    - antigen recognition, **44:209, 210, 212–214**
    - cellular selection within thymus, **44:245–254**
    - ontogeny, **44:215, 219, 220, 221**
    - recognition, **44:209–214**
    - thymocyte subpopulation, **44:228, 239, 241–243**
  - T cell-independent, examples, **40:2–3**
  - T cell receptor and, **38:2**
    - protein properties, **38:3–5**
    - specific binding, **38:19, 20, 23**
    - target recognition, **38:22, 23**
  - three-dimensional structures, **43:117**
  - thymus-dependent and -independent, **60:272–277, 63:43**
  - transplantation, tumor-specific,
    - characteristics, **57:285**
  - tumor, *see* Tumor antigens
  - tumor immunogenicity affected by low
    - level of expression, **57:303–305**
  - uptake by B cells, **39:59–62**
    - comparison with macrophages, **39:60–62**
    - Ig role, **39:60–62**
  - valency, **59:302–305, 308**
  - virus-induced immunosuppression and
    - HIV, **45:351–353, 355–358, 360–362, 365–367**
    - measles, **45:339, 344, 346, 347**
  - Antigen specificity
    - Ir* genes and
      - alloreactivity, **38:121–123**
      - antigen binding, **38:101, 106, 107**
      - antigen processing, **38:96**
      - B cell response, **38:50**
      - cytotoxic T cells, **38:162, 164, 167, 171–174**
      - expression, **38:53, 55, 57, 60**
      - gene function, **38:37, 38, 93**
      - genetic regulation, **38:36, 37, 188**
      - immunodominance, **38:181, 183, 184**
      - macrophages, **38:111**
      - MHC, **38:46**
      - “Schlepper” experiment, **38:39, 40**
    - T cells, **38:41–43**
      - interactions, **38:153–158, 160**
      - receptor, **38:115–117**
        - selection, **38:131**
        - suppression, **38:135, 136, 140, 149, 151, 152**
        - lymphocytes hybridomas and
          - B cells **286, 38:306**
          - human-human hybridomas, **38:296**
    - Antigen-specific recognition, T cell cultures
      - for, **42:165–166**
  - Anti-H-2Kk transgenic model, **52:311–313**
  - Antidiotypes, *see* Antibodies, anti-Id
  - Antidiotypic immunoregulation, B cell
    - repertoire expression and, **42:35, 82**
  - Antidiotypic recognition, B cell repertoire
    - expression and, **42:51–62**
  - Antiinflammatory cytokines
    - IL-6 effect, **54:27–28**
      - during placental/fetal development, **54:32**
      - role in embryonic development, **54:31–32**
    - rheumatoid arthritis and, **64:291, 295–296**
  - Antiinflammatory drugs
    - mode of action, **64:172, 195–196**
    - receptors, **52:402–404**
    - receptors for, **52:402–404**
  - Antiinflammatory and immunosuppressive
    - molecules, NF- $\kappa$ B as target, **65:128–132**
  - antioxidants and, **65:122–123**
  - anti-TNF- $\alpha$  antibodies, **65:123–124**
  - cAMP and, **65:124–125**
  - cyclosporin A and FK506, **65:120**
  - deoxyspergualin and, **65:125–126**
  - gliotoxin and, **65:126–127**
  - glucocorticoids and, **65:118–120**
  - gold compounds and, **65:123–124**
  - rapamycin and, **65:121**
  - reactive oxygen intermediate-generating
    - molecules and, **65:122–123**
  - rheumatoid arthritis drugs and, **65:123–124**
  - salicylates and, **65:121–122**
  - spergualin, **65:125–126**
  - steroids and, **65:118–120**
- Antimicrobial activity, NK cells and, **47:282–291**
- Antimitochondrial antibody, **49:219–220, 233, 249–250**
- Antinuclear antibodies, **44:93, 94; 49:210, 212, 219**
  - autoantibodies
    - biology, **44:136–138**
    - rare occurrence, **44:125–127**

- autoantigen  
   function, **44**:127, 128  
   molecular cloning, **44**:128–131  
 autoimmune response, **44**:131, 132  
   antigen driven, **44**:132  
   epitopes, **44**:134–136  
   immunogens, **44**:132–134  
 dermatomyositis, **44**:113, 118–120  
 drug-induced autoimmunity, **44**:109–111  
 localization, **44**:120  
   autoantibodies, **44**:125, 127  
   autoimmune response, **44**:133  
   scleroderma, **44**:121, 122, 125  
   SLE, **44**:106, 107  
 mixed connective tissue disease, **44**:111, 112  
 polymyositis, **44**:113, 118–120  
 scleroderma, **44**:114, 120, 121  
   centromere antigens, **44**:121, 122  
   nuclear antigens, **44**:122–125  
 Sjögren's syndrome, **44**:111–113, 115–118  
 SLE, **44**:94–97  
   DNA, **44**:97, 98  
   histones, **44**:98–100  
   ku, **44**:104, 105  
   PCNA, **44**:106–109  
   ribosomal RNP, **44**:105, 106  
   RNP, **44**:100–102  
   subcellular particles, **44**:102–104  
 Antioxidants, NF- $\kappa$ B and, **65**:122–123  
 Antipain, T cell receptor and, **45**:124  
 Antiphospholipid antibodies, **49**:193–194, 257–259  
   biochemistry, **49**:194–197  
   clinical aspects  
     autoimmune disorders, **49**:207–210  
     detection methods, **49**:200–206  
     drug-induced antibodies, **49**:212–213  
     genetic studies, **49**:221–222  
     infectious disease, **49**:210–212  
     normal populations, **49**:206  
     syndromes, **49**:213–221  
     treatment, **49**:222–224  
   history, **49**:198–199  
   immunology  
     aCL antibodies, **49**:236–240  
     affinity purification, **49**:228–231  
     antimitochondrial antibodies, **49**:249–250  
     binding, **49**:250–252  
     isotype, **49**:224–228  
     LA antibodies, **49**:240–248  
     reactivity, **49**:248–249  
     reagin, **49**:234–236  
     specificity, **49**:233–234  
     subsets, **49**:231–233  
     pathogenic potential, **49**:252–257  
   Antiphospholipid syndrome, **49**:218–221, 235, 243  
   Antiproliferative effect, IFN- $\gamma$ , **62**:76–77  
   Antisense *myc*, blocking of negative signaling, **54**:413–415  
   Antisense oligonucleotides, **58**:249–250  
   Antisera, anti-MHR, polyclonal, **43**:29  
   Antithrombin III, **49**:256; **66**:238  
   Antithrombotic treatment, **49**:223, 258  
   Anti-TNF- $\alpha$  therapy, **64**:333–334, *see also*  
     cA2 therapy  
     anti-CD4 with, **64**:332  
     combination therapy, **64**:331–333  
     Crohn's disease, **64**:307–309  
     drug modalities, **64**:330–331  
     HIV and AIDS, **64**:311  
     mode of action, **64**:311–323, 330  
     problems, **64**:323–330  
       anti-double-stranded cDNA antibodies, **64**:325  
       anti-Ig antibodies, **64**:323–325  
       malignancy risk, **64**:329–330  
       susceptibility to infection, **64**:325–329  
     rheumatoid arthritis, **65**:124  
     animal models, **64**:298  
     cA2, **64**:299–305, 311, 312–315  
     clinical studies, **64**:299–307  
     sepsis, **64**:310–311  
     synergies with other treatments, **64**:331–333  
     ulcerative colitis, **64**:309–310  
   Anti-transgenic models, with absent or partial B cell tolerance, **52**:315–317  
    $\alpha_1$ -Antitrypsin, **62**:266  
   Antitumor activity, NK cells and, **47**:295–300  
   Antiviral activity, NK cells and, **47**:282–288  
   Antiviral therapy  
     for FeLV, **52**:436–437  
     and vaccines, use to study, **52**:440–441  
   AP-1, interaction with NF-IL6, **65**:18–19  
   AP1-Ets interactions, **64**:81  
   AP-1 family, **65**:29  
   Apamin, synthetic T and B cell sites and, **45**:232



- Apigenin, action of, **65:123**
- aPL antibodies, *see* Antiphospholipid antibodies
- Aplasia, hybrid resistance and, **41:349, 372, 376, 388**
- Aplastic anemia, **41:236, 350**  
graft rejection by patients, **40:383–385**
- Apo-1/Fas membrane-spanning proteins  
induction of PCD, **58:135–136**  
and negative selection, **58:172–173**  
role in T cell death, **58:226**
- Apolipoprotein J, **61:249–251**
- Apo-MHr, monoclonal anti-MHr antibody  
affinity, **43:61–62**
- Apoptosis, **52:157; 59:177; 61:9, 17, see also**  
Cell death  
abnormal regulation, **58:214–215**  
adoptive T cell therapy of tumors and, **49:312**  
Bcl-2 effects, **58:137**  
biochemical pathways, **50:60–61**  
CD4<sup>+</sup>8<sup>-</sup> cells, linomide effects, **58:263–265**  
CD23 antigen and, **49:155, 171**  
*c-myc* gene, **63:162**  
control during intrathymic development, **58:168–174**  
cytotoxic T cells, TCR-driven, **58:243**  
different types, classification, **58:265–267**  
due to cell damaging agents, **58:237–240**  
eosinophil  
aspect of senescence, **60:162**  
in culture, **60:160**  
TGF $\beta$ -induced, **60:184**  
Fas antigen/APO-1 role, **53:241–242**  
Fas ligation, **61:37, 39**  
Fas-mediated, **57:129, 133–134, 140**  
germinal center B cells, **60:282–283**  
and growth arrest induced by anti-IgM, **54:410–411**  
HIV-induced, **58:236–237**  
HIV-specific CTLs, **65:306**  
hypothetical steps, **58:241**  
in immune system, **50:63–70**  
in B cells, **50:63–66**  
clonal abortion, **50:64**  
definitions, **50:55–56**  
faulty recombination, **50:63–64**  
growth arrest of WE III-231 B cell line, **50:64–65**  
mechanisms, **50:56–63**  
apoptosis, morphology, **50:56–57**  
biochemical pathways, **50:60–61**  
DNA damage, **50:57–60**  
phagocytosis, surface changes resulting in, **50:62–63**  
somatic mutation and terminal differentiation, **50:65–66**  
in T cells, **50:66–69**  
CTL targets, death, **50:69**  
deprived of growth factors, **50:68–69**  
hybridomas, activation-induced death, **50:67**  
interphase death of T and B cells and nonspecific damage, **50:69–70**  
non-selected thymocyte, death, **50:67–68**  
splenic B cells, **50:65**  
thymus, negative selection, **50:66**  
triggering and regulation, **50:71–73**  
induction activation of death genes, **50:71–73**  
release of death program, **50:75–76**  
transduction, **50:73–75**  
inducing signals, **58:89**  
induction by Apo-1/Fas, **58:135–136**  
induction via TCR/CD3 complex, **58:216–219**  
inhibition of, **51:272–274**  
leukocyte, **58:280–281**  
as mechanism of T cell negative selection, **58:166–168**  
modulation, functional consequences, **58:272–280**  
morphology, **50:56–57**  
and nuclear DNA fragmentation, **58:212–213**  
and positive and negative selection of T cells, **58:89**  
Ras protein, **63:146–147**  
regulation, multiple pathways, **58:265–268**  
role in neonatal B cell tolerance, **54:403–404**  
role of reactive oxygen species, **58:250**  
and signal transduction pathways, **58:268–269**  
surface antigens of human leukocytes and, **49:117**  
susceptibility of murine lymphocytes, **58:234**

- target cell, Ca<sup>2+</sup>-independent, **58:226**
- T cell  
 and IL-2, **50:166–167**  
 immunopharmacological manipulation *in vivo*, **58:254–255**  
 pharmacology, **58:211–296**  
 role of p53, **58:138**  
 and T cell persistence, **58:273–275**  
 thymocytes, **58:166–170**  
 TNF and, **66:114**
- Appendix, germinal centers, in rabbit,  
 rearrangements of VDJ genes, **56:204**
- Arachidonate  
 cyclooxygenase reaction, **62:178–183**, 198  
 metabolism  
 cachectin and, **42:219**  
 IBD and, **42:314**
- Arachidonic acid, **42:311**  
 corticosteroids and, **42:316**, 318  
 cyclooxygenase pathway, **39:147**  
 inhibition by EPA and docosahexaenoic  
 acid, **39:160**, 164–165  
 formation from N-3 and N-6 fatty acids,  
**39:159–160**  
 hybrid resistance and, **41:360**  
 5-lipoxygenase pathway, **39:147–151**, 153,  
 160–161  
 metabolism  
 in eosinophils, human, **39:204**, 207–208  
 in neutrophils, human  
 dietary EPA and, **39:166–167**  
 nonesterified and esterified EPA and,  
**39:167–168**
- Arachidonic acid metabolite receptors,  
**52:398–402**  
 other arachidonic acid derivatives,  
**52:401–402**  
 prostaglandin binding sites, **52:399–401**
- Arachidonic acid metabolites  
 Fc fragments and, **40:107**  
 immune complexes and, **40:74**  
 receptors, **52:398–402**  
 suppressive properties of, **40:100–106**
- ARDS, *see* Adult respiratory distress  
 syndrome
- Arg120, **62:175**  
 Arg277, **62:174**  
 Arginine, **42:97**, 141–144  
 Arginine analogs, as NOS inhibitors, **60:325**
- Arsonate, genetically engineered antibody  
 molecules and, **44:79**, 84
- Arsonate idiotypic system, A/J mouse  
 general considerations in, **42:95–96**,  
 157–158
- J558 V<sub>H</sub> gene family and, **42:112–115**  
 deletion mapping analysis, **42:133–137**  
 evolution, **42:123**, 125–127  
 expressed and germline sequences,  
**42:127–128**  
 structural features, **42:115–117**  
 subfamilies, **42:117–123**, 124
- light chain  
 arginine, **42:141–144**  
 hybridomas, **42:139–141**  
 K locus, **42:138**  
 Vκ10, **42:144–148**
- methodology for, **42:96–99**
- molecular genetics, heavy chain  
 cross-reactive idiotype-positive  
 molecules, **42:109–110**
- DFL16.1 gene segment, **42:105–107**
- J<sub>H</sub> gene segment, **42:107–108**  
 kinetics, **42:108–109**  
 repetitive substitutions, **42:110–111**  
 serine, **42:111–112**  
 single V<sub>H</sub> gene segment, **42:99–105**
- murine V<sub>H</sub> complex and  
 deletion mapping analysis, **42:133–137**  
 idiotypic V<sub>H</sub> map, **42:129–130**  
 inbred strains, **42:137**  
 preferential utilization, **42:131–133**  
 southern filter hybridization analysis,  
**42:130**
- serologic and structural analysis of Ab2  
 antibodies and, **42:149–150**  
 CR-A, **42:150–151**  
 D<sub>H</sub> segments, **42:154–157**  
 heterogeneity, **42:151–154**  
 V<sub>H</sub> complex organization and, **42:128–129**
- Arthritis, **59:146**, 343; **61:46**, 252, 367, *see*  
*also* Juvenile Rheumatoid arthritis;  
 Rheumatoid arthritis  
 adjuvant-induced, **64:289**  
 antiadhesion therapy, **64:197**  
 antigen-induced, **64:289**  
 autoimmune, **62:99–100**, 107  
 autoimmune thyroiditis and, **46:284**, 310,  
 312

- Arthritis (*continued*)  
 collagen-induced, autoimmune thyroiditis  
 and, **46:312**  
 and IL-1ra  
 in animal models, **54:210**  
 in patients with arthritis, **54:210–211**  
*in vitro* studies, **54:209–210**  
 IL-8 role in, **55:143–144**  
 induction, **64:289**  
 inflammatory, IL-1ra in, **54:209–211**  
 animal models, **54:210**  
 patients with, **54:210–211**  
*in vitro* studies, **54:209–210**  
 joint erosion in, **64:287–288**  
 lymphocyte migration into, **64:191**  
 murine lupus models and, **46:61, 75, 79, 90**  
 NO-induced, **60:343–344**  
 pituitary hormones, **63:421–422**  
 transgenic model, **64:298**  
 Arylsulfatase, in eosinophils, **39:218**  
 ASFV, *see* African swine fever virus  
 ASLC, **48:132**  
 Asn410, **62:178**  
 Asn580, **62:174**  
 Asp<sup>57</sup>  
 IDDM, **48:135–137**  
 location, **48:139**  
 Asparagine  
 cytotoxic T cells and, **41:152; 153**  
 genetically engineered antibody molecules  
 and, **44:69, 84**  
 Aspergillosis, allergic bronchopulmonary, *see*  
 Allergic bronchopulmonary aspergillosis  
 Aspergillus infections, gliotoxin, **65:126–127**  
 Aspirin  
 antiplatelet cardiovascular therapy,  
**62:200**  
 aPL antibodies and, **49:223**  
 colon cancer, **62:190**  
 inhibition of NF- $\kappa$ B activation at high  
 doses, **58:19–20**  
 PGHS, **62:187**  
 Aspirin-induced asthma, **51:353**  
 Aspirin-sensitive asthma, **51:353–358**  
 conclusion, **51:358**  
 mechanism, **51:353–358**  
 abnormal arachidonate metabolism at  
 rest, **51:355**  
 cellular source, **51:355–356**  
 cyclooxygenase inhibition, **51:353**  
 leukotrienes and AIA, **51:353–354**  
 target organ sensitivity, **51:356–358**  
 Assembly deficient cells, **52:47–49**  
 Association rate constants, IL-2 receptor and,  
**42:169–172**  
 Asthma, **59:415–417; 62:283–285**  
 acute response, and airway tone,  
**51:350–351**  
 allergic  
 CD23 antigen and, **49:160**  
 IL-4 storage by lung mast cells, **53:15**  
 aspirin-sensitive, **51:353–358**  
 bronchial, *see* Bronchial asthma,  
 pathobiology of  
 CD23 antigen and, **49:160**  
 eosinophil role, fiberoptic bronchoscopy  
 studies, **60:218–223**  
 human, *see also* Bronchial asthma  
 anti-Id antibody as mediator of, **39:279**  
 bronchoconstrictive response to LTC<sub>4</sub>  
 and LTD<sub>4</sub>, **39:155**  
 leukotrienes in neutrophils, dietary EPA  
 and, **39:166–167**  
 IL-5 role, **57:174–176**  
 monkey model, **60:219**  
 pathophysiology, *see* Eicosanoids, and  
 asthma pathophysiology  
 related deaths, pathology, **60:217**  
 release of leukotrienes in, **51:346**  
 Asthmatic mucosa, pathology of, **51:324–340**  
 eosinophils, **51:331–336**  
 eosinophils and adhesion mechanisms,  
**51:333–336**  
 epithelial cells and basement membrane,  
**51:324–327**  
 lymphocytes, **51:339–340**  
 macrophages and monocytes, **51:337–339**  
 mast cells 327–331, mast cells and  
 cytokines, **51:328–331**  
 neutrophils, **51:336**  
 Astrocytes, **62:84**  
 CD4 molecules and, **44:290**  
 IL-1 and, **44:177**  
 immunological mediator, **48:168–169**  
 Astrocytes, autoimmune thyroiditis and,  
**46:293**  
 Ataxia telangiectasia, **58:67–69; 61:191, 315**  
 T cell receptors and, **38:17**  
 ATF-2, Ets transcription factors and, **64:81**  
 Atk, **59:169**

- Atomic solvation parameter, **43:101**
- ATP  
 cytolysis and, **41:277**  
 as effector molecule in CTL cytotoxicity,  
**60:301–302**  
 effect on target cell killing, **60:310**  
 in IL-3-receptor interactions, **39:39**  
 TAP peptide binding and, **65:84–85, 87–88**  
 TAP peptide transport and, **65:76–77**  
 T cell activation and, **41:16, 18**
- ATPase, antigen-presenting cells and,  
**47:53, 54**
- ATP binding cassette, **52:36**
- Aurin tricarboxylic acid  
 effect on thymic cellularity, **58:262**  
 prevention of T cell PCD, **58:251**
- Autoantibodies, **59:330–331, 342**
- AChR  
 cellular immunology, **42:256–260**  
 detection, **42:255**
- anti-Id, human  
 in abnormal immune responses,  
**39:274–275**  
 in allergic diseases, **39:275–276**  
 to anti-TT antibodies, immune response  
 and, **39:269–274**  
 natural occurrence, **39:274**
- anti-IgG, **38:278**  
 human-human hybridomas, **38:297–299**  
 monoclonal, **38:298**
- antinuclear, *see* Antinuclear antibodies
- antithymocyte, CD5 B cell production,  
**55:316–318**
- aPL antibodies and, **49:212, 226, 257–258**  
 pathogenic potential, **49:252–253, 257**  
 specificity, **49:238, 248–249**
- autoimmune thyroiditis and, **46:298, 317**
- B cell formation and, **41:227, 228, 231**
- CD5 B cell and, **47:133–135**  
 Ig gene expression, **47:150, 155, 157, 158**  
 physiology, **47:130–136**  
 primordial immune network, **47:159**
- CD23 antigen and, **49:150**
- germline origin, **62:19**
- helper T cell cytokines and, **46:120**
- hybrid resistance and, **41:379**
- Ig heavy-chain variable region genes and,  
**49:2, 23, 33–34, 63**  
 V<sub>H</sub> gene expression, **49:41–51**
- in LEMS, **42:252**
- murine lupus models and, **46:99**  
 Ig germline, **46:65–67, 71–77**  
 lupus strains, **46:63, 64**
- spontaneous autoimmune thyroiditis and,  
**47:491, 492**  
 altered thyroid function, **47:456, 457, 459, 462**  
 cellular immune reactions, **47:449**  
 clinical symptoms, **47:439**  
 humoral immune reactions, **47:444, 446–448**  
 potential effector mechanisms, **47:466, 468, 469**
- surface antigens of human leukocytes and,  
**49:101**
- synthetic T and B cell sites and, **45:247, 248**
- targeted adhesion molecules in pemphigus  
 and pemphigoid, **8; 53:309, 314**
- V<sub>H</sub> segments, **62:19**
- Autoantigens, **51:305–306**
- antinuclear antibodies and, **44:93, 94**  
 autoantibodies, **44:136**  
 autoantigen, **44:127–131**  
 autoimmune response, **44:131–134**  
 scleroderma, **44:125**  
 SLE, **44:100, 105**
- cDNA cloning  
 BP antigen, **53:306–310**  
 PF antigen, **53:310–312**  
 PV antigen, **53:312–314**
- hybridomas and, **38:302**
- Ku, and V(D)J recombination and DNA  
 repair, **58:55–60**
- neural, dominant epitope, **48:164–165**
- spontaneous autoimmune thyroiditis and,  
**47:491, 492**  
 cellular immune reactions, **47:456, 459**  
 disturbed immunoregulation, **47:470**  
 humoral immune reactions, **47:445, 446, 448**  
 valency, **59:302–305, 308**
- Autochthonous tumor cells, adoptive T cell  
 therapy of tumors and, **49:284–285, 333**
- Autocrine aspects, B cell growth and  
 differentiation, **52:219–221**
- studies with B cell lines and tumors,  
**52:219–220**
- studies with normal B cells, **52:220–221**

- Autocrine effects, IL-1, **54:201–202**
- Autocytotoxic cells, hybrid resistance and, **41:394**
- Autoimmune, immune, and immunodeficiency states, antigen processing and presentation, **52:106–108**
- autoimmunity, **52:107**
- novel immunodeficiency states, **52:107–108**
- tumor immunology, **52:104–106**
- vaccines, **52:106–107**
- Autoimmune attack, IL-2 and IL-2R at site of, **50:171–172**
- Autoimmune cells, or normal human cells, transfer to SCID mice, **50:304–310**
- Autoimmune demyelinating disease, **49:357**
- multiple sclerosis
- HLA antibodies, **49:368–371**
- TCR V region, antibodies to molecules, **49:372–374**
- TCR V region, vaccination to, **49:374–375**
- myelin basic protein, **49:357–363**
- TCR usage restriction, **49:363**
- EAE in rat, **49:366–368**
- encephalitogenic C terminus, **49:366**
- encephalitogenic N terminus, **49:363–366**
- Autoimmune diabetes, murine model
- autoimmunity, **51:294–306**
- autoantigens, **51:305–306**
- diabetogenic T cells, repertoire of, **51:298–301**
- macrophages and B cells, involvement of, **51:303–305**
- suppressor mechanism controlling development, **51:301–303**
- T cell-dependent autoimmunity, **51:294–296**
- T cell subsets involved in insulinitis and overt diabetes, **51:296–298**
- clinical and histopathological characteristics, **51:289–290**
- conclusions, **51:310–311**
- genetics, **51:290–294**
- MHC-linked diabetogenic genes, **51:290–293**
- non-MNC-linked genes, **51:293–294**
- IDDM, **51:285–286**
- intervention, **51:306–310**
- class II MHC molecule expression, **51:308–310**
- cytokines, **51:307**
- immunopotentiators, **51:306**
- immunosuppressants, **51:307**
- virus infection, **51:308**
- NOD strain, development, **51:287–289**
- Autoimmune diseases, **61:367**
- antiadhesion therapy, **64:197**
- anticolon antibodies and, **42:291**
- aPL antibodies and, **49:193, 198, 258**
- clinical aspects, **49:208–209, 216**
- immunology, **49:225, 235–236, 240, 250**
- bcl-2* gene, **63:163**
- CD5 B cell and, **47:148–150**
- CD5<sup>+</sup> B cells in, **53:182–183**
- CD28 costimulation, **62:143**
- cytokines and, **64:290**
- disrupted T cell therapy for, **42:269**
- elevated serum levels of soluble IL-2Ra in, **50:183–186**
- Fas role, **57:138, 140**
- genetic defects in B lineage cells, **53:144–147**
- HLA and, **66:67, 76, 84–85, 93**
- insulin-dependent diabetes mellitus, **66:91**
- methimazole-induced insulin autoimmune syndrome, **66:87–88**
- multiple sclerosis, **66:88–91**
- pemphigus vulgaris, **66:87**
- rheumatoid arthritis, **66:85, 87**
- IFN- $\gamma$  and, **62:78, 93, 98–101, 105, 107**
- and IL-1ra
- Alzheimer's disease, **54:42–43**
- cachexia, **54:43**
- cardiac myxoma, **54:39–40**
- Castleman's disease, **54:40–41**
- and IL-6, **54:39–43**
- mesangial proliferative glomerulonephritis, **54:41**
- psoriasis, **54:41**
- rheumatoid arthritis, **54:40**
- IL-2, **63:128, 132, 294, 297**
- immunointervention, **66:91–93**
- induction, prevention by apoptosis-inhibitory drugs, **58:278**
- lymphocyte dependence, **64:192**
- MG and, **42:260**

- NF- $\kappa$ B and, **65**:117–118  
 pathogenesis, **64**:331–332  
 pituitary hormones, **63**:420, 425–426, 433  
   diabetes mellitus, **63**:423  
   experimental allergic encephalitis, **63**:424  
   multiple sclerosis, **63**:425  
   rheumatoid arthritis, **63**:421–422  
   SLE, **63**:420–421  
   thyroiditis, **63**:424  
   uveitis, **63**:425  
 radioactive antigen suicide and, **42**:268  
 SLE-like, **54**:141–142  
   B/WF1 mouse, **53**:144–147  
 spontaneous autoimmune thyroiditis, obese strain chicken, **47**:433–435  
   altered thyroid function, **47**:462, 464  
   cellular immune reactions, **47**:449, 455  
   disturbed immunoregulation, **47**:481  
   histopathology, **47**:444  
   humoral immune reactions, **47**:448  
   potential effector mechanisms, **47**:468  
 streptococcal infection-associated, **54**:140–141  
   SLE, **54**:41–42  
 superantigens and, **65**:207  
 TAP and, **65**:92–94  
 treatment, **58**:273–275  
 V<sub>H</sub> polymorphisms, **62**:9  
 Autoimmune manifestations  
   lack of, in mice transgenic for human IL-2 or IL-2R components, **50**:192–193  
   after *in vivo* applications of recombinant IL-2, **50**:189–191  
 Autoimmune response  
   retinal antigen, **48**:217  
   rheumatoid arthritis, **64**:288  
 Autoimmune thyroiditis, **46**:263–266, 317–319, *see also* Experimental autoimmune thyroiditis; Spontaneous autoimmune thyroiditis  
 antigens, **46**:266  
   thyroglobulin, **46**:267–271  
   thyroid peroxidase 272, **46**:273  
 cellular immune responses, **46**:287  
   lymphoid cells, **46**:287–291  
   target thyroid cells, **46**:291–298  
 genetic control, **46**:282  
   experimental induction, **46**:284–287  
   SAT, **46**:282–284  
   humoral responses, **46**:298  
     antiidiotype autoantibodies, **46**:305–309  
     autoantibodies, **46**:298–306  
   prevention, **46**:308, 310–316  
 Autoimmune uveitis  
   experimental, **62**:98–99  
   immune regulation, **48**:215–216  
 Autoimmunity, **43**:26; **52**:107  
   antigen-presenting cells and, **47**:104, 105  
   B cell repertoire expression and, **42**:49  
   B cell tolerance, **59**:342–344  
   CD23 antigen and, **49**:150, 174–175  
   and diabetes, **51**:294–306  
     autoantigens, **51**:305–306  
     diabetogenic T cells, repertoire of, **51**:298–301  
     macrophage and B cell involvement, **51**:303–305  
     suppressor mechanism controlling development of diabetes, **51**:301–303  
   T cell-dependent autoimmunity, **51**:294–296  
   T cell subsets involved in insulinitis and overt diabetes, **51**:296–298  
 Ig heavy-chain variable region genes and, **49**:2–3, 61, 63  
   polymorphism of V<sub>H</sub> gene segments, **49**:21, 26  
   regulation, **49**:53–54  
   V<sub>H</sub> gene expression, **49**:39, 41, 43, 46–47, 50–51  
 and IL-2, **50**:171–187  
   abnormalities in IL-2 expression and responsiveness on circulating lymphocytes, **50**:186–187  
   elevated serum levels of soluble IL-2Ra in autoimmune disease, **50**:183–186  
   at site of autoimmune attack, **50**:171–172  
   *in vitro* IL-2 production in autoimmune disease, **50**:172–178  
     autoantibodies, **50**:176  
     decrease of IL-2 producing cells, **50**:176  
     low IL-2, **50**:175–176  
     signal transduction, **50**:177–178  
     suppressor macrophages, **50**:176  
     suppressor T cells, **50**:176–177

- Autoimmunity (*continued*)  
*in vivo* IL-2 production in autoimmune disease, **50**:178–183  
immunological memory and, **53**:251–252  
*lpr* mouse, **60**:308–309  
Lyl B cells and, **42**:64  
murine, CD5 B cell effect on, **55**:313–315  
role of IL-2-induced cytokines in,  
**50**:210–213  
IFN- $\gamma$  and, **50**:212–213  
IL-6 and, **50**:210–211  
TNF- $\alpha$  and, **50**:211–212  
X-linked agammaglobulinemia, **59**:146–147  
Autologous mixed lymphocyte responses, autoreactive T cells and, **45**:418, 425, 426  
Autologous plaque-forming B cell response, NK cells and, **47**:300, 301  
Autonomous model, interaction of C1q and IgG, **51**:19–20  
Autoradiography  
B cell formation and, **41**:187  
hybrid resistance and, **41**:356  
Autoreactive T cells, **45**:417, 418, 433  
activation  
specificity, **45**:425–427  
thymic stromal cells, **45**:421–425  
deletion, **58**:272–275  
origin, **45**:418, 419  
antigen-specific T cells, **45**:420  
antigen-stimulated precursors, **45**:419, 420  
immature precursors, **45**:421  
physiology  
autoimmune response, **45**:430, 431  
nonspecific helper function, **45**:427–429  
tumor resistance, **45**:428, 430  
regulation, **45**:431  
stimulators, **45**:432, 433  
suppressor T cells, **45**:431, 432  
Autoreactivity, CD1 proteins, **59**:76–78  
Autosomes, murine lupus models and, **46**:63, 94  
Autotolerance, and IL-2, **50**:165–171  
effect *in vivo*, **50**:165–166  
interference with clonal deletion,  
**50**:166–167  
nonspecific killing induced by IL-2,  
**50**:170–171  
the system, **50**:167–170  
Auxiliary signaling receptors, **51**:157–160  
CD2, **51**:157–159  
CD2S, **51**:159–160  
Avian leukosis virus  
B cell neoplasia induced by  
*myb* gene role, **56**:477–478  
*myc* gene role, **56**:472–473  
resistance determinants, **56**:470–471  
susceptibility determinants, **56**:469–471  
in chicken B cell DT40 induction,  
**57**:361–362  
pathogenesis of bursal lymphomas induced by, **56**:471–472  
mechanism, **56**:469  
Azathioprine, MG and, **42**:271, 272  
AZH, DR2 cellular subtype, **48**:135  
Azidodeoxythymidine, *see* AZT  
Azodisalicylate, **42**:318  
Azophenylarsonate, **42**:96–99, *see also*  
Arsonate idiotypic system, A/J mouse  
AZT, **63**:99
- ## B
- B<sub>1</sub> receptors, **66**:239, 240  
B<sub>2</sub> receptors, **66**:240  
B7  
and CD28, costimulation, Td activation of  
B cells, **62**:132, 142–144, 148–157  
costimulatory effects on immunogenicity,  
**57**:305–307  
IFN- $\gamma$  and, **62**:78  
interaction with CD28, **58**:133–134  
B7-1, **62**:132, 135–138, 156–157  
B7-1/B7-2 ligand family, **62**:135–138, 156  
B7-2, **62**:132, 135–138, 156–157  
B7/BB1, **52**:168–169  
B7 receptors, **59**:377  
B8  
DQw2, **48**:134  
DQw3, **48**:134  
DQw3.1, **48**:134  
DQw3.2, **48**:134  
DQw3.3, **48**:134  
DQw7, **48**:134  
DQw8, **48**:134  
DQw9, **48**:134  
HLA-DQ, **48**:134  
IDDM, **48**:137

- B15  
 DQw2, **48**:134  
 DQw3, **48**:134  
 DQw3.1, **48**:134  
 DQw3.2, **48**:134  
 DQw3.3, **48**:134  
 DQw7, **48**:134  
 DQw8, **48**:134  
 DQw9, **48**:134  
 HLA-DQ, **48**:134  
 IDDM, **48**:137  
 I B 236/myelin-associated glycoprotein, **48**:161–162  
 Bacillus Calmette–Guerin, **42**:215  
 Bacillus Calmette–Guerin factor, low molecular-weight, **52**:185  
 Bacteria, *see also specific bacteria*  
 adoptive T cell therapy of tumors and, **49**:308  
 antibodies from combinatorial libraries, **57**:228  
 antigen-presenting cells and, **47**:87  
 aPL antibodies and, **49**:211, 248–249  
 CD5 B cell and, **47**:160  
 complement receptor 2 and, **46**:205  
 cytotoxicity and, **41**:269, 270  
 cytolytic proteins, **41**:317, 318  
 membrane attack complex of complement, **41**:300  
 genetically engineered antibody molecules and, **44**:66–70, 72  
 helper T cell cytokines and, **46**:133  
 HIV infection and, **47**:402  
 hybrid resistance and, **41**:357, 378  
 IL-1 and, **44**:163, 165–167, 194, 195  
 infection  
 IL-6 effects, **54**:36–37  
 pneumonia, **59**:395–402  
 responses in MHC class I-deficient mouse, **55**:412–413  
 X-linked agammaglobulinemia, **59**:135, 136, 143–145, 150  
 leukocyte integrins and, **46**:151, 161  
 lymphocyte homing and, **44**:354, 366  
 maps of Ig-like loci and, **46**:1  
 NK cells and, **47**:216, 224, 235, 263, 289  
 regulators of complement activation and, **45**:388, 409  
 SCID and, **49**:382  
 spontaneous autoimmune thyroiditis and, **47**:462  
 superantigens, **54**:113–115; **65**:14, 208–210  
*Clostridium* and *Pseudomonas* toxins, **54**:114–115  
*Mycoplasma arthritides* mitogen, **54**:113  
 streptococcal M proteins, **54**:114–115  
 surface antigens of human leukocytes and, **49**:81, 111, 115  
 T cell receptor and, **45**:125  
 toxic mitogens, **50**:15–16  
 and murine V $\beta$  gene segments, **50**:15  
 retroviral sequences bearing no homology to, **50**:41  
 Bacterial antigens  
 humoral immune response and, **45**:82, 83  
 IBD and, **42**:290  
 synthetic T and B cell sites and, **45**:230–232, 245  
 Bacterial disease, **60**:128–136  
 multiple antigen peptides as immunogens, **60**:134–136  
 BAF/B03 cell line, IL-2, **61**:156–157  
 BAGE, **62**:229, 233  
 BAL, *see* Bronchoalveolar lavage  
 BALB/c mouse, splenectomized, **48**:208  
 BALB invariant delta chain, **58**:304, 310, 312, 315, 320  
 BALT, *see* Bronchus-associated lymphoid tissue  
 BALU, *see* Bronchus-associated lymphoid unit  
 Bare lymphocyte syndrome, **59**:246–247; **61**:327–338  
 biochemical and genetic heterogeneity, **61**:329–331  
 cell typing, **48**:117  
 CIITA, **61**:331–334, 336–338  
 RFX, **61**:334–336  
 SCID and, **49**:387, 391  
 Basement membrane  
 B cell formation and, **41**:186  
 lymphocyte homing and, **44**:316, 320  
 Basophils, **48**:176, 177; **61**:15, 20, 360–361  
 CD23 antigen and, **49**:165, 170  
 characterization, **53**:2–3  
 chemokine effects  
 CC, **55**:116–117  
 CXC, **55**:116  
 differentiation, **60**:163–164



Basophils (*continued*)

- genetically engineered antibody molecules and, **44:68**, 80
- histamine release
  - major basic protein and, **39:191**
  - somatostatin and, **39:305–306**
- IgE receptor/FcεRI numbers and binding constants, **52:386–387**
- IL-2 and, **44:164**, 187
- and IL-4 production in response to FcR crosslinkage, **53:13**
- IL-5-mediated activity, **57:156**
- IL-8 effects, **55:116**
- major basic protein, detection, **39:186–187**
- and mast cells, human, cell surface structure on
  - adhesion receptors and recognition molecules, **52:357–366**
  - integrins, **52:358–361**
  - other recognition molecules, **52:366**
  - recognition molecules of Ig supergene family, **52:361–364**
  - selectins and related recognition molecules, **52:364–366**
- cells, **52:333–335**
- cell surface typing with mAbs, **52:335–339**
- complementing binder sites, **52:375–377**
- conclusions, **52:404**
- IgE/FcεRI, **52:378–381**
  - assembly, **52:381–382**
  - cell surface structures functionally associated with FcεRI molecules, **52:391–396**
  - control of synthesis and expression of FcεRI molecules, **52:384–386**
  - functional characterization of receptor, **52:387–391**
  - sequence and structural homologies, **52:383–384**
  - topology of, **52:378**
- Ig receptors, **52:378–396**
- negative regulators of growth and differentiations of human basophils and mast cells, **52:355–357**
- interferons, **52:355–356**
- transforming growth factors, **52:356–357**
- receptors for activating peptides, **52:366–375**
- receptors for formyl-methionine peptides and related compounds, **52:371–372**
- receptors for IL-8 and related integrins, **52:367–371**
- receptors for substance P and other neuropeptides, **52:372–375**
- receptors for growth and differentiating factors, **52:339–355**
- hemopoietic growth factor receptor superfamily, HRS, **52:340–351**
- receptors for low-molecular-weight regulators and pharmacological compounds, **52:396–404**
- receptors for adenosine, **52:396–398**
- receptors for antiinflammatory drugs, **52:402–404**
- receptors for arachidonic acid metabolites, **52:398–402**
- RTK family, c-kit, and related oncogenes, **52:351–355**
- neuropeptide production, **39:316–317**
- phenotypic properties, **53:1–2**
- precursors, **53:2**
- properties, **53:1–2**
- role in inflammatory reactions, **53:2**
- secretions, **53:2**
- BB10 antibody, **43:306–307**
- bcl-2* oncogene, immunological memory and, **53:241**
- bcl-2* transgenic mice, pre-B cell differentiation into B cells, **53:143–144**
- B cell activation factor 1, humoral immune response and, **45:67**
- B cell activators, isotype specificity, **61:90–92**
- B cell antigen receptor, **52:136–138**, 185–188; **55:282**
- anti-Ig in study of, **52:185–188**
- Branhamella catarrhalis* and others, **52:188**
- inhibitory effects of anti-Ig antibodies, **52:186–187**
- Staphylococcus aureus* Strain Cowan, **52:187–188**
- stimulatory effects, **52:185–186**
- cytoskeletal attachment, **55:262**
- Ig-α, tyrosine phosphorylation, **55:246–248**
- Ig-β, tyrosine phosphorylation, **55:246–248**

- Ig complex, **52:136–138**  
 ion movement, changes in, **55:265–266**  
 mIg-induced tyrosine phosphorylation targets, **55:234–249**  
 murine lupus models and, **46:61, 65**  
 proteins associated with Ig complex, **52:138**  
 protein tyrosine phosphorylation, **55:231–233**  
 signaling, **55:273**  
 signaling pathway, CD40 expression, **61:37–38**  
 structure, **55:226–230**  
 tyrosine kinase activation, **55:248–256**  
   coreceptors, **55:259–261**  
   signal initiation model, **55:256–259**  
 tyrosine phosphorylation targets, **55:233–234**
- B cell-associated nuclease, as truncation factor in V(D)J joining, **56:80**
- B cell differentiation factor, properties of, **40:31–34**
- B cell growth factor, **40:35**  
 CD5 B cell and, **47:119, 140, 141**  
 function of, **40:14**  
 low-molecular-weight, CD23 antigen and, **49:160, 169**  
 NK cells and, **47:265**  
 properties of, **40:29–31**
- B cell growth factor I, humoral immune response and, **45:65, 66**
- B cell growth factor II, **48:78**  
 B cell formation and, **41:235, 236**  
 T cell subsets and, **41:76**
- B cell growth factors  
 CD23 antigen and, **49:161, 171–172**  
 surface antigens of human leukocytes and, **49:99**
- B cell immunopoiesis, **61:47–54**
- B cell lineage specific activator protein, **63:228–229**
- B cell lines  
 AChR-specific, **42:260–263**  
 Ars A response and, **42:136**  
 cloned, and biochemistry of negative signaling, **52:298–302**  
 deletion mapping of, **42:133–135**  
 V<sub>H</sub> gene segments and, **42:131–132**
- B cell lymphoma, **38:248, 272; 54:144–145; 61:121**  
 A20-2], **43:196–197**  
 as animal models for tolerance, **54:410–415**  
 antigen presentation to T cells, **39:54**  
   cell line differences, **39:86**  
   high activity of, **39:66**  
   Ia structure and, **39:76–78**  
 antigen processing  
   chloroquine-inhibited, **39:63–64**  
   comparison with macrophages, **39:63–66**  
   heterogeneity of time for, **39:64–65**  
   kinetics, **39:63**  
   prefixation-inhibited, **39:64–65**  
 anti-Id antibody therapy  
   lack of response to, **39:285**  
     acquired C1 esterase inhibitor deficiency and, **39:288–291**  
     Id variants and, **39:287–288**  
   remission, **39:285–286**
- CD5 B cell and  
 Ig gene expression, **47:150–152, 154**  
 malignancies, **47:123–125**
- chromosomal translocations and, **40:273–275**
- cytotoxic T cells and, **41:149**
- follicular, human, **50:73**  
 and GM-CSF, expression, **58:435**  
 human B cell neoplasia and, **38:248**  
 stimulation modes, **54:253–254**  
 stimulatory factor 2, **54:1–3**  
 superantigen expression, **54:144–145**  
 T cell functions and, **39:84**  
 T cell receptor  $\beta$  genes and, **40:272**
- B cell neoplasia  
 human  
   Burkitt lymphoma, *c-myc* oncogene in deregulation, **38:254–257**  
     translocation, **38:248–253**  
     variant chromosome translocation, **38:257, 259**  
   chromosomal translocation, **38:246–248**  
   *c-myc* activation, **38:259–264**  
   t(14;18) chromosome translocation, **38:267, 271**  
   t(11;14) chromosome translocation, **38:264, 267**  
   retrovirus-induced, in bursa of fabricius, *see* Bursa of fabricius
- B cell peptide epitope vaccine, **43:78**

- B cell repertoire expression, *see also* Variable region, gene expression**
- B cell subpopulations and**
- adult primary B cell subpopulation, **42:67–68**
  - general considerations, **42:62–64, 79–83**
  - Ly1 B cells, **42:64–65**
  - neonatal, **42:65–67**
  - secondary B cell lineage, **42:68–79**
- environment and, **42:34–35**
- down-regulation, **42:42–43**
    - antiidiotypic recognition, **42:51–62**
    - tolerance to self-antigens, **42:43–51**
  - predominant clonotype expression, **42:39–42**
  - primary B cell repertoire diversification, **42:36–39**
  - sIg bone marrow precursor cells, **42:35–36**
- neonatal sequential development of, **42:29**
- B cell response**
- Ir* gene influence on, **38:50–52**
- to MMTV
- endogenous Mtv, **65:196–208**
  - neonatal, **65:171–175**
  - T–B cell interaction, **65:180–188**
  - T cell-dependent differentiation, **65:178–180**
  - T cell-independent activation, **65:168–171**
- T cell suppression, **38:136**
- B cells, 43:133**
- AChR and, **42:257–258**
- activation
- accessory molecules, **63:56–57**
  - early events, **63:52–53**
  - effector phase, **63:44**
  - extrafollicular, **52:221–224**
  - for proliferation and differentiation, **54:345–346**
  - and proliferation and differentiation, factors affecting, **40:29–50**
  - T-dependent, **63:43**
  - triggered by T<sub>h</sub> membranes, **63:46**
- activation biochemistry, **55:221–222, 282**
- antigen contact, early cellular events following, **55:262–265**
  - antigen uptake, **55:264–265**
  - capping, **55:263–264**
  - contact-dependent T cell help, mechanism, **55:269–273**
  - cytokine receptor structure, **55:274**
  - cytoskeletal attachment, **55:262–264**
  - gene expression induction, **55:266–269**
  - IL-2 receptor, signaling by, **55:274–278**
  - IL-4 receptor, signaling by, **55:278–279**
  - IL-6 receptor, signaling by, **55:279–280**
  - ion movement changes, **55:265–266**
  - models, **55:222–225**
  - survival, **55:280–282**
- adoptive T cell therapy of tumors and, **49:289, 306, 312–315, 330–332**
- adult, abortive signaling and second signals, **54:407–410**
- adult primary subpopulation, repertoire expression, **42:67–68**
- aging and, **63:215–216**
- allelic exclusion, **38:18**
- anergy, **59:321–322**
- antibody class switching, **61:84–85**
- antibody isotype switching, **48:83–84**
- antibody repertoire generation in rabbit GALT, **56:205–209**
- Ig gene rearrangements, **56:189–192**
  - immune response ontogeny, **56:186–187, 209**
  - lymphopoiesis, **56:180–186**
  - somatic mutation, **56:203**
- antibody response to  $\beta$ -galactosidase, **39:88–90**
- helper T cells and, **39:88–90**
- antigen presentation to T cells
- antigen specificity and, **39:57–59**
  - comparison with non-B cells, **39:85–86**
  - fractionation and, **39:68–69**
  - gamma radiation and, **39:67–72**
  - increase by activation, **39:66–72**
    - antigen binding and, **39:72–73**
    - Ia expression in membrane and, **39:74–76**
    - Ia structure and, **39:73–74, 76–78**
    - IL-1-like activity and, **39:78–79**
    - non-Ia molecules and, **39:78**
- LPS and, **39:67, 69, 71**
- NRGG as antigen, **39:55–56**
- RAMIG as antigen, **39:52–53, 55–56**

- antigen-presenting cells and, **47:45, 46, 47, 87**  
*antigen presentation*, **47:66–70, 72–76, 78, 79**  
*antigen processing*, **47:88–90, 92–94**  
 APC-T cell binding, **47:95, 97–99**  
 cell surface, **47:57–64, 59, 61–64**  
 immunogeneity, **47:101, 103, 104**  
 T cell-dependent antibody responses, **47:81–86**  
 T cell growth, **47:99–101**  
 tissue distribution, **47:47–57, 48–51, 53–57**
- antigen-reactive, specific killing, **60:305–306**
- antigen recognition, **43:223**
- antigens and, **38:2**
- antigen uptake, **39:59–62**  
 comparison with macrophages, **39:60–62**  
*Ig role*, **39:60–62**
- aPL antibodies and, **49:249**
- autocrine aspects of cell growth and differentiation, **52:220–221**
- autoimmune disease, **59:342–344**
- autoimmune thyroiditis and, **46:263, 318**  
 antigens, **46:270, 271**  
 cellular immune responses, **46:288, 290, 295, 297**  
 experimental models, **46:275–277, 280, 282**  
 humoral responses, **46:299–304, 306, 307**  
 prevention, **46:314, 315**
- B1 cells, **59:285; 63:207**
- B2 cells, **63:207**
- BALU, **59:386**
- at birth, **63:215**
- bone marrow  
 neonatal, **42:67**  
*repertoire expression in*, **42:32–34**  
 secondary B cells and, **42:76**
- in bone marrow, **63:208–215**
- CD1 distribution, **59:67–68**
- CD4 molecules and, **44:290, 291**
- CD5, **47:117–120, 161; 55:297–299, 330–333**  
 anti-BrMRC specificity, **55:315–316**  
 anticarbohydrate specificity, **55:318**  
 antiphosphorylcholine specificity, **55:318**
- antithymocyte autoantibody specificity, **55:316–318**
- in autoimmune disease, **53:182–183**
- autoreactivity, **55:328–329**
- bone marrow transplantation, **47:129, 130**
- clonal expansions, **55:322–323**  
 in development, **55:327–328**  
 in diseases, **55:327–328**  
 expression on B cells, initial reports, **55:298**  
 from fetal B progenitors, **55:300–304**  
 generation, model for, **55:304–306**  
 human population, homologous, **55:326–330**
- Ig gene expression, **47:150, 152**  
 lineage, **47:128, 129**
- malignancies, **47:125**
- marker for activation, **47:125–128**
- mutation, **55:330**
- neoplasias, **55:322–323**
- ontogeny, **47:121, 122**
- peritoneal cavity localization, **55:299–300**
- physiology, **47:131, 133, 134, 136–138**
- primordial immune network, **47:160**
- response to foreign antigens, **55:318–319**
- specificity, biases in, **55:312–319**
- surface antigen, **47:143, 147**
- V genes  
 human, **55:329–330**  
 rearrangements, **55:323–324**  
 usage, biases in, **55:319–326**
- CD5, murine  
 autoimmune mouse, **55:313–315**  
 cytokine production, **55:310–311**  
 cytokine regulation, **55:310–311**  
 differentiation, **55:309**  
 expression on malignancies, **55:311–312**  
 isotype expression, **55:309–310**  
 properties, **55:306–312**  
 strain variation, **55:308–309**  
 surface phenotype, **55:306, 308–309**
- CD5<sup>+</sup>/CD5<sup>-</sup> dichotomy, **53:178–183**
- CD23 antigen and, **49:149–151, 176**  
 biochemical structure, **49:156, 158**  
 biological activity, **49:167–173, 169, 171**  
 cellular expression, **49:150–151, 153**  
 expression in clinical conditions, **49:174–175**

B cells (*continued*)

- expression regulation, **49**:158–160, 158–161
  - Fc $\epsilon$ RII, **49**:162, 164–167, 165
- CD40 expression, **61**:2, 11–12, 32–35
- CD45 and, **66**:22–31, 36–37
  - monoclonal antibody studies and, **66**:12–15
- CD45-deficient, **66**:22–26
- cell-mediated killing and, **41**:297
- censoring, **59**:302–304, 308–309, 311–312, 331–341
- chicken, repertoire formation in, **57**:353–375
- development
  - allelic exclusion, **57**:372–374
  - antisilencer regulation, **57**:372–374
  - bursa role, **57**:364–367
  - embryonic, **57**:367–369, 374
  - Ig sequence selection, **57**:369–372
  - silencer regulation, **57**:372–374
- gene conversion
  - avian leukosis virus induction of DT40 cell line, **57**:361–362
  - DT40, **57**:361–362
  - Holliday junction, possible formation, **57**:362–365
  - hyperconversion mechanism, **57**:358–361
  - recombination models, **57**:362–365
- Ig gene organization
  - amino acid composition, **57**:356, 358
  - D elements, **57**:356–358
  - heavy chain loci, **57**:354–356
  - light chain loci, **57**:354–356
- chronic lymphocytic leukemia, **54**:50–51
- circulating, functions, **53**:201–203
- classes of, **53**:178–179
- clonal deletion, **58**:257
- c-myc* activation, **38**:261
- complement receptor 1 and, **46**:183, 193, 200, 201
- complement receptor 2 and, **46**:203–211, 213
- C $\mu$ -only transcription, **43**:237–238
- cytolysis and, **41**:273
- delineation of responsive subsets, **40**:4–5
- development, **59**:151–162; **63**:1–3, 203–216
  - bursa of Fabricius, **48**:42–44

- differential expression of lineage-related markers, **53**:125–127
- and gene rearrangements, **60**:38–39
- heavy chain and  $\kappa$  gene rearrangement and expression, **43**:236–237
- $\mu$  heavy chains, **63**:1–4, 11–15, 16–29
- Ig, gene expression, **43**:236–240
- IL-2R $\gamma$  mutation and, **59**:252
- in MHC class I-deficient mouse, **55**:393–394
- in mouse, **64**:221
- pituitary hormones, **63**:412–414
- preimmune repertoire, **59**:281–286
- subpopulation proliferation and differentiation, **53**:127–130
- surrogate light chain, **63**:2–4, 15–25, 29–31
- terminally differentiated plasma cells, **43**:239
- transduction, **63**:25–29
- XLA as defect, **60**:39–42
- development and differentiation, **60**:37–49
- differential expression of lineage related markers, **53**:125–127
- differentiation
  - in CBA/N immunodeficient mice, **53**:142–143
  - cytokines and, **52**:204–218
    - activated T cells, **52**:212–213
    - antigen receptor-dependent activation, **52**:204–206
  - CD40-dependent activation, **52**:206–212
  - IL-2 and autoimmune system, **52**:215
  - isotype switching, **52**:215–218
  - in vivo* activated plasmablasts, **52**:213–215
  - heavy chain isotype expression, **61**:82–84
  - HIGMX-1 as defect, **60**:42–48
  - isotype switching during, **60**:38–39
  - surrogate L chain functions in, **53**:136–143
- differentiation and expression, **54**:338–343
- directly responsive to T cell factors, **40**:19
- Epstein-Barr virus-transformed, **48**:125
- Fc receptors on, **40**:66–67, 68
- FOE receptors, **43**:298–300
- follicular B cells, **59**:283–285

- formation, **41**:181–185, 235–239
- B cell precursors and, **41**:188, 189
  - cell size changes, **41**:202, 203
  - cell surface markers, **41**:189
  - distinctions, **41**:198, 199
  - functional assays, **41**:199–202
  - Ly-5 family of glycoproteins, **41**:189–193
  - markers, **41**:193–195
  - phosphatidylinositol-linked lymphocyte antigens, **41**:197, 198
  - technical considerations, **41**:196, 197
  - tumor cell lines, **41**:195, 196
- bone marrow cultures and, **41**:208, 209
- CBA/N mice, **41**:226
  - characteristics, **41**:216–218
  - inducible cell line, **41**:223
  - lymphocyte adhesion to stromal cells, **41**:214–216
  - recent innovations, **41**:219, 220
  - structural organization, **41**:209–214
  - W/W anemic mice, **41**:224
- genetically determined defects, **41**:223, 224
- C3H/HeJ mice, **41**:230, 231
  - CBA/N mice, **41**:226, 227
  - cyclic neutropenia, **41**:228, 229
  - moth-eaten mice, **41**:231, 232
  - NOB mice, **41**:227–229
  - SCID mice, **41**:224–226
  - W/W anemic mice, **41**:224
- Ig genes, **41**:203–205
- inducible cell line, **41**:220–225
  - lymphohemopoietic tissue organization, **41**:185–188
  - population dynamics, **41**:205–208
  - soluble mediators, **41**:232–235
- frequency of, **42**:19–22
- fusion, **38**:282, 283, 285, 286
- Fyn expression, **63**:135
- gene rearrangement, **38**:8, 12, 14
- genesis, transcription factors, **63**:216–250
- genetically engineered antibodies, **38**:304, 305; **44**:88, 89
- genetic defects leading to autoimmune disease, **53**:144–147
- genomic DNA structure or *mb-1* gene, **54**:355
- germinal center, maintenance of self-tolerance, **60**:280–283
- growth, cytokines and, **52**:195–204
- activated T cells, **52**:203
  - antigen receptor dependent activation, **52**:195–200
  - CD40-dependent activation, **52**:200–203
  - IL-6, **52**:203–204
- growth and differentiation
- autocrine aspects, **52**:219–221
  - B cell lines and tumors, **52**:219–220
  - normal B cells, **52**:220–221
  - complement role, **52**:218–219
  - cytokines involved, **52**:174–185
  - IL-2, **52**:177–178
  - IL-4, **52**:178–181
  - IL-6, **52**:182–184
  - IL-10, **52**:181–182
  - low molecular-weight BCGF-12 kDa, **52**:185
  - TH1 and TH2 CD4+ helper T cells, **52**:175–177
- in vivo* aspects, **52**:221–230
- cytokines and B cells, a synthesis, **52**:227–230
  - extrafollicular B cell activation, **52**:221–224
  - follicular dendritic cells, **52**:225–227
  - germinal centers, development, **52**:224–225
- hapten-specific, T cell hybrid stimulation, **39**:56–57
- helper T cell cytokines and
- cross-regulation of differentiation*, **46**:131
  - differential induction, **46**:128–130
  - functions, **46**:114, 116–122
  - immune responses, **46**:133, 136
  - precursors of differentiation states, **46**:125, 126
- HIV infection and, **47**:390, 397
- human
- in Id recognition by T cells, **39**:259–260
  - interaction with rabbit anti-Id antibodies binding to, **39**:264–266
  - suppression by, **39**:267–268
- human counterpart of IgR-associated proteins, **54**:356–357
- human-human hybridomas, **38**:297
- human-mouse heterohybridomas, **38**:301
- human-mouse hybridomas, **38**:291
- human T cell activation and, **41**:29
- hybridization cell lines, **38**:279–282

- B cells (*continued*)
- hybrid resistance and
    - antibodies, **41:378, 379**
    - antigen expression, **41:397, 408**
    - leukemia/lymphoma cells, **41:366**
    - lymphoid cells, **41:355, 357**
    - marrow engraftment, **41:387**
    - marrow microenvironment, **41:392**
    - NK cells, **41:366**
  - IBD and, **42:297**
    - 6-MP therapy, **42:300**
  - idiotypic-specific inhibition by suppressor T cells, **40:136–143**
  - IFN- $\gamma$ , **62:87**
  - IFN- $\gamma$  and IL-4, **63:278**
  - Ig, enhancer preference, **43:242**
  - Ig class switching, **60:270–271**
  - Ig diversity, **48:52**
  - IgE-binding factor, **43:300–301**
  - IgE biosynthesis and
    - antibody response, **47:5–12**
    - antibody response suppression, **47:28**
    - binding factors, **47:13, 19–23**
  - Ig gene superfamily and
    - evolution, **44:47**
    - nonimmune receptor members, **44:37, 42**
    - receptors, **44:9, 10, 12, 21, 22, 24**
    - somatic diversification, **44:14, 16–18**
  - Ig heavy-chain variable region genes and, **49:2, 3, 21, 33, 53, 56**
    - regulation, **49:53–56**
    - tumors, **49:9, 11**
    - V<sub>H</sub> gene expression, **49:35–38, 41, 43, 49–52**
  - IL-1 and, **44:189, 190, 194, 195**
    - biological effects, **44:164**
    - immunocompetent cells, **44:172, 173, 177, 178**
    - receptor, **44:182, 183, 185**
    - structure, **44:156**
  - IL-1-like activity, **39:78–79**
  - IL-5 effects
    - regulation of development, **57:154–155**
    - signaling in X chromosome-linked immunodeficient mouse, **57:171–172**
  - IL-6 effects, **54:21**
  - IL-10 biological effects, **56:10–11**
  - immature, **59:285–286**
  - immune response results, **52:125**
  - immunosenescence and, **46:253**
    - lymphocyte activation, **46:231–234, 236**
    - mucosal immunity, **46:251, 253**
    - regulatory changes, **46:248, 251**
    - stem cells, **46:240, 242, 243, 246, 247**
  - induction of responses by, **40:12–16**
  - intermittent life span of, **53:237–241**
  - Ir* genes and, **38:50, 73, 153, 156, 188, 189**
    - antigen binding, **38:115**
    - expression, **38:53–55, 57, 58, 63**
    - helper T cells, **38:60**
    - Ia molecules, **38:68, 83, 84**
    - I region mutations, **38:85, 89**
    - MHC restriction, **38:64, 65**
    - T cells, **38:41, 42**
      - interactions, **38:155–158**
      - repertoire, **38:117, 121, 133, 134**
      - suppression, **38:142**
  - isotype-specific inhibition by suppressor T cells, **40:145–148**
  - leukocyte integrins and, **46:151, 154, 166, 171**
  - lineage expression of CD44, **54:293**
  - Ly1, **42:64–65**
    - splenic B cell and, **42:68**
    - subpopulation, **42:82–83**
  - in lymph follicles, **53:185–187**
  - lymphocyte homing and
    - high endothelial venules, **44:315**
    - immune response, **44:330, 334, 335**
    - regional specificity, **44:325, 326, 329, 339**
  - lymphocytotoxic antibodies and, **42:291–292**
  - malignancies, **61:12**
    - Ig heavy-chain variable region genes and, **49:39–40**
    - mature, Ig gene rearrangements in, **40:270–276**
  - malignant, **61:38–39**
    - CD40 expression, **61:11–12, 38–39**
    - T cell-mediated suppression of, **40:144–145**
  - maps of Ig-like loci and, **46:1**
  - marginal zone, **59:284–285**
  - marginal zone B cells, **59:284–285**
  - maternally transmitted antigen, **38:313, 334**
  - maturity and tolerance, **52:290–294**
    - clonal abortion and clonal anergy, **52:291–294**

- memory, *see* Memory B cells
- MG and, **42**:242–245
- in MHC class II-deficient mouse, **55**:429–430
- MHC glycoproteins, **49**:81–82
- MLR stimulation, **39**:79–83, *see also*
- Mixed-lymphocyte reaction
- monoclonal antibodies, **38**:306
- murine lupus models and, **46**:64–66, 76, 98
- murine peritoneal, **54**:377–378
- myc* gene product in, **38**:254
- naive
- adhesion molecules affecting, **53**:248–249
- homing, **58**:350
- migration
- adhesion molecules and, **53**:248–249
- basic pattern, **53**:247–248
- migration pattern, **53**:247–248
- natural history, **52**:126–127
- neoplasia, and IL-6, **54**:33–36
- NK cells and, **47**:188, 199, 225, 232
- adaptive immunity, **47**:291
- alterations, **47**:300
- congenital defects, **47**:225, 226
- differentiation, **47**:230
- effector mechanisms, **47**:255, 264
- hematopoiesis, **47**:281
- malignant expansion, **47**:228
- surface phenotype, **47**:201, 209, 211
- PC-responsive, **42**:65
- in peripheral compartments, **53**:177–186
- in peritoneum, **53**:183–185
- in Peyer's patches, **40**:194, 195–197, 206, 208
- phenotype of, **52**:129–174
- nonclustered antigens, **52**:164–174
- polyclonal activation, **52**:185–195
- activated T cells inducing resting B cells to proliferate and differentiate, **52**:191–193
- anti-CD40, **52**:188–191
- antigen receptor, **52**:185–188
- pools, **53**:135–136
- pre-B cell receptor, **59**:155–156; **63**:20–21, 25–26
- pre-B cells, **59**:286
- 70Z/3 murine, crosslinking of <sup>125</sup>I-labeled ASD-Re595 LPS, **53**:278
- contacts with stromal cells, **53**:133–134
- defined, **63**:6
- differentiation into B cells
- in *bc1-2* transgenic mice, **53**:143–144
- in vitro*, **53**:140–141
- in vivo*, **53**:141–142
- exogenous recombination substrates, **43**:237
- expression D<sub>μ</sub> protein, **63**:22–23
- long-term proliferating, **53**:131–136
- nonproliferating on stromal cells, **53**:134–135
- RAG genes, **63**:20
- surrogate light chain, expression, **63**:6–7, 11–12, 13
- precursors, **61**:11, 38
- B cell formation and, **41**:188, 189
- cell size changes, **41**:202, 203
- cell surface markers, **41**:189
- distinctions, **41**:198, 199
- functional assays, **41**:199–202
- Ly-5 family of glycoproteins, **41**:189–193
- markers, **41**:193–195
- phosphatidylinositol-linked lymphocyte antigens, **41**:197, 198
- technical considerations, **41**:196, 197
- tumor cell lines, **41**:195, 196
- prenatal B cell genesis, **63**:207–208, 212
- pre-pre B cells, **43**:237
- pro-B cells, **59**:286, 298; **63**:23, 25
- long-term proliferating, **53**:131–136
- programmed cell death, **50**:63–66
- clonal abortion, **50**:64
- faulty recombination, **50**:63–64
- growth arrest of WE III-231 B cell line, **50**:64–65
- somatic mutation and terminal differentiation, **50**:65–66
- proliferation, **63**:412–413
- CD40 ligands, **63**:58, 60–61
- CD40 signaling, **63**:53–58
- proliferation and antibody responses, **40**:6–12
- pulmonary immunity, **59**:391–394
- receptor, **43**:133
- receptors, **49**:99, 101
- recognition, **43**:224
- regulatory elements of *mb-1* gene
- expression in restricted stage of B cell differentiation, **54**:355–356



- B cells** (*continued*)
- role in V $\beta$  selective element action, **50:31**
  - SCID and, **49:381–383, 387–390, 393, 400–401**
  - self-tolerance checkpoints, **59:279–281, 342–344**
    - immune repertoire, **59:319–342**
    - preimmune repertoire, **59:281–319**
  - signaling, role of Btk, **60:5–6**
  - signal transduction
    - CD40, **61:32–35**
    - MB-1, **54:351–355**
  - sites of origin, **63:204–207**
  - size, subsets and, **40:18**
  - specific genes involved in IgR complex, **54:348–351**
  - specific proteins in IgR complex identified by molecular cDNA cloning, **54:348–357**
  - splenic, **50:65**
  - spontaneous autoimmune thyroiditis and, **47:434, 467, 469, 481, 492**
    - cellular immune reactions, **47:449, 450, 452, 455**
    - histopathology, **47:440, 444**
    - humoral immune reactions, **47:446–448**
  - steady state production, **53:135–136**
  - stimulatory factor 2, **54:1–3**
  - subpopulations
    - proliferation and differentiation capacities, **53:127–130**
    - responsiveness of, **40:17–29**
  - surface antigens, major, expression, **52:130**
  - surface antigens of human leukocytes and, **49:76, 78, 92, 101, 115–117, 125**
    - adhesion molecules, **49:86**
    - antigen-specific receptors, **49:76–78**
    - Igs, **49:89, 91**
  - switch recombination, **61:83**
- T cell activation** and, **41:22**
- T cell-dependent responses**, **62:131**
- B7-1/B7-2 ligand family, **62:135–138, 140–142**
  - CD28–B7 costimulation, **62:142–144, 148–157**
  - CD28/CTLA-4 receptor family, **62:132–135, 138–140**
    - cellular events, **62:144–148**
    - costimulation, **62:138–144, 148–154**
    - model, **62:131–132**
- T cell development** and, **44:209, 243, 252**
- T cell interactions, **39:57–58, 83–85, 91–92; 63:44, 46, 71–72**
    - epitopic specificity and, **39:87–90**
  - and T cells, interphase death and nonspecific damage, **50:69–70**
- T cell subsets** and, **41:39, 40**
- cell surface molecules, **41:42, 45, 46**
  - H-2 alloantigen recognition, **41:89–91**
  - H-2 molecules in thymus, **41:99, 100, 102**
  - H-2-restricted recognition of antigen, **41:51, 54, 68–71, 76, 77**
  - T cell specificity, **41:112**
- T-dependent** and **-independent**, **42:63–65**
- V-DJ joining**, **43:239**
- V(D)J joining** of antigen receptor genes, rearrangement, **56:47, 49**
- pre-B cells, **56:47, 49**
- VH-only transcription**, **43:236–238**
- Xid mutation**, **59:317–318**
- B cell stimulating factor-1**
- B cell formation** and, **41:236**
- B cell precursors, **41:193, 194, 197**
  - genetically determined defects, **41:231**
  - inducible cell line, **41:222**
  - soluble mediators, **41:234, 235**
- T cell subsets** and, **41:66, 76, 77, 95**
- B cell surface antigens**, **40:17–18**
- major, expression, **52:130**
  - non-Ig, **52:138–174**
  - non-Ig, plasmacyte, **52:174**
    - other antigens of plasmacytes, **52:174**
    - PC-1, a plasma cell threonine-specific protein kinase, **52:174**
  - non-Ig clustered, **52:140–164**
    - CD5, **52:140–144**
    - CD9, **52:144**
    - CD10 or CALLA, **52:144–145**
    - CD20, **52:149–150**
    - CD22, **52:150–151**
    - CD23/FeeRII, **52:151–153**
    - CD24, **52:153**
    - CD37, **52:154–155**
    - CD38, **52:155**
    - CD40, **52:155–158**
    - CD44, **52:158–159**
    - CD45, **52:159–160**
    - CD48, **52:160**
    - CD72, **52:160**

- CD73, **52:160–161**  
 CD74, **52:161**  
 CD76, **52:162**  
 CD77, **52:162–163**  
 CD19, **52:145–148**  
 CDw32/Fc $\gamma$ RII, **52:153–154**  
 CDw75, **52:161–162**  
 complement receptors: CR2, CD21, and CD35, **52:148–149**  
 other clustered antigens, **52:163–164**  
   CD1c, **52:163**  
   CD27, **52:163**  
   CD39, **52:163**  
   CD69, **52:163**  
   CD78, **52:163–164**  
 non-Ig nonclustered, **52:164–174**  
   adhesion molecules, **52:166–168**  
     activation of, **52:168**  
     Ig superfamily, **52:167**  
     integrin family, **52:166**  
     selection family, **52:167–168**  
   B7/BB1, **52:168–169**  
   cytokine receptors, **52:169–173**  
     IL-1, **52:169–171**  
     IL-2, **52:171–172**  
     IL-4, **52:172**  
     IL-6, **52:172**  
     other cytokines, **52:173**  
     TNF- $\alpha$ , **52:172–173**  
     transforming growth factor  $\beta$ , **52:173**  
   HLA class II, **52:164–166**  
     Bgp 95, **52:173**  
     CK226 antigen, **52:173**  
     IgM-binding protein (Fc $\mu$  receptor), **52:173**  
     other antigens of B cells, **52:173–174**  
   B cell tolerance, **52:283–284, 325–326**  
   antigen polymerization and, **52:287–290**  
     Felton's paralysis and other early results with polymers, **52:287–288**  
   polymeric antigens and IgE responses, **52:289–290**  
   size-fractionated polymers: Dintzis model, **52:288–289**  
 biochemical analysis of signal transduction pathways, **54:415–420**  
 direct analysis of signal transduction, **54:418**  
 identifying Ig complex and associated second messengers, **54:419–420**  
   use of inhibitors to block *in vitro* tolerance, **54:415–418**  
 biochemical basis, **52:294–302**  
   anti-Igs as surrogate antigens, **52:295–297**  
   cloned lines and biochemistry of negative signaling, **52:298–302**  
   constraints to study of antigenic signaling, **52:294–295**  
   role of surface IgM and IgD, **52:297–298**  
 early studies affecting antibody formation, **52:284–287**  
   dissection of T cell vs B cell tolerance, **52:285–287**  
   tolerance and antibody formation before T and B cell era, **52:284–285**  
 model systems of analysis, **54:394–415**  
   anti-IgM surrogate systems, **54:402–410**  
   B cell lymphoma model, **54:410–415**  
   hapten-specific, **54:395–402**  
   history, **54:394–395**  
   preliminary studies with transgenic spleen cells *in vitro*, **54:414–415**  
 perspectives including antigen presentation by B cells, **52:321–322**  
 rationale, **54:393**  
   definition, **54:394**  
   value of *in vitro* studies, **54:394**  
 resolution of apparently conflicting models, **52:322–325**  
 in secondary repertoire, **52:317–321**  
 transgenic approaches, **52:303–317**  
   advantages and disadvantages, **52:303–305**  
   anti-DNA transgenic model, **52:314–315**  
   anti-H-2Kk transgenic model, **52:311–313**  
   anti-transgenic models with B cell tolerance absent or partial, **52:315–317**  
     hen egg lysozyme model, clonal energy vindicated, **52:305–311**  
 B cell tumors, *see* B cell lymphoma  
 BCG, **42:215**  
 Bcl-2, **59:344; 62:43, 53; 63:162–163**  
   downregulation, **58:151**  
   effect on apoptosis, **58:137**  
   highly expressed in pro-B cells, **58:256–258**

- bcl-2*, **64**:235, 251  
 antiapoptotic, **58**:233  
 apoptosis-regulatory, manipulation,  
**58**:253–258  
 in CD40 antiapoptotic signal, **60**:46  
 characterization, **58**:136–137  
 defective, and T cell resistance to PCD,  
**58**:215  
 inhibition of apoptosis, **58**:250  
 overexpression, **58**:168, 268, 270  
 regulation of apoptotic cell death in bursa  
 of fabricius, **56**:479, 481
- bcl-3* gene, **65**:14
- Bcl-x, **62**:43, 53
- bcl-x*, **63**:163  
 regulation of apoptotic cell death in bursa  
 of fabricius, **56**:479–480
- BCR, **61**:50, 53
- bcr*, tumor antigens derived from,  
**57**:296–297
- BCR triggering, CD40 signaling differs from,  
**61**:29
- Bence–Jones proteins, structural analyses,  
**43**:112
- Benign monoclonal gammopathy, **64**:229
- Beta-adrenergic mediator, **48**:162
- $\beta$  bulges, **43**:111
- Beta cells, islet, *see* Islet beta cells
- $\beta$  chain, **52**:379–380, *see also* T cell receptor  
 excess of, **42**:176–177  
 IL-2 receptor, **42**:167–168  
 binding characteristics, **42**:168–172  
 mast cell-specific receptor, gene cloning  
 studies, **43**:287–289  
 primary structure, **43**:220
- $\beta$  sheet, **43**:102, 104, 111
- $\beta$  strand, **43**:108–110
- BFP-STs, *see* Biological false positive  
 serological test for syphilis
- Bg/II* RFLP fragment, 4-kDa, celiac disease,  
**48**:145
- Bgp 95, **52**:173
- bic*, retrovirus-induced B cell neoplasia in  
 bursa of fabricius, role in, **56**:477
- Bimolecular reactions, simultaneous, **58**:390
- Binding, via cell-cell and cell-matrix adhesion  
 molecules, **51**:269–271
- Binding constants, basophils/mast cells,  
**52**:386–387
- Biochemical typing, HLA class II,  
**48**:114–116  
 interisotypic association, **48**:116  
 intransotypic hybrid molecule, **48**:116  
*trans*-association, **48**:116
- Biological false positive serological test for  
 syphilis, **49**:198–199, 210  
 isotype, **49**:227–228  
 specificity, **49**:234–236, 241
- Biological filtration, thymocytes, **59**:106–107
- Biological fluids, measurements of prostanoids  
 in, **51**:349
- Biosynthetic radiolabeling methods, for IL-2,  
**42**:166–167
- Birbeck granules, **59**:61, 63
- Bis Q, **42**:249–250
- BIV, *see* Bovine immunodeficiency-like virus
- Black patient  
 DQw9 Asp<sup>57</sup> positive, **48**:140  
 DR7 haplotype, **48**:140  
 DR9-DQ  $\beta$ , **48**:140  
 DR9 haplotype, **48**:140
- Bladder infection, effector cell role, **60**:346
- Blast cells, localization to gut, **58**:348–349
- Blastocysts  
 LIF regulatory role, **53**:34  
 RAG-2-deficient blastocyst  
 complementation, **62**:31–41
- Bleomycin, pulmonary fibrosis, **59**:418–419
- BLIMP, **59**:342
- Blocking, *Ir* genes and, **38**:69–72
- Blood  
 fetal, containing T cell precursors, **58**:140  
 IL-2 receptor subunits, **59**:234–235  
 peripheral, eosinophil counts, **60**:216–218
- Blood clotting, contact activation, *see* Contact  
 activation
- Blood group antigens, **62**:220–221
- Blood stage, *P. falciparum*, antigen Pf322,  
**60**:120–121
- Blood vessels, IL-6 effects, **54**:29–30
- Bloom's syndrome, **61**:316  
 and DNA ligase deficiency, **58**:65–66
- BLS, *see* Bare lymphocyte syndrome
- BLV, *see* Bovine leukemia virus
- B lymphoblasts  
 EBV-transformed, **38**:277, 278  
 IM-9, human, **48**:180  
 NK cells and, **47**:292
- bmi-1, B cell genesis, **63**:220–221, 241–243

- Bmx* gene, **59:184**
- Boc chemistry  
 with benzyl, **60:128–130**  
 and Fmoc, HIV-1, **60:134**  
 in synthesis of multiple antigen peptides,  
**60:106–107**
- Bone  
 metabolism  
 IL-6 effects, **54:28**  
 LIF role, **53:36–37**  
 resorption, cachectin and, **42:224**
- Bone marrow  
 adoptive T cell therapy of tumors and,  
**49:288, 300**  
 antigen-presenting cells and, **47:45, 47,**  
**48, 81**  
 autoimmune thyroiditis and, **46:301**
- B cell, **42:74**  
 neonatal, **42:67**  
 repertoire expression in, **42:32–34**  
 secondary B cells and, **42:76**
- B cell elimination, **59:288–309, 318, 319**
- B cell formation and, **41:183, 184, 235–238**  
 B cell precursors, **41:191, 193–199, 201,**  
**202**
- C3HeJ mice, **41:231**  
 cyclic neutropenia, **41:229, 230**
- Ig genes, **41:204, 205**  
 lymphohemopoietic tissue organization,  
**41:186, 187**  
 moth-eaten mice, **41:231**  
 NZB mice, **41:227–229**  
 population dynamics, **41:205–208**  
 SCID mice, **41:225, 226**  
 soluble mediators, **41:233, 234**
- B cell genesis, **63:208–215**
- CD5 B cell and  
 aging, **47:122**  
 anatomic localization, **47:120, 121**  
 lineage, **47:128**  
 malignancies, **47:124**  
 physiology, **47:132, 142**  
 primordial immune network, **47:161**  
 transplantation, **47:129, 130**
- CD23 antigen and, **49:155**  
 cells from, transplantation in mouse,  
**54:46–47**  
 complement receptor 1 and, **46:203, 204**  
 cytotoxicity and, **41:270**  
 dendritic cells, originating site, **59:380**  
 derived B cells, clonal deletion, **58:257**  
 derived cells, and deletion of thymocytes,  
**58:170**  
 Fc $\epsilon$ RI<sup>+</sup> cells, lymphokine production by  
 (murine), **53:9–14**  
 forbidden  $\alpha\beta$  T cells, **53:166**  
 growth hormone, **63:386**  
 helper T cell cytokines and, **46:115, 117**  
 HIV infection and, **47:395–397**  
 human, CD44 expression, **54:293–294**  
 hybrid resistance and, **41:333, 334**  
 antibodies, **41:376–378**  
 antigen expression, **41:397–399, 401–410**  
 effector mechanisms, **41:370**  
 leukemia/lymphoma cells, **41:362, 365,**  
**367, 369**  
 lymphoid cells, **41:353, 355, 356**  
 marrow engraftment, **41:384–388**  
 marrow microenvironment, **41:391**  
 NK cells, **41:372, 373, 375**  
 normal hemopoetic cells, **41:335–351**  
 syngeneic stem cell functions, **41:388,**  
**390**  
 T cells, **41:380–383**  
*in vitro* assays, **41:393, 395, 396**
- IGF-I, **63:392–393**
- Ig heavy-chain variable region genes and,  
**49:33, 36, 49**
- immunosenescence and  
 regulatory changes, **46:248, 249, 251**  
 stem cells, **46:240–247**
- leukocyte integrins and, **46:160, 166**  
 lymphocyte homing to, **64:177**  
 mast cells derived from, **53:3**  
 murine lupus models and, **46:64, 80, 81**
- NK cells and, **47:188, 201**  
 adaptive immunity, **47:292**  
 antimicrobial activity, **47:289, 290**  
 antitumor activity, **47:298**  
 differentiation, **47:229–233**  
 effector mechanisms, **47:234, 235, 263,**  
**265**  
 hematopoiesis, **47:272–283**  
 reproduction, **47:270, 271**  
 tissue distribution, **47:219, 221**
- prolactin, **63:383**
- rabbit, rearrangements of VDJ genes,  
**56:184**
- spontaneous autoimmune thyroiditis and,  
**47:446, 450**

- Bone marrow (*continued*)  
 surface antigens of human leukocytes and, **49:88, 117**  
 T cells, characterization, **53:171–173**  
 transplantation for severe combined immunodeficiency, *see* Severe combined immunodeficiency  
 X-linked agammaglobulinemia, **59:158**
- Bone marrow cells  
 IL-3-dependent lines from, **39:34–35**  
 20 $\alpha$ SDH activity, **39:35**  
 IL-3 effects  
 colony formation and, **39:20–21**  
 natural cytotoxicity and, **39:21**  
 Thy-1<sup>+</sup> induction and, **39:21–22, 24, 26–29**  
 transplantation  
 graft-versus-host disease and, **39:280–281**  
 T cell role, **39:280–281**
- Bone marrow chimeras, *see* Chimeras
- Bone marrow cultures, B cell formation and, **41:208, 209**  
 CBA/N mice, **41:226**  
 characteristics, **41:216–218**  
 inducible cell line, **41:223**  
 lymphocyte adhesion to stromal cells, **41:214–216**  
 recent innovations, **41:219, 220**  
 structural organization, **41:209–214**
- Bone marrow grafting, MG and, **42:252**
- Bone marrow transplantation  
 cyclophosphamide therapy and, **42:264**  
 histocompatible, **49:392**  
 MG and, **42:252**
- Borrelia burgdorferi*, **54:207**
- Bovine immunodeficiency-like virus (BIV), **52:432**
- Bovine leukemia virus, **52:432**
- Bovine serum albumin, methylated, aPL antibodies and, **49:234–235**
- Bowel disease, inflammatory, *see* Inflammatory bowel disease
- Box1/box2 motifs  
 role in signal transduction, **60:11–12**  
 sequence homology, **60:1**
- Boyden chamber assay, **60:175–176**
- BP-1 marker, B cell formation and, **41:193, 217, 225**
- Bpk, **59:169**
- Bradykinin  
 formation, **66:225, 226, 233–239**  
 function, **66:239**  
 IgE biosynthesis and, **47:18, 25**
- Bradykinin receptors, **66:239–240**
- Brain  
 autoreactive T cells and, **45:430**  
 lesions, autoimmune demyelinating disease and, **49:368**  
 virus-induced immunosuppression and  
 HIV, **45:349, 351, 360, 365**  
 measles, **45:346**
- Brain-derived neurotrophic factor, **61:5**
- Branhamella catarrhalis* and others, **52:188**
- Breast  
 genetically engineered antibody molecules and, **44:87**  
 Ig gene superfamily and, **44:39**  
 lymphocyte homing and, **44:326, 327, 336, 338**
- Breast cancer, etiology, stem cell factor role, **55:78**
- Breast tumors, CD44 expression, **54:323**
- Brefeldin A, **64:105**  
 effects on antigen processing and presentation, **52:42–44**
- Bromocriptine, **63:380, 409, 420, 422**
- Bromodeoxyuridine, T cell subsets and, **41:101, 102**
- Bronchial asthma, corticosteroid resistant, **51:358–361**
- Bronchial asthma, eosinophil role  
 bronchial epithelium damage by major basic protein, **39:219–223**  
 bronchoalveolar eosinophilia, **39:223**  
 bronchospasm induction by LTC<sub>4</sub>, **39:223**  
 degranulation in tissues, **39:223–224**  
 ECP in serum and, **39:224**  
 mechanism of, **39:224–225**
- Bronchial asthma, pathobiology of  
 aspirin-sensitive asthma, **51:353–358**  
 conclusion, **51:358**  
 mechanism, **51:353–358**  
 corticosteroid resistant bronchial asthma, **51:358–361**  
 eicosanoids and pathophysiology of  
 asthma, **51:340–353**  
 leukotrienes, **51:341–347**  
 platelet-activating factor, **51:352**

- prostaglandins and thromboxane, **51:347–352**  
 epidemiologic background, **51:323**  
 pathology of asthmatic mucosa, **51:324–340**  
   eosinophils, **51:331–336**  
   neutrophils, **51:336**  
 summary, **51:361–363**  
 Bronchial hyperresponsiveness, increase after allergen challenge, **60:168–171**  
 Bronchial lymph nodes, immunosenescence and, **46:236, 237, 251**  
 Bronchial mucosa, *in vitro* mucous secretion LTC<sub>4</sub> and LTD<sub>4</sub> effects, **39:155**  
 Bronchiolitis obliterans, **59:421**  
 Bronchoalveolar lavage  
   from asthmatics, **60:203–204**  
   eosinophil recruitment into, **60:171–172**  
   obtained by fiberoptic bronchoscopy, **60:218–223**  
   prechallenge, **60:168–169**  
 Bronchoalveolar lavage fluid, **59:373, 374, 382**  
   assay *in vivo*, **60:177–178**  
 Bronchoconstrictive response  
   indirect to LTB<sub>4</sub>, **39:156**  
   to LTC<sub>4</sub> and LTD<sub>4</sub>  
     in asthmatic subjects, **39:155, 223**  
     in guinea pig, **39:154–155**  
 Bronchopulmonary aspergillosis, allergic, *see* Allergic bronchopulmonary aspergillosis  
 Bronchopulmonary mucomycosis, **62:283**  
 Bronchus-associated lymphoid tissue, **59:382, 385–387**  
 Bronchus-associated lymphoid unit, **59:385–386**  
*Brucella abortus*, **54:257, 397**  
   helper T cell cytokines and, **46:127, 137**  
 Bruton's agammaglobulinemia, *see* X-linked agammaglobulinemia  
 Bruton's disease, *see* X-linked agammaglobulinemia  
 Bruton's tyrosine kinase, *see* Btk  
 BSAP, **63:228–229**  
 Btk, **59:136, 169–176, 178–196, 317; 62:42, 47**  
   in B cell signaling, **60:5–6**  
   role in XLA pathogenesis, **60:40–42**  
   signal transduction, **59:184–185, 317**  
     through CD40, **63:51**  
   in XLA pathogenesis, **60:40–42**  
   BTK family, **59:178–185**  
   *Btk* gene, **59:170–176, 184, 196**  
   B cell development, **63:28–29**  
   mutations, **59:185–192, 195, 317**  
 Bullous pemphigoid antigen  
   180-kDa, uniqueness of, **53:305–310**  
   230-kDa, homology to desmoplakin I, **53:305–310**  
   cDNA cloning, **53:305–310**  
   hemidesmosome localization, **53:297–300**  
   structural and amino acid homologies with desmoplakin I, **53:307**  
   clinical presentation, **53:292–295**  
   histology, **53:292–295**  
   immunopathology, **53:292–295**  
 $\alpha$ -Bungarotoxin, MG and, **42:237–239**  
 Burkitt's lymphoma, **63:388**  
   CD23 antigen and, **49:166**  
   chromosomal translocation, **38:246–248, 271**  
   *c-myc* activation, **38:259–264**  
   *c-myc* oncogene  
     deregulation of, **38:254–257**  
     translocation of, **38:248–253, 271, 272**  
   gene translocations and, **40:272–273**  
   human-human hybridomas, **38:293**  
   Ig heavy-chain variable region genes and, **49:3**  
   translocations, *c-myc* in, **50:124–128**  
   variant chromosome translocation, **38:259, 264**  
 Burnet's clonal selection theory, Ars A response and, **42:109**  
 Bursa of Fabricius  
   B cell clonal expansion, **48:54**  
   B cell development, **48:42–44**  
   B cell formation and, **41:181, 237**  
   development, **48:42–44**  
   early role, **48:49–51**  
   embryogenesis, **48:47**  
   hybrid resistance and, **41:372**  
   Ig gene rearrangement, **48:49**  
   Ig<sup>+</sup> precursor selection, **48:49–51**  
   retrovirus-induced B cell neoplasia  
     analytical views, **56:480**  
     apoptotic cell death, role of, **56:478–481**  
     avian leukosis virus-induced lymphoma, pathogenesis, **56:471–472**

- Bursa of Fabricius (*continued*)  
*bic* role, **56:477**  
*myb* role, **56:477–478**  
*myc* role, **56:472–478**, 481  
*rel* role, **56:477–478**  
 research origins, **56:468–469**  
 resistance and susceptibility  
   determinants, **56:469–471**  
 somatic diversification, **48:54**  
 structure, **56:467–468**
- Bursal anlage, **48:49**
- Bursal follicle  
 epithelial components, **48:42–43**  
 lymphoid components, **48:42–43**
- Bursal lymphocyte  
 diversity, **48:52–54**  
 V gene segment, **48:52–54**
- Bursal stem cell, **48:51–52**  
 decline, **48:52**  
 embryogenesis, **48:52**  
 frequency, **48:51**  
 germ-line gene segment, **48:51–52**
- Burst-forming units-erythroid, hybrid  
 resistance and, **41:396**
- t*-Butoxycarbonyl, *see* Boc chemistry
- Bystander cells, cytotoxicity and, **41:280**,  
 296
- Bystander help, T cell subsets and, **41:76–77**

## C

- C1, activated  
 actions of, **37:202–204**  
 regulation and fate of  
   C1q receptor interaction, **37:206**  
   dissociation of activated C1r2Cls2 and  
   C1, **37:204–206**  
   inhibition of activated C1 by C1-In,  
   **37:204**
- C1 activation, **51:21–25**  
 C1 activation requirements and process,  
**37:195–200**  
 C1 complexing agents and activators,  
**37:194–195**  
 regulation of, **37:200–201**
- C1 activation unit  
 complexes of  
   C1, **37:185–194**  
   C1r2Cls2, **37:183–185**  
   proteins of  
     C1 inhibitor, **37:178–183**  
     C1q, **37:155–165**  
     C1r and C1s, **37:165–178**
- C1 INH deficiency, in hereditary  
 angioedema, **66:257–258**, 259
- C1-Inh gene, **61:205**
- C1 inhibitor, **61:204–206**; **62:80**
- C1q  
 and antibody, interaction of, **51:9–21**  
 C1q-associated IgG at the molecular  
 level, **51:17–21**  
 C1q-IgG interaction at molecular level,  
**51:11–17**  
 C1q-IgM interaction at the molecular  
 level, **51:16–17**  
 complement C1q, **51:8**  
 thermodynamics of interaction, **51:**  
 8–11  
 complement components and, **38:**  
 231–233
- C2, **61:97**, 206  
 complement components and, **38:203**, 204,  
 206, 236  
 C4bp, **38:234**  
 cDNA, **38:209–211**  
 expression, **38:217**, 218  
 Factor B, **38:207–209**, 228  
 genes, cloning of, **38:212–214**  
 MHC class III region, **38:227**  
 restriction fragment length  
 polymorphism, **38:215**, 216
- CIITA, **61:331–334**, 336, 338
- C3  
 activation, **51:25–28**  
 background, **37:217–218**  
 definition of receptors, **37:221**  
 functions of receptors erythrocyte,  
**37:242–251**  
 history, **37:219–221**  
 kidney podocyte, **37:260–261**  
 lymphocyte, **37:257–260**  
 mast cell, **37:261**  
 monocyte macrophage, **37:255–257**  
 neutrophil, **37:251–255**  
 in complement activation pathways,  
**58:9–10**  
 complement components and, **38:204**, 206,  
 223, 233, 236  
 convertase, **38:205**, 206, 213, 219, 222

- eosinophil-mediated parasite killing and, **39:210**
- generation of ligands for receptors, **37:221–222**
- activation of C3 by classical and alternative pathway, **37:223–225**
- covalent binding of C3b, **37:222–223**
- degradation of C4b and C3b by cleavage with factor 1, **37:226–230**
- factors controlling C3 activation, **37:225–226**
- structure and binding site characteristics of receptors
- type four, **37:240–242**
- type one, **37:230–235**
- type three, **37:238–240**
- type two, **37:235–238**
- C3a, **61:255; 62:261, 262, 275, 286**
- C3b
- cleavage, **61:213**
- complement receptors, **61:228–229**
- complement system, **61:201–204**
- degradation, **61:209–210**
- properdin, **61:243–244**
- C3-binding protein
- complement receptor 1 and, **46:185, 189, 195, 196**
- complement receptor 2 and, **46:202**
- C3/C5 convertase, **61:206–210**
- complement receptors, **61:228–230**
- decay-accelerating factor, **61:222–228**
- factor I, **61:210–214**
- fluid-phase
- C4BP, **61:235–241**
- factor H, **61:230–235**
- nephritic factors, **61:245–247**
- properdin, **61:207, 241–245**
- inhibition by membrane cofactor protein, **60:75–76**
- membrane cofactor protein, **61:214–221**
- C4, complement components and, **38:203, 204, 206, 219**
- allotypes
- functional activity, **38:221–223**
- molecular basis, **38:225–227**
- cDNA cloning, **38:223**
- deficiency, **38:208**
- gene expression, **38:228–231**
- isotypes, **38:223–225**
- MHC
- class III region, **38:227–229**
- linkage, **38:220, 221**
- protein structure, **38:219, 220**
- C4, murine, molecular genetics, **38:223, 224, 227, 228**
- C4a, **61:255**
- C4 activation, **51:25–28**
- C4b
- cleavage, **61:213–214**
- complement receptors, **61:228–229**
- degradation, **61:209–210**
- C4b-binding protein, complement components and, **38:205, 211, 221, 222, 234–236**
- C4-binding protein, **61:203, 204, 235–236**
- complement receptor 1 and, **46:184, 185, 189, 195, 197**
- complement receptor 2 and, **46:202**
- function, **61:238–241**
- structure, **61:236–238**
- VCP, **61:241**
- C5, complement components and, **38:204, 205, 234**
- convertases, **38:205, 206, 213, 222, 236**
- C5a, **61:255; 62:261, 269, 275, 286**
- attracting myeloid cells, **58:380**
- as neutrophil receptor, **39:96–97**
- C6, complement components and, **38:204, 205**
- C7, complement components and, **38:204, 205**
- C8, complement components and, **38:205**
- C9, complement components and, **38:205, 234**
- ca2 therapy, **64:312–315**
- clinical studies
- rheumatoid arthritis therapy, **64:299–305**
- sepsis, **64:311**
- problems
- anti-double-stranded cDNA, **64:325**
- anti-Ig antibodies, **64:323–325**
- malignancy risk, **64:329–330**
- susceptibility to infection, **64:325–329**
- rheumatoid arthritis
- anemia and, **64:321–322**
- cardiovascular risk factors, **64:322**
- cell trafficking, **64:317–319**
- clinical studies, **64:299–305**



- cA2 therapy (*continued*)  
   cytokine expression, **64**:315–317  
   neovascularization, **64**:320  
   systemic effects  
     cardiovascular risk, **64**:322  
     hemopoiesis, **64**:321–322  
     immune response, **64**:322–323  
 Cabergoline, **63**:380  
 Cachectin, **61**:5; **62**:96; **66**:105, *see also*  
   Tumor necrosis factor  $\alpha$   
   acute-phase reactants from hepatocytes  
     and, **42**:225  
   amino-terminal sequence of, **42**:216, 217  
   biosynthesis of  
     cell of origin, **42**:220–221  
     control, **42**:221  
     kinetics, **42**:221–222  
   discovery of, **42**:213–216  
   effects of  
     benefits, **42**:226  
     metabolism, **42**:222–223  
     neutrophils, **42**:223  
     other, **42**:224–225  
     receptor distribution, **42**:222  
     toxic, **42**:218–220  
   hybrid resistance and, **41**:400  
   IL-2 and, **44**:185  
   lymphotoxin and, **42**:216–217, 224  
   murine, **42**:216–217  
   and muscle cells, **42**:223  
   structure of, **42**:216–217  
   Cachectin receptor, **42**:225–226  
 Cachexia, **62**:96  
   helper T cell cytokines and, **46**:114  
   and IL-6, **54**:43  
   LIF role, **53**:37–38  
 Cadherin gene superfamily, pemphigus,  
   foliaceous antigen in, **53**:310–312  
*Caenorhabditis elegans*, **50**:72  
 CAF, **65**:282  
   HIV-1 replication, **66**:281, 282–283, 287  
 Calcineurin, **62**:42, 46–47; **63**:166–167  
   cyclosporin A, action of, **65**:120  
 Calcitonin gene-related peptide, **48**:169  
 Calcium, **48**:228  
   adoptive T cell therapy of tumors and,  
     **49**:307  
   aPL antibodies and, **49**:197, 243, 245–246  
   CD4 and CD8 molecules and, **44**:268, 270,  
     300  
   CD5 B cell and, **47**:127, 144, 145  
   CD23 antigen and, **49**:151, 163  
   cell mediated killing and, **41**:288–290, 299,  
     292–297  
   cell mediation, nature of, **41**:271–273  
   complement receptor 1 and, **46**:199  
   complement receptor 2 and, **46**:207, 208  
   cytolysis, **41**:274, 278, 281, 284  
   cytolytic proteins, **41**:317, 318  
   cytoplasmic, **43**:293–298  
     influx of extracellular, **43**:295–298  
     influx pathway, **43**:296–297  
     intracellular stores mobilization,  
       **43**:293–295  
     ionophore dose effect, **43**:297  
     lag times, **43**:294  
     phosphoinositide hydrolysis, **43**:291  
   extracellular, in CTL function, **60**:296–298  
   genetically engineered antibody molecules  
     and, **44**:85, 89  
   HIV infection and, **47**:387  
   human T cell activation and, **41**:31  
   cell surface molecules, **41**:2, 12  
   gene regulation, **41**:27–29  
   receptor-mediated signal transduction,  
     **41**:19–26  
   synergy, phobol esters and, **41**:15–19  
   IgE biosynthesis and, **47**:26  
   IL-2 and, **44**:175, 185  
   immunosenescence and, **46**:222–226, 229,  
     235, 253  
   influx, and cNOS phosphorylation, **60**:324,  
     326–327  
   ion channel, **48**:285–287  
   leukocyte integrins and, **46**:156, 157, 159  
   lymphocyte homing and  
     carbohydrate, **44**:358, 360–362  
     molecules, **44**:346–349  
     regional specificity, **44**:329  
   mobilization, **48**:260–262  
   mobilization response  
     in B lineage cells through MB-1 model,  
       **54**:354  
     role in signal transduction, **54**:418–419  
     to signals through IgR, **54**:367–368  
   in neutrophils  
     protein kinase C and, **39**:128–135  
     release during activation  
       amplification and, **39**:132–135

- inositolphosphate generations and,  
**39:124–127**  
 phospholipase G and, **39:125**  
 receptors and, **39:126**
- NK cells and, **47:291**  
 cytotoxicity, **47:249–251, 253, 254, 261**  
 effector mechanisms, **47:241, 244, 245**  
 lymphokines, **47:265, 266**  
 pore-forming proteins and, **41:317, 318**  
 role in apoptosis, **50:61**  
 SCID and, **49:385–386**  
 spontaneous autoimmune thyroiditis and,  
**47:471**  
 surface antigens of human leukocytes and,  
**49:90, 114–115**
- T cell development and  
 antigen recognition, **44:214**  
 thymocyte subpopulation, **44:226, 227,**  
**229, 236, 241, 243**
- T cell subsets and, **41:65**
- Calcium channels, **48:285–287**  
 LEMS and, **42:234–235**
- Calcium ionophore  
 and factor-dependent mast cell lymphokine  
 production, **53:6**  
 T cell activation, **48:258–260**  
 and transformed mast cell lymphokine  
 production, **53:5**
- Calcium ionophore A23187  
 5-lipoxygenase activation, **39:154**  
 eosinophil degranulation and, **39:**  
**207–208**
- Calf serum  
 B cell formation and, **41:209, 216, 218,**  
**219, 222, 223**  
 hybrid resistance and, **41:395**
- CALLA, *see* CD10
- Calmodulin, NK cells and, **47:249**
- Calnexin, **64:107–108**  
 calnexin-negative cells, phenotype,  
**64:111–112**  
 class I molecules, interaction site,  
**64:110–111**  
 endoplasmic reticulum retention of  
 assembly intermediates of class I  
 molecules, **64:109–110**  
 H-chain assembly, **64:108–109**  
 MHC class I assembly and, **65:89, 90**
- 3' C $\alpha$  enhancer, germline switch transcripts  
 and class switching, **61:121–123**
- Calreticulin, **65:90, 91**  
 MHC class I peptide loading, **64:128**
- CAMPATH-1H, **64:323**
- cAMP response element modulator  $\gamma$ , **61:189**
- cAMP response elements, **62:194**
- Cancer, **59:147–148**  
 adoptive T cell therapy of tumors and,  
**49:283–285, 333**  
 anemia following IL-6 administration,  
**64:321–322**  
 antitumor activity of IL-6, **54:48–50**  
 IFN- $\gamma$  and, **62:94–96**  
 IL-1ra in, **54:213–214**  
 immunotherapy, potential of antigens,  
**58:437**  
 malignant B cells, CD40 expression,  
**61:11–12, 38–39**  
 maps of Ig-like loci and, **46:1**  
 NK cells and, **47:297–300**  
 p53 malignant transformation, **62:226–227**  
 PCSH-2, **62:190, 201**  
 rheumatoid arthritis and, **64:329–330**  
 TAP dysfunction, **65:95**  
 therapy, **54:49–50**  
 gene transfer as, **58:417–454**  
 lymphoid tumors, **58:282**  
 TIL therapy, **64:197**  
 treatment with chemoimmunoconjugates,  
*see* Chemoimmunoconjugates
- Cancer antigens, **62:240**
- Candida albicans*, cachectin and, **42:226**
- Capping  
 B cell antigen receptor, **55:263–264**  
 and resynthesis of receptors, **54:402–403**
- Caprine arthritis encephalitis virus (CAEV),  
 virus-induced immunosuppression and,  
**45:349, 351, 354, 365**
- Carbodiimides, in crosslinkage procedure for  
 chemoimmunoconjugates in cancer  
 treatment, **56:316–318**
- Carbohydrate antigens, **62:219–221**
- Carbohydrate component, mobility, **48:26–32**
- Carbohydrates  
 aPL antibodies and, **49:239**  
 autoimmune thyroiditis and, **46:271**  
 B cell formation and, **41:197**  
 CD8 molecules and, **44:271**  
 CD23 antigen and, **49:155–156, 163–165,**  
**176**

- Carbohydrates (*continued*)  
 complement receptor 2 and, **46:204**  
 cytotoxic T cells and, **41:138, 165, 170, 152–154**  
 epitopes, tumor-associated alterations, **58:420**  
 genetically engineered antibody molecules and, **44:68, 69, 84**  
 IgE biosynthesis and, **47:15–17**  
 IL-2 and, **44:194**  
 leukocyte integrins and, **46:173, 174**  
 lymphocyte homing and, **44:314**  
   cell adhesion, **44:353–355**  
   high endothelial venules, **44:315**  
   homing receptors, **44:369, 370**  
   inhibition, **44:355–357**  
   ligands, **44:363–371**  
   molecules, **44:342**  
   PPME-binding receptor, **44:357–363**  
 NK cells and, **47:207, 241**  
 as selectin ligands, **58:358**  
 spontaneous autoimmune thyroiditis and, **47:460**  
 sulfated complex, in eosinophils, **39:204**  
 surface antigens of human leukocytes and adhesion molecules, **49:88–89**  
   Igs, **49:91**  
   membrane enzymes, **49:113–114**  
   receptors, **49:94, 98**
- Carboxyfluorescein, cell-mediated killing and, **41:290**
- Carboxypeptidase-N, **61:204**
- Carboxyterminal signal sequence, in precursor peptide to be GPI anchored, **60:62–63**
- Carcinoembryonic antigen, **62:221–222**  
 genetically engineered antibody molecules and, **44:67**  
 Ig gene superfamily and, **44:39, 40, 43–45**  
 mAbs in identification, **56:305**  
 monoclonal antibody recognition, **56:305**
- Carcinogenesis, inflammation-induced, NO role, **60:345–346**
- Carcinomas  
 CD40 antigen, **61:14, 39**  
 hybrid resistance and, **41:358, 363, 369**
- Cardiolipin, *see also* Anticardiolipin antibodies  
 aPL antibodies and, **49:193, 258–259**  
 affinity purification, **49:229–231**  
 antibody subsets, **49:232**  
 antimitochondrial antibodies, **49:250**  
 binding to cell membrane, **49:251–252**  
 biochemistry, **49:194, 197**  
 clinical aspects, **49:200, 204–205**  
 history, **49:198**  
 LA antibodies, **49:240, 242–247**  
 pathogenic potential, **49:255**  
 reactivity, **49:248–249**  
 specificity, **49:234–240**  
 Ig heavy-chain variable region genes and, **49:42, 46**
- Cardiopulmonary bypass, therapeutic  
 regulation of complement system in, **56:279–280**
- Cardiotrophin-1, *see* CT-1
- Cardiovascular system, chemokine role in, **55:146**
- Caries, dental, subunit vaccines, **60:135–136**
- Carp IgM antibody, **46:23–24**
- Carrageenan, hybrid resistance and, **41:366, 371–373, 395**
- Cartilage matrix protein, leukocyte integrins and, **46:158**
- Casein, cell-mediated killing and, **41:297**  
 $\beta$ -Casein gene, **65:20**
- Castleman's disease, and IL-6, **54:40–41**
- Cat, mesenteric microvascular models, **60:329–330**
- Catabolic cascades, inhibition at effector level, **58:247–253**
- Catabolic effects, IL-2 and, **44:168**
- Catabolin, IL-2 and, **44:154, 168**
- Catabolism, antigen processing and, **38:95**
- Catalysis  
 antinuclear antibodies and, **44:127, 134–136**
- CD4 molecules, **44:265–270, 297–303**  
 cDNA structure, **44:285**  
 expression, **44:288–291**  
 function, **44:291–295**  
 gene structure, **44:287, 288**  
 HIV-1 receptor, **44:295–297**  
 Ig gene superfamily and, **44:31–33, 36, 41, 42**  
 IL-2 and, **44:189**  
 lymphocyte homing and, **44:325, 340**  
 molecular biology, **44:284**  
 polypeptide structure, **44:285–287**
- CD8 molecules, **44:265–270, 297–303**  
 Ig gene superfamily and, **44:31–33, 35, 41, 47**

- lymphocyte homing and, **44:325, 350**
- molecular biology
  - CD8 $\beta$ , **44:276–278**
  - cDNA structure, **44:272–274**
  - expression, **44:279, 280**
  - function, **44:280–284**
  - gene organization, **44:274–276**
  - polypeptide structure, **44:270–272**
- genetically engineered antibody molecules and, **44:85, 86**
- Cataract, immune-mediated, **48:219–221**
- Cathepsin G, **62:266**
- Cathepsins, **64:2**
- Cations
  - B cell formation and, **41:214, 215**
  - cytolysis and, **41:280, 311**
- Caucasian patient
  - DQw9 Asp<sup>57</sup> positive, **48:140**
  - DR7 haplotype, **48:140**
  - DR9-DQ  $\beta$ , **48:140**
  - DR9 haplotype, **48:140**
- CBA/N mice, B cell differentiation in, **53:142–143**
- c-bcl-2* oncogene, IL-2 signal transduction, **63:162–164**
- CBF family, **65:24**
- CBF $\alpha$  proteins, **65:24**
- CD1, **59:10–11, 90–91**
  - biochemistry, **59:44–45**
  - CD23 antigen and, **49:154, 156**
  - cellular expression, **59:54–55**
  - family, **59:2, 17–37, 90–91**
    - biochemical studies, **59:44–54**
    - cellular expression, **59:10–11, 54–74**
    - genetics, **59:2–10**
    - immunology, **59:74–90**
    - molecular biology, **59:2–10**
    - serology, **59:37–44**
    - structure, **59:10–37**
  - gene, **59:3–10**
  - gene cloning, **59:3–4**
  - group 1, **59:22–25**
    - cellular expression, **59:55–69**
      - by B cells, **59:67–68**
      - by dendritic cells, **59:60–64**
      - by macrophages, **59:66–67**
      - by monocytes, **59:64–66**
      - by neoplastic cells, **59:68–69**
      - in thymus, **59:55–60**
    - immunological function, **59:74–87**
    - group 2, **59:22–25**
      - cellular expression, **59:56, 69–74**
      - function, **59:88–89**
    - human leukocytes and, **49:78, 80–83**
    - serology, **59:37–44**
    - structural features, **59:10–37**
  - CD1a, **59:39, 40, 42, 45, 46, 48, 50–53, 82–85**
    - cellular expression, **59:55–69**
  - CD1b, **59:39, 41–43, 45, 48, 50–53**
    - cellular expression, **59:55–69**
    - mycolic acid restricted by, **59:82–85**
  - CD1c, **52:163; 59:39, 41, 42, 45, 46, 50–54**
    - cellular expression, **59:55–69**
  - CD1d, **59:38, 39, 40, 49–52**
    - cellular expression, **59:69–74**
    - tissue distribution, **59:56**
  - CD1E, gene, **59:22**
  - CD2, **48:235–237; 51:157–159; 64:69**
    - Abs, **48:235**
    - B cell genesis, **63:239**
    - CD45 and, **66:7–8, 33, 35–36**
    - expression, **48:235**
    - human leukocytes and, **49:87, 117**
    - structure, **48:235**
  - CD2S, **51:159–160**
  - CD3, **43:135; 48:162**
    - CD45 and, **66:9–12, 34**
    - CD59 as ligand, **61:254**
    - complex, human leukocytes and, **49:76–79, 81, 87, 90**
    - complex with TCR, *see* CD3/TCR complex
    - $\epsilon$ ,  $\delta$ ,  $\gamma$ , and  $\zeta/\eta$  invariant chains, in T cell development and selection, **58:127–128**
    - $\epsilon$  subunit, **64:69**
    - expression, **43:166, 169**
    - SCID and, **49:384, 386–387, 396–397**
    - T cell lines expressing, **58:122–124**
  - CD3 complex, components, **48:229, 230**
  - CD3–Jurkat mutant, anti-CD2, mAb, **48:236**
  - CD3/TCR complex
    - ligation, **58:248**
    - mediated peripheral T cell deletion, **58:219–224**
    - monoclonal antibodies to, **58:300**
    - second messenger triggered by, **58:230–232**

- CD4, **48:242–245**, **304–306**; **59:119**, **382**;  
**63:84**, **403**  
 as accessory molecule, **53:60**  
 adoptive T cell therapy of tumors and,  
**49:333–335**  
 antigen recognition, **49:318**, **320–321**,  
**324**  
 expression of antitumor responses,  
**49:324–330**, **332**  
 mechanisms, **49:299–306**  
 principles, **49:289–291**  
 autoimmune demyelinating disease and,  
**49:364**, **366–367**, **374**  
 and CD8, **52:363**  
 and CD8, coreceptors, **58:129–131**  
 CD23 antigen and, **49:152**  
 coreceptor effects on selection, **53:103–104**  
 coreceptor/MHC binding sites, **53:68–70**  
 coreceptor model, **53:65–66**  
 cytoplasmic tail  
 protein tyrosine kinase p56<sup>lck</sup> and,  
**53:61–64**  
 role in mediating coreceptor signal,  
**53:73–74**  
 differential signaling, **53:91–94**  
 function in TCR-mediated recognition and  
 activation, **53:59–61**  
 GTP-binding protein association, **53:64–65**  
 human leukocytes and, **49:77–78**, **81–83**,  
**90**, **113**  
 independent signal transduction, **48:243**  
 localization, **44:295**, **297**  
 mechanism of function during thymocyte  
 selection, **53:104–108**  
 MHC class I interactions, **53:60**  
 and negative selection, **53:101–102**  
 and negative signaling, **53:61**  
 and positive selection, **53:97–98**  
 pulmonary immunity, **59:402–406**  
 regulatory functions, **48:242–243**  
 SCID and, **49:384**, **385**, **396**  
 signaling role in thymocytes, **53:82**  
 T cell-specific tyrosine protein kinase,  
**48:243–244**  
 TCR-coreceptor molecule association,  
**53:66–68**  
 and TCR-mediated recognition and  
 activation, **53:59–61**  
 and thymocyte development and selection,  
**53:94–97**
- CD4 accessory molecule, **43:218**  
 CD4 receptor, expression by eosinophils,  
**60:186–187**  
 CD5, **48:246**; **52:140–144**; **63:55–56**, **62**, **69**  
 antigen, **49:151**  
 human leukocytes and, **49:92**, **101**  
 Ig heavy-chain variable region genes and,  
**49:42**  
 CD6, **48:247**  
 CD7, **48:247**  
 CD45 and, **66:34–35**  
 CD8, **48:242–245**, **304–306**; **59:52–54**, **119**,  
**382**  
 as accessory molecule, **53:60**  
 adoptive T cell therapy of tumors and **283**,  
**49:288**, **290–291**, **333–335**  
 antigen recognition, **49:319–321**, **324**  
 expression of antitumor responses,  
**49:324–330**, **332**  
 mechanisms, **49:299–306**, **316**, **318**  
 autoimmune demyelinating disease and,  
**49:374**  
 and CD4, **52:363**  
 coreceptors, **58:129–131**  
 CD8 $\beta$  role in T cell recognition and  
 activation, **53:84–85**  
 CD23 antigen and, **49:152–153**  
 coreceptor effects on selection, **53:103–104**  
 coreceptor/MHC binding sites, **53:68–70**  
 coreceptor model, **53:65–66**  
 cytoplasmic tail, protein tyrosine kinase  
 p56<sup>lck</sup> and, **53:61–64**  
 differential signaling, **53:91–94**  
 down-regulation, versus CD4 down-  
 regulation, **51:185–186**  
 function in TCR-mediated recognition and  
 activation, **53:59–61**  
 GTP-binding protein association, **53:64–65**  
 human leukocytes and, **49:77–78**, **81–83**,  
**101**, **113**  
 IGF-I-R, **63:403**  
 independent signal transduction, **48:243**  
 mechanism of function during thymocyte  
 selection, **53:104–108**  
 MHC class I interactions, **53:60**  
 and negative selection, **53:102–103**  
 and negative signaling, **53:61**  
 and positive selection, development  
 models, **53:98–100** T cells, **108–113**  
 pulmonary immunity, **59:403–405**

- regulatory functions, **48:242–243**  
 TCR-coreceptor molecule association,  
**53:66–68**  
 and thymocyte development and selection,  
**53:94–97**
- CD8 $\alpha$ , **64:69**
- CD8 accessory molecule, **43:218**
- CD8<sup>+</sup> antiviral factor, **65:282**  
 HIV-1 replication, **66:281, 282–283, 287**
- CD9, **52:144**
- CD10, **52:144–145; 64:245**
- CD11, **62:258, 272, 276, 279**  
 human leukocytes and, **49:86, 92**
- CD11a/CD18, **64:146**
- CD14, role in cellular recognition of LPS,  
**53:281–286**
- CD16, **59:382**  
 eosinophils expressing, **60:205**  
 human leukocytes and, **49:77, 90**  
 neutrophils and NK cells expressing,  
**60:179–181**
- CD18, **62:258, 272, 276, 279; 64:169, 187**  
 human leukocytes and, **49:86, 92**  
 mAb, effect on vascular leakage,  
**60:329–330**
- CD19, **52:145–148; 62:225**  
 and CR2 and CR1, molecular complexes  
 on surface of human B cells, **52:146**
- CD20, **52:149–150; 62:225**
- CD21, **62:42, 43–44**  
 human leukocytes and, **49:92**
- CD22, **52:150–151; 63:198**  
 B cell AgR-induced tyrosine  
 phosphorylation of, **55:245–246**  
 CD45 and, **66:50–51**
- CD23, **49:149–150, 176–177**  
 biochemical structure, **49:155–158**  
 biological activity, **49:167, 169**  
 expression in clinical conditions,  
**49:174–175**  
 membrane CD23, **49:167–169**  
 soluble CD23, **49:169–173**  
 cellular expression, **49:150–155, 155**  
 B cells, **49:150–151**  
 eosinophils, **49:154**  
 Langerhans cells, **49:154–155**  
 macrophages, **49:153–154**  
 monocytes, **49:153–154**  
 T cells, **49:151–153**  
 cleavage regulation, **49:158**  
 expression in various clinical conditions,  
**49:174–176**  
 expression regulation, **49:159–161**  
 B cells, **49:158–160**  
 EBV-induced expression, **49:161**  
 macrophages, **49:161**  
 monocytes, **49:160–161**
- Fc $\epsilon$ R1I  
 cloning of cDNA, **49:162–163**  
 genomic structure, **49:165–167**  
 lectins, **49:163–164**  
 structural analysis, **49:164–165**  
 human leukocytes and, **49:90–91**  
 IgE receptor corresponding to, **60:181**  
 ontogeny, **49:150**  
 transcriptional regulation, **49:165–167**
- CD23/Fc $\epsilon$ R1I, **52:151–153**  
 expression, **49:162, 166–167**
- CD24, **52:153**
- CD25, **59:379**  
 eosinophil-bound, **60:187**  
 gp39 stimulatory effect, **63:53**  
 subunit of IL-2 receptor, **60:185**
- CD27, **52:163; 61:7, 8, 17**
- CD27-L, **61:23, 24**
- CD28, **48:244, 245–246, 304; 61:36–37, 148;**  
**62:132–135, 156**  
*costimulatory effects on immunogenicity,*  
**57:305–307**  
 human leukocytes and, **49:101**  
 and negative selection, **58:172**  
 and T cell costimulation, **58:133–134**
- CD28–B7 costimulation, Td activation of B  
 cells, **62:132, 142–144, 148–157**
- CD28–CD80/CD86 signaling pathway, CD40  
 expression, **61:36–37**
- CD30, **61:7, 8–9, 12, 17**
- CD30-L, **61:23, 24, 25**
- CD31  
 leukocyte transmigration, **65:369**  
 lymphocyte homing, **64:159–160**  
 properties, **64:147**  
*redistribution to cell border,* **58:395**  
 shedding, **64:171**  
 six-Ig domain molecule, **58:375**
- CD34  
 B cell genesis, **63:239, 240**  
 ligand for L-selectin, **60:163**  
 lymphocyte–HEV interaction, **65:362, 377**  
 properties, **64:147**

- CD34+ cells, **61**:12
- CD37, **52**:154–155
- CD38, **52**:155  
lymphocyte homing, **64**:163
- CD39, **52**:163
- CD40, **52**:155–158; **61**:1, 2, 7, 54; **62**:41–43, 146, 153–154; **63**:43–44  
B cell proliferation, **63**:53–58  
cloning, **61**:2, 4  
expression, **61**:32–41; **63**:34  
  basophils, **61**:15  
  B cell precursors, **61**:38  
  B cell receptor pathway, **61**:37–38  
  B cells, **61**:2, 11–12, 32–35  
  CD28–CD80/CD86 signaling pathway, **61**:36–37  
  dendritic cells, **61**:13, 40–41  
  endothelial cells, **61**:14, 41  
  epithelial cells, **61**:14, 41  
  Fas–Fas-L signaling pathway, **61**:37  
  fibroblasts, **61**:15, 41  
  follicular dendritic cells, **61**:14, 41  
  hematopoietic progenitors, **61**:12, 39  
  malignant B cells, **61**:11–12, 38–39  
  monocytes, **61**:13, 40  
  Reed Sternberg cells, **61**:12, 39  
  synoviocytes, **61**:15, 41  
  T cells, **61**:13, 39–40  
  gene, **61**:2, 4, 10–11; **63**:45  
  gp39 interactions, **63**:48, 52–53, 73  
  Ig production, **63**:58–70  
    IgA, **63**:64–65  
    IgE, **63**:63–64  
    IgG, **63**:65, 69–70  
    IgM, **63**:59, 62–63  
    signaling, **63**:58–59  
  intracellular signal transduction, **63**:50–52  
  lymphocyte homing, **64**:163  
  memory cell formation, **63**:70–73  
  molecular structure, **63**:45–46  
  signal transduction, **61**:27–31, 92–98  
    cAMP, **61**:98  
    CD58, **61**:97–98  
    IgA, **61**:94–95, 96–97  
    IgE, **61**:93–94, 95–96  
    IgG, **61**:94  
    IgG1, **61**:95–96  
  soluble, **63**:46  
  structure, **61**:2, 4  
CD40-binding proteins, **63**:50–51
- CD40–CD40-L interactions, **61**:54, 55  
  B cell immunopoiesis, **61**:47–55  
  *in vivo* role  
    animal models, **61**:44–45  
    arthritis, **61**:46  
    glomerulonephritis, **61**:46  
    immune response, **61**:45–47  
    X-linked hyper-IgM syndrome, **61**:1, 18, 41–44, 92–93
- CD40-dependent activation, **52**:206–212
- CD40–gp39 interactions, **63**:44, 48, 52–53, 73
- CD40 ligand, **61**:1, 24, 54  
  association with follicular dendritic cells and PALS, **60**:269–271  
  B cell proliferation, **63**:58, 60–61  
  cloning, **61**:17–18; **63**:46–48  
  expression, **61**:18, 20–22; **63**:48  
  gene, **61**:18  
  and germinal center reaction, **60**:273–276  
  identification, **63**:46  
  in IgE isotype switching, **60**:38–39  
  molecular structure, **63**:48–49  
  in pathogenesis of HIGM1, **60**:43–48  
  soluble form, **61**:26  
  structure, **61**:17–18, 19  
  trimerization, **61**:26  
  X-linked hyper-IgM syndrome, **61**:1, 18, 41–44, 92–93
- CD40 receptor associated factor 1, **61**:29–31
- CD42, human leukocytes and, **49**:85
- CD43, **48**:248  
  human leukocytes and, **49**:117
- CD44, **52**:158–159; **59**:384  
  and extracellular matrix, **54**:282–291  
  human, schematic representation, **54**:275, 276  
  human leukocytes and, **49**:85–86, 88  
  isoforms, **54**:275–281  
  ligand recognition, **54**:271–272  
  lymphocyte–HEV interaction, **65**:359–360  
  lymphocyte homing, **64**:160–161, 165, 177  
  to thymus and bone marrow, **64**:177  
  and lymphocytic homing, **54**:291–302  
  molecular isoforms and posttranslational modifications, **54**:272–282  
  properties, **64**:146  
  regulation of interaction with extracellular matrix, **54**:302–318  
  role in lymphocyte development, **54**:271

- and T cell development, **58**:134  
 and tumor cell migration, role of CD44 in metastasis, **54**:318–325
- CD44* gene, **64**:167
- CD45, **48**:283; **52**:159–160; **63**:164–165, 198  
 B cell studies, **66**:12–14, 22–37  
 CD2 and, **66**:7–8, 33, 35–36  
 CD3 and, **66**:9–12, 34  
 CD4<sup>+</sup> cells and, **66**:18, 26, 35–36  
 CD7 and, **66**:34–35  
 CD8<sup>+</sup> cells and, **66**:18, 26, 35–36  
 CD22 and, **66**:50–51  
 CD100 and, **66**:16–17  
 characterization, **58**:131–132; **66**:1–5, 55–56
- deficient cell lines  
 B cells, **66**:22–26  
 T cells, **66**:18–22
- functions, **66**:55  
 CD45-deficient cell line studies, **66**:18–26  
 gene-targeted mouse studies, **66**:26–31  
 lymphocyte development and activation, **66**:4, 5–17  
 molecular mechanisms, **66**:31  
 regulation, **66**:45–49, 56  
 Src family kinases, regulation, **66**:4, 23, 39–45  
 structure-function analysis, **66**:46–49
- Fyn, **63**:135
- human leukocytes and, **49**:87, 113–114
- Lck, **63**:136
- lymphocyte adhesion, **66**:15–17
- p53/56<sup>bn</sup> and, **66**:24, 37, 39, 44
- p56<sup>lck</sup> and, **66**:11, 12, 19–21, 26, 37–39, 39–44, 53
- p59<sup>bn</sup> and, **66**:19–21, 37, 38, 39–43
- p70<sup>pp</sup> and, **66**:21–22, 26
- p72<sup>sk</sup> and, **66**:21, 23–24, 26, 45
- phenotypic identification of memory T cells with, **53**:225–227
- phosphorylation, **66**:53–54
- post-translational modification, **66**:4, 53–55
- proteolysis, **66**:46–47
- regulation, **66**:49–53, 56
- role in negative selection, **58**:172
- structure  
 domain structure, **66**:2  
 isoforms, **66**:2–3, 5  
 structure–function analysis, **66**:46–49  
 substrates, **66**:31–39, 49–53, 55  
 T cell studies, **66**:6–12, 18–22, 32–36  
 ZAP70, **63**:138
- CD45RA, **66**:7, 15, 16, 36  
 CD45RB, **66**:35  
 CD45RO, **66**:7, 15, 16, 35  
 CD46, *see* Membrane cofactor protein  
 CD48, **52**:160  
 CD49d, multiple myeloma, **64**:246, 247  
 CD49d/CD29, properties, **64**:146  
 CD50, lymphocyte homing, **64**:158  
 CD55, *see* Decay-accelerating factor  
 CD56, multiple myeloma, **64**:247  
 CD57, **61**:51  
 CD58, **59**:377–378  
 CD40 expression, **61**:97  
 expression, **64**:160  
 multiple myeloma, **64**:247  
 CD59, **48**:240–241; **61**:204, 251–254  
 deficiencies in PNH, **60**:75–78, 89  
 expression on all blood cells, **60**:78
- CD62E, **65**:354  
 properties, **64**:147
- CD62L, **65**:354
- CD62P, **65**:354  
 properties, **64**:147
- CD69, **48**:248–249; **52**:163  
 expression on lung eosinophils, **60**:186
- CD72, **52**:160
- CD73, **48**:241; **52**:160–161  
 human leukocytes and, **49**:112  
 lymphocyte homing, **64**:162–163  
 properties, **64**:146  
 shedding, **64**:171
- CD74, **52**:161
- CD76, **52**:162
- CD77, **52**:162–163
- CD78, **52**:163–164
- CD80, **62**:132
- CD86, **59**:325–326, 378; **62**:132
- CD95, **59**:329–331; **61**:9  
 in myeloma cells, **64**:259
- CD100, CD45 and, **66**:16–17
- CD102, properties, **64**:147
- CD106, properties, **64**:147
- CD621, properties, **64**:146
- CD antigens, expression on basophils and mast cells, **52**:336–337
- cdk, rapamycin, **61**:183–187
- cDNA, *see* Complementary DNA



- CDP571  
 rheumatoid arthritis, **64**:305, 306  
 ulcerative colitis, **64**:310
- CDR, *see* Complementarity determining region
- CDw32/Fc $\gamma$ RII, **52**:153–154
- CDw75, **52**:161–162
- C/EBP, **65**:3–7, 3–8  
 knockout mice studies, **65**:30  
 structure of, **65**:1  
 transcriptional regulation, **65**:3–8
- C/EBP $\gamma$ , **65**:18–19
- Celiac disease  
 4-kDa Bg/II RFLP fragment, **48**:145  
 4-kDa R5aI class II fragment, **48**:145  
 DP allele, **48**:145  
 DP  $\alpha$  allele, **48**:145  
 DP  $\beta$  allele, **48**:145  
 DP  $\alpha$ -DQw1  $\beta$ , **48**:146–147  
 DP  $\alpha$  polymorphism, **48**:145  
 DP  $\beta$  polymorphism, **48**:145  
 DQw2  $\alpha$  chain, **48**:146  
 DR3, **48**:144, 147  
 DR3-DQw2 haplotype, **48**:144  
 DR5, **48**:144, 147  
 DR7, **48**:144, 147  
 DR  $\alpha$ -DQw1  $\beta$ , **48**:146–147  
 DRw8, **48**:147  
 gluten-derived peptide, **48**:147–148  
 HLA class II, **48**:144  
 HLA class II antigen, **48**:147  
 hybrid HLA-DQ molecule, **48**:147  
 with malignant histiocytosis, gene rearrangements and, **40**:292–293  
 and  $\gamma\delta$  TCR expression, **58**:329  
 triggering factor, **48**:144
- Cell adhesion  
 B cell formation and, **41**:185, 235, 237, 239  
 B cell precursors, **41**:194, 195, 198, 200, 201  
 bone marrow cultures, **41**:209, 212, 213, 219, 220  
 genetically determined defects, **41**:228, 231  
 lymphohemopoietic tissue organization, **41**:186–188  
 population dynamics, **41**:208  
 soluble mediators, **41**:234  
 stromal cells, **41**:214–216  
 cascade, **58**:381–389; **64**:181–184
- CD23 antigen and, **49**:163–165, 169, 176  
 cytotoxicity and, **41**:271, 272  
 deficiencies, **64**:193–195  
 eosinophils, **60**:164–178  
 flowing leukocytes to platelets, **58**:355  
 hybrid resistance and, **41**:368, 393  
 leukocyte–endothelial, **58**:376–378  
 lymphocytes, **66**:15–17  
 in high endothelial venules, **65**:367–372  
 mechanisms, and eosinophils, **51**:333–336  
 neutrophil, IL-8 effects on, **55**:114  
 by stem cell factor and ligand interaction, **55**:37  
 strong, role of integrins, **58**:383–388  
 tight, pro-T cells to endothelium, **58**:393  
 vascular, and emigration of inflammatory cells, **60**:330–332
- Cell adhesion, receptors and recognition molecules, **52**:357–366  
 integrins, **52**:358–361  
 $\beta$ 1 integrins, **52**:358–359  
 $\beta$ 2 integrins, **52**:359–361  
 $\beta$ 3 integrins, **52**:361  
 other recognition molecules, **52**:366  
 recognition molecules  
 CD4 and CD8, **52**:363  
 ICAM-1/CD54, **52**:361–363  
 Ig supergene family, **52**:361–364  
 LFA-2/CD2 and LFA-3/CD58, **52**:361  
 MHC class I and class II, **52**:364  
 other, Ig superfamily, **52**:364  
 stem cell factor receptor/ckit, **52**:363–364  
 VCAM-1, **52**:363  
 selectins and related molecules, **52**:364–366
- Cell adhesion molecules, **52**:166–168; **59**:383,  
*see also specific molecules*  
 activation of, **52**:168  
 affecting migration of naive and memory cells, **53**:248–249  
 clustering, **64**:173  
 cocapping, **64**:173  
 endothelial, and lymphocytes, **58**:352  
 endothelial binding, **64**:146  
 expression and function regulation, **64**:139–140, 146, 147, 163–173  
 Ig superfamily, **52**:167  
 integrin family, **52**:166  
 lymphocyte binding, **64**:147

- multistep adhesion cascade, **64**:181–184  
 in myeloma cells, **64**:246–249  
 parallels with regulatory mechanisms,  
     **54**:308–310  
     LFA-1, **54**:309–310  
     L-selectin, **54**:310  
     Mac-1/CR3, **54**:310  
 platelet gpIIb-IIIa integrin, **54**:309  
 production during inflammation, **58**:10  
 pulmonary inflammation, **62**:267, 288  
 regulation  
     alternative splicing, **64**:167  
     conformational events, **64**:169–170  
     internalization, **64**:170–172  
     oligomerization, **64**:172–173  
     ontogenic, **64**:164–165  
     posttranslational modifications,  
         **64**:168–169  
     secretion, **64**:170–171  
     shedding, **64**:170–171  
     upregulation and induction, **64**:  
         165–167  
 SCID and, **49**:384, 397  
 selection family, **52**:167–168  
 surface antigens of human leukocytes and,  
     **49**:79, 82–89, 86, 88, 114, 116  
     antigen-specific receptors, **49**:78–80  
     complement components, **49**:92–93  
 as targets of autoantibodies in pemphigus  
     and pemphigoid, **53**:309, 312, 314  
**Cell cycle**  
     control, IL-2-dependent G<sub>1</sub>-phase  
         progression, **61**:179–187  
     control mechanisms in tolerance,  
         **54**:411–414  
         blocking negative signaling with  
             antisense myc, **54**:413–414  
         myc, TGF- $\beta$  and pRB, **54**:411–413  
     immunosenescence and, **46**:221–223, 227,  
         234, 235, 253  
     interventions, **58**:248–250  
     regulation of V(D)J recombination and  
         DSB repair, **58**:70–74  
     regulatory kinase p34<sup>cdc2</sup>, blockade, **58**:267  
     switch recombination, **61**:116–117  
**Cell cycle checkpoints**  
     G<sub>0</sub>–G<sub>1</sub>, and induction of apoptosis,  
         **58**:249–250  
     mechanisms, **58**:66–69, 71–74  
     mutations in, **58**:29  
**Cell death, see also Apoptosis**  
     ataxia telangiectasia cells, **58**:69  
     B cells, **59**:296–300, 336–339  
     deficient regulation, and disease states,  
         **58**:212  
     Fas-mediated, **57**:129, 133–134, 140  
     in immune system, *see* Apoptosis, in  
         immune system  
     intrathymic, **58**:166–168  
     T cell  
         induction, **58**:224–240, 238  
         inhibition, **58**:240–265  
             by IL-2, **58**:269  
             *in vitro*, **58**:242–253  
             *in vivo*, **58**:253–265  
         TCR-mediated, **58**:215–224  
**Cell degradation, redundant effector  
 pathways, 58:269–270**  
**Cell density, IL-2 activity and, 42:166**  
**Cell lines, see also specific cell lines**  
     CD44 expression and hyaluronan binding,  
         **54**:303  
     CD44-positive, **54**:304  
     IL-1ra production, **54**:190  
     murine, perforin-deficient, **60**:293–294  
     mutant, and GPI anchor synthesis,  
         **60**:65–67  
     PNH, **60**:79–80  
     T cell, Trac, **60**:43  
     verification of perforin in, **51**:224–227  
**Cell lysis, 51:25–28**  
**Cell-mediated cytotoxicity**  
     HIV infection and, **47**:410, 411  
     NK cells and, **47**:189–196  
**Cell-mediated killing, 41:319, 320**  
     granule proteins and  
         cell lines, **41**:286, 287  
         cytoplasmic granules, **41**:287–291  
         lymphotoxin, **41**:298  
         membrane attack complex, **41**:310  
         proteoglycans, **41**:298, 299  
         serine esterases, **41**:297, 298  
         TNF-related polypeptides, **41**:298  
     pore-forming proteins and  
         amoebas, **41**:312, 313  
         biochemical properties, **41**:292–295  
         eosinophil cationic protein, **41**:311, 312  
         membrane binding, **41**:295, 296  
         purification, **41**:291, 292

- Cell-mediated lympholysis  
 hybrid resistance and, **41:355, 364, 394–396**  
 T cell subsets and, **41:43, 45, 51, 57, 108**
- Cell-mediated lysis, hybrid resistance and, **41:407**
- Cell receptor binding, segmental flexibility, **48:24–26**
- Cell surface molecules  
 T cell activation and, **41:1, 2**  
 accessory molecules, **41:14, 15**  
 IL-1 receptor, **41:13, 14**  
 T1, **41:13**  
 T11, **41:8–10**  
 T cell antigen receptor, **41:2–8**  
 Thy-1, **41:10, 11**  
 Tp44, **41:11–13**  
 T cell subsets and, **41:40, 43–48**  
 accessory molecules, **41:49, 50**  
 T cell receptor, **41:40–43**  
 TH responses, **61:355–357**
- Cell surface structures, functionally associated with Fc $\epsilon$ R1 molecules, **52:391–396**  
 cell surface glycolipids, **52:393–394**  
 Fc $\gamma$  receptors, **52:394–396**  
 G63, **52:394**  
 mast cell chromolyn binding sites, **52:392–393**  
 ME491 (CD63), **52:393**
- Cell surface typing, with mAbs: human mast cells and basophils, **52:335–339**
- Cell survival, role of stem cell factor receptor–ligand interaction, **55:38–39**
- Cell tropism, HIV infection, **63:84, 90**
- Cellular control mechanisms, summary, **52:73–74**
- Cellular distribution, receptors for Fc region of Ig, **63–64**  
 basophils and mast cells, **40:68**  
 B cells, **40:66–67**  
 macrophages and monocytes, **40:64–66**  
 neutrophils, **40:68**  
 platelets, **40:68**  
 T cells, **40:67–68**
- Cellular immune response  
 effector phase, **60:332–346**  
 regulation of, **40:77–79**  
 and Th1 cells, **60:348–349**
- Cellular immunity, **64:3; 65:277–278, 322–323**  
 adenovirus, **65:279**  
 cytomegalovirus infection, **65:278–279**  
 Epstein–Barr virus (EBV), **65:279**  
 evolution of, **52:108–111**  
 antigen processing and presentation, **52:108–110**  
 T cell antigen receptor, **52:110–111**  
 herpes simplex virus, **65:279**  
 HIV-1 disease, **63:97, 98**  
 HIV infection, **65:280**  
 adoptive immunotherapy, **65:317–320**  
 CTL-mediated lysis, **65:280–281**  
 CTLs and, **65:280–322**  
 HLA and, **65:284–286**  
 replication suppression, **65:281–284**  
 in seronegatives, **65:287, 307–309**  
 vaccines, **65:320–322, 323**  
 HLA class I system, **65:279**  
 hybrid resistance and, **41:370**  
 influenza virus, **65:278**  
 pituitary hormones, **63:407**
- Cellular switches, self-tolerance, **59:281**
- Cellulose acetate, hybrid resistance and, **41:372**
- Censoring, B cells, **59:302–304, 308–309, 311–312, 331–341**
- Central nervous system  
 allergic reactions, **61:365–367**  
 autoimmune demyelinating disease and, **49:357, 369**  
 autoimmunity in, **62:98–99**  
 $\beta$ -endorphin receptors, distinction from those on lymphocytes, **39:312**  
 HIV infection and, **47:378, 413**  
 immunopathogenic mechanism, **47:393**  
 neuropsychiatric manifestations, **47:403, 404**  
 IFN- $\gamma$  and, **62:91–92**  
 lesions, immunological effects, **39:299**  
 NK cells and, **47:266–269**
- Centrocytes, **61:51, 53**  
 CD23 antigen and, **49:171**
- Centromeres  
 antinuclear antibodies and, **44:121, 122, 130, 131, 133**  
 maps of Ig-like loci and, **46:26, 30, 33, 44**
- Cerebrovascular disease, aPL antibodies and, **49:220**

- Cervical cancer, antigens, **62:240**
- Cetirizine, modulated eosinophil migration, **60:174**
- c-fms*, and *c-kit*, evolutionary relationship, **55:9–10**
- c-Fos  
 B cell genesis, **63:220–221, 248–250**  
 and c-Jun, **58:138–139**  
 T cell activation and, **41:27, 28**
- c-fos*  
 IL-2 signal transduction, **63:161, 171**  
 SIE, **63:141**  
 T cell activation, **48:291–292**
- CH3 domain  
 Fc, **48:20–21**  
 IgG, **48:20–21**
- Channel formation  
 cytolytic protein and, **41:318, 319**  
 membrane attack complex of complement, **41:301–303, 306, 307, 311**
- Charcot-Leyden crystal  
 in basophils, **39:183**  
 in eosinophils, **39:181–183**  
 lysophospholipase activity, **39:182–183**
- Charcot-Leyden crystal protein, **60:156, 160, 164, 201**
- Chediak-Higashi syndrome, NK cells and, **47:224, 225, 299**
- C-helix, peptide homologs, **43:63**
- Chemiluminescence, NK cells and, **47:263, 266**
- Chemoattractants  
 eosinophil, **60:174–178**  
 lymphocyte homing, **64:152–154**
- Chemoimmunoconjugates, as cancer treatment, *see also* Alkylating agent-antibody conjugates; Anthracycline-antibody conjugates  
 barriers to antibody-targeted chemotherapy biodistribution, **56:348**  
 effects of, **56:347–348**  
 route of administration, **56:348–350**  
 tumor antigen-heterogeneity, **56:352–354**  
 tumor perfusion, **56:350–352**  
 tumor vasculature, **56:350–352**
- chemistry  
*cis*-aconitic anhydride, **56:318–319**  
 carbodimides, **56:316–318**  
 conjugation procedure, **56:312–314, 360**  
 conjugation strategies, **56:314–323**  
 cyanuric chloride, **56:321**  
 design strategy, **56:324–325**  
 diazo reaction, **56:319**  
 ester linkage, **56:323**  
 glutaraldehyde, **56:315**  
 hydrazone linkage, **56:322–323**  
 imidoesters, **56:320–321**  
 intermediary carriers, **56:323–324**  
 mixed anhydrides, **56:319**  
 noncovalent bonds, **56:321–322**  
 periodate oxidation, **56:315–316**  
 photoactivation, **56:323**  
*N*-succinimidyl 3-(2-pyridyldithio) propionate, **56:319–320**  
 thioether linkage, **56:321–322**
- clinical trials, **56:354–361**
- drug-monoclonal antibody conjugates  
 alkylating agent-antibody, **56:328–333**  
 anthracycline-antibody, **56:333–338**  
 antineoplastic drugs, **56:313**  
 cytotoxic drugs, **56:342–343**  
 folic acid antagonists, **56:338–340**  
 functional studies, **56:344–347**  
 mode of action, **56:344–347**  
 morphological studies, **56:347**  
 preclinical testing, **56:326–328, 343**  
 vinca alkaloids, **56:340–342**
- monoclonal antibodies as carriers  
 conjugate size as determinant of permeability, **56:310–311**  
 development, **56:302–304**  
 heterogeneity, **56:306–308**  
 immunogenicity, **56:311–312**  
 internalization, **56:308–310**  
 localization, **56:306–308**  
 modulation, **56:308–310**  
 specificity, **56:305–306**  
 targets, **56:305–306**  
 toxicity, **56:311–312**
- studies, **56:360–361**
- Chemokine receptors  
 C5a, gene mapping, **55:135**
- CC  
 amino acid sequences, **55:129**  
 biochemical studies, **55:125–128**  
 on erythrocytes, **55:128**
- cloning, **55:131, 134**
- CXC  
 amino acid sequences, **55:129**

- Chemokine receptors (*continued*)
- binding, **55**:136
  - biochemical studies, **55**:122–125
  - ELR motif, **55**:136–138
  - on erythrocytes, **55**:128
  - genes, **55**:135
  - G-protein coupling, **55**:138–139
  - LESTR52, cloning of, **55**:131, 134
  - lymphocytes in high endothelial venules, **65**:367–368
  - MCP-1, binding studies of, **55**:125–126
  - MDCR15, cloning of, **55**:131, 134
  - MIP-1 $\alpha$ 
    - cloning, **55**:131
    - gene cloning, **55**:135
  - RANTES, binding studies, **55**:126–128
  - regulation, **55**:139–140
  - structure, **55**:132–135
  - 7-TM, G-protein coupling to, **55**:138
- Chemokines, **62**:80, *see also* Cytokines
- allergic airway inflammation, **62**:285
  - arthritis role, **55**:143–144, 147
  - biological effects, **55**:115–122
  - cardiovascular system role, **55**:146
- CC
- biological effects, **55**:120
    - on basophils, **55**:116–117
  - cellular sources, **55**:105
  - chemical properties, **55**:98, 100–102
  - inactivation, **55**:102–103
  - molecular structure, **55**:98, 100–102
  - proteolytic processing, **55**:102–103
- cellular effects
- basophils, **55**:116–117
  - eosinophils, **55**:117
  - neutrophils, **55**:115–116
- cellular sources, **55**:105–112
- leukocytes, **55**:105–107
  - macrophages, **55**:106
  - monocytes, **55**:105–106
  - tissue cells, **55**:107, 111
- connective tissue-activating peptide III
- biological effects on neutrophils, **55**:115
  - chemical properties, **55**:97, 99
- CXC
- biological effects, **55**:115, 118–120
    - on basophils, **55**:116
    - on lymphocytes, **55**:119
    - on monocytes, **55**:118
    - on neutrophils, **55**:115–116
  - cellular sources, **55**:105
  - chemical properties, **55**:97–101
  - inactivation, **55**:102–103
  - molecular structure, **55**:97–101
  - proteolytic processing, **55**:102–103
  - in eosinophil migration, **60**:177–178
  - genes
    - chromosomal localization, **55**:103–104
    - expression regulation, **55**:104–105
    - organization, **55**:103
  - granulomatous lesions, **62**:282
  - GRO $\alpha$ , chemical properties, **55**:100
  - HIV-1 antiviral effect, **66**:281–282
  - in integrin activation, **58**:378–379
  - in vivo* effects, **55**:121–122
  - lung disease role, **55**:144–147
  - lymphocyte adhesion and, **64**:152–154
  - lymphocytes in high endothelial venules, **65**:367–368
- MCP-1
- biological effects on monocytes, **55**:118
  - chemical properties, **55**:101
  - production by monocytes, **55**:106
- MIP-1 $\alpha$
- biological effects on neutrophils, **55**:115–116
  - chemical properties, **55**:101
- MIP-1 $\beta$ , chemical properties, **55**:101
- NAP-2, chemical properties, **55**:99–100
- in neutrophil recruitment, **60**:339
- pathology role, **55**:142–148
- platelet factor 4
- biological effects on neutrophils, **55**:115
  - chemical properties, **55**:97, 99–100
- pulmonary immunity, **59**:373
- pulmonary inflammation, **62**:259, 268–270
- RANTES, biological effects on eosinophils, **55**:117
- rheumatoid arthritis and, **64**:294, 316, 317
- sepsis and
- IL-8, **66**:135–141
  - MCP-1, **66**:141–142
- signal transduction, **55**:140–142
- skin disease role, **55**:142–143, 147
- Chemotactic receptor, surface antigens of human leukocytes and, **49**:93, 111
- Chemotaxis
- adoptive T cell therapy of tumors and, **49**:328, 335
  - complement receptor 1 and, **46**:192, 199

- eosinophils, **60**:174–178  
 IBD and, **42**:307, 308  
 IL-2 and, **44**:166, 169  
 leukocyte integrins and, **46**:151, 160, 161, 163, 164, 166, 167  
 lymphocyte homing and, **44**:320  
 stem cell factor–ligand interaction in, **55**:37–38
- Chemotherapeutic agents, MG and, **42**:265–268, *see also* specific agents
- Chemotherapy  
 adoptive T cell therapy of tumors and, **49**:287, 292–296, 311  
 hybrid resistance and, **41**:350  
 SCID and, **49**:388, 390, 396–397  
 targeted, concept of, **56**:301–303
- CH gene, **43**:239
- Chicken  
 B cells, repertoire formation in, *see* B cells  
 Ig $\lambda$  gene, **48**:41–64  
 genomic organization, **48**:44–46  
 germ-line allele, **48**:49–51  
 Ig $\lambda$  allele, **48**:49–51  
 J $\lambda$  gene segment, **48**:44–46  
 rearrangement, **48**:46–49  
 somatic diversification, **48**:41–64  
 structure, **48**:44–46  
 V gene segment, **48**:44–46  
 V segment, **48**:52–54
- ovalbumin, T cell subsets and, **41**:53
- retrovirus-induced B cell neoplasia in bursa of fabricius  
 research, **56**:468–469  
 resistance, **56**:470  
 susceptibility, **56**:469–470  
 transformed follicles in lymphoma-resistant strains, **56**:471
- Chimeras, *Ir* genes and, **38**:58–61, 70  
 allogeneic, **38**:62, 64  
 allophonic, **38**:62, 63  
 antigen binding, **38**:114  
 complementation, **38**:73, 74  
 cross-reactive lysis, **38**:186  
 H-Y antigen, **38**:176–179  
 immunodominance, **38**:182–184
- T cells, **38**:64  
 cytotoxic, **38**:165–167, 172  
 interactions, **38**:158–160  
 selection, **38**:131, 133, 134  
 tolerance, **38**:120, 123, 126–129
- Chimeras, radiation, **59**:106, 109–111
- Chimeric antibodies, **44**:79–82; **48**:2; **64**:261, 263, 323  
 therapeutic, **44**:87, 88
- Chimeric genes, genetically engineered antibody molecules and, **44**:76, 77, 83, 84
- Chimeric mouse, RAG-2-deficient blastocyst complementation, **62**:36
- Chimerism, **59**:106, 109–111, *see also* Genetic chimerism  
 functional, involving DNA binding and protein dimerization, **50**:133–138  
 IL-2 receptors, **59**:258–259
- Chimpanzee, HIV-1 infection, **52**:455–461  
 model for testing HIV-1 vaccines, **52**:457–459  
 pathogenesis of HIV-1 infection in, **52**:455–457  
 use to test CD4-based therapies, **52**:459–461
- Chlamydia trachomatis*, vaccine design, **60**:136
- C $_{II}$  locus, **62**:1
- Chlorambucil, chemotherapeutic use in cancer treatment, **56**:328–330, 344–345
- Chloroleukemia, cell line, rat, observation, **50**:73
- Chloroquine, **41**:56, 57, 281; **42**:176  
 antigen processing and, **39**:63–64  
 humoral immune response and  
 antigens, **45**:13–15, 17, 20  
 physical interaction, **45**:38, 51  
 synthetic T and B cell sites and, **45**:223
- Chlorpromazine, aPL antibodies and, **49**:203, 212–213, 221, 224, 257
- Cholecystokinin receptor, **48**:181
- Cholera toxin, **61**:98
- Cholestasis, intrahepatic severe, **50**:190–191
- Cholesterol  
 aPL antibodies and  
 affinity purification, **49**:229–230  
 LA antibodies, **49**:244–245  
 specificity, **49**:234–236, 248  
 cytotoxicity and, **41**:279, 300, 302, 317, 318  
 spontaneous autoimmune thyroiditis and, **47**:439  
 surface antigens of human leukocytes and, **49**:116

- Cholinergic nerve differentiation factor, *see*  
Leukemia inhibitory factor
- Chondroitin sulfate A, cell-mediated killing  
and, **41:298, 299**
- CHOP-10, **65:3–6**
- Chromatids  
maps of Ig-like loci and, **46:3**  
murine lupus models and, **46:83**
- Chromatin  
antinuclear antibodies and, **44:130**  
B cell formation and, **41:204, 221**  
configuration during V(D)J joining of  
antigen receptor genes, **56:37, 41–46**  
cytolysis and, **41:283**  
Ig gene superfamily and, **44:12**  
Ig heavy-chain variable region genes and,  
**49:37, 56**  
immunosenescence and, **46:234**  
NK cells and, **47:214**  
structure, transcription regulation,  
**63:200–201**  
T cell development and, **44:217**
- Chromosomal abnormalities  
on adjacent oncogenes, consequences,  
**50:124–132**  
*c-myc* in Burkitt's lymphoma  
translocations, **50:124–128**  
gene fusion resulting from chromosome  
translocation, **50:128–129**  
helix-loop-helix oncogenes in  
chromosome translocations,  
**50:129–130**  
oncogene location after translocation,  
**50:131–132**  
transcriptional disruption of LIM domain  
oncogenes by translocation,  
**50:130–131**  
lymphoid cells, effect, **50:132–140**  
differentiation-related translocation  
oncogenes, **50:139**  
functional chimerism involving DNA  
binding and protein dimerization,  
**50:133–138**  
other unusual proteins affected by  
chromosome translocations,  
**50:139–140**
- Chromosomal mapping  
B cell surface antigens, **52:129, 137**  
T cell receptor and, **38:16, 17**
- Chromosomal translocation, *see also*  
Translocation  
Ars A response and, **42:129–130**  
Burkitt's lymphoma, *c-myc* in, **50:124–128**  
*c-myc* gene, **64:227–229**  
gene fusion resulting, **50:128–129**  
helix-loop-helix oncogenes in, **50:129–130**  
human B cell neoplasia and, **38:245–248,**  
**272**  
in Burkitt lymphoma, **38:253–259, 271**  
*c-myc* activation, **38:261, 263**  
*c-myc* oncogene, **38:248, 253–259, 271**  
t(8;14), **38:249–251, 254, 260**  
t(11;14), **38:264–267**  
t(14;18), **38:267–271**  
and inversion, in lymphoid tumors,  
mechanism, **50:121–122**  
other unusual proteins affected by,  
**50:139–140**  
t(8;14)  
*c-myc* activation, **38:260, 264**  
human B cell neoplasia, **38:249–251,**  
**254, 269**  
t(11;14) chromosome translocation,  
**38:264–267, 272**  
t(14;8) chromosome translocation,  
**38:264**  
t(14;18) chromosome translocation,  
**38:267–272**  
T cell receptor  $\delta$  genes, **43:160–161**  
and timing of inversion, **50:122–124**
- Chromosome 1  
CD1 locus, **58:319**  
selectins on, **58:353**
- Chromosome 2, radiation hybrid with *xrs*  
cells, **58:57**
- Chromosome 4q, IL-2, gene, human, **39:5**
- Chromosome 5, transfer into *XR-1* cells,  
**58:52**
- Chromosome 8, complementation of *scid*  
defects, **58:50–51**
- Chromosome 11  
GM-CSF gene, murine 9, **39:18**  
IL 3-gene, murine 7–8, **39:18**
- Chromosome 14  
q region shared by ECP and eosinophil-  
derived neurotoxin, **60:193**  
rearrangement in ataxia telangiectasia,  
**58:68**  
V<sub>H</sub> locus mapping, **62:4–7, 23, 24**

- Chromosome 15  
 orphan  $V_H$  and  $D_H$  loci, **62**:10–12, 19, 20, 23  
 translocation, **64**:228
- Chromosome 16, orphan  $V_H$  and  $D_H$  loci, **62**:10–12, 19, 20, 23
- Chromosome 19, integration of adeno-associated virus, **58**:424–425
- Chromosome 22, location of  $p70^{ku}$ , **58**:57
- Chromosomes  
 antinuclear antibodies and, **44**:99, 105, 121, 122, 125  
 autoimmune thyroiditis and, **46**:268, 272  
 CD5 B cell and, **47**:132, 148, 157  
 CD8 molecules and, **44**:271, 276–278  
 chemokine gene, localization, **55**:103–104  
*c-kit* location, **55**:7–9  
 complement receptor 1 and, **46**:190  
 complement receptor 2 and, **46**:202  
 errors, **58**:72–74  
 GPI synthesis genes, location, **60**:71  
 HIV infection and, **47**:380  
 humoral immune response and, **45**:32  
 Ig gene superfamily and, **44**:9, 34, 47  
 Ig heavy-chain variable region genes and, **49**:1, 3, 6, 55  
 IL-1 and, **44**:156  
 IL-1ra genes, localization, **54**:177–180  
 interchromosomal recombination during V(D)J joining of antigen receptor genes, **56**:120–121  
 leukocyte integrins and, **46**:159, 160, 170  
 maps of Ig-like loci and, **46**:2, 3, 5–7  
 MHC, **46**:28, 31, 33  
 structure, **46**:7, 9–13, 18, 19, 21, 23, 25–27  
 T cell receptor, **46**:36, 39, 42, 43, 45  
 murine and human Jaks, location, **60**:3–4  
 murine lupus models and, **46**:63, 64  
 NK cells and, **47**:227, 228, 231  
 regulators of complement activation and, **45**:381, 403, 404, 411  
 stem cell factor location, **55**:13–15  
 surface antigens of human leukocytes and, **49**:91–92  
 T cell receptor and, **45**:110, 115
- Chronic graft-versus-host disease  
 cellular mechanisms, **40**:408–409  
 clinical manifestations, **40**:406–407  
 pathologic manifestations, **40**:407–408  
 risk factors, **40**:409–410  
 treatment and prevention, **40**:410
- Chronic granulomatous disease, X-linked, **59**:248
- Chronic inflammatory disease, *see*  
*Inflammatory bowel disease*
- Chronic lymphocytic leukemia  
 CD5 B cell and  
 aging, **47**:123  
 autoimmune diseases, **47**:150  
 Ig gene expression, **47**:153–159  
 malignancies, **47**:123, 124  
 physiology, **47**:136, 140, 141  
 surface antigen, **47**:146, 147  
 NK cells and, **47**:298
- Chronic myelogenous leukemia  
 circulating IL-4 levels, **53**:14–15  
 leukocyte integrins and, **46**:160  
 lymphoid blast crisis of, gene rearrangements and, **40**:290–291
- Chronic myeloid leukemia, B cell formation and, **41**:188
- Chronic obstructive pulmonary disease, **62**:261, 286
- Churg–Strauss syndrome  
 complication of asthma, **60**:216  
 in pulmonary eosinophilia, **60**:226
- Ciliary neurotrophic factor, **65**:20  
 CNTF/LIF/OSM/IL-6 subfamily, **61**:151–152
- Ciliary neurotrophic factor receptor and high-affinity LIF receptor, **53**:43–44, 46  
 pleiotropic nature of, **53**:46–47  
*ctm*, **65**:48–49, 78
- Circumsporozoite proteins  
 derived T cell epitopes, **60**:108–123  
 sporozoite malaria vaccine and, **45**:292–294, 319–322  
 antibodies, **45**:300  
 cloning, **45**:294–296  
 endemic areas, **45**:315–317  
 human trials, **45**:315  
 immunity, **45**:291, 292  
 interferon- $\gamma$ , **45**:306  
*Plasmodium vivax*, **45**:317, 318  
 repeats, **45**:296–300  
 synthetic T and B cell sites and, **45**:228, 258



- Circumsporozoite reaction, sporozoite malaria vaccine and, **45:288, 290**
- Cirrhosis, primary biliary, and antibodies to self-antigens from human donors, **57:244–245**
- Cisplatin  
and apoptosis, **58:237–240**  
in cancer treatment, **56:329, 332**
- cis*-regulatory elements, **62:37, 42–43, 49–52**
- c-Jun, **62:42, 48**  
and c-Fos, **58:138–139**
- c-jun* oncogene, IL-2 signal transduction, **63:160–161, 171**
- CK-2 sequence, **48:81–82**
- CK226 antigen, **52:173**
- CK-I sequence, **48:81–82**
- c-kit, **60:26**
- c-kit*  
allelism with *W*, **55:6–7**  
and *c-fms*, evolutionary relationship, **55:9–10**  
characteristics, **55:3–6**  
chromosomal localization, **55:7–9**  
genomic organization, **55:7–9**  
and *PDGFR*, evolutionary relationship, **55:9–10**
- c-kit, stem cell factor receptor, **52:352–354**
- C3 complement component degradation fragments, **52:147**  
third component of, **52:148**
- CLA, *see* Cutaneous lymphocyte antigen
- Classic CD1 proteins, *see* CD1, group 1
- Class II inactivator (CHITA), **62:106**
- Class I modifiers, **65:48–49, 78**
- Class switching, **61:79–81**  
B cell differentiation, **61:82–84**  
heavy chain isotype expression, **61:82–84**  
isotype specificity regulation, **61:84–99**  
B cell activators, **61:90–92**  
CD40 signaling, **61:92–98**  
cytokines, **61:84–89**  
problems in other studies, **61:81–82**  
switch recombination, **61:129–130**  
3'  $\alpha$  enhancer, **61:121–123**  
control during cell cycle, **61:116–117**  
fine sequence specificity, **61:107–108**  
germline transcripts, **61:111–116**  
illegitimate priming model, **61:108–111**  
intrachromosomal deletion, **61:99–100**  
mutations, **61:108**  
protein-binding sites, **61:117–122**  
RNA splicing, **61:101–102**  
sequential switching, **61:105–107**  
sites, **61:102–105**  
substrates, **61:123–129**  
transchromosomal switching, **61:100–101**
- Clathrin-coated pits, complement receptor 1 and, **46:199**
- CLC, *see* Charcot-Leyden crystal
- CLC protein, *see* Charcot-Leyden crystal protein
- Cleavage  
CD23 antigen and, **49:156, 158, 160, 173**  
coupled, V(D)J recombination, **64:53–54**  
cytolytic protein and, **41:318**  
membrane attack complex of complement and, **41:299, 306**  
model, V(D)J recombination, **58:38–39**  
RAC, **64:57–58**  
reactions, in V(D)J recombination pathway, **58:30, 33–35**  
V(D)J recombination and, **64:52–54**
- Clinical disorders, and IL-6, **54:44, 45**
- Clonal abortion, **50:64; 52:312**  
and clonal anergy, **52:291–294**
- Clonal anergy, **48:217, 218**
- Clonal deletion, *see also* Deletion  
intrathymic, **51:165–173**  
cell biology of negative selection, **51:165–170**  
search for mechanism, **51:170–173**  
lymphocyte, physiology, **58:270–272**  
MTV superantigen-reactive T cells, **65:203–204, 210**  
nascent bone marrow B cells, **58:257**  
and peripheral tolerance to cancer, **58:421**  
putative interference of IL-2.VVith, **50:166–167**
- Clonal dominance, *PIG-A* mutant cells, **60:90–91**
- Clonal expansion, and V gene expression, **42:32–34**
- Clonal inactivation, by  $V\beta$  selective elements, **50:35–36**
- Clonality, definition based on Ig and T cell receptor gene rearrangements, **40:295–305**
- Clonal origin, PNH cells, **60:80–81**
- Clonal suppression, **48:218**

## Clones

- adoptive T cell therapy of tumors and,
  - 49:284, 289–290, 298, 334**
  - antigen recognition, **49:321, 324**
  - expression of antitumor responses, **49:325–326, 330**
  - mechanisms, **49:299, 301, 303–305, 311**
- antigen-presenting cells and, **47:45**
- antigen presentation, **47:65, 66, 68–71, 73**
- antigen processing, **47:91, 92**
- APC-T cell binding, **47:95, 99**
- cell surface, **47:61, 62**
- immunogeneity, **47:102, 103**
- interaction with T cells, **47:94**
- T cell-dependent antibody responses, **47:83**
- T cell growth, **47:99**
- tissue distribution, **47:48, 49**
- antinuclear antibodies and autoantibodies, **44:127, 137**
- autoantigen, **44:128–131**
- autoimmune response, **44:132**
- scleroderma, **44:122**
- SLE, **44:101, 108**
- aPL antibodies and, **49:238–239, 246, 249**
- autoimmune demyelinating disease and, **49:357**
- multiple sclerosis, **49:370, 372, 374**
- myelin basic protein, **49:358–361**
- TCR usage restriction, **49:363–368**
- autoimmune thyroiditis and, **46:263, 317, 318**
- antigens, **46:270, 272**
- cellular immune responses, **46:288, 289, 296**
- experimental models, **46:276, 279, 281, 282**
- humoral responses, **46:298, 301, 306, 308**
- prevention, **46:312, 313**
- autoreactive T cell, **45:418, 433**
- activation, **45:421–426**
- origin, **45:418–420**
- physiology, **45:427, 428, 430, 431**
- regulation, **45:431, 432**
- B cell formation and, **41:182, 184, 185, 238**
- B cell precursors, **41:191, 196, 200, 201**
- bone marrow cultures, **41:213, 216, 217, 219, 220**
- C3H/HeJ mice, **41:231**
- Ig genes, **41:203, 205**
- inducible cell line, **41:220–222**
- lymphohemopoietic tissue organization, **41:187**
- NZB mice, **41:226, 229**
- population dynamics, **41:207**
- SCID mice, **41:225, 226**
- W/W anemic mice, **41:224**
- CD4 and CD8 molecules and, **44:266–269, 298, 299, 301**
- CD4 molecular biology, **44:285, 292, 293**
- CD5 B cell and
  - aging, **47:122**
  - Ig gene expression, **47:151, 152, 154, 156, 158**
  - physiology, **47:133, 134, 136, 140, 142**
  - surface antigen, **47:146**
- CD8 molecular biology, **44:271, 273, 274, 276–280, 282**
- CD23 antigen and, **49:151–152, 154, 162–165**
- complement receptor 1 and, **46:188, 199**
- complement receptor 2 and, **46:201, 202, 211**
- cytolysis and, **41:274, 276, 280, 281, 285**
- cytotoxicity and, **41:319, 320**
- granule proteins, **41:286, 287, 291, 297**
- nature of mediation, **41:271, 273**
- pore formers, **41:317, 319**
- cytotoxic T cells and, **41:167**
- $\beta_2$ -microglobulin, **41:156**
- amino acid changes, **41:162**
- carbohydrate moieties, **41:154**
- exon shuffling, **41:138, 142, 144–146, 149**
- HLA class I antigens, **41:149–151**
- mAbs and, **41:162, 166, 167**
- genetically engineered antibody molecules and, **44:73–75, 78–80**
- helper T cell cytokines and, **46:111, 115, 116, 118, 121, 122**
- cross-regulation of differentiation, **46:130, 131**
- differential induction, **46:130**
- functions, **46:114, 117, 119, 120**
- human subsets, **46:139**
- immune responses, **46:136–138**

- Clones (*continued*)
- precursors of differentiation states, **46:123**
  - secretion patterns, **46:112, 113**
  - HIV infection and, **47:400, 411**
    - etiological agent, **47:380, 385**
    - immunopathogenic mechanism, **47:388, 390, 394**
  - humoral immune response and
    - antigens, **45:16, 17, 24**
    - cellular interactions *in vivo*, **45:80, 83**
    - helper T cells, **45:25–28, 30–32**
    - interleukins, **45:62, 63, 66, 69, 74, 75**
    - physical interaction, **45:35–37**
  - hybrid resistance and antibodies, **41:377**
    - antigen expression, **41:405**
    - marrow engraftment, **41:387**
    - NK cells, **41:375**
    - T cells, **41:383**
    - in vitro* assays, **41:394**
  - IgE biosynthesis and
    - antibody response, **47:6, 7, 10–12**
    - antibody response suppression, **47:33, 39**
    - binding factors, **47:13, 15–18, 20, 21, 27**
  - Ig gene superfamily and
    - evolution, **44:46**
    - MHC complex, **44:29**
    - receptors, **44:17, 18, 22–24**
  - Ig heavy-chain variable region genes and, **49:5, 8, 22, 32**
    - regulation, **49:55**
    - V<sub>H</sub> gene expression, **49:41–42, 47–48**
  - IL-1 and, **44:155, 179, 189**
  - immunosenescence and, **46:237, 249**
  - leukocyte integrins and, **46:156, 164, 171, 172**
  - maps of Ig-like loci and, **46:3–5**
    - MHC, **46:29, 32, 33**
    - structure, **46:11, 13, 15, 17, 18, 21, 23–27**
    - T cell receptor, **46:36, 37, 45**
  - murine lupus models and, **46:99, 100**
    - Ig germline, **46:66, 67, 71, 76–78**
    - lupus strains, **46:63**
    - T cell antigen receptor, **46:79, 82, 83, 88, 90, 91, 93, 95–97**
  - NK cells and, **47:188, 199, 291**
    - cytotoxicity, **47:252**
    - differentiation, **47:231, 234**
    - effector mechanisms, **47:240, 243, 245–248, 254, 264, 265**
    - hematopoiesis, **47:273, 274, 277, 279**
    - malignant expansion, **47:228**
    - morphology, **47:217**
    - surface phenotype, **47:202, 204–207, 209, 210, 212**
  - regulators of complement activation and, **45:391, 396, 398, 399**
  - SCID and, **49:393, 398, 402**
  - self-reactive, **58:213**
  - spontaneous autoimmune thyroiditis and, **47:464, 477**
  - sporozoite malaria vaccine and
    - antibodies, **45:300**
    - CS proteins, **45:292, 294–296, 299**
    - CS-specific T cells, **45:310–312**
  - surface antigens of human leukocytes and, **49:79, 91, 98, 111, 114, 116**
  - synthetic T and B cell sites and, **45:261, 262**
    - bacterial antigens, **45:230–232**
    - globular protein antigens, **45:211, 214**
    - parasitic antigens, **45:229**
    - viral antigens, **45:218–220, 222–224**
  - T cell activation and, **41:1**
    - gene regulation, **41:27**
    - IL-1 receptor, **41:13**
    - receptor-mediated signal transduction, **41:20–22, 24**
    - synergy, **41:17**
    - T11, **41:9**
    - T cell antigen receptor, **41:2, 3, 6, 7**
    - Thy-1, **41:10**
  - T cell development and, **44:207, 255**
    - antigen recognition, **44:209, 210, 213**
    - cellular selection within thymus, **44:245–247, 250, 251, 253**
    - ontogeny, **44:215**
    - thymocyte subpopulation, **44:233, 242**
  - T cell receptor and
    - accessory molecules, **45:111**
    - alloreactivity, **45:149, 151–156**
    - antigen processing, **45:119, 120, 125, 126**
    - epitopes, **45:143**
    - experimental systems, **45:131**
    - polymorphic residues, **45:159–162**
    - structure-function relationships, **45:135, 140, 141**

- T cell subsets and  
 cell surface molecules, **41**:40, 49, 50  
 H-2 alloantigen recognition, **41**:79,  
 87, 94  
 H-2-restricted antigen recognition,  
**41**:52, 53, 57, 59–61, 64, 66, 71, 72,  
 74, 75  
 virus-induced immunosuppression and  
 HIV, **45**:349–351, 366  
 measles, **45**:346
- Cloning  
 activin type II receptor cDNA, **55**:188–192  
 antibodies from combinatorial libraries,  
**57**:203–206  
 B cells, **54**:399–400  
 B cell specific proteins in IgR complex,  
**54**:348–357  
 CD1 genes, **59**:3–4  
 complement components and, **38**:209–214  
 cytokine genes, **58**:425  
 directional, **38**:205  
 expansion, V gene usage in, **55**:322–323  
 IL-2R genes, **59**:226, 227  
 IL-9, from human and mouse, **54**:80–82  
 LIF, **53**:31–32  
 LIF receptor, **53**:38–40  
 NK cells, **55**:354–357  
 positional, X-linked agammaglobulinemia  
 gene, **59**:165–169  
 XLA genes, **59**:165–176
- Clonotypes  
 murine lupus models and, **46**:78, 99  
 predominant, expression  
 in B cell subpopulations, **42**:22–26  
 environment and, **42**:39–42  
 repertoire of B cell subpopulations, *see* B  
 cell repertoire expression
- Clostridium* toxin, and *Pseudomonas* toxin,  
**54**:114–115
- Clotting, aPL antibodies and  
 affinity purification, **49**:232  
 clinical aspects, **49**:200–202  
 pathogenic potential, **49**:253, 256–257  
 specificity, **49**:241, 244–245, 247
- Clustered antigens, B cell, **52**:140–164  
 CD5, **52**:140–144  
 CD9, **52**:144  
 CD10 or CALLA, **52**:144–145  
 CD20, **52**:149–150  
 CD22, **52**:150–151  
 CD23/FcεRII, **52**:151–153  
 CD24, **52**:153  
 CD37, **52**:154–155  
 CD38, **52**:155  
 CD40, **52**:155–158  
 CD44, **52**:158–159  
 CD45, **52**:159–160  
 CD48, **52**:160  
 CD72, **52**:160  
 CD73, **52**:160–161  
 CD74, **52**:161  
 CD76, **52**:162  
 CD77, **52**:162–163  
 CD19, **52**:145–148  
 CDw32/FcγRII, **52**:153–154  
 CDw75, **52**:161–162  
 complement receptors: CR2, CD21, and  
 CD35, **52**:148–149  
 other clustered antigens, **52**:163–164  
 CD27, **52**:163  
 CD39, **52**:163  
 CD69, **52**:163  
 CD78, **52**:163–164  
 CD1c, **52**:163
- Clusterin, **61**:204, 249–251  
*c-myb*, **62**:227  
 B cell genesis, **63**:238–239  
 and *c-myc*, **62**:227  
 T cell activation, **48**:293–294  
*c-Myc*, **63**:202  
 and thymocyte cell death, **58**:138  
*c-myc*, **62**:227; **63**:147; **64**:232  
 apoptosis, **63**:162  
 in Burkitt lymphoma, **38**:271, 272  
 activation, **38**:263, 264, 271  
 deregulation, **38**:254–257, 260  
 t(14;18) chromosomal translocation,  
**38**:269  
 translocation, **38**:248–253  
 variant chromosome translocations,  
**38**:257–259  
 in Burkitt's lymphoma translocations,  
**50**:124–128  
 chromosomal translocation, **64**:227–229  
 and *c-myb*, **62**:227  
 deregulated expression of, **64**:230  
 human B cell neoplasia and, **38**:259  
 activation, **38**:259–264  
 expression, **38**:259  
 translocation, **38**:271

- c-myc* (*continued*)  
 IL-2 signal transduction, **63**:161–162  
 immunosenescence and, **46**:223, 227, 228  
 overexpression and cell death, **58**:249  
 role in thymocyte apoptosis, **58**:169  
 T cell activation, **48**:292–293  
 T cell activation and, **41**:27, 28
- c-myc/v-Ha-ras* retrovirus,  
 plasmacytomagenesis, **64**:230–231
- CNTF, **65**:20  
 CNTF/LIF/OSM/IL-6 subfamily, **61**:151–152  
 CNTFR, **61**:151  
 and high-affinity LIF receptor, **53**:43–44, 46  
 pleiotropic nature of, **53**:46–47
- Coagulation  
 aPL antibodies and, **49**:200, 258  
 pathogenic potential, **49**:256  
 specificity, **49**:239, 241–244, 246  
 disseminated intravascular, endotoxic shock, **66**:260
- Coagulation/kinin-forming cascade, intrinsic,  
*see* Intrinsic coagulation/kinin-forming cascade
- Cobra toxin, MG and, **42**:237  
 Cobra venom factor, **61**:207; **62**:287–288
- Coding ends  
 with P nucleotides, **58**:37–38  
 and RSS ends, passage through DSB intermediates, **58**:33–36  
 TCR $\delta$ , hairpin accumulation at, **58**:48
- Coding flanks, **64**:55–56
- Coding joints  
 formation, microheterogeneity, **58**:39–40  
 microhomology, **58**:40–42  
 terminal deoxynucleotidyl transferase, **64**:51  
 V-3 cells, **58**:51–52  
 V(D)J recombination, **64**:40, 41–42
- Coding junctions  
 and RSS junctions, **58**:42  
 and *scid* mutant features, **58**:46–48
- Codominance, *Ir* genes and antigen processing, **38**:97  
 blocking, **38**:71  
 complementation, **38**:72  
 gene dosage, **38**:80, 81  
 genetic control, **38**:36  
 immunodominance, **38**:181  
 T cells 131, **38**:164  
 tolerance, **38**:119, 120
- Cofactor proteins, **61**:210  
 Cognate help, T cell subsets and, **41**:77  
 Cognate target lysis, by CD4<sup>+</sup> CTLs, **60**:304  
 Coimmunoprecipitation, T cell activation and, **41**:4, 5  
 Coincidental transmission, **38**:327  
 Colchicine  
 cytolysis and, **41**:282  
 immunosenescence and, **46**:224  
 Cold agglutinins, Ig heavy-chain variable region genes and, **49**:46–47, 51–52  
 Cold-reactive antilymphocyte antibodies, IBD and, **42**:292  
 Cold target cell competitors, hybrid resistance and, **41**:396, 402  
 Coley's broth, **42**:215  
 Colicins, cytolysis and, **41**:318, 319  
 Colitis, *see* Ulcerative colitis  
 Colitis colon-bound antibody, IgG levels in, **42**:298
- Collagen  
 aPL antibodies and, **49**:197  
 complement components, **38**:232, 233  
 helper T cell cytokines and, **46**:128  
 IL-1 and, **44**:168, 169, 186, 195  
*Ir* genes and, **38**:61, 86  
 leukocyte integrins and, **46**:153, 159  
 murine lupus models and, **46**:79, 90  
 surface antigens of human leukocytes and, **49**:85–86, 88
- Collagen arthritis, autoimmune thyroiditis and, **46**:312
- Collagenase, **62**:266, 288  
 antigen-presenting cells and, **47**:52  
 in eosinophils, **39**:203
- Colloid osmotic killing  
 membrane attack complex of complement, **41**:300  
 membrane damage, **41**:280  
 pore formers, **41**:315, 318  
 pore-forming protein, **41**:295, 312
- Colon  
 genetically engineered antibody molecules and, **44**:87  
 lymphocyte homing and, **44**:330, 332, 333, 338  
 Colon cancer, **62**:190, 201  
 properties of associated gangliosides, **40**:364–366  
 Colon tumors, CD44 expression, **54**:323

- Colony-forming B cells,  $V_H$  utilization and, **42:133**
- Colony-forming cells  
 B cells and, **41:182, 191, 200, 230, 237**  
 hybrid resistance and  
 bone marrow cells, **41:336, 344**  
 leukemia/lymphoma cells, **41:359**  
 NK cells, **41:376**  
 T cells, **41:381, 382**
- Colony-forming unit, hybrid resistance and, **41:336, 396**
- Colony-stimulating factor  $\alpha$ , eosinophil activation, **39:215**
- Colony-stimulating factor, murine, **48:73**
- Colony-stimulating factor 1, **48:71**
- Colony-stimulating factor gene, expression  
 posttranscriptional regulation, **48:83**  
 transcriptional regulation, **48:81–83**
- Colony-stimulating factor receptor  
 biochemical nature, **48:72–74**  
 distribution, **48:74**
- Colony-stimulating factors, **46:116; 48:69–77**,  
*see also* Granulocyte colony-stimulating factor; Granulocyte–macrophage colony-stimulating factor  
 B cell formation and, **41:219, 234, 236, 237, 228–230**  
 biochemical nature, **48:72–74**  
 biological actions, **48:74–76**  
 cell survival, **48:75**  
 cellular sources, **48:76–77**  
 characterization, **48:70–72**  
 chronic deregulated production, **48:93–94**  
 colony-stimulating activity, **48:94**  
 detection in vivo, **48:94–96**  
 differentiation commitment, **48:75**  
 discovery, **48:70–72**  
 eosinophil, **48:92**  
 functional activation, **48:76**  
 granulocyte, **39:2–3; 48:75**  
 hemopoietic recovery, **48:93**  
*high-affinity membrane receptors*, **48:73–74**  
 hybrid resistance and, **41:382**  
 macrophage, **48:75, 92**  
 maturation induction, **48:75**  
 monocyte, **39:2–3; 48:92**  
 multi-CSF, *see* Interleukin-3  
 myelosuppression, **48:93**  
 neutralizing antibody, **48:95–96**  
 neutrophil, **48:92**  
 proliferative stimulation, **48:74–75**  
 target cell selectivity, **48:74–75**  
 secondary structure, **48:73**  
 sequence homology, **48:73**  
 serum half-lives, **48:93**  
 single unique gene encoding, **48:73**  
 surface antigens of human leukocytes and, **49:99, 113**  
 synthesis  
 induction, **48:78–81**  
 pathways, **48:78–81**
- T cell  
 studies in vitro, **48:77–78**  
 studies in vivo, **48:92–98**
- T cell synthesis, **48:96–98**  
 antigen-presenting cell, **48:97**  
 local polarization secretion, **48:97**  
 local response, **48:96**  
 target cells, **48:97**  
 therapeutic effects, **48:93**
- Combinatorial libraries, human antibodies  
 from, *see* Antibodies, human, from combinatorial libraries
- Common acute lymphoblastic leukemia-associated antigen, *see* CD10
- Common  $\gamma$ -chain, multiple cytokine receptors, **59:239**
- Common variable immunodeficiency, **59:138, 143, 147, 150; 65:256–260**  
 CD23 antigen and, **49:174**  
 and SCID mice, **50:308**
- Competition, autoimmune demyelinating disease and, **49:370–371**
- Competitive elimination, B cells, **59:312–315**
- Competitive inhibition, *I<sub>r</sub>* genes and, **38:108–110, 182, 183**
- Complement, **61:201–204**  
 alternative pathway  
 antibodies as activators, **51:28–29**  
 particulate activators, **38:384–386; 392**  
 anaphylatoxins, **61:255**  
 cascade, pulmonary inflammation, **62:260–262, 271, 286–288**  
 classical pathway, history of, **37:153–154**  
 membrane attack complex, **61:203, 247–255**  
 molecular genetics, **38:203–207**  
 C1q, **38:231–233**  
 C2 and Factor B, **38:207–209, 228**

- Complement (*continued*)
- C3, **38**:233–234
  - C4, **38**:219–231
  - C4b-binding protein (C4bp), **38**:234–236
  - C9, **38**:234
  - cDNA, **38**:209–211
  - cloning, **38**:212–214
  - expression, **38**:217, 218
  - restriction fragment length polymorphism, **38**:215, 216
  - pathway, products, in IBD, **42**:308–310
  - role in B cell growth and differentiation, **52**:218–219
  - therapeutic inhibition in acute injury states, soluble CRI
    - ARDS, **56**:284–286
    - ischemia, **56**:282–284
    - local injuries, **56**:286
    - range of use, **56**:289
    - reperfusion, **56**:282–284
    - tissue transplantation, **56**:286–287
  - therapeutic regulation in acute injury states
    - activation
      - clinical assessment, **56**:270–271
      - clinical injury, **56**:278–281
      - intrinsic regulation, **56**:271–274
      - mechanisms, **56**:267–270
    - ARDS, **56**:278–279
    - C1 esterase inhibitor, **56**:272
    - cardiopulmonary bypass, **56**:279–280
    - clinical injury, **56**:278–281
    - deficiency states, **56**:277–278
    - hemodialysis, **56**:278–279
    - leukocyte interaction, **56**:274–277
    - sepsis, **56**:281–282
    - septic shock, **56**:281–282
    - study approaches, **56**:267
    - therapeutic inhibition
      - fungal products, **56**:288–289
      - heparin, **56**:287–288
      - thermal injury, **56**:280–281
- Complement activation, *see also* Regulation of complement activation; Regulators of complement activation
- by antibody effector function, **51**:7–29
  - antibodies as activators of alternative pathway, **51**:28–29
  - C1 activation, **51**:21–25
  - C3 activation, **51**:25–28
  - C4 activation, **51**:25–28
  - cell lysis, **51**:25–28
  - interaction of C1q and antibody, **51**:8–21
  - segmental flexibility, **48**:24–26
- Complementarity
- antibody-antigen complexes, **43**:122
  - induced
    - antigen, **43**:20–23
    - differential contributions, **43**:73
    - evidence, **43**:42–46
    - protein folding, **43**:83
    - protein-protein interactions, **43**:101–103
    - structural, protein-protein interactions, **43**:104–105
- Complementarity-determining region, **43**:9–10, 107
- Ars A response and, **42**:113, 115, 126–128
    - nucleotide sequence of, **42**:119
  - buried surface, **43**:111
  - conformational changes, **43**:18–20, 124
  - diversity, **43**:222
  - forming antigen binding site, **43**:13
  - framework residues, **43**:16
  - genetically engineered antibody molecules and, **44**:75, 84, 85
  - Ig heavy-chain variable region genes and
    - 34, **49**:51, 61, 63
    - D segments, **49**:28, 31
    - V<sub>H</sub> families, **49**:9, 14–15, 18
  - length, **43**:222
  - loop
    - flexibility, **43**:107
    - structures, **43**:20
  - maps of Ig-like loci and, **46**:7
  - mobility, **43**:20
  - models, **43**:10
  - modulating VL–VH pairing, **43**:125
  - movement from canonical positions, **43**:127
  - murine lupus models and, **46**:72, 78
  - sequences, **43**:125
  - size, **43**:120–121
  - spatial arrangement, **43**:109
  - structural variability, **43**:73
  - structures, **43**:107–108
  - T cell subsets and, **41**:52
  - variable domain, **43**:79
  - V module interface modification, **43**:113, 126

- Complementary DNA  
  actinin type II receptor, cloning,  
  **55:188–192**  
   $\alpha$  chain, **43:284–286**  
  antinuclear antibodies and  
  autoantibodies, **44:127**  
  autoantigen, **44:128–131**  
  autoimmune response, **44:132**  
  scleroderma, **44:122**  
  SLE, **44:101, 108**  
  biosynthetically engineered peptides based  
  constructs, **43:281**  
  CD4 and CD8 molecules and, **44:297,**  
  **298**  
  CD4 molecular biology, **44:290, 292,**  
  **293, 296**  
  CD8 molecular biology, **44:272–274,**  
  **276–278**  
  CD5 B cell and, **47:145–147, 154**  
  CD23 antigen and  
  biological activity, **49:169, 172**  
  cellular expression, **49:152, 154**  
  Fc $\epsilon$ RII, **49:162–163, 165**  
  CD44 constructs, transfection and  
  expression, **54:286–287**  
  clones  
  characterization, **43:148**  
  for IL-10, **56:3–5**  
  T cell receptor  $\delta$  genes, **43:154–155**  
  T cell-specific, **43:135**  
  cloning of autoantigens  
  BP antigen, **53:306–310**  
  PF antigen, **53:310–312**  
  PV antigen, **53:312–314**  
  coding, **43:287, 304**  
  complement components and  
  C1q, **38:232, 233**  
  C2, **38:209, 211, 212**  
  C3, **38:233, 236**  
  C4, **38:223–226, 228, 236**  
  C4bp, **38:234**  
  C5, **38:234**  
  C9, **38:234**  
  expression, **38:217**  
  Factor B, **38:209, 211, 212**  
  from liver, **38:209, 234**  
  restriction fragment length  
  polymorphism, **38:215, 216**  
  complement receptor I and, **46:187, 188,**  
  **191, 193, 194, 199**  
  complement receptor 2 and, **46:211**  
  cytotoxicity and, **41:319, 320**  
  cell-mediated killing, **41:297**  
  hydrolytic enzymes, **41:276**  
  lymphotoxin-like molecules, **41:284,**  
  **285**  
  pore farmers, **41:317**  
  cytotoxic T cells and, **41:138, 148**  
  genetically engineered antibody molecules  
  and, **44:67, 68, 73–75**  
  for GM-CSF, **39:9–10**  
  helper T cell cytokines and, **46:112, 115,**  
  **116**  
  human LIF receptor, **53:38–40**  
  human-murine hybridomas, **38:291**  
  human T cell antigen and, **41:3, 10, 13**  
  humoral immune response and, **45:63, 66,**  
  **72, 74, 75**  
  IgE biosynthesis and, **47:16–18, 21**  
  Ig gene superfamily and, **44:33–35, 39, 40**  
  Ig heavy-chain variable region genes and,  
  **49:19, 22, 33**  
  V<sub>H</sub> gene expression, **49:35, 37–38, 44–45**  
  IL-1ra clones, purification and expression,  
  **54:171–176**  
  IL-2 and, **44:155**  
  for IL-3, **39:5, 7–8**  
  IL-5, organization, **57:148–149**  
  IL-10, **56:3–5**  
  *Ir* genes, **38:116, 117, 148**  
  *Ir* genes and, **38:117**  
  leukocyte integrins and, **46:154–158, 160,**  
  **174, 176**  
  maps of Ig-like loci and, **46:34, 43**  
  maternally transmitted antigen, **38:348**  
  murine lupus models and, **46:83, 87, 95**  
  NK cells and, **47:209**  
  normal and mutant in PNH, **60:83–84**  
  regulators of complement activation and  
  genes, **45:403, 405**  
  protein expression, **45:396, 398, 399**  
  short consensus repeat, **45:391**  
  spontaneous autoimmune thyroiditis and,  
  **47:462, 483**  
  surface antigens of human leukocytes and,  
  **49:79, 114, 118**  
  T cell receptor 7, **43:145**  
  T cell receptor and  
  in peripheral T cells, **38:13**  
  protein, **38:4, 6, 8, 9**



- Complementary DNA (*continued*)  
 receptor-like genes, **38:10**  
 T3, **38:18**  
 in thymus, **38:12**  
 T cells, **38:10**  
 chromosomal mapping, **38:16**  
 peripheral, **38:13, 14**  
 rearrangement, **38:11, 12**  
 receptor proteins, **38:5, 6, 8, 9**  
 V region genes, **38:15, 16**  
 T cell-specific, **43:135, 220**  
 T cell subsets and, **41:41, 50**  
 transfection experiments, **42:168**  
 virus-induced immunosuppression and,  
**45:349–351**  
 X-linked agammaglobulinemia, **59:165–167**
- Complementation, MHC-linked *Ir* genes and,  
**38:72–84**  
 H-Y antigen, **38:177, 178**  
 I region mutations, **38:85, 88**  
 T cells  
 interactions, **38:160**  
 repertoire, **38:133**  
 suppression, **38:140, 145, 148, 149**
- Complementation classes, mutants,  
 biochemical defects, **60:66–67**
- Complement binding activity  
 hinge region structure, **48:13, 15, 22**  
 segmental flexibility, **48:13, 15, 22**
- Complement control, **61:255–257**  
 C3/C5 convertases, **61:206–247**  
 initiation, **61:201–206**
- Complement control protein repeats,  
**61:207–208**
- Complement deficiency alleles, aPL  
 antibodies and, **49:222**
- Complement fixation, by Fc region of Ig,  
**40:70–71**
- Complementing binder sites, **52:375–377**
- Complement lysis sensitivity test, **60:75**
- Complement-mediated cytotoxicity, *see*  
 Cytotoxicity, lymphocyte and  
 complement-mediated
- Complement receptors  
 C3b and C4 on eosinophils, **39:179–180**  
 C5a, gene mapping, **55:135**  
 CR1, **46:183, 208, 209; 60:182;**  
**61:228–230**  
 allotypes, **46:187–190**  
 aPL antibodies and, **49:255**  
 and CR2 and CD19, molecular  
 complexes on surface of human B  
 cells, **52:146**  
 function  
 endocytosis, **46:198–200**  
 erythrocytes, **46:198**  
 immunoregulation, **46:200, 201**  
 ligand binding sites, **46:193–196**  
 regulation, **46:196, 197**  
 soluble, in therapeutic complement  
 inhibition, **56:284–286**  
 ischemia, **56:282–284**  
 local injuries, **56:286**  
 range of use, **56:289**  
 reperfusion, **56:282–284**  
 tissue transplantation, **56:286–287**  
 structure, **46:183–187**  
 in therapeutic complement activation,  
**56:274–277**  
 tissue distribution, **46:190–193**  
 CR2, **46:183; 61:228, 230**  
 and CR1 and CD19, molecular  
 complexes on surface of human B  
 cells, **52:146**  
 function, **46:205**  
 EBV tropism, **46:210–213**  
 immunoregulation, **46:205–210**  
 structure, **46:201–203**  
 tissue distribution, **46:203–205**  
 CR2, CD21, and CD35, **52:148–149**  
 CR3, **46:209, 210; 60:182–183**  
 leukocyte integrins and, **46:150, 163, 164**  
 leukocyte interactions, **56:276–277**  
 regulators, **61:228–230**  
 surface antigens of human leukocytes and,  
**49:91–97**
- Complement regulatory proteins,  
**61:201–204, 202, 203–204**
- Complete Freund's adjuvant, *see* Freund's  
 complete adjuvant
- Conalbumin  
 humoral immune response and, **45:37**  
 IgE biosynthesis and, **47:11**
- Concanavalin A, **48:90, 233**  
 activated spleen cells, T cell subsets and,  
**41:64, 65, 70**  
 antigen-presenting cells and, **47:84, 100**  
 autoimmune thyroiditis and, **46:281**  
 autoreactive T cells and, **45:421**  
 B cell formation and, **41:198, 229**

- B cell proliferation, **63:57**  
 CD5 B cell and, **47:121**  
 humoral immune response and, **45:45**  
 hybrid resistance and, **41:375, 409**  
 IBD and, **42:299**  
 IgE biosynthesis and, **47:15, 18–20**  
 IL-1 and, **44:173, 174, 182, 189**  
 immunosenescence and  
   lymphocyte activation, **46:223, 225, 226, 228–230**  
   mucosal immunity, **46:252**  
   stem cells, **46:245**  
 murine lupus models and, **46:98**  
 pore-forming protein and, **41:313**  
 spontaneous autoimmune thyroiditis and, **47:492**  
   cellular immune reactions, **47:452–455**  
   disturbed immunoregulation, **47:470–473, 475, 477–479**  
   genetics, **47:487, 488, 490**  
   potential effector mechanisms, **47:467**  
 T cell activation and, **41:8, 28**  
 T cell development and, **44:243**  
 T cell subsets and, **41:63–65**  
 virus-induced immunosuppression and, **45:357, 362**
- Conditioning, allergic reactions, **61:368–369**  
 Congenic strain, cross-reactive idiotype expression and, **42:141**  
 Congenital agammaglobulinemia, **59:138–139**  
 Congenital myasthenic syndrome, **42:252–253, see also Myasthenia gravis**
- Conjugate formation  
   cell mediation and, **41:272**  
   cytolysis and, **41:274–276, 278, 282, 283**
- Connective tissue  
   cachectin and, **42:225**  
   IFN- $\gamma$ , **62:90–91**
- Connective tissue-activating peptide III, **50:240–243**  
   biological effects on neutrophils, **55:115**  
   chemical properties of, **55:97, 99**  
   comparison with histamine releasing factor, **50:242**  
   conversion of to NAP-2, **50:242–243**  
   in T cell development in MHC class I-deficient mouse, **55:399–401**
- Consensus sequences  
   CD23 antigen and, **49:162**  
   Ig heavy-chain variable region genes and, **49:30**
- Constant region, heavy chain, gene order and class switching, **40:257–258**  
 Constant region complex, Ig heavy-chain variable region genes and, **49:3–4, 6**
- Contact activation, **66:225, 233–239**  
 allergic diseases and, **66:258–259**  
 bradykinin, **66:225, 226, 233–240**  
 defined, **66:225**  
 disease states and  
   allergic diseases, **66:258–259**  
   Alzheimer's disease, **66:260–261**  
   endotoxic shock, **66:260**  
   hereditary angioedema, **66:257–258**  
   pancreatitis, **66:260**  
   rheumatoid arthritis, **66:260**  
 factor XI, **66:225, 226, 230, 237, 244**  
 factor XII, **66:225, 226–229, 234–236, 244, 246, 249–257**  
 high-molecular-weight kininogen, **66:225, 226, 230–233, 245, 247–257**  
 interaction with cells and, **66:258–259**  
 kallikrein, **66:225, 238, 243–244**  
 low-molecular weight kininogen, **66:233**  
 mechanism, **66:225–226**  
 prekallikrein, **66:225, 226, 229–230, 236**  
 regulation, **66:235–239**
- Contactin, **48:161–162**  
 Contact residue, **43:26, 72, 119**  
 Converter protein, **42:168**
- Coreceptor model, of CD4 and CD8 and adhesiveness during TCR triggering, **53:83–84**  
 coreceptor/MHC binding sites, **53:68–70**  
 cytoplasmic tail role in signal mediation, **53:73–74**  
 description, **53:65–68**  
 effects on positive vs. negative selection, **53:103–104**  
 function, gene transfer for, **53:70–78**  
 p56<sup>lck</sup> role in TCR-mediated signaling, **53:74**  
 TCR-coreceptor simultaneous binding, **53:66–68**
- Coreceptors  
   T cell, recognition/auxiliary, **51:91–92**  
   TCR/CD3, signalling through, **51:92–98**
- Cornea, MHC antigen, **48:193–194**

- Corneal allograft  
 graft bed  
 afferent blockade theory, **48:195–196**  
 avascular, **48:195**  
 graft location, **48:195**  
 host cellular component, **48:195**  
 orthotopically placed, **48:195**  
 immunological privilege, **48:192–203**
- Corneal endothelial graft, cytotoxic T cell, **48:194**
- Corneal epithelial cell, accessory antigen-processing cell, **48:202**
- Corneal epithelial cell-derived T cell-activating factor, **48:201–202**
- Corneal epithelium, Langerhans cell, **48:197**
- Corneal graft  
 Ia antigen, **48:199**  
 MHC class II antigen  
 cell-surface expression, **48:199**  
 expression, **48:199**  
 expression timing, **48:199–200**  
 MHC class II loci, **48:199–200**  
 latex bead treatment, **48:200**  
 rejection, donor Langerhans cells, **48:196–200**
- Corneal transplantation, **48:191**  
 HLA matching, **48:193**  
 immunological recognition, **48:193–196**  
 immunosuppressive drug, **48:193**  
 success, **48:193**
- Coronary artery bypass grafting, aPL antibodies and, **49:220, 222–223**
- Coronary heart disease, dietary fish oil and, **39:145–146**
- Coronavirus, neutrotrophic, **48:141**
- Cortical cells, loss of responsiveness in, **51:153–156**
- Corticosteroid-binding globulin, **47:492, 494**  
 genetics, **47:488–490**  
 immunoregulation, **47:476, 479, 481**
- Corticosteroid resistant bronchial asthma, **51:358–361**
- Corticosteroids, **42:311**  
 adrenal, MG therapy and, **42:270–271**  
 B cell formation and, **41:197**  
 and estrogens, **54:50**  
 IBD and, **42:316–319**  
 IL-1 and, **44:160, 161, 182, 186, 189, 190**  
 MG therapy and, **42:270–271**  
 mode of action, **64:195–196**  
 prostaglandin synthesis and, **42:312–313**  
 spontaneous autoimmune thyroiditis and, **47:477**
- Corticosterone, spontaneous autoimmune thyroiditis and, **47:493**  
 disturbed immunoregulation, **47:476–481**  
 genetics, **47:488, 489**
- Corticotropin-releasing factor  
*in vitro* IgE synthesis, **61:370–372**  
 lymphocyte-produced, **39:316**  
 NK cells and, **47:268, 269**  
 spontaneous autoimmune thyroiditis and, **47:493**
- Corticotropin-releasing hormone, **48:170–172**
- Cortisone, hybrid resistance and, **41:338, 359, 360**
- Corynebacterium parvum*  
 B cell formation and, **41:208**  
 hybrid resistance and  
 bone marrows, **41:340, 347**  
 macrophages, **41:370**  
 marrow microenvironment, **41:391, 392**  
 syngeneic stem cell functions, **41:389**
- Cosignals, inactivation of death programs, **58:243–245**
- Cosmid clones  
 complement components and, **38:213**  
 C2, **38:218**  
 C4, **38:228**  
 Factor B, **38:212, 218**  
 Ig heavy-chain variable region genes and, **49:5–6, 8**
- Cosmids, maps of Ig-like loci and, **46:4, 5**  
 MHC, **46:29, 32, 33**  
 structure, **46:17, 18, 27**  
 T cell receptor, **46:36, 37**
- Costimulation, **62:132**  
 B7-1 and B7-2, **62:140–142**  
 CD28 and CTLA-4, **62:138–139**  
 CD28–B7, **62:132**  
 Td B cell response, **62:148–157**  
*in vivo* immune response, **62:142–144**
- Costimulator activities, vascular endothelial cells, **50:267–274**
- EC costimulators  
 in alloantigen responses, **50:271–272**  
 in polyclonal CD4+ T cell activation, **50:268–270**

- in polyclonal CD8+ T cell activation, **50:270-271**
  - soluble, EC production of, **50:272-274**
- Costimulators, soluble, EC production of, **50:272-274**
- Costimulus, **59:280, 325-326**
- Coupled cleavage, V(D)J recombination, **64:53-54**
- Coupling proteins, *see also* G proteins
  - G<sub>i</sub>-receptor interaction in neutrophils, **39:114-116**
  - amplification during transduction and, **39:116-117**
  - model of, **39:115-116**
  - termination of, **39:117-118**
- G<sub>s</sub>
  - catecholamine interaction, **39:112-113**
  - guanyl nucleotide binding, **39:112**
  - neutrophil activation and, **39:113-114, 118**
  - in retina, rhodopsin and, **39:112**
  - stimulatory and inhibitory, **39:112-113**
  - subunit activities, **39:112**
- CpG islands, **65:50, 51**
- CRAF1 (CD40 receptor associated factor 1), **61:29-31**
- C-reactive protein, surface antigens of human leukocytes and, **49:111**
- CREB, interaction with NF-IL6, **65:19**
- C-REL knockout mice, cytokine induction, **65:31-32**
- CREST, antinuclear antibodies and, **44:120, 122, 131**
- CRF, *see* Corticotropin-releasing factor
- Critical residue, Ab binding to protein antigens, **43:27, 72**
  - amino acids, **43:67-68**
  - antigen binding, **43:61, 63**
  - antiprotein antibodies, **43:42**
  - buried, **43:42-43**
  - identification, **43:39-42**
  - peptide mapping, **43:74**
  - properties, **43:40-41**
  - sequential epitope, **43:64**
  - stereochemical relationships, **43:43**
- Crohn's disease, **59:146, see also**
  - Inflammatory bowel disease
  - 6-MP therapy and, **42:300**
  - anti-TNF- $\alpha$  therapy, **64:307-310**
  - granulomas in, **42:297**
  - helper T cell function and, **42:300, 301**
  - IgG response to infectious agent in, **42:305**
  - infections with cA2 treatment, **64:326-328**
  - intestinal MNC and, **42:303-304**
  - K cell function and, **42:295**
  - lymphocytes 290, number, **42:297**
  - skin test antigens and, **42:289**
  - submucosa of specimens of, **42:298**
- Cromolyn-binding protein, **43:297**
- Cross-hybridization
  - CD23 antigen and, **49:162**
  - Ig heavy-chain variable region genes and, **49:1, 8**
- Crosslinking
  - CD23 antigen and, **49:156, 168-169, 172-173**
  - cell mediation and, **41:272**
- FC $\epsilon$ RI
  - and factor-dependent mast cell lymphokine production, **53:6**
  - and IL-3 regulation of lymphokine production, **53:21-22**
  - and IL-4 production by splenic and bone marrow Fc $\epsilon$ RI<sup>+</sup> cells, **53:10**
  - and signaling of IL-4 production, **53:19-22**
  - and transformed mast cell lymphokine production, **53:5**
  - photochemical, for lipid A receptor identification, **53:277-279**
  - surface antigens of human leukocytes and, **49:89-90, 101, 111, 125**
  - T cell activation and, **41:4, 5, 9, 11, 12, 25**
  - T cell subsets and, **41:62, 111**
- Cross-priming, T cell subsets and, **41:74**
- Cross-reactive idiotype, **42:11**
  - Ars A response and, **42:97-99, 109-110, 139-141**
  - autoimmune thyroiditis and, **46:303-305, 308**
  - CD5 B cell and, **47:150, 151, 153-158**
  - Ig heavy-chain variable region genes and, **49:43, 46, 48-49, 51**
  - secondary B cell lineage and, **42:70-71**
- Cross-reactivity
  - aPL antibodies and, **49:209, 211, 236, 243, 248-249**
  - Cytotoxic T cells and, **41:144, 147, 162, 170**
  - hybrid resistance and, **41:357**

- Cross-reactivity (*continued*)  
 Ig heavy-chain variable region genes and, **49:47**  
 membrane attack complex of complement and, **41:307, 309**  
 T cell subsets and, **41:79, 88, 112**
- Cryptococcus neoformans*, pneumonia, **59:402–408**
- Crystallographic temperature factors, mobility data from, **43:20**
- Crystallography, reconciling data, **43:23–27**
- Crystal packing, Fab Kol, **43:19–20**
- Crystal studies, two-dimensional, major features, **51:18**
- Csa effects, development of autoimmune phenomena, **50:209–210**
- CSF, *see* Colony-stimulating factors
- Csk, **62:42, 45**
- CT-1, **64:256**
- CTL, *see* Cytotoxic T cells
- CTLA-4, **62:132–135**  
 costimulatory effects on immunogenicity, **57:305–307**  
 T cell receptor for B7, **58:134**
- CTLA4Ig, **62:138, 141, 143, 149, 150**
- Culture supernatants, CD23 antigen and, **49:157, 159**
- Curare, MG and, **42:237**
- Curcumin, action of, **65:123**
- Cutaneous diseases  
 eosinophil degradation and, **39:225–226**  
 major basic protein extracellular deposition, **39:225–226**
- Cutaneous lymphocyte antigen, **64:146, 151**  
 chronic inflammation and, **64:190**  
 properties, **64:146**
- CVID, *see* Common variable immunodeficiency
- CX5a, **62:261**
- C-X-C family, **62:269–270**
- CXCR4, **65:283; 66:282**
- Cyanuric chloride, linkage procedure for chemoimmunoconjugates in cancer treatment, **56:321**
- Cyclic AMP  
 in activated neutrophils, **39:113–116, 118**  
 autoimmune thyroiditis and, **46:268, 272**  
 CD40 expression, **61:98**  
 IL-1 and, **44:160, 161, 195**  
 immunosenescence and, **46:223, 226, 227, 232**  
 immunosuppressive activity of, **65:124–125**  
 intracellular levels, elevation, **54:379**  
 NK cells and, **47:249, 250**
- Cyclic AMP response element modulator  $\gamma$ , **61:189**
- Cyclic AMP response elements, **62:194**
- Cyclic GMP, immunosenescence and, **46:223**
- Cyclic neutropenia, B cell formation and, **41:222, 228–230, 234, 237**
- Cyclic nucleotides, immunosenescence and, **46:226, 227, 232**
- Cyclin-cdk complexes, **61:183, 184**
- Cycloheximide, **42:174**  
 antigen-presenting cells and, **47:59**  
 effect on apoptosis induction, **58:265–267**
- Cyclooxygenase  
 active site, PGHS-2, **62:174–176**  
 cachectin and, **42:219**  
 IBD and, **42:317**  
 IL-1 and, **44:160, 168, 195**  
 isozymes  
 catalysis by PGHS, **62:178–188**  
 cellular and physiologic action of PGHS, **62:196–200**  
 future work, **62:201–202**  
 pathophysiologies, **62:200–201**  
 regulation of gene expression, **62:188–196**  
 structure–function relationships, **62:169–178**
- NO role, **60:349–350**
- NSAIDs and, **42:313**
- Cyclophosphamide  
 adoptive T cell therapy of tumors and, **49:293, 295–297, 302–303, 317**  
 diabetes induced by, **62:100–101**  
 hybrid resistance and  
 bone marrow cells, **41:347, 348**  
 effector mechanisms, **41:370, 388, 390, 393**  
 leukemia/lymphoma cells, **41:366, 368**  
 lymphoid cells, **41:354**  
 MG therapy and, **42:263–264, 271**
- Cyclosporin, **41:60, 350; 59:424**  
 autoimmune thyroiditis and, **46:294**  
 effect on thymocyte death, **58:173**  
 mAbs and, **38:277, 286**  
 treatment, **50:104–105**

- Cyclosporin A  
 autoimmune side effects, **58:278–279**  
 and autoimmunity, **50:208–210**  
 blockade of CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58:267**  
 CD40-L expression, **61:21**  
 effect on CD40L expression, **60:47–48**  
 effect on PCD induction, **58:261–262**  
 GM-CSF in T cells and, **39:14–15**  
 humoral immune response and, **45:47**  
 IL-2 in T cells and, **39:14–15**  
 IL-3 in T cells and, **39:14–15**  
 inhibition of B cells, **54:408**  
 for MG, **42:264**  
 NF- $\kappa$ B, **65:120**  
 suppressor T cells and, **42:258–259**  
 T cell activation and, **41:29, 30**  
 and thymic T cell maturation, **58:314–315**
- CYP2D5 gene, **65:23**
- Cysteine  
 autoimmune thyroiditis and, **46:316**  
 CD4 molecules and, **44:285–287**  
 CD8 molecules and, **44:273, 274, 276, 277**  
 CD23 antigen and, **49:163–164**  
 $\alpha$  chain of IgA, **40:155, 163**  
 complement receptor 1 and, **46:184, 194**  
 complement receptor 2 and, **46:202**  
 cytotoxic T cells and, **41:148, 163**  
 genetically engineered antibody molecules  
 and, **44:81, 82**  
 IgE biosynthesis and, **47:17**  
 J chain of IgA, **40:160**  
 leukocyte integrins and, **46:154, 155**  
 maps of Ig-like loci and, **46:2, 13**  
 membrane attack complex of complement  
 and, **41:307, 309**  
 relationship between loops, Ig domains,  
**43:285**  
 residues, **43:137, 156**  
 secretory component of IgA, **40:162–163**  
 surface antigens of human leukocytes and,  
**49:116**
- Cytochalasin B. cytolysis and, **41:282**
- Cytochrome. secondary B cells and, **42:71–72**
- Cytochrome c  
 acetymidylated, **43:200**  
 as antigen, **43:198–200**  
 autoreactive T cells and, **45:419**  
 beef, **43:199**  
 cross-reactive, **43:202**  
 immune response, **43:224**
- Ir* genes and, **38:77–79, 82, 89**  
 antigen binding, **38:98–107**  
 antigen processing, **38:94, 96**  
 competitive inhibition, **38:108**  
 gene dosage, **38:82**
- T cells  
 activation, **38:104**  
 repertoires, **38:116, 119, 132–134**
- moth, **43:203**
- mouse, **43:199**
- pigeon, **43:199–200**
- secondary structure, **43:204**
- sequence differences in, **43:4**
- synthetic T and B cell sites and  
 bacterial antigens, **45:240**  
 globular protein antigens, **45:203, 204,**  
**210, 211, 214**  
 immunological considerations, **45:201**
- T cell receptor and  
 antigen processing, **45:121, 127**  
 epitopes, **45:143**  
 experimental systems, **45:131, 132**  
 structure-function relationships, **45:135,**  
**136**
- T cell subsets and, **41:53**
- Cytochrome P450, **65:23**
- Cytofluorographic analysis, two-color, T cell  
 receptor  $\gamma\delta$  proteins, **43:146–147**
- Cytofluorometry, IBD and, **42:295**
- Cytokine-endotoxin score, **66:123**
- Cytokine-hemopoietin receptors,  
**63:393–394, 397**
- Cytokine-modulating therapy, **66:151**
- Cytokine receptors, **63:269–270, 273, see also**  
*specific receptors*
- B cell, **52:169–173**  
 IL-2, **52:171–172**  
 IL-4, **52:172**  
 IL-6, **52:172**  
 IL-1, **52:169–171**  
 other cytokines, **52:173**  
 TGF- $\beta$ , **52:173**  
 TNF- $\alpha$ , **52:172–173**
- common  $\gamma$ -chain for multiple receptors,  
**59:225–267**
- disease and, **63:310–314**  
 disease models, **63:312–314**  
 IL-2R, **63:296–299**  
 IL-6R, **63:302**  
 TNF-R, **63:306**

- Cytokine receptors (*continued*)  
 family, **52:170**  
 HLA class II molecules, **52:164–166**  
 human, **52:171**  
 human basophils, mast cells, KU-812 cells  
 and HMC-1 cells, **52:340, 341**  
 IL-1R type I, **63:312–313**  
 membrane-bound form, **63:273–274,**  
 279–280  
 membrane proximal domains, role in Jaks  
 association, **60:11–12**  
 nonreceptor proteins, **63:277–278**  
 other antigens of B cells, **52:**  
 173–174  
   Bgp 95, **52:173**  
   CK226 antigen, **52:173**  
   IgM-binding protein (Fell receptor,  
   **52:173**  
 receptor antagonists, **63:277**  
 soluble forms, **63:275–276, 279–280,**  
 314–315  
   GM-CSF-R, **63:308**  
   IFN, **63:307–308**  
   IFN- $\gamma$ -R, **63:307, 309–310, 314**  
   IL-1R, **63:290–292**  
   IL-1R type II, **63:310**  
   IL-2R, **63:292–294, 296–298**  
   IL-4R, **63:281–282, 284, 285, 294–295,**  
   299, 313  
   IL-5R, **63:275, 299–300**  
   IL-6R, **63:275, 280, 282, 300–303**  
   IL-7R, **63:303**  
 immunoregulatory function, **63:**  
 285–290  
 production, **63:280–285, 314–315**  
 TNF-R, **63:303–307, 313–314**  
 TNF-R type II, **63:309**  
 viral, **63:308–310**  
 structure, **55:274**  
 TGF- $\beta$  regulation, **55:187**  
 as therapeutic agents, **63:311–312**  
 Cytokine release syndromes, IFN- $\gamma$  and,  
**62:103–104**  
 Cytokine response element, **65:20**  
 Cytokines, **42:165; 48:70, 71; 62:195; 63:127,**  
 269, *see also* Chemokines  
 activation of Jak and Stat isoforms,  
**61:174**  
 acute effects, **48:174–175**  
 adoptive T cell therapy of tumors and,  
**49:285, 289–290, 308**  
 expression of antitumor responses,  
**49:324, 326, 330, 332**  
 mechanisms, **49:309–310**  
 alarm, **58:394–395**  
 antigen-presenting cells and, **47:47, 104**  
 antigen presentation, **47:72**  
 cell surface, **47:63**  
 immunogeneity, **47:103**  
 T cell growth, **47:100**  
 tissue distribution, **47:53**  
 antiinflammatory, *see* Antiinflammatory  
 cytokines  
 aPL antibodies and, **49:257**  
 and autoimmune diabetes, **51:307**  
 autoimmune thyroiditis and, **46:275, 298,**  
 307, 317  
 B cell differentiation, **52:204–218**  
 activated T cells, **52:212–213**  
 antigen receptor-dependent activation,  
**52:204–206**  
   IL-2, **52:204–205**  
   IL-4, **52:205–206**  
   other stimulatory cytokines, **52:206**  
 CD40-dependent activation, **52:206–212**  
 general considerations on, **52:215–217**  
 IL-4 and IgE switching, **52:217–218**  
 IL-6 and autoimmune system, **52:215**  
*in vivo-activated* plasmablasts,  
**52:213–215**  
 isotype switching of human B cells,  
**52:215–218**  
 B cell growth, **52:195–204**  
 activated T cells, **52:203**  
 antigen receptor dependent activation,  
**52:195–200**  
   antigen-dependent activation, **52:199**  
   polyclonal activators, **52:195–196,**  
   195–199, 196–198, 198–199,  
   199  
   CD40-dependent activation, **52:200–203**  
   IL-6 and B cell growth, **52:203–204**  
 B cell growth and differentiation,  
**52:174–185**  
 IL-2, **52:177–178**  
 IL-4, **52:178–181**  
   pleiotropic effects of, **52:179–181**  
   sources and structure of and its  
   receptor, **52:178–179**

- IL-6, **52**:182–184  
 pleiotropic effects of transforming growth factor  $\beta$ , **52**:184  
 sources and structure of transforming growth factor  $\beta$  and its receptor, **52**:183–184
- IL-10, **52**:181–182  
 pleiotropic effects of, **52**:181–182  
 sources and structure of, **52**:181
- low molecular-weight bacillus Calmette Guerin factor (BCGF-12 kDa), **52**:185
- notions of TH1 and TH2 CD4+ helper T cells, **52**:175–177
- B cell production, **61**:33, 47
- B cell proliferation, **63**:54–55
- and B cells, a synthesis, **52**:227–230
- binding, coupled to tyrosine phosphorylation, **60**:4–9
- binding activity, **63**:285–290
- biological activity, **59**:254
- CD1 expression, **59**:64–65
- CD5 B cell and, **47**:120  
 marker for activation, **47**:127  
 physiology, **47**:139, 142  
 surface antigen, **47**:145
- CD23 antigen and, **49**:159, 169–170, 172  
 and chemicals inhibiting IL-6 synthesis, **54**:50–51
- circulating levels, measurement, **66**:104–105
- complement receptor 1 and, **46**:192, 199
- disease and, **63**:270, 310–311
- downregulation, **64**:315–316
- effects on IL-1ra production by monocytes, **54**:182–184
- enhancement and inhibition of iNOS, **60**:333–339
- and eosinophils, **60**:203–205
- fibrosis, **59**:418
- function, **66**:103–104
- functional effects, **48**:167–179
- gene regulation  
 description of, **52**:263  
 interferon system, **52**:264–265  
 by NF-IL6 and NF- $\kappa$ B, **65**:1–33  
 regulatory DNA sequences in type I interferon genes, **52**:265–267  
 transcriptional regulation of IFN-inducible genes, and role of IRF-1 and IRF-2, **52**:272–275
- transcription factors binding to regulatory elements of type I interferon genes  
 IFN regulatory factors 1 and 2, **52**:267–271  
 NF- $\kappa$ B, **52**:271–272  
 other factors, **52**:272  
 understanding, **52**:263–264
- genes  
 cloning and expression, **58**:425–427  
 in tumor cell engineering, **57**:321–323  
 upregulated by NF- $\kappa$ B, **58**:10–12
- germline transcripts, **61**:84–89
- granulomatous lesions, **62**:281
- growth hormone secretion, **63**:385
- helper T cell, *see* T helper cells, cytokines and histamine release, **50**:247–248
- HIV infection and, **47**:401–404
- human, properties, **52**:175
- humoral immune response and, **45**:1, 55–61, 73
- Ig production, **63**:58
- induced by NF- $\kappa$ B, **58**:10–12
- induction of, **51**:274
- inflammatory process, **65**:111
- inflammatory response, **63**:310
- inhibition of viral replication, **66**:288, 290
- Jak isoforms, **61**:174
- Jak kinases, **63**:138–139
- leukocyte integrins and, **46**:170, 172, 176
- LPS-induced release, CD14 role, **53**:284
- lung transplant rejection, **59**:424, 426
- lymphocyte–HEV interaction, **65**:374  
 and mast cells, **51**:328–331
- membrane receptors and, **63**:274–275  
 modulation of histamine release by, **50**:248–250
- mRNA expression, Th2-like profile, **60**:222
- multiple myeloma pathogenesis and, **64**:252–260
- network, position of IL-2 in, **50**:160
- neural generation, **48**:168–169
- NK cells and, **47**:241, 263, 265, 266
- persistent effects, **48**:173–174
- pleiotropy of, **53**:47
- produced by different vector systems, **58**:429–430
- production, **48**:167–179  
 by CD5 B cells, **55**:310–311  
 by human CD4+ T cells, **61**:347–355  
 TGF- $\beta$  regulation, **55**:187



Cytokines (*continued*)

- proinflammatory, **64**:291–294
  - IL-6 effects, **54**:27–28
- pulmonary immunity, **59**:373
- pulmonary inflammation, **62**:267–271, 280, 288
- receptor antagonists, **63**:277
- redundancy of, **53**:47
- regulation, **63**:270–275, 310–311
- regulation of apoptosis, **58**:229–230
- regulatory effects, **64**:165–166, 315–317
- rheumatoid arthritis, **64**:290–298, 316; **65**:123–124
  - neovascularization, **64**:320
- role in peripheral clonal deletion, **58**:271–272
- role in regulating committed progenitors, **60**:163–164
- SCID and, **49**:386, 393
- sepsis and, **66**:101–102, 104
  - G-CSF, **66**:149–150
  - GM-CSF, **66**:150
  - IFN- $\gamma$  and, **66**:145–146
  - IL-1, **66**:104, 117–127, 150
  - IL-4, **66**:144–145
  - IL-6, **66**:130–135
  - IL-8, **66**:135–141
  - IL-10, **66**:142–145
  - IL-12, **66**:146–147
  - LIF, **66**:147–148
  - MCP-1, **66**:104, 135, 141–142
  - MIF, **66**:147–148
  - TNF, **66**:104, 117–127, 150
- signaling, **58**:369
  - negative regulation, **60**:25–26
  - role of Stats, **60**:19–22
  - shared signals through GP130, **54**:15–19
- signal transduction, **63**:127–176
  - adapter molecules, **63**:134, 141–143
  - calcineurin, **63**:166–167
  - CD45, **63**:164–165
  - Jak-Stat pathway, **63**:138–141
  - MAPK family, **63**:148–149
  - nuclear transcription factor NF- $\kappa$ B, **63**:157–160
  - PAC-1, **63**:167
  - phosphatidylinositol 3-kinase, **63**:149–154
  - phosphoprotein phosphatases, **63**:164–167
  - protein kinase C, **63**:154–157
  - protein tyrosine kinases, **63**:133–143
  - PTP-1C, **63**:165–166
  - Raf kinase, **63**:147–148
  - Ras, **63**:143–147
  - Rho protein, **63**:149
  - Src family, **63**:133–137
  - SYK family, **63**:134, 137–138
- spontaneous autoimmune thyroiditis and, **47**:494
  - disturbed immunoregulation, **47**:471, 477, 478
  - genetics, **47**:488, 489
- Stat protein activation, **61**:174–175
- stimulatory, **52**:198–199
- surface antigens of human leukocytes and, **49**:98–100, 111
- synthesis and secretion, **63**:271, 273
- synthesis coordination by NF- $\kappa$ B, **58**:1–2
- TH2, **60**:177
  - functional similarities to IL-10, **56**:12–13
- TH responses, **61**:347–348
- Cytokine synthesis inhibitory factor, **46**:131, 133, 135; **62**:85, *see also* Interleukin-10
- discovery, **56**:1–2
- Cytokinoplasts, L-NMMA effect, **60**:352
- Cytolysis, cell-mediated killing and, **41**:291
- Cytolysis
  - adoptive T cell therapy of tumors and antigen recognition, **49**:319
  - expression of antitumor responses, **49**:325, 328, 332
  - mechanisms, **49**:299–303, 305–308, 312–313, 316
  - principles, **49**:290, 295
- af27 polarity, **41**:273–275
- cell mediation, **41**:272
- cognate target, by CD4<sup>+</sup> CTLs, **60**:304
- colloid osmotic killing, **41**:280
- cytoplasmic granules, **41**:287, 288, 291
- granule exocytosis, **41**:281, 282
- HIV-1-specific, **66**:283–284, 287–298
- HIV-infected cells, **65**:280–281
- hydrolytic enzymes, **41**:273–275
- intracellular damage, **41**:282–284
- leukoregulin, **41**:286
- lymphotoxin-like molecules, **41**:284–286

- membrane attack complex of complement, **41:299, 300, 310**
- membrane damage, **41:277–281**
- NK cell-mediated, p58 in, **55:354–357, 362–363**
- perforin role, **51:215–216, 224–232**
- perforin-independent mechanisms, **51:231–232**
- verification by genetic approach, **51:227–231**
- verification in cell lines, **51:224–227**
- polypeptide toxins, **41:316–319**
- pore-forming proteins amoebas, **41:312, 313**
- cytolytic proteins, **41:316–319**
- eosinophil cationic protein, **41:311, 312**
- polypeptide toxins, **41:316–319**
- small peptides, **41:313–316**
- reactive. inhibition by CD59, **60:76–77**
- reactive oxygen metabolism intermediates, **41:286**
- TCR  $\gamma\delta$  cells, **43:172–174**
- Cytolysis inhibitor, **61:204, 249–251**
- Cytolytic effector cells, NK cells and, **42:204–205**
- Cytolytic T cells, **41:365, 367, 368; 42:165**
- CD5 B cell and, **47:144, 145**
- clones, **41:9, 12, 14**
- CTLL, **42:165**
- CTLL-2, **61:155**
- IL-2 activation, **61:176–179**
- rapamycin, **61:182**
- hybrid resistance and, **41:364, 380, 395, 396, 402, 404**
- Cytomegalovirus
- cytotoxic T cells and, **65:278–279**
- HIV infection and immune response, **47:409**
- immunopathogenic mechanism, **47:390, 392, 400**
- neuropsychiatric manifestations, **47:392, 403, 405**
- human, antibodies from combinatorial libraries, **57:220–221**
- Cytoplasm
- adoptive T cell therapy of tumors and, **49:283**
- antigen-presenting cells and
- antigen presentation, **47:81**
- antigen processing, **47:87**
- cell surface, **47:60**
- T cell growth, **47:101**
- tissue distribution, **47:48, 51**
- autoimmune thyroiditis and, **46:295**
- CD5 B cell and, **47:144–146**
- CD23 antigen and, **49:162, 166**
- complement receptor 1 and, **46:184, 188–190**
- complement receptor 2 and, **46:202, 209**
- HIV infection and, **47:393, 396, 397**
- IgE biosynthesis and, **47:4, 20, 21**
- leukocyte integrins and, **46:154–156, 166, 171**
- NK cells and, **47:197**
- congenital defects, **47:225**
- effector mechanisms, **47:249, 253, 262**
- morphology, **47:214**
- SCID and, **49:386**
- surface antigens of human leukocytes and, **49:87, 89, 117**
- membrane enzymes, **49:113–114**
- receptors, **49:98–100**
- Cytoplasmic domains, **54:281–282**
- IL-2R $\beta$ , **59:255–258**
- IL-2R $\gamma$ , **59:254–255, 258**
- LIF receptor, **53:39–40**
- regulation through, **54:311–313**
- role of phosphorylation, **54:311–313**
- Cytoplasmic granules, cytotoxicity and, **41:281, 287–291**
- Cytoplasmic tails, CD1 proteins, **59:17**
- Cytoskeletal interactions, **54:346**
- Cytoskeleton
- attachment to B cell antigen receptor, **55:262–264**
- autoimmune thyroiditis and, **46:298**
- complement receptor 1 and, **46:186, 198**
- complement receptor 2 and, **46:210, 213**
- immunosenescence and, **46:224, 235**
- leukocyte integrins and, **46:163, 169, 171, 176**
- surface antigens of human leukocytes and, **49:85–86, 92–93, 113**
- Cytosol
- IL-1 and, **44:161, 163, 175, 176, 179, 184**
- TAP system, **64:5–6**
- T cell activation and, **41:17, 22**
- Cytotoxic effector cells
- IBD and, **42:296–297**
- immune reconstitution and, **40:416–417**

- Cytotoxicity, **43:173**  
 ADCC, *see* Antibody-dependent cellular cytotoxicity  
 allogeneic lymphocyte, hybrid resistance and, **41:356; 357**  
 CTL-mediated  
 Fas/APO-1 pathway, **60:294–296**  
 perforin pathway, **60:292–294**  
 role of effector molecules, **60:300–302**  
 and eosinophil mediator release, **60:205–208**  
 hybrid resistance and, **41:359, 361, 362, 366, 372, 393, 394**  
 lectin-mediated, **60:300**  
 lymphocyte and complement-mediated, **41:269, 270, 319, 320**  
 af27 polarity, **41:273–275**  
 colloid osmotic killing, **41:280**  
 CTL cells, **41:270–273**  
 granule exocytosis, **41:281, 282**  
 hydrolytic enzymes, **41:275–277**  
 intracellular damage, **41:282–284**  
 leukoregulin, **41:286**  
 lymphotoxin-like molecules, **41:284–286**  
 membrane attack complex of complement, **41:299–307**  
 membrane damage, **41:277–281**  
 NK cells, **41:270–273**  
 pore-forming proteins, **41:311–319**  
 reactive oxygen metabolism intermediates, **41:286**  
 SCID and, **49:395**  
 Cytotoxic T cell differentiation factor, T cell subsets and, **41:64, 76**  
 Cytotoxic T cell recognition, maternally transmitted antigen and, **38:313, 315, 316**  
 class I antigens, **38:330, 331, 334–337**  
 generation, **38:348–350**  
 maternally transmitted factor, **38:328**  
 polymorphisms, **38:320**  
 Cytotoxic T cells, **38:2, 10, 86, 87, 105, 121, 122, 126, 127, 133; 41:269, 270; 43:195; 62:87, 228, 231; 64:2; 65:277–278**  
 adenovirus, **65:279**  
 adoptive T cell therapy of tumors and, **49:283, 290–291**  
 antigen recognition, **49:319–321, 324**  
 mechanisms, **49:300, 303–305, 316, 318**  
 anterior chamber-associated immune deviation, **48:208, 209**  
 antigen-presenting cells and, **47:73, 79–81**  
 antigen processing, **47:92**  
 immunogeneity, **47:104**  
 antiviral therapy, **66:295–298**  
 autoimmune demyelinating disease and, **49:363**  
 autoimmune thyroiditis and, **46:288**  
 autoreactive T cells and, **45:425**  
 CD4<sup>+</sup>, **60:303–310**  
 CD4<sup>+</sup> and CD8<sup>+</sup>, **60:289–292**  
 CD8<sup>+</sup>  
 class II-restricted, **60:309–310**  
 and HIV-1 immunopathology, **66:273–274, 276, 277, 281**  
 in HIV-1 infection, **60:133–134**  
 cell-mediated killing and, **41:287–289, 291, 297**  
 class I antigens, **65:279–280**  
 clones, **38:20**  
 CTL epitope, *P. yoelii* circumsporozoite protein, **60:112**  
 cytolysis and, **41:273**  
 cytomegalovirus infection, **65:278–279**  
 differentiation of, **40:97–98**  
 effector T cell, **48:197**  
 epitopes, **66:276–280**  
 Epstein–Barr virus, **65:279**  
 Fas expression in, **57:138**  
 gene expression, **38:13, 14**  
 granule exocytosis, **41:281**  
 granule proteins, **41:286, 287**  
 cytoplasmic granules, **41:287**  
 pore-forming protein, **41:291, 296, 297**  
 serine esterase, **41:297, 298**  
 helper T cell cytokines and, **46:111**  
 cross-regulation of differentiation, **46:132**  
 functions, **46:114–117**  
 immune responses, **46:133, 135**  
 precursors of differentiation states, **46:125**  
 secretion patterns, **46:112, 113**  
 herpes simplex virus, **65:279**  
 HIV and, **45:356, 358, 365, 366**  
 HIV infection, **47:390, 410, 411, 413; 65:280**  
 adoptive immunotherapy, **65:317–320**  
 CTL-mediated lysis, **65:280–281**  
 CTLs and, **65:280–322**

HLA and, **65:284–286**  
 replication suppression, **65:281–284**  
 in seronegatives, **65:287, 307–309**  
 vaccines, **65:320–322, 323**  
 HIV-1 persistence, **66:287, 292–294**  
 HLA class I system, **65:279**  
 HLA-DR antigens and, **42:293**  
 hybrid resistance and, **41:385**  
 hydrolytic enzymes, **41:275–277**  
 immunosenescence and, **46:244, 245, 249, 250**  
 influenza virus, **65:278**  
 intracellular damage, **41:283**  
*Ir* gene control of responses  
 allogeneic cross-reactive lysis,  
**38:185–187**  
 class I molecules, **38:171–174**  
 H-Y antigen, **38:175–180**  
 immunodominance, **38:180–185**  
 I region genes, **38:161–171**  
*Ir* genes and, **38:87, 116, 174**  
 Langerhans cell, **48:197–198**  
 leukocyte integrins and, **46:150**  
 inflammation, **46:161, 163, 164**  
 ligand molecules, **46:172**  
 lymphotoxin-like molecules, **41:284, 285**  
 measles and, **45:341, 345, 346**  
 mediated antigen-specific killing,  
**60:292–296**  
 mediated cytotoxicity, **60:300–302**  
 mediation, **41:270–273**  
 MHC recognition, **41:135–138; 55:364**  
 carbohydrate moieties, **41:152–154**  
 exon shuffling, **41:138–149**  
 H-2 mutant strains, **41:158–163**  
 HLA class I antigens, **41:149–152**  
 HLA subtypes, **41:163–165**  
 $\beta$ -microglobulin, **41:154–156**  
 monoclonal antibodies, **41:156–158**  
 somatic cell class I variants, **41:165–167**  
 MHC restriction, **43:214–215**  
 monoclonal antibodies, **38:277**  
 mononuclear cells and, **42:294**  
 mRNA, **38:21**  
 NK cells and, **47:187, 188, 196, 283, 295, 302**  
 congenital defects, **47:225**  
 cytotoxicity, **47:252–254**  
 differentiation, **47:229, 232**  
 effector mechanisms, **47:241, 245, 246**

hematopoiesis, **47:282**  
 reproduction, **47:272**  
 surface phenotype, **47:208, 211**  
 ocular HSV infection, **48:210**  
 polarity, **41:273–275**  
 response to foreign antigens, **43:205**  
 response to virus infection, **43:205**  
 SCID and, **49:396, 398–399**  
 self-MHC class I recognition by effector  
 cells, **57:314–315**  
 sporozoite malaria vaccine and, **45:312**  
 synthetic T and B cell sites and, **45:262, 264**  
 antigens, **45:234, 235**  
 immunological considerations, **45:199**  
 viral antigens, **45:218–220, 226, 227**  
 target recognition, **38:22**  
 targets, death of, **50:69**  
 T cell receptor and  
 accessory molecules, **45:110**  
 alloreactivity, **45:151–157**  
 antigen processing, **45:118–120, 125–127**  
 experimental systems, **45:137**  
 MHC molecules, **45:116**  
 peptides, **45:137, 138**  
 polymorphic residues, **45:159, 162**  
 structure-function relationships,  
**45:139–141**  
 T cell repertoire, **45:166**  
 T cell subsets and, **41:39, 51**  
 activated T cells and hybridomas, **41:54, 56, 57**  
 alloreactivity, **41:78, 81, 82**  
 effector phase, **41:75, 92, 94, 95**  
 H-2 molecules in thymus, **41:97, 99–103, 108**  
 resting T cell subsets, **41:83–88**  
 T accessory molecules, **41:60**  
 unprimed and resting T cells, **41:65, 71–75**  
 transplant, **48:197–198**  
 transporters, need for, **65:47–48**  
 tumor immunity and, **65:94, 95**  
 Cytotoxins, **41:269, 270**

## D

DI.3, **43:20–21, 222**  
 DAG, *see* Diacylglycerol

- Daudi cells, stimulation with CD40, **63:51**
- Daunomycin  
 in cancer treatment  
 antitumor activity, **56:333–334**  
 functional studies, **56:345**  
 monoclonal antibody conjugation,  
**56:334–336, 338**  
 MC and, **42:265–268**  
 MG and, **42:265–268**
- DBA/2 mastocytoma cell, anterior chamber,  
**48:204**
- Death domain, **61:9, 27, 31**
- Death factor, Fas as, **57:129–140**
- Death genes, induction activation, **50:71–73**
- Death program, release, **50:75–76**
- Decay-accelerating factor, **48:241; 61:203, 204, 222–228**  
 complement receptor 1 and, **46:189, 197**  
 deficiencies in PNH, **60:75–78**  
 expression on all blood cells, **60:78**  
 function, **61:219, 224–228**  
 gene, **61:222–223**  
 in GPI-anchored proteins, **60:60–66**  
 regulators of complement activation and  
 genes, **45:403, 408**  
 protein expression, **45:395–402**  
 protein interactions, **45:383**  
 protein roles, **45:385–388, 390, 391**  
 structure, **61:207, 222–224**  
 surface antigens of human leukocytes and,  
**49:93**  
 therapeutic complement activation role,  
**56:273–274**
- Deep venous thrombosis, aPL antibodies and,  
**49:219**
- Degradation, *Ir* genes and, **38:93, 95–97**
- Degranulation  
 cytotoxicity and, **41:282, 296, 297, 312**  
 eosinophils  
 and  $\beta 2$  integrins, **60:207**  
 morphology, **60:160–162**  
 mast cells, NO effect, **60:332**
- Dehydroepiandrosterone, **61:357**
- Delayed-type hypersensitivity  
 adoptive T cell therapy of tumors and,  
**49:289, 327**  
 anterior chamber-associated immune  
 deviation, **48:219**  
 antigen-specific down-regulation, **48:208, 209**  
 intraocular tumor allograft, **48:208, 209**
- antigen-presenting cells and, **47:57, 104**  
 effector T cell, **48:197**  
 helper T cell cytokines and  
 cross-regulation of differentiation, **46:131**  
 differential induction, **46:127–130**  
 functions, **46:117**  
 human subsets, **46:139**  
 immune responses, **46:133, 137, 138**  
 precursors of differentiation states,  
**46:125**
- humoral immune response and, **45:24, 27, 79, 85**  
 hybrid resistance and, **41:383**  
 IFN- $\gamma$  and, **62:96–98**  
 immunosenescence and, **46:221, 237**
- Ir* genes and  
 expression, **38:55, 57, 60, 61**  
 genetic control, **38:34–36**  
 H-Y antigen, **38:180**  
 I region mutations, **38:86**  
 MHC restriction, **38:65**  
 “Schlepper” experiment, **38:39, 40**  
 T cells, **38:41, 42**  
 interaction, **38:157, 158**  
 suppression, **38:135**
- Langerhans cell, **48:197–198**
- leukocyte integrins and, **46:162**
- NK cells and, **47:226**
- ocular HSV infection, **48:210**
- spleen, **48:211–212**
- spontaneous autoimmune thyroiditis and,  
**47:450**
- T cell subsets and, **41:76, 77, 94**
- transplant, **48:197**
- tumor allograft, **48:208, 209**
- UV5C25, **48:214**
- Delbrück model, antigenic variation,  
**38:340–344**
- Deletion, *see also* Clonal deletion  
 autoreactive T cells, **58:272–275**  
 B cell formation and, **41:203**  
 CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58:166–168, 170–171, 259**  
 complement components, **38:229**  
 cytotoxic T cells and, **41:139, 167**  
 $\gamma\delta$  T cells, **58:313**  
 Ig heavy-chain variable region genes and,  
**49:9, 14, 25, 31**

- intrachromosomal, switch recombination, **61:99**
- Ir* genes, **38:189**  
 antigen-specific clones, **38:121**  
 clonal, **38:92, 125**  
 macrophages, **38:114, 115**  
 T cell selection, **38:131, 132**  
 tolerance, **38:127, 130**
- peripheral, *in vitro* models, **58:215–219**
- peripheral T cell, CD3/TCR-mediated, *in vitro* models, **58:219–224**
- reduced level in C<sub>10</sub> or C<sub>10</sub> coding ends, **58:40**
- RSS junctional, **58:54**
- single and multiple base, in PNH, **60:84–88**
- Deletional switch recombination, in B cells, **60:38–39**
- Deletion mapping analysis, **42:133–137**
- Delta-kaolin clotting time, aPL antibodies and, **49:201, 206**
- Demyelinating disease, autoimmune, *see* Autoimmune demyelinating disease
- Dendritic cells  
 adoptive T cell therapy of tumors and, **49:330**  
 afferent lymph, CD1 protein expression, **59:63–64**  
 antigen-presenting cells and, **47:45–47, 87, 104, 105**  
 antigen presentation, **47:71, 72, 74–76, 78–81**  
 antigen processing, **47:88–92**  
 APC-T cell binding, **47:95–97, 99**  
 cell surface, **47:57–64**  
 immunogeneity, **47:101–104**  
 interaction with T cells, **47:93, 94**  
 T cell-dependent antibody responses, **47:83, 84, 86**  
 T cell growth, **47:99–101**  
 tissue distribution, **47:47–57**
- autoimmune thyroiditis and, **46:280, 281, 296, 297, 300**
- CD1 protein distribution, **59:60–64**
- CD23 antigen and, **49:155, 171**
- CD40 expression, **61:13, 40–41**
- complement receptor 1 and, **46:190**
- complement receptor 2 and, **46:209**
- distinction of FDCs from other, **51:244–247**
- helper T cell cytokines and, **46:128**
- IBD and, **42:293, 296**
- lung transplants, **59:423**
- pulmonary, **59:376–381, 412**
- role in V $\beta$  selective element action, **50:31**
- SCID and, **49:402**
- as target for vaccination strategies, **58:435–436**
- T cell subsets and  
 H-2 alloantigen recognition, **41:89–92**  
 H-2 molecules in thymus, **41:103–106, 108–110**  
 H-2-restricted antigen recognition, **41:74, 75, 77**
- Dengue virus, IFN- $\gamma$  and infection, **62:77**
- Density, alterations during eosinophil activation, **60:202–203**
- Dental caries, subunit vaccines, **60:135–136**
- Deoxyguanosine, T cell subsets and, **41:104, 106, 108**
- Deoxynucleotidyltransferase, B cell formation and, **41:194, 203, 204, 220, 231**
- Deoxyspergualin, **65:125–126**
- Depletion  
*Ir* genes  
 complementation, **38:74**  
 immunodominance, **38:182, 184**  
 macrophages, **38:113, 115**  
 tolerance, **38:127**
- SCID and, **49:381, 394–397, 399, 401**
- Depolarization  
 cell-mediated killing and, **41:273**  
 pore-forming protein and, **41:293, 294**
- Dermatitis  
 CD23 antigen and, **49:154**  
 SCID and, **49:398**
- Dermatomyositis, antinuclear antibodies and, **44:111–113, 118–120, 137**
- Desetope, *Ir* genes and, **38:107**
- Desmoglein  
 amino acid sequence homologies and conserved sites with PV antigen, **53:314**  
 characterization, **53:300–303**  
 comparison with PV antigen and cadherins, **53:311**
- Desmoplakin I  
 homology with 230-kDa pemphigoid antigen, **53:305–310**

- Desmoplakin I (*continued*)  
 structural and amino acid homologies with  
 BP antigen, **53:307**
- Desmosomes  
 pemphigus foliaceus antigen localization,  
**53:300–303**  
 ultrastructure diagram, **53:297**
- Desotope, T cell subsets and, **41:53, 58**
- Determinant selection  
*Ir* genes and, **38:98, 99**  
 model, MHC restriction, **43:207**
- Development  
 fetal, acquisition of clonotype repertoire  
 during, **42:26–30**  
 IL-6 role  
 embryo, **54:31–32**  
 fetus, **54:32**  
 placenta, **54:32**  
 intrathymic, *see* T cells, intrathymic  
 development  
 LIF role in, **53:33–37**  
 neonatal, *see* Neonatal development  
 regulation of IgR functional components,  
**54:375–378**
- DEX, *see* Dextran
- Dexamethasone, **62:192, 195**  
 GM-CSF mRNA in T cells and, **39:14**  
 hybrid resistance and, **41:387**  
 IL-2 mRNA in T cells and, **39:14**  
 IL-3 mRNA in T cells and, **39:14**  
 induced T cell death, **58:262–265**  
 NF- $\kappa$ B and, **65:119**
- Dexter's culture system, B cell formation and  
 bone marrow, **41:208–210, 213, 215–217,**  
**219, 220**  
 W/W anemic mice, **41:224**
- Dextran  
 Ars A response and, **42:131**  
 B cell repertoire expression and, **42:58–62**  
 as intermediate carrier in  
 anthracycline–antibody conjugation,  
**56:337–338**  
 secondary B cell lineage and, **42:70**
- DFL16.1 gene segment, Ars A antibodies  
 and, **42:105–107**
- DHA, **62:186**
- DH segments, **62:1, 23**  
 Ig heavy-chain variable region genes and,  
**49:2–3**  
 mouse and human, **62:17–19**  
 organization, **62:9–10**
- Diabetes, *see also* Autoimmune diabetes,  
 murine model  
 autoimmune thyroiditis and, **46:269, 284,**  
**298**  
 insulin-dependent, *see* Insulin-dependent  
 diabetes mellitus  
 murine lupus models and, **46:79**  
 NK cells and, **47:301**  
 overt, T cell subsets involved in insulinitis  
 and, **51:296–298**  
 patients, IL-2 deficiency of, **50:173–174**  
 spontaneous autoimmune thyroiditis and,  
**47:448, 468, 492**  
 suppressor mechanism controlling  
 development of, **51:301–303**
- Diabetes mellitus  
 antiadhesion therapy, **64:197**  
 human-human hybridomas and, **38:299**  
 IFN- $\gamma$  and, **62:100–101**  
 insulin-dependent, *see* Insulin-dependent  
 diabetes mellitus  
 mucosa-derived effector cells, **64:192**  
 NO role, **60:344–345**  
 pituitary hormones, **63:423**  
 role of IL-1ra, **54:214**
- Diabetogenic genes, MHC-linked,  
**51:290–293**
- Diabetogenic T cells, repertoire of,  
**51:298–301**
- Diacylglycerol, **48:228, 309**  
 IL-1 and, **44:175, 176, 185**  
 immunosenescence and, **46:223, 224**  
 in neutrophils  
 amplification and, **39:131–135**  
 protein kinase C and, **39:130–131**  
 T cell activation and, **41:15–19, 30**
- Diamphotoxin, cytotoxicity and, **41:318**
- Diapedesis, **65:369**
- Diazo reaction, as procedure for  
 chemioimmunoconjugation, **56:319**
- Dibutyl cyclic AMP, autoimmune thyroiditis  
 and, **46:294**
- Dicetyl phosphate, aPL antibodies and,  
**49:229–230**
- Diclofenac, **62:184, 186**
- Dif, in rel family, characterization, **58:14**
- Differentiation  
 antigen-presenting cells and, **47:48,**  
**83, 84**  
 autoimmune thyroiditis and, **46:266**

- B cell
- in CBA/N immunogenic mice, **53**:142–143
  - and growth, *in vivo* aspects, **52**:221–230
  - HJGMX-1 as defect, **60**:42–48
  - isotype switching during, **60**:38–39
  - murine CD5 B cells, **55**:309–310
- B cell formation and, **41**:181, 235–237, 239
- B cell precursors, **41**:188, 189, 191–192, 194, 195, 197, 199–201
- bone marrow cultures, **41**:210, 212, 214–218, 220
- genetically determined defects, **41**:223–226, 230, 231
- inducible cell line, **41**:220, 221, 223
- lymphohemopoietic tissues, **41**:185, 187
- population dynamics, **41**:206, 207
- soluble mediators, **41**:232, 235
- CD5 B cell and, **47**:117, 118, 123, 125
- physiology, **47**:139, 141, 142
- complement receptor 2 and, **46**:204, 206
- cytolysis and, **41**:270
- eosinophils, **60**:162–164
- helper T cell cytokines and
- cross-regulation, **46**:130–133
  - human subsets, **46**:139
  - immune responses, **46**:137
  - induction, **46**:127–130
  - precursors, **46**:122–127
- HIV infection and, **47**:379, 393
- hybrid resistance and
- antigen expression, **41**:400
  - bone marrow cells, **41**:336
  - leukemia/lymphoma cells, **41**:369
  - marrow microenvironment, **41**:390, 392
  - NK cells, **41**:372, 373
  - syngeneic stem cells, **41**:388
  - T cells, **41**:381
- IgE biosynthesis and
- antibody response, **47**:8, 9, 11
  - binding factors, **47**:12, 13, 21, 23
- immunosenescence and, **46**:221, 253
- lymphocyte activation, **46**:231, 232
  - stem cells, **46**:240, 242–247
- NK cells and, **47**:188, 198
- adaptive immunity, **47**:291, 292, 294
  - congenital defects, **47**:225
  - effector mechanisms, **47**:235, 239
  - hematopoiesis, **47**:272, 276
  - morphology, **47**:216
  - surface phenotype, **47**:201, 205, 208
  - in vitro*, **47**:232–234
  - in vivo*, **47**:229–232
- pre-B cells into B cells
- in *bc1-2* transgenic mice, **53**:143–144
  - in vitro*, **53**:140–141
  - in vivo*, **53**:141–142
- related translocation oncogenes, **50**:139
- spontaneous autoimmune thyroiditis and, **47**:447
- stem cell factor–ligand interaction in, **55**:40–42
- subpopulations, **53**:127–130
- surrogate L chain functions in, **53**:136–143
- T cell activation and, **41**:22
- T cells, CD4 and CD8 roles, **53**:94–113
- negative selection, **53**:101–103
  - positive selection, **53**:97–98
  - thymocyte development and selection, **53**:94–97
- T cell subsets and
- H-2 molecules in thymus, **41**:98–102, 104, 105, 107, 108
  - H-2-restricted antigen recognition, **41**:52, 64, 66, 76, 77
  - terminal, and somatic mutation, apoptosis and, **50**:65–66
- Differentiation-inhibiting factor/differentiation-retarding factor, *see* Leukemia inhibitory factor
- Diffuse large cell lymphoma, gene rearrangements and, **40**:292
- DiGeorge syndrome, **59**:247
- SCID and, **49**:383–384, 391
- Dilute Russell viper venom time, aPL antibodies and, **49**:201, 242
- Dimerization, through SH2 domain, **60**:19
- Dimerization/oligomerization, Epo receptor, **60**:9–11
- Dimethyl sulfoxide, for MC, **42**:264
- Dinitrophenyl
- IgE biosynthesis and, **47**:28
  - synthetic T and B cell sites and, **45**:199
- Dinitrophenyl-Asc, IgE biosynthesis and, **47**:3–5
- Dinitrophenyl-KLH, IgE biosynthesis and antibody response, **47**:5, 6
- antibody response suppression, **47**:29, 31, 33, 34, 37



- Dinitrophenyl-OVA, IgE biosynthesis and antibody response, **47:5**  
 antibody response suppression, **47:28–30**,  
 32–34, 37  
 binding factors, **47:12**, 14
- Dinitrophenyl-Rag, IgE biosynthesis and, **47:4**
- Dintzis model, size fractionated polymers, **52:288–289**
- Diphtheria, **38:32**, 289, 295
- Direct cDNA selection, **59:165**
- Direct cellular cytotoxicity, spontaneous autoimmune thyroiditis and, **47:451**, 452, 469
- Directional cloning, **38:205**
- Direct two-color immunofluorescence, for NK cell surface antigens, **42:200**
- DIR segments, Ig heavy-chain variable region genes and, **49:30–31**, 33
- Disease, *see also* Xenograft models  
 clinical  
 fiberoptic bronchoscopy studies, **60:219–223**  
 and IL-6, **54:44**, 45  
 cytokines, **63:270**, 310–314  
 IL-2R, **63:294**, 296–298  
 and IL-6, **54:39–43**, 44–45  
 IL-6, **63:301**, 302  
 immunity, role of IELs, **58:326–329**  
 role of eosinophils, **60:151–228**  
 TNF, **63:306**  
 virulence factors, **63:308–309**
- Disseminated intravascular coagulation, endotoxic shock, **66:260**
- Dissociation rate constants, **42:168–172**
- Disulfide  
 CD4 molecules and, **44:285**, 286  
 CD8 molecules and, **44:270–273**  
 genetically engineered antibody molecules and  
 biological properties, **44:83**  
 chimeric antibodies, **44:81**, 82  
 expression, **44:76**  
 production, **44:67**, 69  
 Ig gene superfamily and  
 homology unit, **44:3**  
 nonimmune receptor members, **44:31**,  
 34, 35, 38, 41, 42  
 receptors, **44:9**  
 lymphocyte homing and, **44:342**  
 T cell development and, **44:207**, 213, 233
- Disulfide bridge, **48:13**
- Dithiocarbamates, action of, **65:123**
- Divergence, functional, and positive selection  
 T cell mechanism, **51:186–189**
- Diversification  
 germinal centers, **60:283–284**  
 somatic  
 Ig gene superfamily and, **44:12–20**  
 Ig VL gene, **48:60–62**
- Diversity  
 combinatorial, in leukocyte–endothelial cell recognition, **58:389–390**  
 N region, **58:301–303**
- DNA, *see also* Complementary DNA;  
 Mitochondrial DNA; Recombinant DNA  
 antigen-presenting cells and, **47:75**  
 antigen processing, **47:92**  
 APC-T cell binding, **47:95–97**  
 T cell growth, **47:99–101**
- antinuclear antibodies and, **44:93**  
 autoantibodies, **44:125**, 127, 137, 138  
 autoantigen, **44:127**, 128, 131  
 drug-induced autoimmunity, **44:109**  
 scleroderma, **44:121**, 122  
 SLE, **44:95–100**, 105–107
- aPL antibodies and, **49:209**, 226, 240,  
 248–249, 251, 256
- autoimmune thyroiditis and, **46:267**, 303
- B cell formation and, **41:183**, 184, 203,  
 217, 235
- breakage  
 immunodeficiency syndromes,  
**61:314–316**  
 KU 70/86, **61:301–303**  
*scid* mutation, **61:299–301**, 317  
 V–D–J recombination, **61:298–303**  
 broken, in V(D)J recombination, **64:43–45**
- CD4 molecules and, **44:286–288**
- CD5 B cell and, **47:161**  
 Ig gene expression, **47:152**, 154–156  
 marker for activation, **47:127**  
 physiology, **47:131**, 133, 134, 136, 137
- CD8 molecules and, **44:272**, 275, 277
- CD23 antigen and, **49:167**
- cell-mediated killing and, **41:298**
- cloning, **44:74**  
 expression, **44:70**, 71, 77, 78  
 fusion proteins, **44:85**, 86

- complement receptor 1 and, **46:188**  
 complement receptor 2 and, **46:206**  
 cytolysis and, **41:277, 283–285**  
 damage, *see* DNA damage  
 degradation, target cells, by CTLs,  
**60:300–301**  
 deletion and looping out, **54:234**  
 double-strand break repair, **64:49, 51**  
   model, **61:111**  
   relevance of joining activity, **58:45**  
   and V(D)J recombination, **58:29–85;**  
   **64:49–51**  
     cell cycle regulation, **58:70–74**  
     and Ku autoantigen, **58:55–60**  
 double-strand breaks, role in V(D)J  
 recombination, **58:32–36**  
 Ets transcription factor binding, **64:66–68**  
 fragmentation, **58:246–248, 251–253,**  
**262–264, 270–271**  
 genetically engineered antibody molecules  
 and, **44:66, 89**  
 genomic rearrangement, **38:9**  
 HIV infection and  
   etiological agent, **47:380, 382**  
   immunopathogenic mechanism, **47:387,**  
   **401, 402**  
   neuropsychiatric manifestations, **47:403**  
 humoral immune response and, **45:6,**  
**32, 35**  
 hybrid resistance and, **41:343, 377, 378**  
 IgE biosynthesis and, **47:17**  
 Ig gene superfamily and  
   evolution, **44:46**  
   homology unit, **44:8**  
   receptors, **44:12, 14, 17, 20**  
 Ig heavy-chain variable region genes and,  
**49:1, 3**  
   D segments, **49:29, 31–33**  
   J<sub>H</sub> segments, **49:33**  
   polymorphism of V<sub>H</sub> gene segments,  
   **49:23–24**  
   regulation, **49:53, 55, 61**  
   V<sub>H</sub> families, **49:8, 9, 11**  
   V<sub>H</sub> gene expression, **49:35, 39–40,**  
   **42–43, 46, 48–50**  
 IL-1 and, **44:165, 177**  
 immunosenescence and, **46:230, 234, 253**  
 Ir genes and  
   cytotoxic T cells, **38:169**  
   recombination, **38:86**  
   T cell repertoire, **38:116, 145**  
   T cell suppression, **38:148, 150**  
 –Ku complex, **58:55–57, 61–62**  
 leukocyte integrins and, **46:160, 174, 175**  
 maps of Ig-like loci and, **46:3–6, 46**  
   structure, **46:11–13, 15, 18, 25, 27**  
   T cell receptor, **46:36, 37, 39, 41–43, 45**  
 MHC class I molecule-encoding, **58:433**  
 mitochondrial, *see* Mitochondrial DNA  
 murine lupus models and  
   Ig germline, **46:66, 69, 71, 72, 76–78**  
   T cell antigen receptor, **46:83, 84, 87**  
 naked  
   and cytotoxic T cell responses,  
   **58:436–437**  
   linkage of cell-surface protein, **58:423**  
 NK cells and, **47:209, 235, 253, 254**  
 nuclear, fragmentation, and PCD,  
**58:212–213**  
*PIG-A*, analysis, **60:84**  
 promoters and enhancers, **43:239**  
 –protein intermediates, **58:38–39**  
 and rabbit antibody repertoire  
   B cell rearrangements, **56:190–192**  
   probes to molecules, **56:182–183**  
 repair, plasmacytoma development,  
**64:240–241**  
 repair defects, **61:310–311**  
 repair syndromes, **58:62–69**  
 repair synthesis, across double-strand gap,  
**58:44**  
 replication, role in immune response,  
**54:237–238**  
 RNA-duplex switch region complex,  
**61:114–116**  
 SCID patients, **61:310–311**  
 spontaneous autoimmune thyroiditis and,  
**47:435, 493**  
   altered thyroid function, **47:458, 464**  
   disturbed immunoregulation, **47:470**  
   genetics, **47:483, 484**  
 sporozoite malaria vaccine and  
   antibodies, **45:301**  
   CS proteins, **45:297**  
   immunity, **45:291**  
   interferon- $\gamma$ , **45:302**  
   *Plasmodium vivax*, **45:317**  
 strand polarity, **60:279**  
 surface antigens of human leukocytes and,  
**49:116**

- DNA (*continued*)  
 synthetic T and B cell sites and, **45:231**  
 T cell activation and, **41:29**  
 T cell receptor and, **45:109, 165**  
 T cell subsets and, **41:41, 44, 46–48, 78**  
 transcription inhibition, **58:240**  
 transfection, **38:280, 305, 306**  
   expression of IgR on cell surface,  
     **54:360–361**  
   as substrate introduction method in  
     V(D)J joining, **56:50–53**  
 virus-induced immunosuppression and  
   HIV, **45:354, 355**  
   measles, **45:344, 348**
- DNA binding  
 effect of Stats, **60:28**  
 Stat homology blocks in, **60:18–19**
- DNA damage  
 and p53 accumulation, **58:258**  
 in programmed cell death, **50:57–60**  
 fragmentation, **50:57–58**  
 methods, **50:59–60**  
 observations in rodent thymocyte,  
   **50:58–59**  
 pattern of fragments, **50:58**
- DNA-dependent protein kinase, **61:300–301**;  
**63:154**  
 association with Ku, **58:60–62**  
 DNA-PK<sub>CS</sub>, **64:49–50, 60**
- DNA duplication, **38:211, 212**
- DNA flap, **61:304**
- DNA ligase, deficiency in Bloom syndrome,  
**58:65–66**
- DNA-PK, *see* DNA-dependent protein kinase
- DNA polymerase  
 antinuclear antibodies and, **44:94, 108, 135**  
 genetically engineered antibody molecules  
 and, **44:85**
- DNA rearrangement, T cell receptor and,  
**38:5, 9**
- DNA RFLP typing strategy, **48:117–118**
- DNase I  
 sensitivity as indicator of gene  
 recombination, **56:43–44**  
 T cell-specific hypersensitive site, **43:268**
- DNA sequence  
 complement components, **38:212**  
 human B cell neoplasia, **38:266**  
 maternally transmitted antigen and, **38:330**  
 T cell receptor and, **38:7, 15**
- DNA topoisomerase 1, antinuclear antibodies  
 and, **44:94, 121, 131, 133, 134, 137**
- Dob, Fc, **48:21**
- Dob antibody structure, **43:8**
- Docosahexaenoic acid  
 arachidonic acid metabolism and,  
   **39:159–160, 164**  
 in human neutrophils, **39:165–166**  
 formation from N-3 and N-6 fatty acids,  
   **39:159–160**  
 metabolism, 5-lipoxygenase and,  
   **39:160–161**
- Dog leukocyte antigen, hybrid resistance and,  
**41:349, 350**
- Domain, defined, **63:201**
- Domain-domain interactions, **43:110**
- Domain organization, CD1 proteins,  
**59:35–36**
- Domain structure  
 genetically engineered antibody, **48:14**,  
   16, 22  
 segmental flexibility, **48:14, 16, 22**
- Dominant resistance, IDDM, **48:143–144**
- Double-homologous recombination, **48:56**
- Down-regulation  
 in clonotype repertoire expression, *see*  
   Environment, B cell repertoire  
   expression and  
 signal transduction through B cell Ig  
 receptor, **54:374**
- Down syndrome, leukocyte integrins and,  
**46:160**
- DP, **48:109, 110–111**
- DP allele, celiac disease, **48:145**
- DP  $\alpha$  allele, celiac disease, **48:145**
- DP  $\beta$  allele, celiac disease, **48:145**
- DP  $\alpha$ -DQ  $\beta$ , multiple sclerosis, **48:149**
- DP  $\alpha$ -DQw1  $\beta$ , celiac disease, **48:146–147**
- DPML*, **60:73–74**
- DP  $\alpha$  polymorphism, celiac disease, **48:145**
- DP  $\beta$  polymorphism, celiac disease, **48:145**
- D $\mu$  protein, **63:7, 22–23**
- D-proximal V<sub>H</sub> genes, **49:5**  
 V<sub>H</sub> families, **49:18, 20–21**  
 V<sub>H</sub> gene expression, **49:36–39**
- DPw4, multiple sclerosis, **48:149–150**
- DQ, **48:109, 110–111**  
 allele, linkage disequilibrium, **48:121–122**  
 heterodimer, DQ2-DQ3 cell, **48:120–121**

- linkage disequilibrium phenomenon,  
48:136–137
- DQ  $\alpha$
- cis*-complementation, 48:139–140
  - functional dimer, 48:123
  - gene polymorphism, multiple sclerosis,  
48:149
  - polymorphism, 48:121
  - structural requirement, 48:138–139
  - trans*-complementation, 48:139–140
- DQ  $\beta$
- amino acid 57, location, 48:139
  - cis*-complementation, 48:139–140
  - functional dimer, 48:123
  - IDDM, 48:134–136
    - position 57 aspartic acid, 48:135–136,  
137
  - polymorphism, 48:121
  - structural requirement, 48:138–139
  - trans*-complementation, 48:139–140
- DQ  $\alpha$ -DQ  $\beta$ , multiple sclerosis, 48:149
- DQ6, 65:286
- DQR2-6, multiple sclerosis, 48:148–149
- DQw1, multiple sclerosis, 48:148
- DQw1a, multiple sclerosis, 48:148
- DQw1b, multiple sclerosis, 48:148
- DQw2
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw2  $\alpha$  chain, celiac disease, 48:146
- DQw3
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw3.1
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw3.2
- B8, 48:134
  - B15, 48:134
  - $\beta$  chain, 48:136
  - DR3, 48:134
  - DR4, 48:134
- DQw3.3
- B8, 48:134
- B15, 48:134
- DR3, 48:134
- DR4, 48:134
- DR3, 48:134
- DR4, 48:134
- DQw7
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw8
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw9
- B8, 48:134
  - B15, 48:134
  - DR3, 48:134
  - DR4, 48:134
- DQw9 Asp<sup>57</sup> positive
- black patient, 48:140
  - caucasian patient, 48:140
- DR, 48:109, 110–111
- linkage disequilibrium phenomenon,  
48:136–137
- DR1, 48:127
- DR2, 48:112; 65:286
- IDDM, 48:136, 143
  - AZH, 48:136
  - multiple sclerosis, 48:148–150
- DR3
- celiac disease, 48:144, 147
- DQw2, 48:134
- DQw3, 48:134
- DQw3.1, 48:134
- DQw3.2, 48:134
- DQw3.3, 48:134
- DQw7, 48:134
- DQw8, 48:134
- DQw9, 48:134
- DR4, 48:112
- DQw2, 48:134
  - DQw3, 48:134
  - DQw3.1, 48:134
  - DQw3.2, 48:134
  - DQw3.3, 48:134
  - DQw7, 48:134
  - DQw8, 48:134
  - DQw9, 48:134
  - HLA-DQ, 48:134
  - juvenile rheumatoid arthritis, 48:131

- DR4 Dw haplotype, **48:118**  
 DR4 haplotype, **48:127**  
 DR5  
   celiac disease, **48:144, 147**  
   juvenile rheumatoid arthritis, **48:131**  
 DR7, celiac disease, **48:144, 147**  
 DR7 haplotype  
   black patient, **48:140**  
   caucasian patient, **48:140**  
 DR9-DQ  $\beta$   
   black patient, **48:140**  
   caucasian patient, **48:140**  
 DR9 haplotype  
   black patient, **48:140**  
   caucasian patient, **48:140**  
 DR allele, linkage disequilibrium, **48:121–122**  
 DR antigens, IBD and, **42:288, 292–294**  
 DRB1, RA susceptibility associated with,  
   **56:410–416**  
 DR  $\alpha$ -DQ  $\beta$ , multiple sclerosis, **48:149**  
 DR  $\alpha$ -DQw2  $\beta$ , **48:125**  
 DR  $\alpha$ -DQw3  $\beta$ , **48:125**  
 DR  $\alpha$ -DQw1  $\beta$ , **48:125**  
   celiac disease, **48:146–147**  
 DR  $\alpha$  gene, **48:124**  
   expression modulation, **48:125**  
 DR  $\beta$  gene, rheumatoid arthritis, **48:131**  
*Drosophila*  
   antinuclear antibodies and, **44:129**  
   dorsal gene, **52:271**  
   identification of Jak homolog, **60:3–4**  
   leukocyte integrins and, **46:153**  
   maternally transmitted antigen and, **38:322**  
 DR  $\alpha$  protein, **48:124**  
 Drug development, HIV-1 infection,  
   **63:95–99, 107**  
 Drug-induced autoimmunity, antinuclear  
   antibodies and, **44:109–111**  
   autoantibodies, **44:136**  
   autoimmune response, **44:131**  
   scleroderma, **44:124**  
   Sjögren's syndrome, **44:112**  
 Drug-induced syndromes, aPL antibodies  
   and, **49:193, 209, 212–213, 250**  
 Drug-monoclonal antibody conjugates, as  
   cancer treatment, *see*  
   Chemoimmunoconjugates  
 Drugs  
   cytotoxic, and apoptosis, **58:237–240**  
   therapeutic, and leukocyte homing,  
     **58:395–396**  
 DRw8  
   celiac disease, **48:147**  
   juvenile rheumatoid arthritis, **48:131**  
 DRw9, IDDM, **48:137**  
 DRw15, IDDM, **48:143**  
 DRw16, IDDM, **48:143**  
 DRw52, **48:112**  
 DRw53, **48:112**  
 DRw53 molecule, rheumatoid arthritis,  
   **48:128**  
 DSB repair, *see* DNA, double-strand break  
   repair  
 D segments, Ig heavy-chain variable region  
   genes and, **49:18, 28–34, 36, 53**  
   organization, **49:3–6**  
 DuP697, **62:186**  
 Dw10, **48:127**  
   rheumatoid arthritis, **48:126–127**  
 Dw4  
   position 67, **48:128–129**  
   position 70, **48:128–129**  
   position 71, **48:128–129**  
   rheumatoid arthritis, **48:126–127**  
 DW14, rheumatoid arthritis, **48:126–127**  
 DX  $\alpha$  polymorphism, **48:139**  
 Dyscrasias, *see* Plasma cell dyscrasias

## E

- E $\alpha$ , **62:69**  
 E $\beta$ , **62:43, 51–52**  
 E $\gamma$ , **62:69**  
 E1A, **65:11**  
 E1B 19K, NF- $\kappa$ B activation and, **65:128**  
 E2A gene, B cell genesis, **63:218–219,**  
   **232–235**  
 E3/19K glycoprotein, adenovirus, effects on  
   antigen processing and presentation,  
   **52:44–47**  
 $\alpha$ E $\beta$ 7, lymphocyte homing and, **64:156**  
 $\alpha$ E $\beta$ 7 Integrin, **65:359**  
 E47/E12, binding site, switch recombination,  
   **61:117, 118–119**  
 EA-1, **48:248–249**  
 EAF, *see* Eosinophil-activating factor  
 EAMG, *see* Experimental autoimmune  
   myasthenia gravis

- Early activation antigen-1, **48:248–249**  
 Early response cytokines, **62:267, 276, 280**  
 EBF, **63:250**  
 EBP, **43:307–308**  
 EBPγ, **65:18**  
 EBV, *see* Epstein–Barr virus  
 EC, *see* Endothelial cells  
 ECF-A, *see* Eosinophil chemotactic factor of anaphylaxis  
 E chain, **43:278**  
   biosynthetically engineered peptides based cDNA constructs, **43:281**  
   digestion, **43:282**  
   peptide immunogens, **43:279–280**  
   sites protected by receptor interaction, **43:280**  
   stabilization, **43:282**  
 Echoviral infections, X-linked agammaglobulinemia, **59:145**  
 ECP, *see* Eosinophil cationic protein  
 ECP1, **61:10**  
 Ecto-5'-nucleotidase, **48:241**  
 Edema, paw, NO role, **60:328–329**  
 Edema, tissue, in IBD, **42:310**  
 EDN, *see* Eosinophil-derived neurotoxin  
 Effector cells  
   activated in immune response, **58:298**  
   adoptive T cell therapy of tumors and, **49:284, 333–334**  
   antigen recognition, **49:318–319, 324**  
   expression of antitumor responses, **49:324–325, 327, 329, 332**  
   mechanisms, **49:299, 301–302, 306, 308–313, 315**  
   NK cells, **49:316–318**  
   principles, **49:286, 288–290, 294–295, 297**  
   cell-mediated killing and, **41:296**  
   cytolysis and, **41:274, 275**  
     granule exocytosis, **41:281**  
     hydrolytic enzymes, **41:276**  
     intracellular damage, **41:283, 284**  
     membrane damage, **41:277**  
   cytolytic, generation by CD4<sup>+</sup>8<sup>+</sup> αβ T cells, **58:108**  
   cytotoxicity and, **41:269, 270, 272**  
   cytotoxic T cells and, **41:148, 150, 170**  
   hybrid resistance and, **41:334, 370**  
     antibodies, **41:376, 378, 379**  
     antigen expression, **41:402, 403**  
     bone marrow cells, **41:346**  
     leukemia/lymphoma cells, **41:359, 366, 368**  
     lymphoid cells, **41:353**  
     macrophages, **41:371**  
     marrow microenvironment, **41:390**  
     NK cells, **41:372, 373**  
     syngeneic stem cells, **41:390**  
     T cells, **41:382–384**  
     *in vitro* assays, **41:393–396**  
   lymphocyte homing and, **44:332**  
   NK cells and, **47:196, 302**  
     antimicrobial activity, **47:286, 287**  
     hematopoiesis, **47:273, 274, 277, 280**  
     trafficking to vascularized tumors, **58:432**  
     variance with introduced gene, **58:427**  
 Effector cell–target cell interaction, mediated by leukocyte Fc receptors, **51:51–54**  
 Effector mechanisms  
   hybrid resistance, **41:369, 370**  
   antibodies, **41:376–380**  
   macrophages, **41:370–372**  
   marrow engraftment, **41:384–388**  
   marrow microenvironment, **41:390–393**  
   NK cells, **41:372–376**  
   syngeneic stem cell functions, **41:388–390**  
   T cells, **41:380–384**  
   *in vitro* assays, **41:393–396**  
 in IBD, **42:321**  
 NK cells and, **47:234, 235**  
   cytotoxicity, **47:248–254**  
   lymphokines, **47:262–266**  
   receptors, **47:242–248**  
   regulation, **47:254–262**  
   target cells, **47:235–242**  
 spontaneous autoimmune thyroiditis and, **47:446, 449, 465–469**  
 Effector molecules  
   ATP, in CTL cytotoxicity, **60:301–302**  
   downregulation during inflammation, **60:338–339**  
   macrophage, in cell-mediated immune response, **60:333–341**  
   NO, during inflammation, **60:332–346**  
   perforin, in cytotoxicity, **60:290–292**  
 Effector phase  
   B cell activation, **63:44**  
   T cell subsets and, **41:75–77, 92–95**

- Effector T cells  
 cytotoxic T cell, **48:197**  
 delayed-type hypersensitivity,  
**48:197**  
 functional and phenotypic properties,  
**53:225–227**  
 functional differences with memory and  
 naive cells, **53:227–228**  
 maturation into, **53:229–230**  
 migration  
 basic pattern, **53:242–244**  
 tissue topic subsets, **53:244–247**  
 primary and secondary, **53:227–228**  
 EGF, *see* Epidermal growth factor  
 Eicosanoids, and asthma pathophysiology,  
**51:340–353**  
 leukotrienes, **51:341–347**  
 biological activities, **51:343**  
 leukotriene antagonists and inhibitors,  
**51:346–347**  
 leukotrienes and airway  
 hyperresponsiveness, **51:344–346**  
 potency, **51:343**  
 release of leukotrienes in asthma,  
**51:346**  
 synthesis and metabolism, **51:341–**  
**343**  
 platelet-activating factor, **51:352**  
 prostaglandins and thromboxane,  
**51:347–352**  
 biological activities, **51:347**  
 measurements of prostanoids in  
 biological fluids, **51:349**  
 pharmacological modulation of  
 airway hyperresponsiveness,  
**51:351–352**  
 airway tone and acute asthmatic  
 response, **51:350–351**  
 prostanoid action, **51:350–352**  
 potency, **51:347–349**  
 prostanoids and airway  
 hyperresponsiveness, **51:349**  
 synthesis and metabolism, **51:347**  
 Eicosanoids, as eosinophil-derived lipid  
 mediators, **60:188–190**  
 Eicosapentaenoic acid  
 cyclooxygenase pathway inhibition, **39:160,**  
**164–165**  
 dietary, animal studies leukotriene  
 production and, **39:162–163**  
 dietary, human studies  
 arachidonic acid in neutrophils and,  
**39:166**  
 in asthma patients, **39:166–167**  
 T cell subpopulations and, **39:167**  
 dietary N-3 fatty acids and, **39:160**  
 esterified and nonesterified, arachidonic  
 acid in human neutrophils and,  
**39:167–168**  
 formation from N-3 and N-6 fatty acids,  
**39:159–160**  
 metabolism  
 5-lipoxygenase pathway, **39:160–161**  
 leukotriene production, **39:160–162**  
 SLE and, **39:164**  
 ELAM-1, **59:414**  
 Elastase, IL-1 and, **44:163**  
 Elastin, **62:266**  
 Electron microscopy  
 antigen-presenting cells and  
 antigen processing, **47:91**  
 interaction with T cells, **47:94**  
 tissue distribution, **47:51, 52, 57**  
 antinuclear antibodies and, **44:124**  
 autoimmune thyroiditis and, **46:267, 274,**  
**291**  
 B cell formation and, **41:212**  
 cell-mediated killing and, **41:292, 294, 295**  
 complement receptor 1 and, **46:184**  
 cytolysis and, **41:282**  
 humoral immune response and, **45:37**  
 IL-1 and, **44:184**  
 leukocyte integrins and, **46:167**  
 lymphocyte homing and, **44:319**  
 membrane attack complex of complement  
 and, **41:300, 306**  
 NK cells and, **47:218**  
 regulators of complement activation and,  
**45:392, 393**  
 spontaneous autoimmune thyroiditis and  
**440, 47:462**  
 T cell subsets and, **41:106**  
 Electron-spin resonance, membrane attack  
 complex of complement and, **41:303**  
 Electrophoresis  
 complement receptor 1 and, **46:189, 190,**  
**192**  
 Ig heavy-chain variable region genes and,  
**49:4–5, 11**  
 immunosenescence and, **46:230**

- leukocyte integrins and, **46:154**, 157  
 maps of Ig-like loci and, **46:5**  
   MHC, **46:28**, 30, 33  
   structure, **46:15**, 18, 27  
   T cell receptor, **46:36**, 37, 44
- Electrophoretic mobility shift assays, **54:255**
- Electrostatic complementarity, **43:12–13**
- Electrostatic forces, binding role, **43:13**
- Electrostatic potential, MHR, **43:35**
- Electrostatic recognition, between antigen and antibody, **43:12–13**
- Elf-1  
   binding sites, **64:76–77**  
   domain, **64:76–77**  
   expression, **64:91**  
   gene targeting, **64:92**  
   structure, **64:78**  
   structure–function studies, **64:91–92**
- ELISA, aPL antibodies and, **49:205**,  
 235–236, 242–244, 247
- Embryo  
   anti-TCR1, -TCR2, -TCR3 antibody treatment, **50:103–105**  
   thymectomy, **50:102**
- B cell formation, **41:181**, 193, 199, 201,  
 224, 227
- chicken, B cell, early commitment in,  
**57:367–369**, 374
- development, role of IL-6, **54:31–32**
- Embryogenesis  
   bursal stem cell, **48:52**  
   maternally transmitted antigen and, **38:321**,  
   330, 333  
   V-J joint, **48:49**, 50
- Embryonic stem cells  
   B cells from, **53:124–130**  
   LIF effects, mouse, **53:33–34**  
   mutant, **62:32**, 36–37, 40
- Emphysema, **62:188**, 266
- Encephalitis, experimental allergic, *see*  
 Experimental allergic encephalitis
- Encephalomyelitis, experimental autoimmune,  
*see* Experimental autoimmune  
 encephalomyelitis
- End-joining  
   and nonhomologous recombination,  
   **58:43–45**  
   and *scid* mutation, **58:50**  
   in *xrs* group mutants, **58:54**
- Endocrine cells, IFN- $\gamma$  and, **62:93–94**
- Endocytosis  
   antigen-presenting cells and  
   antigen presentation, **47:64**, 67, 68, 71, 81  
   antigen processing, **47:87–91**  
   immunogeneity, **47:102**  
   tissue distribution, **47:51**
- CD4 molecules and, **44:296**
- cell-mediated killing and, **41:298**
- complement receptor 1 and, **46:193**,  
 198–200
- complement receptor 2 and, **46:210**
- HIV infection and, **47:379**
- Ig gene superfamily and, **44:31**
- IL-1 and, **44:181**
- and processing of membrane IgR/antigen  
 complex, **54:348**
- surface antigens of human leukocytes and,  
**49:89**, 98, 115, 125
- Endogenous pyrogen, cachectin as, **42:224**
- Endogenous retroviral insertions, inseparable  
 from Vbse, **50:38–39**
- Endoglin, *see* Transforming growth factor  $\beta$   
 receptor
- Endoglycosidase F, autoimmune thyroiditis  
 and, **46:270**, 271
- Endoglycosidase H  
   autoimmune thyroiditis and, **46:271**  
   leukocyte integrins and, **46:154**, 174
- Endonuclease  
   in apoptotic cell degradation, **58:269–270**  
   blockade, in apoptosis inhibition, **58:251**
- Endoplasmic reticulum, **64:105**
- adoptive T cell therapy of tumors and,  
**49:283**, 320, 323
- antinuclear antibodies and, **44:120**, 128
- binding of PIC-1, **60:67**
- cytoplasmic face, **60:65**
- GPI anchoring in, **60:60**
- MHC class I molecules  
   peptide anchoring, **64:124–127**  
   peptide binding, **64:114–115**, 118,  
   127–128  
   peptide loading, **64:105–128**
- regulators of complement activation and,  
**45:400**
- T cell receptor and, **45:123**, 125
- $\alpha$ -Endorphin, immunosuppressive,  
**39:309–310**
- $\beta$ -Endorphin, **48:170–172**  
   effects on lymphocytes  
   chemotaxis and, **39:307–308**



- $\beta$ -Endorphin** (*continued*)  
 immune responses and, **39:310**  
 natural killing activity and, **39:310**  
 production by leukocytes, **39:315–316**
- $\beta$ -Endorphin receptors**  
 in CNS, **39:312**  
 on lymphocytes, **39:312**
- Endosteum, B cell genesis, **63:214**
- Endothelial cell costimulators  
 in alloantigen responses, **50:271–272**  
 in polyclonal CD4+ T cell activation, **50:268–270**  
 in polyclonal CD8+ T cell activation, **50:270–271**  
 soluble, production, **50:272–274**
- Endothelial cells, **54:29–30**, *see also* Human umbilical vein endothelial cells; Vascular endothelial cells  
 adhesion molecules, regulation, **64:139–140, 146, 147, 163–173**  
 adhesion to leukocytes, **58:376–378, 381–389**  
 antigen-independent recruitment of T cells into tissues by, **50:274–287**  
 extravasation of T cells, **50:285–287**  
 migration of memory T cells to inflammatory sites, **50:278–288**  
 endothelial leukocyte adhesion molecules, **50:279–281**  
 migration of naive T cells to lymph nodes, **50:275–278**  
 migration of pre-T cells to thymus, **50:275**  
 tissue-specific homing of lymphocytes, **50:284–285**
- B cell formation and, **41:186, 235, 236, 222–225**
- cachectin and, **42:223–224**
- CD40 expression, **61:14, 41**
- cultured, alloantigen presentation by, **50:266–267**
- high endothelial, lymphocyte homing and, **44:315, 316, 318, 320**
- hybrid resistance and, **41:400**
- IFN- $\gamma$ , **62:81**
- IL-1 and, **44:153, 190**  
 biological effects, **44:166–168**  
 gene expression, **44:159, 160**  
 human disease, **44:194, 195**  
 immunocompetent cells, **44:177**  
 receptor, **44:181**  
 structure, **44:158**  
 systemic effects, **44:169, 171**  
 TNF, **44:185, 186**
- leukocyte integrins and  
 inflammation, **46:162, 164, 165, 168**  
 ligand molecules, **46:170–172**
- lymphocyte homing and, *see* High endothelial cells; High endothelial venules
- lymphocyte interaction with, **64:140–143**
- migration of memory T cells to inflammatory sites, endothelial leukocyte adhesion molecules expression *in vivo*, **50:283–284**  
 role in lymphocyte binding *in vitro*, **50:281–283**  
 production of soluble costimulators, **50:272–274**  
 as source of chemokines, **55:107**  
 T cell subsets and, **41:46, 90**
- Endothelial-derived relaxant factor, **54:29–30**  
 effects via NO, **60:326**
- Endothelialitis, **59:420**
- Endothelial leukocyte adhesion molecules, **50:279–281**  
 expression *in vivo*, **50:283–284**  
 role in lymphocyte binding *in vitro*, **50:281–283**  
*in vitro* binding in lymphocyte, **50:281–283**  
*in vivo* expression, **50:283–284**  
*in vivo* expression of, **50:283–284**
- Endothelial venules, L-selectin association with lymphocyte adhesion, **62:257**
- Endothelium  
 aPL antibodies and, **49:193, 250, 252–254**  
 autoimmune thyroiditis and, **46:275**  
 integrity alterations, NO role, **60:327–330**  
 leukocyte transmigration, **58:388–389**  
 surface antigens of human leukocytes and, **49:86–88**  
 tumor vasculature, **64:180**  
 vascular, injury caused by TNF, **56:351**
- Endotoxemia, *see also* Sepsis  
 human experimental  
 IL-1, **66:116–117**  
 IL-8, **66:137–138**

- model, **66**:102
  - TNF, **66**:114–116
- IL-1, **66**:116–117
- sepsis and, **66**:130–131
- TNF and, **66**:114–116
- Endotoxic shock, contact activation proteins, **66**:260
- Endotoxin
  - B cell formation and, **41**:224, 230
  - cachectin and, **42**:214–216
  - and IL-1, **54**:31
  - IL-1 and
    - biological effects, **44**:166, 167
    - gene expression, **44**:159–161, 163, 164
    - human disease, **44**:192, 194, 195
    - TNF, **44**:185–188
  - lymphotoxin and, **42**:216
- Endplates, in MC patient, **42**:261–262
- Enhancers, Ig heavy-chain variable region genes and, **49**:52–62
  - sequences, **49**:39
- Enkephalin, helper T cell cytokines and, **46**:116
- Enkephalin heptapeptide, in pulmonary airways, **39**:304
- Enterotoxin, *see* Staphylococcal enterotoxin A; Staphylococcal enterotoxin B
- Enteroviral infections, X-linked
  - agammaglobulinemia, **59**:145–146, 150
- env*, adoptive T cell therapy of tumors and, **49**:320–321
- Environment, B cell repertoire expression and, **42**:35
  - assessment of, **42**:35–36
  - diversification and, **42**:36–39
  - down-regulation in clonotype repertoire expression and, **42**:42–43
  - antidiotypic recognition, **42**:51–62
  - self antigens, **42**:43–51
  - predominant clonotype expression and, **42**:39–42
  - up-regulation, **42**:22–23
- Environmental agents, aPL antibodies and, **49**:221–222
- Enzymes
  - antinuclear antibodies and, **44**:122, 127, 133
  - aPL antibodies and, **49**:203, 239
  - CD23 antigen and, **49**:156–157, 172–173
  - genetically engineered antibody molecules and, **44**:70, 75, 85
  - granule-stored, **60**:201
  - Ig gene superfamily and, **44**:12, 17, 47
  - Ig heavy-chain variable region genes and, **49**:17
  - IL-1 and, **44**:160, 170
  - lymphocyte homing and, **44**:317, 320, 360, 365, 369
  - metal-requiring, **60**:340
  - mitochondrial, action of, **65**:122
  - myeloid-specific, **60**:25–26
  - SCID and, **49**:382–383, 398
  - surface antigens of human leukocytes and, **49**:100, 111–114
- Eosinopenia, ascribed to treatment with glucocorticoids, **60**:227
- Eosinophil-activating factor, from monocytes, **39**:215–216
- Eosinophil cationic protein, **41**:311, 312
  - amino acid sequence, **39**:192–195
  - homology to pancreatic RNase, **39**:195
- BAL, **60**:220–222
- bronchial asthma and, **39**:224
- coagulation and, **39**:196
- fibrinolysis and, **39**:196
- in granule matrix, **39**:195
- induced damage to schistosomula, **60**:212–213
- lymphocyte proliferation inhibition, **39**:196–197
- neurotoxicity, **39**:196
- parasite killing, **39**:196, 213
- purification, **39**:191–194
- release from eosinophils, **60**:204–205
- sharing chromosome 14q with eosinophil-derived neurotoxin, **60**:193
- Eosinophil chemotactic factor of anaphylaxis
  - eosinophil activation, **39**:214–215
  - production by mast cells, **39**:214
- Eosinophil-derived neurotoxin, **41**:311
  - antihelminthic activity, **60**:212
  - Gordon phenomenon induction, **39**:198–199
  - in granule matrix, **39**:198
  - purification and properties, **39**:197–198
  - ribonuclease activity, **60**:194
  - sharing chromosome 14q with ECP, **60**:193
- Eosinophil differentiation factor, **48**:78

- Eosinophilia**  
 experimental, IL-5 role, **57:173**  
 helper T cell cytokines and, **46:133, 137**  
 IL-5 role  
   asthmatic patients, **57:174–176**  
   experimental, **57:173**  
   guinea pig, **57:173–174**  
   mRNA expression in patients, **57:158–159**  
   parasite infection association, **57:172**  
   tumors associated with, **57:177–178**  
 pulmonary, including Churg–Strauss syndrome, **60:226**  
*Eosinophilia myalgia syndrome*, from ingestion of L-tryptophan, **60:224–225**
- Eosinophil mediators**  
 cytokines, **60:195–201**  
 granule proteins, **60:191–194**  
 lipid, **60:188–191**  
 release, and cytotoxicity, **60:205–208**
- Eosinophil myelocytes, morphology**, **60:155–158**
- Eosinophil peroxidase**  
 antihelminthic activity, **60:212**  
 binding to  
   effector cells, **39:202**  
   mast cell granules, **39:201–202**  
 concentration in BAL, **60:171**  
 deficiency, **60:227**  
   in cat family, **39:200**  
   in granule matrix, **39:200**  
   in humans, Yemenite Jews, **39:200–201**  
 IgE effects, **60:207**  
 leukotriene inactivation, **39:202–203**  
 oxidation of halides, **60:194**  
 parasite killing and, **39:201**  
 purification and properties, **39:199–200**  
 tumor cell killing and, **39:202**
- Eosinophils**, **51:331–336**  
 activation, **60:201–210**  
   morphology, **60:158–160, 202–203**  
 activation by  
    $\alpha$ -CSF, **39:215**  
   EAF from monocytes, **39:215–216**  
   ECF-A from mast cells, **39:214–215**  
   ESP from lymph node cells, **39:214**  
   LTB<sub>4</sub>, **39:215**  
   M-ECEF from monocytes, **39:216**  
   T cell-produced factor, **39:217**  
   TNF, **39:216**  
   worm-produced factors, **39:217**  
 adhesion and migration, **60:164–178**  
 and adhesion mechanisms, **51:333–336**  
 as antigen-presenting cells, **60:200**  
 asthma, **62:283, 285**  
 autofluorescence, **39:205**  
 biology, overview, **60:151–155**  
 cachectin and, **42:224**  
 in cardiac disease, **39:226–227**  
 CD23 antigen and, **49:154, 161, 167**  
 chemokine action on, **55:117**  
 complement receptor 1 and, **46:190, 191**  
 in cutaneous diseases, **39:225–226**  
 and cytokines, **60:203–205**  
 cytotoxicity and, **41:269, 270, 291, 312**  
 degranulation  
   arachidonic acid metabolism and, **39:207**  
   in diseased tissues, **39:208, 223–226**  
   induction, methods of, **39:206–207**  
 differentiation and maturation, **60:162–164**  
 discovery, **39:177**  
 and disease, **60:216–227**  
 eicosanoid production, **39:204, 218**  
 enzymes  
   arylsulfatase, **39:218**  
   collagenase, **39:203**  
   EPO, **39:199–203**  
   variety of, **39:203–204**  
 granule proteins  
   ECP, **39:191–197**  
   EDN, **39:197–199**  
   major basic protein, **39:185–189**  
 high-density  
   activation, **39:205–206**  
   eosinophilia and, **39:205**  
   partial degranulation, **39:206**  
 in human reproduction  
   cyclic eosinopenia, ovulation and, **39:228**  
   major basic protein production by placenta, **39:228**  
 IgE, **43:306–307**  
 IL-1 and, **44:164, 188**  
 IL-5-mediated production, **57:156**  
 in immediate hypersensitivity, **39:217–219**  
   histamine release and, **39:217–218**  
   leukotrienes and, **39:218**  
   major basic protein and, **39:219**  
 mature  
   granule populations, **60:153–154**  
   morphology, **60:155–158**

- membrane proteins  
 antigens, **39**:183–184  
 CLC, **39**:181–183  
 lysophospholipase activity, **39**:182–183  
 complement receptors, **39**:179–180  
 Ig receptors, **39**:179–181  
 receptor for sheep erythrocytes, **39**:181  
 PAF production, **39**:205  
 parasite killing  
 AES effects, animals, **39**:209  
 cationic protein release and, **39**:213–214  
 by moving into tissues and degranulation,  
**39**:212–213  
*in vitro*, mediated by  
 C3, **39**:210  
 IgE, **39**:210–211  
 IgG, **39**:209–211  
 IgG2a, **39**:210–212  
 and parasites, **60**:210–216  
 phagocytosis, **39**:208  
 proliferation, CM-CSF, **48**:75  
 recruitment, **58**:431  
 in rodent uterus  
 estrogen-induced eosinophilia and  
 edema, **39**:227–228  
 infiltration during estrus cycle, **39**:227  
 role in asthma, fiberoptic bronchoscopy  
 studies, **60**:218–223  
 signal transduction, **60**:208–210  
 sulfated complex carbohydrates, **39**:204  
 toxicity to various cells, **39**:219  
 ultrastructure, **39**:177–179  
 Eosinophil stimulation promoter  
 eosinophil activation, **39**:214  
 production by lymph node cells, **39**:214  
 EPA, *see* Eicosapentaenoic acid  
 Epidermal cells  
 dendritic  
 expressing Ly-5, **58**:299  
 reactivity, **58**:320  
 Thy-1<sup>+</sup>, **58**:301–303  
 V $\gamma$ 5V $\delta$ 1, colonization of skin, **58**:317  
 Ig gene superfamily and, **44**:31  
 Epidermal growth factor  
 autoimmune thyroiditis and, **46**:272, 294, 295  
 complement receptor 1 and, **46**:187  
 connection with NO production,  
**60**:350–351  
 IL-1 and, **44**:168, 169, 184  
 leukocyte integrins and, **46**:159  
 Epidermal growth factor domain, PGHS,  
**62**:169, 171  
 Epidermal growth factor receptor  
 activation of Stats and Jaks, **60**:27  
 in chimeric receptors, **60**:10  
 Episialin, **62**:223  
 Episomal vectors, **61**:124–128  
 Epistasis, cytotoxic allogeneic T cells and  
 allogeneic cross-reactive lysis, **38**:185–187  
 H-Y antigen, **38**:175–180  
 immunodominance, **38**:180–185  
 Epithelial antigens, **62**:238–239  
 Epithelial barriers, IFN- $\gamma$ , **62**:90  
 Epithelial cells  
 and basement membrane, **51**:324–327  
 CD1 protein distribution, **59**:56, 68, 72  
 CD40 expression, **61**:14, 41  
 corneal  
 accessory antigen-processing cell, **48**:202  
 derived T cell-activating factor,  
**48**:201–202  
 hybrid resistance and, **41**:335  
 IBD and, **42**:292–294, 319–320, 321  
 interaction with IgA, **40**:174–177  
 positive selection, **59**:120–121  
 respiratory tract, **59**:372–373, 382  
 as source of chemokines, **55**:107  
 T cell activation and, **41**:1, 10  
 T cell subsets and  
 cell surface molecules, **41**:46  
 restricted T cells, **41**:103–106  
 T cell development, **41**:96–98  
 T cell specificity, **41**:113  
 tolerance induction, **41**:107–110  
 thymic, induction of positive selection,  
**58**:164–165  
 and thymocyte deletion, **58**:170  
 thyroid, *see* Thyroid epithelial cells  
 Epithelial tumors, antigens, **62**:220–221,  
 223–224  
 Epithelium  
 antigen-presenting cells and, **47**:54  
 autoimmune thyroiditis and, **46**:266, 287,  
 296, 297  
 CD23 antigen and, **49**:150, 155, 161,  
 170–171  
 complement receptor 2 and, **46**:204, 210,  
 213  
 corneal, Langerhans cell, **48**:197

Epithelium (*continued*)

- development in MHC class I-deficient mouse
  - intestinal, **55:395–396**
  - thymic, **55:396–398**
- intestinal, derived T cell lineages, **58:110–112**
- leukocyte integrins and, **46:164, 172**
- SCID and, **49:384, 393, 402**
- Epitopes, **42:71–72; 43:106**, *see also* Sequential epitope
  - in AChR
    - B cells, **42:258**
    - T cells, **42:257**
  - adoptive T cell therapy of tumors and, **49:334**
    - antigen recognition, **49:321–324**
    - expression of antitumor responses, **49:329–330**
    - mechanisms, **49:312–313, 315**
  - agglutination, **48:23**
  - amino acids, **43:65–67**
  - antigen-presenting cells and, **47:60, 62, 63**
  - antinuclear antibodies and, **44:118, 119, 127**
    - autoantigen, **44:128–130**
    - autoimmune response, **44:132, 134–136**
    - SLE, **44:97, 100, 101, 108**
  - aPL antibodies and, **49:193, 234–235, 239–240, 259**
    - affinity purification, **49:228**
    - antibody subsets, **49:232–233**
    - binding to cell membranes, **49:252**
    - clinical aspects, **49:213**
    - LA antibodies, **49:241, 246–248**
    - pathogenic potential, **49:256–257**
    - specificity, **49:234–235, 239–240, 248, 250**
  - autoimmune demyelinating disease and multiple sclerosis, **49:369–370, 372, 374**
    - myelin basic protein, **49:357–363**
    - TCR usage restriction, **49:363–368**
  - autoimmune thyroiditis and, **46:318, 319**
    - antigens, **46:270, 271, 273**
    - cellular immune responses, **46:291**
    - experimental models, **46:278, 282**
    - humoral responses, **46:302–305, 307**
    - prevention, **46:312, 314, 315**
  - autoreactive T cells and, **45:420**

B cell, **43:78**

- multiple antigen peptides containing, **60:109–124**
- B cell formation and, **41:191, 192**
- binding energy contribution, **43:24**
- CD4 and CD8 molecules and, **44:268, 295**
- CD5 B cell and, **47:155**
- CD23 antigen and, **49:157**
- cell surface-expressed, **48:114**
- character, **43:121–122**
- complement receptor 1 and, **46:196**
- complement receptor 2 and, **46:206, 207**
- conformational, **48:114**
  - sites mapped by peptides cluster into, **43:38–39**
- crystallographically defined, **43:24–25**
- cytotoxic T cells and, **41:138, 169, 170**
  - $\beta$ 2-microglobulin, **41:155**
  - amino acid changes, **41:159, 162, 163**
  - carbohydrate moieties, **41:152, 154**
  - exon shuffling, **41:139–142, 144, 145, 147**
  - HLA class I antigens, **41:150, 151**
  - monoclonal antibodies, **41:156–158, 165–167**
- definition, **43:25–26, 72**
- dominant, **43:46–49**
- epicenter, **43:27**
- flexibility, **43:63, 119**
- helper T cell cytokines and, **46:124**
- HIV CTL, **66:276–280**
- HIV infection and, **47:384, 386**
  - immune response, **47:407, 410, 411**
- HLA class II, **48:112**
- humoral immune response and
  - antigens, **45:8, 19**
  - cellular interactions *in vivo*, **45:80**
  - helper T cells, **45:28**
  - physical interaction, **45:44**
- Ig gene superfamily and, **44:11, 32, 33**
- Ir* genes and
  - antigen binding, **38:107**
  - competitive inhibition, **38:108**
- leukocyte integrins and, **46:168, 173**
- lymphocyte homing and, **44:321, 342, 343, 348, 368**
- methods, **43:75–76**
- mobility, **43:121**
- murine lupus models and, **46:74, 76**

- NK cells and, surface antigens of; **42:187**;  
**47:221**, 245, 247, *see also* Natural  
killer cells
- observed and predicted, **43:52–55**
- overlapping, fine specificity studies, **43:25**
- precipitation, **48:23**
- prediction, **43:56–58**
- sequence variability, **43:77**
- sequential, *see* Sequential epitope
- shared, RA susceptibility associated with  
concept, **56:403–404**, 416–418  
DRB1 genes, **56:410–416**  
ethnic differences, **56:408–410**  
haplotype encoding, **56:438–440**
- size, **43:120–121**
- spontaneous autoimmune thyroiditis and,  
**47:462**
- sporozoite malaria vaccine and, **45:283**,  
319–322  
CS proteins, **45:292**, 299  
CS-specific T cells, **45:307**, 308,  
310–313  
endemic areas, **45:315**  
human trials, **45:313**  
interferon- $\gamma$ , **45:306**  
*Plasmodium vivax*, **45:317**, 318
- surface antigens of human leukocytes and,  
**49:87**, 125
- synthetic T and B cell sites and,  
**45:195–197**, 260–264  
antigens, **45:236**  
bacterial antigens, **45:230–232**  
globular protein antigens, **45:210–214**  
immunological considerations, **45:201**,  
202  
parasitic antigens, **45:228–230**  
peptides, **45:250**  
vaccines, **45:252**, 255–258  
viral antigens, **45:217–220**, 222, 223
- T cell, *see* T cell epitopes
- T cell activation and, **41:1**, 9, 11, 20
- T cell receptor and, **45:142**  
amphipathic character, **45:144**, 145  
antigen processing, **45:121**, 122  
conformation, **45:145**, 146  
experimental systems, **45:132**  
helical conformation, **45:142–144**  
location, **45:146–148**  
peptides, **45:137**  
structure-function relationships,  
**45:135**
- T cell repertoire, **45:164–166**
- T cell subsets and  
cell surface molecules, **41:44**, 47  
H-2 alloantigen recognition, **41:79**,  
80, 83  
H-2-restricted antigen recognition,  
**41:53**, 54, 56, 62  
T cell specificity, **41:111**, 112  
T helper, pathogen-derived, **60:140–141**  
three-dimensional structure, **43:76–77**  
as vaccines, **43:59–60**  
virus-induced immunosuppression and,  
**45:363–365**, 367
- EPO, *see* Eosinophil peroxidase
- Epo  
relation to tyrosine phosphorylation, **60:5–6**  
role in Stat phosphorylation, **60:22**
- Epo receptors  
association with Jak2, **60:11–12**  
cytoplasmic domain, **60:13–14**  
induction of dimerization/oligomerization,  
**60:9–11**
- Epstein-Barr virus, **52:193–195**, 464;  
**54:143–144**  
abnormal infection, associated disorders,  
**37:129–138**  
adoptive T cell therapy of tumors and,  
**49:283**  
antibodies from transformed cell lines,  
**57:229–230**  
antigen-presenting cells and, **47:63**, 99  
associated lymphoproliferative disease in  
hu-PBL-SCID mice, **50:310–313**  
autoimmune thyroiditis and, **46:300**, 306  
CD4 molecules and, **44:290**  
CD5 B cell and, **47:136**  
CD23 antigen and, **49:149**, 161–162, 167,  
171  
complement receptor 1 and, **46:192**  
complement receptor 2 and, **46:204**, 205,  
208, 210–213  
cytotoxic T cells and, **65:279**  
cytotoxic T cells and, **41:144**, 165, 167  
and herpesvirus saimiri, **54:115–116**  
HIV infection and, **47:397**, 400  
HLA and, **65:286**  
human B cell neoplasia and, **38:271**  
Burkitt lymphoma, **38:246**, 247, 254

- Epstein-Barr virus (*continued*)  
 transformed lymphoblastoid cell line,  
**38:256**  
 humoral immune response and, **45:16, 17**  
 Ig heavy-chain variable region genes and,  
**49:2, 33, 35, 38, 42, 49-50**  
 Ig production induced by, and  
 immortalization, **37:110-112**  
 IL-1 and, **44:156, 190**  
 induced disease, **54:143-144**  
 infectious mononucleosis and, **37:112-115**  
 leukocyte integrins and, **46:173**  
 mAbs and, **38:278, 279**  
   B cell hybridomas, **38:280**  
   donor lymphocytes, **35:284, 285**  
   genetically engineered antibodies, **38:304**  
   human-human hybridomas, **38:292, 293,**  
   **300**  
   human-mouse heterohybridomas, **38:301**  
 NK cells and, **47:224, 227, 267, 283, 292**  
 persistent infection in normal individuals,  
**37:122-129**  
 polyclonal B cell activation by, **37:102-110**  
 QKRAA  
   Dw4 peptide, **48:130**  
   gp 110 peptide, **48:130**  
 regulators of complement activation and,  
**45:388, 409**  
 SCID and, **49:398**  
 surface antigens of human leukocytes and,  
**49:92**  
 synthetic T and B cell sites and, **45:226,**  
**240, 241**  
 T cell receptor and, **45:138**  
 transformation mediated by  
   genetically engineered antibodies, **38:305**  
   human-human hybridomas, **38:293, 294**  
   human-murine hybridomas, **38:289**  
   monoclonal antibody production,  
   **38:277-279, 301**  
 transformed B cells, NK clones and,  
**42:182-184**  
 tumor antigen induction, **57:292**  
 virus-induced immunosuppression and,  
**45:351, 352, 356, 358**
- Equilibrium dissociation constant,  
**42:168-172; 43:101**
- Equine infectious anemia virus, **52:431**
- Erg, **64:65**
- Erythroblasts, hybrid resistance and, **41:376**
- Erythrocytes, *see also* Sheep red blood cells  
 with abnormalities in complement  
 interaction, **60:74-75**  
 aPL antibodies and, **49:231, 239, 250-252,**  
**254-255**  
 B cell formation and, **41:189, 208**  
 CD23 antigen and, **49:157**  
 CD59 deficiency, **60:76-77**  
 cell-mediated killing and, **41:289, 290, 293,**  
**295**  
 complement receptor 1 and, **46:190, 191,**  
**194, 196, 198, 199**  
 complement receptor 2 and, **46:203, 206,**  
**210**  
 cytolysis and, **41:277, 278, 280**  
 equine, T cell subsets and, **41:68**  
 GPI anchor-deficient, **60:93**  
 humoral immune response and, **45:17,**  
**63, 65**  
 hybrid resistance and, **41:337, 342, 349,**  
**351, 352, 359, 376, 386, 388, 400**  
 IgE biosynthesis and, **47:8, 12, 19**  
 IL-8 binding to, **55:128**  
 interaction with IgA, **40:170-174**  
 leukocyte integrins and, **46:163**  
 lysis by complement, protection from,  
**60:77-78**  
 membrane, LPS-binding proteins, **53:279**  
 membrane attack complex of complement  
 and, **41:299-301, 303, 304, 306**  
 pore formers and, **41:314, 316, 317, 319**  
 protein roles, **45:388, 389**  
 regulators of complement activation and  
 protein expression, **45:395, 396, 399,**  
**400, 402**  
 SCID and, **49:383, 388**  
 surface antigens of human leukocytes and,  
**49:114-115, 117**  
 types I and II, **60:89**
- Erythroid cells, B cell formation and, **41:186,**  
**213**
- Erythroleukemia, hybrid resistance and,  
**41:336, 372, 378**
- Erythropoiesis  
 hybrid resistance and, **41:336, 337, 339,**  
**348**  
 IFN- $\gamma$  and, **62:93**
- Erythropoietin  
 hybrid resistance and, **41:348**  
 properties, **39:2-3**

- Escherichia coli*, **41**:302, 318; **50**:162; **54**:174, 236  
 expression library, immunoscreening, **54**:13  
 genetically engineered antibodies and, **38**:304  
 expression, **44**:72, 78  
 fusion proteins, **44**:85  
 production, **44**:66–69  
 human-mouse heterohybridomas, **38**:300, 301  
 IBD and, **42**:290–291, 294  
 leukocyte integrins and, **46**:163  
 lipopolysaccharide, structure, **53**:269–270  
 maps of Ig-like loci and, **46**:5  
 maternally transmitted antigen, **38**:344  
 sporozoite malaria vaccine and, **45**:315  
 synthetic T and B cell sites and, **45**:257  
 T cell receptor and, **45**:126, 165  
 E-Selectin, **59**:383; **62**:259, 267, 277; **64**:144, 145; **65**:354, 355, 363, 367  
 crystal structure, **64**:172  
 downregulation, **64**:172  
 downregulation by degradation in lysosomes, **58**:357–358  
 genetic studies, **64**:194  
 ligands, **64**:150, 151  
 CLA, 250-kDa, and SSEA-1, **58**:361–362  
 CLA<sup>+</sup> memory T cells, **58**:392  
 properties, **64**:147  
 soluble form, **64**:171, 317  
 upregulation, **64**:165  
 ESL-1, **64**:146, 151, 173  
 ESP, *see* Eosinophil stimulation promoter  
 Esterase  
 B cell formation and, **41**:212, 213  
 cell-mediated killing and, **41**:287  
 Esterase inhibitors, MC and, **42**:237  
 Ester linkage, in chemoinmunoconjugation, **56**:323  
 Estradiol  
 depletion of CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58**:227–229  
 hybrid resistance and, **41**:374, 389–392  
 Ethanolaminephosphate, in GPI-anchored proteins, **60**:60–67  
 Ethnicity, *see also* Race  
 RA susceptibility associated with, **56**:408–410  
 N-Ethylcarboxyamido-adenosine, **52**:397  
 Etodolac, **62**:186  
 Ets-1, **62**:42, 47–48; **63**:250  
 binding sites, **64**:70–73, 76–77  
 domains, **64**:76–77  
 expression, **64**:74–77  
 gene, **64**:75  
 gene targeting, **64**:81–82, 84–85  
 oncogenic potential, **64**:65  
 structure, **64**:79  
 structure–function studies, **64**:79–81, 83–84  
 Ets-2  
 binding sites, **64**:70–73, 76–77  
 building sites, **64**:76–77  
 domains, **64**:76–77  
 expression, **64**:74–77, 82–83  
 gene, **64**:84  
 building sites, **64**:76–77  
 gene targeting, **64**:81–82, 84–85  
 oncogenic potential, **64**:65  
 structure, **64**:79  
 structure–function, **64**:79–81, 83–84  
 Ets binding sites, **64**:68–74  
 Ets domain, *PU.1P* domain, **63**:217, 222  
 Ets–Jun interaction, **64**:86  
 Ets transcription factors, **64**:65–66, 94–96  
 binding sites, **64**:66, 68–74  
 Elf-1 protein, **64**:76–77, 91–92  
 Ets-1 protein, **64**:65, 74–82  
 Ets-2 protein, **64**:76–77, 82–85  
 Fli-1 protein, **64**:65, 76–77, 89–90  
 GABP $\alpha$  protein, **64**:66, 76–77, 94  
 PU.1 protein, **64**:65, 66, 76–77, 85–87  
 Spi-B protein, **64**:76–77, 87–88  
 ternary complex factors, **64**:76–77, 93–94  
 Eukaryotes, maternally transmitted antigen and, **38**:319, 320  
 Eu protein sequence, Ig heavy-chain variable region genes and, **49**:6, 8  
 Evolution  
 CD23 antigen and, **49**:165  
 Ig heavy-chain variable region genes and, **49**:14, 16, 26, 55, 61  
 J558 V<sub>H</sub> family, **42**:123–127  
 surface antigens of human leukocytes and, **49**:79, 117  
 V<sub>H</sub> loci, **62**:19–26  
 Exocytosis  
 autoimmune thyroiditis and, **46**:271  
 IL-1 and, **44**:163



- Exocytosis (*continued*)  
 lymphocyte homing and, **44:349**  
 in neutrophils, IL-8-dependent, **55:113**
- Exoerythrocytic forms, sporozoite malaria  
 vaccine and, **45:284, 319**  
 antibodies, **45:301**  
 CS-specific T cells, **45:307, 312**  
 human trials, **45:314**  
 immunity, **45:285, 286, 289–291**  
 interferon- $\gamma$ , **45:301–303, 305, 306**
- Exogenous help, T cell subsets and, **41:84, 85, 87, 112**
- Exons  
 CD1 genes, **59:7–8**  
 CD4 molecules and, **44:287–289**  
 CD8 molecules and, **44:274, 276, 278**  
 complement components and, **38:211, 213, 214, 236**  
 genetically engineered antibody molecules and  
 biological properties, **44:82, 83**  
 cloning, **44:73, 75**  
 fusion proteins, **44:86**  
 humoral immune response and, **45:32**
- Ig gene superfamily and  
 evolution, **44:43–45, 47, 48**  
 homology unit, **44:8, 9**  
 nonimmune receptor members, **44:31, 34, 39**
- IL-1 and, **44:157**  
 regulators of complement activation and, **45:404–406, 411**  
 T cell receptor and, **45:136**
- Exon sequences, T cell receptor protein and, **38:6, 7**
- Exon shuffling, CTL and, **41:144–148, 169**  
 altered cytoplasmic regions, **41:148, 149**  
 class I gene transfection, **41:138, 139**  
 CTL recognition, **41:141–144**  
 mAbs, **41:156, 165**  
 serology, **41:139–141**
- Experimental allergic autoimmune encephalomyelitis, synthetic T and B cell sites and, **45:235, 236**
- Experimental allergic encephalitis, pituitary hormones, **63:424**
- Experimental allergic encephalomyelitis, **46:79; 49:357**  
 antibodies and, **49:369–375**  
 myelin basic protein and, **49:357–358, 360–362**  
 TCR usage restriction and, **49:363, 366–368**
- Experimental autoimmune encephalitis, myelin basic and proteolipid proteins and, **66:88, 90**
- Experimental autoimmune encephalomyelitis, **46:291, 293, 312; 47:433, 449; 48:163–167; 62:98–99, 105, 107**  
 anti-CD4 antibody, **48:164, 166**  
 anti-Ia antibody, **48:164, 166**  
 immunomodulation, **48:166–167**  
 inflammatory demyelination, **48:166–167**  
 T cell receptor V gene, **48:166**  
 TH cell receptor, **48:166**
- Experimental autoimmune myasthenia gravis, *see also* Acetylcholine receptor; Myasthenia gravis  
 acute phase response in, **42:260–261**  
 development of, **42:232**  
 diagnosis of, **42:254**  
 etiology of, **42:248–250**  
 penicillamine and, **42:235**  
 T cell proliferation and, **42:256**  
 therapy for, **42:263–269**
- Experimental autoimmune thyroiditis, **46:266, 273, 317, 318; 47:433, 440, 442, 447**  
 antigens, **46:267, 270**  
 cellular immune responses, **46:287, 290, 296–298**  
 genetic control, **46:284–287**  
 humoral responses, **46:301, 302, 306, 308**  
 induction, **46:276–282**  
 models, **46:273–275**  
 prevention, **46:308, 310–315**  
 SAT, **46:273–276**
- Experimental autoimmune uveitis, **62:98–99**  
 immune privilege, **48:216–219**  
 induction, **48:215–216**  
 pathogenesis, **48:215–216**  
 S antigen, **48:219**  
 self-tolerance, **48:216–219**  
 T cell, **48:216**
- Experimental eosinophilia, IL-5 role, **57:173**
- Extracellular domain  
 LIF receptor, **53:39**  
 modification, **54:313–315**
- Extracellular matrix  
 and CD44, **54:282–291**

- CD44 as receptor for hyaluronan, **54:284–287**  
 eosinophil adhesion, **60:173–174**  
 features of CD44 molecule mediating interaction with hyaluronan, **54:287–290**  
 general features, **54:282–284**  
 leukocyte integrins and, **46:149, 153**  
   ligand molecules, **46:171**  
   structure, **46:156–159**  
 and metastasis, **54:318–322**  
 production, TGF- $\beta$  activation, **55:186**  
 protein interaction with CD44, **54:290–291**  
 regulation, and interaction with CD44, **54:302–318**  
   mechanisms for regulating CD44 receptor function, **54:310–318**  
   regulated hyaluronan binding, **54:302–308**  
   and regulatory mechanisms of other adhesion molecules, **54:308–310**  
 surface antigens of human leukocytes and, **49:82–86**
- Extracellular processing, synthetic peptides, **52:84–85**
- Extravasation  
 activated T cells in skin, **58:392**  
 lymphocytes, **64:142; 65:360, 365–367**  
 lymphocytes in high endothelial venules, **58:347**  
 T cells, and endothelium, **50:285–287**
- Extrinsic allergic alveolitis, **62:267**
- Extrinsic factors, TH responses, **61:357–358**
- Extrinsic pathway inhibition, aPL antibodies and, **49:256**
- Eye, *see also* Anterior chamber; Cornea  
 anatomy, **48:192**  
 autoimmune diseases, **48:216–219**  
 HSV-1 infection, anterior chamber, **48:210**  
   contralateral eye, **48:210**  
   delayed-type hypersensitivity suppression, **48:210**
- HSV infection  
 anterior chamber-associated immune deviation, **48:208–210**  
 cytotoxic T cell, **48:210**  
 delayed-type hypersensitivity, **48:210**
- immune privilege, **48:191–221**  
 immune regulation, **48:191–221**  
 self-tolerance, strategies, **48:217**  
 trabecular meshwork, **48:206–207**  
 transplantation, **48:191**
- ## F
- Fab  
 constant domain, **48:19**  
 C portion, **48:20**  
 elbow bend, **48:19**  
 heavy chain, **48:19**  
 hinge region structure, **48:21–23**  
 internal motions, **48:19–21**  
 light chain, **48:19**  
 protein antigen antibodies, **48:20**  
 switch region flexibility, **48:19**  
 V portion, **48:20**
- Fab-lysozyme complexes, **43:121**
- Fab subunit, rotation modes, **48:33**
- Faciogenital dysplasia, **63:149**
- Factor B, complement components and, **38:203, 206, 236**  
 C2 and, **38:207–209, 228**  
 C4b-binding protein and, **38:235**  
 cDNA, **38:209–211**  
 cloning, **38:212–214**  
 deficiency, **38:208**  
 expression, **38:217, 218**  
 restriction fragment length polymorphism, **38:215, 216**
- Factor H, **61:203, 204, 209, 221, 230–235**  
 complement components and, **38:204, 211, 235, 236**  
 complement receptor 1 and, **46:189, 197**
- Factor I, **61:210–214, 239–240**  
 complement components and, **38:235**  
 in therapeutic complement activation, **56:272–273**
- Factor IX, complement components and, **38:236**
- Factor X  
 aPL antibodies and, **49:242–243, 256**  
 complement components and, **38:236**
- Factor XI, **66:225**  
 activation, **66:230, 237**  
 platelet receptors, **66:244**  
 properties, **66:226**  
 structure, **66:230**

- Factor XIa  
 inhibition, **66:239**  
 platelet receptors, **66:244**
- Factor XII, **66:225**  
 activation, **66:225, 227, 234, 235–236**  
 autoactivation, **66:234–235, 236, 245, 248**  
 endothelial cell receptor, **66:249–257**  
 function, **66:241**  
 interaction with cells, **66:244, 246**  
 properties, **66:226**  
 structure, **66:226–229**
- Factor XIIa, **66:225, 228, 229**  
 inactivation, **66:238**
- Factor XIIi, **66:227–228, 229**  
 function, **66:241**  
 inactivation, **66:238**
- FADD, **61:31**
- Family studies, RA susceptibility, **56:433–435**
- Fanconi's anemia, **61:315**
- Farnesyltransferase inhibitors, in cancer therapy, **58:417**
- Fas, **57:129–131, 129–140; 61:9, 17, 30, 31**  
 apoptosis role, **57:129, 133–134, 140**  
*in vitro*, **57:133–134**  
*in vivo*, **57:133–134**  
 autoimmune diseases associated with, **57:138, 140**  
 dependent cell lysis by CD4<sup>+</sup> CTLs, **60:304–305**  
 dependent MHC class II-restricted CTLs, **60:303–310**  
 expressing B cells, **60:292**  
 expression, **57:130–132**  
 gene, **61:9, 10–11**  
 mutation in *lpr* mouse, **57:132–133**  
 loss of function mutation, **57:139**  
 mutation in *lpr* mouse, **57:132–133**  
 physiologic roles, **57:137–139**  
 signal transduction role, **57:134–135, 139**  
 T cell development role, **57:137**  
 transmission of death signal, **60:299**
- Fas/APO-1  
 immunological memory and, **53:241**  
 in myeloma cells, **64:259–260**  
 in target cell killing, **60:294–296**
- Fasciitis, eosinophilic, **60:227**
- Fas–Fas-L signaling pathway, **61:32, 37**
- Fas–Fc chimeric protein, **60:295–296**
- Fas ligand, **57:130, 135–139; 61:24, 25, 26**  
 characteristics, **57:135–137**  
 expression, **60:295–298, 303**  
 expression in cytotoxic T cells, **57:138**  
 mediated killing, **60:308–309**
- Fatty acids  
 aPL antibodies and, **49:194–197, 238, 251**  
 IL-2 and, **44:161, 176**  
 N-3 polyunsaturated  
 dietary  
 coronary heart disease and, **39:145–146**  
 hypolipidemic effects, **39:145–147**  
 in mammalian phospholipids, dietary fish oil and, **39:160**  
 metabolism, **39:159–160**  
 N-6 polyunsaturated, metabolism, **39:159–160**  
 NK cells and, **47:249**
- FBL, adoptive T cell therapy of tumors and antigen recognition, **49:320–321, 324**  
 expression of antitumor responses, **49:325–329, 331–332**  
 mechanisms, **49:300, 302–304, 308–310, 313–315**  
 NK cells, **49:317–318**  
 principles, **49:292, 295–296, 298**
- Fc  
 Asn<sup>297</sup> residue, carbohydrate unit, **48:27**  
 CH2 domain lateral contact, **48:20**  
 CH3 domain, **48:20–21**  
 Dob, **48:21**  
 hinge region structure, **48:21–23**  
 internal motions, **48:19–21**  
 Mcg, **48:21**  
 rotational properties, **48:20**  
 structure, considerations, **51:2–4**  
 three-dimensional structure, **48:20**
- Fc-binding factors, **43:277**
- Fc carbohydrate, **48:27**
- Fc fragment, active sequence, **40:116–118**
- Fc oligosaccharide, protein surface, **48:28–29**
- Fc receptors, **43:277, 305; 51:29–54**  
 adoptive T cell therapy of tumors and, **49:312–313**  
 bacterial, **51:56–60, 56–61**  
 B cell formation and, **41:194**  
 binding sites, localization, **40:68–69**  
 cells bearing, IBD and, **42:297**  
 cellular distribution, **40:63–68**  
 characteristics, **57:1**  
 characterization of, **40:68–70**

- complement activation by, **51:7–29**  
 antibodies as activators of alternative pathway, **51:28–29**  
 C1 activation, **51:21–25**  
 C3 activation, **51:25–28**  
 C4 activation, **51:25–28**  
 cell lysis, **51:25–28**  
 interaction of C1q and antibody, **51:8–21**
- complement receptor 1 and, **46:198**  
 cytotoxicity and, **41:269, 271, 279, 296**  
 Fc $\alpha$ R, **51:48–50**  
 characteristics, **57:38–39**  
 Fc $\alpha$ -IgA interaction at molecular level, **51:49–50**  
 positive cells, IBD and, **42:290**
- Fc $\gamma$ R, **51:29–41; 52:394–396**  
 biological function, **57:69–70**  
 characteristics, **57:2–3**  
 signal transduction role  
 mechanisms, **57:72–77**  
 phosphorylation, **57:74–77**  
 second messenger interactions, **57:72–74**  
 structural factors, **57:82, 84–89**
- Fc $\delta$ R, **51:51**  
 characteristics, **57:43**
- Fc $\epsilon$ R, **51:41–48; 62:77**  
 characteristics, **57:30**  
 IgE biosynthesis and antibody response, **47:8, 9**  
 binding factors, **47:12, 15, 17, 19–23**
- Fc $\mu$ R, **51:50–51; 52:173**  
 characteristics, **57:41–42**
- FcRI  
 bacterial, **51:56–58**  
 expressed by monocytes, **60:179–181**
- Fc $\alpha$ RI  
 biochemical structure, **57:39–40**  
 cell distribution, **57:40–41**  
 characteristics, **57:39**  
 ligand properties, **57:40**  
 mAbs, **57:9, 40–41**  
 molecular structure, **57:39–40**  
 polymorphisms, **57:41**
- Fc $\gamma$ RI, **51:30; 62:77**  
 biochemical structure, **57:3–7**  
 biological function, **57:69**  
 cell distribution, **57:8**  
 characteristics, **57:2–4, 4**  
 gene structure, **57:4–5, 7**  
 IgG interaction at molecular level, **51:30–34**  
 Ig interactions, molecular basis, **57:48–54**  
 ligand properties, **57:7–8**  
 molecular structure, **57:3–7**  
 monoclonal antibodies, **57:8–9**  
 polymorphisms, **57:8–10**  
 signal transduction role  
 phosphorylation, **57:76–77**  
 structural factors, **57:84**  
 structure, **57:5, 7**
- Fc $\epsilon$ RI, **51:41–43**  
 biochemical structure, **57:31–36**  
 biological function, **57:70–71**  
 cell distribution, **57:36–37**  
 $\alpha$  chain, **52:379; 57:32–33**  
 molecules related to, **52:383–384**  
 $\beta$  chain, related molecules, **52:379–380, 383–384; 57:33–34**  
 $\gamma$  chain, **52:380–381; 57:34–36**  
 characteristics, **57:30**  
 control of synthesis and expression, **52:384–386**  
 dependence on IgE, **52:385**  
 half-life, internalization, degradation and reexpression, **52:385–386**  
 synthesis during cell cycle, **52:385**  
 synthesis during differentiation of basophils/mast cells from hemopoietic precursor cells, **52:384–385**
- crosslinking  
 and basophil ILL production, **53:13**  
 and factor-dependent mast cell lymphokine production (*murine*), **53:6**  
 and ILL production by splenic and bone marrow Fc $\epsilon$ RI<sup>+</sup> cells, **53:10**  
 and signaling of IL-4 production, **53:19–22**  
 and transformed mast cell lymphokine production, **53:5**
- functional characterization, **52:387–391**  
 binding to IgE, **52:387–388**

Fc receptors (*continued*)

- effector mechanisms and functional changes of mast cells/basophils following activation through IgE binding sites, **52:391**
  - signal transduction and distal events, **52:388–391**
  - gene structure, **57:31–34**
  - IgG interaction at molecular level, **51:43–46**
  - Ig interactions, molecular basis, **57:49–50, 61–68**
  - ligand properties, **57:36**
  - molecular structure, **57:31–36**
  - monoclonal antibodies, **57:9, 36–37**
  - polymorphisms, **57:37**
  - polypeptide components  $\alpha$ ,  $\beta$ , and  $\gamma$ , **53:21**
  - positive cells
    - bone marrow, lymphokine production by (murine), **53:9–14**
    - human, lymphokine production by, **53:14–15**
  - signal transduction role
    - mechanisms, **57:77–81**
    - phosphorylation in, **57:79–81**
    - second messenger interactions, **57:77–79**
    - structural factors, **57:89–90**
  - structure, **57:31–34**
  - transcripts, **57:31**
- FcRII**
- bacterial, **51:58–59**
  - expressed by resting eosinophils, **60:179–181**
- Fc $\gamma$ RII**, **51:34–36; 62:77**
- biochemical structure, **57:10–16**
  - biological function, **57:70**
  - cell distribution, **57:17–19**
  - characteristics, **57:2–3, 11**
  - gene structure, **57:11–13, 15–16**
  - IgG interaction at molecular level, **51:36–38**
  - Ig interactions, molecular basis, **57:49–50, 54–59**
  - ligand properties, **57:16–17**
  - molecular structure, **57:10–16**
  - monoclonal antibodies, **57:9, 17–19**
  - polymorphisms, **57:19–21**
  - signal transduction role
    - phosphorylation, **57:75–77**
    - structural factors, **57:82, 84–87**
  - structure, **57:12–13, 15–16**
  - transcripts, **57:13**
- Fc $\epsilon$ RII**, **51:46–47**
- biochemical structure, **57:37–38**
  - CD23 antigen and, **49:149, 162–167**
  - cell distribution, **57:38**
  - characteristics, **57:30**
  - gene structure, **57:37**
  - IgE interaction at molecular level, **51:47–48**
  - ligand properties, **57:38**
  - molecular structure, **57:37–38**
  - monoclonal antibodies, **57:38**
  - structure, **57:37**
- FcRIII**
- bacterial, **51:59–60**
  - eosinophils expressing, **60:205**
  - neutrophils and NK cells expressing, **60:179–181**
- Fc $\gamma$ RIII**, **51:38–40; 62:77**
- biochemical structure, **57:21–27**
  - biological function, **57:70**
  - cell distribution, **57:28–29**
  - characteristics, **57:2–3, 22**
  - gene structure, **57:22–26**
  - IgG interaction at molecular level, **51:40–41**
  - Ig interactions, molecular basis, **57:49–50, 59–61**
  - ligand properties, **57:27–28**
  - molecular structure, **57:21–27**
  - monoclonal antibodies, **57:9, 28–29**
  - polymorphisms, **57:29–30**
  - signal transduction role
    - phosphorylation, **57:76–77**
    - structural factors, **57:84, 87–88**
  - structure, **57:23–26**
  - transcripts, **57:23**
- FcRIV**, bacterial, **51:61**
- FcRV**, bacterial, **51:61**
- FcRVI**, bacterial, **51:61**
- FcRn**, characteristics, **57:46–47**
- function
  - biological, **57:69–71**
  - Fc $\gamma$ R, **57:69–70**
  - Fc $\epsilon$ RI, **57:70–71**
  - signal transduction
    - mechanism, **57:71–81**
    - structural basis, **57:81–90**

- genetically engineered antibodies and, **44:68, 80, 83, 87**
- human leukocyte, **51:29–54**
- hybrid resistance and, **41:371, 376–378, 394**
- Ig gene superfamily and, **44:39, 43, 45**
- Ig interactions, molecular basis
- FcγRI, **57:48–54**
  - FcεRI, **57:49–50, 61–68**
  - FcγRII, **57:49–50, 54–59**
  - FcγRIII, **57:49–50, 59–61**
  - overview, **57:48–50**
- leukocyte, effector cell-target cell interaction mediated by, **51:51–54**
- lung dendritic cells, **59:379–380**
- phagocytosis and
- IgG, **38:362, 367, 392**
  - nonelicited murine macrophages, **38:377, 379**
  - zymosan, **38:370, 371, 393**
- polymeric IgR, characteristics, **57:43–46**
- research directions, **57:91**
- signal transduction, mechanism, **57:71–81**
- phosphorylation role, **57:74–77, 79–81**
  - protein kinase role, **57:74–77, 79–81**
  - second messenger interactions, **57:72–74, 77–79**
- signal transduction, structural basis, **57:81–90**
- antigen receptor homology motif role, **57:81–83**
  - FcγR role, **57:82, 84–89**
- surface antigens of human leukocytes and, **49:80, 83, 89–91, 111**
- T cell, role for isotype response, **40:212–216**
- T cell activation and, **41:9**
- Fc region, biological properties of
- activity of peptide fragments of Fc, **40:111–119**
  - complement fixation, **40:70–71**
  - enhancement of *in vitro* specificity of humoral immune response, **40:90–95**
  - enhancement of specific *in vitro* T cell-mediated immune response, **40:95–100**
  - nonspecific lymphocyte activation by Fc, **40:79–90**
  - regulation of cell-mediated immune response, **40:77–79**
  - regulation of specific humoral immune response, **40:71–77**
  - stimulation of macrophages by Fc region, **40:100–111**
- FDC, *see* Follicular dendritic cells
- Feedback, spontaneous autoimmune thyroiditis and, **47:476, 478**
- Feedback loop, NF-κB induction by cytokines and vice versa, **58:7**
- Feline immunodeficiency virus, **52:437–441**
- LTR, **65:10**
  - in study antiviral therapy and vaccines, **52:440–441**
- Feline leukemia virus, model, **52:434–436**
- antiviral therapy, **52:436–437**
  - pathogenic mechanism of FeLVFAIDS, **52:436**
- Felton's paralysis, and other early results with polymers, **52:287–288**
- FeLV, *see* Feline leukemia virus
- FELV-FAIDS, pathogenic mechanism of, **52:436**
- Ferritin, complement receptor 1 and, **46:200**
- Fetal calf serum, autoreactive T cells and, **45:426**
- Fetal development
- acquisition of clonotype repertoire during, **42:26–30**
  - role of IL-6, **54:32**
- Fetal loss, aPL antibodies and, **49:252–253, 257–258**
- clinical aspects, **49:213–216, 218–224**
  - isotype, **49:225–226**
- Fetal tissues, transplantation with, SCID and, **49:392–393**
- Fever
- cachectin and, **42:224**
  - IL-1 and, **44:154, 155, 190, 194**
  - biological effects, **44:166**
  - immunocompetent cells, **44:178**
  - systemic effects, **44:170, 171**
  - TNF, **44:185–187**
- Fiberoptic bronchoscopy, for obtaining BAL fluid, **60:218–223**
- Fibrillarin, antinuclear antibodies and, **44:122–124**

- Fibrinogen  
 IL-1 and, **44**:164, 189  
*Ir* genes and, **38**:97
- Fibrinolysis, aPL antibodies and, **49**:254–255
- Fibrinolytic cascade, **66**:240–254
- Fibrinopeptide B  
 helper T cell cytokines and, **46**:128  
 human, synthetic T and B cell sites and, **45**:233
- Fibroblast growth factor, IL-1 and, **44**:153, 154  
 biological effects, **44**:164, 167–169  
 structure, **44**:158
- Fibroblasts  
 B cell formation and, **41**:235, 236, 238  
 genetically determined defects, **41**:230  
 Ig genes, **41**:205  
 lymphohemopoietic tissue organization, **41**:186, 188  
 CD4 and CD8 molecules and, **44**:272, 302  
 CD40 expression, **61**:15, 41  
 CTL and, **41**:145, 150–153  
 growth factor receptors, **54**:365  
 hybrid resistance and  
 antigen expression, **41**:400  
 leukemia/lymphoma cells, **41**:359, 361  
 NK cells, **41**:372  
 in vitro assays, **41**:393, 394
- IFNs, **62**:61
- Ig gene superfamily and, **44**:36
- IL-1 and, **44**:153, 190  
 biological effects, **44**:165, 166, 168, 169  
 human disease, **44**:195  
 receptor, **44**:179, 181, 183  
 structure, **44**:158  
 TNF, **44**:186, 188
- IL-1ra production, **54**:188–189  
 induction of positive selection, **58**:164–165  
 leukocyte integrins and, **46**:162, 171, 172  
 maps of Ig-like loci and, **46**:6  
 regulators of complement activation and  
 protein expression, **45**:395, 397, 399  
 protein roles, **45**:387  
 RCA-like protein utilization, **45**:410  
 as source of chemokines, **55**:107  
 synthetic T and B cell sites and, **45**:217
- T cell activation and, **41**:10
- T cell receptor and, **45**:121
- T cell subsets and, **41**:46, 89–91, 94  
 trans-acting negative factors, **43**:248
- Fibronectin, **38**:362  
 antigen-presenting cells and, **47**:61  
 B cell formation and, **41**:215  
 eosinophil adherence to, **60**:173–174  
 leukocyte integrins and, **46**:149, 153  
 inflammation, **46**:168, 169  
 leukocyte adhesion deficiency disease, **46**:176  
 structure, **46**:157, 158  
 lymphocyte homing, **64**:191  
 multiple myeloma, **64**:248–249  
 opsonic effects, **38**:388–391, 393  
 structure, **38**:386–388
- Fibrosarcoma  
 CTL and, **41**:45  
 hybrid resistance and, **41**:359, 361, 363
- Fibrosis, cytokines, **59**:418
- Filariasis, major basic protein in blood, human, **39**:213
- Fine sequence specificity, switch recombination, **61**:107–108
- Fine specificity, **43**:3  
 HyHEL5, **43**:26  
 overlapping epitopes, **43**:25
- Fish oil, dietary  
 arachidonic acid metabolism and, **39**:168–169  
 coronary heart disease and, **39**:145–146  
 guinea pig pulmonary response to antigen and, **39**:164–165  
 plasma LTB<sub>4</sub> and, **39**:164  
 murine SLE and, **39**:163–164  
 rat rheumatoid arthritis and, **39**:163
- FIV, *see* Feline immunodeficiency virus
- FK506, **61**:180–187  
 antiapoptotic effects, **58**:267  
 effect on eosinophil survival, **60**:197–198  
 inhibition of negative selection, **58**:261–262  
 NF- $\kappa$ B, **65**:120
- FK506-binding proteins, **61**:180–181
- FKBP12, **61**:181, 187
- FKBP12–rapamycin complex, **61**:181–190
- FLA-3, multiple myeloma and, **64**:247
- Flanking regions  
 Ig heavy-chain variable region genes and, **49**:26, 39  
 probes, **49**:23  
*J558 V<sub>H</sub>* subfamilies, **42**:122–123
- Flap endonuclease-1, **61**:304

- Flexibility  
 antigenicity, **43:105**, 118  
 epitope, **43:57**, 63, 119  
 loop, CDR, **43:107**  
 main-chain parameters, **43:50**
- Fli-1*, **64:90**
- Fli-1  
 binding sites, **64:76–77**  
 domain, **64:76–77**  
 expression, **64:89**  
 gene targeting, **64:90**  
 oncogenic potential, **64:65**  
 structure, **64:78**  
 structure–function studies, **64:89–90**
- Florid glomerulonephritis, **59:343**
- Flow cytometry, histograms of antigen expression, **52:131–135**
- Fluorenyl-methoxy-carbonyl, *see* Fmoc chemistry
- Fluorescein, specific neonatal B cells, **54:399**
- Fluorescein isothiocyanate, CTL and, **41:166**, 167
- Fluorescence  
 antigen-presenting cells and, **47:86**, 94  
 antinuclear antibodies and, **44:105**  
 B cell formation and, **41:196**  
 CD5 B cell and, **47:118**, 127  
 cell-mediated killing and, **41:298**  
 complement receptor 2 and, **46:204**, 207, 211  
 genetically engineered antibody molecules and, **44:65**  
 immunosenescence and, **46:229**, 231, 232, 242  
 lymphocyte homing and, **44:318**, 323, 358, 359  
 NK cells and, **47:198**, 213, 219  
 spontaneous autoimmune thyroiditis and, **47:454**  
 T cell development and, **44:237**
- Fluorescence-activated cell sorter, T cell subsets and, **41:84**
- Fluorescence microscopy, CD5 B cell and, **47:149**
- Fluorescence polarization  
 IgA, rotational correlation times, **48:16–17**  
 IgE, rotational correlation times, **48:16–17**  
 IgM, rotational correlation times, **48:16–17**
- 5-Fluoro-2-deoxyuridine, use in cancer treatment, monoclonal antibody conjugation procedure, **56:344–345**
- Flurbiprofen, **62:184**, 186  
 IBD and, **42:313**
- FMLP, *see* Formyl-methionyl-leucyl-phenylalanine
- Fmoc chemistry  
 and Boc chemistry, HIV-1, **60:134**  
 MAP synthesis, **60:106–107**  
 Pf322 blood-stage antigen synthesis, **60:120–121**  
 with *tert*-butyl, **60:128–130**  
 TPI epitopes constructed with, **60:125–126**
- FOE receptors, **43:282**  
 degradation, **43:302**  
 human B cells, **43:298–300**  
 murine B cells, **43:302**  
 T cells, **43:301**, 303
- Folic acid antagonists, as cancer treatment, **56:338–340**
- Follicles, transformed, avian leukosis virus infection, response to, **56:471–472**
- Follicular B cell lymphoma, human, **50:73**
- Follicular B cells, **59:283–285**
- Follicular dendritic cells, **52:225–227**; **61:33**  
 antigen complex binding, **60:269**  
 CD40 expression, **61:14**, 41  
 cellular origin, **51:261–263**  
 central role of in lymphoid tissues  
 antigen expression of, **51:257–261**  
 cellular origin of, **51:261–263**  
 conclusions, **51:278–280**  
 distinction of from other dendritic cells, **51:244–247**  
 expression of in malignant lymphomas, **51:274–275**  
 process, **51:243–244**  
 regulation of normal germinal center by, **51:263–274**  
 apoptosis, inhibition of, **51:272–274**  
 in germinal center light zone, **60:271**  
 humoral immune response and, **45:9**, 24, 79, 80  
 role in lymphoid tissues  
 regulation of normal germinal center by  
 binding via cell-cell and cell-matrix adhesion molecules, **51:269–271**  
 cytokines, induction of, **51:274**  
 requirements of FDC's for ontogeny of germinal center, **51:263–265**



- Follicular dendritic cells (*continued*)  
 secondary immune response,  
 regulation of, **51:271–272**  
 trapping of immune complexes and  
 alternative antigen, **51:265–269**  
 as targets of HIV, **51:275–278**  
 technical difficulties, solution of,  
**51:246–257**  
 stored antigen on, **53:222, 231**
- Follicular exclusion, autoreactive B cells,  
**59:310–319**
- Folliculostellate cells, IFN- $\gamma$  effects,  
**62:94**
- Food poisoning, **54:128**
- Foot and mouth disease virus  
 MAP vaccines, **60:130**  
 synthetic T and B cell sites and, **45:227,**  
**253, 254**
- Footprinting studies, **43:2–3**
- Forbidden T cells, in peripheral immune  
 system, **53:164–166**
- N-Formyl-kynurenine, **62:71**
- Formyl-methionine peptides, and related  
 compounds, receptors for, **52:371–372**
- Formyl-methionyl-leucyl-phenylalanine,  
**42:315, 64:154**  
 5-lipoxygenase activation, **39:154**
- Formyl peptides  
 comparison with leukotrienes in neutrophil  
 activation, **39:135**  
 as neutrophil receptor ligand, *see*  
 Neutrophil receptors
- Forskolin, action of, **65:124–125**
- fos* gene family, **63:248**
- 4-1BB, **61:7, 10, 17**
- 4-1BB-L, **61:24, 25**
- Four-way developmental choice, molecular  
 basis of, **51:180–186**  
 CD4 vs CD8 down-regulation, **51:185–**  
**186**  
 positive selection vs two kinds of death,  
**51:175–177**  
 positive vs negative selection, **51:180–183**  
 signaling pathways controlling positive  
 selection, **51:183–185**
- Fractionation  
 antinuclear antibodies and, **44:102**  
 lymphocyte homing and, **44:344**  
 T cell development and, **44:238**
- Fragment cultures, specific, and limiting  
 dilution, **54:395–398**  
 importance of affinity and valence,  
**54:396–398**  
 role of B cell maturational stage,  
**54:395–397**
- Fragmentins  
 induced DNA degradation, **60:301**  
 or granzymes, cytotoxic T cells containing,  
**58:240**  
 peptide hydrolysis by, **58:243**
- FRAP, **63:154**
- FRAP1, **61:181**
- Free energy, protein-protdn interactions,  
**43:100**
- Free radicals  
 formation or action, inhibition, **58:250**  
 NO, scavenging, **60:340–341**
- Freund's adjuvant  
 HIV V3 loop in, **60:131**  
 multiple antigen peptides emulsified in,  
**60:111–112, 116–117**
- Freund's complete adjuvant  
 autoimmune thyroiditis and  
 experimental models, **46:276–282**  
 genetic control, **46:286, 287**  
 humoral responses, **46:301, 302, 307**  
 prevention, **46:309–312, 314**  
 helper T cell cytokines and, **46:137**  
 IgE biosynthesis and, **47:2–5, 14, 24**  
 T cell subsets and, **41:70, 71**
- Friend erythroleukemia, hybrid resistance  
 and, **41:389**
- Friend leukemia virus, hybrid resistance and  
 antigen expression, **41:400, 403**  
 bone marrow cells, **41:345**  
 lymphoid cells, **41:354**  
 marrow engraftment, **41:387**  
 NK cells, **41:376**
- Friend murine leukemia virus, adoptive T cell  
 therapy of tumors and, **49:320–321, 324**
- Friend spleen focus-forming virus, hybrid  
 resistance and, **41:389**
- Friend virus, **41:168, 378, 389**
- FS cells, IFN- $\gamma$  effects, **62:94**
- Fucoidin, lymphocyte homing and  
 carbohydrate, **44:356–358, 360–362**  
 high endothelial venules, **44:320**
- Fucosyltransferases, **64:168, 169**
- Fuc-TVII, **65:364–365, 373**

- Functional divergence, and positive selection  
 T cell mechanism, **51**:186–189
- Functional redundancy, defined, **63**:173
- Fungal pneumonia, **59**:397–406  
*Cryptococcus neoformans*, **59**:402–405
- Fungal products, in therapeutic complement inhibition, **56**:288–289
- Fungi, cytotoxicity and, **41**:269, 270
- Fusion  
 antinuclear antibodies and, **44**:130, 131  
 CD4 molecules and, **44**:295, 296  
 donor lymphocyte preparation, **38**:282–286  
 genetically engineered antibody molecules and  
 expression, **44**:70, 71, 77  
 production, **44**:67  
 proteins, **44**:85, 86  
 human-human hybridomas, **38**:297, 300  
 human-mouse heterohybridomas, **38**:300, 301  
 hybridoma propagation, **38**:322  
 maternally transmitted antigen, **38**:314, 324, 341, 343  
 phagocytosis, **38**:363  
 somatic, B cell hybridization and, **38**:279  
 T cell development and, **44**:215
- Fyn, **63**:135, 165, 399  
 expression, **51**:144–145  
 IL-2R $\beta$  coupling, **61**:155
- G**
- G<sub>1</sub>-phase progression  
 IL-2 dependent, **61**:179–180  
 rapamycin, **61**:182–183
- G63, **52**:394
- GABP $\alpha$   
 binding sites, **64**:76–77  
 domains, **64**:76–77  
 expression, **64**:94  
 gene targeting, **64**:94  
 structure, **64**:78  
 structure–function studies, **64**:94
- gag*, adoptive T cell therapy of tumors and, **49**:320–321, 323–324
- GAGE, **62**:229, 233
- Galactans, phagocytosis and, **38**:368, 381
- Galactose, surface antigens of human leukocytes and, **49**:88–89, 91
- $\beta$ -Galactosidase, antibody response in B cells to, **39**:88–90  
 helper T cells and, **39**:88–90
- GALT, *see* Gut-associated lymphoid tissue, rabbit
- Gamma-activated factor, **62**:68
- Gamma chains  
 $\gamma$ -common chain, **61**:150, 151–152  
 mast cell-specific receptor, gene cloning studies, **43**:288–289
- Gamma globulin  
 agammaglobulinemia, history, **59**:137–141  
 aPL antibodies and, **49**:222–223  
 normal rabbit, presentation by B cells, **39**:55–56  
 replacement therapy, **59**:150  
 XLA, *see* X-linked agammaglobulinemia
- Gamma radiation, B cells  
 antigen presentation and, **39**:67–72  
 dose effects, **39**:67, 71–72  
 LPS activation and, **39**:71  
 MLR stimulation and, **39**:80–81
- Ganglionic nicotinic AChR, **42**:239, *see also* Acetylcholine receptor
- Ganglioside antigens, tumor antigens, **40**:351–352  
 cell-associated gangliosides, properties, **40**:353–355  
 tumor cell-associated, properties  
 colon cancer, **40**:364–366  
 melanoma, **40**:357–364  
 neuroblastoma, **40**:355–357
- Gangliosides, **62**:219–220  
 abnormal expression in PNH, **60**:92
- Gaps, **63**:144
- GAS-binding proteins, cytokine activation, **63**:141
- GAS elements  
 DNA-binding activity, **60**:21–22  
 Stat dimer affinities for, **60**:24–25
- Gastrin receptor, **48**:181
- Gastrointestinal side effects,  
 anticholinesterase drugs, **42**:270
- GATA-2, B cell genesis, **63**:217, 218–219
- CBP-1, **62**:76
- gC1aR, as endothelial cell receptor, **66**:249–257
- G-CSF, *see* Granulocyte colony-stimulating factor
- GD2, **62**:219

- GD3, **62:219**  
 GDP $\beta$ S, **43:292**  
 Gelatinase, **62:288**  
 Gel electrophoresis  
   *Ir* genes and, **38:78, 147**  
   two-dimensional, **38:225**  
 Gelonin, MG and, **42:265, 266**  
 Gender, RA susceptibility studies, **56:434**  
 Gene amplification, human B cell neoplasia and, **38:254**  
 Gene conversion, **62:24–26**  
   Ars A response and, **42:120**  
   avian Ig gene, **48:60–62**  
   chicken B cell genes, **57:358–365**  
   complement components and, **38:227**  
   Ig heavy-chain variable region genes and, **49:15, 52, 61**  
     D segments, **49:28–29, 32**  
     polymorphism of V<sub>H</sub> gene segments, **49:24, 26**  
   Ig VL gene, **48:60–62**  
   *Ir* genes and, **38:86**  
   somatic, and antibody repertoire generation in rabbit, **56:198–202**  
    $\psi$ -V gene segment, **48:58**  
   VL gene segment, **48:56–60**  
 Gene dosage  
   hybrid resistance and, **41:357**  
   *Ir* genes and, **38:79–83, 139**  
 Gene duplication  
   Ig heavy-chain variable region genes, **49:25, 29**  
   in *J558* V<sub>H</sub> family, **42:123–127**  
 Gene expression  
   B cell hybridomas, **38:279**  
   donor lymphocytes, **38:285**  
   genetically engineered antibodies, **38:304**  
   induction via B cell antigen receptor, **55:266–269**  
   maternally transmitted antigen and, **38:314**  
     antigenic variation, **38:342, 343**  
     MHC, **38:329**  
   Gene fusion, resulting from chromosome translocation, **50:128–129**  
   Gene knockouts, **59:116–118, 124, 128**  
   Genealogy, *J558* V<sub>H</sub> gene segments, **42:124**  
   Generalized lymphoproliferative disease, murine lupus models and, **46:63, 64, 94–97**  
 Gene rearrangements  
   *cis*-acting elements for, **58:30–31**  
   DNA sequencing, **58:33–36**  
   endogenous, **58:37**  
   lymphoid-restricted, **58:43**  
   TCR, **38:8, 10, 11**  
     allelic exclusion, **38:17, 18**  
     developmentally programmed, **58:308–309**  
     peripheral T cells, **38:13–15**  
     thymus, **38:13**  
   TCR $\gamma$ , **58:142**  
   V $\alpha$  TCR, **58:112**  
   V $\gamma$ , developmentally regulated program, **58:301**  
   V $\gamma$  $\delta$ , **58:311**  
   V $\gamma$ J $\gamma$ , **58:314**  
 Gene regulation, by cytokines, NF-IL6 and NF- $\kappa$ B, **65:1–33**  
 Genes  
   chicken B cell, conversion  
     DT40, **57:361–362**  
     Holliday junction, possible formation of, **57:362–365**  
     hyperconversion mechanism, **57:358–361**  
     recombination models, **57:362–365**  
   cytokine  
     cloning and expression, **58:425–427**  
     in tumor cell engineering, **57:321–323**  
     upregulated by NF- $\kappa$ B, **58:10–12**  
   in DSB repair and V(D)J recombination, **58:45–55**  
   in GPI anchor synthesis, **60:67–74**  
   heavy chain, assembly of, **40:252–253**  
   in hematopoietic cells, **60:23–25**  
   of human  $\kappa$  light chains, **40:249–251**  
   IL-2, localization, human, **39:5, 18**  
   IL-3, localization, murine, **39:7–8, 18**  
    $\lambda$  light chain, **40:251–252**  
   lymphocyte, function, **62:31–53**  
   *mb-1*, genomic structure, **54:355**  
   MHC, *see* Major histocompatibility complex  
   natural and artificial mutations, **58:90–101**  
   NF- $\kappa$ B-responsive, **58:5–6**  
   non-MHC-linked, **51:293–294**  
   oncogenes, *see* Oncogene  
   perforin, **60:291–294**  
   RA susceptibility-associated, alleles, **56:441–446**

- suicide, **58**:428–429  
 transgenes, *see* Transgene
- Gene silencer, TCR $\gamma$ , **58**:120
- Gene splicing, adhesion molecules, **64**:167
- Gene targeting  
 Elf-1 protein, **64**:92  
 Ets-1 protein, **64**:81–82  
 Ets protein, **64**:84–85  
 Fli-1 protein, **64**:90  
 GABP $\alpha$  protein, **64**:94  
 PU.1 protein, **64**:86–87  
 Spi-B protein, **64**:88  
 ternary complex factor, **64**:94
- Gene therapy, X-linked agammaglobulinemia, **59**:150–151
- Genetically engineered antibodies, **38**:304–306; **44**:65, 66, 89  
 antigen-combining sites, **44**:84, 85  
 biological properties, **44**:82, 83  
 chimeric antibodies, **44**:79–82, 87, 88  
 cloning, **44**:73–75  
 domain structure, **48**:14, 16, 22  
 expression, **44**:75–79  
 expression vectors, **44**:70–72  
 fusion proteins, **44**:85, 86  
 lymphoid mammalian cells, **44**:69, 70  
 production  
   in bacteria, **44**:66–69  
   in yeast, **44**:69  
 segmental flexibility, **48**:14, 16, 22  
 surface Ig, **44**:89
- Genetic chimerism, **59**:106, 109–111, *see also* Chimerism
- Genetic defects, in B lineage cells leading to autoimmune disease, **53**:144–147
- Genetic drift, *Ir* genes, **38**:87, 148
- Genetic mapping  
 autoimmune demyelinating disease and, **49**:369  
 CD1 loci, **59**:4–5  
 CD23 antigen and, **49**:156, 165–166  
 Ig heavy-chain variable region genes and, **49**:1, 29, 55  
   organization, **49**:3–4  
   V<sub>H</sub> families, **49**:18, 20–21  
 IL-2R genes, **59**:226, 227  
 V<sub>H</sub> locus, **62**:4–7  
 Xid mutation, **59**:175  
 XLA gene, **59**:163–165, 194–195
- Genetic maps, Ig-like loci, **46**:1–3  
 chromosomal locations, **46**:6, 7  
 mechanisms, **46**:45–47  
 methods, **46**:3–6  
 MHC, **46**:28  
   human HLA, **46**:30–34  
   mouse H-2, **46**:28–30  
 structure, **46**:7  
   human  $\kappa$  chain, **46**:15–19  
   human  $\lambda$  chain, **46**:10–12  
   human heavy chain, **46**:24–28  
   mouse  $\kappa$  chain, **46**:12–15  
   mouse  $\lambda$  chain, **46**:8–10  
   mouse heavy chain, **46**:19–24
- T cell receptor, **46**:34, 35  
 $\alpha$ -chain, **46**:41–45  
 $\beta$ -chain, **46**:35–37  
 $\gamma$ -chain, **46**:38–41  
 $\delta$  chain, **46**:42, 43, 45
- Genetic mosaicism, X-chromosome, **59**:159, 195
- Genetic recombination, *see* Recombination
- Genetics  
 adoptive T cell therapy of tumors and, **49**:283, 297  
 aPL antibodies and, **49**:222, 255  
 B cell progenitors, **59**:152  
*Btk* gene, **59**:170–176, 184, 196  
   mutations, **59**:185–192, 195, 317  
 CD1 family, **59**:2–10  
 CD23 antigen and, **49**:162  
 and diabetes, **51**:290–294  
   MHC-linked diabetogenic genes, **51**:290–293  
   non-MNC-linked genes, **51**:293–294  
 gene inactivation, **59**:108  
 gene knockouts, **59**:116–118, 124, 128  
 reconstitution, IL-2 receptors, **59**:231–234, 254  
 rheumatoid arthritis susceptibility studies  
   family, **56**:433–435  
   female sex, **56**:434  
   number of genes, **56**:434–438  
   twins, **56**:433–435, 446–449  
 somatic cell  
   complement components and, **38**:204, 233  
   human B cell neoplasia and, **38**:247

- Genetics (*continued*)  
 maternally transmitted antigen and,  
**38:320**  
 spontaneous autoimmune thyroiditis and,  
**47:481–491**  
 transgenes, **59:107–108, 113–116, 124–127**  
 X-linked agammaglobulinemia, **59:161–176, 187, 193–194**
- Gene transfer  
 as cancer therapy, **58:417–454**  
 for CD4/CD8 coreceptor function,  
**53:70–78**  
 retroviral-mediated, **58:437–438**  
 techniques, **58:422–425**
- Genome  
*c-kit*, organization of, **55:7–9**  
 stem cell factor, organization of, **55:13–15**
- Genomic mapping, *see* Genetic mapping
- Genomic organization  
 T cell receptor protein and, **38:7**  
 TCR  $\delta$  gene segments, **43:155–156**
- Genomic structure, CD23 antigen and,  
**49:165–167**
- Genotype, autoimmune demyelinating disease  
 and, **49:364, 366**
- Geographic distribution  
*PfPR*-A mutations, **60:81, 87**  
*Plasmodium vivax* malaria, **60:122**  
 PNH, **60:74**
- Germ cells, development, stem cell factor  
 receptor effect on, **55:66–69**
- Germinal center cells, **62:146–148, 150**
- Germinal center reaction, responses to  
 thymus-dependent antigens, **60:272–276**
- Germinal centers  
 B cell censoring, **59:331–341**  
 development, **52:224–225**  
 diversification, **60:283–284**  
 formation, CD40 and, **63:72**  
 and memory B cells, **53:231–233**  
 normal, regulation of by FDCs,  
**51:263–274**  
 apoptosis, inhibition of, **51:272–274**  
 binding via cell-cell and cell-matrix  
 adhesion molecules, **51:269–271**  
 cytokines, induction of, **51:274**  
 formation of, **51:243–244**  
 requirements of FDC's for ontogeny of  
 germinal center, **51:263–265**  
 secondary immune response, regulation  
 of, **51:271–272**  
 trapping of immune complexes and  
 alternative antigen pathway,  
**51:265–269**  
 ontogeny, requirement of FDCs for,  
**51:263–264**  
 pathways of cell differentiation,  
**53:232–233**  
 phenotypic selection, **60:280**  
 polarization, **60:271–272**  
 requirements of FDC's for ontogeny of,  
**51:263–265**  
 somatic hypermutation in, **53:233–234**
- Germline  
*C<sub>H</sub>* transcription, **54:240–245**  
 counterparts, Ig heavy-chain variable region  
 genes and, **49:25**  
 genes  
*V<sub>H</sub>* segment, **42:113–115**  
*Vk10* family, **42:144–148**  
 sequences  
 Ig heavy-chain variable region genes,  
**49:27**  
*J558 V<sub>H</sub>* gene, **42:127–128**  
*V<sub>H</sub>* segments, **62:1–26**  
 VL, sequence comparison, **48:55**
- Germline mutational approach, **62:31, 34–36**
- Germline transcripts  
 CD40 signaling, **61:92–98**  
 class switching, cytokines, **61:84–85**  
*I $\mu$*  transcripts, **61:106–107**  
 regulation of transcription, **61:89–90**  
 structure and function, **61:89**  
 switch recombination, **61:111–116**
- GF109203X, **63:155**
- GFA, *see* Granulocyte functional antigen
- GH-N gene, **63:384–385**
- Glial cells, retinal, T helper lymphocyte,  
**48:218**
- Glial growth-promoting factor, **48:173**
- Glioblastoma cells, immunological mediator,  
**48:168–169**
- Glutathione, **65:126–127**
- Globular protein antigens, synthetic T and B  
 cell sites and, **45:203–216, 240**
- Glomerulonephritis, **61:46, 245**  
 florid, **59:343**  
 membranoproliferative, **61:245**  
 mesangial proliferative, and IL-6, **54:41**

- Glucagon, spontaneous autoimmune thyroiditis and, **47:440**
- $\beta$ -Glucan receptor, phagocytosis and alternative complement pathway activators, **38:285, 386**
- fibronectin, **38:390**
- particulate activators, **38:381, 382, 393**
- zymosan
- by human monocytes, **38:362, 363, 365–372, 374–376, 392**
  - by nonelicited murine macrophages, **38:377, 379, 380**
- $\alpha$ -Glucans
- alternative complement pathway, **38:384–386**
  - phagocytosis, **38:366–368, 381**
- Glucocorticoid-inducing factors, spontaneous autoimmune thyroiditis and, **47:477–479, 488**
- Glucocorticoid receptors
- and antigen-driven T cell deletion, **58:258–260**
  - interaction with NF-IL6, **65:21–22, 23**
  - linomide effects, **58:264–265**
  - NF- $\kappa$ B and, **65:118–120**
  - and T cell fate determination, **58:137–138**
- Glucocorticoid response element, **65:22**
- Glucocorticoids, **62:259; 65:21, 22, 23**
- cachectin and, **42:221**
  - CD5 B cell and, **47:145**
  - CD23 antigen and, **49:154, 160–161**
  - effect on CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58:166–170**
  - IgE biosynthesis and, **47:24**
  - immune system and, **66:197, 218**
  - induced thymocyte apoptosis, **58:245–246**
  - mode of action, **64:172**
  - NF- $\kappa$ B and, **65:118–120**
  - spontaneous autoimmune thyroiditis and, **47:493, 494**
  - disturbed immunoregulation, **47:476, 477–479, 480**
  - genetics, **47:488, 489**
  - T cell death and, **58:227–228, 269**
  - treatment with
    - asthma and hypereosinophilic syndrome, **60:222–224**
    - eosinopenia ascribed to, **60:227**
    - in vitro* IgE synthesis, **61:370–371**
- Glucosamines, and GlcNAc, in GPI-anchored proteins, **60:60–72**
- Glucose, membrane attack complex of complement and, **41:300**
- $\gamma$ -Glutamyl transpeptidase, LTC<sub>4</sub> conversion to LTD<sub>4</sub>, **39:152–153**
- Glutaraldehyde
- in crosslinkage procedure for chemoimmunoconjugates in cancer treatment, **56:315**
  - T cell subsets and, **41:53**
- Gluten-derived peptide, celiac disease, **48:147–148**
- Gluten enteropathy, *see* Celiac disease
- GlyCAM-1, **64:149, 168**
- lymphocyte-HEV interaction, **65:361–362, 363, 364, 373, 377**
  - as selectin ligand, **58:359**
- Glycans, CTL and, **41:152, 153**
- Glycogen, cell-mediated killing and, **41:287**
- Glycolipid anchor, GPI, **60:57–74**
- Glycolipids
- aPL antibodies and, **49:228–230, 239, 255**
  - cell surface, **52:393–394**
  - membrane attack complex of complement and, **41:301**
  - surface antigens of human leukocytes and, **49:111**
- $\beta$ -Glycoprotein, complement receptor 1 and, **46:184, 185**
- $\beta$ -2-Glycoprotein-1, aPL antibodies and, **49:240, 247, 252, 256–257, 259**
- Glycoprotein antibodies, phase I clinical trials, **40:366–370**
- Glycoprotein antigens
- biosynthesis and intracellular transport, **40:337–341**
  - immunochemical and molecular profiles, **40:328–337**
  - immunochemical profile, **40:326–327**
  - immunological characterization, **40:324–328**
  - preclinical models for immunotherapy
    - in vitro* studies, **40:341–345**
    - in vivo* reactions in animal model systems, **40:345–351**
- Glycoproteins
- adoptive T cell therapy of tumors and, **49:320**
  - antigen-presenting cells and, **47:92**
  - aPL antibodies and, **49:239–240, 255–256, 259**

Glycoproteins (*continued*)

- autoimmune thyroiditis and, **46:267, 270**
- B cell formation and, **41:189–193, 227**
- CD4 molecules and, **44:265, 285, 295, 297**
- CD5 B cell and, **47:118, 146**
- CD23 antigen, **49:149, 155, 158**
- complement receptor 2 and, **46:203, 205, 210**
- CTL and, **41:152**
- HIV and SIV, envelope variation, **52:451**
- HIV infection and, **47:378, 395**
  - immune response, **47:405, 407–409**
- human T cell activation and, **41:2, 4, 8**
- humoral immune response and, **45:42**
- hybrid resistance and, **41:378, 403**
- Ig gene superfamily and, **44:39, 40, 42**
- IL-1 and, **44:165, 166**
- leukocyte integrins and, **46:149, 151, 153**
  - ligand molecules, **46:171, 172**
  - structure, **46:157, 159**
- lymphocyte homing and, **44:317, 341, 350, 365, 369**
- maps of Ig-like loci and, **46:34**
- myelin-associated, *see* Myelin-associated glycoprotein
- NK cells and, **47:298**
  - antimicrobial activity, **47:286, 287**
  - effector mechanisms, **47:237, 248**
  - morphology, **47:218**
  - surface phenotype, **47:207**
- regulators of complement activation and, **45:399, 400, 410**
- SCID and, **49:395**
- surface antigens of human leukocytes and, **49:112–114, 118, 125**
  - adhesion molecules, **49:82–88**
  - antigen-specific receptors, **49:76–78**
  - complement components, **49:93**
  - Igs, **49:90–91**
  - MHC glycoproteins, **49:80–82**
  - receptors, **49:94, 98, 100**
- synthetic T and B cell sites and, **45:225, 226, 255**
- T cell subsets and, **41:43, 44, 46, 49**
- virus-induced immunosuppression and, **45:350**
  - HIV, **45:361, 364–366**
  - measles, **45:339, 346**
- Glycosylation, **52:59–61**
  - aPL antibodies and, **49:256**
  - autoimmune thyroiditis and, **46:267, 271**
  - B cells and, **41:190, 192, 215**
  - CD4 molecules and, **44:285**
  - CD8 molecules and, **44:271, 273, 274, 277, 279**
  - CD23 antigen and, **49:156–158, 162–164**
  - complement components and, **38:218, 220**
  - complement receptor 1 and, **46:192**
  - complement receptor 2 and, **46:202, 204, 205**
  - CTL and, **41:135, 138, 152, 153**
  - cytotoxicity and, **41:272**
  - genetically engineered antibodies and, **38:304; 44:69, 76, 79, 80, 84**
  - humoral immune response and, **45:42**
  - IgE biosynthesis and, **47:16, 17, 20, 23, 25, 26**
  - Ig gene superfamily and, **44:35, 39**
  - IL-1 and, **44:179, 183, 194**
  - leukocyte integrins and, **46:154, 170, 174**
  - lymphocyte homing and, **44:342**
  - maternally transmitted antigen and, **38:331**
  - patterns, cell-type specific, **54:314**
  - regulators of complement activation and, **45:400–403**
  - surface antigens of human leukocytes and, **49:93, 99, 113**
  - T cell development and, **44:233**
  - T cell receptor proteins, **38:4, 5, 10, 18**
  - T cell subsets and, **41:41, 50**
- Glycosylation-enhancing factor, IgE
  - biosynthesis and, **47:32, 36, 38**
  - binding factors, **47:23, 25, 26, 27**
- Glycosylation-inhibiting factor, IgE
  - biosynthesis and, **47:32–39**
  - binding factors, **47:23–27**
- N-Glycosylation sites, PGHS, **62:173–174**
- Glycosylphosphatidylinositol
  - anchor
    - core backbone, **60:60–61**
    - post-translational modification by, **60:65**
  - anchored proteins, **60:57–74, 79**
  - anchor precursor, biosynthesis, **60:63–65**
  - anchor synthesis
    - defective, **60:78–80**
    - genes, **60:67–74**
  - hydrolysis, signal transduction, **59:264–265**
  - signal transduction, **59:264–265**
  - surface antigens of human leukocytes and, **49:75, 93–94, 112, 116, 125**

- Glycosylphosphatidylinositol activation antigen, **48**:237–241
- Glycosyltransferase, *Ir* genes and, **38**:94
- Glycyrrhizin, **64**:196
- GM2, **62**:219
- GM3, **62**:219
- GM-CSF, *see* Granulocyte–macrophage colony-stimulating factor
- Goitrous thyroiditis, **46**:284
- Gold compounds, action of as rheumatoid arthritis treatment, **65**:124
- Golgi apparatus  
cytolysis and, **41**:275, 281, 282  
lymphocyte homing and, **44**:317, 320, 360  
NK cells and 214, **47**:216, 303  
T cell subsets and, **41**:57
- Gordon phenomenon, induction by EDN, animal, **39**:198–199
- Gout, inflammation in, **66**:260
- Gp, activation, **43**:290
- gp33  
covalent association of TCR $\beta$  protein, **58**:150  
gene, cloning, **58**:145
- gp39  
B cell proliferation, **63**:54  
CD40-dependent B cell activation, **63**:56–57  
cloning, **63**:46–48  
expression, **63**:44, 48  
gene, hyper-IgM syndrome, **63**:49–50  
identification, **63**:46  
molecular structure, **63**:48–49  
structure, in hyper-IgM syndrome, **63**:49–50
- gp39–CD8 fusion protein, **63**:65
- gp48, **64**:116–117, 128
- gp75, **62**:229, 236–237
- gp96, **62**:244
- gp100, **62**:229, 235–236
- gp120  
binding by eosinophils, **60**:187  
CD4-binding domain, **60**:138  
HIV infection, **63**:84  
induction of NO production, **60**:353–354  
V3 loop, **60**:131–134
- gp130, **66**:127–128  
and high-affinity OSM/LIF receptor, **53**:43  
IL-6-related cytokines and, **64**:256
- GPI, *see* Glycosylphosphatidylinositol
- GPI-H*, **60**:72–73
- GPL, aPL antibodies and, **49**:203–204
- G proteins, *see also* Coupling proteins  
in chemokine activation of integrin, **58**:379  
coupling to chemokine receptors, **55**:138–139  
CTL and, **41**:154  
phosphoinositide-specific phospholipase, **48**:266  
role in IgR-mediated signaling, **54**:364–365  
role in phosphoinositide hydrolysis, **43**:291–292
- SCID and, **49**:386  
surface antigens of human leukocytes and, **49**:76, 98, 111
- T cell, **48**:267–269
- T cell antigen receptor-CD3 complex, **48**:306–307
- Graft bed, corneal allograft  
afferent blockade theory, **48**:195–196  
avascular, **48**:195  
graft location, **48**:195  
host cellular component, **48**:195  
orthotopically placed, **48**:195
- Graft rejection  
adoptive T cell therapy of tumors and, **49**:301, 305, 328  
antiadhesion therapy, **64**:197  
hybrid resistance and  
antigen expression, **41**:404–407  
bone marrow cells, **41**:344, 350  
effector mechanisms, **41**:370, 371  
antibodies, **41**:376, 378  
marrow engraftment, **41**:385, 388  
NK cells, **41**:375  
syngeneic stem cells, **41**:390
- IL-5 role, **57**:177
- lymphocyte dependence, **64**:192
- SCID and, **49**:397
- Grafts, *see also specific type*  
autoimmune thyroiditis and, **46**:286, 287  
hybrid resistance and  
antigen expression, **41**:397, 399, 401, 402, 404–407, 410  
bone marrow cells, **41**:336–351  
effector mechanisms antibodies, **41**:376, 377  
macrophages, **41**:371  
marrow, **41**:384–388, 390



- Grafts (*continued*)
- NK cells, **41:373–375**
  - in vitro* assays, **41:393, 395**
  - leukemia/lymphoma cells, **41:362, 364–367**
  - lymphoid cells, **41:352–355**
  - syngeneic stem cell functions, **41:388, 390**
  - liver cell, hybrid resistance and, **41:333**
  - in MHC class I-deficient mouse
    - hematopoietic cell, **55:388**
    - liver cell, **55:391**
    - pancreatic islet, **55:390**
    - skin, **55:388–390**
- Graft-versus-host disease, **59:420–426**
- acute
- clinical manifestations, **40:397**
  - pathologic manifestations and pathogenesis, **40:397–399**
  - prevention, **40:403–406**
  - prognostic factors, **40:399–402**
  - treatment, **40:402–403**
- autoreactive T cells and, **45:432**
- cachectin and, **42:220**
- CD5 B cell and, **47:129, 130**
- CD40-L expression, **61:47**
- hematopoietic engraftment and
- acute, **40:397–406**
  - chronic, **40:406–410**
  - pathogenesis, **40:395–396**
- hybrid resistance and
- antigen expression, **41:403**
  - bone marrow cells, **41:335, 336, 340, 350**
  - leukemia/lymphoma cells, **41:360, 367**
  - lymphoid cells, **41:351–356**
  - marrow engraftment, **41:385–387**
  - T cells, **41:380**
  - in vitro* assays, **41:394**
- IFN- $\gamma$ , **62:101–103, 105**
- IL-1ra effects, **54:215**
- NK cells and, **47:231, 280–282**
- rat, in bone marrow transplantation, **39:280–281**
- idiotypic network and, **39:281**
- SCID and, **49:388, 391–395, 397–399**
- spontaneous autoimmune thyroiditis and, **47:455, 474, 482, 483**
- T cell subsets and
- cell surface molecules, **41:43**
  - H-2 alloantigen recognition, **41:83, 84, 86, 88, 92, 95**
  - H-2-restricted antigen recognition, **41:71, 72**
- Graft-versus-leukemia, **40:419–422**
- Gramicidin A, cytolysis and, **41:316**
- Granule proteins
- cell-mediated killing and cell lines, **41:286, 287**
  - cytoplasmic granules, **41:287–291**
  - lymphotoxin, **41:298**
  - membrane attack complex of complement, **41:310**
  - pore-forming protein, **41:291–297**
  - proteoglycans, **41:298, 299**
  - serine esterases, **41:297, 298**
  - TNF-related polypeptides, **41:298**
- eosinophil, **60:191–194, 205–208, 221**
- role in DNA fragmentation, **60:300–301**
- Granules
- eosinophil, **60:155–162, 191–194**
  - exocytosis
    - cytotoxicity and, **41:273, 281, 282**
    - model, **60:290–291**
- Granule-stored enzymes, **60:201**
- Granulocyte colony-stimulating factor, **48:72; 66:149**
- activation of Jaks, **60:7**
  - gene regulation, **65:28–29**
  - and GM-CSF, in immune response, **58:10–11**
  - sepsis and, **66:104, 149–150**
  - single receptor chain, **60:10**
- Granulocyte functional antigen, GFA-2 on eosinophils, parasite killing and, **39:184**
- Granulocyte-macrophage colony-stimulating factor, **42:221; 46:112, 115, 117, 122, 133; 48:71, 169; 54:174**
- and antitumor immunity, **58:429–432**
  - cellular sources of, **39:2, 3, 10–13**
  - and CR3 expression, **60:182–183**
  - effect on genetically modified cells, **58:427**
  - eosinophil-derived, **60:196–197**
  - eosinophil proliferation, **48:75**
  - expressing tumor cells, **58:438**
  - factor-dependent mast cell production of, **53:8–9**
  - functions, **39:2–3**
  - and G-CSF, in immune response, **58:10–11**

- GM-CSF/IL-3/IL-5 subfamily, **61**:151, 166–167
- GMS/BCG vaccine, **62**:220
- IL-5, **48**:75
- production by T cells
- cyclosporin A-inhibited, **39**:13–14
  - dexamethasone-inhibited, **39**:14
  - mRNA accumulation and, **39**:14
- purification and properties, murine, **39**:9
- rheumatoid arthritis, **64**:319
- role in cytokine signaling, **60**:5
- sepsis and, **66**:150
- single gene-coded, human, murine, **39**:9–10
- transformed mast cell production of, **53**:4–6
- Granulocyte–macrophage colony-stimulating factor receptors, **52**:351; **63**:275, 276, 308
- expression by eosinophils, **60**:183–185
- Granulocyte–macrophage response, sequential nature, **48**:70
- Granulocytes, **48**:69
- B cells and, **41**:238
  - B cell precursors, **41**:191, 195
  - bone marrow cultures, **41**:209, 210, 219
  - genetically determined defects, **41**:229, 230
  - cell-mediated killing and, **41**:312
  - colony-stimulating factor, **48**:75
  - helper T cell cytokines and, **46**:115, 117
  - hybrid resistance and, **41**:336, 370, 380
  - IL-4, **48**:75
  - IL-6, **48**:75
  - leukocyte integrins and, **46**:151, 161–163, 166
  - leukocyte surface antigens and, **49**:88, 90, 93, 111–112, 116
  - nonrecirculating, **58**:350–351
  - opioid receptor, human, **48**:180
  - pituitary hormones, **63**:411–412
  - PNH, clonal origin, **60**:81
  - with two PNH clones, **60**:89
- Granuloma
- in Crohn's disease, **42**:297
  - oil, plasmacytomagenesis and, **64**:224–225
  - in pulmonary inflammation, **62**:280–283
- Granulopoiesis, hybrid resistance and, **41**:336
- Granzymes, **64**:1
- and apoptosis, **58**:226
  - as effector molecules in CTL cytotoxicity, **60**:300–301
  - or fragmentins, cytotoxic T cells containing, **58**:240
- Graves' disease, **62**:19
- autoimmune thyroiditis and, **46**:263
- Graves' ophthalmopathy
- antibodies to self-antigens from human donors, **57**:245
  - autoimmune thyroiditis and, **46**:268
- Grb2, **63**:143, 144, 146
- signal transduction, **59**:262
- GRB2, recruitment of ras exchange factor, **60**:13
- G reactive protein, NK cells and, **47**:246, 247
- Grooves, MHC molecules
- mutations, **58**:161
  - peptide antigens bound to, **58**:330
- Growth, B cells, and differentiation, *in vivo* aspects, **52**:221–230
- Growth arrest, and apoptosis induced by anti-IgM, **54**:410–411
- Growth factor receptor, **48**:253
- Ig gene superfamily and, **44**:30, 39
  - IL-1 and, **44**:180
- Growth hormone, **48**:172; **63**:379–380
- expression, **63**:386–388
  - gene regulation, **63**:400
  - gene regulation by, **65**:20
  - immune system, **63**:377–378
  - leukemia, **63**:428
  - lymphohemopoietic system, **63**:386–388, 431–432
  - macrophage, **48**:178
  - regulation, **63**:385–388
  - structure and physiology, **63**:384–385
- Growth hormone deficiency
- in humans, **63**:408–409, 432–433
  - X-linked agammaglobulinemia, **59**:149, 194
- Growth hormone receptor, **63**:396–401
- Growth hormone-releasing hormone, **63**:385
- GRs, *see* Glucocorticoid receptors
- GTP
- binding of ras, **60**:209
  - neutrophil activation and, **39**:99, 100, 116, 120, 121, 132
- GTPase
- G proteins and, **39**:112
  - in neutrophil activation, **39**:113–115

- GTP-binding protein, **43**:290  
 association with CD4-p56<sup>lck</sup> and CD8<sup>α</sup>,  
**53**:64–65  
 T cell signal transduction, **48**:265–269  
 GTPγS, **43**:292  
 Guanylyl cyclase, **62**:74  
 Gut, lymphokine production by isolated T  
 cells, **53**:167  
 Gut-associated lymphoid tissue  
 immunosenescence and, **46**:252, 253  
 rabbit  
 antibody repertoire generation role,  
**56**:180, 209  
 as bursal equivalent, **56**:180, 204  
 follicular structure, **56**:203  
 germfree rabbits, **56**:204–206  
 model, **56**:206–209  
 Gut-associated tissues, homing to,  
**58**:391–392  
 GVHD, *see* Graft-versus-host disease
- ## H
- 2H1, **48**:249–250  
 H-2 molecules  
 alloantigen recognition and, **41**:78  
 alloreactivity, **41**:78–83  
 antigen-presenting cells, **41**:88–92  
 effector phase, **41**:92–95  
 resting T cell subsets, **41**:83–88  
 antigen recognition and, **41**:51, 52  
 effector phase, **41**:75–77  
 T accessory molecule function, **41**:59–62  
 triggering of activated T cells and  
 hybridomas, **41**:52–59  
 triggering of unprimed and resting T  
 cells, **41**:62–75  
 B cell formation and, **41**:213  
 CTL and, **41**:136, 170  
 β<sub>2</sub>-microglobulin, **41**:155, 156  
 carbohydrate moieties, **41**:152–154  
 exon shuffling, **41**:138–148  
 HLA class I antigens, **41**:149, 152  
 monoclonal antibodies, **41**:156, 157, 166,  
 167  
 mutant strains, **41**:158–163, 165  
 cytotoxicity and, **41**:269, 279–281  
 hybrid resistance and  
 antibodies, **41**:376–378  
 antigen expression, **41**:397–404  
 bone marrow cells, **41**:336–348  
 leukemia/lymphoma cells, **41**:358–369  
 lymphoid cells, **41**:352–354  
 marrow engraftment, **41**:386–388  
 NK cells, **41**:375, 376  
 syngeneic stem cells, **41**:390  
 T cells, **41**:381–383  
*in vitro* assays, **41**:395, 396  
 T cell subsets and, **41**:40, 43–48  
 thymus, and, **41**:95, 96  
 development, **41**:96–99  
 restricted T cells, **41**:99–107  
 tolerance induction, **41**:107–110  
*Haemophilus influenzae*  
 pulmonary infection, **59**:396–397  
 type B, **38**:289, 295, 296, 302  
 Hageman factor, *see* Factor XII  
 Hairpin  
 defined, **64**:45  
 formation, **64**:55, 56–59  
 opening end, **64**:60  
 Hairpin resolution model, for P nucleotide  
 formation, **58**:36–38  
 Hairy cell leukemia  
 gene rearrangements and, **40**:291–292  
 leukocyte integrins and, **46**:151  
 Hairy leukemia, **54**:50–51  
 Ham1/2, **64**:4  
 HAM genes, **65**:49  
 Haplotype  
 aPL antibodies and, **49**:222  
 autoimmune demyelinating disease and,  
**49**:365, 368  
 autoimmune thyroiditis and, **46**:275, 279,  
 284–286, 319  
 complement components and, **38**:236  
 C4, **38**:220, 229–231  
 MHC, **38**:208  
 restriction fragment length  
 polymorphism, **38**:215, 216  
 CTL and, **41**:159  
 hybrid resistance and  
 antigen expression, **41**:397–399,  
 409  
 bone marrow cells, **41**:341, 343  
 leukemia/lymphoma cells, **41**:364  
 lymphoid cells, **41**:353  
 Ig heavy-chain variable region genes and,  
**49**:23

- Ir* genes and  
 antigen binding, **38**:114  
 antigen specificity, **38**:121, 122  
 complementation, **38**:72, 73, 79  
 gene function, **38**:91  
 Ia molecules, **38**:70–72, 83  
 I region mutations, **38**:84, 90  
 polypeptides, response to, **38**:46, 49  
 T cell, cytotoxic, **38**:161, 166, 185  
 T cell interactions, **38**:153, 157–159  
 T cell selection, **38**:131  
 T cell suppression, **38**:135, 138–140, 142–145, 149  
 tolerance, **38**:126, 128  
 maps of Ig-like loci and, **46**:32  
 maternally transmitted antigen and, **38**:318  
 class I antigens, **38**:333, 335, 336, 351  
 strain combinations, **38**:349  
 MHC, RA susceptibility associated with, **56**:438–446  
 murine lupus models and, **46**:99  
 Ig germline, **46**:66, 67, 69, 71, 72  
 T cell antigen receptor, **46**:84–86, 88, 90  
 T cell subsets and, **41**:47, 48, 78, 79, 102  
 Haplotype *b*, **48**:123  
 Haplotype *d*, **48**:123  
 Haplotype *k*, **48**:123  
 Hapten  
 augmentation, immunosenescence and, **46**:247, 248, 252  
 binding, **43**:17  
 CD8 molecules and, **44**:280, 282  
 derived T suppressor-inducer cell, **48**:212  
 genetically engineered antibody molecules and  
 antigen-combining sites, **44**:84, 85  
 chimeric antibodies, **44**:79–81  
 expression, **44**:79  
 fusion proteins, **44**:85  
 production, **44**:66  
 helper T cell cytokines and, **46**:120, 121  
 immunosenescence and, **46**:247  
*Ir* genes and  
 antigen binding, **38**:103  
 B cell responses, **38**:51  
 cytotoxic T cells, **38**:165  
 “Schlepper” experiment, **38**:39, 40  
 T cell activation, **38**:106, 107  
 T cells, **38**:41  
 pulmonary hypersensitivity, **59**:417–418  
 specific B cell tolerance, **54**:395–402  
 analysis with affinity-purified B cells, **54**:398–401  
 differential signaling via IgM and IgD, **54**:401–402  
 specific fragment cultures and limiting dilution, **54**:395–398  
 Hapten-carrier effect, humoral immune response and, **45**:3, 4, 6, 7  
 Haptotaxis, stem cell factor receptor-ligand interaction in, **55**:37–38  
 Hashimoto’s thyroiditis, **46**:263, 266, 317  
 antigens, **46**:268, 269, 271–275  
 cellular immune responses, **46**:287–291, 293  
 genetic control, **46**:284  
 humoral 298-301, **46**:303, 305, 306  
 Hay fever, IgE biosynthesis and, **47**:1, 28  
 H-CAM, multiple myeloma and, **64**:247, 248  
 Heart, myxoma, and IL-6, **54**:39–40  
 Heart disease  
 coronary, dietary fish oil and, **39**:145–146  
 eosinophil degranulation and, **39**:226  
 eosinophil localization and, **39**:226–227  
 Heat-shock proteins, **62**:78, 244  
 antinuclear antibodies and, **44**:90, 96, 109, 132  
 hsp70, **62**:244  
 MHC class I peptide loading, **64**:128  
 mycobacterial, recognition, **58**:321–322  
 surface antigens of human leukocytes and, **49**:79, 82  
 Heat-stable antigen, for B and T cells, **53**:235–236  
 Heavy chain  
 allotypes, Crohn’s disease and, **42**:288  
 Ars A response and, *see* Arsonate idiotypic system, *A/J* mouse, molecular genetics  
 constant region gene order and class switching, **40**:257–258  
 genes, **48**:41  
 assembly of, **40**:252–253  
 expression, sequences upstream of Ig promoter, **43**:253–254  
 hypermutations, **60**:277–278  
 locus, **62**:1–26  
 mu heavy chain  
 allelic exclusion, **63**:2, 19–21

- Heavy chain (*continued*)
- B cell development, **63**:1-4, 11-15, 16-25, 31
  - ligand for PreB cell receptor, **63**:25-26
  - signal transduction through PreB cell receptors, **63**:26-29
  - surrogate, **63**:8, 25
- Heavy chain diseases, **64**:219, 220
- Ig gene defects in, **40**:305-306
- Heavy chain variable region, *see also* Variable region, gene expression
- Ars A response and, **42**:99-105, *see also* Arsonate idiotypic system, A/J mouse cross-reactive idiotype-positive molecules, **42**:109-110
  - kinetics, **42**:108-109
  - repetitive substitutions, **42**:110-111
  - serine, **42**:111-112
- Heavy chain variable region, genes, **43**:237-238; **49**:1-3, 61, 63
- and antibody repertoire generation in rabbit allotype, **56**:195
  - organization, **56**:188-191
  - preferential rearrangement, **56**:197-198
  - preferential selection, **56**:197-198
  - preferential use, **56**:195-196
- D-proximal genes, **49**:20-21
- D segments, **49**:28-33
- expression, *see* Variable region, gene expression
- J<sub>H</sub> segments, **49**:33-35
- ontogeny, **49**:2, 33, 36-39, 41, 57
  - organization, **49**:3-6
  - polymorphism of V<sub>H</sub> gene segments, **49**:21-28
- promoter, **43**:238
- activation, **43**:243
  - conserved octanucleotide and activity, **43**:252-253
  - enhancer independence and dependence, **43**:265-266
- regulation, **49**:52-54
- enhancer elements, **49**:56-62
  - promoter elements, **49**:54-56
- V<sub>H</sub> families, **49**:6-8
- V<sub>H</sub> gene expression, **49**:35-36, 51-52
- autoantibodies, **49**:41-51
  - B cell malignancies, **49**:39-40
  - ontogeny, **49**:36-39
  - V<sub>H</sub>I genes, **49**:5-9, 11, 14-15, 61
    - expression, **49**:37, 40, 42-43, 47, 49
    - polymorphism, **49**:22-23, 27
  - V<sub>H</sub>II genes, **49**:6-9, 11, 61
    - expression, **49**:37, 40, 42, 50
    - polymorphism, **49**:22-23, 27
  - V<sub>H</sub>III genes, **49**:5, 7-9, 11-15, 61
    - expression, **49**:37-38, 40, 42-43, 48
    - myasthenia gravis, **49**:50-51
    - polymorphism, **49**:22-27
    - regulation, **49**:58-61
  - V<sub>H</sub>IV genes, **49**:5, 11, 14-17, 61, 63
    - expression, **49**:38, 40, 42-43, 47-51
    - polymorphism, **49**:26-27
  - V<sub>H</sub>V genes, **49**:4, 17-19, 61
    - expression, **49**:40, 50
    - polymorphism, **49**:26-27
  - V<sub>H</sub>VI genes, **49**:4-5, 19-20, 61
    - expression, **49**:37-38, 40, 42
    - polymorphism, **49**:26, 28
  - YH families, **49**:6-11, 14-20
- Helioglossomites polygyrus*, **54**:94
- Helix, movement, **43**:104
- Helix-loop-helix oncogenes, in chromosome translocations, **50**:129-130
- Helminth infections
- eosinophil role, **60**:210-216, 227-228
  - IL-5 role, **57**:176-177
  - multiple antigen peptides as immunogens, **60**:124-128
- Helper T cells, *see* T helper cells
- Hemagglutinin
- lymphocyte homing and, **44**:354, 355, 363
  - spontaneous autoimmune thyroiditis and, **47**:435, 445, 488, 489
  - sporozoite malaria vaccine and, **45**:307
  - synthetic T and B cell sites and
    - peptides, **45**:241, 242
    - vaccine, **45**:253-255
    - viral antigens, **45**:216, 219
  - T cell receptor and, **45**:122, 125, 133, 135
  - T cell subsets and, **41**:57
  - virus-induced immunosuppression and, **45**:346
- Hematopoiesis, **48**:83-84
- B cell formation and, **41**:181, 182, 235-238
  - B cell precursors, **41**:188, 191, 196, 197, 200, 201
  - bone marrow cultures, **41**:208-210, 212, 214, 215, 217, 219, 220

- genetically determined defects, **41:224**,  
225, 228, 229, 231, 232
- inducible cell line, **41:220**, 221, 223
- lymphohemopoietic tissues, **41:185–188**
- soluble mediators, **41:233**
- B cell genesis, **63:203–211**
- cachectin and, **42:224**
- CD44 activation states, **54:306**
- by CD44-specific antibodies *in vitro*,  
inhibition, **54:299–300**
- IFN- $\gamma$  and, **62:92–93**
- IL-6 effects, **54:22–25**
- LIF role, **53:35–36**
- NK cells and, **42:182**, 183
- physiological experiments implying role for  
CD44, **54:296–302**
- pituitary hormones, **63:404–405**
- stem cell factor receptor effect on,  
**55:43–48**
- transcription factors, **63:216–250**
- vav, **63:142**
- Hematopoietic cells
- CD23 antigen and, **49:150**, 169
- CD44 expression, **54:291–296**
- during hematopoietic development in  
mouse and human, **54:291–294**
- on memory T cells and activated T cells,  
**54:294–296**
- cell lines, IL-2 $\alpha$  and  $\beta$ , **61:150**
- gene regulation by Stat proteins, **60:23–25**
- grafts, in MHC class I-deficient mouse,  
**55:388**
- helper T cell cytokines and, **46:115–117**
- HIV infection and, **47:395**
- hybrid resistance and
- antigen expression, **41:400**, 403,  
405–407, 410
- bone marrow cells, **41:335–351**
- effector mechanisms, **41:369**, 370
- macrophages, **41:371**, 372
- marrow engraftment, **41:385–388**
- marrow microenvironment, **41:391**,  
392
- NK cells, **41:373**, 374, 376
- syngeneic stem cell functions,  
**41:388–390**
- T cells, **41:380**
- in vitro* assays, **41:396**
- leukemia/lymphoma cells, **41:361**, 363
- Ig gene superfamily and, **44:30**
- induction of positive selection, **58:164–165**
- leukocyte integrins and, **46:160**, 166
- NK cells and, **47:187**, 198, 303
- differentiation, **47:233**
- effector mechanisms, **47:235**
- malignant expansion, **47:228**
- surface phenotype, **47:201**, 212
- normal, **54:304–305**
- phosphatase, **63:165**
- role in cytokine signaling, **60:25–26**
- T cell development and, **44:215**, 226, 250,  
254
- TGF- $\beta$  effect on, **55:186–187**
- Hematopoietic engraftment, **40:382–383**
- engraftment of HLA-incompatible marrow,  
**40:386–387**
- experimental studies of transfusion effects,  
**40:386**
- facilitation of engraftment by T cells,  
**40:391–392**
- graft rejection in patients receiving T cell-  
depleted marrow, **40:389–391**
- graft rejection in patients transplanted for  
aplastic anemia, **40:383–385**
- marrow graft resistance, **40:387–389**
- reconsideration of marrow graft failure in  
humans, **40:392–395**
- Hematopoietic growth factor receptor  
superfamily, **52:340–351**
- granulocyte-macrophage colony-stimulating  
factor receptor, **52:351**
- IL-2 receptor, **52:342–343**
- IL-3 receptor, **52:343–349**
- IL-4 receptor, **52:349–350**
- IL-5 receptor, **52:350–351**
- Hematopoietic progenitors
- CD40 expression, **61:12**, 39
- IL-6 effects, **54:22–23**
- Hematopoietic stem cells
- immunosenescence and, **46:240–247**
- murine lupus models and, **46:64**, 65
- mutants, **60:90–91**
- SCID and, **49:382**, 385
- engraftment, **49:388–391**
- lack of engraftment, **49:396–397**
- transplantation with T cell-depleted bone  
marrow, **49:394**
- Hematopoietic system, **54:83–84**
- receptor superfamily, **54:82–83**

- Hematopoietic tumors, stem cell factor role  
in etiology of, **55:72–74**
- Hemidesmosomes  
pemphigoid antigen localization,  
**53:297–300**  
ultrastructure diagram, **53:297**
- Hemodialysis, therapeutic regulation of  
complement system in, **56:278–279**
- Hemolysis, cell-mediated  
cytolytic proteins and, **41:317, 318**  
cytoplasmic granules, **41:288–290**  
membrane attack complex of complement  
and, **41:299, 305, 306, 309**  
membrane damage and, **41:279**  
pore-forming proteins and, **41:291, 293,**  
**295, 296**  
proteoglycans and, **41:299**
- Hemolytic anemia, **59:146–147, 343**  
in PNH, **60:74–75**
- Hemolytic overlay, **38:208**
- Hemophiliacs, HIV-infected, **65:291–292**
- Hemopoiesis, *see* Hematopoiesis
- Hemopoietic growth factor receptor  
granulocyte-macrophage colony-stimulating  
factor receptor, **52:351**  
superfamily, HRS, **52:340–351**
- Hemopoietin I, B cell formation and, **41:234**
- Hen egg lysozyme, synthetic T and B cell  
sites and  
globular protein antigens, **45:204, 211–214**  
peptides, **45:240**
- Hen egg lysozyme model, clonal anergy,  
vindicated, **52:305–311**
- Heparin  
aPL antibodies and, **49:223, 240, 256**  
cell-mediated killing and, **41:295, 299**  
hybrid resistance and, **41:371**  
leukocyte integrins and, **46:159**  
SCID and, **49:395**  
surface antigens of human leukocytes and,  
**49:88**  
in therapeutic complement inhibition,  
**56:287–288**
- Hepatic growth factor, **64:153**
- Hepatitis, **59:68, 150**  
chronic infection, effector cell role,  
**60:345–346**
- Hepatitis B virus  
antibodies from combinatorial libraries,  
**57:220**  
C/EBP and, **65:10**  
MAP immunogenicity, **60:128–130**  
rabbit, anti-Id antibodies as vaccines  
against, **39:283**  
synthetic T and B cell sites and, **45:196,**  
**261, 263**  
bacterial antigens, **45:230**  
globular protein antigens, **45:206, 212,**  
**214**  
immunological considerations, **45:201,**  
**202**  
peptides, **45:202, 239, 242, 243**  
vaccine, **45:254–256**  
viral antigens, **45:220, 221, 224**
- Hepatitis virus, helper T cell cytokines and,  
**46:129**
- Hepatocyte growth factor, effects on  
lymphocytes, **58:379–380**
- Hepatocytes  
acute-phase protein synthesis, **54:25–27**  
grafts in MHC class I-deficient mouse,  
**55:391**  
helper T cell cytokines and, **46:116**  
IL-1ra production, **54:188**  
iNOS production, **60:351–352**  
interaction with IgA, **40:171, 177–184**  
leukocyte integrins and, **46:162**  
T cell activation and, **41:16**
- Hepatocyte-stimulating factor  
IL-1 and, **44:165**  
and IL-6, **54:4**
- Hepatocyte-stimulating factor III, *see*  
Leukemia inhibitory factor
- Hepatoma, adoptive T cell therapy of tumors  
and, **49:301, 305**
- HER-2/*neu*, **62:223–224, 237–238**
- Hereditary angioedema, **61:206**  
contact activation and, **66:239**  
kinin formation in, **66:257–258, 259**
- Hereditary primary immunodeficiency  
disorders, gene defects in Ig and T cell  
receptor, **40:306–309**
- HERMES-3, **65:360**
- Hermes antigen, mediating PLN adhesion,  
**54:296–298**
- Herpes simplex virus, **41:153, 375, 376**  
cytotoxic T cells and, **65:279**  
ocular infection, **48:208–210**  
regulators of complement activation and,  
**45:409, 410**

- synthetic T and B cell sites and, **45:225**,  
243, 256
- T cell receptor and, **45:132**
- thymidine kinase gene, **58:434**
- virus-induced immunosuppression and,  
**45:367**
- Herpes simplex virus type 1, **48:210**
- antibodies from combinatorial libraries,  
**57:222-227**
- intraocular infection, anterior chamber,  
**48:210**
- multiple antigen peptides, **60:130**
- Herpes simplex virus type 2, antibodies from  
combinatorial libraries, **57:222-227**
- Herpesvirus, *IL-10* gene acquisition,  
**56:11-12**
- Herpesvirus saimiri, and Epstein-Barr virus,  
**54:115-116**
- Herpesvirus type 6, human, and HIV-1,  
exacerbation of AIDS disease  
progression, **58:16**
- 5-HETE, *see* 5-Hydroxyeicosatetraenoic acid
- Heterogeneity
- autoimmune thyroiditis and, **46:274**, 281,  
300
- B cell formation and, **41:196**, 216, 217
- CTL and, **41:138**, 139, 152
- cytotoxicity and
- cell-mediated killing, **41:312**
- mediation, **41:271**
- membrane attack complex of
- complement, **41:305**, 306, 309, 310
- helper T cell cytokines and, **46:125**, 126
- hybrid resistance and, **41:372**
- leukocyte integrins and, **46:151**, 154, 174,  
175
- T cell activation and, **41:27**
- T cell subsets and, **41:43**, 79, 98
- Heterohybridoma antibodies, **38:288-290**,  
296
- Heterohybridomas, human-mouse, **38:300**,  
301
- Heterokaryons, hybridomas and, **38:287**, 291,  
302
- Heterozygosity, Ig gene superfamily and,  
**44:26**, 28, 29
- High endothelial binding factors, lymphocyte  
homing and
- carbohydrate, **44:364**, 370
- molecules, **44:344-346**, 349, 351
- High endothelial cells, lymphocyte homing  
and, **44:315**, 316, 318, 320
- High endothelial venules, **59:385**, 386;  
**62:257**; **64:142**; **65:379-380**
- binding assay, **64:185-186**
- flattening, **65:373**
- history, **65:347-348**
- lymph node, **58:353**, 359, 390-391
- lymphocyte binding to, role of CD44,  
**58:376-377**
- lymphocyte extravasation in, **58:347**
- lymphocyte homing and, **44:314**
- cell adhesion, **44:353-355**
- inhibition, **44:355-357**
- interaction, **44:318-322**
- ligands, **44:363-371**
- molecule attachment, **44:342-353**
- receptors, **44:357-363**, 369, 370
- regional Specificity, **44:322-330**,  
333-341
- structure, **44:315-318**
- lymphocyte migration and, **65:350-351**
- lymphocytes and, **64:142**; **65:352**
- addressins, **65:361-363**, 377-379
- adhesion, **65:365-372**
- CD34, **65:362-377**, 377
- CD44, **65:359-360**
- extravasation, **65:360**, 365-367
- GlyCAM-1, **65:361-362**, 363, 364, 373,  
377
- homing receptor ligands, **65:360-365**
- integrins, **65:352**, 358-359, 368-369,  
370
- MAdCAM-1, **65:352**, 359, 362-363, 367,  
370, 377, 379
- migration, **65:350-352**
- mucins, **65:360-361**
- selectins, **65:352**, 354-357, 363-365,  
367
- Sgp200, **65:362**, 377
- sugars, **65:360-361**, 363-365
- VAP-1, **65:365**
- in vitro* binding assay, **65:351-352**
- ontogenesis, **64:164-165**
- regulation, **65:372-375**
- differentiation, **65:377-379**
- immune response and, **65:375-377**
- rolling, **65:367**, 368
- structure of, **65:348-350**
- tethering, **65:367**



- High-molecular-weight kininogen  
 contact activation and, **66:236, 237**  
 endothelial cell receptor, **66:249–257**  
 inactivation, **66:245**  
 properties, **66:226, 256**  
 structure, **66:230–233**
- High-performance liquid chromatography,  
 complement receptor 1, **46:187**
- Hinge region  
 IgA molecules, **40:158**  
 structure, **48:11**  
 complement binding activity, **48:13, 15, 22**  
 Fab, **48:21–23**  
 Fc, **48:21–23**  
 segmental flexibility, **48:13, 15, 22**  
 upper part  
 complement activation, **48:25**  
 Fab motion, **48:25**  
 length, **48:25**  
 segmental flexibility, **48:25**
- Histamine  
 genetically engineered antibody molecules  
 and, **44:80**  
 IL-1 and, **44:164, 187**
- Histamine receptors, **52:402**
- Histamine release  
 basophil  
 major basic protein and, **39:191**  
 somatostatin and, **39:305–306**  
*basophil/mast cell*  
 clinical considerations, **50:250–254**  
 cytokines and histamine release,  
**50:247–248**  
 factors, **50:237**  
 modulation of histamine release by  
 cytokines, **50:248–250**  
 mast cell  
 major basic protein and, **39:191**  
 SP and, **39:305–306**
- Histamine releasing factor, **43:307**  
 cell sources, **50:243–244**  
 mechanism of action, **50:244–247**  
 purification, **50:238–243**
- Histidine, IL-1 and, **44:158, 181–182**
- Histiocytes, hybrid resistance and, **41:335**
- Histiocytosis, malignant, complicating celiac  
 disease, gene rearrangements and,  
**40:292–293**
- Histocompatibility antigen modifier gene,  
**65:49**
- Histocompatibility antigens, **38:382**  
 H-2 alloantigen recognition and, **41:82, 87**  
 H-2 molecules in thymus, and, **41:99, 100**  
 H-2-restricted antigen recognition and,  
**41:51, 57, 71–75**  
 hybrid resistance and, **41:333, 334, 350**
- Histocompatible bone marrow  
 transplantation, **49:392**
- Histones, antinuclear antibodies and  
 autoantibodies, **44:125, 127**  
 autoantigen, **44:128, 130**  
 drug-induced autoimmunity, **44:109, 110**  
 SLE, **44:95, 96, 98–100**
- Histoplasma capsulatum*, leukocyte integrins  
 and, **46:163**
- Histotope  
*Ir* genes and, **38:107**  
 T cell subsets and, **41:53, 58**
- HIV, *see* Human immunodeficiency virus  
 HIVEN86A, **48:298**
- HLA  
 autoimmune demyelinating disease and,  
**49:367**  
 class II molecules, **49:357, 362–363, 368–371, 374**  
 CTL and, **41:168, 170**  
 $\beta_2$ -microglobulin, **41:155, 156**  
 amino acid, **41:163–165**  
 carbohydrate moieties, **41:153**  
 exon shuffling, **41:138, 139, 141, 142, 144**  
 monoclonal antibodies, **41:158, 165, 167**  
 transfected cells, **41:149–152**  
 cytotoxicity and, **41:270**  
 human leukocyte antigen, oligosaccharide  
 mobility, **48:31**  
 hybrid resistance and, **41:350, 369, 400–403**  
 idiotypic network in responses to,  
**39:281–283**  
 matching, corneal transplantation, **48:193**  
 NK cells and, **47:198, 223**  
 polymorphisms, RA susceptibility associated  
 with  
 remission during pregnancy, **56:431**  
 testing, **56:432–433**  
 toxicity, **56:431–432**  
 population distribution, **48:126**

- rheumatoid arthritis, **48:126**  
 rheumatoid arthritis susceptibility  
   associated with  
     risk ratios, **56:439**  
     studies, **56:436–438**  
 rotational correlation times, **48:28–29**  
 SCID and, **49:392–393, 398**  
 type, IBD and, **42:288**
- HLA A1-B8-DR3, HIV progression to AIDS  
 and, **65:285**
- HLA-A2  
 allele  
   composition, **64:127**  
   MHC class I molecule peptide binding,  
   **64:126–127**  
 structure, **43:215**  
 synthetic T and B cell sites and, **45:219,**  
   **223, 234, 235**  
 T cell receptor and  
   alloreactivity, **45:150, 151, 153, 155, 156**  
   epitopes, **45:142, 144**  
   homogeneity, **45:129**  
   MHC molecules, **45:111, 112, 115, 116**  
   peptides, **45:137, 138**  
   polymorphic residues, **45:158, 160, 161**  
   structure-function relationships,  
   **45:139–141**
- HLA-A2.1, **62:234**
- HLA-A3, multiple sclerosis, **48:148–150**
- HLA-B7, multiple sclerosis, **48:148–150**
- HLA-B8, HIV and, **65:285**
- HLA-B27  
 HIV and, **65:285**  
 spondyloarthritic diseases, **65:94**
- HLA-B35, HIV progression to AIDS and,  
**65:285**
- HLA-B37, **65:286**
- HLA-B49, **65:286**
- HLA-B57, HIV and, **65:285**
- HLA class I  
 crystal structure, **48:111**  
 system  
   cytotoxic T cells and, **65:279**  
   HIV infection and, **65:284–286**
- HLA class II  
 allelic variability amino acid stretches,  
**48:111–112**  
 amino acid sequence, **48:108**  
 antigen recognition site, **48:111**  
 autoimmune disease associations, **66:67, 76,**  
   **84–85, 93**  
   immune intervention, **66:91–93**  
   insulin-dependent diabetes mellitus,  
   **66:91**  
   methimazole-induced insulin  
     autoimmune syndrome, **66:87–88**  
   multiple sclerosis, **66:88–91**  
   pemphigus vulgaris, **66:87**  
   rheumatoid arthritis, **66:85, 87**  
 biochemical typing, **48:114–116**  
 interisotypic association, **48:116**  
 intransisotypic hybrid molecule, **48:116**  
 trans-association, **48:116**  
 celiac disease, **48:144, 147**  
 disease associations, **48:107–153**  
 disease susceptibility, **48:108**  
 DP, **48:109, 110–111**  
 DQ, **48:109, 110–111**  
 DQ gene, **48:120–121**  
 DQ haplotype, **48:120–121**  
 DQ molecule, **48:120–121**  
 DR, **48:109, 110–111**  
 epitope, **48:112**  
   molecular localization, **48:152–153**  
 gene location, **48:109**  
 genes, **66:67**  
 gene structure, **48:109–112**  
 homologous, **48:109**  
 hybrid molecule, **48:119–126**  
   cell surface expression, **48:119**  
   stable heterodimer, **48:119**  
 ligands  
   class II-binding groove, **66:68–69**  
   class II-binding motifs, **66:69–77**  
   computational identification, **66:77–84**  
   HLA-DP and -DQ, **66:76–77**  
   HLA-DR, **66:70, 72–76**  
   pocket specificity profiles, **66:74–76**  
   quantitative matrices, **66:72–76**  
 molecules, **52:164–166**  
 interisotypic hybrid, **48:124–126**  
   transfected genes, **48:124**  
 other antigens of B cells, **52:173–174**  
   Bgp 95, **52:173**  
   CK226 antigen, **52:173**  
   IgM-binding protein (*Fcμ* receptor),  
   **52:173**  
 structure, **48:109–112**  
 synovial cell, **48:132**

- HLA class II (*continued*)  
 one-dimensional isoelectrofocusing,  
**48:114–116**  
 peptide binding motifs, **66:69–77**  
 structure, **66:68–69**  
 polymorphism, **48:109, 112–119**  
 serology, **48:112–114**  
 two-dimensional polyacrylamide gel  
 electrophoresis, **48:114–116**  
 silver staining, **48:116**  
 theoretical limitations, **48:116**  
 typing, **48:112–119**  
 Western blotting, **48:116**
- HLA-D  
 deletion mutants, **37:15–18**  
 function of, **37:63–65**  
 genes, **37:53–60**  
 invariant ( $\gamma$ ) chain, **37:50–53**  
 restriction fragment length polymorphism,  
**37:60–63**  
 supertypic specificity localization, **37:47–50**
- HLA-DP  
 biochemistry, **37:43–47**  
 serology/HTC, **37:14–15**
- HLA-DQ  
 B8, **48:134**  
 B15, **48:134**  
 biochemistry, **37:31–43**  
 DR4, **48:134**  
 homologous hybrid, **48:137**  
 serology, **37:9–14**
- HLA-DQ hybrid molecule, **48:119–124**  
 celiac disease, **48:147**  
 cell surface expression, **48:122**  
 disease susceptibility, **48:122**  
*trans*-complementation, **48:119–120**  
 transectants, **48:122**
- HLA-DR  
 aPL antibodies and, **49:222**  
 biochemistry, **37:23–31**  
 cachectin and, **42:224**  
 CD23 antigen and, **49:156, 170**  
 IBD and, **42:292–293**  
 serology/HTC, **37:5–9**
- HLADR3-DQ2, **65:286**HLA-DR5, **65:286**  
 HLA-DR13, **65:286**  
 HLA-D region, **48:108**  
 HLA-D region products, monoclonal  
 antibodies to, **37:18–21**  
 HLA-D region specificity, **48:113–114**
- HLA DR specificity, HLA D typing,  
**48:113–114**  
 HLA-Dw14, T cell clone reactivity, **48:129**  
 HLA factor, IDDM, **48:133–144**  
 HLA markers, MG and, **42:251**  
*hlx*, **63:240–241**  
*hlx*, B cell genesis, **63:239–241**  
*Hmt*, maternally transmitted antigen and,  
**38:315, 316**  
 antigenic variation, **38:342, 344**  
 class I antigens, **38:333, 336**  
 mitochondrial transmission, **38:347, 348**  
 phylogenetic considerations, **38:338**
- Hmt,101-104  
 nature of, **52:102**  
 nature of antigen presented by,  
**52:102–104**
- HNK-I, NK cells and, **47:291, 292**  
 CNS, **47:266**  
 differentiation, **47:234**  
 effector mechanisms, **47:257**  
 genetic control, **47:222**  
 hematopoiesis, **47:275**  
 malignant expansion, **47:226**  
 morphology, **47:218**  
 surface phenotype, **47:206, 207**  
 tissue distribution, **47:221**
- Hodgkin's disease, **38:299–301; 61:8, 12, 39**  
 gene rearrangements and, **40:294**  
 IL-5 mRNA expression in patients, **57:158**
- Holoricin-AChR conjugates, MG and, **42:265**
- Homeobox domain, Ig heavy-chain variable  
 region genes and, **49:55, 57**
- Homeodomain proteins  
*hlx*, **63:239–241**  
*hox11*, **63:244–245**  
*oct-2*, **63:243–244**
- Homeostasis, B cell formation and, **41:185,**  
**208, 236**
- Homing  
 to gut-associated tissues, **58:391–392**  
 leukocytes  
 integrins in, **58:362**  
 molecular basis, **58:389–390**  
 therapeutic drug development and,  
**58:395–396**  
 naive B cells, **58:350**  
 PLN, **58:390–391**  
 preferences, avian, **50:96–97**  
 skin, **58:392**

- tissue-specific, lymphocytes, endothelium and, **50:284–285**
- Homing receptors  
 surface antigens of human leukocytes and, **49:87–88**  
 tissue-specific, **58:316–318**
- Homodimerization,  $\beta$  cytoplasmic domains, **60:10**
- Homogeneity  
 B cell formation and, **41:221, 228**  
 cytotoxicity and, **41:270, 284, 287, 300**  
 hybrid resistance and, **41:338, 339**  
 T cell activation and, **41:13**  
 T cell receptor and, **45:128–131**
- Homologous recombination, **54:242**  
 gene inactivation, **59:108**  
 switch recombination, **61:110–111**
- Homologous restriction factor, **61:254–255, 257**  
 NK cells and, **47:252, 254**
- Homology  
 antinuclear antibodies and, **44:129**  
 autoimmune demyelinating disease and, **49:367**  
 CD4 molecules and, **44:285, 286, 288, 295, 302**  
 CD8 molecules and, **44:272, 276, 278, 302**  
 CD23 antigen and, **49:162–164, 166**  
 CTL and, **41:136**  
 $\beta_2$ -microglobulin, **41:154, 155**  
 exon shuffling, **41:140–142, 144–146**  
 monoclonal antibodies, **41:156, 158**  
 cytotoxicity and, **41:285, 307, 309, 314, 316**  
 genetically engineered antibody molecules and, **44:81**  
 human T cell activation and, **41:3**  
 accessory molecules, **41:14**  
 gene regulation, **41:29**  
 synergy, **41:17**  
 T cell antigen receptor, **41:4**  
 Thy-1, **41:10**  
 hybrid resistance and, **41:335**  
 Ig heavy-chain variable region genes and D segments, **49:29, 32–33**  
 polymorphism of  $V_H$  gene segments, **49:24, 26**  
 $V_H$  families, **49:8, 15, 17**  
 $V_H$  gene expression, **49:35, 39, 44–45, 48–51**  
 IL-1 and, **44:155–158, 167**  
 lymphocyte homing and, **44:346**  
 sequence and structural conservation during evolution, **52:383**  
 conversation during evolution, **52:383**  
 Fc $\epsilon$ RI  $\alpha$  chain related molecules, **52:383**  
 Fc $\epsilon$ RI  $\beta$  chain related molecules, **52:383–384**  
 Fc $\epsilon$ RI  $\gamma$  chain related molecules, **52:384**  
 surface antigens of human leukocytes and, **49:76, 88, 92–93, 99, 114**  
 T cell subsets and, **41:41, 46, 49, 50**
- Homology blocks  
 in Jaks, **60:4**  
 in Stats, **60:18–19**
- Homology unit, Ig gene superfamily and, **44:1, 3–9**  
 evolution, **44:43–46, 48**  
 MHC complex, **44:24, 25, 27–29**  
 nonimmune receptor members, **44:31–35, 37–42**  
 receptors, **44:9–11**
- Hormone radioreceptor assay, IL-2, **42:166–167**
- Hormones  
 autoimmune thyroiditis and antigens, **46:267, 272**  
 cellular immune responses, **46:298**  
 experimental models, **46:274, 278, 280**  
 genetic control, **46:283**  
 B cell formation and, **41:196, 229**  
 comparison with cytokines, **63:271**  
 hybrid resistance and, **41:402**  
 IL-1 and, **44:164, 171**  
 immunosenescence and, **46:244, 246, 247**  
 murine lupus models and, **46:63**  
 myasthenia gravis and, **42:263**  
 NK cells and, **47:299**  
 reproduction, **47:269, 270**  
 pore formation and, **41:314**  
 spontaneous autoimmune thyroiditis and, **47:491, 493**  
 altered thyroid function, **47:456, 461**  
 cellular immune reactions, **47:450**  
 clinical symptoms, **47:439**  
 disturbed immunoregulation, **47:476, 480, 481**  
 potential effector mechanisms, **47:465**  
 sporozoite malaria vaccine and, **45:305, 312**  
 surface antigens of human leukocytes and, **49:94, 101**

- Hormones (*continued*)  
 synthetic T and B cell sites and, **45:232**,  
 246, 247, 259  
 T cell development and, **44:236**
- Horror autotoxicus*, **54:394**
- Horse red blood cells, T cell subsets and,  
**41:68**
- Horse serum, B cell formation and, **41:209**,  
 219
- Host defense mechanisms, **66:101**
- Host response, sequential nature, **48:70**
- Household contacts, IBD and, **42:291**
- Housekeeping, immunosenescence and,  
**46:234**
- Hox11, **63:244–245**
- hox11*, **63:244**
- HPA axis, **54:30–31**; **61:367–368**, 375
- 5-HPETE, *see* 5-Hydroperoxy-5,8,11,13-  
 eicosatetraenoic acid
- HS1, B cell development, **63:29**
- 8HS-20 gene, **63:29**
- HSP, *see* Heat shock proteins
- hst-1*, **65:155**
- HSV, *see* Herpes simplex virus
- HT-2 cells, IL-2 activation, **61:176–179**
- HTLV-I, *see* Human T lymphotropic virus  
 type I
- Human  
 antibodies from combinatorial libraries, *see*  
 Antibodies, human, from  
 combinatorial libraries  
 antibody effector function, *see* Antibody  
 effector function, human  
 common mucosal systems in, **40:199–204**  
 $\kappa$  light chain genes of, **40:249–251**  
 lymphoid neoplasms, Ig and T cell receptor  
 gene rearrangements and, **40:264–270**  
 and mouse, heavy chain locus organization,  
**54:231–233**  
 mutations affecting stem cell factor or SCF  
 receptor, **55:23–24**
- Human chorionic gonadotropin, synthetic T  
 and B cell sites and, **45:259**
- Human cytomegalovirus, antibodies from  
 combinatorial libraries, **57:220–221**
- Human herpesvirus type 6, and HIV-1,  
 exacerbation of AIDS disease  
 progression, **58:16**
- Human immunodeficiency syndromes, and  
 DNA repair syndromes, **58:62–69**
- Human immunodeficiency virus, **47:377**, 378,  
 411–414; **52:192–193**, *see also* Human  
 immunodeficiency virus type 1  
 anti-TNF- $\alpha$  therapy, **64:311**  
 aPL antibodies and  
 clinical aspects, **49:202**, 205, 210–211  
 isotype, **49:224**, 226–227  
 CD8<sup>+</sup> antiviral factor, **65:282–284**  
 chemokine receptor family, **65:283**  
 cytotoxic T cells, **65:286–287**  
 acute infection, **65:293–296**  
 adoptive immunotherapy, **65:317–320**  
 adverse effects of CTL activity,  
**65:308–311**  
 apoptosis, **65:306**  
 asymptomatic period of infection,  
**65:296–297**  
 CTL decline in late disease, **65:300**  
 CTL exhaustion, **65:304–305**  
 disease progression, **65:297–298**  
 epitopes, **65:291–293**, 301, 312, 313  
 escape mutation, **65:311–317**, 322–323  
 infection, **65:290–307**  
 long-term nonprogressors, **65:298–300**  
 lysis of infected cells, **65:280–281**  
 measurement of HIV-specific CTLs,  
**65:287–290**  
 replication suppression, **65:281–284**  
 in seronegatives, **65:287**, 307–309  
 Th1 to Th2 switch, **65:302–304**  
 therapeutic implications, **65:317–322**  
 vaccines, **65:320–322**, 323  
 enhanced apoptotic decay, **58:233–237**  
 etiological agent, **47:378**  
 genome, **47:380–384**  
 HIV-2, **47:384**, 385  
 life cycle, **47:379**, 380  
 FDCs as targets of, **51:275–278**  
 HLA class I system, **65:284–286**  
 humoral immune response and, **45:78**  
 IgE biosynthesis and, **47:22**  
 Ig heavy-chain variable region genes and,  
**49:57**  
 immune response, **47:405**  
 cellular response, **47:409–411**  
 humoral response, **47:405–409**  
 immunopathogenic mechanism, **47:397**  
 activation, **47:398–403**  
 CD4 cell depletion, **47:386–389**  
 CD4-HIV interaction, **47:385**, 386

- macrophages, **47:392–395**
  - monocytes, **47:392–395**
  - precursor cells, **47:395–397**
  - T4 cells, **47:389–392**
  - induced immunosuppression, **45:335, 336, 355–363**
    - history of infection, **45:352–355**
    - immune response, **45:363–368**
    - virology, **45:347–352**
  - infected CD4<sup>+</sup> eosinophil precursors, **60:187**
  - infection, **47:377**
    - CTL-mediated lysis, **65:280–281**
    - etiological agent, **47:378, 380, 383, 384**
    - hu-PBL-SCID mouse, **50:314–317**
      - other tumor models in SCID mice, **50:313–314**
    - and IL-6, **54:37–38**
    - immune response, **47:406, 407, 409**
    - immunopathogenic mechanism, **47:391**
    - in seronegatives, **65:287, 307–309**
  - inhibition of lymphocyte death, **58:279**
  - integrases of, **64:57**
  - lymphocytic tendency to undergo PCD, **58:214**
  - lysis of infected cells, **65:280–281**
  - and mitosis, **58:424**
  - neuropsychiatric manifestations
    - brain, **47:403, 404**
    - mechanisms, **47:404, 405**
  - NK cells and, **47:302, 303**
  - progression to AIDS, **65:285, 299, 302, 304**
  - pseudotypes, in HIV-infected hu-PBL-SCID mice, biosafety issues and, **50:317–319**
  - replication suppression, **65:281–284**
  - sporozoite malaria vaccine and, **45:308–310**
  - synthetic T and B cell sites and, **45:196, 263**
    - globular protein antigens, **45:207**
    - peptides, **45:243**
    - viral antigens, **45:219, 220**
  - variants, **65:306–307**
- Human immunodeficiency virus type 1, **63:83–87**
- animal infection, **52:454–466**
    - chimpanzee, infection of, **52:455–461**
    - model for testing HIV-1 vaccines, **52:457–459**
  - pathogenesis of HIV-1 infection in, **52:455–457**
    - use to test therapies based on CD4, **52:459–461**
  - mouse, SCID-hu, **52:463–466**
  - rabbit, infection with HIV-1, **52:461–463**
- antibodies
- from combinatorial libraries, **57:211–217**
  - to self-antigens from human donors, **57:246–250**
- CD4 molecules and, **44:290, 295–297**
- CD8<sup>+</sup> cells and, **66:285–291, 297–298**
- antiviral activity, **66:274–275**
  - antiviral therapy, **66:295–299**
  - lytic activity, HIV-1-specific, **66:275–277**
- dissemination, **63:88**
- genomic organization, **63:84–85**
- infection in rabbits, **52:461–463**
- inhibition, **66:280–291**
- CD8<sup>+</sup> cell-derived antiviral factor, **66:282–283**
  - chemokines and, **66:281–282**
  - IL-16, **66:283**
- LTR and, **65:10**
- MAP immunogens designed for, **60:130–134**
- models using viruses distantly related to, **52:430–432**
- murine leukemia virus, **52:432–434**
- and NF- $\kappa$ B, **58:14–17**
- pathogenesis, **63:90–95, 100**
- progression, **66:283**
  - persistence, **66:291–295**
- replication, **63:85, 89–90**
- targets for therapy, **66:295–297**
- CTLs, **66:283, 286, 292–293**
  - cytolysis, **66:284–286**
  - epitopes, **66:276–280**
- transmission, **63:88**
- ungulate lentiviruses, **52:430–432**
- V3 loop, **60:137–138**
- Human leukocyte antigen, *see* HLA
- Human papillomavirus, **62:229, 239–240, see also Papillomavirus**
- C/EBP and, **65:10**
- Human T lymphotropic virus
- HIV infection and
- etiological agent, **47:378**
  - immunopathogenic mechanism, **47:388, 391, 393, 400, 402**

- Human T lymphotropic virus (*continued*)  
 IgE biosynthesis and, **47:21**  
 NK cells and, **47:229**
- Human T lymphotropic virus type I, **50:180**,  
 182; **52:429**; **63:285**, 310  
 tax protein, **58:17–18**
- Human umbilical vein endothelial cells  
 CD40 antigen, **61:14**  
 cytokines, regulatory effects, **64:165–166**  
 as endothelial cell model, **64:186**  
 eosinophil adhesion to, **60:167–170**  
 lymphocytes and, **64:142**
- Humoral immune response, **45:1**; **64:2**, *see*  
*also* Antibody response  
 antigen-bridging model, **45:7**, 8  
 antigen presentation, **45:9–12**, 22  
 B cells, **45:15–17**  
 class II molecules, **45:18–21**  
*in vitro*, **45:21**  
*in vivo*, **45:21**, 23, 24  
 antigen processing, **45:12**, 22  
 B cells, **45:17**, 18  
 intracellular events, **45:12–14**  
 macrophages, **45:14**, 15  
 requirements, **45:8**, 9  
 antigen-specific receptors, **45:6**, 7  
 cellular interactions *in vivo*, **45:78**, 79, 85  
 bacterial antigens, **45:82**, 83  
 lymphoid organ, **45:79–82**  
 parasites, **45:84**, 85  
 viral antigens, **45:83**, 84  
 hapten-carrier effect, **45:3**, 4  
 helper T cells, **45:24**, 25  
 activation, **45:29–31**  
 clones, **45:29**  
 differences, **45:27**, 28  
 heterogeneity, **45:25–27**  
 isotype switching in B cells, **45:32–35**  
 subtype surface markers, **45:28**, 29  
*in vivo*, **45:31**, 32  
 HIV infection and, **47:405–410**  
 immune reconstitution and, **40:414–416**  
 to infection, IBD and, **42:299–300**  
 interleukins, **45:54–62**, 75–77  
 IL-1, **45:72**, 73  
 IL-2, **45:67–70**  
 IL-3, **45:73**, 74  
 IL-4, **45:62–65**  
 IL-5, **45:65–67**  
 IL-6, **45:74**, 75  
 interferon- $\gamma$ , **45:70**, 71  
 mechanisms, spontaneous autoimmune  
 thyroiditis and, **47:465–470**  
 against MMTV, **65:188–192**  
 models, **45:1–3**  
 physical interaction, **45:35**, 36  
 biochemical events, **45:38**, 39  
 cell surface Ig, **45:40**, 41  
 cell surface molecules, **45:41–46**  
 functional outcome, **45:38**  
 intracellular events, **45:39**  
 lymphokines, **45:46–54**  
 model systems, **45:36–38**  
 monogamous nature, **45:39**, 40  
 pituitary hormones, **63:407**  
 spontaneous autoimmune thyroiditis and,  
**47:444–449**, 491  
 suppression, **45:5**
- Humoral memory, germinal center B cells,  
**60:283**
- Hu-PBL-SCID mouse  
 EBV-associated lymphoproliferative disease  
 in, **50:310–313**  
 HIV infection of, **50:314–317**
- Hyaluronan  
 binding regulation, evidence, **54:302–308**  
 CD44 as receptor for, **54:284–287**  
 evidence, **54:284–287**  
 features, **54:287–290**  
 sequence of CD44 in hyaluronan  
 recognition, **54:284**  
 CD44-specific antibody binding, inhibition,  
**54:284–286**
- Hyaluronate, IGF-I, **63:390**
- Hyaluronic acid  
 CD44 binding to, **58:376–377**  
 Ig gene superfamily and, **44:40**, 41, 44
- H-Y antigen, cytotoxic T cells and,  
**38:175–180**  
 cross-reactive lysis, **38:186**  
 immunodominance, **38:181**
- Hybrid histocompatibility antigens  
 antigen expression, **41:397–399**, 401, 409,  
 410, 405–407  
 trans gene model, **41:401–403**  
 bone marrow cells, **41:340–343**, 345, 347  
 genetics of expression, **41:397**  
 leukemia/lymphoma cells, **41:360–367**  
 lymphoid cells, **41:352**, 353  
 marrow engraftment, **41:385**, 386  
*in vitro* assays, **41:394–396**

- Hybrid hyperreactivity, **41:360, 379**
- Hybridization, *see also* Somatic cell hybridization
- antigen-presenting cells and, **47:65–67, 70, 71, 87**
  - autoreactive T cells and, **45:420, 424**
  - CD5 B cell and, **47:134**
  - CD23 antigen and, **49:152, 162, 170**
  - complement components and
    - C4 genes, **38:228, 231**
    - cloning, **38:209, 212**
    - restriction fragment length polymorphism, **38:215**
  - complement receptor 1 and, **46:188–190**
  - cytotoxicity and, **41:276, 288**
  - helper T cell cytokines and, **46:112**
  - human B cell neoplasia and, **38:257**
    - Burkitt lymphoma cells, **38:260**
    - chromosome translocation, **38:266, 268**
  - IgE biosynthesis and, **47:17**
  - Ig heavy-chain variable region genes and polymorphism of V<sub>H</sub> gene segments, **49:23, 27**
    - V<sub>H</sub> families, **49:8–9, 15, 17**
    - V<sub>H</sub> gene expression, **49:37–38**
  - leukocyte integrins and, **46:159, 160, 173**
  - maps of Ig-like loci and, **46:2–4**
    - MHC, **46:30, 33**
    - structure, **46:10, 12, 13, 15, 17, 18, 21, 25, 27**
  - maternally transmitted antigen and, **38:324, 326**
  - murine lupus models and, **46:74, 83, 85, 87**
  - NK cells and
    - genetic control, **47:223**
    - hematopoiesis, **47:273, 274, 280**
    - surface phenotype, **47:204, 209**
  - regulators of complement activation and, **45:405**
  - SCID and, **49:397**
  - spontaneous autoimmune thyroiditis and altered thyroid function, **47:462**
    - genetics, **47:483, 484, 486–491**
  - subtractive, **43:135**
  - T cell receptor and, **45:135, 139, 140**
  - T cell receptors and, **38:15**
  - T cell subsets and, **41:41, 100, 101**
  - virus-induced immunosuppression and, **45:354**
- Hybrid joints, V(D)J recombination, **64:41**
- Hybridoma/plasmacytoma growth factor, **54:3**
- Hybridoma reagents, **38:276**
- Hybridomas, **42:1, 2**
  - activation-induced death, **50:67**
  - adoptive T cell therapy of tumors and, **49:301**
  - A/J mice, **42:131–132, 135**
  - antiarsenate, **42:97–98, 99–101, 128–129**
  - antibodies from, **57:229–230**
  - antigen-presenting cells and, **47:65, 68–70, 77**
    - antigen processing, **47:87**
    - T cells, **47:86, 93**
  - antinuclear antibodies and, **44:98**
  - aPL antibodies and, **49:246, 249**
  - Ars A, **42:102, 108–109**
    - light chains, **42:139–141**
  - autoimmune demyelinating disease and, **49:358–359, 365, 367**
  - autoimmune thyroiditis and, **46:289, 296, 304, 312**
  - autoreactive T cells and, **45:420, 424–426**
  - B cell formation and, **41:223, 225, 237**
  - CD4 and CD8 molecules and, **44:268, 270, 299, 302**
    - CD4 molecular biology, **44:291–293, 297**
    - CD8 molecular biology, **44:280, 282, 284**
  - CD5 B cell and, **47:159**
    - Ig gene expression, **47:151, 152, 156**
    - physiology, **47:133–135, 138**
  - CTL and, **41:150, 168, 169**
  - fetal liver, **42:131–132**
  - genetically engineered antibody molecules and, **44:65, 66**
    - chimeric antibodies, **44:79–81, 87**
    - cloning, **44:73, 75**
    - expression, **44:70, 71, 75, 77, 78**
    - fusion proteins, **44:86**
    - lymphoid mammalian cells, **44:69**
    - production, **44:67**
  - helper T cell cytokines and, **46:116**
  - HIV infection and, **47:391**
  - human–human
    - advantages, **38:300**
    - antigens, **38:294–297, 299**
    - autoantibodies, **38:297–299**
    - fusion, **38:292, 293**
    - propagation, **38:302–304**
  - human–murine
    - advantages, **38:291, 292**



- Hybridomas (*continued*)
- heterohybridoma antibodies, **38:288–290**
  - Ig secretion, **38:287, 288**
  - propagation, **38:302**
  - humoral immune response and
    - antigens, **45:15**
    - interleukins, **45:63, 65, 74, 75**
    - physical interaction, **45:36–39, 44, 50**
  - IgE biosynthesis and
    - antibody response, **47:8, 32, 33, 35–39**
    - binding factors, **47:13, 15, 17, 18, 21, 25–27**
  - Ig heavy-chain variable region genes and, **49:2, 35, 37, 41**
  - IL-1 and, **44:178, 189**
  - immunosenescence and, **46:249**
  - mAbs and, **38:279, 302, 306**
  - murine lupus models and, **46:72, 74, 78**
  - neonatal development and, **42:28–29**
    - A/J mice, **42:131–132**
    - somatic mutation, **42:66–67**
  - synthetic T and B cell sites and
    - antigens, **45:232, 234, 237**
    - globular protein antigens, **45:213, 215, 216**
    - immunological considerations, **45:200**
    - viral antigens, **45:217, 225, 228**
  - T cell, *see* T cell hybridomas
  - T cell activation and, **41:1, 23, 25**
  - T cell development and, **44:215, 216, 218**
  - T cell receptor and, **45:151**
    - cDNA, **38:6**
    - gene expression*, **38:13, 14**
    - mice, **38:5, 14**
    - protein properties, **38:3, 4**
    - rearrangement, **38:11, 12**
    - specific binding, **38:19–21**
    - target recognition, **38:122, 123**
    - V region genes, **38:15, 16**
  - T cell subsets and
    - H-2 alloantigen recognition, **41:79, 82, 91**
    - H-2-restricted antigen recognition, **41:62, 70, 52–60**
    - T cell receptor, **41:41, 42**
    - T cell triggering, **41:111**
    - technology, **43:1**
  - Hybrid resistance, **41:333, 334**
    - antigen expression genetics, **41:397–401**
    - hemopoietic cell grafts, **41:404–407**
    - Hh-1, **41:401–403**
    - marrow allograft reactivity, **41:408–410**
    - transplanted cells, **41:403, 404**
  - effector mechanisms, **41:369, 370**
    - antibodies, **41:376–380**
    - macrophages, **41:370–372**
    - marrow engraftment, **41:384–388**
    - marrow microenvironment, **41:390–393**
    - NK cells, **41:372–376**
    - syugeneic stem cell functions, **41:388–390**
    - T cells, **41:380–384**
    - in vitro* assays, **41:393–396**
  - hemopoietic cells
    - bone marrow cells, **41:335–351**
    - lymphoid cells, **41:351–358**
    - leukemia/lymphoma cells, **41:358–369**
  - Hybrids
    - antinuclear antibodies and, **44:108, 129**
    - B cell formation and, **190, 41:226**
    - CD4 molecules and, **44:285, 296**
    - CD8 molecules and, **44:272, 273, 282**
    - CTL and, **41:169**
      - $\beta_2$ -microglobulin, **41:156**
      - exon shuffling, **41:139, 142, 144, 145, 147**
      - HLA class I antigens, **41:150, 151**
      - mAbs, **41:158**
    - genetically engineered antibody molecules and, **44:77, 78, 80**
    - Ig gene superfamily and, **44:12, 27, 31, 40, 47**
    - IL-1 and, **44:167**
  - Ir* genes
    - competitive inhibition, **38:109**
    - complementation, **38:72**
    - cross-reactive lysis, **38:186**
    - cytotoxic T cells, **38:163, 164, 169**
    - gene dosage, **38:80, 82, 83**
    - H-Y antigen, **38:176**
    - I region mutations, **38:85, 90**
    - T cell repertoire, **38:116, 117, 144, 145**
    - T cell-T cell interactions, **38:155, 160**
  - lymphocyte homing and, **44:329, 336, 337, 353**
  - resistance phenomenon, NK cells in, **55:366–367**
  - T cell development and, **44:217, 218, 227**
- Hydrazine, *in linkage procedure for chemoimmunoconjugates in cancer treatment*, **56:322–323**

- Hydrocortisone  
*hybrid resistance and*, **41**:387, 390  
*in vitro* IgE synthesis, **61**:370–371
- Hydrolysis  
 in signal transduction, **54**:418–419  
 T cell activation and, **41**:15, 16, 23, 25, 30
- Hydrolytic enzymes, cytolysis and,  
**41**:275–277, 281
- Hydrophobicity, mast cell-specific receptor,  $\beta$   
 subunit profile, **43**:288
- 5-Hydroperoxy-5,8,11,13-eicosatetraenoic  
 acid, dehydration to LTA<sub>4</sub>, **39**:150–151
- Hydrophilicity, **43**:76  
 epitope prediction, **43**:56  
 intrinsic parameters, **43**:49  
 MHR, **43**:35  
 profiles, **43**:14
- Hydrophobic domains  
 human T cell activation and, **41**:5, 13, 25  
 T cell subsets and, **41**:45, 54
- Hydrophobicity  
 B cell formation and, **41**:197, 198  
 CD1 proteins, **59**:37, 38  
 CD4 molecules and, **44**:285  
 CD8 molecules and, **44**:273  
 cytotoxicity and  
 cell-mediated killing, **41**:295  
 cytolysis, **41**:279, 280  
 membrane attack complex of  
 complement, **41**:299–302  
 pore formers, **41**:314–317  
 genetically engineered antibody molecules  
 and, **44**:67  
 Ig gene superfamily and, **44**:3, 6, 35, 46  
 IL-1 and, **44**:158, 181
- Hydrophobic regions, **43**:76
- 5-Hydroxyeicosatetraenoic acid  
 in neutrophils, human, **39**:153–154,  
 166–167  
 production by eosinophils, **39**:204
- 21-Hydroxylase, maps of Ig-like loci and,  
**46**:28, 32, 33
- 4-Hydroxy-3-nitrophenyl acetyl, genetically  
 engineered antibody molecules and,  
**44**:66, 69, 80, 85, 86
- 20 $\alpha$ -Hydroxysteroid dehydrogenase  
 in IL-3-dependent cell lines, **39**:35, 36  
 IL-3-induced in T cells, **39**:2, 5, 18–19,  
 23–31
- N*-Hydroxysuccinimide, in  
 chemioimmunoconjugate crosslinking in  
 cancer treatment, **56**:316–318
- Hydroxyurea  
 Ig-secreting cells and, **40**:9  
 NK cells and, **47**:230, 231, 283
- HyHEL5  
 binding, **43**:20–21  
 blind peptide mapping study, **43**:26  
 fine specificity study, **43**:26  
 lysozyme binding, **43**:12–13, 122  
 model, **43**:121
- HyHEL10, blind peptide mapping study,  
**43**:26
- Hyper eosinophilia, reactive, and neoplasms,  
**60**:225
- Hyper eosinophilic syndrome  
 clinical picture, **60**:223–224  
 eosinophils  
 cocultured with cytokines, **60**:185  
 synthesis of cytokines, **60**:199–200  
 high eosinophil counts, **60**:217  
 small granules in, **60**:160
- Hypergammaglobulinemia, murine lupus  
 models and, **46**:63, 64
- Hyper IgE recurrent infection, **62**:89
- Hyper IgM, HIGM-1  
 defect of B cell differentiation, **60**:42–48  
 and XLA, immunodeficiency diseases,  
**60**:37
- Hyper IgM syndrome  
 gp39 structure in, **63**:49–50  
 X-linked, **59**:248
- Hyperimmunization, secondary B cells and,  
**42**:72
- Hyperlipidemia, spontaneous autoimmune  
 thyroiditis and, **47**:440
- Hypermutation  
 in germinal centers, **53**:233–234  
 Ig gene superfamily and, **44**:18, 20, 22, 23  
 Ig somatic, **60**:277–278  
 locus-specific, **60**:278–280  
 somatic  
 in germinal centers, **53**:233–234  
 T cell subsets and, **41**:42, 88, 106  
 V(D)J, **60**:284
- Hyperprolactinemia, **63**:409–410, 430
- Hypersensitivity  
 antigen-presenting cells and, **47**:104, 105  
 B cell formation and, **41**:183

- Hypersensitivity (*continued*)  
 delayed-type, *see* Delayed-type hypersensitivity  
 immediate  
   eosinophil effects, **39:217–219**  
   histamine secretion and, **39:217, 218; 304–306**  
   neuropeptide effects, **39:304–307**  
 Hypersensitivity lung diseases, **59:387, 412–420**  
 Hypersensitivity pneumonitis, **59:419–420**  
 Hypertriglyceridemia, cachectin and, **42:214, 218**  
 Hypogammaglobulinemia, hybridomas and, **38:287**  
 Hypogammaglobulinemia, **59:141**  
   CD23 antigen and, **49:174**  
   Crohn's disease and, **42:300**  
   Ig heavy-chain variable region genes and, **49:3**  
 Hypophysis, IFN- $\gamma$  effect on, **62:93**  
 Hypothalamic-pituitary-adrenal axis, **54:30–31; 61:367–368, 375**  
 Hypothalamus, NK cells and, **47:266**  
 Hypothyroidism, **46:263, 269, 274, 275, 278**  
   spontaneous autoimmune thyroiditis and altered thyroid function, **47:456**  
   breeding, **47:435–437**  
   clinical symptoms, **47:438**  
   disturbed immunoregulation, **47:470**  
   histopathology, **47:442, 444**  
 Hypoxanthine-aminopterin-thymidine, lymphocyte hybridomas and, **38:280, 286**  
   heterohybridomas, **38:288, 289**  
   human-human hybridomas, **38:293–296, 300**  
   human-mouse heterohybridomas, **38:300, 301**  
 Hypoxanthine-guanine phosphoribosyl-transferase  
   B cell hybridomas and, **38:279, 280**  
   human-murine hybridomas, **38:289**  
 Hypoxanthine ribosyl transferase gene, **61:113–114**  
 Hypoxia, IL-6 expression, **65:27**
- I
- I $\epsilon$ , **62:43, 49–50**  
 I $\gamma$ 2b, **62:43, 49–50**  
 Ia-like molecules, expression by T cells **156, 38:157, 159, 160**  
 Ia molecules  
   on activated and resting B cells  
     B cell antigen-presenting capacity and, **39:73–78**  
     expression, **39:74–76**  
     MLR and, **39:81–82**  
     structure, **39:73–74, 76–78**  
 allogeneic, *Ir* genes and, **38:115, 126, 132**  
 corneal graft, **48:199**  
 IgE biosynthesis and, **47:9, 23, 27**  
*Ir* genes and, *see also* Ia molecules,  
   allogeneic; Self-antigens, self-Ia antigen binding, **38:98–100, 103**  
   antigen processing, **38:96, 97**  
   antigen-specific clones, **38:121**  
   blocking, **38:69–72**  
   competitive inhibition, **38:108, 110**  
   complementation, **38:75–77**  
   cytochrome c, pigeon, **38:77–79**  
   discovery of, **38:67, 68**  
   gene dosage, **38:79–83**  
   gene function, **38:91–93**  
   H-Y antigen, **38:179**  
   immunodominance, **38:184**  
   I region mutations, **38:84–91**  
   macrophage factors, **38:111–114**  
 T cells  
   activation, **38:104–107**  
   cytotoxic, **38:161, 163, 165, 167**  
   proliferation, inhibition of, **38:68, 69**  
   selection, **38:131, 132, 134**  
   suppression, **38:131, 135, 136, 138, 139, 142, 143, 149–152**  
   T cell-T cell interactions, **38:153, 156, 159, 160**  
   tolerance, **38:122, 123, 125, 126**  
   *xid* gene, **38:83, 84**  
 MG and, **42:256–257**  
 positive cell, **48:197**  
 I-A molecules, role in V $\beta$  selective element action, **50:20–21**  
 I $\kappa$ B, **63:157–159; 65:117**  
   deficiency effects, **65:32**  
   description, **58:2–4**  
   family, **65:14–15**  
   knockout mice, cytokine induction, **65:32**  
   phosphorylation by TNF $\alpha$ , **58:8**

- rapid degradation and release of NF- $\kappa$ B, **58:4–5**
- I $\kappa$ B $\alpha$ , **65:14**  
gene, **65:23**
- I $\kappa$ B family, transcriptional regulation, **65:14–15**
- IBD, *see* Inflammatory bowel disease
- Ibuprofen, **62:184, 186**
- ICAM, *see* Intercellular adhesion molecule
- Iccomes, humoral immune response and, **45:24**
- ICP47, **65:279**
- Id, *see* Idiotype
- IDDM, *see* Insulin-dependent diabetes mellitus
- Idiopathic pulmonary fibrosis, **62:261, 267, 270, 286**
- Idiotope-determining region, **43:14, 16**
- Idiotype  
autoimmune thyroiditis and, **46:318, 319**  
humoral responses, **46:302, 304–308**  
prevention, **46:315**  
binding to rabbit anti-Id antibodies, **39:261–263**  
cross-reactivity, **39:263–265**  
network theory, **39:255–257**  
recognition by suppressor T cells, **40:142**  
recognition by T cells, **39:257–261**  
B cells and, **39:259–260**
- Idiotypic determinants, Ars A response and, **42:138**
- Idiotypic interactions, human  
allergic responses and, **39:175–176**  
antiself antibodies and, **39:278–279**  
autoimmune diseases and, **39:277–278**  
anti-Id antibodies as mediators of, **39:279–280**  
B cell tumor therapy with anti-Id antibodies and, **39:289, 291**  
immune responses to HLA and, **39:281–283**  
during pregnancy, **39:281–282**  
self-tolerance and, **39:276–277**
- Idiotypic map, **42:129–130**
- Idiotypic regulation, immunosenescence and, **46:247–249**
- IELs, *see* Intraepithelial lymphocytes
- I-E molecules, role in V $\beta$  selective element action, **50:18–19**
- Ig- $\alpha$ , B cell AgR, tyrosine phosphorylation, **55:246–248**
- Ig- $\beta$ , B cell AgR, tyrosine phosphorylation, **55:246–248**
- IgA, **61:79, 80, 94–97**  
antibody concentration on mucosal surfaces, **58:298**  
antigen-presenting cells and, **47:52, 53**  
aPL antibodies and, **49:204, 224–226, 232, 238**  
biosynthesis, **40:184–226; 47:7, 19**  
cellular and molecular aspects, **40:184–190**  
common mucosal immune system in human and animal models, **40:197–207**  
factors regulating S-IgA immune response, **40:207–226**  
IgA and, induction of, **40:190–192**  
induction of IgA immune response, **40:190–192**  
isotype-specific, accessory cells and, **40:219**  
mucosa-associated lymphoid tissue, **40:192–197**  
specific humoral, regulation by Fc region of Ig, **40:71–77**  
specific *in vitro* humoral, enhancement by Fc portion of Ig, **40:90–95**  
specific *in vitro* T cell-mediated, enhancement by Fc fragments of Ig, **40:95–100**
- CD5 B cell and, **47:138**  
distribution of cells producing, **40:189–190**  
in eosinophil degranulation, **60:182**  
fluorescence polarization, rotational correlation times, **48:16–17**  
function, **65:251**  
heavy chain class switch of, **40:219–223**
- IBD and, **42:298, 301–303, 306–307, 321**  
interaction with nonlymphoid cells, **40:168–184**  
epithelial cells, **40:174–177**  
erythrocytes, **40:174**  
hepatocytes, **40:177–184**  
phagocytic cells, **40:168–174**  
production, **65:248–251**  
CD40 signaling, **63:64–65, 66–67**  
respiratory immunity, **59:373, 387, 396, 411, 414**

- IgA (*continued*)
- secretory, interaction of component polypeptide chains, **40:163–168**
  - secretory component
    - binding of, **40:165–166, 167, 186**
    - epithelial cells and, **40:175–177**
    - hepatocytes and, **40:179–180, 182**
    - structure and function, **40:160–163**
  - segmental flexibility, **48:14–18**
  - of serum and secretory, structure and function of component polypeptide chains, **40:154–168**
  - structure, **65:248**
  - surface antigens of human leukocytes and, **49:91**
  - transforming, expression, **54:262**
- IgA<sub>1</sub>, wide extreme, **48:30**
- IgA<sub>2</sub>, rotation freedom, **48:31**
- IgA deficiency, **65:251–256, 263**
- clinical manifestations, **65:246–248, 256**
  - common variable immunodeficiency (CVID) and, **65:256**
  - genetic susceptibility, **65:256–260**
  - pathogenesis, **65:260–263**
  - treatment, **65:263**
- Ig complex, **52:136–138**
- IgD, **61:82–83**
- antigen-presenting cells and, **47:48**
  - B cell expression, **59:322–324**
  - biosynthesis and, **47:7, 19**
  - CD5 B cell and, **47:121, 122**
  - CD23 antigen and, **49:150, 168, 175**
  - expression by B cells, **40:19–26**
  - and IgM, differential signaling, **54:401–402**
  - surface, and surface IgM, respective roles, **52:297–298**
  - surface antigens of human leukocytes and, **49:76, 91**
- IgE, **61:91**
- 60-kDa factor, **43:304–305**
  - allergic airway inflammation, **62:283**
  - allergic response, **61:374–375**
  - $\alpha$  chain, **43:282**
  - anti-dinitrophenol, **43:294**
  - antigen-presenting cells and, **47:63**
  - anti-ovalbumin, **43:294**
  - binding site localization, **43:279–280**
  - biosynthesis, **43:303; 47:1**
    - antibody response, **47:1–3**
    - B cells, **47:7–12**
    - T cells, **47:8, 10–12**
    - in vitro*, **47:3–7**
  - antibody response suppression, **47:28**
  - antigens, **47:28–30**
  - anti-IL-4, **47:31**
  - GIF, **47:32–35**
  - interferon- $\gamma$ , **47:31, 32**
  - T cell hybridomas, **47:36–39**
  - binding factors
    - biological activities, **47:12–15**
    - Fc $\epsilon$ RII structure, **47:19–22**
    - formation, **47:22–28**
    - physicochemical properties, **47:15–19**
  - CD23 antigen and, **49:149–150, 174, 176**
  - biochemical structure, **49:155–157**
  - biological activity, **49:167–173**
  - cellular expression, **49:150–152, 154–155**
  - cleavage regulation, **49:158**
  - expression regulation, **49:161**
  - Fc $\epsilon$ RII, **49:162–163, 165**
  - CD40 expression, **61:93–94, 95–96**
  - dependent granule protein stimulation, **60:207**
  - eosinophils, **43:306–307**
  - $\epsilon$  chain, **43:278**
  - Fc $\epsilon$  molecules dependence on, **52:385**
  - Fc receptors, **43:277**
  - fluorescence polarization, rotational correlation times, **48:16–17**
  - functional characteristics, **43:305**
  - functions, **48:18**
  - high-affinity receptor, **43:281**
  - histamine-releasing factors, **43:307**
  - IL-4 stimulated production, **54:247–248**
  - and IL-4 switching, **52:217–218**
  - interaction with eosinophils, **60:181**
  - isotype switching, **60:38–39**
  - macrophage receptor, **43:306**
  - monoclonal anti- $\beta$  antibody, **43:283**
  - monocytes, **43:305–306**
  - myeloma, ESR spectra, **48:30–31**
  - plate-bound, IL-4 production in response to, **53:20–21**
  - platelets, **43:306–307**
  - production, CD40 signaling, **63:62–64, 66–67**
  - protein-binding sites, **43:281–282**
  - receptor binding to, **52:387–388**
  - regulation, **61:369–370**
  - role, **43:277**

- segmental flexibility, **48:18–19**  
 sequential switching, **61:105**  
 sites interacting with receptors, **43:278–279**  
   anti-IgE antibody studies, **43:279–281**  
   inhibition studies, **43:281–282**  
 structural properties  
   comparative studies on rodent cells,  
     **43:302–305**  
   Fc $\epsilon$  receptors, **43:298–301, 303**  
   IgE-binding factor, **43:300–302**  
 surface antigens of human leukocytes and,  
   **49:77, 81, 90–91**  
 synthesis, **43:277; 61:342–344, 370–374**  
 wide extreme, **48:30**
- IgE-binding factors  
 CD23 antigen and, **49:149**  
 cDNA coding, **43:304**  
   functional characteristics, **43:305**  
   human B cells, **43:300–301**  
   retroviral protein, **43:304**  
   T cells, **43:301–303**
- IgE-binding proteins, **43:307–308**
- Ig/EBP, **65:3–5**
- IgE/Fc $\epsilon$ RI,  $\gamma$  dimer, **52:380–381**
- IgE/Fc $\epsilon$ RI receptor, high-affinity,  
   **52:378–381**  
 assembly, **52:381–382**  
 cell surface structures functionally  
   associated with Fc $\epsilon$ RI molecules,  
     **52:391–396**  
   cell surface glycolipids, **52:393–394**  
   Fc $\gamma$  receptors, **52:394–396**  
   G63, **52:394**  
   mast cell chromolyn binding sites,  
     **52:392–393**  
   ME491 (CD63), **52:393**  
 chromosomal location, genomic  
   organizations, and mRNA species,  
     **52:382–383**
- control of synthesis and expression of  
 dependence on IgE, **52:385**  
 Fc $\epsilon$ RI molecules, **52:384–386**  
 half-life, internalization, degradation and  
   reexpression, **52:385–386**  
 synthesis during cell cycle, **52:385**  
 synthesis during differentiation of  
   basophils/mast cells from  
   hemopoietic precursor cells,  
     **52:384–385**
- functional characterization of receptor,  
   **52:387–391**  
   binding to IgE, **52:387–388**  
   effector mechanisms and functional  
     changes of mast cells/basophils  
     following activation through IgE  
     binding sites, **52:391**  
   signal transduction and distal events,  
     **52:388–391**
- numbers and binding constants on  
 basophils/mast cells, **52:386–387**  
 sequence and structural homologies,  
   **52:383–384**  
 conversation during evolution, **52:383**  
 molecules related to Fc $\epsilon$ RI  $\alpha$  chain,  
   **52:383**  
 molecules related to Fc $\epsilon$ RI  $\beta$  chain,  
   **52:383–384**  
 molecules related to Fc $\epsilon$ RI  $\gamma$  chain,  
   **52:384**  
 topology of, **52:378**  
    $\alpha$  chain, **52:379**  
    $\beta$  chain, **52:379–380**  
    $\gamma$  dimer, **52:380–381**  
   nomenclature, **52:378**
- IgE-potentiating factor, **47:5**
- IgE receptors, eosinophil, and killing of  
 schistosomula, **39:180–181**
- Ig fold, **43:221**
- IgG, **61:80, 94**  
 adoptive T cell therapy of tumors and,  
   **49:296**  
 antigen-presenting cells and, **47:62, 67, 85**  
 aPL antibodies and, **49:199, 242, 251, 255,**  
   **258**  
 affinity purification, **49:229**  
 clinical aspects, **49:204–206, 210, 212,**  
   **222, 224**  
 isotype, **49:224–228**  
 pathogenic potential, **49:253, 255**  
 specificity, **49:238, 242–243**  
 syndromes, **49:220**
- B cell formation and, **41:223, 237**  
 biosynthesis and  
   antibody response, **47:2–11, 31, 32**  
   binding factors, **47:12, 19, 27**  
 CD5 B cell and, **47:132, 134, 136, 144**  
 CD23 antigen and, **49:157**  
 CD40 signaling, **63:63, 65–66, 69–70**  
 CH3 domain, **48:20–21**

- IgG** (*continued*)  
 complex and associated second messengers, identification, **54:419–420**  
 conformation and flexibility, **51:4–7**  
 cytotoxicity and, **41:271**  
 eosinophil-bound, parasite killing, **39:209–211**  
 hybrid resistance and, **41:336, 355, 357**  
 effector 376–378, **41:394**  
 IBD and, **42:297–298**  
 antibody expression in, **42:321**  
 subclass expression in, **42:305**  
 Ig heavy-chain variable region genes and, **49:2, 6, 49–51**  
 IL-4-stimulated production, **54:247–248**  
 induced monocytes, **54:172, 173**  
 NK cells and, **47:189, 293**  
 cell-mediated cytotoxicity, **47:190, 196**  
 cytotoxicity, **47:249, 256**  
 effector mechanisms, **47:237, 243–245, 247, 248**  
 malignant expansion, **47:227**  
 surface phenotype, **47:201, 202, 212**  
 physicochemical characterization of Fc receptor for, **40:69–70**  
 segmental flexibility, **48:5–19**  
 early studies, **48:5–6**  
 fluorescence polarization, **48:6–10**  
 hinge region structure, **48:21–23**  
 IgG subclasses, **48:11–14**  
 spin-label method, **48:10–11, 12**  
 X-ray crystallography, **48:11**  
 surface antigens of human leukocytes and, **49:83, 89–90**
- IgG1**, **48:13**  
 CD40 expression, **61:95–96**  
 heavy chain, hinge region structure, **48:21–22**  
 oligosaccharide, <sup>13</sup>C nuclear magnetic resonance, **48:29**
- IgG2**, **48:13**  
**IgG2a**, eosinophil-bound, parasite killing, **39:210–212**  
 inhibition by IgG2C, **39:211–212**
- IgG-Fc<sub>μ</sub>RIII** interaction at molecular level, **51:40–41**
- IgG** receptor, isotypes, **54:343–344**
- IgH**  
 B cell formation and, **41:198**  
 CD5 B cell and, **47:129, 161**
- Igh** haplotypes, *J558* and, **42:135**  
 Igh recombinant strains, *V<sub>H</sub>* gene segment and, **42:6**
- Igκ**  
 gene 3' enhancer, **62:43, 49**  
 gene enhancers, **62:43, 50–51**
- Ig<sub>i</sub>** gene  
 diversification, potential mechanisms, **48:58**  
 somatic diversification, **48:52, 53**
- IgM**, **42:13; 48:16–18; 61:79, 80, 82, 93**  
 adoptive T cell therapy of tumors and, **49:314, 331**  
 antigen-presenting cells and, **47:48, 85**  
 aPL antibodies and  
 affinity purification, **49:228–229**  
 clinical aspects, **49:204, 206, 209–210, 212, 222**  
 B cell expression, **59:322–324**  
 B cell formation and, **41:183**  
 B cell precursors, **41:194, 200**  
 inducible cell line, **41:221, 222**  
 population dynamics, **41:206**  
 soluble mediators, **41:234**  
 B cells secreting, **40:22–23**  
 biosynthesis and, **47:4, 6, 7, 9–11**  
 CD5 B cell and, **47:129**  
 physiology, **47:130–133, 135, 136**  
 CD23 antigen and, **49:159, 167–168, 172, 175**  
 CD40 signaling, **63:59, 62–63, 66–67**  
 fluorescence polarization, rotational correlation times, **48:16–17**  
 human myeloma, **48:16–18**  
 hybrid resistance and, **41:336, 377, 378**  
 IBD and, **42:299, 300**  
 and IgD, differential signaling, **54:401–402**  
 Ig heavy-chain variable region genes and, **49:38, 41–43, 48–51**  
 myeloma, ESR spectra, **48:30–31**  
 NK cells and, **47:207, 292, 293**  
 normal or elevated, **60:37–49**  
 secondary B cells and, **42:76**  
 secretion in NZB spleen cells, **55:313–314**  
 segmental flexibility, **48:14–18**  
 surface, and surface IgD, respective roles, **52:297–298**  
 surface antigens of human leukocytes and, **49:76, 91, 101**  
 X-linked hyper IgM syndrome, **59:248**  
 IgM-binding protein, **52:173**

- IgM hybridoma, somatic mutation and, **42:67**  
 IgM receptors, on eosinophils, human, **39:180**  
 Ig oligosaccharide, spin-labeling, **48:27–28**  
 Ig+ precursor selection, bursa of Fabricius, **48:49–51**  
 IGUP I-5111, **64:21, 23**  
 Ig VL gene  
   gene conversion, **48:60–62**  
   somatic diversification, **48:60–62**  
 Ikaros  
   B cell genesis, **63:218–219, 224–226**  
   gene expression, **63:224–226**  
 IL-1ra, *see* Interleukin-1 receptor antagonist  
<sup>125</sup>I-labeled antigen therapy, for MC, **42:268**  
<sup>125</sup>I-labeled IL-2, **42:172**  
 Ileum, lymphocyte homing and, **44:330**  
 Illegitimate priming model, switch recombination, **61:108–111**  
 Imidoesters, in chemoimmunoconjugation, **56:320–321**  
 Immune complex disease, pulmonary, rat model, **60:345**  
 Immune complexes  
   and alternative antigen pathway, trapping, **51:265–269**  
   cell-mediated immune responses and, **40:77–79**  
   lung inflammation, **62:277–283**  
   regulation of immune responses and, **40:71–72, 73–76**  
   regulators of complement activation and, **45:388, 389, 410, 411**  
 Immune function, animal models  
   EBV-associated lymphoproliferative disease in hu-PBL-SCID mice, **50:310–313**  
   HIV-infection of hu-PBL-SCID mice, **50:314–317**  
   other tumor models in SCID mice, **50:313–314**  
   search for better models, **50:303–304**  
   transfer of normal or autoimmune human cells to SCID mice, **50:304–310**  
   viral pseudotypes in HIV-infected hu-PBL-SCID mice, biosafety issues and, **50:317–319**  
 Immune interferon, *see* Interferon- $\gamma$   
 Immune intervention, IL-2R-targeted, **50:187–189**  
 Immune privilege  
   experimental autoimmune uveitis, **48:216–219**  
   eye, **48:191–221**  
 Immune reconstitution, marrow grafts and cytotoxic cells, accessory cells and neutrophils, **40:416–417**  
   effects of T cell depletion, **40:417–419**  
   humoral immunity, **40:414–416**  
   phenotype and function of peripheral T cells, **40:412–414**  
   repopulation of lymph nodes and thymus, **40:411–412**  
 Immune regulation  
   autoimmune uveitis, **48:215–216**  
   eye, **48:191–221**  
   intraocular tumor rejection, **48:212–215**  
   neoplasm, **48:212**  
   spontaneous neoplasm, **48:212**  
 Immune repertoire, self-tolerance checkpoints, **59:319–342**  
 Immune response, **52:125; 65:111**, *see also* Antibody response; Cellular immune response; Cellular immunity; Humoral immune response  
   affinity maturation, **43:126–127**  
   antigens, **64:1–3**  
   assessment, **43:6**  
   cellular dynamics, **60:267–268**  
   diversity in, antigen receptors, **43:106**  
   environmental antigen influences, **40:207–209**  
   factors regulating, accessory cells and isotype-specific response, **40:219**  
   gene control, **43:206–208**  
   heavy chain class switch, **40:219–223**  
   to HIV, **65:290–293**  
     acute infection, **65:293–296**  
     adverse effects of CTL activity, **65:309–311**  
     apoptosis, **65:306**  
     asymptomatic period of infection, **65:296–297**  
   CTL decline in late disease, **65:300**  
   CTL exhaustion, **65:304–305**  
   disease progression, **65:297–298**  
   escape mutation, **65:311–317**  
   long-term nonprogressors, **65:298–300**  
   in seronegatives, **65:287, 307–309**  
   Th1 to Th2 switch, **65:302–304**  
   therapeutic implications, **65:317–322**



- Immune response (*continued*)
- to MMTV, **65**:167–168, 212
    - adult T cell response, **65**:175–178
    - cellular response, **65**:192–194
    - humoral response, **65**:188–192
    - neonatal response, **65**:171–175, 203
    - receptors for, **65**:194–196
    - superantigen and T cell-independent, **65**:168–171
    - superantigen dependent, **65**:171–194
    - T–B interaction, **65**:180–188
    - T cell-dependent B cell differentiation, **65**:178–180
  - negative regulation, role of CTLs, **60**:303–310
  - ontogeny, in rabbits, **56**:186–187, 209
  - oral tolerance, **40**:223–226
  - phenotype, correlation with antigen-MHC interactions, **43**:212
  - plasmacytomagenesis, **64**:225–226
  - primary humoral, histology, **60**:269–272
  - regulation, IL-6 effects, **54**:21–22
    - B cells, **54**:21
    - T cells, **54**:21–22
  - role of T cell Fc receptor for isotype response, **40**:212–216
  - to superantigens, **54**:117–127
    - binding to major histocompatibility complex, **54**:117–120
    - direct non-T cell effects, **54**:127
    - recognition by T cell receptor, **54**:121–124
    - role of accessory CD4 or CD8 molecules, **54**:124–125
    - T cell deletion and anergy in injected animals, **54**:125–127
    - T cell signaling in response to superantigens vs conventional antigens, **54**:127
  - T cell networks in secretory immune system, **40**:217–218
  - T cell regulation of IgA response, **40**:209–212
  - Td B cell response, **62**:131–157
  - tumor antigens, **62**:217–245
  - against tumors. *see* Tumors, immune response
- Immune response genes, **38**:32, 33; **43**:207, 212
- antigen binding, **38**:98–115
  - antigen processing, **38**:93–97
  - antigen specificity, **38**:36, 37
  - complementation, **38**:72–83
  - cytotoxic T cells
    - classical type, **38**:161–174
    - epistatic effects, **38**:175–187
  - expression
    - in antigen-presenting cells, **38**:55–57
    - B cell responses, **38**:50, 52
    - in B cells, **38**:57, 58
    - codominance, **38**:36, 71, 80, 81, 97
    - complementation, **38**:73, 79, 82, 83
    - H-Y antigen, **38**:175, 177
    - Ia molecules, **38**:83, 84
    - I region mutations, **38**:84, 88, 90, 91
    - in lymphoid tissue, **38**:52–55
    - MHC restriction **65**, **38**:67
    - T cells, **38**:40–43, 58–63
      - cytotoxic, **38**:165, 167
      - interaction, **38**:156, 157, 159, 160
      - positive selection, **38**:130, 134
      - repertoire, **38**:116, 117
      - tolerance, **38**:127
  - function, theories of, **38**:91–93
  - gene function models, **38**:37–39
  - genetic locus, **38**:33–37
  - humoral immune response and, **45**:5
  - hybrid resistance and, **41**:361
  - Ia molecules, **38**:67–72
  - I region mutations, **38**:84–91
  - MHC, **38**:43–46
  - MHC restriction, **38**:63–67
  - polypeptides, responses to, **38**:46–50
  - “Schlepper” experiment, **38**:39, 40, 42
  - sporozoite malaria vaccine and, **45**:308–310
  - synthetic T and B cell sites and antigens, **45**:232
    - globular protein antigens, **45**:210, 211, 214
    - immunological considerations, **45**:198–201
    - viral antigens, **45**:221
  - T cells
    - germline repertoire limitations, **38**:115–118
    - interactions, **38**:153–160
    - positive selection, **38**:130–134
    - receptors, **38**:2
    - suppression, **38**:134–152

- T cell subsets and, **41:44**, **51**, **54**, **55**  
tolerance, **38:119–130**
- Immune states, and autoimmune and immunodeficiency states, antigen processing and presentation, **52:106–108**  
autoimmunity, **52:107**  
novel immunodeficiency states, **52:107–108**  
tumor immunology, **52:104–106**  
vaccines, **52:106–107**
- Immune surveillance theory, **48:212**
- Immune system, **63:269**
- B cell, and memory  
affinity maturation, **53:233–234**  
*bcl-2* oncogene role, **53:241**  
Fas antigen/APO-1 role, **53:241–242**  
germinal centers role, **53:231–233**  
intermitotic life span and, **53:237–241**  
memory cells  
functional properties, **53:236**  
generation of, **53:236–238**  
phenotype of, **53:234–236**  
peripheral, compartmentalization  
anatomic localization of colonizing lymphocytes, **53:159**  
CD5<sup>+</sup>/CD5 cell dichotomy, **53:178–183**  
generation of compartments, **53:187–194**  
lymph follicle B cells, **53:185–186**  
peritoneal B cells, **53:183–185**  
significance of, **53:199–203**  
site-dependent tolerance, **53:201–203**  
specialized functions of, **53:199–201**
- T cells  
intestinal intraepithelial, **53:163–167**  
 $\gamma/\delta$  invariant intraepithelial cells, **53:167–169**  
in liver, **53:169–171**  
in lymph nodes, **53:161–163**  
in peritoneum, **53:173–177**  
in spleen, **53:161–163**  
common mucosal, **40:197–199**  
in humans, **40:199–204**  
mechanism of homing of plasma cells to mucosal tissues and secretory glands, **40:204–207**  
complement system, **61:201–257**  
Ets transcription factors, **64:65–94**  
evolution of antigens, T<sub>CD8</sub><sup>+</sup>, what it recognizes, structure of class I molecules, **52:6–8**  
glucocorticoids and, **66:197**, **218**  
high endothelial venules, **65:373**, **375–377**  
hyperprolactinemia, **63:409–410**  
IL-1ra effects, **54:202–204**  
lymphocyte migration, HEVs and, **65:350–372**  
nonspecific, pituitary hormones, **63:407–408**  
peripheral compartments  
B cell, **55:429–430**  
T cell, **55:424–429**  
pituitary gland, **63:377**, **407–408**  
programmed cell death in, *see* apoptosis, in immune system  
secretory, T cell networks in, **40:217–218**  
soluble cytokine receptors, **63:285–290**  
T cell, and memory  
*bcl-2* oncogene role, **53:241**  
differentiation after antigenic stimulation, **53:229–230**  
effector cells, **53:227–230**  
Fas antigen/APO-1 role, **53:241–242**  
intermitotic life span and, **53:237–241**  
memory cells, **53:227–230**  
naive cells, **53:227–230**  
phenotypic identification of memory T cells, **53:224–227**  
TCR and signal transduction, **53:238–239**  
V(D)J recombination, **64:39–61**
- Immunity, *see also* Cellular immune response; Cellular immunity; Humoral immune response  
adaptive, NK cells and, **47:291–295**  
antitumor, antigen-presenting cells for, **58:436–437**  
epithelial and mucosal, **58:297–298**  
HIV-1 disease, **63:95–98**  
IL-2, **63:132**  
to infections and diseases, role of IELs, **58:326–329**
- innate  
and gene products regulated by NF- $\kappa$ B, **58:20–21**  
role of NF- $\kappa$ B and rel proteins, **58:1–27**  
role of IELs, **58:326–329**
- systemic  
enhancement, **58:428–429**  
and MHC class II molecules, **58:433–434**
- tumor-specific, **58:418–419**

- Immunity/tolerance phenomena, **59:279–281**
- Immunization
- antigen-presenting cells and, **47:67, 72, 86, 94**
  - with anti-Id antibodies, animal, **39:283–284**
  - HIV infection and, **47:407–410**
  - IgE biosynthesis and
    - antibody response, **47:2–6, 8, 9**
    - antibody response suppression, **47:30–32, 36**
    - binding factors, **47:14, 15, 23**
  - NK cells and, **47:282, 292, 293**
  - spontaneous autoimmune thyroiditis and, **47:433**
  - with TT, human responses to, *see* Tetanus toxoid
- Immunoadhesins, **64:310**
- Immunocytes, immature, **52:285**
- Immunodeficiencies, **54:142–143; 61:41, 311–312, 317**
- adenosine deaminase deficiency, **59:151, 246**
  - angioedema, **61:206**
  - ataxia telangiectasia, **61:191, 315**
  - autoimmune diseases, **59:146–147; 61:367; 342–344**
  - bare lymphocyte syndrome, **59:246–247; 61:327–338**
  - B cell formation and, **41:199, 200, 207, 216**
  - genetically determined defects, **41:224–226, 231**
  - Bloom's syndrome, **61:316**
  - Bruton's agammaglobulinemia, **61:312–314**
  - common variable immunodeficiency (CVID), **59:138, 143, 147, 150**
  - DiGeorge syndrome, **59:247**
  - DNA breakage syndromes, **61:314–316**
  - factor I, **61:213**
  - Fanconi's anemia, **61:315**
  - idiotypic network and, **39:274–275**
  - IgA deficiency, **65:245–263**
  - Lesch-syndrome, **59:159**
  - major histocompatibility complex, **61:327–338**
  - prevention by apoptosis-inhibitory drugs, **58:278–280**
  - purine nucleotide phosphorylase deficiency, **59:246**
  - selective T cell defect, **59:247**
  - severe combined, *see* Severe combined immunodeficiency
  - Wiskott-Aldrich syndrome, **59:159, 248**
  - xeroderma pigmentosum, **61:315**
  - X-linked, **59:248, 317**
    - murine, Btk implicated in, **60:41–42**
    - severe combined immunodeficiency, *see* Severe combined immunodeficiency
  - X-linked agammaglobulinemia, *see* X-linked agammaglobulinemia
- Immunodeficiency states, **52:106–108**
- and immune and autoimmune states,
    - antigen processing and presentation, **52:106–108**
    - autoimmunity, **52:107**
    - novel immunodeficiency states, **52:107–108**
    - tumor immunology, **52:104–106**
    - vaccines, **52:106–107**
  - novel, **52:107–108**
  - tumor immunology, **52:104–106**
  - vaccines, **52:106–107**
- Immunodeficient mouse
- HuSCID-derived antibodies, **57:230–231**
  - IL-5 production in, **57:171–172**
- Immunodepression
- hybrid resistance and, **41:385**
  - systemic, and T cell PCD, **58:214**
- Immunodiffusion, antinuclear antibodies and, **44:118, 120, 121**
- Immunodominance, cytotoxic T cells and, **38:180–185**
- Immunofixation, **38:207**
- Immunofluorescence
- anticomplement, **38:293**
  - antinuclear antibodies and, **44:109, 113, 120, 125**
  - autoimmune response, **44:133, 136**
  - scleroderma, **44:121, 122, 124, 125**
  - SLE, **44:104–106**
  - autoimmune thyroiditis and, **46:293**
  - B cell formation and, **41:188, 221**
  - CD5 B cell and, **47:118**
  - Ig gene expression, **47:153, 157**
  - lineage, **47:129**
  - marker for activation, **47:127**
  - complement receptor 1 and, **46:193**
  - complement receptor 2 and, **46:204, 210**
  - cytotoxicity and, **41:275, 298**

- direct two-color, for NK cell surface antigens, **42:200**  
 Epstein-Barr virus transformation, **38:277**  
 human-human hybridomas, **38:295, 296, 299**  
 human-murine hybridomas, **38:290**  
 IgE biosynthesis and, **47:4, 8, 19, 21**  
 immune response (*Ir*) gene complementation, **38:78**  
 indirect, in studies of CD antigen expression on basophils and mast cells, **52:336-337**  
 leukocyte integrins and, **46:158, 171**  
 murine lupus models and, **46:88, 95**  
 NK cells and, **47:211**  
 spontaneous autoimmune thyroiditis and, **47:445, 446, 462**  
 two-color, NKHI antigen analysis, **42:189**  
 Immunofluorescent cell sorting, NK clones and, **42:182-184**  
 Immunogenicity, **43:75**  
   antigen-presenting cells and, **47:101-105**  
   multiple antigen peptides based on schistosome antigens, **60:125-128**  
   multiple-branched multiple antigen peptides, **60:140-141**  
   (T1B)<sub>4</sub>, MAP construct, **60:114-120**  
 Immunogens  
   (BT)<sub>4</sub>, **60:109**  
   multiple antigen peptides  
     in helminthic diseases, **60:124-128**  
     in protozoan diseases, **60:108-124**  
     for viral and bacterial diseases, **60:128-136**  
 Immunoglobulin, **42:95; 43:235, see also** specific Igs  
   adoptive T cell therapy of tumors and, **49:312, 314, 330-331**  
   in antigen presentation by B cells, **39:52-53, 55-56, 58-59**  
   antigen-presenting cells and  
     antigen presentation, **47:66-70**  
     antigen processing, **47:89, 90**  
     cell surface, **47:62-64**  
     immunogenicity, **47:103**  
     interaction with T cells, **47:93**  
     tissue distribution, **47:47**  
   in antigen uptake by B cells, **39:60-62**  
   antinuclear antibodies and, **44:104, 110, 111, 120, 124**  
   aPL antibodies and, **49:194, 199, 259**  
   affinity purification, **49:228, 230**  
   antibody subsets, **49:232**  
   binding to cell membranes, **49:250, 252**  
   clinical aspects, **49:200, 203, 211**  
   isotype, **49:224**  
   pathogenic potential, **49:253-254, 257**  
   specificity, **49:237, 241, 243-244, 248**  
 autoimmune thyroiditis and, **46:318**  
   cellular immune responses, **46:288, 297**  
   experimental models, **46:274**  
   humoral responses, **46:300, 303-308**  
   prevention, **46:315, 316**  
 autoreactive T cells and, **45:427**  
 avian, V<sub>L</sub> gene diversification by gene conversion, **48:60-62**  
 B cell formation and, **41:182, 183, 237, 238**  
   B cell precursors, **41:188, 189, 191, 193-195, 199-202**  
   bone marrow cultures, **41:209, 217, 218**  
   CBA/N mice, **41:226**  
   inducible cell line, **41:221, 223**  
   lymphohemopoietic tissue organization, **41:187**  
   population dynamics, **41:206, 207**  
   SCID mice, **41:225**  
 carbohydrate component, mobility, **48:26-32**  
 CD4 and CD8 molecules and, **44:268, 269, 297, 302**  
   CD4 molecular biology, **44:286-288, 296**  
   CD8 molecular biology, **44:272, 274-276**  
 CD5 B cell and, **47:161, 162**  
   gene expression, **47:150-159**  
   genetic influence, **47:148**  
   lineage, **47:128**  
   malignancies, **47:123**  
   physiology, **47:137, 138, 140-142**  
   surface antigen, **47:143, 146**  
 CD23 antigen and, **49:150-151, 156-158**  
 cell-mediated killing and, **41:291**  
 characterization, **43:7**  
 CH switching rearrangement, **43:239**  
 class switching by B cells, **60:270-271**  
 complement receptor 1 and, **46:193, 198, 200**  
 complement receptor 2 and, **46:203, 205, 207, 208, 211**  
 CTL and, **41:168**

- Immunoglobulin (*continued*)  
 definition of clonality based on,  
**40:295–305**  
 distribution in body, **40:153**  
 diversification  
   evolutionary mechanism, **48:62**  
   mechanisms, **48:62**  
 domains, cysteine loop relationships,  
**43:285**  
 effector functions, I flexible, **48:1**  
 Fc receptors for, *see* Fc receptors  
 fold, **43:108**  
 genetically engineered antibody molecules  
   and, **44:66, 89**  
   antigen-combining sites, **44:84**  
   biological properties, **44:82, 83**  
   chimeric antibodies, **44:80–82, 87, 88**  
   cloning, **44:73–75**  
   expression, **44:71, 72, 75–79**  
   fusion proteins, **44:85, 86**  
   lymphoid mammalian cells, **44:69, 70**  
   production, **44:67–69**  
   surface Ig, **44:89**  
 heavy chain, *see* Heavy chain  
 heavy chain variable region genes, *see*  
   Heavy chain variable region, genes  
 helper T cell cytokines and  
   cross-regulation of differentiation, **46:132**  
   differential induction, **46:127, 128, 130**  
   functions, **46:114, 116, 118–122**  
   human subsets, **46:139**  
   immune responses, **46:133, 135, 137, 138**  
   precursors of differentiation states,  
     **46:126**  
   secretion patterns, **46:113**  
 HIV and, **45:351, 353, 356, 362, 365**  
 HIV infection and, **47:390, 406, 408**  
 human, rotational correlation times,  
**48:28–29**  
 humoral immune response and, **45:4, 6, 8**  
   antigens, **45:10, 12, 13, 16–18, 21**  
   cellular interactions *in vivo*, **45:80, 82–84**  
   helper T cells, **45:26, 27, 29, 32–35**  
   interleukins, **45:55, 63–72, 76**  
   physical interaction, **45:40, 43, 44, 49, 50, 52**  
 hybrid resistance and, **41:357, 365, 366, 378, 379**  
 IBD and, **42:301–307**  
 IL-1 and, **44:177–179, 183, 190**  
 IL-5-regulated production, **57:151–154**  
   IgA, **57:152–153**  
   IgE, **57:153**  
   IgG, **57:153**  
 immunosenescence and  
   lymphocyte activation, **46:223, 224, 231, 232, 234, 236**  
   lymphocyte subsets, **46:237, 239**  
   mucosal immunity, **46:251**  
   regulatory changes, **46:248, 249, 251**  
   stem cells, **46:240, 242, 243**  
 internal movement, **48:1–34**  
 intravenous, replacement therapy with,  
**60:40**  
 isotype, B cell subsets and, **40:19**  
 isotype switching  
   history, **54:229–231**  
   in humans, **54:260–262**  
     IL-4 role in regulation, **54:260–262**  
     TGF- $\beta$  and IgA expression, **54:262**  
 IFN- $\gamma$  regulation, **54:256–257**  
   mechanism of switch recombination,  
     **54:234–240**  
   organization of heavy chain locus in  
     mouse and human, **54:231–233**  
   switch regions, **54:233–234**  
 IL-4-induced regulation  
   enhancement of switching to IgE and  
     IgG, **54:248–249**  
   molecular mechanisms, **54:252–256**  
   role in T cell-dependent switching,  
     **54:249–252**  
   stimulation of IgE and IgG  
     production, **54:247–248**  
 molecular mechanism, **54:231–246**  
   directed switching and germline C<sub>H</sub>  
     transcription, **54:240–245**  
   expression of downstream isotypes  
     without switch recombination,  
     **54:245–246**  
   TGF- $\beta$ -induced, **54:257–259**  
 leukocyte integrins and, **46:149, 150, 168, 171**  
 ligand, **48:1**  
 light chain, *see* Light chain  
 lymphocyte homing, **44:326, 327, 335, 336, 64:147, 157–160**  
 measles and, **45:340, 341**

- membrane, induced tyrosine phosphorylation, targets, **55:248–249**  
 CD22, **55:245–246**  
 Ig- $\alpha$ , **55:246–248**  
 Ig- $\beta$ , **55:246–248**  
 mitogen-activated protein kinase, **55:244–245**  
 p21<sup>ras</sup>, **55:238–240**  
 p95<sup>ras</sup>, **55:243–244**  
 phosphatidylinositol 3-kinase, **55:241–243**  
 phospholipase, **55:234–238**  
 rasGAP, **55:239–240**  
 rasGAP-associated proteins, **55:240–241**  
 Vap-1, **55:243**  
 mRNA, **43:239**  
 $\mu$  chains, **43:238–239**  
 NK cells and, **47:203, 292–294**  
 production  
   Cd40 and, **63:58–70**  
   switch recombination signals, **63:58–59**  
 promoter elements, **43:269**  
   B cell preference, **43:258**  
   enhancer interactions, **43:263–265**  
   heavy chain, common factors with enhancers, **43:256–257**  
   interaction between multiple proteins and conserved octanucleotide, **43:254–255**  
   light chain, sequence conservation, **43:257**  
   nuclear factor interaction with conserved heptamer, **43:255**  
   sequence conservation, heavy chain V gene promoters, **43:252**  
   sequences required for heavy chain gene expression, **43:253–254**  
   tissue and stage specificity, **43:251, 255–256**  
   VH promoter activity, **43:252–253**  
    $\kappa$  activity, required octamer, **43:257–258**  
    $\kappa$  V gene promoters, **43:258**  
 rabbit anti-mouse  
   presentation by B cells, **39:52–53, 55–56**  
   B cell activation and, **39:70**  
   uptake by B cells and macrophages, **39:60–62**  
 recognition function, **48:1**  
 regulating transcription, **43:240**  
 regulators of complement activation and, **45:382, 390, 398**  
 replacement therapy, **59:150**  
 rotational correlation times, **48:28–29**  
 SCID and, **49:388, 400–401**  
 secretion  
   human-murine hybridomas, **38:287, 288**  
   hybridoma propagation, **38:302**  
   requirements for, **40:83–90**  
 segmental flexibility, **48:5–19**  
   electron microscopy, **48:2–3**  
   fluorescence polarization, **48:3–5**  
   hydrodynamic study methods, **48:2**  
   nanosecond, **48:4–5**  
   spin-label approach, **48:5**  
   steady state, **48:4**  
   study methods, **48:1–34**  
   X-ray crystallography, **48:3**  
 sequence selection in chicken B cell development, **57:369–372**  
 sequence variability, **43:11, 14**  
 somatic rearrangement of gene elements to create functional antibody gene  
    $\gamma$  light chain genes, **40:251–252**  
   heavy chain gene assembly, **40:252–253**  
   heavy chain gene order and class switching, **40:257–258**  
   human  $\mu$  light chain genes, **40:249–251**  
   recombinational mechanisms in joining of segments of variable region, **40:253–256**  
   sequential activation of Ig genes, **40:256–257**  
 spontaneous autoimmune thyroiditis and altered thyroid function, **47:458**  
 cellular immune reactions, **47:452**  
 histopathology, **47:440**  
 humoral immune reactions, **47:445, 446, 448**  
   potential effector mechanisms, **47:469**  
 sporozoite malaria vaccine and, **45:286, 307**  
 structure of, **40:61–63**  
 superfamily molecules, **58:372–376**  
 superfamily of adhesion molecules, **52:167**  
 supergene family, recognition molecules of, **52:361–364**  
   CD4 and CD8, **52:363**  
   ICAM-1/CD54, **52:361–363**  
   LFA-2/CD2 and LFA-3/CD58, **52:361**  
   MHC class I and class II molecules, **52:364**

- Immunoglobulin (*continued*)
- other recognition molecules of Ig superfamily, **52:364**
  - stem cell factor receptor (SCF-R)/c-kit, **52:363–364**
  - VCAM-1, **52:363**
  - surface antigens of human leukocytes and, **49:81–82, 98, 118**
    - antigen-specific receptors, **49:76–79**
    - receptors, **49:89–91**
  - surface Ig, B cell proliferation, **63:56**
  - synthesis, hybridomas and, **38:293, 299**
  - T cell development and, **44:209, 217, 243**
  - T cell receptor and, **38:1, 2**
    - accessory molecules, **45:109**
    - antigen processing, **45:118**
    - experimental systems, **45:131**
    - homogeneity, **45:129**
    - MHC molecules, **45:111**
    - protein properties, **38:3–5**
  - and T cell receptor gene rearrangements as lineage markers
    - acute lymphoid leukemia with 4:11 chromosomal translocation, **40:293**
    - diffuse large cell lymphoma, **40:292**
    - hairy cell leukemia, **40:291–292**
    - Hodgkin's disease, Lennert's lymphoma and angioimmunoblastic lymph adenopathy, **40:294**
    - lymphoid blast crisis of chronic myelogenous leukemia, **40:290–291**
    - malignant histiocytosis complicating celiac disease, **40:292–293**
    - pseudo T cell lymphoma, **40:294–295**
  - transcriptional enhancer elements, *see also* Protein-binding sites
    - activation and V-DJ joining, **43:241–242**
    - B cell preference, **43:258**
    - common factors with heavy chain promoters, **43:256–257**
    - containing bind sites, **43:264**
    - dependent transcription, **43:246**
    - EcoRI* site, **43:249**
    - IgH enhancer-binding proteus, **43:247–248**
    - increase local concentration of factors, **43:264**
    - in vivo* protein-binding sites, **43:243–244**
    - $\kappa$  enhancer, **43:249**
    - light chain enhancer elements, **43:249–250**
    - location, **43:242**
    - mechanism, **43:240–241**
    - negative regions, **43:248–249**
    - promoter interactions, **43:263–265**
    - tissue specificity, **43:242**
    - transcription initiation, **43:242–243**
  - transcriptional regulation mechanisms, **43:258–259**
    - enhancer independence and dependence of VH promoter, **43:265–266**
  - lymphoid-specific octamer factor, **43:261–262**
  - octamer as tissue-specific element, **43:260–263**
  - octamer-binding protein forms, **43:261**
  - promo/a-enhancer interactions, **43:263–265**
  - tissue and stage specificity, **43:259–260**
  - ubiquitous factor, **43:263**
  - V-D-J joining, **43:237–239, 241–242**
  - transgenic mouse, CD5 B cells in, **55:324–326**
  - V(D)J joining of antigen receptor genes at loci
    - endogenous substrate, **56:34–37**
    - gene assembly, **56:28–32**
  - Immunoglobulin genes, **59:332**, *see also* Heavy-chain variable region, genes and antibody repertoire generation in rabbit
    - C<sub>H</sub>, **56:191–193**
    - D, **56:189–191**
    - IgA, **56:192**
    - IgD, **56:192**
    - J<sub>H</sub>, **56:188–191**
    - $\kappa$  light-chain, **56:193–194**
    - $\lambda$  light-chain, **56:194**
    - organization, **56:187–188**
  - B cell development, **63:20–21**
  - chicken B cell
    - conversion
      - allelic exclusion, **57:372, 374**
      - avian leukosis virus induction of DT40 cell line, **57:361–362**
      - rearrangement in bursa, **57:365–367**
      - recombination models, **57:362–365**
    - organization
      - D elements, **57:356–358**

- heavy chain loci, **57:354–356**  
 light chain loci, **57:354–356**
- defects  
 heavy chain disease and, **40:305–306**  
 hereditary primary immunodeficiency disorders, **40:306–309**
- expression  
 during B cell development, **43:236–240**  
 B cell-specific, **43:253**  
 heavy chain and  $\kappa$  chain, **43:236–237**  
 tissue specific, **43:235**
- germline, murine lupus models and, **46:65, 66**  
 autoantibodies, **46:71–76**  
 inducing agent, **46:78**  
 murine lupus, **46:66–71**  
 somatic mutation, **46:76, 77**
- T cell antigen receptor, **46:98**
- H- and L-chain, **60:277–278**
- human T cell antigen and, **41:3, 10**
- rearrangements, **58:31, 37–41**  
 aberrant, **58:63**  
 applications to clinical medicine, **40:264–270**  
 regulation, **54:375**
- superfamily, **44:1–3**
- evolution  
 diversity, **44:44–46**  
 DNA, **44:46, 47**  
 homology unit, **44:43, 44**  
 implications, **44:47–49**  
 homology unit, **44:3–9**
- MHC complex, **44:24–29**
- nonimmune receptor members, **44:29, 30**  
 growth factor, **44:39**  
 Ig-binding molecules, **44:38, 39**  
 kinase, **44:39**  
 $\beta$ 2-microglobulin, **44:30, 31**  
 miscellaneous members, **44:39–41**  
 nervous system molecules, **44:35–38**  
 T cell-associated molecules, **44:31–36**  
 uncertain members, **44:41, 42**
- receptors, **44:9–12**  
 diversification strategies, **44:20–24**  
 organization, **44:12**  
 somatic diversification, **44:12–20**
- T cell subsets and, **41:40, 41, 46, 52**
- Immunoglobulin receptors, **52:378–396**  
 B cell, signal transduction through, downregulation, **54:374**  
 B cell differentiation and expression, **54:338–343**  
 B cell-specific proteins in IgR complex identified by molecular cDNA cloning, **54:348–357**
- Fc $\alpha$ , **60:182**  
 Fc $\gamma$ , **60:179–181**  
 Fc $\epsilon$ , **60:181**
- functions, **54:345–348**  
 activation of B cells for proliferation and differentiation, **54:345–346**  
 cytoskeletal interactions, **54:346**  
 endocytosis and processing of membrane IgR/antigen complex, **54:348**  
 transportation of assembled IgR structure retaining functions, **54:347**
- future perspectives, **54:379–380**
- high affinity receptor for IgE/Fc $\epsilon$ RI, **52:378–381**  
 assembly, **52:381–382**  
 cell surface structures functionally associated with Fc $\epsilon$ RI molecules, **52:391–396**  
 cell surface glycolipids, **52:393–394**  
 Fc $\gamma$  receptors, **52:394–396**  
 G63, **52:394**  
 mast cell chromolyn binding sites, **52:392–393**  
 ME491 (CD63), **52:393**
- chromosomal location, genomic organizations, and mRNA species, **52:382–383**
- control of synthesis and expression of dependence on IgE, **52:385**  
 Fc $\epsilon$ RI molecules, **52:384–386**  
 half-life, internalization, degradation and reexpression, **52:385–386**  
 synthesis during cell cycle, **52:385**  
 synthesis during differentiation of basophils/mast cells from hemopoietic precursor cells, **52:384–385**
- functional characterization of receptor, **52:387–391**  
 binding to IgE, **52:387–388**



- Immunoglobulin receptors (*continued*)  
 effector mechanisms and functional changes of mast cells/basophils following activation through IgE binding sites, **52:391**  
 signal transduction and distal events, **52:388–391**  
 numbers and binding constants on basophils/mast cells, **52:386–387**  
 sequence and structural homologies, **52:383–384**  
 conversation during evolution, **52:383**  
 molecules related to FcεRI α chain, **52:383**  
 molecules related to FcεRI β chain, **52:383–384**  
 molecules related to FcεRI γ chain, **52:384**  
 topology of, **52:378**  
 α chain, **52:379**  
 β chain, **52:379–380**  
 γ dimer, **52:380–381**  
 nomenclature, **52:378**  
 IgM-RF, **64:288**  
 isotypes of IgG receptor, **54:343–344**  
 membrane, **63:43**  
 membrane and secreted, **54:342–343**  
 membrane IgM receptor induction by Ig gene transfection, **54:357–359**  
 polymeric, **65:249**  
 regulation by interaction of CD44 extracellular domain, **54:315–317**  
 signal transduction and pathway through IgR transmembrane signaling, **54:359–378**  
 T cell subsets and, **41:77**
- Immunointervention  
 in autoimmune diseases, **66:91–93**  
 in sepsis, **66:150–151**
- Immunological antigen receptors, **43:133–136**
- Immunological cell, neuropeptide mediation, **48:176, 177**
- Immunological factor  
 low-molecular-weight mediators, **48:175**  
 neural effects, **48:173–174**
- Immunological mediator  
 astrocyte, **48:168–169**  
 glioblastoma cell, **48:168–169**  
 microglial cell, immune synthetic capabilities, **48:168**  
 neural sources, **48:168–169**
- Immunological memory  
 and autoimmunity, **53:251–252**  
*bcl-2* oncogene and, **53:241**  
 and B cell immune system, germinal centers role, **53:231–233**  
 Fas antigen/APO-1 and, **53:241**  
 generation, theories of, **53:219–220**  
 life span of, **53:218–219**  
 lymphocyte migration and, **53:242**  
 maintenance  
 by constant antigenic stimulation, **53:221–222**  
 by long- and short-lived cells, **53:223–224**  
 by long-lived clonally expanded cells, **53:220–221**  
 and self-tolerance, **53:249–251**  
 and T cell immune system  
 differentiation after antigenic stimulation, **53:229–230**  
 effector T cell function, **53:227–228**  
 memory T cell functions, **53:227–228**  
 naive T cell function, **53:227–228**  
 TCR and signal transduction, **53:228–229**
- Immunological privilege  
 anterior chamber, **48:203–212**  
 corneal allograft, **48:192–203**  
 hapten model, **48:211–212**
- Immunological systems, programmed cell death in, **50:63–70**  
 in B cells, **50:63–66**  
 clonal abortion, **50:64**  
 faulty recombination, **50:63–64**  
 growth arrest of WE III-231 B cell line, **50:64–65**  
 somatic mutation and terminal differentiation, **50:65–66**
- interphase death of T and B cells and nonspecific damage, **50:69–70**  
 splenic B cells, **50:65**  
 in T cells, **50:66–69**  
 CTL targets, death, **50:69**  
 deprived of growth factors, **50:68–69**  
 hybridomas, activahon-induced death, **50:67**  
 non-selected thymocyte, death, **50:67–68**  
 thymus, negative selection, **50:66**

- Immunomodulation, experimental  
 autoimmune encephalomyelitis,  
**48:166–167**
- Immunopathology, IFN- $\gamma$  and, **62:96–104**,  
 106–107
- Immunopoiesis, T cell-dependent B cell,  
 antigen-induced, in secondary lymphoid  
 organs, schematic representation,  
**52:222–223**
- Immunopotentiators, and autoimmune  
 diabetes, **51:306**
- Immunoprecipitation  
 antinuclear antibodies and, **44:111**, 120,  
 129  
 autoimmune response, **44:135**, 136  
 scleroderma, **44:123**, 124  
 Sjögren's syndrome, **44:113**, 115  
 SLE, **44:104**, 105  
 B cell formation and, **41:221**  
 CD1 proteins, **59:45–46**  
 CD4 and CD8 molecules and, **44:271**, 285  
 IL-1 and, **44:163**  
 T cell activation and, **41:19**  
 T cell development and, **44:218**, 233, 243
- Immunoprophylaxis, role of MAP  
 immunogens, **60:105–106**
- Immunoproteasomes, **64:16**, 17
- Immunoregulation  
 antiidiotypic, B cell repertoire expression  
 and, **42:35**, 82  
 complement receptor 1 and, **46:200**, 201  
 complement receptor 2 and, **46:205–210**  
 immunosenescence and, **46:247**  
 NO role, **60:348–349**
- Immunoregulation disorders, IBD and,  
**42:286**
- Immunosenescence, **46:221**, 253  
 lymphocyte activation, **46:221**, 222,  
 234–236  
 cell cycle, **46:222**, 223  
 chromatin, **46:234**  
 early events, **46:223–227**  
 housekeeping, **46:234**  
 protein, **46:227–230**  
 secondary signal, **46:230–234**  
 lymphocyte subsets, **46:240**  
 human, **46:238**, 239  
 murine, **46:236–238**  
 marker density, **46:239**  
 mucosal immunity, **46:251–253**  
 regulatory changes, **46:247**  
 idiotypic, **46:247–249**  
 suppressor cells, **46:249–251**  
 stem cells, **46:246**, 247  
 lymphoid, **46:242–244**  
 pluripotent, **46:240**, 241  
 thymus, **46:244–246**
- Immunostimulation, by apoptosis-inhibitory  
 drugs, **58:278**
- Immunosuppressants, and autoimmune  
 diabetes, **51:307**
- Immunosuppression  
 aPL antibodies and, **49:223**, 258  
 hybrid resistance and, **41:340**, 353, 354,  
 386–388  
 IFN- $\gamma$  as mediator, **62:89–90**, 105–107  
 virus-induced, *see* Virus-induced  
 immunosuppression
- Immunosuppressive drug, corneal  
 transplantation, **48:193**
- Immunosuppressive factors, tumor  
 immunogenicity affected by, **57:307–309**
- Immunosuppressive molecules, *see*  
 Antiinflammatory and  
 immunosuppressive molecules
- Immunosuppressive therapy, in PNH, **60:91**
- Immunotherapy  
 active, **62:219**  
 adoptive, **58:437–438**  
 for EAMG, **42:263–269**  
 HIV, **65:317–320**  
 for MG, **42:235**, 269–272  
 NF- $\kappa$ B inhibition, **58:19–20**  
 pulmonary inflammation, **62:259**, 285–290  
 tumors, **62:218–219**
- Immunotoxins, MG and, **42:264–265**
- Importin- $\alpha$  family, **64:48**
- Incomplete Freund's adjuvant, autoimmune  
 thyroiditis and, **46:277**
- Indirect immune precipitation assay, for MG,  
**42:254–255**
- Indoleamine-2,3-dioxygenase, **62:71**
- Indomethacin, **62:184**, 186, 201  
 IBD and, **42:313**  
 Ig secretion and, **40:103**, 106  
 mode of action, **64:172**
- Inducing agents, murine lupus models and,  
**46:78**
- Induction, mechanism of action of death  
 genes, **50:71–73**

- Infection, *see also* Viral infection  
 cachectin and, **42:213, 219**  
 gut microflora and, **40:208–209**  
 IBD and, **42:319**  
 IgG response, **42:305**  
 IFN- $\gamma$  and, **62:94–96**  
 and IL-1ra administration *in vivo*,  
**54:204–209**  
 in animal models of sepsis, **54:204–207**  
 in human infections and sepsis,  
**54:207–209**
- IL-5 role  
 helminth, **57:176–177**  
 parasite, **57:172–173**  
 immunity, role of IELs, **58:326–329**  
 lung, immunity, **59:394–412**
- MHC class I-deficient mouse responses  
 bacterial infections, **55:412–413**  
 filarial parasites, human, **55:415**  
*Leishmania major*, **55:414–415**  
 pathogens, **55:404–415**  
*Trypanosoma cruzi*, **55:414–415**  
 viral infections, **55:406–412**
- models, NO role, **60:341–343**  
 retroviral, as substrate introduction method  
 in V(D)J joining, **56:50–51**  
 rheumatoid arthritis, **64:289–290**  
 susceptibility, cA2 therapy, **64:325–329**  
 X-linked agammaglobulinemia, **59:**  
**135–136, 143–146, 150**
- Infections, mycoplasmic, X-linked  
 agammaglobulinemia, **59:146**
- Infectious disease  
 aPL antibodies and, **49:193, 210–212, 221,**  
**257**  
 protective immune responses to, role of  
 multiple antigen peptides, **60:105–141**  
 role of multiple antigen peptides,  
**60:105–141**
- Infectious mononucleosis  
 acute, immunoregulatory cell functions in,  
**37:115–122**  
 associated suppressor T cells activity,  
 reversal by aD D-mannose and  
 saccharides, **37:138–142**  
 Epstein-Barr virus and, **37:112–115**  
 NK cells and, **47:224**
- Infectivity, SIVmac and SIVsm molecular  
 clones, **52:448**
- Inflammation  
 adoptive T cell therapy of tumors and,  
**49:290–291, 311, 328**  
 allergic  
 chronic, **60:164–165**  
 and eosinophils, **60:217–223**  
 expression of selectins and integrins,  
**60:169–173**  
 generation of SRS-A leukotrienes,  
**60:190**  
 CD23 antigen and, **49:161**  
 chemokines and, **66:135**  
 clinical stages, **60:325–326**  
 complement receptor 2 and, **46:205**  
 cytokines, **63:310**  
 eosinophilic, **60:159–162**  
 helminth-induced, **60:214**  
 helper T cell cytokines and, **46:115–117**  
 IFN- $\gamma$  and, **62:103–104, 105, 281, 288–289**  
 IL-5-associated, in asthmatic patients,  
**57:174–176**  
 IL-6 and, **66:129**  
 induced carcinogenesis, **60:345–346**  
 intrinsic coagulation/kinin-forming cascade  
 and, **66:225–261**  
 leukocyte integrins and, **46:149–151, 160,**  
**161, 177**  
 animal models, **46:165**  
 expression, **46:166–169**  
 function, **46:161–165**  
 ligand molecules, **46:170**  
 mAbs, **46:165, 166**  
 leukocyte recruitment during, **58:394–395**  
 LIF role, **53:37–38**  
 lymphocyte homing, **64:185–187, 188–193**  
 lymphocyte homing and  
 high endothelial venules, **44:315, 317**  
 molecules, **44:344, 349, 352**  
 regional specificity, **44:338–341**  
 mediators of, **42:286, see also** Cachectin  
 in IBD, **42:310–315**  
 MIF, **66:206–207**  
 and NF- $\kappa$ B, **58:9–14**  
 nonspecific, IFN- $\gamma$  and, **62:103–104**  
 PGHS-2, **62:201**  
 pulmonary, *see* Pulmonary inflammation  
 role of NO, **60:323–354**  
 sepsis  
 contact cascade and, **66:235**  
 cytokines and, **66:103–150**  
 MIF and, **66:210–212**

- surface antigens of human leukocytes and, **49:87**, 111  
and T helper cell activation, **58:106**
- Inflammatory arthritis, IL-1ra in, **54:209–211**  
animal models, **54:210**  
patients with, **54:210–211**  
*in vitro* studies, **54:209–210**
- Inflammatory bowel disease, *see also* Crohn's disease; Ulcerative colitis  
antibody secretion in, **42:301–307**  
anti-TNF- $\alpha$  therapy, **64:307–310**  
cell-mediated cytotoxicity in, **42:294–297**  
clinical characteristics of, **42:285**  
complement pathway products in, **42:308–310**  
cytotoxicity as cause of, **42:295–297**  
etiology of, **42:285**  
general considerations in, **42:285–286**, 287  
genetic defect in, **42:319**  
genetic markers in, **42:288**  
granulocyte function in, **42:307–308**  
household contacts and, **42:291**  
IL-1ra in, **54:214–215**  
immunopathology of, **42:297–298**  
immunoregulatory alterations in, **42:299–301**  
inflammatory cells in lesions of, **42:297**  
lipid extract of mucosa in, **42:315**  
mediators of inflammation in, **42:310–315**  
pathogenesis of, **42:319–322**  
peripheral blood lymphocyte function in, **42:288–290**  
pitfalls in study of, **42:286**  
sequence of immunologic events in, **42:287**  
serum antibodies  
DR antigens, **42:292–294**  
*Escherichia coli*, **42:291–292**  
lymphocytotoxic antibodies, **42:291–294**  
therapy for, **42:316–319**
- Inflammatory conditions, complement components and, **38:233**
- Inflammatory demyelination, experimental autoimmune encephalomyelitis, **48:166–167**
- Inflammatory diseases  
and IL-6, **54:39–43**  
MIF, **66:210**  
acute respiratory distress syndrome, **66:214–215**  
arthritis, **66:213–214**  
delayed-type hypersensitivity, **66:212**  
glomerulonephritis, **66:212–213**  
malaria, **66:215–216**  
septic shock, **66:210–212**  
models, **60:343–345**  
NF- $\kappa$ B and, **65:117–118**
- Inflammatory joint diseases, cachectin and, **42:225**
- Inflammatory mediators, **66:101**
- Inflammatory reactions, **65:11**, 122–123
- Inflammatory response  
autoreactive T cells and, **45:428–430**, 433  
B cell formation and, **41:208**, 237  
lymphoid cells and, **41:354**  
therapy, NF- $\kappa$ B inhibition, **58:19–20**
- Influenza  
sporozoite malaria vaccine and, **45:307**  
synthetic T and B cell sites and antigens, **45:234**  
vaccine, **45:253–255**  
viral antigens, **45:216–219**
- T cell receptor and  
antigen processing, **45:119**, 122, 125, 126  
epitopes, **45:143**  
homogeneity, **45:128**  
peptides, **45:133**  
structure-function relationships, **45:135**, 141  
virus-induced immunosuppression and, **45:356**
- Influenza virus  
cachectin and, **42:220**  
CTL and, **41:136**, 168  
amino acid, **41:165**  
exon shuffling, **41:144**, 146  
HLA class I antigens, **41:151**, 152  
mAbs, **41:151**, 166, 167  
cytotoxic T cells and, **38:165**, 172; **65:278**  
type A, **38:165**  
hybrid resistance and, **41:375**  
and memory  $\gamma\delta$  T cells, **58:328–329**  
pneumonia, **59:408–409**  
responses in MHC class I-deficient mouse, **55:406–407**
- Inheritance  
Mendelian, maternally transmitted antigen and, **38:338**  
RA susceptibility, **56:441–446**

- Inhibition, *see also* Allogeneic inhibition  
 adoptive T cell therapy of tumors and,  
   **49:285, 320, 327**  
   mechanisms, **49:307, 313**  
   principles, **49:287–289**  
 antigen-presenting cells and, **47:69, 77**  
 aPL antibodies and, **49:193, 259**  
   clinical aspects, **49:200–202**  
   history, **49:198–199**  
   pathogenic potential, **49:253–254,**  
     **256–257**  
   specificity, **49:236, 239, 241–244, 247,**  
     **252**  
 autoimmune demyelinating disease and,  
   **49:358, 370–371**  
 B cell formation and, **41:236**  
   B cell precursors, **41:91, 92**  
   bone marrow cultures, **41:216**  
   inducible cell line, **41:222, 223**  
 CD5 B cell and, **47:161**  
 CD23 antigen and  
   biochemical structure, **49:156–157**  
   biological activity, **49:168–170, 172–173**  
   cellular expression, **49:152, 154**  
   expression regulation, **49:160–161**  
   Fc $\epsilon$ RII, **49:164**  
 CTL and, **41:168, 169**  
   amino acid, **41:162**  
   carbohydrate moieties, **41:152–154**  
   exon shuffling, **41:139**  
   HLA class I antigens, **41:149–151**  
   mAbs, **41:157, 158**  
 cytotoxicity and  
   cell-mediated killing, **41:295, 296**  
   cytolysis, **41:276, 281, 282**  
   cytolytic proteins, **41:317**  
   membrane attack complex of  
     complement, **41:309**  
 HIV infection and  
   etiological agent, **47:379**  
   immune response, **47:406, 408**  
   immunopathogenic mechanism, **47:386,**  
     **390–392, 394, 395**  
 hybrid resistance and  
   antibodies, **41:378**  
   antigen expression, **41:397, 402, 404, 409**  
   bone marrow cells, **41:337–340, 347, 348**  
   effector mechanisms, **41:370**  
   leukemia/lymphoma cells, **41:358, 364,**  
     **367**  
   lymphoid cells, **41:351, 352, 354, 356**  
   macrophages, **41:371, 372**  
   marrow engraftment, **41:387**  
   marrow microenvironment, **41:390–392**  
   NK cells, **41:374–376**  
   syngeneic stem cells, **41:388, 390**  
   T cells, **41:381, 382**  
   *in vitro* assays, **41:394–396**  
 IgE, **43:281–282**  
 IgE biosynthesis and  
   antibody response, **47:7, 9, 33, 39**  
   binding factors, **47:12, 19, 23–25**  
 Ig heavy-chain variable region genes and,  
   **49:46**  
 NK cells and, **47:298**  
   adaptive immunity, **47:291–294**  
   antimicrobial activity, **47:284, 287–290**  
   CNS, **47:268, 269**  
   cytotoxicity, **47:249, 253, 254, 257, 259**  
   effector mechanisms, **47:237, 238, 240,**  
     **242, 243, 245–247**  
   hematopoiesis, **47:273, 274, 276–280**  
   morphology, **47:218**  
 SCID and, **49:383**  
 spontaneous autoimmune thyroiditis and,  
   **47:477**  
 surface antigens of human leukocytes and,  
   **49:89, 92–93, 111–112, 114**  
 T cell activation and, **41:9, 22, 26**  
 T cell subsets and  
   H-2 alloantigen recognition, **41:79, 82,**  
     **85, 86, 90, 91**  
   H-2 molecules in thymus, **41:109, 110**  
   H-2-restricted antigen recognition,  
     **41:60, 61, 74, 76**  
 Inhibitors, use to block *in vitro* tolerance,  
   **54:415–418**  
 Inhibitory proteins,  $\text{I}\kappa\text{B}$ , **63:157–159**  
   description, **58:2–4**  
   phosphorylation by  $\text{TNF}\alpha$ , **58:8**  
   rapid degradation and release of  $\text{NF-}\kappa\text{B}$ ,  
     **58:4–5**  
 Injury  
   acute states, therapeutic regulation of  
     complement system in, *see*  
     Complement  
   thermal, therapeutic regulation of  
     complement system in, **56:280–281**  
   vascular endothelial, by  $\text{TNF}$ , **56:351**

- Inner core matrix, branched, in multiple antigen peptides, **60**:106–108
- myo*-Inositol, structure, **48**:255
- Inositol 1-monophosphate, phosphoinositide-specific phospholipase, **48**:253
- Inositol phosphates  
in cells undergoing PI hydrolysis, **43**:292  
isomers, dephosphorylation pathways, **48**:255
- Inositol triphosphate, T cell activation and, **41**:15, 16, 21, 24, 26, 30
- Inositol 1,4,5-trisphosphate, **43**:295; **48**:228  
Ca<sup>2+</sup> release by neutrophils and, **39**:124–127  
PIP<sub>2</sub> hydrolysis in neutrophils and, **39**:124
- Insertions, endogenous retroviral, inseparable from Vbse, **50**:38–39
- Insulin  
autoimmune thyroiditis and, **46**:269  
autoreactive T cells and, **45**:420  
B cell formation and, **41**:197  
bovine  
B chain, processing by B cells, **39**:87  
intact, defective processing by B cells, **39**:87  
CD4 molecules and, **44**:293  
gene, transcriptional factor, **48**:142  
hexamers, **43**:103–104  
hybrid resistance and, **41**:402  
IL-1 and, **44**:169, 184, 188  
immune response genes and, **38**:32  
I region mutations, **38**:86–89  
MHC restriction, **38**:66, 84  
T cell suppression, **38**:142–144  
tolerance, **38**:125, 126  
murine lupus models and, **46**:79  
spontaneous autoimmune thyroiditis and, **47**:440  
synthetic T and B cell sites and, **45**:202, 209, 214, 237  
T cell receptor and, **45**:117, 124, 131
- Insulin autoimmune syndrome, **66**:88  
methimazole-induced, HLA class II peptide binding and, **66**:87–88
- Insulin-dependent diabetes mellitus, **51**:285–286  
aberrant HLA class II expression, **48**:141–142  
Asp<sup>57</sup>, **48**:135–137  
B8, **48**:137  
B15, **48**:137  
dominant resistance, **48**:143–144  
DQ  $\beta$  chain, **48**:134–136  
position 57 aspartic acid, **48**:135–136, 137  
DR2, **48**:136, 143  
AZH, **48**:136  
DRw9, **48**:137  
DRw15, **48**:143  
DRw16, **48**:143  
HLA factor, **48**:133–144  
suppression phenomenon, **48**:143–144  
HLA class II peptide binding and, **66**:91  
TAP and, **65**:92–93
- Insulin-like growth factor-binding proteins, **63**:419
- Insulin-like growth factor I, **63**:379–380  
expression, **63**:389–393  
immune system, **63**:377–378  
leukemia, **63**:427  
lymphohemopoietic system, **63**:389–393, 431–432  
regulation, **63**:389–393  
structure and physiology, **63**:388–389, 401
- Insulin-like growth factor I receptor, **63**:401, 427
- Insulin-like growth factor II, **63**:417–419
- Insulin-like growth factor II receptor, **63**:401, 418
- Insulin-like growth factor receptors, **63**:401–404
- Insulin promoter gene, **48**:141–142
- Insulin receptor, **63**:146, 168  
surface antigens of human leukocytes and, **49**:100, 113
- Insulin receptor substrate-1, phosphorylation, **60**:15–16
- Insulinitis  
autoimmune, **62**:100–101  
and diabetes, development of, **51**:292  
and overt diabetes, T cell subsets involved in, **51**:296–298
- Integral membrane proteins  
leukocyte integrins and, **46**:154, 156  
types, **52**:144; 145
- Integrases, HIV, **64**:57

- Integrins**, **52:166**, 358–361; **59:383**, *see also*  
   Leukocyte integrins  
    $\alpha 4\beta 1$ , **58:371**; **65:358**, 368  
     conformational effects, **64:169**  
     lymphocyte homing, **64:146**, 156  
    $\alpha 4\beta 7$ , **58:371**; **64:154**, 173  
     lymphocyte–HEV interactions and,  
       **65:352**, 358–359, 368  
     lymphocyte homing, **64:146**, 156, 192  
    $\alpha 6\beta 1$ , **58:371**  
    $\alpha 6\beta 7$ , lymphocyte homing and, **64:157**  
    $\alpha E\beta 7$ , **58:372**  
     defined by monoclonal antibody HML-1,  
       **58:317–318**  
     expression on intraepithelial  
       lymphocytes, **58:392**  
    $\alpha v\beta 3$ , lymphocyte homing and, **64:157**  
    $\beta 1$ , **52:358–359**; **58:370**  
    $\beta 1\alpha 4$ , **62:258**  
    $\beta 2$ , **52:359–361**; **58:370**; **62:279**  
     and degranulation, **60:207**  
    $\beta 3$ , **52:361**  
   activation, chemotactic molecules in,  
     **58:378–381**  
   antigen-presenting cells and, **47:61**, 97  
   CD23 antigen and, **49:163**  
   characterization, **58:362–370**  
   conformational effects, **64:169**  
   expression in allergic inflammation,  
     **60:172–173**  
   expression on human mast cells and  
     basophils, assessment by mAbs and  
     indirect immunofluorescence, **52:359**  
   family of adhesion receptors and ligands,  
     **58:366–367**  
   interaction with eosinophils, **60:169–172**  
   lymphocyte–HEV interactions and, **65:352**,  
     358–359, 368–369, 370  
   lymphocyte homing, **64:154–157**  
   properties, **64:146**  
   subunits, biochemical characterization,  
     **58:364–365**  
   surface antigens of human leukocytes and,  
     **49:83–86**, 92  
**Intercellular adhesion molecule**, **59:383**, 414  
**Intercellular adhesion molecule-1**,  
   **52:361–363**; **59:377–378**; **62:77–78**;  
   **64:147**, 154  
   adhesion molecule, **62:77–78**  
   as anti-adhesive, **64:171**  
   CD23 antigen and, **49:161**  
   central nervous system cells, **62:91**  
   downregulation, **64:172**  
   expression, **64:179**  
   expression in allergic inflammation,  
     **60:172–173**  
   gene, NF- $\kappa$ B and, **65:119**  
   humoral immune response and, **45:43**  
   IFN- $\gamma$ , **62:92**  
   IL-1 and, **44:166**  
   interaction with LFA-1 in negative  
     selection, **58:172**  
   leukocyte integrins and, **46:149**, 150, 176,  
     177  
     inflammation, **46:163**, 166, 167  
     ligand molecules, **46:169–172**  
     structure, **46:158**  
   lymphocyte homing and, **44:350**; **64:147**,  
     157  
   mAbs, **60:168–170**  
   Mac-1 receptor, **58:370**  
   modifications, **64:168**  
   multiple myeloma, **64:246**, 247  
   multiple myeloma and, **64:246**, 247  
   properties, **64:147**  
   pulmonary inflammation, **62:267**, 272, 276,  
     277, 281, 288  
   recruitment of leukocytes to inflammation  
     site, **58:395**  
   rheumatoid arthritis, cell trafficking,  
     **64:317–319**  
   rolling cells containing, **58:381–382**  
   synergistic activation of, **65:21**  
   T cell activation, **63:44**  
   upregulation, **64:165**, 166  
**Intercellular adhesion molecule-2**  
   expression, **64:179**  
   and ICAM-1, affinity for LFA-1,  
     **58:373–374**  
   lymphocyte homing and, **64:157**, 158  
   properties, **64:147**  
**Intercellular adhesion molecule-3**  
   five-Ig domain molecule, **58:373–374**  
   lymphocyte homing and, **64:158**  
**Interdigitating cell antigen**, **59:379**  
**Interdigitating cells**  
   antigen-presenting cells and, **47:**  
     50–52  
   hybrid resistance and, **41:356**, 357  
   within PALS, **60:269**

- Interdigitating dendritic cells, **51**:245–246  
 staining of, **51**:248–249, 250–251, 259
- Interdigitation, *J558* V<sub>H</sub> subfamily, **42**:122
- Interface adaptor hypothesis, **43**:125–128
- Interferon, *see also specific interferon*  
 adoptive T cell therapy of tumors and, **49**:289–290, 307–308, 311, 316  
 autoimmune demyelinating disease and, **49**:361  
 autoimmune thyroiditis and, **46**:265  
 antigens, **46**:272  
 cellular immune responses, **46**:289, 293–298  
 B cell formation and, **41**:228, 234, 265  
 cachectin and, **42**:221  
 CD23 antigen and, **49**:152, 154, 158, 161, 174–175  
 helper T cell cytokines and, **46**:112  
 cross-regulation, **46**:131  
 functions, **46**:114, 117, 120–122  
 immune responses, **46**:133, 137, 138  
 precursors of differentiation states, **46**:122, 123, 125  
 HIV infection and, **47**:394, 402  
 hybrid resistance and, **41**:368, 377  
 antigen expression, **41**:405, 406  
 bone marrow cells, **41**:345  
 macrophages, **41**:371, 372  
 marrow microenvironment, **41**:392  
 syngeneic stem cells, **41**:388–390
- IBD and, **42**:295
- IL-1 and, **44**:189, 195  
 gene expression, **44**:161  
 immunocompetent cells, **44**:178  
 structure, **44**:157  
 systemic effects, **44**:171
- immunosenescence and, **46**:231, 232, 237
- inducible genes, transcriptional regulation and role of IRF-1 and IRF-2, **52**:272–275
- leukocyte integrins and, **46**:168, 170
- lymphocyte homing and, **44**:321
- NK cells and, **42**:183  
 adaptive immunity, **47**:291, 293–295  
 alterations, **47**:300, 301, 303  
 antimicrobial activity, **47**:283–290  
 antitumor activity, **47**:295, 298  
 cell-mediated cytotoxicity, **47**:195, 196  
 CNS, **47**:269  
 congenital defects, **47**:225, 226  
 cytotoxicity, **47**:250, 251, 254–260, 262  
 differentiation, **47**:229, 233, 234  
 effector mechanisms, **47**:235, 237, 238, 241–244  
 genetic control, **47**:222–224  
 hematopoiesis, **47**:274, 277–280, 283  
 identification, **47**:198  
 lymphokines, **47**:264–266  
 reproduction, **47**:271  
 surface phenotype, **47**:201  
 tissue distribution, **47**:219
- SCID and, **49**:385–386
- spontaneous autoimmune thyroiditis and, **47**:493  
 altered thyroid function, **47**:461–463  
 disturbed immunoregulation, **47**:472, 477  
 surface antigens of human leukocytes and, **49**:99
- T cell development and, **44**:219
- T cell receptor and, **45**:117
- type I, *see* Interferon- $\alpha$ ; Interferon- $\beta$   
 type II, *see* Interferon- $\gamma$   
 virus-induced immunosuppression and, **45**:343, 361
- Interferon- $\alpha$ , **48**:168, 169; **52**:264–275; **61**:353; **62**:61, 84–85; **63**:275  
 effect on L-selectin cell surface density, **58**:353–354  
 IgE biosynthesis and, **47**:9  
 Jak kinases, **63**:140  
 multiple myeloma, **64**:258–259  
 regulators of complement activation and, **45**:397  
 soluble form, **63**:276, 307  
 sporozoite malaria vaccine and, **45**:302  
 TH responses, **61**:353  
 virus-induced immunosuppression and, **45**:339, 344
- Interferon- $\alpha/\beta$   
 genes  
 regulatory DNA sequences in, **52**:265–267  
 transcriptional regulation of IFN-inducible genes and role of IRF-1 and IRF-2, **52**:272–275



- Interferon- $\alpha/\beta$**  (*continued*)
- transcription factors binding to
    - regulatory elements of: interferon regulatory factors 1 and 2, **52:267–271**
    - NF- $\kappa$ B, **52:271–272**
    - other factors, **52:272**
  - induction of ISGF3, **60:17**
  - role in cytokine signaling, **60:7–9**
- Interferon- $\beta$** , **48:168, 169; 52:264–275; 62:61, 84–85; 63:275**
- regulators of complement activation and, **45:397**
  - released by macrophages, **60:334–335**
  - soluble form, **63:276, 307**
  - sporozoite malaria vaccine and, **45:302**
- Interferon- $\beta/26$ -kDa**, **54:3**
- Interferon- $\gamma$** , **48:70, 71, 78, 132, 162; 52:264–275; 62:61–62, 105–107; 63:275; 64:106; 65:282; 66:145**
- antagonists, **62:82–83, 105**
  - antigen-presenting cells and, **47:59, 83, 97**
  - and autoimmunity, **50:213**
  - autoreactive T cells and, **45:427, 430**
  - B7 expression, **62:136**
  - B cell formation and, **41:197, 222, 230**
  - B cell proliferation, **40:37–38, 42–44; 63:55**
  - B cells, **63:278**
  - biochemistry
    - cellular, **62:71–76**
    - signal transduction, **62:67–71**
  - biological effects
    - adipocytes and, **62:91**
    - antibody formation, **62:87–89**
    - antigen presentation, **62:80**
    - antiproliferative effect, **62:76–77**
    - central nervous system cells and, **62:91–92**
    - connective tissue and, **62:90–91**
    - endocrine cells and, **62:93–94**
    - endothelial cells, **62:81**
    - epithelial barriers and, **62:90**
    - in hematopoiesis, **62:92–93**
    - immune suppression mediator, **62:89–90, 105**
    - lymphocytes and, **62:86–87**
    - membrane protein expression, **62:77–78**
    - mononuclear phagocytes, **62:78–80**
    - natural IFN- $\gamma$  antagonists, **62:82–86**
    - synergy between IFN- $\gamma$  and TNF, **62:81–82**
  - CD1 expression, **59:65**
  - CD28 costimulation, **62:139**
  - class switching, **61:98**
  - cytotoxicity and, **41:272, 284**
  - factor H, **61:232**
  - function, **66:145**
  - genes, transcriptional regulation, **52:272–275**
  - germline transcripts, **61:86, 88–90**
  - human T cell antigen and, **41:6, 11, 27–29**
  - humoral immune response and, **45:61, 62, 68, 70–72, 76**
    - cellular interactions *in vivo*, **45:82, 84, 85**
    - helper T cells, **45:26–30, 33**
  - hybrid resistance and, **41:371**
  - IgE biosynthesis and
    - antibody response, **47:9, 10, 12, 31, 32**
    - binding factors, **47:22–24**
  - immunopathology
    - allograft rejection, **62:101–103**
    - autoimmune disease, **62:98–101**
    - cytokine release syndrome, **62:103–104**
    - delayed-type hypersensitivity, **62:96–98**
    - granulomatous lesions, **62:281**
    - nonspecific inflammation, **62:103–104**
  - infection and cancer, **62:94–96**
  - Jak kinases, **63:140**
  - MHC class I gene expression, **61:328–329**
  - monocytes, **62:136**
  - multiple myeloma, **64:259**
  - in NO production, **60:334–337**
  - production, **62:63–66, 105**
  - proteasomes, **64:106**
    - regulation, **64:12–32**
  - pulmonary inflammation, **62:281, 288–289**
  - recent research, **62:106–107**
  - regulation of isotype switching, **54:256–257**
  - regulators of complement activation and, **45:397**
  - secreting IEL, **58:329**
  - sepsis and, **66:104, 145–146**
  - soluble form, **63:276, 307**
  - sporozoite malaria vaccine and, **45:319**
    - CS-specific T cells, **45:307, 312**
    - liver stages, **45:301–306**
  - structure–function relationship, **62:62–63**
  - T cell receptor and, **45:117, 119, 129**

- T cell subsets and  
  H-2 alloantigen recognition, **41:89, 90, 94, 95**  
  H-2 antigen recognition, **41:16, 64, 66, 69, 77**  
  H-2 molecules in thymus, **41:106**  
  TH responses, **61:350, 358**  
  upregulation of adhesion molecules, **64:165**  
  upregulation of FcRIII, **60:180–181**  
  virus-induced immunosuppression and, **45:356, 357, 360, 361, 363, 366**
- Interferon- $\gamma$  receptor  
  biochemistry, **62:66–67, 105**  
  IFN- $\gamma$ R $\alpha$ , **62:66**  
  IFN- $\gamma$ R $\beta$ , **62:66**  
  soluble forms, **63:307, 309–310, 311, 314**
- Interferon receptor, soluble forms, **63:307–308**
- Interferon regulatory factor, *see* IRF
- Interferon response factor-1, *see* IRF-1
- Interferons, **52:355–356; 66:145**
- Interferon-sensitive response elements, **62:69–70**
- Interferon-stimulated response element, **61:174**
- Interferon system, **52:264–265**
- Intergenic probes, **62:19–20**
- Interleukin, **48:70, 71**  
  adoptive T cell therapy of tumors and, **49:289, 312**  
  and CD1 expression, **59:64–65**  
  CD23 antigen and, **49:151, 154–155, 176**  
  enhancement of antibody responses and, **40:107–110**  
  humoral immune response and, **45:54–62, 75–77**  
  neuroimmunology and, **39:301**  
  surface antigens of human leukocytes and, **49:94, 98, 101**
- T cell development and  
  ontogeny, **44:219**  
  thymocyte subpopulation, **44:225–233, 236, 241**
- Interleukin-1, **44:153–155; 48:168, 169; 52:169–171; 61:232, 353, 354; 63:290–291**  
  adhesion molecules, **62:81**  
  adoptive T cell therapy of tumors and, **49:287, 289, 325–329, 334**  
  antigen-presenting cells and, **47:64, 99–101, 103**  
  anti-IL-1, **66:140**  
  autocrine or paracrine effects, **54:34–35, 201–202**  
  autoimmune arthritis, **62:99–100**  
  autoimmune thyroiditis, **46:295**  
  autoreactive T cells and, **45:423, 424**  
  B cell formation and, **41:192, 208, 222, 236, 237**  
  genetically determined defects, **41:228, 230**  
  soluble mediators, **41:234, 235**  
  B cell responses and, **40:13–14, 35–36**  
  biochemistry, **66:105–107**  
  biological effects, **44:164, 165**  
  catabolic effects, **44:168**  
  endothelial cells, **44:166–168**  
  fibroblasts, **44:168, 169**  
  hepatic protein synthesis, **44:165, 166**  
  cachectin and, **42:224**  
  cardiomyocytes and, **66:114**  
  CD5 B cell and, **47:142, 143, 145, 146**  
  CD23 antigen and, **49:169–171**  
  CD28 costimulation, **62:139**  
  cell-mediated killing and, **41:288**  
  circulating levels, **66:104–107**  
  in endotoxemia, **66:116–117**  
  gene expression, **44:159–164**  
  gene regulation, **65:25–26**  
  granulomatous lesions, **62:281**  
  growth hormone secretion, **63:385**  
  helper T cell cytokines and, **46:130**  
  HIV infection and, **47:394, 404**  
  human disease, **44:191–195**  
  humoral immune response and, **45:56, 68, 70–75, 80**  
  IFN- $\gamma$ , **62:80**  
  IgE biosynthesis and, **47:22**  
  IL-6 and, **44:189–192**  
  immunocompetent cells  
    B cell activation, **44:177, 178**  
    diacylglycerol, **44:175, 176**  
    IL-2 production, **44:174, 175**  
    NK cells, **44:178**  
    peripheral blood T cells, **44:177**  
    T cell activation, **44:172, 173**  
    thymocytes, **44:173, 174**  
  immunosenescence and, **46:228**

- Interleukin-1 (*continued*)
- in induction of acute-phase proteins by liver, **58**:10–12
  - induction of NF- $\kappa$ B, **58**:7–9
  - inhibition of iNOS, **60**:338
  - in iNOS expression, **60**:351–352
  - in vitro* effects, **66**:110–112
  - in vivo* effects, **66**:112–114
  - leukocyte integrins and, **46**:170
  - local effects, **44**:171, 172
  - localization, **44**:162, 163, 167
  - membrane-bound, T cell subsets and, **41**:90
  - multiple myeloma pathogenesis, **64**:258
  - neuropeptide, **48**:178
  - neutrophils and, **66**:111
  - NF- $\kappa$ B-induced, **58**:10–12
  - NK cells and, **47**:233, 262, 266
  - NO production in response to, **60**:337
  - prolactin secretion, **63**:382
  - pulmonary hypersensitivity, **59**:418, 419
  - pulmonary inflammation, **62**:259, 267, 273, 276, 277, 279, 280, 288–289
  - regulation, **66**:108–110
  - regulators of complement activation and, **45**:397
  - SCID and, **49**:396
    - deficiency, **49**:384–385, 390
    - receptor deficiency, **49**:385
  - sepsis and, **66**:104, 126–127, 150
    - animal models, **66**:117–121
    - clinical, **66**:121–124
    - treatment, **66**:124–126, 134
  - signaling events, **65**:117
  - spontaneous autoimmune thyroiditis and, **47**:477, 478, 493
  - structure, **44**:155–158
  - systemic effects, **44**:169–171
  - systemic inflammatory response syndrome, **63**:310
  - T cell activation and
    - cell surface molecules, **41**:2, 8, 13, 14
    - receptor-mediated signal transduction, **41**:20, 22, 23, 26
  - T cell subsets and, **41**:63–66, 84, 85, 107, 111
  - TNF, **44**:185–189
  - TNF- $\alpha$ , **64**:293, 316
  - virus-induced immunosuppression and, **45**:357
- Interleukin-1 $\alpha$ , **66**:106, 107, 117
  - binding to type I receptors, **54**:193
  - synthesis by eosinophils, **60**:195
- Interleukin-1 $\beta$ , **66**:106–107, 116, 117, 122
- Interleukin-1 inhibitors, IL-1ra, **54**:168–169
- Interleukin-1-like activity, in B cells, **39**:78–79
- Interleukin-1 receptor, **44**:178–180; **63**:275, 290–292; **66**:108
  - binding, **44**:181, 182
  - expression regulation, **44**:182
  - IL2, **44**:180, 181
  - post-receptor-binding events, **44**:184, 185
  - structure, **44**:182, 183
  - type I, **63**:276, 291–292, 312–313
  - type II, **63**:274, 276, 291–292, 310
- Interleukin-1 receptor antagonist, **54**:168–169; **63**:277; **66**:104, 116–117, 120, 121
  - binding
    - soluble IL-1 receptors, **54**:195–197
    - type II IL-1 receptors, **54**:194–195
  - biological relevance, **54**:217–219
  - cDNA clones, purification and expression, **54**:171–176
  - chromosomal localization and gene structure, **54**:177–180
  - chromosomal location and structure, **54**:177–180
  - in diabetes mellitus, **54**:214
  - discovery, **54**:169–171
  - effects on immune system, **54**:202–204
  - function as receptor antagonist, **54**:197–200
  - identification, **54**:167–168
  - IL-6 and, **66**:132
  - in infection and sepsis *in vivo*, **54**:204–209, 215–217
  - in inflammatory arthritis, **54**:209–211
  - in inflammatory bowel disease, **54**:214–215
  - inhibitors, **54**:168–169
  - in vitro* and *in vivo* effects, **54**:200–202
  - in malignancies, **54**:213–214
  - murine, cloning and expression, **54**:175–176
  - in nervous system, **54**:211–213
  - receptor binding of IL-1ra, **54**:192–200
  - regulation of IL-1ra production, **54**:180–192
  - structural variants, **54**:176–177
  - treatment with, **66**:124–126

- Interleukin-2, **44**:189; **48**:77; **52**:171–172, 177–178, 195–196, 204–205; **59**:225, 254; **61**:147, 149, 190, 351–352; **62**:88; **63**:292; **64**:69
- adoptive T cell therapy of tumors and, **49**:284, 289–291, 293, 334
- expression of antitumor responses, **49**:324–329, 332
- mechanisms, **49**:300, 302–305, 307, 309–310, 315–316
- allograft rejection, **62**:102, 103
- antigen-presenting cells and, **47**:75
- cell surface, **47**:63–65
- T cells, **47**:84, 86, 100
- tissue distribution, **47**:53, 55
- autoimmune demyelinating disease and, **49**:361
- autoimmune disease, **63**:128, 132, 294, 297
- autoimmune thyroiditis and, **46**:275, 289, 310
- autoimmunity, **50**:171–187
- abnormalities in IL-2 expression and responsiveness on circulating lymphocytes, **50**:186–187
- elevated serum levels of soluble IL-2Ra in autoimmune disease, **50**:183–186
- in vitro* IL-2 production in autoimmune disease, **50**:172–178
- autoantibodies, **50**:176
- decrease of IL-2 producing cells, **50**:176
- low IL-2, **50**:175–176
- signal transduction, **50**:177–178
- suppressor macrophages, **50**:176
- suppressor T cells, **50**:176–177
- in vivo* IL-2 production in autoimmune disease, **50**:178–183
- at site of autoimmune attack, **50**:171–172
- autolerance, **50**:165–171
- effect *in vivo*, **50**:165–166
- interference with clonal deletion, **50**:166–167
- nonspecific killing induced by IL-2, **50**:170–171
- the system, **50**:167–170
- autoreactive T cells and, **45**:425
- B7 expression, **62**:136
- B cell activation and, **40**:36–37, 41–50
- B cell formation and, **41**:193, 228, 237
- B cell proliferation, **63**:54, 55
- $\beta$  chain interaction, **42**:177
- binding constants, kinetic and equilibrium, **42**:169–172
- bioavailability, **50**:164
- cachectin and, **42**:221
- CD4 and CD8 molecules and, **44**:298, 299
- CD4 molecular biology, **44**:291–293
- CD5 B cell and, **47**:144, 145, 161
- CD23 antigen and, **49**:159, 168–169, 175
- CD28 costimulation, **62**:139
- cell-mediated killing and, **41**:287, 288
- cells producing or expressing, detection and distribution, **50**:152–154
- chain specific internalization of, **42**:175–176
- complement receptor 1 and, **46**:185
- cytotoxic T cells and, **38**:175
- dependent cells, rescue, **58**:244
- dependent T cell line, **39**:41
- v-abl* effect, **39**:41
- eosinophil granule-associated, **60**:197
- expression, **63**:44
- functions, **39**:1, 3
- gene, transcriptional regulation, **48**:294–297
- gene regulation, case study, **51**:103–105
- helper T cell cytokines and, **46**:112
- cross-regulation of differentiation, **46**:130, 131
- functions, **46**:114, 120–122
- immune responses, **46**:136, 138
- precursors of differentiation states, **46**:122–126
- high-affinity binding sites, **42**:174
- history of, **50**:147–149
- HIV and, **65**:282
- HIV infection and, **47**:390, 392, 398, 399, 411
- human T cell activation and, **41**:1, 6, 11–14
- gene regulation, **41**:27–300
- hybrid resistance and, **41**:351, 380, 382, 396
- receptor-mediated signal transduction, **41**:22, 25
- synergy, **41**:15, 19
- T11, **41**:9, 10
- humoral immune response and, **45**:57, 62, 66–71, 73, 76
- cellular interactions *in vivo*, **45**:84

- Interleukin-2 (*continued*)
- helper T cells, **45**:26, 28–33
  - physical interaction, **45**:44
  - IBD and, **42**:296
  - IFN- $\gamma$ , **62**:80
  - IgE biosynthesis and
    - antibody response, **47**:10, 11, 36, 37
    - binding factors, **47**:22
  - Ig production, **63**:60, 62
  - and IL-2R, gene regulation, **50**:154–157
  - and IL-2R, physiology, **50**:149–165
    - compartmentalization reduces pleiotropy, **50**:163–165
    - IL-2 bioavailability, **50**:164
    - IL-2 production, **50**:163–164
    - IL-2 responsiveness, **50**:164–165
  - detection and distribution of cells
    - producing or expressing, **50**:152–154
  - effects on peripheral immune system and toxicity, **50**:160–163
  - gene regulation, **50**:154–157
  - mechanics of IL-2/IL-2 system, **50**:149–152
  - and thymocyte differentiations, **50**:158–160
  - IL-2R system, **63**:127
    - cytokine signal transduction, **63**:127–176
    - signal transduction, **63**:127, 173–176
      - signaling pathways, **63**:169–173
      - signal molecules, **63**:167–169
      - target genes, **63**:160–164
    - three-channel model, **63**:171–173
  - immunocompetent cells, **44**:173–176, 178
  - immunosenescence and
    - lymphocyte activation, **46**:222, 226, 228–230, 232
    - lymphocyte subsets, **46**:237, 238
    - mucosal immunity, **46**:252
    - regulatory changes, **46**:250
  - induced cytokines, role in autoimmunity, **50**:210–213
    - IFN- $\gamma$  and autoimmunity, **50**:212–213
    - IL-6 and autoimmunity, **50**:210–211
    - TNF- $\alpha$  and autoimmunity, **50**:211–212
  - inhibition of T cell death, **58**:269
  - in vitro* production in autoimmune disease, **50**:172–178
    - autoantibodies, **50**:176
    - decrease of IL-2 producing cells, **50**:176
    - low IL-2, **50**:175–176
    - signal transduction, **50**:177–178
    - suppressor macrophages, **50**:176
    - suppressor T cells, **50**:176–177
  - in vitro* production in response to T cell mitogens ConA or PHA, **50**:173
  - in vivo* antitolerance effect, **50**:165
  - in vivo* interventions in autoimmunity, **50**:187–210
    - cyclosporin A and autoimmunity, **50**:208–210
    - effects of *in vivo* applications of rIL-2, **50**:189–191
    - IL-2R-targeted immune intervention, **50**:187–189
    - induction of manifest autoimmunity in athymic mice by IL-2/vaccina virus, **50**:203–206
      - effect of IL-2.VV on neonatally thymectomized mice, **50**:206–208
      - effect of IL-2.VV on nu/nu mice, **50**:203–205
    - lack of autoimmune manifestations in mice transgenic for human IL-2 or IL-2R components, **50**:192–193
    - recombinant IL-2/vaccina virus construct
      - effect on SLE of MRL/Mp-lpr/lpr mice, **50**:193–203
      - effect of IL-2.VV on life expectancy and autoimmune manifestations, **50**:195–196
      - effect of IL-2.VV on T cell compartments, **50**:196–200
      - mechanism of beneficial effect of IL-2 on lymphoproliferation and autoimmunity, **50**:200–203
  - Jak kinases, **63**:140
  - lung transplant rejection, **59**:424, 426
  - lymphocyte proliferation, **63**:127
  - NK cells and, **42**:184; **47**:189, 292
    - adaptive immunity, **47**:294, 295
    - antitumor activity, **47**:295, 296, 298
    - cell-mediated cytotoxicity, **47**:196
    - congenital defects, **47**:226
    - cytotoxicity, **47**:250, 252, 253, 257–262
    - differentiation, **47**:231–234
    - effector mechanisms, **47**:235, 237, 238, 242–244, 247
    - genetic control, **47**:222, 223

- hematopoiesis, **47:280**  
 identification, **47:199**  
 lymphokines, **47:264, 265**  
 malignant expansion, **47:228**  
 surface phenotype, **47:206, 207, 209**  
 tissue distribution, **47:221**  
 nuclear responses induced by, **63:158**  
 pituitary hormones, **63:385**  
 production, **50:163–164**  
 production by  
   LBRM-33 cells, **39:17**  
   T cells, **39:1, 3, 10–13**  
     cyclosporin A and, **39:14–15**  
     dexamethasone and, **39:14**  
     mRNA and, **39:13–14**  
 production by activated T cells, **58:18–19**  
 prolactin secretion, **63:382**  
 protein kinase C, **63:155**  
 purification and properties, **39:4–5**  
 Ras proteins, **63:145**  
 recombinant, autoimmune manifestations  
   after *in vivo* application of,  
   **50:189–191**  
 recombinant vaccine virus infection,  
   **50:205**  
 regulators of complement activation and,  
   **45:394, 402, 404**  
 responsiveness, **50:164–165**  
 SCID and, **49:384, 386–387**  
   deficiency, **49:385, 390**  
   lack of stem cell engraftment,  
   **49:396**  
   posttransplant immunocompetence,  
   **49:400**  
   receptor deficiency, **49:385–386**  
   stem cell engraftment, **49:390–391**  
   tolerance, **49:399**  
   transplantation with fetal tissue,  
   **49:393**  
 sepsis and, **66:104**  
 signaling, **48:299–304**  
 signal transduction, **59:253–259, 265–266;**  
   **63:174**  
   *bcl-2*, **63:162–164**  
   *c-fos*, **63:161, 171**  
   *c-jun*, **63:160–161, 171**  
   *c-myc*, **63:161–162**  
   Jak/Stat pathway, **63:171–172**  
   Lck, **63:171**  
   PI3K, **63:171**  
   Ras, **63:171**  
   Rho, **63:171**  
   single gene-coded, human, **39:5**  
   spontaneous autoimmune thyroiditis and,  
   **47:492**  
     altered thyroid function, **47:461**  
     cellular immune reactions, **47:454–456**  
     disturbed immunoregulation,  
       **47:471–474, 479**  
     genetics, **47:488**  
     histopathology, **47:442**  
     humoral immune reactions, **47:446**  
 Stat proteins, **63:141**  
 stimulation of NK cells, **58:426–429**  
 structure, **48:299–300**  
 sulfasalazine and, **42:317**  
 surface antigens of human leukocytes and,  
   **49:94, 98**  
 T cell subsets and  
   H-2 alloantigen recognition, **41:87,**  
   **93–95**  
   H-2 molecules in thymus, **41:98, 99, 107**  
   H-2-restricted antigen recognition,  
   **41:52, 53, 56, 62–66, 72–74, 76, 77**  
   T cell triggering, **41:111, 112**  
 Th cells, **62:146**  
 virus-induced immunosuppression and  
   HIV, **45:356, 358, 360, 362, 363, 366,**  
   **367**  
   measles, **45:342, 344**  
   *in vivo* production in autoimmune disease,  
   **50:178–183**  
 Interleukin-2 $\beta$ , Jak kinases, **63:139**  
 Interleukin-2 $\gamma$ , Jak kinases, **63:139**  
 Interleukin-2 receptor, **44:180, 181;**  
   **52:342–343; 59:226; 61:148–153;**  
   **63:128–132**  
   activation, **61:148–149**  
    $\alpha$ , $\beta$  heterodimer receptor structure, **42:168**  
    $\alpha$ , $\beta$  interaction, **42:176**  
   assays for, **42:166–167**  
   binding characteristics of, **42:168–172, 176**  
   cachectin and, **42:224**  
    $\gamma$ -chain, Jak2 associated with, **60:12**  
   cell division and, **42:167, 178**  
   cellular expression, **59:234–237**  
   chimerism, **59:258–259**  
   *c-myc* expression, **63:162**  
   expressions, **42:173–176**  
   function, **48:300–302**

- Interleukin-2 receptor (*continued*)  
 gene cloning, **59**:226, 227  
 and IL-2, gene regulation, **50**:154–157  
 induction by IL-5, **57**:155  
 membrane form, **63**:285  
 membrane proximal region, **60**:14  
 noncovalent interaction of, **42**:176–177  
 production, **58**:19  
 reconstitution, **59**:231–234  
 signaling, **61**:153–191, 191  
   in B cells, **55**:274–278  
   G<sub>1</sub>-phase progression, **61**:179–187  
   Jaks, **61**:160–161, 173–176  
   mTOR, **61**:188–190  
   PI3-K pathway, **61**:167–173  
   proximal signaling events  
   initiation, **61**:160–161  
   Jak PTK's, **61**:158–159  
   Src family kinases, **61**:153–158  
   syk, **61**:159–160  
   ZAP-70, **61**:160  
 rapamycin, **61**:180–183  
   cdk activities, **61**:183–187  
   FKBP12-rapamycin cycle,  
     **61**:187–190  
   Ras/MAP kinase pathway, **61**:161–167  
   Stats, **61**:162, 176–179  
 soluble form, **63**:276, 279, 284, 292–294,  
   296–298  
 structure, **42**:167–168; **55**:274; **61**:149–153  
 structure and function, **59**:227–238  
 X-linked severe combined  
   immunodeficiency, **59**:248–253
- Interleukin-2 receptor  $\alpha$ , **42**:167–168;  
**59**:227–228, 231–234; **61**:149–150, 152;  
**63**:128–130, 274, 275, 276, 279, 284,  
 293–294  
 binding characteristics and, **42**:168–172  
 gene, transcriptional regulation,  
**48**:294–295, 297–299  
 T cell development and selection,  
**58**:134–135
- Interleukin-2 receptor  $\beta$ , **59**:228–229,  
 231–234, 254; **61**:150, 152–153, 155;  
**63**:129, 130–131, 137–138, 274, 275,  
 276, 293  
 chimeric molecules, **59**:258  
 cytoplasmic domain, **59**:255–258  
 T cell development and selection,  
**58**:134–135
- Interleukin-2 receptor  $\gamma$ , **59**:229–234, 241,  
 243, 254; **63**:129, 131, 133, 274, 275  
 cellular expression, **59**:237–238  
 chimeric molecules, **59**:258  
 cytoplasmic domain, **59**:254–255  
 gene, **59**:227, 254–255  
 mutations, **59**:246–253  
 sharing among multiple cytokine receptors,  
**59**:238–246  
 T cell development and selection,  
**58**:134–135  
 X-linked severe combined  
   immunodeficiency and, **59**:246–253
- Interleukin-2 receptor chain, gene, NF- $\kappa$ B,  
**63**:160
- Interleukin-2 receptor complex  
 signal transduction, **59**:253–259  
 T cell development and selection,  
**58**:134–135
- Interleukin-2/vaccinia virus  
 effect of on neonatally thymectomized  
   mice, **50**:206–208  
 effect of on *nulnu* mice, **50**:204–206  
 induction of manifest autoimmunity in  
   athymic mice by, **50**:203–208
- Interleukin-3, **48**:71, 72, 168, 169; **63**:55, 139  
 B cell formation and, **41**:228–230,  
 232–234, 236, 237  
 CD23 antigen and, **49**:170  
 eosinophil proliferation, **48**:75  
 helper T cell cytokines and, **46**:116, 117  
 humoral immune response and, **45**:26, 57,  
 65, 73–75  
 hybrid resistance and, **41**:389  
 IgE biosynthesis and, **47**:10, 22  
 multiple myeloma pathogenesis, **64**:256,  
 258  
 murine  
   20 $\alpha$ SDH induction in T cells, **39**:2, 5,  
     18–19, 23–31  
   activities *in vivo*  
   hematopoiesis and, **39**:30  
   during immune responses, **39**:31–34  
   amino acid sequence, **39**:5–7  
   in bone marrow cell culture  
   CSF activity, **39**:20–21  
   natural cytotoxicity increase, **39**:21  
   Thy-1<sup>+</sup> induction, **39**:21–22, 24,  
     26–31  
   burst-promoting activity, **39**:20

- cDNA library for, **39:5**, 7  
 -dependent cells  
   *c-myc* expression, **39:40**, 42  
   IL-3 receptor activity, **39:38–39**,  
     42–43  
   properties, **39:34–37**  
   protein kinase C redistribution, **39:39**  
   *v-abl* effect, **39:40–41**  
   *v-myc* effect, **39:40**  
 functions, **39:2–3**  
 growth regulation, mechanism of,  
   **39:37–42**  
   future research, **39:43–45**  
 hematopoietic growth and, **39:19**  
 hemopoietin-2 activity, **39:20**  
 mast cell growth and, **39:19–20**  
 production by  
   mast cells, **39:17**  
   T cells, **39:2–3**, 10–13  
   WEHI-3 cells, **39:13**, 15–17, 19  
 purification and properties, **39:5**  
 single gene-coded, **39:7–8**  
 NK cells and, **47:232**, 233, 266, 277, 278  
 produced by eosinophils, **60:197–198**  
 production  
   by crosslinkage of FcεR on peritoneal  
     mast cells, **53:9**  
   by factor-dependent mast cell lines,  
     **53:6–8**  
   by transformed mast cells, **53:4–6**  
 regulation of lymphokine production by  
   FcεRI<sup>+</sup> cells, **53:21–22**  
 signaling, role of protein tyrosine kinases,  
   **60:5–9**  
 Interleukin-3 receptor, **52:343–349**; **63:139**  
 expression by eosinophils, **60:183–185**  
 murine, IL-3 interaction with, **39:38–39**,  
   42, 43  
 ATP role, **39:39**  
 Interleukin-3 receptor α, **63:275**  
 Interleukin-3 receptor β, **63:275**  
 Interleukin-4, **44:172**, 174, 177; **48:71**, 72;  
   **52:172**, 178–181, 196–198, 205–206;  
   **59:235–236**, 254; **62:83–84**, 85; **63:168**,  
   295, 299  
 adoptive T cell therapy of tumors and,  
   **49:290**, 307, 327–328, 334  
 allergic reactions, **63:310**  
 allograft rejection, **62:102**  
 antibody response, **62:88**  
 antigen-presenting cells and, **47:75**, 84, 100  
   cell surface, **47:59**, 63, 64  
   immunogeneity, **47:103**  
 asthma, **62:283**, 285  
 autoreactive T cells and, **45:427**  
 B7 expression, **62:136**  
 B cell production, **61:34**  
 B cells, **63:278**  
   proliferation, **63:54**, 55  
 biological activity, **59:238–240**  
 CD5 B cell and, **47:120**  
 CD23 antigen and biochemical structure,  
   **49:157**  
   biological activity, **49:169–170**, 172–173  
   cellular expression, **49:150–155**  
   cleavage regulation, **49:158**  
   expression, **49:159–161**, 174–175  
   FcεRII, **49:162**, 166–168  
 CD28 costimulation, **62:139**  
 CD40, **61:38**  
 class switching, **61:98**  
 effect on nitrite production, **60:353**  
 enhancement of isotype switching to IgE  
   and IgC, **54:248–249**  
 eosinophil granule-associated, **60:198**  
 expression, **63:44**  
 functional similarities with IL 10,  
   **56:12–13**  
 gene promoter, **65:29**  
 germline transcripts, **61:86–90**  
 granulocyte, **48:75**  
 granulomatous lesions, **62:281**, 290  
 helper T cell cytokines and, **46:113**  
   cross-regulation of differentiation,  
     **46:130–131**  
   functions, **46:114–116**, 119–122  
   immune responses, **46:133**, 136–138  
   precursors of differentiation states,  
     **46:122–125**  
 humoral immune response and, **45:58**,  
   62–67, 69–71, 75, 76  
   cellular interactions *in vivo*, **45:82–84**  
   helper T cells, **45:26–34**, 42, 44  
 IFN-γ, **62:105**  
 IgE biosynthesis and  
   antibody response, **47:6–12**, 31  
   binding factors, **47:13**, 21–23  
 and IgE switching, **52:217–218**  
 Ig production, **63:58–67**, 69, 79–80



- Interleukin-4 (*continued*)
- and IL-10, in CD40 system, growth-promoting activity of, **52:202**
  - immunosenescence and, **46:231, 232, 234, 237, 238**
  - inhibition of iNOS, **60:338–339**
  - Jak kinases, **63:140**
  - lung transplant rejection, **59:424**
  - macrophage, **48:75**
  - molecular mechanisms of IL-4-induced switching, **54:252–256**
  - NK cells and, **47:233, 262**
  - pleiotropic effects of, **52:179–181**
  - preferential rescue of Th2 cells, **58:244**
  - production
    - FcεR<sup>+</sup> cells in infected/immunized mice, **53:15–17**
    - FcεRI<sup>+</sup> bone marrow cells, **53:10**
    - FcεRI<sup>+</sup> cells, and lymphokine producing phenotypes of CD4<sup>+</sup> T cells, **53:17–19**
    - FcεRI<sup>+</sup> spleen cells, **53:9–10**
    - human FcεR<sup>+</sup> cells, **53:14–15**
    - N. brasiliensis*-infected mice, **53:15–17**
    - response to plate-bound IgE, **53:20–21**
    - signaling mechanisms, **53:17–22**
    - and T cell lymphokine-producing phenotype, **53:18**
    - molecular regulation, **53:22**
    - murine, infected or immunized, **53:15–17**
    - peritoneal, **53:9–14**
    - role in disease process, **53:17**
    - signaling processing in response to FcR crosslinkage, **53:20–21**
    - splenic, **53:9–14**
    - by transformed mast cells, **53:4–6**
    - pulmonary inflammation, **62:260, 290**
    - role of Stat6 in response to, **60:21–22**
    - role in T cell-dependent isotype switching, **54:249–252**
  - SCID and, **49:386**
  - selective induction of VCAM-1 on HUVEC, **60:170**
  - sepsis and, **66:144–145**
  - signaling molecules for, **63:167–168**
  - sources and structure, **52:178–179**
  - Stat protein activation, **61:176–179**
  - stimulation of IgE and IgG production, **54:247–248**
  - surface antigens of human leukocytes and, **49:89, 91**
  - TH responses, **61:348–350, 350, 354, 358, 374**
  - transcription induced by, **65:19**
  - upregulation of adhesion molecules, **64:165**
- Interleukin-4 receptor, **52:349–350; 59:240–241; 63:132**
- activation, **63:168**
  - production, **63:281–282, 284, 285**
  - Ras proteins, **63:145**
  - signaling, in B cells, **55:278–279**
  - soluble form, **63:276, 281–282, 284, 294–295, 299, 311, 313**
  - sources and structure, **52:178–179**
- Interleukin-4 receptor α, **63:275**
- association with 4PS, **60:16**
- Interleukin-4 receptor antagonist, **63:277**
- Interleukin-4 receptor complex, **59:238–241, 254**
- Interleukin-4 receptor F, Ras activation, **61:161**
- Interleukin-5, **48:71, 72, 78; 61:98, 352–353, 358; 63:299**
- allergic airway inflammation, **62:283–285**
  - animal models of production
    - airway hypersensitivity, **57:173–174**
    - eosinophilia in guinea pigs, **57:173–174**
    - experimental eosinophilia, **57:173**
    - parasite infection, **57:172–173**
    - transgenic mouse, **57:169–170**
    - tumor rejection, **57:174**
  - X chromosome-linked immunodeficient mouse, **57:171–172**
- antigen-presenting cells and, **47:63, 64, 103**
- B cell proliferation, **63:55**
- characteristics, **57:145–146**
  - expression, **63:44**
  - functional properties
    - basophil regulation, **57:156**
    - B cell development regulation, **57:154–155**
    - eosinophil production, **57:156**
    - Ig production regulation, **57:151–154**
    - IL-2 receptor induction, **57:155**
  - future perspectives, **57:178–179**
  - and gene, molecular structure, **57:148–149**
  - GM-CSF, **48:75**

- helper T cell cytokines and, **46**:113  
   functions, **46**:116, 119, 120  
   immune responses, **46**:133, 136, 137  
   precursors of differentiation states,  
     **46**:122, 123, 125  
 histological background, **57**:146–148  
 in human disease  
   asthma, **57**:174–176  
   graft rejection, **57**:177  
   helminth infections, **57**:176–177  
   tumors, **57**:177–178  
 humoral immune response and  
   cellular interactions in vivo, **45**:82–84  
   helper T cells, **45**:26, 28, 32, 33  
   physical interaction, **45**:48  
 IgE biosynthesis and, **47**:9, 10  
 Ig production, **63**:60–62  
 immunosenescence and, **46**:231, 232, 237,  
   238  
 inhalation at time of challenge, **60**:176  
 Jak kinases, **63**:139  
 mAbs, **60**:215  
 mediated eosinophil signal transduction,  
   **60**:209–210  
 messenger RNA expression, **57**:156–159  
 molecular structure  
   biological activity, **57**:149  
   cDNA organization, **57**:148–149  
   gene organization, **57**:148–149  
   polypeptides, **57**:149–151  
   mRNA, **60**:198–199, 222  
   production by factor-dependent mast cell  
     lines, **53**:6–8  
   recombinant human, **60**:204–205  
   Th cells, **62**:146  
 Interleukin-5 receptor, **52**:350–351;  
   **63**:299–300  
   expression  
     aberrations in mouse, **57**:170–172  
     analysis, **57**:168–169  
     by eosinophils, **60**:183–185  
     function, **57**:165–166  
     signaling pathway, **57**:166–168  
     signal transduction, **57**:146  
     structure, **57**:159–165  
 Interleukin-5 receptor  $\alpha$ , **63**:275, 276  
   gene structure, **57**:162–163  
   soluble forms, **57**:163–164  
   structure, **57**:160–164, 162–163  
 Interleukin-5 receptor  $\beta$ , structure,  
   **57**:164–165  
 Interleukin-6, **44**:153–155; **48**:71, 72, 168,  
   169; **52**:172, 182–184; **61**:33, 353, 354,  
   370; **62**:86; **63**:300; **66**:127  
   and acute-phase protein synthesis in  
     hepatocytes, **54**:25–27  
   antibody response, **62**:88  
   antigen-presenting cells and, **47**:64, 100,  
     103  
   anti-IL-6, **66**:132  
   and autoimmune system, **52**:215  
   and autoimmunity, **50**:210–211  
   and B cell growth, **52**:203–204  
   biochemistry, **66**:127–128  
   biological function, **54**:20–33  
     in blood vessels, **54**:29–30  
     and bone metabolism, **54**:28  
     effect on skin, **54**:28–29  
     growth regulatory functions, **54**:20  
     during hematopoiesis, **54**:22–25  
     immune regulation, **54**:21–22  
     in neuronal cells, **54**:30–31  
     in placental/fetal development, **54**:32  
     proinflammatory and antiinflammatory  
       cytokine, **54**:27–28  
     role in embryonic development,  
       **54**:31–32  
   CD23 antigen and, **49**:160  
   CD28 costimulation, **62**:139  
   cell sources and inducers, **54**:6  
   clinical applications, **54**:48–50  
   common signaling pathways, **53**:44–46  
   comparison to IL-1 186, **44**:189–191  
   description, **54**:1–2  
   as diagnostic marker, **54**:47–48  
   and disease, **54**:33–47  
     AIDS, **54**:37–39  
     bacterial and parasite infection,  
       **54**:36–37  
     B cell neoplasia, **54**:33–36  
     IL-6 transgenic mouse, **54**:45–47  
     inflammatory or autoimmune diseases,  
       **54**:39–43  
     viral infection, **54**:37  
   downregulation, **64**:315, 316  
   eosinophil-derived, **60**:199  
   expression regulation, **54**:8–10  
     NF- $\kappa$ B, **54**:10  
     NF IL-6, **54**:9–10

- Interleukin-6 (*continued*)
- gene
    - NF- $\kappa$ B and, **65:119**
    - regulation 23, **65:25**, 26–28
  - gene promoter, **65:26**
  - granulocyte, **48:75**
  - helper T cell cytokines and, **46:116**, 133
  - hemopoiesis, **64:321–322**
  - historical overview, **54:1–4**
  - HIV infection and, **47:403**, 404
  - human disease, **44:192**, 194
  - humoral immune response and, **45:60**, 74, 75, 82
  - Ig production, **63:64**
  - immunocompetent cells, **44:172**, 177, 178
  - immunosenescence and, **46:231**
  - inflammatory cytokine, interaction with NF- $\kappa$ B, **58:12–14**
  - inhibitors, clinical applications, **54:50–51**
  - in vitro* effects, **66:128–129**
  - in vivo* effects, **66:129–130**
  - Jak kinases, **63:139**, 140
  - Jaks interdependence in response to, **60:8–9**
  - and LIF, **53:44–47**
  - multiple myeloma pathogenesis, **64:252–256**
  - pituitary hormones, **63:385**
  - plasmacytomagenesis, **64:234–235**
    - pristane-induced, **64:226–227**
  - pleiotropic effects of transforming growth factor B, **52:184**
  - pleiotropic nature of, **53:44**
  - production
    - by crosslinkage of Fc $\epsilon$ R on peritoneal mast cells, **53:9**
    - by factor-dependent mast cell lines, **53:6–8**
  - prolactin secretion, **63:382**
  - pulmonary hypersensitivity, **59:418**, 419
  - pulmonary inflammation, **62:289**
  - schematic ternary structure, **54:5**
  - sepsis and, **66:104**, 127, 130–135
  - signal transduction
    - all-*trans* retinoic acid, **64:261–262**
    - reshaped human PM-1, **64:261**
    - therapies using, **64:260–263**
  - structure and expression, **54:4–11**, 12
    - inducers and producers, **54:6–8**
    - regulation of IL-6 expression, **54:8–10**
    - repression of IL-6 expression, **54:10–11**
    - structure, **54:4–5**
    - transcriptional regulatory elements, **54:9**
  - Interleukin-6 receptor, **54:11–19**; **61:151**; **63:275**, 276, 280, 282, 300–303
    - signaling, in B cells, **55:279–280**
    - structure, **66:127**
  - Interleukin-6 receptor  $\alpha$ , **63:275**, 276, 280, 300–301
  - Interleukin-6 receptor  $\beta$ , **63:275**, 276
  - Interleukin-7, **59:235–236**, 254; **61:178**; **63:140**, 303
    - B cell development, **59:298**
    - biological activity, **59:241–243**
    - cytotoxic T cells, **65:306**
    - Jak protein activation, **61:178**
    - pre-B cells nonproliferating on stromal cells, **53:134–135**
    - pro- and pre-B cells reactive to, **53:131–136**
    - signal induction, **59:259**
    - T cell development, **59:251**
    - and TCR $\beta$  regulation, **58:142**
  - Interleukin-7 receptor, **59:243–244**; **63:139**, 303
    - T cell activation, **48:250–253**
    - signal transduction, **48:251–252**
  - Interleukin-7 receptor  $\alpha$ , **63:275**, 276
  - Interleukin-7 receptor complex, **59:241–244**, 254
  - Interleukin-8, **55:97**
    - biochemistry, **66:135–136**
    - biological effects
      - basophils, **55:116–117**
      - eosinophils, **55:117**
      - lymphocytes, **55:118–119**
      - monocytes, **55:117–118**
      - neutrophils, **55:113–115**
      - in vivo*, **55:118–119**
    - cellular sources, **55:108**
    - endothelial cells, **55:107**
    - epithelial cells, **55:107**
    - fibroblasts, **55:107**
    - keratinocytes, **55:111**
    - leukocytes, **55:105–107**
    - macrophages, **55:106**
    - mesangial cells, **55:111**
    - monocytes, **55:105–106**
    - production, regulation, **55:111–112**
    - synovial cells, **55:111**
    - tissue cells, **55:107**, 111

- chemical properties, **55**:97–101  
chemotactic for primed eosinophils,  
**60**:177–178  
gene regulation, **65**:23, 28  
genes  
chromosomal localization, **55**:103–104  
expression, regulation, **55**:104–105  
organization, **55**:103  
IFN- $\gamma$ , **62**:80  
immunoreactivity, **60**:199  
inactivation, **55**:102–103  
inflammatory cytokine, transcription, **58**:12  
molecular structure, **55**:97–101  
pathology role, **55**:147–148  
arthritis, **55**:143–144, 147  
lung disease, **55**:144–147  
skin diseases, **55**:142–143, 147  
production by factor-dependent mast cell  
lines, **53**:8  
proteolytic processing, **55**:102–103  
pulmonary inflammation, **62**:260, 270, 273,  
274  
regulation, **66**:136  
and related integrins, receptors for,  
**52**:367–371  
sepsis and, **66**:104, 137–141  
signal transduction, **55**:140–142  
TNF- $\alpha$ , **64**:294, 295, 316  
Interleukin-8 receptor, **66**:136  
binding, **55**:136  
biochemical studies, **55**:122–125  
cloning, **55**:128–134  
ELR motif, **55**:136–138  
on erythrocytes, **55**:128  
expression, **55**:135  
genes, **55**:135  
G-protein coupling, **55**:138–139  
mapping, **55**:135  
regulation, **55**:139–140  
signal transduction, **55**:141  
Interleukin-9, **59**:244, 254; **63**:140, 167,  
168  
in hematopoietic system, **54**:83–84  
in human and mouse, cloning and  
characterization, **54**:80–82  
and human T cells, **54**:85–88  
and mast cells, **54**:93–95  
and mouse T cells, tumorigenesis,  
**54**:88–93  
studies with, **54**:79–80  
Interleukin-9 receptor, **54**:82–83;  
**59**:244–245; **63**:139  
Interleukin-9 receptor complex, **59**:244–245,  
254  
Interleukin-10, **52**:181–182; **62**:85; **63**:54, 55,  
60–67, 69, 139, 140  
allograft rejection, **62**:102  
antibody response, **62**:88  
B cell production, **61**:34  
biological effects  
B cells, **56**:10–11  
macrophages, **56**:6–8  
mast cells, **56**:10  
NK cells, **56**:10  
T cells, **56**:8–10  
CD40, **61**:38  
characterization, **56**:1  
class switching, **61**:98–99  
complementary DNA clones, **56**:3–5  
discovery  
cytokine synthesis inhibitory factor,  
**56**:1–2  
TH1/TH2 dichotomy, **56**:1–2  
functions, **56**:7, 18  
gene acquisition by herpesvirus, **56**:  
11–12  
gene structure, **56**:4  
granulomatous lesions, **62**:281  
herpesvirus acquisition of, **56**:11–12  
IFN- $\gamma$ , **62**:105  
and IL-4, in CD40 system, growth-  
promoting activity of, **52**:202  
levels, *in vivo* manipulation, **56**:16–17  
multiple myeloma pathogenesis, **64**:258  
PGHS-2, **62**:192, 195  
physical properties, **56**:3  
pleiotropic effects of, **52**:181–182  
as potent B cell differentiation factor,  
**52**:207  
in pregnancy, **56**:17  
production, **56**:4–6  
properties, **56**:3  
pulmonary inflammation, **62**:259–260,  
274–275, 279, 289  
related proteins, properties, **56**:3  
removal, **56**:16–17  
sepsis and, **66**:104, 142–145  
sources and structure of, **52**:181  
structure, **56**:4  
Th cell, **62**:146

- Interleukin-10 (*continued*)  
 Th2 cell  
   functional similarities of cytokines, **56:12–13**  
   responses correlated with expression, **56:13–15**  
 Th responses, **61:351, 358**  
 treatment, **56:16**  
 tumor immunogenicity reduced by, **57:307–309**
- Interleukin-10 receptor, characteristics, **56:18**
- Interleukin-11, **63:139**  
 biological function, **54:16–17**  
 multiple myeloma pathogenesis, **64:256**  
 relationship to LIF, OSM, CNTF, and IL-6, **53:47**
- Interleukin-12, **61:350–351; 63:139, 140; 66:146–147**  
 granulomatous lesions, **62:281**  
 IFN- $\gamma$ , **62:105, 107**  
 sepsis and, **66:104, 147**  
 and Stat4 phosphorylation, **60:21**  
 Th cells, **62:146**
- Interleukin-13, **61:34, 354, 374; 62:85–86, 260**  
 B cell proliferation, **63:55**  
 Ig production, **63:64, 69**  
 Jak kinases, **63:139, 140**  
 signaling molecules for, **63:169**  
 upregulation of adhesion molecules, **64:165**
- Interleukin-13 receptor, **63:133**
- Interleukin-15, **59:245, 254; 61:178; 62:106–107; 63:140, 173**
- Interleukin-15 receptor, **59:245; 63:139**
- Interleukin-15 receptor complex, **59:245–246, 254**
- Interleukin-16, **62:136, 146; 65:282**  
 HIV-1, **66:281, 283**
- Interleukin hybridoma plasmacytoma 1, **64:226**
- Interleukin receptor antagonist, **62:289**
- Intermitotic life span, of B and T cells, **53:237–241**
- Internalization  
 CD4 molecules and, **44:296**  
 evidence for, **52:87–89**  
 IL-1 and, **44:181, 184, 185**  
 signals, **52:89–92**  
 T cell development and, **44:226, 228, 229**
- Interphotoreceptor retinoid-binding protein, **48:215–216**
- Interstitial macrophages, **59:375**
- Interstitial nephritis, induced by IL-2, **50:200–201**
- Interstitial T cell surface glycoprotein, avian, **50:97–101**
- Intestinal antigens, IBD and, **42:290**
- Intestinal mononuclear cells  
 antibody secretion and, **42:302–307**  
 IBD and, **42:295–296**
- Intestine  
 infectious and diseases, immunity, **58:329**  
 inflammation, lymphocyte homing, **64:145**  
 intraepithelial lymphocytes, **53:163–167**  
   majority as CD8<sup>+</sup>, **58:307**  
   lymphocyte homing and  
     immune response, **44:331, 332, 334–336**  
     molecules, **44:352**  
     regional specificity, **44:323, 327, 329, 339**
- int* genes, **65:154, 155**
- Intrachromosomal deletion, switch recombination, **61:99**
- Intracisternal A particle core protein, polyclonal antibody, **43:304**
- Intraepithelial lymphocytes  
 CD4 and CD8 on, **58:306–307**  
 effector potential, **58:324–326**  
 and immune system, **58:297–343**  
 immunosenescence and, **46:237**  
 intestinal, differentiation, **53:163–167**  
 invariant  $\gamma/\delta$  T cells (skin, female reproductive tract), **53:167–169**  
 origin, **58:308–311**  
 role in immunity  
   intestine, **58:329**  
   lung, **58:328–329**  
   skin, **58:326–328**
- T cell lineages, **58:110–112**  
 as T cells, **58:298–300**  
 as T cells bearing  $\gamma\delta$  TCR, **58:301**
- Intrahepatic cholestasis, severe, **50:190–191**
- Intraocular tumor rejection  
 basic patterns, **48:215**  
 cytolytic T cell, **48:215**  
 hemorrhagic necrosis, **48:215**  
 immune regulation, **48:212–215**  
 immune rejection, **48:215**

- Intrathymic clonal deletion, **51:165–173**  
 cell biology of negative selection,  
**51:165–170**  
 search for mechanism, **51:170–173**
- Intrathymic defects, SCID and, **49:383–384**
- Intrathymic development, *see* T cells,  
 intrathymic development
- Intrathymic induction, clonal anergy,  
 examples, **50:169**
- Intrauterine influences, maternally  
 transmitted antigen and, **38:321, 322,**  
**338**
- Intrinsic affinity, **59:305**
- Intrinsic coagulation/kinin-forming cascade,  
**66:240–243**  
 bradykinin  
 formation, **66:225, 226, 233–239**  
 functions, **66:239**  
 receptors, **66:239–240**  
 contact activation, **66:225, 233–239**  
 allergic diseases, **66:258–259**  
 Alzheimer's disease, **66:260**  
 disease states and, hereditary  
 angioedema, **66:257–258**  
 endotoxic shock, **66:260**  
 interaction with cells, **66:243–248**  
 pancreatitis, **66:260**  
 rheumatoid arthritis, **66:260**  
 endothelial cells and, **66:245**  
 factor XI, **66:225, 226, 230, 237, 244**  
 factor XII, **66:225, 226–229, 234–236, 244,**  
**246, 249–257**  
 high-molecular-weight kininogen, **66:225,**  
**226, 230–233, 245, 247–257**  
 kallikrein, **66:225, 238, 243–244**  
 low-molecular-weight kininogen, **66:233**  
 mechanism, **66:225–226**  
 platelets and, **66:244–245**  
 prekallikrein, **66:225, 226, 229–230, 236**
- Intron/exon mapping, CD1 genes, **59:7–8**
- Inulin, cytotoxicity and, **41:304, 306**
- Inversion  
 T cell receptor protein and, **38:8**  
 and translocation, in lymphoid tumors,  
 mechanism, **50:121–122**
- Iodine  
 autoimmune thyroiditis and  
 antigens, **46:267, 269–272**  
 cellular immune responses, **46:294**  
 experimental models, **46:278**  
 humoral responses, **46:303**  
 spontaneous autoimmune thyroiditis and  
 altered thyroid function, **47:456, 459,**  
**460**  
 genetics, **47:487–490**
- Iodo-2'-deoxyuridine, hybrid resistance and  
 antigen expression, **41:397, 404**  
 bone marrow cells, **41:340, 342, 345,**  
**347**  
 effector mechanisms, **41:370**  
 leukemia/lymphoma cells, **41:364–368**  
 lymphoid cells, **41:352, 354**  
 T cells, **41:380**
- Ion channels, T cell, **48:285–288**  
 regulation, **48:285, 286**
- Ion-exchange chromatography, leukemia  
 inhibitory factor, **53:32**
- Ionizing radiation  
 and *scid* defect, **58:49–51**  
 sensitivity of ataxia telangiectasia cells,  
**58:68–69**
- Ionomycin, **48:80, 90**  
 effects  
 factor-dependent mast cell lymphokine  
 production, **53:6**  
 IL-3 production by mast cells, **53:5**  
 immunosenescence and, **46:228**  
 T cell subsets and, **41:65, 98**
- Ionotypic regulation, murine lupus models  
 and, **46:65**
- IP<sub>3</sub>, *see* Inositol 1,4,5-trisphosphate
- IP-10, **62:76, 80**
- Ipr* gene, **61:9**
- IRAK, **63:159; 65:117**
- IRF, **62:69–70**  
 model for, **52:276**
- IRF-1, **62:69–70**  
 B cell genesis, **63:235–236**  
 and IRF-2, **52:267–271**  
 knockout mouse, **60:335**  
 requirement for NOS expression,  
**60:17**
- IRF-1*, **60:24–25**
- IRF-2, **62:69–70; 63:218–219, 235–238**  
 B cell genesis, **63:218–219, 235–238**  
 and IRF-1, **52:267–271**
- IRF-2*, **63:235–236**
- IRF-binding sites, in IFN-inducible genes,  
**52:273**
- IRG-47, **62:76**
- Ir* genes, *see* Immune response genes

- Irradiation  
 and apoptosis, **58**:237–240  
 hybrid resistance and  
 antigen expression, **41**:397, 403, 404,  
 408–410  
 bone marrow cells, **41**:339, 344,  
 346–348, 350  
 effector mechanisms, **41**:369, 370  
 antibodies, **41**:376, 377, 379  
 marrow, **41**:384–386, 388, 390  
 NK cells, **41**:373–375  
 syngeneic stem cells, **41**:389, 390  
 T cells, **41**:380–384  
*in vitro* assays, **41**:394, 396  
 leukemia/lymphoma cells, **41**:358, 359,  
 361, 363–367  
 lymphoid cells, **41**:352, 354–357  
 NK cells and, **47**:291, 295  
 differentiation, **47**:229–232  
 effector mechanisms, **47**:260, 261  
 hematopoiesis, **47**:273, 274, 276  
 IRS-1, **63**:146, 168–169  
 IRS-2, **63**:169  
 Ischemia  
 aPL antibodies and, **49**:218–219, 258  
 leukocyte integrins and, **46**:165, 166, 177  
 therapeutic complement inhibition using  
 soluble CRI, **56**:282–284  
 Ischemia/reperfusion  
 model, role of NO, **60**:330–332, 346–348  
 pulmonary inflammation, **62**:275–277  
 ISGF3 transcription complex, induction by  
 IFN- $\alpha/\beta$ , **60**:17  
 Islet beta cells, **48**:140–141  
 antigen presentation, **48**:142  
 dysfunction, NO role, **60**:345  
 lymphokine, **48**:141  
 T cell cytotoxicity, **48**:142  
 Islets of Langerhans, IFN- $\gamma$  and, **62**:100–101  
 Isoelectric focusing, complement components  
 and, **38**:207, 208, 215  
 Isoelectrofocusing, one-dimensional, HLA  
 class II, **48**:114–116  
 Isotype-mismatched molecule, **48**:125  
 Isotypes  
 IgG receptor, **54**:343–344  
 production, secondary B cells and,  
**42**:75–76  
 response, role of T cell Fc receptors and,  
**40**:212–216  
 Isotype specificity, regulation, **61**:84–89,  
 90–92  
 Isotype switching, **65**:253–254  
 during B cell differentiation, **60**:38–39  
 B cells, human, **52**:215–218  
 general considerations on, **52**:215–217  
 IL-4 and IgE switching, **52**:217–218  
 defect in HIGMX-1, **60**:42–48  
 directed, and germline C<sub>H</sub> transcription,  
**54**:240–245  
 dual isotype expression without  
 recombination, **54**:246  
 expression of downstream isotypes without  
 switch recombination, **54**:245–246  
 in humans, **54**:260–262  
 IL-4 regulation, **54**:260–262  
 TGF- $\beta$  and IgA expression, **54**:262  
 to IgE and IgC, IL-4 enhancing,  
**54**:248–249  
 nondeletional, **54**:245–246  
 sequential, **54**:238–239  
 by TGF- $\beta$ , regulation, **54**:257–259  
 Itk, **59**:265–266  
 signal transduction, **59**:265–266
- J**
- J558* V<sub>H</sub> gene family, *see* Arsonate idiotypic  
 system, A/J mouse, *J558* V<sub>H</sub> gene family  
 and  
*J774.1* cell line, specific binding of LPS,  
**53**:277–278  
*Jak*, and *JAK*, **60**:3–4  
*JAK*-1, **62**:68–69, 106; **63**:139, 168  
*JAK*-1/2, IL-2, **61**:173–174  
*JAK*-2, **62**:68, 69, 106; **63**:139  
 activation of, **65**:20–21  
*JAK*-3, **63**:139  
*JAK*-STAT-GAS pathway, pituitary  
 hormones, **63**:399–400  
*Jak*-STAT mechanism, IFN- $\gamma$  binding,  
**62**:67–71  
*Jak*-Stat pathway, **61**:179, 190; **63**:138–141,  
 171–172, *see also* Janus kinase family  
 Janus kinase family, **62**:68–69, 106; **63**:134,  
 138–141  
 activation  
 by EGF receptor, **60**:27

- role of receptor dimerization/  
 oligomerization, **60:9–11**  
 association with cytokine receptors,  
**60:11–12**  
 coupling of cytokine binding to tyrosine  
 phosphorylation, **60:4–9**  
 origins and structure, **60:2–4**  
 PTK's, IL-2R coupling, **61:158–161**, 190  
 Stat1 as substrate, **60:19**  
 Tyk2, **62:68**  
   in IFN- $\alpha/\beta$  response, **60:7–9**  
 Jarisch–Herxheimer reaction, release of IL-6,  
**66:11–34**  
 J $C_{\kappa}$ , B cell development, **63:29–30**  
 J chain, **65:248**  
   cells producing, **40:186**, 188–189  
   of IgA, structure and function of,  
**40:158–160**  
   IgA polymerization and, **40:187–188**  
 Jejunum, lymphocyte homing and, **44:330**,  
 332, 333  
 Jerne hypothesis, **59:99–100**  
 Jerne model, T cell repertoire and,  
**38:130–132**  
 J gene segments, Ig heavy-chain variable  
 region genes and, **49:4–6**, 28  
 J $H$  gene segments, **62:1**  
   Ars A antibodies, **42:107–108**  
   deletion, **62:32–33**, 42  
   Ig heavy-chain variable region genes and,  
**49:2–3**, 29, 31, 33–35, 53  
   in mouse and human, **62:17–19**  
   organization, **62:9–10**  
 Joining, V(D)J, antigen receptor genes, *see*  
 V(D)J joining, antigen receptor genes  
 Joints  
   morphology of, **64:287–288**  
   NO-induced destruction, **60:344**  
   open-and-shut, V(D)J recombination,  
**64:42**  
   rheumatoid arthritis, **64:287–288**, 291, 315  
   joint destruction mechanism, **64:**  
   320–321  
   neovascularization, **64:319–320**  
*jsd*, **60:20–21**  
 Junction, diversity of, variable region and,  
**40:255–256**  
*jun* genes, **63:160**, 248  
 Jun kinases, **63:148**  
   Ets transcription factors and, **64:81**  
 Jurkat leukemic T cells, **48:182**  
   IL-1 and, **44:174–176**, 185  
 Juvenile rheumatoid arthritis  
   DR4, **48:131**  
   DR5, **48:131**  
   DRw8, **48:131**
- ## K
- K562 cells, as target cells for NK activity,  
**42:184**  
 Kallikrein, **66:225**  
   in allergic reactions, **66:259**  
   IgE biosynthesis and, **47:25**  
   inhibition, **66:238**  
   interactions with cells, **66:243–244**  
 Kaolin clotting time, aPL antibodies and,  
**49:201–202**, 241  
 Kaposi's sarcoma, and IL-6, **54:38–39**  
 $\kappa$  enhancer, **43:249–251**  
 $\kappa$  gene, **43:238**, 240  
 $\kappa$  light chain, **63:5**, 10, 13, 24  
   rearrangement, **61:305**  
   variability, **42:4**  
 $\kappa$  light chain promoter, **43:257**  
 $\kappa$  locus, murine, Ars A response and,  
**42:138**  
 $\kappa$  promoter, **43:257–258**  
 Karyotype, SCID and, **49:388**, 392  
 KAVYNFATC, induced positive selection of  
 thymocytes, **59:126**  
 Kawasaki syndrome, **54:133–137**  
   analysis of T cell receptors, **54:135**  
   diagnostic criteria for, **54:133**  
 KC, **62:80**  
 K cell function, Crohn's disease and,  
**42:295**  
 KEKE motif, **64:30**  
 Keratinocytes  
   B cell formation and, **41:234**  
   expression of dendritic epidermal cell  
   ligand, **58:320**  
   helper T cell cytokines and, **46:115**  
   IFN- $\gamma$  effect on, **62:76**  
   IL-1 and, **44:153**, 160, 177, 185  
   IL-1ra production, **54:190–192**  
   and NO production, **60:350–351**  
   as source of chemokines, **55:111**  
 Ketorolac tromethamine, **62:186**



- Keyhole limpet hemocyanin, **61**:369; **62**:149, 220  
 antigen-presenting cells and, **47**:66, 69, 70  
 autoreactive T cells and, **45**:419, 421  
 HIV infection and, **47**:400  
 humoral immune response and, **45**:10, 11, 15, 33  
 IgE biosynthesis and, **47**:6, 14, 34, 35  
 sporozoite malaria vaccine and, **45**:301  
 synthetic T and B cell sites and, **45**:227, 255, 256  
 T cells, **47**:86, 97, 99  
 T cell subsets and, **41**:70, 71  
 TNP-KLH-sensitized B cells, **60**:305–308  
 virus-induced immunosuppression and, **45**:361, 362
- Ki antigen, **64**:22–23
- Kidney  
 antigen-presenting cells and, **47**:76  
 CD5 B cell and, **47**:134  
 CTL and, **41**:149  
 hybrid resistance and, **41**:338, 348, 356, 404  
 IgE biosynthesis and, **47**:16  
 NK cells and, **47**:187, 282  
 regulators of complement activation and, **45**:389  
 spontaneous autoimmune thyroiditis and, **47**:462, 493  
 transplant, SCID and, **49**:399  
 virus-induced immunosuppression and, **45**:337
- Kinase inhibitor protein-1, **61**:186–187
- Kinases, **59**:169, 178–179  
 Ig gene superfamily and, **44**:30, 39, 44  
 in signal transduction, **59**:261–266
- Kinetics  
 125I-labeled IL-2 internalization, **42**:175  
 Ars A response, **42**:108–109
- Kinin  
 in hereditary angioedema, **66**:257–258, 259  
 inactivation, **66**:240
- Kininogen  
 genes, **66**:233  
 high-molecular-weight  
 contact activation and, **66**:236, 237  
 endothelial cell receptor, **66**:249–257  
 inactivation, **66**:245  
 properties, **66**:226, 256  
 structure, **66**:230–233  
 low-molecular-weight, **66**:233
- Kit ligand, *see* Stem cell factor; Stem cell factor receptor
- Klebsiella pneumoniae*, **50**:162
- Knockout animals  
 adhesion studies, **64**:187–188  
 lymphocyte homing, **64**:194–195
- Knockout experiments  
 cytokine induction, **65**:29–32  
 with perforin gene, **60**:291–292
- Knockout mouse, LIF knockout, **53**:33, 48
- KOL, crystal packing, **43**:113
- KSH 4.13.6.  
 changes in after deprivation of RCS, **51**:226  
 characterization of CTL activity of, **51**:225
- Ku, **64**:49, 60  
 antinuclear antibodies and, **44**:96, 97, 104, 105
- KU 70/86, **61**:301–303, 317
- Kuppfer cells, CD1 proteins, **59**:67
- Kynurenine, **62**:71
- L**
- L- $\beta$ , **61**:22
- L1 cell adhesion molecule, 200-kDa glycoprotein, **58**:375–376
- L3T4, humoral immune response and, **45**:25, 26, 44, 45
- Labeling, CD1 proteins, **59**:45–46
- Lactate dehydrogenase B, suppressor T cells and, **38**:149–152, 184
- Lactation, lymphocyte homing and, **44**:321, 326, 327, 335
- LAK cells, *see* Lymphokine-activated killer cells
- LAM-1, surface antigens of human leukocytes and, **49**:87–88
- $\lambda_5$ , **63**:7–8
- $\lambda_5$  gene, **63**:2  
 expression, **63**:5–15  
 $\mu$  heavy chains, **63**:2–3  
 regulation, **63**:4–5  
 structure, **63**:4
- $\lambda$  light chain, **63**:4, 13
- $\lambda$  light chain promoter, **43**:257
- $\lambda$  phage repressor protein, **43**:209–210

- Lambert Eaton myasthenic syndrome,  
**42:234**, *see also* Myasthenia gravis  
 etiology, **42:251, 252**
- Lamina propria, **59:372**  
 lymphocytes, immunosenescence and,  
**46:237**  
 MNC, IBD and, **42:297**  
 T cells, IBD and, **42:300–301**
- Laminarin, phagocytosis of zymosan and,  
**38:366, 377**  
 alternative complement pathway,  
**38:384–386**  
 ingestion inhibition, **38:381**
- Laminin  
 complement receptor 1 and, **46:199**  
 hybrid resistance and, **41:403**  
 leukocyte integrins and, **46:153**  
 NK cells and, **47:246**
- Laminine, multiple myeloma and, **64:249**
- Langerhans' cells, **59:60–62, 377, 379, 61:13**  
 antigen-presenting cells and, **47:71–73, 75**  
 antigen processing, **47:90–92**  
 APC-T cell binding, **47:96, 97**  
 cell surface, **47:57, 59, 62, 63**  
 immunogeneity, **47:102**  
 interaction with T cells, **47:94**  
 T cell growth, **47:100**  
 tissue distribution, **47:50, 51, 53–57**
- CD23 antigen and, **49:154–155, 161, 167, 171**  
 corneal epithelium, **48:197**  
 corneal graft rejection, **48:196–200**  
 cytotoxic T cell, **48:197–198**  
 delayed-type hypersensitivity, **48:197–198**  
 dynamic distribution, **48:200–202**  
 epithelial distribution, **48:201**  
 Fc $\epsilon$ R1 expression, **53:1–2**  
 Ia+, **48:197**  
 IBD and, **42:296**  
 immunoregulatory effects, **48:203**  
 male vs. female tissue, **48:198–199**  
 migration, **48:201**  
 orthotopic graft, **48:198**  
 regulatory process, **48:202**  
 T cell subsets and, **41:69, 92, 94**
- LAP, **65:2**
- Large granular lymphocytes, **47:188, 222, 283, 295**  
 adoptive T cell therapy of tumors and,  
**49:315**  
 CD23 antigen and, **49:155**  
 congenital defects, **47:226**  
 cytotoxicity, **47:250, 253, 257**  
 cytotoxicity and, **41:271, 287, 289, 291, 309**  
 differentiation, **47:231, 234**  
 effector mechanisms, **47:248**  
 hematopoiesis, **47:275, 276, 278**  
 hybrid resistance and, **41:376, 380**  
 identification, **47:197–199**  
 leukocyte integrins and, **46:151**  
 lymphocytosis, **47:227–229, 275, 276, 279**  
 lymphokines, **47:262, 263**  
 malignant expansion, **47:226–228**  
 morphology, **47:214, 216–218**  
 NK cells and, surface antigens of; **42:182**,  
*see also* Natural killer cells  
 reproduction, **47:271**  
 surface phenotype, **47:204, 205, 208, 211, 213**  
 tissue distribution, **47:219–221**
- Laron dwarfism, **63:397**
- Latent membrane protein, synthetic T and B  
 cell sites and, **45:226**
- Latent membrane protein 1, CD23 antigen  
 and, **49:161**
- L cells  
 B cell formation and, **41:198**
- CTL  
 and amino acid, **41:163**  
 exon shuffling 138-140, **41:144, 147, 148**  
 HLA class I antigens, **41:149–152**
- Lck, **63:135–137, 165, 171**  
 IL-2R $\beta$  coupling, **61:155**
- lck*, expression regulation  
 restricted accumulation of transcripts,  
**56:151–152**  
 transcription, **56:152–153**
- LCL, *see* Large granular lymphocytes
- Lectin  
 antigen-presenting cells and, **47:99, 100**  
 autoimmune thyroiditis and, **46:294**  
 B cell formation and, **41:201, 210**  
 CD4 and CD8 molecules and, **44:267, 268, 300, 302**  
 CD23 antigen and, **49:163–165, 176**  
 CTL and, **41:150**  
 human T cell activation and, **41:7–9, 12, 28**  
 IgE biosynthesis and, **47:15–20**  
 immunosenescence and, **46:221, 223, 245**

- Lectin (*continued*)  
 lymphocyte homing and, **44:354**, 363, 367, 368  
 NK cells and, **47:241**, 250, 261, 286  
 spontaneous autoimmune thyroiditis and, **47:470**, 471  
 surface antigens of human leukocytes and, **49:88–91**, 94, 100  
 T cell subsets and, **41:60**, 76  
 Lectins, mitogenic, IBD and, **42:289**  
 Lederberg's theory, tolerance induction, **42:48**  
*Legionella pneumophila*, **59:398**  
*Leishmania*  
 complement receptor 1 and, **46:200**  
 leukocyte integrins and, **46:163**  
*Leishmania donovani*, and diabetes, **51:294**  
*Leishmania major*  
 helper T cell cytokines and, **46:128**, 129, 137, 138  
 NO expression during infection, **60:342–343**  
 responses in MHC class I-deficient mouse to infection, **55:414–415**  
 Leishmaniasis, and  $\gamma\delta$  T cell accumulation, **58:326–328**  
 LEMS, *see* Lambert Eaton myasthenic syndrome  
 Lennert's lymphoma, gene rearrangement and, **40:294**  
 Lens  
 anatomical sequestration, **48:220**  
 autoantigens, **48:220**  
 crystallin, **48:219**  
 $\alpha$ , **48:220**  
 antigen, **48:191**  
 $\gamma$ , **48:220**  
 self-tolerance, **48:220**  
 Lentiviruses  
 HIV infection and, **47:395**, 411  
 etiological agent, **47:378**, 384, 385  
 nonhuman primate, phylogeny, **52:442–443**  
 primate, phylogenetic tree, **52:444**  
 ungulate, **52:430–432**  
 virus-induced immunosuppression and, **45:347–349**, 351, 355  
 Leprosy  
 CD1 proteins in lesions, **59:66**  
 Ig heavy-chain variable region genes and, **49:46**, 48  
 and  $\gamma\delta$  T cell accumulation, **58:326–328**  
 Lesch-Nyhan syndrome, **59:159**  
 Lesions, cytotoxicity and, **41:288–291**, 318, 305–307  
 LESTR, **66:282**  
 Leu-1, **48:246**  
 Leu-7  
 antigen, NK cells and, **47:275**, 291, 292  
 CNS, **47:266**  
 congenital defects, **47:225**  
 differentiation, **47:234**  
 genetic control, **47:222**  
 malignant expansion, **47:226**  
 morphology, **47:218**  
 surface phenotype, **47:206**, 207  
 tissue distribution, **47:220**, 221  
 Leu-19  
 antigen, NK cells and, **47:289**, 293, 294, 302  
 CNS, **47:266**, 267  
 differentiation, **47:233**, 234  
 reproduction, **47:271**  
 surface phenotype, **47:205**, 206  
 Leucine  
 antinuclear antibodies and, **44:115**  
 CTL and, **41:166**  
 Leukemia  
 adoptive T cell therapy of tumors and mechanisms, **49:300–305**, 308, 311, 313, 317  
 principles, **49:286**, 291–293, 295–296  
 B cell formation and, **41:185**, 191, 193, 205, 220, 233  
 B-lineage, **61:11–12**  
 CD1 proteins, **59:60**  
 CD5 B cell and, **47:123**, 124  
 bone marrow transplantation, **47:129**, 130  
 Ig gene expression, **47:153**, 154, 156, 157  
 physiology, **47:136**, 140, 141, 143  
 surface antigen, **47:147**  
 CD23 antigen and, **49:150–151**, 175  
 diagnosis of, **40:247–248**, 249  
 eosinophilic, **60:223–224**  
 graft-versus, **40:419–422**  
 human B cell neoplasia and, **38:245**, 271  
 acute B cell, **38:268**  
 acute lymphocytic, **38:247**, 264, 269  
 chromosome translocation, **38:266**  
 chronic lymphocytic, **38:264**, 265

- chronic myelogenous, **38:245**  
 human promyelocytic, **38:254**  
 hybrid resistance and, **41:358–369**  
   antibodies, **41:378, 380**  
   antigen expression, **41:401, 403**  
   bone marrow cells, **41:346, 348**  
 IgE biosynthesis and, **47:20**  
 Ig heavy-chain variable region genes and, **49:17, 39–40**  
 IL-1 and, **44:194**  
 lymphocyte hybridomas and  
   chronic lymphatic, **38:282, 288, 291, 299, 302**  
   human-human, **38:292**  
   Immunoglobulin secretion, **38:288**  
 maps of Ig-like loci and, **46:7**  
 mature T cell, receptor gene  
   rearrangements in, **40:276–284**  
 myeloid  
   20 $\alpha$ SDH activity, **39:36**  
   *c-mpb* locus rearrangement, **39:36–37**  
   IL-3-dependent lines from, **39:35–37**  
 NK cells and, **47:190, 199, 298**  
   congenital defects, **47:227**  
   differentiation, **47:231**  
   effector mechanisms, **47:238, 262**  
   hem atop oie i s i s, **47:276, 277**  
   malignant expansion, **47:226**  
   surface phenotype, **47:205**  
   pituitary hormones, **63:426, 427**  
     growth hormone, **63:409, 428**  
     prolactin receptor, **63:396**  
 in PNH patients, **60:92**  
 risk in rheumatoid arthritis patient, **64:329–330**  
 SCID and, **49:397**  
 surface antigens of human leukocytes and, **49:92, 114, 117–118**  
 T cell, *see* T cell leukemia  
 Leukemia inhibitory factor, **54:15–16, 24–25; 61:151; 64:256; 66:147–148**  
   and blastocyst regulation, **53:34**  
   in cachexia, **53:37–38**  
   in development, **53:33–37**  
   effects on mouse embryonic stem cells, **53:33–34**  
   in hematopoiesis, **53:35–36**  
   human, amino acid sequence, **53:40**  
   and IL-6, **53:44–47**  
   immobilized form, **53:34**  
   in inflammation, **53:37–38**  
   LIF knockout mouse, **53:48–49**  
   local action of, **53:49**  
   matrix-associated form, **53:34**  
   molecular cloning, **53:31–32**  
   pleiotropic nature of, **53:44**  
   polyfunctionality in vitro, **53:32–33**  
   pseudonyms for, **53:32–33**  
   purification, **53:31–32**  
   sepsis and, **66:104, 148**  
   soluble form, **53:34**  
   as stem cell factor, **53:35**  
 Leukemia inhibitory factor receptor  
   alternatively spliced versions (murine), **53:39**  
   cloned, **53:38–39**  
   cytoplasmic domain, **53:39–40**  
   extracellular domain, **53:39**  
   genes, chromosome locations, **53:39**  
   high affinity  
     characterization, **53:38**  
     and CNTF receptor, **53:43–44, 46**  
     oncostatin M binding, **53:41–43**  
   human, **53:38–39**  
   low affinity, **53:38**  
   transfected, **53:41**  
   types, **53:38**  
 Leukemia inhibitory factor receptor  $\beta$ , **61:151**  
 Leukemia virus, cytotoxic T cells and, **38:173, 174**  
 Leukemic cell lines, **42:168, 169, 172, 175**  
 Leukemic cells  
   cell typing, **48:117**  
   depletion, **58:272–275**  
 Leukocyte adhesion deficiency, types I and II, **64:193**  
 Leukocyte adhesion deficiency disease, **46:151, 173–176**  
   inflammation, **46:161, 162, 165, 168**  
   ligand molecules, **46:170**  
 Leukocyte adhesion molecules, endothelial, *see* Endothelial leukocyte adhesion molecules  
 Leukocyte common antigen, antigen-presenting cells and, **47:60, 61**  
 Leukocyte elastase, *see* Neutrophil elastase  
 Leukocyte–endothelial cell recognition, models, **58:381–389**  
 Leukocyte function antigen, *see* LFA

- Leukocyte integrins, **46:149–153**, *see also*  
 Integrins  
 chromosomal localization, **46:159, 160**  
 future research, **46:176, 177**  
 inflammation, **46:160, 161**  
 adhesion deficiency, **46:161**  
 animal models, **46:165**  
 expression, **46:166–169**  
 function, **46:161–164**  
 functional redundancy, **46:164, 165**  
 mAbs, **46:165, 166**  
 leukocyte adhesion deficiency disease,  
**46:173–176**  
 ligand molecules, **46:169–173**  
 structure, **46:153, 154**  
 biosynthesis, **46:154**  
 ligand binding, **46:158, 159**  
 primary, **46:154–158**
- Leukocytes*  
 adhesion to endothelial cells, **58:376–378, 381–389**  
 antigen-presenting cells and, **47:76**  
 APC-T cell binding, **47:97**  
 cell surface, **47:61, 63**  
 tissue distribution, **47:48, 51, 53**  
 B cell formation and, **41:192, 194, 198, 229**  
 cachectin and, **42:222**  
 CD5 B cell and, **47:145**  
 as cellular source of chemokines,  
**55:105–107**  
 cytotoxicity and, **41:270, 312**  
 growth hormone, **63:386–388**  
 helper T cell cytokines and, **46:117**  
 HIV infection and, **47:400**  
 hybrid resistance and, **41:349, 350, 356**  
 IFNs, **62:61**  
 IGF-I, **63:389–391**  
 interaction with complement in acute  
 injury states, **56:274–277**  
 lymphocyte homing and  
 carbohydrate, **44:369**  
 molecules, **44:342, 350**  
 regional specificity, **44:339, 341**  
 migration, **58:345–351**  
 NK cells and, **47:188, 189, 295**  
 effector mechanisms, **47:243, 263**  
 genetic control, **47:222**  
 surface phenotype, **47:201, 208**  
 perforin expression, **51:222–223**  
 prolactin, **63:382–384, 383**  
 recruitment during inflammation,  
**58:394–395**  
 SCID and, **49:383–384, 398**  
 spontaneous autoimmune thyroiditis and,  
**47:492**  
 surface antigens, *see* HLA  
 T cell subsets and, **41:108**  
 and transendothelial migration, **58:388–389**
- Leukopenia, hybrid resistance and, **41:388**  
 Leukophoresis, donor lymphocytes and,  
**38:284**
- Leukoregulin, cytolysis and, **41:286**  
 Leukotriene A<sub>4</sub>  
 5-HPETE conversion to, **39:150–151**  
 LTC<sub>4</sub> formation from, **39:151–152**  
 Leukotriene A<sub>4</sub> hydrolase, **39:152**  
 Leukotriene antagonists and inhibitors,  
**51:346–347**
- Leukotriene B<sub>4</sub>, **62:269**  
 attracting myeloid cells, **58:381**  
 biological effects, **39:156–157**  
 receptor-mediated, **39:158**  
 CD23 antigen and, **49:154, 159, 161**  
 corticosteroids and, **42:316, 318–319**  
 eosinophil receptors for, **60:185–186**  
 eosinophil response to, **60:174–176**  
 IBD and, **42:314–315**  
 immunoreactive, dietary fish oil and,  
**39:164**  
 inactivation by EPO, **39:202–203**  
 neutrophil activation by, **39:135**  
 produced by neutrophils, **60:189**
- Leukotriene B<sub>4</sub> 20-hydroxylase, **39:152**  
 Leukotriene B<sub>4</sub> receptors, neutrophil  
 characteristics, **39:96–98**  
 heterogeneity, **39:99**
- Leukotriene B<sub>5</sub>  
 biological effects, **39:161–162**  
 EPA conversion to, **39:160–161**
- Leukotriene C<sub>4</sub>  
 5-HPETE conversion to, **39:151–152**  
 biological effects, **39:154–156**  
 receptor-mediated, **39:157–158**  
 bronchial asthma and, **39:223**  
 and eosinophil antihelminthic activity,  
**60:212–214**  
 inactivation by EPO, **39:202–203**  
 LTD<sub>4</sub> formation from, **39:152–153**
- Leukotriene C<sub>4</sub> synthetase, **39:151–152**

- Leukotriene C<sub>5</sub>  
 biological effects, **39:162**  
 EPA conversion to, **39:160–161**
- Leukotriene D<sub>4</sub>  
 biological effects, **39:154–156**  
 receptor-mediated, **39:157–158**  
 inactivation by EPO, **39:202–203**  
 LTC<sub>4</sub> conversion to, **39:152–153**
- Leukotriene E, IBD and, **42:315**
- Leukotriene E<sub>4</sub>, biological effects,  
**39:154–155**  
 receptor-mediated, **39:157–158**
- Leukotrienes, **51:341–347**  
 arachidonic acid conversion to, **39:147–149**  
 5-lipoxygenase and, **39:147–150**  
 cell specificity, **39:153**  
 biological activities, **51:343**  
 EPA-derived  
 5-lipoxygenase pathway, **39:160–161**  
 biological properties, **39:161–162**  
 in human neutrophils, dietary EPA and,  
**39:166**  
 in asthmatic subjects, **39:166–167**  
 hybrid resistance and, **41:360**  
 IBD and, **42:310–315**  
 immediate hypersensitivity and,  
**39:218**  
 leukotriene antagonists and inhibitors,  
**51:346–347**  
 leukotrienes and airway  
 hyperresponsiveness, **51:344–346**  
 metabolism  
 5-HPETEdehydration to LTA<sub>4</sub>,  
**39:150–151**  
 γ-glutamyl transpeptidase and,  
**39:152–153**  
 LTA<sub>4</sub> hydrolase and, **39:152**  
 LTB<sub>4</sub> 20-hydroxylase and, **39:152**  
 LTC<sub>4</sub> synthetase and, **39:151–152**  
 as neutrophil activators, **39:135–136**  
 potency, **51:343**  
 production by  
 eosinophils, **39:204**  
 marine mastoeytoma, dietary EPA and,  
**39:162**  
 rat peritoneal cavity  
 EPA-enriched diet and, **39:163**  
 fish oil-enriched diet and, **39:162–163**  
 release of leukotrienes in asthma, **51:346**  
 sulfidopeptide  
 binding sites for, **39:157–158**  
 biological effects, **39:154–156**  
 synthesis and metabolism, **51:341–343**
- Leupeptin  
 synthetic T and B cell sites and, **45:223**  
 T cell receptor and, **45:124**
- LFA  
 CTL and, **41:136, 139, 150–152, 154**  
 cytotoxicity and, **41:271, 272**  
 IL-1 and, **44:166**  
 LFA-1, **48:247; 54:309–310**  
 activation by chemokine, **58:381**  
 affinity of ICAM-1 and ICAM-2,  
**58:373–374**  
 B cell formation and, **41:194**  
 CD23 antigen and, **49:161**  
 conformational effects, **64:169–170**  
 humoral immune response and, **45:39, 41, 43, 45, 51, 52, 54**  
 IFN-γ and, **62:78, 81**  
 integrins, **58:369–370**  
 interaction with ICAM-1 in negative  
 selection, **58:172**  
 leukocyte integrins and, **46:149–153**  
 inflammation, **46:160–164, 166–169**  
 leukocyte adhesion deficiency disease,  
**46:173, 174**  
 ligand molecules, **46:169–172**  
 structure, **46:153, 154, 156, 158**  
 lymphocyte-HEV interactions and, **65:352, 358, 368, 370**  
 lymphocyte homing and, **44:350, 351, 361; 64:146, 155, 157**  
 multiple myeloma and, **64:247**  
 surface antigens of human leukocytes and,  
**49:86, 88, 92**  
 LFA-2/CD2 and LFA-3/CD58, **52:361**  
 LFA-3, **48:236; 64:160**  
 CD23 antigen and, **49:161**  
 surface antigens of human leukocytes and,  
**49:87**
- LH, *see* Luteinizing hormone
- LIF, *see* Leukemia inhibitory factor
- Life expectancy, and autoimmune  
 manifestations, effect of IL-2.VV,  
**50:195–296**
- Life span  
 of immunological memory, **53:218–219**  
 intermitotic, of B and T cells, **53:237–241**

- Li-Fraumeni syndrome, and mutant p53 allele, **58:66–67**
- Ligand binding  
 association with hematopoietic cell phosphatase, **60:26**  
 cellular consequences, **60:1–2**  
 induced receptor aggregation, **60:8**
- Ligand blotting, for LPS receptor identification, **53:279–280**
- Ligand–receptor interactions, **38:363; 51:148**  
 T cell activation and, **41:1, 26**
- Ligand recognition, and CD44, **54:271–272**
- Ligands  
 antigen-presenting cells and, **0; 47:64, 65, 68, 87**  
 antigen processing, **47:88, 89, 92**  
 cell surface, **47:61**  
 T cells, **47:94–96, 101**  
 aPL antibodies and, **49:228–231**  
 CD4 and CD8 molecules and, **44:267, 282, 298, 300, 302**  
 CD5 B cell and, **47:146**  
 CD23 antigen and, **49:158, 165, 167**  
 complement receptor 1 and, **46:183, 192–196, 199, 200**  
 complement receptor 2 and, **46:205, 211**  
 CTL and, **41:168, 169**  
 carbohydrate moieties, **41:154**  
 exon shuffling, **41:139, 142, 147**  
 HLA class I antigens, **41:149–152**  
 mAbs, **41:158**  
 cytotoxicity and, **41:307**  
 HIV infection and, **47:391**  
 Ig gene superfamily and evolution, **44:43, 44**  
 IL-1 and, **44:180, 181, 184, 185**  
 immunosenescence and, **46:224**  
*Ir* genes and, **38:105, 173**  
 leukocyte integrins and, **46:150, 153, 169–173, 176, 177**  
 inflammation, **46:163, 167**  
 structure, **46:156, 158, 159**  
 lymphocyte homing and, **44:314**  
 carbohydrate, **44:355, 360, 362–371**  
 high endothelial venules, **44:319–322**  
 molecules, **44:344, 349, 350, 352, 353**  
 regional specificity, **44:323, 324, 326, 335, 336, 340**  
 murine lupus models and, **46:94**  
 NK cells and, **47:221, 247, 265**  
 nonimmune receptor members, **44:32, 33, 35, 39**  
 phagocytosis and, **38:367–369, 371**  
 positive selection, **58:160–164; 59:122–128**  
 preB cell receptors, **63:25–26**  
 and receptors, in positive selection, **51:178–180**  
 SCID and, **49:385**  
 specificity, **38:381, 385**  
 surface antigens of human leukocytes and, **49:113, 115, 117**  
 adhesion molecules, **49:81, 86–87**  
 antigen-specific receptors, **49:76**  
 Igs, **49:89**  
 receptors, **49:99, 101, 111**  
 T cell activation and, **41:30**  
 cell surface molecules, **41:2, 7, 8, 10–13**  
 gene regulation, **41:28, 30**  
 receptor-mediated signal transduction, **41:20, 22**  
 synergy, **41:17**  
 T cell development and  
 antigen recognition, **44:213, 214**  
 cellular selection within thymus, **44:245, 246**  
 thymocyte subpopulation, **44:228, 229**  
 T cell subsets and, **41:40, 50–53**  
 TCR, inducing deletion of thymocytes, **58:170–171**
- Light chain, *see also*  $\kappa$  light chain;  $\lambda$  light chain  
 B cell development, **63:1–2**  
 genes, **48:41–64; 63:4**  
 diversity, **48:41**  
 gene conversion, **48:41–42**  
 hypermutations, **60:277–278**  
 independent genes, **48:41**  
 joining events, **48:41**  
 surrogate  
 B cell development, **63:1–31**  
 expression, **63:5–20**  
 genes, **63:4–5**  
 transduction in complex, **63:25–29**  
 variable region gene expression, **42:3–5**
- Light microscopy, antigen-presenting cells and, **47:51, 52**
- LIM domain, oncogenes by translocation, transcriptional disruption of, **50:130–131**

- Limiting dilution analysis  
 NK clones and, **42:182–184**  
 SCID and, **49:394, 400**
- Limnea*, maternally transmitted antigen and, **38:322**
- Lineage fidelity, B cell formation and, **41:195**
- Lineage-related markers, differential expression during development (murine B cells), **53:125–127**
- Linear tracking, Ig heavy-chain variable region genes and, **49:33, 38**
- Linkage disequilibrium phenomenon  
 DQ, **48:136–137**  
 DR, **48:136–137**
- Linked substitution, Ig heavy-chain variable region genes and, **49:9, 14**
- Linomide  
 autoimmune side effects, **58:278–279**  
 reduction of DNA fragmentation, **58:263–265**
- LIP, **65:2**
- Lipid  
 antigen-presenting cells and, **47:65**  
 aPL antibodies and, **49:252, 256–257, 259**  
 affinity purification, **49:228–230**  
 antibody subsets, **49:232**  
 biochemistry, **49:195, 197**  
 clinical aspects, **49:205**  
 specificity, **49:234, 238–240, 243, 246–248**  
 B cell formation and, **41:197, 213**  
 cell-mediated killing and, **41:290, 291, 312, 313, 294–296**  
 complement receptor 2 and, **46:210**  
 CTL and, **41:169**  
 cytolysis and, **41:275, 278–280**  
 helper T cell cytokines and, **46:114**  
 HIV infection and, **47:387**  
 IL-8 bioactivation in neutrophils, **55:114**  
 leukocyte integrins and, **46:170**  
 membrane attack complex of complement and, **41:299–303, 305, 306**  
 NK cells and, **47:217**  
 pore formers, **41:315, 317, 318**  
 spontaneous autoimmune thyroiditis and, **47:439, 491**  
 T cell receptor and, **45:120, 124**
- Lipid A  
 antagonists, **53:272–274**  
 binding proteins, **53:274–281**  
 chemical structure, **53:270**  
 from enterobacteria, **53:269**  
 from nonenterobacteria, **53:269–270**  
 receptor identification, **53:274–281**  
 recognition by receptor-mediated mechanisms, **53:271–272**  
 structure, **53:269**  
 structure-function relationships, **53:272–274**
- Lipid bodies, eosinophil, characterization, **60:155–156**
- Lipid IVa  
 32P-labeled, for lipid A binding site characterization, **53:278–279**  
 recognition by scavenger receptor, **53:280**
- Lipid mediators, eosinophil-derived, **60:188–191**
- Lipoarabinomannan, **59:85, 90; 65:26**
- Lipocortin, IgE biosynthesis and, **47:24, 25, 38**
- Lipodystrophy, partial, **61:245**
- Lipomodulin, **42:312**  
 IBD and, **42:316, 318–319**
- Lipopolysaccharide, **54:373–374; 65:27**  
 adoptive T cell therapy of tumors and, **49:307–310, 314**  
 antigen-presenting cells and, **47:68, 70, 76, 80**  
 antigen processing, **47:89, 90, 92**  
 cell surface, **47:57, 59, 61–63**  
*immunogeneity*, **47:104**  
 tissue distribution, **47:49**  
 aPL antibodies and, **49:211**  
 autoimmune thyroiditis and  
 cellular immune responses, **46:294**  
 experimental models, **46:276, 277, 279**  
 genetic control, **46:286**  
 prevention, **46:310, 311**  
 autoreactive T cells and, **45:428**  
 bacterial, structure, **53:268–271**
- B cell activation  
 antigen presentation and, **39:67, 69**  
 radiosensitivity and, **39:71**
- B cell formation and, **41:196, 200, 221, 222, 231**
- cachectin and, **42:215, 218, 220, 223**
- CD5 B cell and, **47:159**  
 anatomic localization, **47:121**



- Lipopolysaccharide (*continued*)  
 marker for activation, **47:126**  
 physiology, **47:133–135, 142, 143**  
 CD23 antigen and, **49:150–151**  
 cellular recognition, role of LBP/CD4  
 pathway, **53:281–286**  
 complement receptor 2 and, **46:205**  
 enhancement of iNOS, **60:333–337**  
 helper T cell cytokines and, **46:116, 119, 121**  
 hepatotoxicity, **60:347**  
 heterodimeric receptor models,  
**53:285–286**  
 HIV infection and, **47:402**  
 humoral immune response and  
 helper T cells, **45:27, 33, 34**  
 interleukins, **45:63, 64, 66, 68, 70**  
 physical interaction, **45:44, 46, 53**  
 IgE biosynthesis and, **47:6, 8, 9, 11**  
 immunosenescence and, **46:223, 234, 242**  
 leukocyte integrins and, **46:171**  
 lipid A  
 antagonists, **53:272–274**  
 binding proteins, **53:274–281**  
 chemical structure, **53:270**  
 from enterobacteria, **53:269**  
 from nonenterobacteria, **53:269–270**  
 receptor identification, **53:274–281**  
 recognition by receptor-mediated  
 mechanisms, **53:271–272**  
 structure, **53:269**  
 structure-function relationships,  
**53:272–274**  
 murine lupus models and, **46:63, 72**  
 NK cells and, **47:289**  
 pore-forming protein and, **41:313**  
 regulators of complement activation and,  
**45:397**  
 SCID and, **49:384**  
 spontaneous autoimmune thyroiditis and,  
**47:474**  
 stimulated splenic B cells, IL-4 effects,  
**54:247–248**  
 treatment with, **50:65**  
 virus-induced immunosuppression and,  
**45:357**  
 Lipopolysaccharide-binding protein, in LPS-  
 induced macrophage stimulation,  
**53:281–286**  
 Lipopolysaccharide–cytokine score, **66:134**
- Lipoprotein, aPL antibodies and, **49:213, 256**  
 Lipoprotein lipase  
 aPL antibodies and, **49:257**  
 cachectin and, **42:214–216**  
 Liposomes  
 aPL antibodies and affinity purification,  
**49:228–230**  
 LA antibodies, **49:242, 244–246**  
 specificity, **49:234–236, 239, 250**  
 CTL and, **41:154**  
 cytotoxicity and  
 cytolytic proteins, **41:319**  
 membrane attack complex of  
 complement, **41:300, 302, 305, 309**  
 pore-forming proteins, **41:312, 313**  
 with Ia from normal and lymphoma B  
 cells, antigen-presenting capacity,  
**39:76–77**
- Lipoxygenase  
 action of, **65:122**  
 products, IBD and, **42:313–314**  
 5-Lipoxygenase  
 activation by  
 calcium ionophore A23187, **39:154**  
 FMLP, **39:154**  
 leukotriene biosynthesis and, **39:147–151, 153, 160–161**  
 5-HPETE dehydration to LTA<sub>4</sub>,  
**39:150–151**  
 properties, **39:150–151**  
*Listeria monocytogenes*, **54:207; 59:398**  
 and IFN- $\gamma$ -secreting IEL, **58:329**
- Liver  
 acute phase protein synthesis, **54:25**  
 antinuclear antibodies and, **44:110, 123, 125, 129, 130**  
 B cell formation and, **41:181, 182, 224, 225**  
 B cell precursors, **41:191, 193**  
 bone marrow cultures, **41:216**  
 Ig genes, **41:204**  
 lymphohemopoietic tissue organization,  
**41:187**  
 population dynamics, **41:207**  
 CD1 protein distribution, **59:73**  
 CD5 B cell and, **47:141, 158**  
 complement components and  
 cDNA, **38:234**  
 Factor B synthesis, **38:217**  
 mRNA, **38:226**  
 complement receptor 1 and, **46:198**

- complement receptor 2 and, **46:204**  
 CTL and, **41:149**  
 hybrid resistance and, **41:335, 351, 356, 363, 366, 373, 386**  
 Ig gene superfamily and, **44:37**  
 IL-1 and, **44:166, 168, 178, 189**  
 lymphocyte homing and, **44:328**  
 lymphocyte homing to, **64:178–179**  
 NK cells and, **47:283, 296, 297**  
   genetic control, **47:222**  
   hematopoiesis, **47:276**  
   tissue distribution, **47:220, 221**  
 protein synthesis  
   cachectin and, **42:225**  
   IL-1 and, **44:165, 166**  
 regulators of complement activation and, **45:410**  
   protein expression, **45:397, 399**  
   protein interactions, **45:384**  
   protein roles, **45:388, 389**  
 SCID and, **49:392–393, 401**  
 sporozoite malaria vaccine and, **45:319**  
   antibodies, **45:301**  
   CS proteins, **45:300**  
   CS-specific T cells, **45:312**  
   immunity, **45:287, 289, 290**  
   interferon- $\gamma$ , **45:301–306**  
   *Plasmodium vivax*, **45:317**  
   synthetic T and B cell sites and, **45:228**  
   T cell receptor and, **45:129**  
   T cell subsets and, **41:67, 69**  
   T lymphopoiesis in, **53:169–171**  
 Liver cell grafts, hybrid resistance and, **41:333**  
 Liver diseases, aPL antibodies and, **49:250**  
 Liver-enriched transcriptional activator protein, **65:2**  
 Liver inhibitory protein, **65:2**  
 L-IVS regions,  $V_H$  gene segments and, **42:116, 117–119**  
 LM34 antibody, **63:14–15**  
 LMP1-associated protein 1, **61:29**  
 LMP-2, **64:12, 14, 106, 107**  
   LMP-2, **64:12, 14, 19–20, 106**  
   LMP-7, **64:12, 14, 106, 107**  
   LMP-7, **64:12, 14, 19–20, 106**  
   LMP-9, **64:106**  
   LMP-10, **64:107**  
   LMP-10, **64:106**  
   LMP-17, **64:106**  
   LMP-19, **64:106**  
 LNGFR, *see* Low-affinity nerve growth factor receptor  
 Lock-and-key fit, **43:78**  
 Loefflers syndrome, in pulmonary eosinophilia, **60:226**  
 Long homologous repeat  
   complement receptor 1 and, **46:185, 187–189, 191, 194–196**  
   complement receptor 2 and, **46:203**  
 Long terminal repeat enhancer, viral infection and, **65:9–10**  
 Long terminal repeats  
   HIV-1, **58:14–17**  
   HIV infection and  
     etiological agent, **47:380, 382, 385**  
     immunopathogenic mechanism, **47:399–402**  
     spontaneous autoimmune thyroiditis and, **47:464**  
   Long-term nonprogressors, HIV, **65:298–300**  
 Low-affinity nerve growth factor receptor, **61:1, 2, 7**  
 Low-density lipoprotein  
   antigen-presenting cells and, **47:89**  
   B cell formation and, **41:212, 213**  
   cytotoxicity and, **41:295, 307, 309**  
   regulators of complement activation and, **45:402**  
 Lower respiratory tract, pulmonary immunity regulation and, **59:372–373**  
 Low-molecular-weight B cell growth factor, CD23 antigen and, **49:160, 169**  
 Low-molecular-weight kininogen, **66:233**  
 LPAM-1, **65:359**  
 LPL, cachectin and, **42:214–216**  
*lpr* mouse, Fas gene mutation in, **57:132–133**  
*lpr* phenomenon, and IL-2, **50:202**  
 LPS, *see* Lipopolysaccharide  
 LR1, binding site, **61:120**  
 L-Selectin, **54:310; 59:384; 62:257–258; 64:144–145, 173; 65:352, 354, 367**  
   activation and signaling via, **65:357**  
   downregulation, **64:172**  
   genetic studies, **64:194**  
   lymphocyte–HEV interaction, **65:355, 357, 358, 361**  
   in PLNs, **64:174**  
   properties, **64:146**  
   as pro-T cell homing molecule, **58:393**

- L-Selectin (*continued*)  
 regulation of, **65**:356–357  
 shedding, **64**:170  
 shedding of, **65**:356  
 soluble form, **64**:171  
 structure and function of, **65**:354–356  
 sugar structure of, **65**:363–365  
 T cells positive and negative for,  
**58**:390–391  
 upregulation, **64**:165  
 widespread distribution on leukocytes,  
**58**:353–354
- LT- $\beta$ , **61**:22, 23, 24
- Ltk, **59**:169
- Lung  
*Cryptococcus neoformans* clearance, **59**:403  
 expansion of resident  $\gamma\delta$  T cells, **58**:321  
 genetically engineered antibody molecules  
 and, **44**:68, 87  
 hybrid resistance and, **41**:356, 366, 373  
 Ig gene superfamily and, **44**:39  
 inflammation, *see* Pulmonary inflammation  
 invariant  $\gamma\delta$  T cell receptors of murine  
 IEL, **58**:303–304  
 lymphocyte homing, **64**:178–179  
   carbohydrate, **44**:363  
   regional specificity, **44**:328–330, 334,  
   336–338  
 lymphocyte occurrence, **58**:299  
 mast cells, IL-4 storage by, **53**:15  
 pulmonary immunity, **59**:369–427  
 sensitized guinea pig, hypersensitivity,  
 dietary fish oil and, **39**:164–165  
 structure, **59**:370–373  
   BALT, **59**:385–387  
   dendritic cells, **59**:376–381  
   lymphocytes, **59**:381–385  
   macrophages, **59**:373–376  
 transplantation, **59**:420–426  
   graft-versus-host disease, **59**:420–426  
 Lung-associated lymph nodes, **59**:372, 376,  
 379, 381, 388–389, 391  
 Lung cancer, etiology, stem cell factor role,  
**55**:77–78  
 Lung disease  
   chemokine role, **55**:144–146  
   graft-versus-host disease, **59**:420–426  
   hypersensitivity diseases, **59**:387, 412–420  
   IL-1ra effects, **54**:215–216  
   IL-8 role, **55**:144–146  
   immunity, **58**:328–329  
   pneumonia, **59**:379, 383, 395–408  
 Lupus, *see* Systemic lupus erythematosus  
 Lupus anticoagulant, aPL antibodies and,  
**49**:193, 258–259  
   affinity purification, **49**:229–231  
   antibody subsets, **49**:231–233  
   clinical aspects, **49**:200–210, 212, 221, 224  
   history, **49**:198–199  
   isotype, **49**:227  
   pathogenic potential, **49**:253–256  
   specificity, **49**:234, 239–248, 251–252  
   syndromes, **49**:215–218  
 Lupus mouse, *see also* Systemic lupus  
 erythematosus, murine  
   cellular abnormalities  
     defects in tolerance, **37**:330–332  
     functional abnormalities of B cells, T  
     cells, macrophages and related  
     interleukins, **37**:308–330  
     surface characteristics and numerical  
     abnormalities of T and B cells,  
     **37**:303–308  
     thymic defects, **37**:332–336  
     transfer of autoimmune disease,  
     **37**:301–303  
   derivation of, **37**:271–273  
   inbred strains, **50**:193  
   natural history and pathology of,  
     **37**:273–274  
     morphologic manifestations, **37**:276–284  
     serologic manifestations, **37**:284–300  
     survival and body weight, **37**:274–276  
 Luteinizing hormone  
   synthetic T and B cell sites and, **45**:259  
   thymic factor-induced release, **39**:315  
 L-VAP-2, and VAP-1, **58**:377–378  
 Ly1 B cell, **42**:64–65  
   splenic B cell and, **42**:68  
   subpopulation, **42**:82–83  
 Ly1 lineage, CD23 antigen and, **49**:150–151  
 Ly-6, **48**:240–241  
 Lymphadenopathy  
   and autoimmune symptoms in MRL/Mp-  
   lpr/lpr mice, amelioration, **50**:199  
   cardinal feature of HIV-related, **51**:277  
   murine lupus models and, **46**:63  
 Lymph follicles  
   B cell populations, **53**:186–187  
   zonal organization, **53**:185–186

- Lymph node cells  
 ESP production, **39:214**  
 IgE biosynthesis and  
 antibody response, **47:3-5**  
 binding factors, **47:12, 14, 16, 17**
- Lymph nodes  
 adoptive T cell therapy of tumors and,  
**49:284, 331**  
 antigen-presenting cells and, **47:65,**  
**71-73, 76**  
 immunogeneity, **47:102**  
 T cells, **47:85, 94**  
 tissue distribution, **47:50-52, 54, 55**  
 autoimmune demyelinating disease and,  
**49:358-359, 364, 372**  
 autoimmune thyroiditis and, **46:280, 296**  
 autoreactive T cells and, **45:419**  
 B cell formation and, **41:191, 223**  
 CD4 molecules and, **44:288**  
 CD8 molecules and, **44:271**  
 complement receptor 2 and, **46:204, 209**  
 forbidden  $\alpha/\beta$  T cells, **53:166**  
 helper T cell cytokines and, **46:129, 137,**  
**138**  
 high endothelial venules, **65:373-377**  
 HIV infection and, **47:410**  
 humoral immune response and  
 antigens, **45:23, 24**  
 cellular interactions *in vivo*, **45:79, 81**  
 physical interaction, **45:54**  
 hybrid resistance and, **41:359, 384, 393**  
 bone marrow cells, **41:337, 338**  
 lymphoid cells, **41:352, 353, 355, 356**  
 NK cells, **41:372**  
 IL-1 and, **44:194**  
 immunosenescence and, **46:236, 245, 250,**  
**251**  
 lymphocyte homing and  
 carbohydrate, **44:363, 365**  
 high endothelial venules, **44:315, 317,**  
**318, 321**  
 mesenteric, *see* Mesenteric lymph nodes  
 molecules, **44:344**  
 mucosal immune system, **44:328, 329**  
 peripheral, *see* Peripheral lymph nodes  
 regional specificity, **44:322, 323, 325,**  
**331, 336, 337**  
 murine lupus models and, **46:95, 96, 98**  
 NK cells and, **47:211, 219, 220, 228, 298**  
 peripheral, *see* Peripheral lymph nodes  
 prolactin, **63:382-383**  
 repopulation, immune reconstitution and,  
**40:411-412**  
 reticular conduit system, **65:375**  
 sporozoite malaria vaccine and, **45:305**  
 T cell development and, **44:243, 244**  
 T cell populations, **53:161-163**  
 T cell receptor and, **45:134**  
 T cells, **41:381**  
 T cell subsets and  
 H-2 alloantigen recognition, **41:78, 92**  
 H-2 molecules in thymus, **41:99**  
 H-2-restricted antigen recognition,  
**41:67-71**  
 virus-induced immunosuppression and,  
**45:350, 353, 354, 360**
- Lymphoblast foci, PALS-associated,  
**60:270-271**
- Lymphoblastoid cells  
 complement receptor 1 and, **46:194**  
 complement receptor 2 and, **46:201-204,**  
**207, 209, 210, 213**  
 human B cell neoplasia and, **38:254, 257**  
*c-myc* activation, **38:260, 261, 263**  
 IM-9, SP receptor recovery from, **39:313**  
 leukocyte integrins and, **46:172**
- Lymphoblasts, *see also* B lymphoblasts; T  
 lymphoblasts  
 antigen-presenting cells and, **47:94, 96, 103**  
 B cell hybridomas, **38:282**  
 CTL and, **41:139**  
 Epstein-Barr virus-transformed, **38:280**  
 germinal center, **53:186**  
 human-human hybridomas, **38:293**  
 leukocyte integrins and, **46:162**  
 lymphocyte homing and, **44:314**  
 high endothelial venules, **44:317**  
 regional specificity, **44:322-324, 328,**  
**330**  
 NK cells and, **47:231**  
 spontaneous autoimmune thyroiditis and,  
**47:469**
- Lymphochoriomeningitis virus, *see*  
 Lymphocytic choriomeningitis virus
- Lymphocyte activating determinants, **38:88**
- Lymphocyte-activating factor, IL-1 and,  
**44:154, 172, 173, 189**
- Lymphocyte function-associated antigen, *see*  
 LFA

- Lymphocyte homing, **44**:313, 314;  
**64**:139–140, 173–174, 198  
 carbohydrate  
 cell adhesion, **44**:353–355  
 homing receptors, **44**:369, 370  
 inhibition, **44**:355–357  
 ligands, **44**:363–371  
 PPME-binding receptor, **44**:357–363  
 CD44 role *in vivo*, **54**:298–299  
 expression of CD44 on hematopoietic cells,  
**54**:291–296  
 and hematopoiesis  
 inhibition *in vitro* by CD44-specific  
 antibodies, **54**:299–300  
 physiological experiments implying role  
 for CD44, **54**:296–302  
 hermes antigen mediating PLN adhesion,  
**54**:296–298  
 high endothelial venules  
 HEV-associated molecules, **44**:352, 353  
 interaction, **44**:318–322  
 lymphocyte associated molecules,  
**44**:342–352  
 structure, **44**:315–318  
 inflammation and, **64**:188–193, 195–197  
 liver and lung, **64**:178–179  
 migration, role of CD44 *in vivo*,  
**54**:298–299  
 mucosa, **64**:175–177  
 PLN, **64**:174–175  
 regional specificity  
 blast cell migration, **44**:322, 323  
 breast, **44**:326, 327  
 immune response, **44**:330–336  
 inflammation, **44**:339–341  
 mucosal immune system, **44**:327–330  
 regulation, **44**:336–339  
 selective homing model, **44**:323–326  
 regulation, **64**:173–188  
 signaling through CD44-ligand interactions,  
**54**:300–302  
 thymocyte progenitors, migration  
 inhibition, **54**:299  
 thymus and bone marrow, **64**:177  
 Lymphocyte hybridomas  
 cell lines for, **38**:279–282  
 fusion, **38**:286, 287  
 mAbs, **38**:275–277  
 Lymphocyte receptors, **62**:41–44  
 neuromediator, **48**:179–184  
 Lymphocytes, **51**:339–340  
 adhesion, **66**:15–17  
 adhesion deficiencies, **64**:193–195  
 adhesion molecules  
 multistep adhesion cascade, **64**:181–184  
 regulation, **64**:139–140, 146, 147,  
 163–173  
 anatomic compartments colonized by,  
**53**:159  
 antiadhesion and proadhesion therapy,  
**64**:195–197, 198–199  
 antigen-presenting cells and, **47**:65, 91, 95,  
 105  
 antinuclear antibodies and  
 autoimmune responses, **44**:132  
 scleroderma, **44**:120  
 SLE, **44**:95, 102, 107, 108  
 aPL antibodies and, **49**:239, 249  
 autoimmune demyelinating disease and,  
**49**:368–369  
 autoimmune thyroiditis and, **46**:263, 318  
 antigens, **46**:269  
 cellular immune responses, **46**:287–289,  
 293, 294, 296–298  
 experimental models, **46**:273, 274, 276,  
 278, 279, 281, 282  
 genetic control, **46**:285, 286  
 humoral responses, **46**:299–301, 303,  
 306  
 prevention, **46**:310, 312, 315  
 B, *see* B cells  
 biology, LIF role, **53**:36  
 CD4 and CD8 molecules and, **44**:265,  
 288  
 CD5 B cell and, **47**:117, 118, 149, 150,  
 153, 157, 161  
 bone marrow transplantation, **47**:130  
 lineage, **47**:128, 129  
 malignancies, **47**:123  
 marker for activation, **47**:125, 126  
 ontogeny, **47**:121, 122  
 physiology, **47**:135, 137–139  
 surface antigen, **47**:143–145  
 CD23 antigen and, **49**:164, 173, 175  
 CD45 and, **66**:4, 5–31  
 B cells, **66**:12–15, 36–37  
 lymphocyte adhesion, **66**:15–17  
 monoclonal antibody studies, **66**:1, 3,  
 5–17  
 T cells, **66**:6–12, 32–36

- chemotaxis effects of  
 opioid peptides, **39**:307–308  
 SP, **39**:308
- circulating, abnormalities in IL-2 and IL-2R expression and responsiveness, **50**:186–187
- circulating, functions of, **53**:201–203
- compartments  
 generation  
 by different lineages, **53**:188–189  
 by local selection, **53**:192–199  
 by selective migration and extravasation, **53**:189–192  
 site-dependent tolerance, **53**:201–203  
 specialized functions of, **53**:199–201
- complement-mediated cytotoxicity and, *see* Cytotoxicity, lymphocyte and complement-mediated
- complement receptor 1 and, **46**:190, 191, 193, 198–201
- complement receptor 2 and, **46**:203, 205, 207, 209, 210, 213
- CRF production, **39**:316
- cytokines produced, **48**:71
- cytotoxic T, *see* Cytotoxic T cells
- deficient development, **55**:393–394
- epithelium, intestinal, **55**:395–396
- lymphoid organs, **55**:394
- models, instructive, **55**:398–399
- models, selective, **55**:398–399
- thymus, **55**:394
- development  
 CD44 involvement, **54**:271  
 self-tolerance checkpoints, **59**:279–344
- $\beta$ -endorphin receptors, **39**:312
- endothelial cell interactions, **64**:140–143, 163, 185–186  
 model, **64**:182
- function, neuroendocrine mediator, **48**:177–179
- gene function  
 Bcl-2 and Bcl-x, **62**:43, 53  
 cis-regulatory elements, **62**:42–43, 49–52  
 perforin, **62**:43, 52–53  
 signal transduction, **62**:42, 44–47  
 TdT, **62**:43, 52  
 transcription, **62**:42, 47–49
- genetically engineered antibody molecules and, **44**:76
- helper T, *see* T helper cells
- helper T cell cytokines and, **46**:123, 124
- hemopoietic regulators produced, **48**:71
- hepatocyte growth factor effects, **58**:379–380
- HIV, and programmed cell death, **58**:214
- HIV infection and  
 immune response, **47**:410, 411  
 immunopathogenic mechanism, **47**:390, 392, 393, 397, 398, 400
- homing, *see* Lymphocyte homing
- homing receptors, **62**:257; **64**:143, 146, 147  
 CD40, **64**:163  
 CD73, **64**:162–163  
 chemoattractants, **64**:152–154  
 Ig superfamily, **64**:147, 157–160  
 integrins, **64**:146, 154–157  
 MEL-14, **64**:142–143  
 multiple myeloma, **64**:246  
 proteoglycans, **64**:146, 160–161  
 selectins, **64**:144–145, 146, 147, 148–152  
 sialomucins, **64**:144, 146, 147, 148–152  
 vascular adhesion protein, **64**:161–1662
- hybrid resistance and  
 antigen expression, **41**:400  
 bone marrow cells, **41**:348, 350  
 leukemia/lymphoma cells, **41**:361, 364  
 lymphoid cells, **41**:353, 355–357  
 marrow, **41**:387, 390  
 T cells, **41**:380
- IBD and, **42**:295–296, 297, 321, *see also* Peripheral blood lymphocytes  
 antibodies and, **42**:291  
 Crohn's disease and, **42**:297
- IFN- $\gamma$  and, **62**:86–87
- IgE biosynthesis and  
 antibody response, **47**:3–8, 11  
 antibody response suppression, **47**:33, 38  
 binding factors, **47**:13, 14, 19–22, 24, 25
- IL-1, **44**:153  
 biological effects, **44**:166  
 human disease, **44**:192  
 immunocompetent cells, **44**:173  
 receptor, **44**:181  
 structure, **44**:155  
 TNF, **44**:185, 186
- IL-8 effects on, **55**:118–119
- immune responses, neuropeptides and, **39**:309–311
- immunosenescence and, **46**:221, 253  
 activation, **46**:221–234

- Lymphocytes (*continued*)
- mucosal immunity, **46**:251, 252
  - regulatory changes, **46**:249
  - stem cells, **46**:240, 246, 247
  - subsets, **46**:236–240
  - interaction with IgA, **40**:171
  - intraepithelial, *see* Intraepithelial lymphocytes
  - Ir* genes and, **38**:37, 56, 62
    - H-Y antigen, **38**:177
    - macrophages, **38**:113
    - positive T cell selection, **38**:130
    - T cell suppression, **38**:147
  - lamina propria, immunosenescence and, **46**:237
  - leukocyte integrins and, **46**:149, 151
    - inflammation, **46**:162–164, 169
    - leukocyte adhesion deficiency disease, **46**:173
    - ligand molecules, **46**:170–172
  - mAbs and, **38**:276
    - Epstein-Barr virus, **38**:277
    - fusion, **38**:282–286
    - human-human hybridomas, **38**:293, 294, 296–298
    - human-mouse heterohybridomas, **38**:301
    - human-murine hybridomas, **38**:290–292
  - maps of Ig-like loci and, **46**:1
  - mediated cytotoxicity, perforin role
    - expression, **51**:219–224
      - in human leukocyte, **51**:222–223
      - regulation of, **51**:223–224
    - perspectives, **51**:232–233
    - role of in cytotoxicity, **51**:215–216, 224–232
    - perforin-independent mechanisms, **51**:231–232
    - verification by genetic approach, **51**:227–231
    - verification in cell lines, **51**:224–227
    - structure of, **51**:216–219
  - memory and effector, **58**:347–350
  - migration
    - diapedesis, **65**:369
    - extravasation, **65**:360, 365–367
    - GlyCAM-1, **65**:361–362, 363, 364, 373, 377
      - CD34, **65**:362, 377
      - Sgp200, **65**:362, 377
    - high endothelial venules and, **65**:350–351
      - addressins, **65**:361–363, 377–379
      - adhesion, **65**:365–372
      - CD44, **65**:369–370
      - extravasation, **65**:360, 365–367
      - GlyCAM-1, **65**:361–362, 363, 364, 373, 377
      - homing receptor ligands, **65**:360–365
      - integrins, **65**:352, 358–359, 368–369, 370
      - MAdCAM-1, **65**:352, 359, 362–363, 367, 370, 377, 379
      - mucins, **65**:360–361
      - selectins, **65**:352, 354–357, 363–365, 367
      - sugars, **65**:360–361, 363–365
      - VAP-1, **65**:365
        - in vitro* binding assay, **65**:351–352
        - organ specificity, **65**:370–372
        - recirculation pathways, **65**:371–372
  - mixed, met-enkephalin receptors, **39**:312
  - naive, **58**:389; **64**:180–181
  - neuropeptide, **48**:177
    - differentiation, **48**:178
    - immunological functions, **48**:178
    - tissue cycles, **48**:178
    - tissue homing, **48**:178
  - neuropeptide receptor, **48**:180
  - NK cells and, **47**:187–189
    - adaptive immunity, **47**:291
    - alterations, **47**:302
    - antimicrobial activity, **47**:289
    - antitumor activity, **47**:297, 299
    - cell-mediated cytotoxicity, **47**:190, 194–196
    - congenital defects, **47**:224–226
    - cytotoxicity, **47**:252–255, 257, 258, 260, 261
    - differentiation, **47**:230, 231, 234
    - effector mechanisms, **47**:243, 246
    - genetic control, **47**:222, 223
    - hematopoiesis, **47**:272–274, 276, 280, 282
    - identification, **47**:197, 199
    - malignant expansion, **47**:226
    - morphology, **47**:214, 216
    - reproduction, **47**:270
    - surface phenotype, **47**:201, 205–207, 209–213
    - tissue distribution, **47**:219, 220

- nonspecific, activation by Fc fragment of Ig, **40:79–90**  
 opioid receptor, **48:180**  
 of peripheral blood, IgA and, **40:202–203**  
 phagocytosis and, **38:364**  
 pituitary hormones, **63:391–392, 405–407**  
 pulmonary, **59:381–385**  
 RAG-2-deficient blastocyst complementation, **62:31–41**  
 recirculation, **64:139–143, 198**  
   genetic studies, **64:184–188**  
   naive and memory lymphocytes, **64:180–181**  
   through spleen, **64:177–178**  
 regulation, **59:176–178, 383–385**  
 resident pulmonary, CD4<sup>+</sup>8<sup>-</sup>  $\alpha\beta$  T cells, **58:319**  
 responses, maternally transmitted antigen and, **38:313**  
 retinal glial cell, **48:218**  
 SCID and, **49:386–388**  
 shedding, **64:170**  
 as source of chemokines, **55:106**  
 spontaneous autoimmune thyroiditis and altered thyroid function, **47:456, 462**  
   cellular immune reactions, **47:451, 453, 455**  
   disturbed immunoregulation, **47:470–472, 474, 477, 481**  
   genetics, **47:487**  
   potential effector mechanisms, **47:466, 467, 469**  
 SP receptors, **39:313**  
 stem cell factor and SCF receptor effects, **55:48–51**  
 surface antigens of human leukocytes and, **49:94, 113, 115**  
 T, *see* T cells  
 T9 positive, in Crohn's disease, **42:290**  
 T cell development and, **44:213, 229, 236**  
 T cell subsets and, **41:70, 81, 110**  
 TGF- $\beta$  regulation, **55:187**  
 thyroid-infiltrating, **47:492**  
   effector mechanisms, **47:466, 467, 469**  
   immunoregulation, **47:473, 475**  
 tumor-infiltrating, *see* Tumor-infiltrating lymphocytes  
 turnover and clonal deletion, physiology, **58:270–272**  
 VIP receptors, **39:312–313**
- Lymphocyte tumors, **64:179**  
 Lymphocytic choriomeningitis virus, **52:316**  
   hybrid resistance and, **41:355, 390**  
   infection, cytotoxic T cells and, **65:278**  
   NK cells and, **47:244, 245, 283, 284**  
   responses in MHC class I-deficient mouse, **55:409–410**  
     clearance, **55:411–412**  
     immunopathology, **55:410–411**  
     synthetic T and B cell sites and, **45:226**  
 Lymphohematopoiesis, stem cell factor and SCF receptor effects  
   hematopoiesis, **55:43–48**  
   lymphocytes, **55:48–51**  
   NK cells, **55:48–51**  
 Lymphohematopoietic cells, T cell subsets and, **41:107–109**  
 Lymphohemopoietic tissue, organization, B cell formation and, **41:185–188**  
 Lymphoid blast crisis, chronic myelogenous leukemia, **40:290–291**  
 Lymphoid cells, **48:69**  
   adoptive T cell therapy of tumors and, **49:302**  
   autoimmune thyroiditis and cellular immune responses, **46:287–291, 293, 295**  
   experimental models, **46:274, 275, 279, 280, 282**  
   B cell formation and, **41:196, 213, 220, 225, 226**  
   CD1 protein distribution, **59:56**  
   CD5 B cell and, **47:125**  
   effect of chromosomal abnormalities, **50:132–140**  
     differentiation-related translocation oncogenes, **50:139**  
     functional chimerism involving DNA binding and protein dimerization, **50:133–138**  
     proteins affected by chromosome translocations, **50:139–140**  
   genetically engineered antibody molecules and, **44:71, 87**  
   HIV infection and, **47:382, 388**  
   hybrid resistance and, **41:333**  
     antibodies, **41:376, 380**  
     antigen expression, **41:401, 405**



- Lymphoid cells (*continued*)
- bone marrow cells, **41:338, 339**
  - leukemia/lymphoma cells, **41:359, 369**
  - marrow engraftment, **41:386**
  - NK cells, **41:374, 375**
  - normal hemopoietic cells, **41:351–358**
  - T cells, **41:380, 383**
  - in vitro* assays, **41:393, 394**
- IgE biosynthesis and, **47:11**
- Ig heavy-chain variable region genes and, **49:52–53, 55**
- immunosenescence and, **46:242–244, 246, 247**
- leukocyte integrins and, **46:162, 168, 171**
- mammalian, genetically engineered
- antibody molecules and, **44:69, 70**
- NK cells and, **47:188, 221**
- precursors, maturation, role of CD44, **58:377**
- SCID and, **49:393**
- spontaneous autoimmune thyroiditis and, **47:435, 491**
- cellular immune reactions, **47:454**
  - disturbed immunoregulation, **47:475, 476, 481**
  - histopathology, **47:440, 442, 443**
- T cell subsets and, **41:44, 78, 90, 96, 101, 109**
- Lymphoid hyperplasia, murine lupus models and, **46:63**
- Lymphoid organs
- antigen-presenting cells and, **47:104**
  - APC-T cell binding, **47:95**
  - immunogeneity, **47:102, 103**
  - interaction with T cells, **47:82–84**
  - tissue distribution, **47:50–52**
- CD5 B cell and, **47:122**
- deficient development of lymphocytes, **55:394**
- humoral immune response and, **45:79–82**
- NK cells and, **47:211, 266**
- spontaneous autoimmune thyroiditis and
- cellular immune reactions, **47:449, 450**
  - disturbed immunoregulation, **47:477**
  - histopathology, **47:444**
  - humoral immune reactions, **47:446, 447**
  - potential effector mechanisms, **47:469**
- Lymphoid sheath, periarteriolar, *see* Periarteriolar lymphoid sheath
- Lymphoid stem cells, SCID and, **49:384, 389, 400–401**
- absence, **49:382, 390–391, 393**
- Lymphoid tissues
- central role of FDCs in,
    - antigen expression of, **51:257–261**
    - cellular origin of, **51:261–263**
    - conclusions, **51:278–280**
    - distinction of from other dendritic cells, **51:244–247**
    - expression of in malignant lymphomas, **51:274–275**
    - process, **51:243–244**
    - regulation of normal germinal center by, **51:263–274**
  - as targets of HIV, **51:275–278**
  - technical difficulties, solution of, **51:246–257**
- human, cell types and antigenic profiles, **52:129, 136**
- immunosenescence and, **46:236, 252, 253**
- Ir* gene expression in, **38:52–55**
- mucosa-associated
- functional anatomy of Peyer's patches, **40:192–195**
  - studies on disassociated Peyer's patches cells, **40:195–197**
- tyrosine protein kinase, **48:277–280**
- Lymphoid tumors
- chromosomal translocation in
    - development of T cell leukemia, **50:141–142**
    - effect of chromosomal abnormalities on adjacent oncogenes, **50:124–132**
    - c-myc* in Burkitt's lymphoma translocations, **50:124–128**
    - gene fusion resulting from chromosome translocation, **50:128–129**
    - helix-loop-helix oncogenes in chromosome translocations, **50:129–130**
    - oncogene location after translocation, **50:131–132**
    - transcriptional disruption of LIM domain oncogenes by translocation, **50:130–131**
  - effect of chromosomal abnormalities on lymphoid cells, **50:132–140**

- developmentally regulated translocation oncogenes, **50:139**
- functional chimerism involving DNA binding and protein dimerization, **50:133–138**
- other unusual proteins affected by chromosome translocations, **50:139–140**
- mechanism of translocation and inversion, **50:121–122**
- presence of abnormalities, **50:119–121**
- timing of chromosome translocation and inversion, **50:122–124**
- therapy, **58:282**
- Lymphokine-activated killer cells, **42:182, 190, 47:188, 259, 260, 296, see also**
  - Natural killer cells
  - adoptive T cell therapy of tumors and, **49:284–285, 302, 306**
  - antigen-nonspecific killing, **60:302–303**
  - humoral immune response and, **45:68, 70**
  - IBD and, **42:296**
- Lymphokine receptors, **59:177**
- Lymphokines, **42:165–166**
  - adoptive T cell therapy of tumors and antigen recognition, **49:319**
  - expression of antitumor responses, **49:324, 328–329**
  - mechanisms, **49:299–301, 307–309, 313, 316**
  - principles, **49:289–290**
  - antigen-presenting cells and, **47:75, 80, 87**
  - cell surface, **47:63**
  - immunogeneity, **47:103, 104**
  - T cells, **47:83, 84, 99–101**
- autoimmune demyelinating disease and, **49:360**
- autoimmune thyroiditis and, **46:283, 289, 291, 294, 298**
- autoreactive T cells and, **45:430, 431, 433**
- B cell formation and, **41:199, 222, 231**
- B cell growth and, **40:16**
- CD4 and CD8 molecules and, **44:299**
- cytolysis and, **41:284, 286**
- fresh tissues, **48:95**
- human T cell antigen and, **41:1, 6, 20**
  - gene regulation, **41:27, 29**
  - synergy, **41:15**
- humoral immune response and, **45:5**
  - cellular interactions *in vivo*, **45:85**
  - helper T cells, **45:24–35**
  - interleukins, **45:55, 62, 65, 67, 69, 71–76**
  - physical interaction, **45:36, 39, 41, 46–54**
- hybrid resistance and, **41:407**
- IgE biosynthesis and
  - antibody response, **47:7–11**
  - antibody response suppression, **47:32, 33, 39**
  - binding factors, **47:12, 22–28**
- immunosenescence and, **46:253**
  - lymphocyte activation, **46:230–236**
  - lymphocyte subsets, **46:237**
  - regulatory changes, **46:250**
- islet beta cell, **48:141**
- NK cells and, **42:183, 47:189, 289, 290, 293**
  - differentiation, **47:233**
  - effector mechanisms, **47:235, 262–266**
  - morphology, **47:216**
  - reproduction, **47:271**
  - tissue distribution, **47:220**
- production
  - AB-Mul V-transformed mast cells, **53:4–6**
  - factor-dependent mast cell lines, **53:6–9**
  - human FcεR<sup>+</sup> cells, **53:14–15**
  - murine FcεRI<sup>+</sup> cells, **53:9–14**
- regulators of complement activation and, **45:389**
- role in B cell activation, **40:38–39**
- spontaneous autoimmune thyroiditis and, **47:472, 473, 477**
- sporozoite malaria vaccine and, **45:303, 304, 306, 312**
- as substitutes for T cells, **40:92**
- surface antigens of human leukocytes and, **49:101**
- synthesis, **48:78–81**
  - IL-2-induced, **48:81**
  - transcription, **48:81**
- synthetic T and B cell sites and, **45:219, 248**
- T11, **41:9, 10**
- T cell development and, **44:219, 221, 229**
- T cell subsets and
  - H-2 alloantigen recognition, **41:94**
  - H-2 molecules in thymus, **41:107**
  - H-2-restricted antigen recognition, **41:52, 62–66, 76, 77**
  - T cell trigger, **41:112**

- Lympholysis, hybrid resistance and, **41:388**
- Lymphoma, *see also specific types*  
 adoptive T cell therapy of tumors and,  
**49:283, 286, 291–292, 295, 305**  
 avian leukosis virus-induced  
*myc* gene role, **56:472–476**  
 pathogenesis, **56:471–472**  
 resistance, **56:470**  
 susceptibility, **56:471**  
 B cell, *see* B cell lymphoma  
 B cell formation and, **41:202**  
 BSAP binding, **63:229**  
 Burkitt's, *see* Burkitt's lymphoma  
 CD1 proteins, **59:60**  
 CD5 B cell and, **47:123–125**  
   Ig gene expression, **47:150–152, 155, 156**  
 CD23 antigen and, **49:161, 164, 175**  
 CD40, **61:39**  
 cell-mediated killing and, **41:293**  
 chromosomal translocations, **38:247, 266**  
*c-myc* activation, **38:261**  
 development, and *bcl-2* gene  
   overexpression, **58:270**  
 follicular, **38:264, 267, 268, 271, 272**  
 Hodgkin's disease, **61:8, 12, 39**  
 human B cell neoplasia and, **38:245**  
 hybrid resistance and, **41:334, 358–369**  
   antigen expression, **41:401, 403**  
   NK cells, **41:373, 374**  
 Ig heavy-chain variable region genes and,  
**49:40, 51**  
 induction by MMTV, **65:155–156**  
 malignant, differential expression of FDCs  
   in, **51:274**  
 NK cells and, **47:190, 228**  
 pituitary hormones, **63:388, 400, 427**  
 prolactin, **63:400**  
 prolactin receptor, **63:396**  
 risk in rheumatoid arthritis patient,  
**64:329–330**  
 SCID and, **49:393**  
 surface antigens of human leukocytes and,  
**49:114, 117**  
 T cell  
   depletion, **58:272–275**  
   murine, **54:289**
- Lymphoma cells, lymphocyte homing and  
 carbohydrate, **44:359, 361**  
 molecules, **44:343**  
 regional specificity, **44:324, 338**
- Lymphopenia  
 chronic AIDS-associated, and lymphocyte  
   PCD, **58:214**  
 and viral infection, **58:233–237**
- Lymphopoiesis  
 B cell, in fetal and neonatal rabbit,  
**56:180–186**  
 B cell formation and, **41:213, 237, 238, 229–231**  
 hybrid resistance and, **41:339**  
 T cell, in liver, **53:169–171**
- Lymphoproliferation  
 and autoimmunity, mechanism of beneficial  
   effect of IL-2 on, **50:200–203**  
 B cell formation and, **41:193, 208**  
 defective mouse, CD5 B cell analysis,  
**55:314–315**  
 treatment, **58:273–275**
- Lymphoproliferation gene, murine lupus  
 models and, **46:63, 94–98**
- Lymphoproliferative disease, **54:143–145**  
 B cell lymphoma, **54:144–145**  
 CD23 antigen and, **49:175**  
 Epstein-Barr virus, **54:143–144**  
 in hu-PBL-SCID mice, EBV-associated,  
**50:310–313**
- Lymphoproliferative disorder, post-transplant,  
**54:35–36**
- Lymphoproliferative syndrome, X-linked,  
**59:248**
- Lymphosarcoma cells, hybrid resistance and,  
**41:358**
- Lymphotoxin, **42:216–217**  
 adoptive T cell therapy of tumors and,  
**49:308**  
 autoimmune demyelinating disease and,  
**49:360**  
 B cell formation and, **41:236**  
 cytotoxicity and, **41:284–286, 298**  
 helper T cell cytokines and, **46:112**  
   functions, **46:114, 115, 117, 122**  
   immune responses, **46:133**  
 hybrid resistance and, **41:400, 407**  
 IgE biosynthesis and, **47:10**  
 IL-2 and, **44:153, 154, 185**  
 maps of Ig-like loci and, **46:30, 33, 34**  
 multiple myeloma and, **42:224**  
 NK cells and, **47:278, 279**
- Lymphotoxin- $\alpha$ , **61:5, 22, 24, 26**
- Lymphotoxin- $\beta$ , **61:22, 23, 24**
- Lymphotoxin-like molecules, cytolysis and,  
**41:284–286**

- Lyn, **59:324**  
 IL-2R $\beta$  coupling, **61:155**  
 in myeloid cells, **60:209**
- lyn, in CD40-induced signaling, **60:45–46**
- Lysine, **42:97**  
 cell-mediated killing and, **41:297**  
 coupling to Boc, **60:107**  
 Ig gene superfamily and, **44:33**
- Lyso-phosphatidylethanolamine, **49:246, 248**
- Lysophospholipase, CLC identification with, **39:182–183**
- Lysosomes  
 antigen-presenting cells and, **47:52**  
 autoimmune thyroiditis and, **46:267, 268**  
 CAL and, **41:168**  
 complement receptor 1 and, **46:200**  
 cytotoxicity and, **41:276, 281, 288**  
 humoral immune response and  
 antigens, **45:12–14, 20, 21**  
 cellular interactions *in vivo*, **45:79**  
 IL-1 and, **44:163, 184**  
 lymphocyte homing and, **44:360**  
 NK cells and, **47:214, 218, 225, 238**  
 synthetic T and B cell sites and, **45:215**
- Lysozyme  
 antibody complex, **43:22–23**  
 antigenic structure, **43:118**  
 hen egg, T cell response, **43:201**  
 H-Y antigen and, **38:179**  
 HyHEL5 binding, **43:12–13, 122**  
 mobility, **43:21**  
 side-chain movement, **43:22**  
 synthetic T and B cell sites and, **45:204, 211, 213, 214**  
 T cell receptor and  
 antigen processing, **45:122, 123**  
 experimental systems, **45:131**  
 homogeneity, **45:129**  
 peptides, **45:133, 134**  
 structure-function relationships, **45:135, 136**  
 T cell suppression and, **38:139–142**  
 T cell-T cell interactions and, **38:159, 160**
- Lyt-1, **48:246**
- M**
- mAbs, *see* Monoclonal antibodies
- Mac-1, leukocyte integrins and, **46:149–153, 176**  
 chromosomal localization, **46:160**  
 inflammation, **46:163, 164, 166–168**  
 ligand molecules, **46:173**  
 structure, **46:153, 154, 156, 158, 159**
- Mac-1/CR3, **54:310**
- Macaque, SIV pathogenesis  
 genetic drift of SIV molecular clones *in vivo*, **52:451–452**  
 immunodeficiency virus infection of, **52:443–452**  
 natural history of SIV infection of, **52:443–448**  
 use of SIV molecular clones to define viral determinants of pathogenesis, **52:448–451**
- $\alpha_2$ -Macroglobulin, **63:278–279**  
 complement component and, **38:234, 236**
- Macrophage-activating factor, **48:78; 62:61–62, 96**  
 adoptive T cell therapy of tumors and, **49:307, 309–311**
- Macrophage colony-stimulating factor, **48:71**
- Macrophage inflammatory protein, **46:115**
- Macrophage inflammatory protein-1, **62:260, 270, 280, 285**
- Macrophage inflammatory protein-1 $\alpha$ , mRNA  
 expression in hypereosinophilic syndrome, **60:200**
- Macrophage inflammatory protein-2, **62:274**
- Macrophage migration inhibitory factor, **66:197**  
 background, **66:197–199**  
 history, **66:198**  
 in IBD, **42:290**  
 immune system and, **66:218–219**  
 localization, **66:202–206**  
 MIF gene, **66:199–202, 206**  
 properties, **66:199, 206–210**  
 sepsis and, **66:104, 148–149**  
 structure-function studies, **66:216–218**  
 surface antigens of human leukocytes and, **49:111**
- Macrophages, **48:69**  
 activation, **62:78–80, 86, 277**  
 adoptive T cell therapy of tumors and, **49:287, 289–290, 333**  
 antigen recognition, **49:319**  
 expression of antitumor responses, **49:325–328, 330**  
 mechanisms, **49:300, 302, 306–313, 316**  
 alveolar, **59:370, 374–375, 381**  
 human, iNOS in, **60:353–354**  
 IL-1ra production, **54:185**

Macrophages (*continued*)

- antigen-presenting cells and, **47:68, 80, 104**
  - antigen processing, **47:89, 90**
  - cell surface, **47:61, 62**
  - immunogenicity, **47:103, 104**
  - interaction with T cells, **47:93, 94**
  - T cell, **47:86, 95, 97, 99**
  - tissue distribution, **47:48, 51, 54, 55**
- antinuclear antibodies and, **44:134**
- autoimmune thyroiditis and, **46:265, 287, 307**
- B cell formation and, **41:186, 208, 234–236, 238**
  - B cell precursors, **41:191, 192, 194, 195**
  - bone marrow cultures, **41:212, 213, 218**
  - cytotoxicity and, **41:269, 285, 293**
  - genetically determined defects, **41:230–232**
  - hybrid resistance and, **41:340, 356, 366**
  - antigen expression, **41:402, 405**
    - effector mechanisms, **41:370–372, 374, 387, 392, 393**
- and B cells, involvement of, **51:303–305**
- cachectin and, **42:214, 215, 220, 221**
- CD1 protein distribution, **59:66–67**
- CD4 molecules and, **44:288, 290**
- CD5 B cell and, **47:120–122, 132**
- CD23 antigen and, **49:157, 160, 166**
  - biological activity, **49:167, 171**
  - cellular expression, **49:153–154**
  - expression in clinical conditions, **49:176**
- colony-stimulating factor, **48:75**
- comparison with B cells
  - antigen processing, **39:62–66**
  - antigen uptake, **39:60–62**
- complement components and
  - bronchoalveolar, **38:218**
  - C2, **38:218**
  - C4, **38:220**
  - Factor B, **38:217, 218**
- complement receptor 1 and, **46:190, 192, 200**
- cosignals from, **58:243–245**
- differentiation, IL-6 effects, **54:24–25**
- effector cells in cell-mediated immune response, **60:333–341**
- Fc* receptors on, **40:64–66**
- fibronectin and, **38:388**
- GM-CSF production, **39:2, 3, 11**

- growth hormone, **48:178**
- helper T cell cytokines and
  - differential induction, **46:128–130**
  - functions, **46:114–117, 122**
  - immune responses, **46:133**
- HIV infection and, **47:413**
  - activation, **47:400, 402**
  - immunopathogenic mechanism, **47:392–397**
  - neuropsychiatric manifestations, **47:404**
- hybridomas and
  - B cells, **38:283**
  - genetically engineered antibodies, **38:306**
  - heterohybridoma antibodies, **38:289**
- IBD and, **42:285, 287O, 292, 297**
- IgE biosynthesis and
  - antibody response suppression, **47:30, 33, 36, 37**
  - binding factors, **47:20, 21, 27**
- IGF-I, **63:389–391**
- Ig gene superfamily and, **44:39**
- IL-1 and, **44:153, 190**
  - biological effects, **44:169**
  - gene expression, **44:159–161, 164**
  - human disease, **44:192, 195**
  - immunocompetent cells, **44:173, 177**
  - structure, **44:155**
  - systemic effects, **44:171**
  - TNF, **44:185, 187**
- IL-4, **48:75**
- IL-10 biological effects, **56:6–8**
- immunosenescence and, **46:228**
- interaction with IgA, **40:170**
- interstitial, **59:375**
- in vitro*-derived, IL-1ra production, **54:185–186**
- Ir* genes and
  - antigen binding, **38:98, 109, 111–115**
  - antigen processing, **38:93–97**
  - expression in
    - antigen-presenting cells, **38:55–57**
    - B cells, **38:57, 58, 189**
    - in lymphoid tissue, **38:55**
    - in T cells, **38:59–63**
- H-Y antigen, **38:179**
- Ia molecules, **38:68, 70, 83, 84**
- MHC restriction, **38:64–67**
- T cells
  - cytotoxic, **38:161, 162, 164**
  - interactions, **38:155–157**

- selection, **38**:133, 134
  - suppression, **38**:136–139
  - tolerance, **38**:125, 126
- leukocyte integrins and, **46**:151, 154, 163, 164, 167
- lymphocyte homing and, **44**:368
- lymphotoxin and, **42**:216
- and monocytes, **51**:337–339
- neuropeptide, **48**:177
- NK cells and 189, **47**:288–290
  - congenital defects, **47**:224
  - differentiation, **47**:229
  - effector mechanisms, **47**:235, 237, 262, 263, 265, 266
  - hematopoiesis, **47**:274, 278
  - identification, **47**:296
  - malignant expansion, **47**:228
  - reproduction, **47**:270
  - surface phenotype, **47**:201, 202, 211–213
  - tissue distribution, **47**:220
- peritoneal, IL-1ra production, **54**:188
- PGHS-2, **62**:191–192
- phagocytosis and, **38**:361, 362, 369
  - human alveolar, **38**:365
  - nonelicited murine, **38**:376–380, 383, 384
  - rat alveolar, **38**:374
- pituitary hormones, **63**:411–412
- present at vaccinating site, **58**:431
- pulmonary, **59**:373–376
  - interstitial, **59**:375
  - lung transplants, **59**:423
- response to Fc fragments, **40**:80–83
- SCID and, **49**:384–385, 389–391, 401–402
- soluble factors, antibody responses and, **40**:35
- as source of chemokines, **55**:106
- spontaneous autoimmune thyroiditis and, **47**:492, 494
  - disturbed immunoregulation, **47**:475, 476
  - genetics, **47**:488
  - histopathology, **47**:440, 442
  - potential effector mechanisms, **47**:467, 468
- stimulation by Fc fragments of Ig, **40**:100–111
- suppressor, **50**:176
- surface antigens of human leukocytes and, **49**:89, 91–92, 98–99, 116
- synovial, IL-1ra production, **54**:187–188
- T cell development and, **44**:248
- T cell stimulation, **39**:84
- T cell subsets and
  - cell surface molecules, **41**:46
  - H-2 alloantigen recognition, **41**:89, 90, 94
  - H-2 molecules in thymus, **41**:103–106, 108–110
  - H-2-restricted antigen recognition, **41**:51, 69–71, 74, 75, 77
  - TGF- $\beta$  regulation, **55**:187
- Macrophages/dendritic cells, antigen presentation, **39**:85–86
- MadCAM-1, **62**:101, 257, **64**:188
  - lymphocyte–HEV interaction, **65**:352, 359, 362–363, 367, 370, 377, 379
  - lymphocyte homing, **64**:147, 158–159
    - to thymus and bone marrow, **64**:177
  - in mucosal lymphocyte homing, **64**:176
  - ontogenesis, **64**:164
- Maedi-visna virus, **52**:431
- MAGE, **62**:228, 229, 231–232
- MAGE-3, **62**:232
- Magnesium
  - cytotoxicity and, **41**:271, 294
  - genetically engineered antibody molecules and, **44**:85
  - leukocyte integrins and, **46**:150, 156, 157, 163
  - lymphocyte homing and, **44**:351, 360, 361
  - NK cells and, **47**:249, 250
- MAH cell line, LIF/CNTF receptors, **53**:43–44
- MAIDS, *see* Murine acquired immunodeficiency syndrome
- Main-chain flexibility parameters, Ab binding to protein antigens, **43**:50
- Main immunogenic region, AChR, antibodies to, **42**:240–241, 262
  - specificity and, **42**:246
- Major basic protein
  - antihelminthic activity, **60**:212–213
  - basophil, **39**:186–187
  - cell-mediated killing and, **41**:311, 312
  - cytotoxicity for mammalian cells, **60**:191–193
  - eosinophil
    - biochemical properties, **39**:185
    - bronchial epithelium damage by, **39**:219–223

- Major basic protein (*continued*)  
 granule core, **39**:185–186  
 histamine release stimulation, **39**:191  
 parasite killing, **39**:188–190, 209,  
 212–213  
 toxicity to various cells, **39**:190–191, 219  
 HL-60 promyelocyte, **39**:187–188  
 hypereosinophilic syndrome, **60**:160  
 placenta, **39**:188, 228  
 tissue from asthma deaths, **60**:217
- Major histocompatibility complex, **48**:78, 107
- ABC protein  
 function, **52**:38–42  
 genes, **52**:35–38  
 restriction, history of discovery of,  
**52**:4–6
- adoptive T cell therapy of tumors and,  
**49**:281, 283, 294–295, 334
- antigen recognition, **49**:319, 322–323  
 expression, **49**:324–325, 327–330, 332  
 mechanisms, **49**:299, 315
- allele, **43**:219
- antigen-presenting cells and, **47**:45, 47, 87,  
 104, 105  
 antigen presentation, **47**:64, 66–69,  
 71–73, 75–80  
 antigen processing, **47**:87–89, 91, 92  
 APC-T cell binding, **47**:95–97, 99  
 cell surface, **47**:57–60  
 immunogeneity, **47**:103  
 T cells, **47**:82, 83, 85, 101  
 tissue distribution, **47**:51–54
- autoimmune demyelinating disease and,  
**49**:357–358  
 multiple sclerosis, **49**:369–371, 374–375  
 TCR usage restriction, **49**:363, 365–367
- autoimmune thyroiditis and, **46**:263, 265,  
 266, 317, 319  
 antigens, **46**:268  
 cellular immune responses, **46**:289, 290,  
 295  
 experimental models, **46**:275, 279, 280  
 genetic control, **46**:282–286  
 humoral responses, **46**:299, 301, 305,  
 307  
 prevention, **46**:310, 315
- autoreactive T cells and, **45**:417, 418, 433  
 activation, **45**:421, 423, 427  
 origin, **45**:418–420  
 physiology, **45**:428, 430  
 regulation, **45**:432
- B cell formation and, **41**:194, 197  
 CD4 and CD8 molecules and, **44**:265–267,  
 297, 299, 300, 302, 303  
 CD4 molecular biology, **44**:291–293,  
 296  
 CD8 molecular biology, **44**:271, 272,  
 282, 284  
 CD5 B cell and, **47**:137, 142, 160  
 CD23 antigen and, **49**:150–151, 169  
 class I, **43**:213–214  
 binding process, **43**:214  
 determinant nature, **43**:205–206
- class II alleles, RA susceptibility associated  
 with  
 ethnic differences, **56**:409–410  
 penetrance influenced by, **56**:440–441  
 properties, **56**:444–446  
 risk for severe disease, **56**:441–444
- class II  $\alpha$  chain, **48**:141–142  
 class II  $\beta$  chain, **48**:141–142  
 class II loci, corneal graft, **48**:199–200  
 latex bead treatment, **48**:200
- complement components and, **38**:203, 207,  
 236  
 C2 and, **38**:208  
 C4 deficiency, **38**:229  
 C4 linkage to, **38**:220, 221  
 class III region, **38**:227–229  
 Factor B, **38**:209
- complement receptor 1 and, **46**:189
- contact amino acids, **43**:210
- control of anticollagen type II response,  
**48**:130–131
- cytotoxicity and, **41**:270
- electron density in cleft, **43**:214
- helper T cell cytokines and, **46**:112, 117,  
 118
- HIV and, **45**:349, 361, 365–367
- HIV infection and, **47**:380, 411  
 immunopathogenic mechanism, **47**:386,  
 389, 391, 392
- human T cell activation and, **41**:2, 3, 5, 14
- humoral immune response and, **45**:5–8, 80  
 antigens, **45**:8, 10, 19, 20  
 helper T cells, **45**:25, 26  
 interleukins, **45**:62, 66, 67  
 physical interaction, **45**:37, 41, 43,  
 46–48, 52–54
- hybrid resistance and, **41**:348, 357, 361,  
 369, 378, 403

- IgE biosynthesis and  
 antibody response, **47:2**, **29**, **33**  
 binding factors, **47:25**, **27**
- Ig gene superfamily and  
 gene organization, **44:24–29**  
 receptors, **44:9–12**
- immunosenescence and, **46:239**
- Ir* genes and, **38:33**, **43–46**, **188**, **190**  
 adoptive transfer, **38:52**, **53**  
 antigen binding, **38:98**, **99**, **105**, **114**  
 antigen processing, **38:94**, **97**  
 B cell response, **38:51**  
 complementation, **38:72–83**  
 cross-reactive lysis, **38:186**  
 expression, **38:57**, **59**, **63**  
 gene function, **38:91**  
 H-Y antigen, **38:175**, **180**  
 Ia molecules, **38:170**, **171**  
 immunodominance, **38:180**, **181**, **185**  
 I region mutations, **38:84**, **85**, **87**  
 restriction, *see* Major histocompatibility complex restriction  
 self, *see* Self-antigens, self-MHC
- T cells  
 cytotoxic, **38:161**, **163**, **164**, **167–169**, **173**  
 interaction, **38:153**, **154**, **157**, **159**, **160**  
 positive selection, **38:130**, **131**  
 repertoire, **38:118**, **144**, **145**  
 suppression, **38:138**, **147**, **151**  
 tolerance, **38:121**, **122**, **124**, **125**, **127**, **129**
- linked diabetogenic genes, **51:290–293**  
 locus, MMTV-induced tumors and, **65:156**  
 lymphocyte homing and, **44:340**, **350**  
 maps of Ig-like loci and, **46:1**, **28–34**, **46**  
 structure, **46:19**  
 T cell receptor, **46:34**
- maternally transmitted antigen and, **38:313**, **315**, **318**, **351**, **352**  
 class I genes, **38:329**, **330**  
 mitochondrial transmission, **38:347**
- measles and, **45:345**, **346**  
 membrane proximal and distal domains, **43:214**
- murine lupus models and, **46:65**, **79**, **81**, **82**, **85**, **86**, **90**, **91**, **94**
- NK cells and, **47:187**, **188**, **292**  
 cytotoxicity, **47:190**  
 effector mechanisms, **47:239**, **240**, **242**, **257**, **259**, **261**  
 surface phenotype, **47:201**, **211**  
 recognition, **43:194–196**, **224**  
 regulators of complement activation and, **45:404**  
 restricted antigen recognition, AChR and, **42:256–259**  
 restriction, *see* Major histocompatibility complex restriction  
 SCID and, **49:384**, **386–387**, **391**  
 self-encoded, **43:213**  
 spontaneous autoimmune thyroiditis and, **47:435**, **491**, **493**, **494**  
 breeding, **47:436–438**  
 effector mechanisms, **47:467**, **469**  
 function, **47:459**, **461**, **462**, **464**  
 genetics, **47:481–491**  
 immune reactions, **47:450**, **455**  
 immunoregulation, **47:470–472**, **476**, **477**
- sporozoite malaria vaccine and  
 CS-specific T cells, **45:307**, **310**  
 immunity, **45:287**  
 interferon- $\gamma$ , **45:304**, **305**  
 structure, **66:68–69**
- surface antigens of human leukocytes and, **49:78–79**
- T cell development and, **44:207**  
 antigen recognition, **44:209**, **210**, **212–214**  
 cellular selection within thymus, **44:245–254**  
 ontogeny, **44:221**
- T cell receptor and, *see* T cell receptor
- T cell subsets and, **41:39**, **71**, **78**, **81**, **101**, **108**  
 cell surface molecules, **41:43**, **44**, **50**  
 transgenic, transcriptional factor, **48:142**
- Major histocompatibility complex antigens, **59:1–2**, **99–100**, **112**, **120**; **61:327–338**  
 alloantigens, B cell repertoire expression and, **42:78–79**  
 binding in solution, **43:211–213**  
 blocking by analogs in trimolecular complex, **56:244–247**  
 CD4-CD8 coreceptor/MHC binding sites, **53:68–70**  
 class I, **64:2**, **31**; **65:48–49**  
 assembly, **52:42–76**



## Major histocompatibility complex antigens

*(continued)*

- assembly, subcellular location, **52:42–50**
- assembly deficient cells, **52:47–49**
- class I molecules associated with antigen, place of, **52:49–50**
- effects of adenovirus E3/19K glycoprotein on antigen processing and presentation, **52:44–47**
- effects of brefeldin A on antigen processing and presentation, **52:42–44**
- assembly and transport, posttranslational modifications of, **52:59–62**
  - glycosylation, **52:59–61**
  - palmitylation, **52:61–62**
  - phosphorylation, **52:62**
- calnexin, **64:107–112, 119–121**
- cell surface-associated, mechanism of peptide binding to, **52:81–84**
- cytotoxic T cells and, *see* Cytotoxic T cells
- deficient mouse, *see* Mouse
- entry into processing pathways, **52:13–14**
- exogenous  $\beta_2m$  association with, **52:86–87**
- exogenous peptide association with, site of, **52:79–81**
- export to cell surface, control of, **52:62–76**
  - general considerations, **52:62–63**
  - induction of class I transport by exogenous peptides or hypothermia, **52:69–73**
  - retention of  $\beta_2m$ - $\alpha$  chain complexes, **52:65–68**
  - retention of free  $\alpha$  chains, **52:63–64**
  - summary of cellular control mechanisms, **52:73–74**
  - viral subterfuges, **52:74–76**
- folding and assembling of, **52:50–52**
- generation, model, **64:26**
- induction of transport by exogenous peptides or hypothermia, **52:69–73**
- interaction of exogenous peptides with, **52:78–86**
- internalization, **52:87–92**
  - evidence for internalization, **52:87–89**
  - internalization signals, **52:89–92**
  - phosphorylation involvement, **52:90–92**
    - region of proteins, **52:89–90**
  - Ir* genes and, **38:163, 164**
    - cross-reactive specificity, **38:185, 186**
    - cytotoxic T cells, **38:168–171, 173, 174**
    - epistasis, **38:176, 180**
    - immunodominance, **38:185**
  - maternally transmitted antigen and, **38:330–337, 348, 350**
  - membrane proximal domains, **43:214**
  - $\beta_2$ -microglobulin, **58:380**
  - molecular structure, **64:24**
  - murine NK cell receptors for, **55:364, 366**
  - nature of antigens bound to, **52:8–10**
  - NK cell receptors for, **55:356, 358–362, 372**
  - NK cell recognition, **55:363, 365**
  - in NK cell-specific functions, **55:349–353**
  - peptide anchoring, **64:124–127**
  - peptide building, **64:114–115, 118, 127–128**
  - peptide loading, **64:105–128**
  - properties, **52:78–92**
    - association of exogenous  $\beta_2m$  with class I molecules, **52:86–87**
    - extracellular processing of synthetic peptides, **52:84–85**
    - interaction of exogenous peptides with class I molecules, **52:78–86**
    - mechanism of peptide binding to cell surface-associated class I molecules, **52:81–84**
    - physiological relevance of exogenous peptide association, **52:85–86**
    - site of exogenous peptide association with class I molecules, **52:79–81**
  - proteasomes, **64:3, 105–107**
  - in proteolysis, role of, **52:29–30**
  - restoration by single peptides, **58:162**
  - role in proteolysis, **52:29–30**
  - self-, **57:314–320**
    - metastatic phenotype affected by, **57:318–320**
    - nonimmunological effects on tumor cells, **57:317–318**
    - recognition by cytotoxic T cell effector cells, **57:314–315**

- recognition by natural killer effector cells, **57:315–317**  
 TAP and, **65:87–92**  
 TAP system, **64:3–5, 30–31, 112–121**  
 T cell recognition, **55:364**  
 tumor immunogenicity affected by low level of expression, **57:303–305**  
 class Ia, as trimolecular complex target, **56:247–250**  
 class I and class II, **52:364**  
   and  $\alpha\beta$  T cells, **58:107–112**  
   deficient mouse, **58:156**  
   and  $\gamma\delta$  T cell function, **58:103–104**  
   and  $\gamma\delta$  T cell reactivities, **58:323–324**  
   interaction with CD4 and CD8 coreceptors, **58:129–131**  
   ligation of  $\alpha\beta$ TCR and coreceptor, **58:159**  
   peptide binding for T cell recognition, **58:88**  
   as potential tumor antigens, **58:420–421**  
 class Ib, **52:92–104**  
   characteristics of individual class Ib products, **52:94–104**  
     Hmt, **52:101–104**  
     Q10, **52:94–95**  
     Qa-2, **52:95–98**  
     TL region gene products, **52:98–101**  
   general aspects of structure and function, **52:92–94**  
 class II, **62:80; 64:2**  
   appropriate, expression, **51:308–310**  
   on B cells, MLR and, **39:81–83**  
   corneal graft  
     cell-surface expression, **48:199**  
     expression, **48:199**  
     expression timing, **48:199–200**  
   deficiency, **61:327–328**  
     CIITA, **61:331–334, 336–338**  
     RFX, **61:334–336**  
   deficient mouse, *see* Mouse  
   HLA types, HIV and, **65:286**  
   incompetent, **50:22**  
   *Ir* genes and, **38:168–171, 189**  
   MMTV superantigens and, **65:164–165**  
   MUC-1 mucin, **62:229, 238–239**  
   mucins, **62:222–223, 238–239**  
   MUM-1, **62:229, 237**  
   mutated antigens, **62:236–237**  
   mutated oncogene products, **62:226–227**  
   oncogenic proteins, **62:237–238**  
   *p53*, **62:226–227, 237–238**  
   Pmel17, **62:229, 235**  
   prostate-specific antigen, **62:224–225**  
   protein antigens, **62:221–225**  
   RA susceptibility associated with alleles, **56:429–430**  
     DR4, **56:404–408, 420–426**  
     Dw determinants, **56:407–408**  
     serologic identification, **56:402–404**  
   restricted antigen presentation, **58:319**  
   restricted CTLs, **60:303–310**  
   restricted soluble, **60:306–308**  
   self-, tumor immune response to increased expression, **57:313**  
   transducing signals, **48:142**  
   tyrosinase, **62:233–234**  
   viral antigens, **62:239–240**  
   class II-containing vesicle, **64:2**  
   conformation, **43:203–205**  
   cornea, **48:193–194**  
   determinants, polymorphic, **58:304**  
   expression on vascular endothelium, regulation, **50:262–265**  
   gene expression, **61:328–329**  
   in graft-versus-host disease, rat, **39:280–281**  
     T cell reaction, **39:280–281**  
   and immunological interactions of T cells with vascular endothelium, **50:261–266**  
   and positive selection, **58:164**  
   presentation, **58:330–331**  
   RA susceptibility associated with concepts, **56:390–397**  
     determinants, **56:400–402**  
     DR1, **56:420–426**  
     DR6, **56:419–420, 426**  
     DR10, **56:424–427, 429**  
   function influenced by structure, **56:451**  
   function of molecules, **56:449–450**  
   genetic studies, **56:436–438**  
   mapping region, **56:418–419**  
   polymorphism, **56:398–399**  
   terminator, **56:390–397**  
   role in  $V\beta$  selective element action, **50:17–22**  
   I-A molecules, **50:20–21**  
   I-E molecules, **50:18–19**

- Major histocompatibility complex antigens  
(*continued*)  
incompetent MHC class II molecules,  
**50:22**  
superantigen binding, **54:117–120**  
T cell receptor and, **61:148**  
three-dimensional structure, **43:213–215**  
tumor immune response to increased  
expression of allo-MHC, **57:312–313**
- Major histocompatibility complex glyco-  
protein, surface antigens of human  
leukocytes and, **49:80–82, 125**  
adhesion, **49:82–83**  
receptors, **49:77–78, 94, 100**
- Major histocompatibility complex restriction  
determinant selection model, **43:207**
- Ir* genes and  
antigen binding, **38:98**  
epistasis, **38:175**  
gene control, **38:63–67**  
gene function, **38:91, 92**  
Ia molecules, **38:71, 76**  
I region mutations, **38:88–90**  
macrophages, **38:112**  
T cells  
interactions, **38:157–160**  
selection, **38:131, 133**  
tolerance, **38:120, 125–129**
- Malaria  
cachectin and, **42:220, 226**  
human, **60:112–124**  
regulators of complement activation and,  
**45:389**  
rodent, **60:108–112**  
synthetic T and B cell sites and  
globular protein antigens, **45:207**  
parasitic antigens, **45:228, 229**  
vaccine, **45:254**  
viral antigens, **45:222**  
T cell receptor and, **45:132, 138**  
vaccine, *see* Sporozoite malaria vaccine
- Malignancy, cachectin and, **42:213, see also**  
Cachectin
- Malignant histiocytosis, complicating celiac  
disease, gene rearrangements and,  
**40:292–293**
- Malignant lymphomas, expression of FDCs  
in, **51:274–275**
- Malnutrition, IBD and, **42:289**
- Maloney sarcoma virus, **38:163**
- MALT, **65:251**
- Mammalian TOR, **61:181, 188–190**
- Mammary gland, lymphocyte homing and  
high endothelial venules, **44:321**  
molecules, **44:353**  
regional specificity, **44:326, 327, 335**
- Mammary gland factor, Stat5, **60:21**
- Mammary tumors, in mice, *see* Mouse  
mammary tumor virus
- Mammary tumor virus  
in B cells with Vbse expression, **50:39**  
superantigens, **54:102**  
transcripts expressed in activated B cells,  
**50:40**
- Mangano-heme PGHS-1, **62:188**
- $\alpha$ -Mannan, phagocytosis of zymosan  
by human monocytes, **38:365, 367, 368,**  
**374–376**  
by nonelicited murine macrophages, **38:377**
- Mannose  
CD23 antigen and, **49:163, 165**  
complement receptor 2 and, **46:202, 204**  
in GPI-anchored proteins, **60:60–74**  
leukocyte integrins and, **46:154**  
surface antigens of human leukocytes and,  
**49:98**
- MAPK, *see* MAP kinase
- MAP kinase, **63:148–149, 166**  
activation, **60:13–14**  
in B cell activation, **55:244–245**  
signal transduction, **59:262–263, 341**
- MARE-I, **43:279**
- Marek's disease virus, induced tumors,  
**50:105–107**
- Marginal zone B cells, **59:284–285**
- Marker density, immunosenescence and,  
**46:237, 239**
- Markers, lineage-related, differential  
expression during development (murine  
B cells), **53:125–127**
- Marrow  
HLA-incompatible, engraftment of,  
**40:386–387**  
microenvironment, hybrid resistance and,  
**41:390–393**  
T cell-depleted, rejection by patients,  
**40:389–391**
- Marrow grafts  
hybrid resistance and  
hemopoietic cells, **41:386–388**  
specific unresponsiveness, **41:384–386**

- immune reconstitution and, **40:410–411**  
 cytotoxic effector cells, accessory cells  
 and neutrophils, **40:416–417**  
 effects of T cell depletion, **40:417–419**  
 humoral immunity, **40:414–416**  
 phenotype and function of peripheral T  
 cells, **40:412–414**  
 repopulation of lymph nodes and  
 thymus, **40:411–412**  
 reconsideration of failure in humans,  
**40:392–395**
- MART-1, **62:229, 235**
- Masking, in regulation of CD44 receptors,  
**54:317–318**
- Mast cell growth enhancing activity, **54:93**
- Mast cell leukemia, etiology, stem cell factor  
 role, **55:74**
- Mast cells, **48:176, 177; 51:327–331**  
 AB-Mul V-transformed, lymphokine  
 production (murine), **53:4–6**  
 and basophils, human, cell surface  
 structure on  
 adhesion receptors and recognition  
 molecules, **52:357–366**  
 integrins, **52:358–361**  
 other recognition molecules, **52:**  
**366**  
 recognition molecules of Ig supergene  
 family, **52:361–364**  
 selectins and related recognition  
 molecules, **52:364–366**
- cells, **52:333–335**
- cell surface typing with mAbs,  
**52:335–339**
- complementing binder sites, **52:**  
**375–377**
- conclusions, **52:404**
- IgE/FcεRI, **52:378–381**  
 assembly, **52:381–382**  
 cell surface structures functionally  
 associated with FcεRI molecules,  
**52:391–396**  
 control of synthesis and expression of  
 FcεRI molecules, **52:384–386**  
 functional characterization of receptor,  
**52:387–391**  
 sequence and structural homologies,  
**52:383–384**  
 topology of, **52:378**
- Ig receptors, **52:378–396**
- negative regulators of growth and  
 differentiations of human basophils  
 and mast cells, **52:355–357**  
 interferons, **52:355–356**  
 transforming growth factors,  
**52:356–357**  
 receptors for activating peptides,  
**52:366–375**  
 formyl-methionine peptides and  
 related compounds, **52:371–372**  
 IL-8 and related integrins, **52:367–371**  
 substance P and other neuropeptides,  
**52:372–375**  
 receptors for growth and differentiating  
 factors, **52:339–355**  
 hemopoietic growth factor receptor  
 superfamily, HRS, **52:340–351**  
 receptors for low-molecular-weight  
 regulators and pharmacological  
 compounds, **52:396–404**  
 adenosine, **52:396–398**  
 antiinflammatory drugs, **52:402–404**  
 arachidonic acid metabolites,  
**52:398–402**  
 RTK family, c-kit, and related  
 oncogenes, **52:351–355**  
 bone marrow-derived, **53:3**  
 cachectin, **42:220**  
 CD40-L expression, **61:20**  
 characterization, **53:2–3**  
 chromolyn binding sites, **52:392–393**  
 connective type, **53:2–3**  
 and cytokines, **51:328–331**  
 differentiation/dedifferentiation, **53:3**  
 ECF-A production, **39:214**  
 factor-dependent cell lines, lymphokine  
 production (murine), **53:6–9**  
 Fc receptors, **40:68**  
 granules, EPO binding to, **39:201–202**  
 helper T cell cytokines and, **46:113, 114,**  
**116, 117**  
 histamine release  
 major basic protein and, **39:191**  
 SP effect, **39:305–306**
- IgE receptor/FcεRI, numbers and binding  
 constants on primary cells,  
**52:386–387**
- IL-3 effects, **39:19–20**  
 IL-3 production, **39:17**  
 and IL-9, **54:93–95**

- Mast cells** (*continued*)  
 IL-10 biological effects, **56:10**  
 lung, IL-4 storage by, **53:15**  
 mucosal, **53:2-3**  
 neuropeptide production, **39:316-317**  
 phenotypic properties, **53:1-2**  
 precursors, **53:2**  
 properties, **53:1-2**  
 role in inflammatory reactions, **53:2**  
 secretions, **53:2**  
 stem cell factor effects  
   development, **55:52-60**  
   function, **55:60-64**  
   secretion, **55:43**  
 Substance P, **61:372**  
 TH2 type cells, **61:360-361**  
 triggered by oxidative events, **60:331-332**
- Mast cell-specific receptor**, **43:282-283**  
 $\beta$  subunit, hydropathicity profile, **43:288**  
 characteristics, **43:283**  
 gene cloning studies, **43:283-289**  
 $\alpha$  chain, **43:284-287**  
 $\beta$  and  $\gamma$  chains, **43:287-289**  
 mechanisms of action, **43:289-298**  
   aggregation of receptors, **43:289-291**  
   cytoplasmic calcium rise, **43:293-298**  
   intrinsic and extrinsic, **43:289**  
   phosphoinositide hydrolysis, **43:290-293**
- Mast cell tumors, hybrid resistance and**, **41:361**
- Mastocytoma, anterior chamber**, **48:213-215**
- Mastocytosis, *Nipponstronglyus*-induced**, **54:95**
- Maternal effect, maternally transmitted antigen and**, **38:321, 323, 339, 343**
- Maternally transmitted antigen**, **38:313-317, 351, 352**  
 class I antigens and, **38:330, 331, 336, 337**  
 CTL generation, **38:348-350**  
 expression, **38:331, 336, 344, 345, 351, 352**  
 gene activation, **38:342**  
 genetic mechanism models, **38:338-340**  
   Delbrück model of antigenic variation, **38:340-344**  
   mitochondrial transmission, **38:344-348**
- MHC, class I genes and**, **38:329, 330**  
 phylogenetic considerations, **38:337, 338**  
 polymorphisms, **38:314, 318-329, 336, 337**  
 repressors, **38:341, 342**
- Maternally transmitted factor**, **38:321, 323, 327, 329, 351, 352**  
 class I antigens, **38:337**  
 CTL responses, **38:328**  
 genetic mechanism models, **38:339, 340, 345-348**  
 hybridization, **38:324**  
 phylogenetic, **38:338**
- Maternal transmission, maternally transmitted antigen and**, **38:321, 322, 326, 343, 352**
- Matrix metalloproteinases, rheumatoid arthritis**, **64:297, 320-321**
- Maturation**  
 eosinophils, **60:162-164**  
 functional, vs commitment to T cell lineage, **51:162-164**  
 phenotypic, sequence, **58:141**  
 post-thymic, T cells, **51:160-162**  
 stem cell factor receptor-ligand interaction in, **55:40-42**
- Maturation arrest**, **52:312**
- Max**, **63:161**
- MB-1 molecule**  
 induction of calcium mobilization in early B lineage cells, **54:354**  
 signal transduction through, **54:351-355**
- MCI, rheumatoid arthritis**, **48:128**
- M cells**, **65:251**
- Mcg, and Ig flexibility**, **48:21**
- MCP, see Membrane cofactor protein**
- McPC603**  
 binding site, **43:9, 19**  
 electrostatic complementarity with phosphorycholine, **43:10**  
 variable domains, **43:18-19**
- ME491 (CD63)**, **52:393**
- Mean fluorescence intensity, immunosenescence and**, **46:222**
- Measles**  
 antibodies from combinatorial libraries, **57:227-228**  
 infection, membrane cofactor protein, **61:220-221**  
 T cell receptor and, **45:124, 127**  
 virus-induced immunosuppression and, **45:335-347, 358**
- Measles virus, hybridomas against**, **38:294**
- MECA79**, **64:149, 174; 65:361-363, 365**
- MECA367**, **65:361, 362**

- M-ECEF, *see* Monocyte-derived eosinophil cytotoxicity enhancing factor  
**MECL1**, **64**:16, 20  
 MECL1, proteasome subunits, **64**:16–18  
 Meclofenamate, **62**:184, 186  
 Medulloblastoma, *pax5*, **63**:229–230  
 Megakaryocytes, IL-6 effects, **54**:23–24  
 Megakaryopoiesis, LIF effects, **53**:36  
 MEK kinase, **63**:149  
 MEL-14, **64**:142–143; **65**:352, 354  
   lymphocyte homing and  
     carbohydrate, **44**:360–362, 370  
     molecules, **44**:342–345, 347, 348, 350–352  
     regional specificity, **44**:341  
 MELAN-A, **62**:229, 235  
 Melanocytes, stem cell factor effects, **55**:64–66  
 Melanocytic differentiation antigens, **62**:233–236  
 Melanoma  
   adoptive T cell therapy of tumors and, **49**:285–286, 288, 290, 305  
   etiology, stem cell factor role, **55**:74–76  
   structural and functional properties of associated gangliosides, **40**:357–364  
 Melanoma antigens, **62**:219–220, 228, 230, 231–236  
 Melanoma-derived lipoprotein lipase inhibitor, *see* Leukemia inhibitory factor  
 $\alpha$ -Melanotropin, *in vitro* IgE synthesis, **61**:371–372  
 Melittin, pore formation and, **41**:313–316  
 Melphalan, chemotherapeutic use in cancer treatment, **56**:329–331  
 Membrane attack complex  
   amphiphilic nature of C5b-9, **41**:299–304  
   analogues, **41**:307–311  
   and C3 and C5 convertases, **60**:75–76  
   complement activation role, **56**:269–270  
   deposited CD59, **61**:251–254  
   fluid phase  
     clusterin, **61**:249–251  
     S protein, **61**:247–249  
   homologous restriction factor, **61**:254–255, 257  
   regulation, **61**:204  
   subunit composition, **41**:304–307  
 Membrane-binding domain, PGHS, **62**:172–173  
 Membrane cofactor protein, **61**:214–221  
   biosynthesis and tissue distribution, **61**:216–219  
   complement receptor 1 and, **46**:189, 197  
   function, **61**:218–221  
     AIDS, **61**:221  
     measles, **61**:220–221  
     reproduction, **61**:219–220  
     *Streptococcus*, **61**:221  
     transplantation, **61**:220  
   inhibition of C3 and C5 convertases, **60**:75–76  
   precursor, **61**:216  
   regulators of complement activation and genes, **45**:403, 404, 408  
     protein expression, **45**:395–398, 400–402  
     protein interactions, **45**:383  
     protein roles, **45**:386, 387, 390  
     RCA-like protein utilization, **45**:410  
     short consensus repeat, **45**:391  
   structure, **61**:214–216  
 Membrane cofactor protein 1, **62**:80, 282; **64**:154, 318  
 Membrane damage  
   cytolysis and, **41**:277–281  
   pore formation and cytolytic proteins, **41**:316–319  
   small peptides, **41**:313–316  
 Membrane enzymes, surface antigens of human leukocytes and, **49**:111–114  
 Membrane proteins  
   aPL antibodies and, **49**:197  
   Apo-1/Fas, membrane-spanning  
     induction of PCD, **58**:135–136  
     and negative selection, **58**:172–173  
     role in T cell death, **58**:226  
   CD23 antigen and, **49**:164  
   IFN- $\gamma$ , **62**:66, 77–78  
   surface antigens of human leukocytes and, **49**:93–97, 111, 114, 117  
   T3, **43**:116  
 Membranes  
   IgM receptor expression by Ig gene transfection, **54**:357–359  
   IgR/antigen complex processing, **54**:348  
   Ig receptors, **63**:43  
   integral proteins of, **52**:144, 145  
   and secreted Ig molecules, **54**:342–343  
 Membranoproliferative glomerulonephritis, **61**:245

- Memory. *see also* Immunological memory  
 humoral, germinal center B cells, **60:283**
- Memory B cells, **59:340–341, 393, 412**  
 adhesion molecules affecting migration,  
**53:248–249**  
 affinity maturation, **53:233–234**  
 functional properties, **53:236**  
 generation, alternative models for,  
**53:236–238**  
 generation, alternative models for,  
**53:236–238**  
 germinal centers and, **53:231–233**  
 life span, **53:240–241**  
 migration, **60:274–277**  
 adhesion molecules and, **53:248–249**  
 basic pattern, **53:247–248**  
 migration pattern, **53:247–248**  
 pathways of differentiation, **53:232–233**  
 phenotype of, **53:234–235**  
 Ig isotypes, **53:235**  
 surface markers, **53:235–236**  
 switched, **59:340–341**
- Memory cells  
 formation, CD40 and, **63:70–72, 73**  
 immunosenescence and, **46:246, 247**  
 lymphocyte homing and, **44:314, 325, 330–334, 337**
- Memory phenotype, peripheral T cells  
 expressing, **58:216**
- Memory T cells  
 CD44 expression, **54:294–295**  
 differentiation after antigenic stimulation,  
**53:229–230**  
 functional differences with naive and  
 effector cells, **53:227–228**  
 maturation into, **53:229–230**  
 migration  
 adhesion molecules affecting,  
**53:248–249**  
 basic pattern, **53:242–244**  
 to inflammatory sites, endothelium and,  
**50:278–284**  
 tissue-specific, **53:244–247**  
 phenotypic identification with CD45,  
**53:224–227**  
 TCR and signal transduction, **53:228–229**
- Mendelian inheritance, maternally  
 transmitted antigen and, **38:338**
- 6-Mercaptopurine, NK activity and, **42:300**
- Mesangial cells, as source of chemokines,  
**55:111**
- Mesangial proliferative glomerulonephritis,  
 and IL-6, **54:41**
- Mesenteric lymph node cells, IgE  
 biosynthesis and  
 antibody response, **47:3–5**  
 binding factors, **47:12, 14, 16, 17**
- Mesenteric lymph nodes, lymphocyte homing  
 and  
 carbohydrate, **44:351, 353**  
 regional specificity, **44:323, 326–328, 333, 335–338**
- Mesenteric microvascular models, anti-CD18  
 effect, **60:329–330**
- Messenger RNA  
 antinuclear antibodies and, **44:94**  
 autoantibodies, **44:137**  
 autoantigen, **44:129**  
 autoimmune response, **44:131, 134**  
 scleroderma, **44:122**  
 SLE, **44:101**  
 autoimmune demyelinating disease and,  
**49:360**  
 autoimmune thyroiditis and, **46:273, 294, 295, 297**  
 cachectin and, **42:215, 221–222, 223**  
 CD4 and CD8 molecules and, **44:298**  
 CD4 molecular biology, **44:288–291, 293, 296, 297**  
 CD8 molecular biology, **44:271, 272, 274–278, 280**  
 CD5 B cell and, **47:147**  
 CD23 antigen and  
 biological activity, **49:170**  
 cellular expression, **49:152–155**  
 cleavage regulation, **49:158**  
 expression in clinical conditions,  
**49:174–175**  
 expression regulation, **49:158–160**  
 Fc $\epsilon$ R11, **49:162, 166**
- CD40L, **60:48**  
 complement components and  
 C1q, **38:232**  
 C2, **38:212, 217**  
 C4, **38:223, 226**  
 Factor B, **38:209, 211, 212, 218**  
 complement receptor 1 and 184, **46:193**  
 complement receptor 2 and, **46:202**  
 CTL and, **41:148**

- cytokines, **60:222**  
 genetically engineered antibody molecules  
 and, **44:73**  
 GM-CSF, induction in T cells, **39:14**  
 helper T cell cytokines and, **46:112, 115,**  
**138**  
 HIV infection and, **47:380, 381, 392, 397**  
 humoral immune response and, **45:40, 62**  
 Ig, **43:239**  
 IgE biosynthesis and, **47:16**  
 Ig gene superfamily and, **44:18**  
 Ig heavy-chain variable region genes and,  
**49:2, 55**  
 IL-1 and, **44:174, 195**  
   biological effects, **44:165, 167**  
   gene expression, **44:159–161, 163, 164**  
   structure, **44:155, 156**  
 IL-2, induction in T cells, **39:13–14**  
 IL-3, induction in T cells, **14**  
 IL-5, **57:156–159; 60:198–199**  
 IL-5 receptor, **60:184**  
 immunosenescence and, **46:222, 228, 229**  
 leukocyte integrins and, **46:174, 175**  
 lymphocyte hybridomas and, **38:279, 291**  
 major basic protein, **60:192**  
 maps of Ig-like loci and, **46:3, 12, 32**  
 maternally transmitted antigen and, **38:344,**  
**345**  
 murine lupus models and, **46:72, 86–88,**  
**90, 91, 96**  
 NK cells and, **47:210, 246, 254, 263, 265,**  
**266**  
*PTC-A*, **60:82–84**  
 regulators of complement activation and,  
**45:397–400**  
 SCID and, **49:386**  
 sporozoite malaria vaccine and, **45:294**  
 surface antigens of human leukocytes and,  
**49:83, 89, 101, 113**  
 T cell activation and, **41:28**  
 T cell development and, **44:207**  
   ontogeny, **44:216, 217**  
   thymocyte subpopulation, **44:226–229,**  
**231, 233**  
 T cell receptor and, **45:165**  
 T cell receptor  $\gamma$ , **43:145**  
 T cells and, **38:2**  
   cDNA, **38:8**  
   clones, **38:5**  
   cytotoxic, **38:21**  
   expression, **38:13, 14**  
   *Ir* genes, **38:159, 189**  
   rearrangement, **38:12, 13**  
   transcription, **38:2, 10, 11**  
   V region genes, **38:15, 21**  
 T cell subsets and  
   cell surface molecules, **41:41–43, 45,**  
**47, 50**  
   H-2 molecules in thymus, **41:97, 99**  
   TGF $\alpha$ , **60:195**  
   virus-induced immunosuppression and,  
**45:344, 361**  
 Metalloproteases, **62:266–267, 288**  
 Metal-requiring enzymes, **60:340**  
 Metaphase, B cell formation and, **41:206**  
 Metastasis  
   adoptive T cell therapy of tumors and,  
**49:286, 297, 305**  
   and leukocyte homing, **58:396**  
 Met-enkephalin, **48:172**  
   lymphocyte chemotaxis and, **39:307–308**  
 Met-enkephalin receptors  
   on mixed lymphocytes, **39:312**  
   on T cells, **39:312**  
 Methimazole, induced insulin autoimmune  
 syndrome, HLA class II peptide binding  
 and, **66:87–88**  
 Methionine  
   antinuclear antibodies and, **44:118, 120**  
   CD4 molecules and, **44:289, 290**  
 Methotrexate, in cancer treatment  
   functional studies, **56:346–347**  
   monoclonal antibody conjugation  
   procedure, **56:338–340**  
 Methotrexate serum, hybrid resistance and,  
**41:350**  
 Methylated bovine serum albumin, aPL  
 antibodies and, **49:234–235**  
 Methylation  
   status in *cis*, role in gene rearrangements,  
**58:30–31**  
   V(D)J joining, of antigen receptor genes,  
   endogenous substrate, **56:44–46**  
 MG, *see* Myasthenia gravis  
 Mg21, **62:76**  
 MGF/STAT5, **65:20**  
 MGUS, **64:219, 220**  
 MHC, *see* Major histocompatibility complex;  
 Major histocompatibility complex  
 antigens



- MHr, *see* Myohemerythrin
- Micelles, cytotoxicity and, **41:303**
- Microfilaments, complement receptor 1 and, **46:199**
- $\beta$ -Microglobulin  
 T cell receptor and  
 alloreactivity, **45:155, 156**  
 MHC molecules, **45:111, 115**  
 structure-function relationships, **45:140**  
 virus-induced immunosuppression and, **45:353**
- $\beta_2$ -Microglobulin, **64:115-116**  
 - $\alpha$  chain complexes, retention, **52:65-68**
- B cell formation and, **41:198**
- CD1 heavy chains and, **59:43, 47-50**
- CD8 molecules and, **44:271, 272**
- chemotactic for pro-T cells, **58:380**
- CTL and, **41:135, 138, 165, 170**  
 exon shuffling, **41:138, 139, 147**
- HLA class I antigens, **41:149, 150**  
 T cell recognition, **41:154-156**
- deficient mouse, *see* Mouse, MHC class I-deficient
- exogenous, association with class I molecules, **52:86-87**
- Ig gene superfamily and, **44:24, 25, 30, 31**
- maps of Ig-like loci and, **46:2**
- T cell subsets and, **41:44, 75**
- Microsomal antigens, autoimmune thyroiditis and, **46:266, 273, 298, 299**
- Microtubule organizing center  
 cytolysis and, **41:275, 282**  
 humoral immune response and, **45:37, 38, 42**
- Microtubules, immunosenescence and, **46:224**
- MIF, *see* Macrophage migration inhibitory factor
- Migration, *see also* Transmigration  
 CD23 antigen and, **49:164, 169**  
 defect, in IBD, **42:307-308**  
 effector T cells  
 basic pattern, **53:242-244**  
 tissue-specific, **53:244-247**  
 eosinophils, **60:164-178**  
 inflammatory cells, NO role, **60:330-332**  
 leukocytes, **58:345-351**  
 lymphocyte, and immunological memory, **53:242**  
 memory B cells, **60:274-276**  
 adhesion molecules and, **53:248-249**  
 basic pattern, **53:247-248**  
 memory T cells  
 adhesion molecules and, **53:248-249**  
 basic pattern, **53:242-244**  
 tissue tropic subsets, **53:244-247**  
 naive B cells  
 adhesion molecules and, **53:248-249**  
 basic pattern, **53:247-248**  
 naive T cells  
 adhesion molecules and, **53:248-249**  
 basic pattern, **53:242-244**  
 tissue-specific, **53:244-247**  
 plasma cell precursors, **40:198-199**  
 plasma cells, **53:247-248**
- Migration inhibition factor, *see* Macrophage migration inhibitory factor
- Milk, S-IgA antibodies in, **40:201**
- mim-1* gene, **65:22**
- Minor histocompatibility antigens, maternally transmitted antigen and, **38:333, 334**
- MIP-1 $\alpha$ , HIV and, **65:282**
- MIP-1 $\beta$ , HIV and, **65:282**
- MIP-1 $\alpha$  receptor, cloning, **55:135**
- MIR, antibodies to, *see* Main immunogenic region, AChR, antibodies to
- Mitochondria, *see also* Antimitochondrial antibody  
 aPL antibodies and, **49:197, 239, 249-250, 256**  
 autoimmune thyroiditis and, **46:272**  
 cell-mediated killing and, **41:288**  
 defects, maternally transmitted antigen and, **38:333**  
 lymphocyte homing and, **44:317**  
 maternally transmitted antigen and, **38:337, 352**  
 genetic mechanism models, **38:340**  
 maternal transmission, **38:322, 323**  
 polymorphisms, **38:319, 320, 324, 326**  
 strain combinations, **38:349**  
 transfer via cell fusion, **38:314**  
 natural killer cells and, **47:214**  
 protein export, maternally transmitted antigen and, **38:315**  
 spontaneous autoimmune thyroiditis and, **47:442, 448**  
 surface receptor, maternally transmitted antigen and, **38:341**  
 T cell receptor and, **45:123**

- Mitochondrial DNA  
 damage, **38**:319  
 genetic mechanism models, **38**:339  
 maternally transmitted antigen, **38**:316, 317, 329, 351  
 polymorphism, **38**:323–327  
 rearrangement, **38**:320  
 restriction enzyme polymorphism, **38**:337  
 restriction patterns, **38**:327, 328
- Mitochondrial enzymes, action of, **65**:122
- Mitochondrial transmission, maternally transmitted antigen and, **38**:351  
 of class I-like antigen, **38**:348  
 of conventional antigen, **38**:346–348  
 of enzymatic activity, **38**:346  
 induced nuclear response, **38**:344–346
- Mitogen-activated protein kinase, *see* MAP kinase
- Mitogenic lectins, IBD and, **42**:289
- Mitogen signaling, Ig, **59**:326–328
- Mitogens  
 adoptive T cell therapy of tumors and, **49**:314  
 antigen-presenting cells and, **47**:71, 73, 100  
 antinuclear antibodies and, **44**:107  
 autoimmune thyroiditis and, **46**:289, 310  
 autoreactive T cells and, **45**:426  
 B cell formation and, **41**:192, 200, 228, 231  
 CD5 B cell and, **47**:140, 142, 147  
 CD23 antigen and, **49**:170  
 complement receptor 2 and, **46**:206, 208  
 cytotoxicity and, **41**:272, 284, 285  
 donor lymphocytes and, **38**:283, 284  
 helper T cell cytokines and, **46**:122  
 HIV infection and, **47**:390, 391, 398, 399  
 human T cell activation and, **41**:7, 8, 11, 12, 26, 27  
 humoral immune response and, **45**:67, 70, 72  
   antigens, **45**:23  
   helper T cells, **45**:26, 29, 33–35  
   interleukins, **45**:64, 73, 75  
   physical interaction, **45**:43  
 hybrid resistance and, **41**:350, 393, 395  
 IL-1 and, **44**:154, 168, 189  
   human disease, **44**:192, 194  
   immunocompetent cells, **44**:173–177  
 immunosenescence and, **46**:221  
   lymphocyte activation, **46**:223–225, 228, 234  
   mucosal immunity, **46**:252  
   regulatory changes, **46**:250  
   stem cells, **46**:244, 245  
 leukocyte integrins and, **46**:173  
*Mycoplasma arthritides*, **54**:113, 141  
 NK cells and, **47**:206, 261, 264  
 potential effector mechanisms, **47**:467  
 SCID and, **49**:382–385, 387, 398, 400  
 spontaneous autoimmune thyroiditis and, **47**:491, 493  
   cellular immune reactions, **47**:452, 456  
   disturbed immunoregulation, **47**:470–474, 476  
   genetics, **47**:488
- T cell development and cellular selection within thymus, **44**:248  
 ontogeny, **44**:221  
 thymocyte subpopulation, **44**:229, 236, 241
- T cell subsets and, **41**:60, 63–66, 111  
 tissue distribution, **47**:54  
 virus-induced immunosuppression and  
   HIV, **45**:355, 356, 358, 359, 361, 362  
   measles, **45**:338, 339, 342, 344
- Mitomycin C, in cancer treatment, **56**:329, 332–333
- Mitosis  
 B cell formation and, **41**:184  
 HIV and, **58**:424  
 immunosenescence and, **46**:241, 246
- Mixed connective tissue disease, antinuclear antibodies and, **44**:93, 111  
 autoantibodies, **44**:136, 138  
 autoantigen, **44**:130  
 autoimmune response, **44**:131  
 scleroderma, **44**:124  
 SLE, **44**:100
- Mixed-isotype dimer, formation, **48**:125
- Mixed leukocyte cultures, NK cells and, **47**:295
- Mixed-leukocyte reaction, *see* Mixed-lymphocyte reaction
- Mixed-lymphocyte reaction, **59**:376  
 antigen-presenting cells and, **47**:65, 71–73, 75, 76, 78–80  
   APC-T cell binding, **47**:95, 97, 99  
   cell surface, **47**:59, 61  
   T cell, **47**:83, 84, 99  
   tissue distribution, **47**:48, 49, 53, 54  
 Ia role, **39**:81

- Mixed-lymphocyte reaction (*continued*)  
 immunosenescence and, **46:243, 244**  
 MHC class II-mediated, B cells and,  
**39:81, 83**  
 Mls-mediated, B cells and, **39:81–83**  
 primary, activated B cells and, **39:80–81**  
 secondary, resting B cells and, **39:80**  
 T cell subsets and  
 cell surface molecules, **41:43**  
 H-2 alloantigen recognition, **41:81, 83–87**  
 APC, **41:88–92**  
 H-2 molecules in thymus, **41:107, 108**  
 virus-induced immunosuppression and,  
**45:341**
- Mixed-lymphocyte response, *see* Mixed-lymphocyte reaction
- MLA-144 leukemic cell line, **42:172**
- MLR, *see* Mixed-lymphocyte reaction
- mls  
 identification as product of MMTV,  
**54:100–102**  
*in vitro* response to, **54:124–125**
- Mls antigen, **50:7–10; 65:139, 196**  
 antigen-presenting cells and, **47:47**  
 antigen presentation, **47:64, 76–79**  
 APC-T cell binding, **47:95, 99**  
 and bacterial toxic mitogen action, working  
 model, **50:4, 5–6**
- B cell  
 MLR and, **39:81–83**  
 during ontogeny, **39:81**  
 definition, **50:7–9**  
 multiple loci, **50:9–10**
- Mls loci, multiple, **50:9–10**  
 current nomenclature for, **50:11**
- MMTV, *see* Mouse mammary tumor virus
- 6-MNA, **62:186**
- Mobility, **43:33–35**  
 crystallographic temperature factors, **43:20**  
 functional significance, **43:73–74**  
 interacting structural elements, **43:80**  
 local, relationship with antigenicity, **43:61**  
 secondary structure, **43:76**  
 T cell receptor  $\gamma\delta$  proteins, **43:150**
- Molecular adaptation, **64:20**
- Molecular complexes, CD19, CR2, and CR1  
 on surface of human B cells, **52:146**
- Moloney leukemia virus, **41:364, 400**
- Moloney sarcoma–leukemia virus, **41:153**
- Moloney sarcoma virus, **41:378**
- Monensin, **41:281**
- Monkey  
*Ascaris* antigen challenge, **60:168–169**  
 asthma model, **60:219**  
 complement components and, **38:207–209**  
 (T1B)<sub>4</sub> MAP immunization, **60:116–117**  
 Monoclonal antibodies, **53:5D3, 276–277; 64:323**  
 5D3, LPS mimesis, **53:276–277**  
 109d6, RA susceptibility associated with,  
**56:422–425**  
 109 D6, rheumatoid arthritis, **48:128**  
 AChR and, **42:240–241**  
 adoptive T cell therapy of tumors and,  
**49:283, 320, 327**  
 mechanisms, **49:308, 312–314, 317**  
 principles, **49:290, 296–297**  
 anti- $\beta$ , **43:283**  
 antigen-presenting cells and, **47:70, 76, 77, 96**  
 cell surface, **47:58, 60–62**  
 tissue distribution, **47:50, 51, 53**  
 anti-Id, **42:149–157**  
 antinuclear, **44:98, 108, 118, 134–136**  
 antiphospholipid, **49:239, 242, 245, 248–249, 251**  
 anti-Tac, **42:167**  
 Ars A response and, **42:98**  
 autoimmune demyelinating disease, **49:357, 363, 366**  
 autoimmune thyroiditis  
 antigens, **46:267, 269, 272, 273**  
 cellular immune responses, **46:287, 295**  
 experimental models, **46:274, 275, 277, 280**  
 humoral responses, **46:300, 302–306, 308**  
 prevention, **46:310, 314**  
 autoreactive T cells and, **45:420**
- B cell formation, **41:181, 182, 235, 238**  
 B cell precursors, **41:188, 189**  
 bone marrow cultures, **41:213**  
 cell size changes, **41:202**  
 functional assays, **41:200, 201**  
 Ig genes, **41:204**  
 Ly-5 family of glycoproteins, **41:189, 192**  
 lymphohemopoietic tissues, **41:187**  
 markers, **41:193, 194**  
 NZB mice, **41:227**

- PI-linked lymphocyte antigens, **41:198**  
 SCID mice, **41:225**  
 tumor cell lines, **41:195**  
 CD1 proteins, **59:39–43**  
 CD2, **48:235–236**  
   CD3- Jurkat mutant, **48:236**  
   CD3- thymocyte, **48:236**  
   NK cell, **48:236**  
 CD3, effect on IL-9 expression in T cells, **54:85**  
 CD4 and CD8, **44:298–303**  
   CD4 molecular biology, **44:284, 285, 290, 291, 293, 295–297**  
   CD8 molecular biology, **44:271, 278, 280, 282**  
 CD5 B cell and, **47:117**  
   genetic influence, **47:143–147**  
   Ig gene expression, **47:153, 155**  
   physiology, **47:133, 134**  
   primordial immune network, **47:160**  
 CD23, **49:177; 60:181**  
   biochemical structure, **49:155, 157**  
   biological activity, **49:171–172**  
   cellular expression, **49:152–153, 155**  
   Fc $\epsilon$ RII, **49:162, 164–165**  
 CD28, **48:245**  
   mediated T cell activation, mechanism, **48:246**  
 CD40, **60:45–49**  
 CD44, *in vitro* synthesis, **54:301**  
 CD45, studies, **66:1, 3, 5–17**  
 in chemoimmunoconjugates for cancer treatment  
   agents, **56:302**  
   alkylating agent–antibody conjugates, **56:328–333**  
   anthracycline–antibody conjugates, **56:333–338**  
   antigen heterogeneity affected by, **56:352**  
   barriers to chemotherapy, **56:347–354**  
   clinical trials, **56:354–356, 358–359**  
   conjugation strategies, **56:312–314, 318–319, 323**  
   cytotoxic drugs, **56:342–343**  
   design strategy, **56:324–325**  
   development, **56:302–304**  
   folic acid antagonists, **56:338–340**  
   functional studies, **56:344–347**  
   immunogenicity, **56:311–312**  
   intermediary carriers, **56:323–324**  
   internalization, **56:308–310**  
   localization, **56:306–308**  
   mode of action, **56:344–347**  
   modulation, **56:308–310**  
   morphological studies, **56:347**  
   preclinical studies, **56:326–328, 343**  
   radiolabeling, **56:354**  
   size effects, **56:310–311**  
   targets, **56:305–306**  
   toxicity, **56:311–312**  
   vinca alkaloids, **56:340–342**  
 complement receptor 1 and, **46:196, 200, 201**  
 complement receptor 2 and, **46:203, 204, 206, 211**  
 CTL and, **41:169, 170**  
    $\beta_2$ -microglobulin, **41:155, 156**  
   amino acid, **41:163**  
   blocking, **41:156–158**  
   exon shuffling, **41:140, 141, 145, 148**  
   HLA class I antigens, **41:150**  
   somatic cell class I variants, **41:165–167**  
 cytotoxicity and, **41:285, 291, 307, 309**  
 EG1, **60:193**  
 EG2, **60:193, 220**  
 Fc receptors  
   Fc $\epsilon$ R, **43:299–300**  
   Fc $\alpha$ RI, **57:9, 40–41**  
   Fc $\gamma$ RI, **57:8–9**  
   Fc $\gamma$ RII, **57:9, 17–19**  
   Fc $\gamma$ RIII, **57:9, 29–30**  
   Fc $\delta$ RI, **57:9, 36–37**  
   Fc $\delta$ RII, **57:38**  
 fibronectin and, **38:387–389**  
 helper T cell cytokines and, **46:112, 119, 123–125**  
 HIV infection and, **47:386**  
 human B cell neoplasia and, **38:269**  
 hybrid resistance and, **41:336, 374, 377, 378, 386**  
 IBD and, **42:289**  
 ICAM-1 and VCAM-1, **60:168–170**  
 IgE biosynthesis and  
   antibody response, **47:8, 31, 33–35**  
   binding factors, **47:16, 18–22, 24, 27**  
 Ig gene superfamily and, **44:33, 41**  
 Ig heavy-chain variable region genes and, **49:46, 48, 51**  
 IL-1, **44:174**

- Monoclonal antibodies (*continued*)
- IL-2Ra, treatment with, **50**:188–189
  - IL-5, **60**:215
  - immunosenescence and, **46**:249
  - Ir* genes and
    - antigen binding, **38**:99, 107
    - Ia molecules, **38**:68–72, 75, 77, 78
    - mutations, **38**:88, 90
    - T cell repertoire, **38**:116
    - T cell suppression, **38**:150, 151
    - tolerance, **38**:125
  - J11D, **42**:74, 76
  - leukocyte integrins and, **46**:150, 151, 177
    - inflammation, **46**:162–166, 168
    - leukocyte adhesion deficiency disease, **46**:173
    - ligand molecules, **46**:170, 172, 173
    - structure, **46**:153
  - lymphocyte homing and
    - carbohydrate, **44**:354, 361, 364, 371
    - high endothelial venules, **44**:317, 318
    - molecules, **44**:342–346, 348, 350–352
    - regional specificity, **44**:327, 329, 338
  - lymphocyte hybridomas and, **38**:275–277, 306
    - antitetanus toxoid, **38**:303
    - B cell hybridization, **38**:279, 280
    - donor lymphocytes, **38**:282, 286
    - EBV-transformed B cells, production by, **38**:277–279
    - genetic engineering, **38**:304, 305
    - human, **38**:301, 302
    - human-human hybridomas, **38**:292, 293, 296, 299
    - human-mouse heterohybridomas, **38**:301
    - human-murine hybridomas, **38**:289, 290
  - maternally transmitted antigen and, **38**:331, 351
  - MC therapy and, **42**:272
  - to MHR, protein and peptide-induced, **43**:61–62
  - mouse, segmental flexibility, **48**:13, 14
  - multiple myeloma, **64**:242–243, 260–263
  - multiple sclerosis and, **49**:369, 372–375
  - murine lupus models and, **46**:95
  - neoplastic plasma cells as immunogens, **64**:243–244
  - NK cells and, **42**:182; **47**:198, 296
    - CD16, **42**:188, 190–191
    - congenital defects, **47**:224, 225
    - differentiation, **47**:233
    - effector mechanisms, **47**:243, 258
    - hematopoiesis, **47**:278, 279
    - HNK-1, **42**:191–192
    - NK1.1 antigen, **42**:188–190
    - phenotype, **42**:186
    - surface phenotype, **47**:200, 201, 205, 207, 208, 210, 211
    - tissue distribution, **47**:219, 220
  - phagocytosis of zymosan, **38**:369, 370
  - reactivity with isolated FDCs, **51**:259
    - negative, **51**:250–251
    - positive, **51**:248–249
  - regulators of complement activation and, **45**:390, 396, 397, 410
  - reshaped human PM-1, construction, **64**:261
  - SCID and, **49**:394–395, 397
  - spontaneous autoimmune thyroiditis and, **47**:435
    - altered thyroid function, **47**:460–462
    - cellular immune reactions, **47**:454, 455
    - disturbed immunoregulation, **47**:472, 479
    - histopathology, **47**:442
    - potential effector mechanisms, **47**:466
  - sporozoite malaria vaccine and, **45**:292, 293, 306, 312
  - in studies of CD antigen expression on basophils/mast cells, **52**:336–337
  - surface antigens of human leukocytes and, **49**:87, 117, 125–126
    - receptors, **49**:98, 100–101, 111
  - synthetic T and B cell sites and, **45**:238, 239
  - T cell activation and, **41**:30
    - accessory molecules, **41**:14
    - cell surface molecules, **41**:1, 2
    - gene regulation, **41**:28
    - IL-1 receptor, **41**:14
    - receptor-mediated signal transduction, **41**:19–22, 24–26
    - TI, **41**:13
    - TI1, **41**:9, 10
    - T cell antigen receptor, **41**:2, 4–8
    - Thy-1, **41**:11
    - Tp44, **41**:11
  - T cell development and, **44**:209
    - cellular selection within thymus, **44**:245–247, 254, 255
    - ontogeny, **44**:218, 220, 224

- thymocyte subpopulation, **44**:227, 228, 232, 239, 243
- T cell receptors and, **45**:130, 141, 153, 156  
 protein properties, **38**:3–5  
 target interaction, **38**:21  
 thymus, **38**:12
- T cell subsets and  
 H-2 alloantigen recognition, **41**:79, 84, 89, 93  
 H-2-restricted antigen recognition, **41**:53  
 T cell receptor, **41**:40, 43  
 therapeutic use, **64**:196  
 virus-induced immunosuppression and, **45**:346, 357, 362  
 to VSAG, structure–function studies, **54**:105–106
- Monoclonal gammopathies, undetermined significance, *see* MGUS
- Monocyte chemoattractant protein-1, **66**:135
- sepsis and, **66**:104, 141–142
- Monocyte-derived eosinophil cytotoxicity enhancing factor, **39**:216
- Monocyte/macrophages  
 LIF role in, **53**:35–36  
 LPS receptors, **53**:274–281
- Monocytes  
 adherent IgG effects on inductor of IL-1ra production, **54**:182  
 adoptive T cell therapy of tumors and, **49**:328  
 antinuclear antibodies and, **44**:95  
 autoimmune thyroiditis and, **46**:294  
 CD1 protein distribution, **59**:64–66  
 CD5 B cell and, **47**:142  
 CD23 antigen and, **49**:153, 158, 174, 176  
 biological activity, **49**:167, 169, 171, 173  
 expression regulation, **49**:160–161  
 Fc $\epsilon$ RII, **49**:166  
 CD40 expression, **61**:13, 40  
 complement receptor 1 and, **46**:190, 199–201  
 complement receptor 2 and, **46**:207  
 differential regulation of IL-1 $\beta$  and IL-1ra production, **54**:181–184  
 effects on cytokines in IL-1ra production by, **54**:182–184  
 Fc receptors on, **40**:64–66  
 fibronectin and, **38**:390  
 HIV infection and  
 activation, **47**:400, 402, 403  
 immunopathogenic mechanism, **47**:392–397  
 neuropsychiatric manifestations, **47**:404  
 human, phagocytosis  
 alternative complement pathway, **38**:385  
 particulate activators, **38**:380, 382  
 zymosan, **38**:363–376  
 IFN- $\gamma$  and, **62**:80, 136  
 IgE, **43**:305–306  
 IGF-1, **63**:389–391  
 IL-1 and, **44**:153, 190  
 biological effects, **44**:166, 167, 169  
 gene expression, **44**:159–161, 163, 164  
 human disease, **44**:193, 194  
 immunocompetent cells, **44**:178  
 structure, **44**:155, 157  
 TNF, **44**:185, 186  
 IL-8 effects, **55**:117–118  
 immunosenescence and, **46**:228  
 leukocyte integrins and, **46**:161, 163–167  
 lymphocyte homing and, **44**:339, 352  
 opioid receptor, **48**:180  
 PGHS-2, **62**:191–192  
 pituitary hormones, **63**:411–412  
 purification of IL-1ra from IgG-induced supernatants, **54**:172  
 SCID and, **49**:384–385, 389–391, 396, 401  
 as source of chemokines, **55**:105–106  
 spontaneous autoimmune thyroiditis and, **47**:475  
 surface antigens of human leukocytes and, **49**:111, 116  
 adhesion molecules, **49**:86, 88  
 Igs, **49**:89, 91  
 MHC glycoproteins, **49**:82  
 TGF- $\beta$  regulation, **55**:187
- Monocytoids, CD5 B cell and, **47**:141–143
- Monocytopenia, hybrid resistance and, **41**:392
- N<sup>G</sup>-Monomethyl-L-arginine, **62**:72, 75, 99  
 in arthritis and diabetes, **60**:344–345  
 in conjunction with lipopolysaccharide, **60**:347  
 effect on  
 cytokinoplasts, **60**:352  
 infection, **60**:341, 343  
 inhibition of F-BSA extravasation, **60**:328

- Mononuclear cells  
 IBD and, **42:289**, 294–297  
 antibody secretion and, **42:301–307**  
 intestinal  
 antibody secretion and, **42:302–307**  
 IBD and, **42:295–296**  
 lamina propria, IBD and, **42:297**
- Mononuclear phagocytes, IFN- $\gamma$  and, **62:78–80**
- Mononucleosis, virus-induced  
 immunosuppression and, **45:352**
- MOPC-315, antigen-specific inhibition by  
 suppressor T cells, **40:143–144**
- Morphine, NK cells and, **47:268**
- Morphology  
 B cell formation and, **41:182**, 186, 204,  
 213, 219, 238  
 cytotoxicity and, **41:271**  
 cytolysis, **41:274**, 276, 281–283  
 cytolytic proteins, **41:317**  
 granule proteins, **41:287**, 291, 294, 295  
 membrane attack complex of  
 complement, **41:300**, 304, 305, 309,  
 311  
 degranulating eosinophils, **60:160–162**  
 eosinophil activation, **60:158–160**  
 HIV infection and, **47:378**  
 NK cells and, **47:214–218**, 292  
 antimicrobial activity, **47:283**, 290  
 cytotoxicity, **47:249**, 250, 253, 256, 258  
 differentiation, **47:234**  
 hematopoiesis, **47:275**, 281  
 identification, **47:197**, 198  
 malignant expansion, **47:226**, 227  
 reproduction, **47:271**  
 surface phenotype, **47:210**, 213  
 tissue distribution, **47:219**, 220  
 normal mature eosinophils and eosinophil  
 myelocytes, **60:155–158**  
 spontaneous autoimmune thyroiditis and,  
**47:444**, 467, 472
- MORT-1, **61:31**
- Mosaicism, X-chromosome, **59:159**, 195
- Mouse  
 acquired immunodeficiency disease  
 syndrome, **54:115**  
 A/J Inbred strains,  $V_H$  genes in, **42:137**  
 athymic nude, **58:309–311**  
 B cell repertoire expression, *see* B cell  
 repertoire expression  
 bearing male-specific transgenic T cell  
 receptor, effect of IL-2 on,  
**50:170–171**  
 CD2-deficient, **58:172**  
 class A gene *Pig-a*, **60:72**, 93  
 EAE-susceptible, MBP epitope  
 identification, **48:164–165**  
 erythrocytes, rosette formation with human  
 B cells, **40:18**  
 genome, non-MIs elements in, **50:11–14**  
 and human  
 heavy chain locus organization,  
**54:231–233**  
 IL-9 characterization and cloning,  
**54:80–82**  
 HuSCID, antibodies derived from,  
**57:230–231**  
 IELs, invariant  $\gamma\delta$  T cell receptors,  
**58:301–304**  
 Ig-transgenic, CD5 B cells in, **55:324–326**  
 IL-1 receptor antagonist, cloning and  
 expression, **54:175–176**  
 IL-6 transgenic, **54:45–47**  
 IL-9 receptor cDNA, **54:82**, 84  
 immunodeficient, IL-5 production,  
**57:171–172**  
 IRF-1 knockout, **60:335**
- lpr*  
 etiology of autoimmunity, **60:308–309**  
 Fas gene mutation in, **57:132–133**
- lpr/lpr*, accumulation of CD4<sup>+</sup>8<sup>+</sup>  $\alpha\beta$  T  
 cells, **58:112**
- malaria model, **60:108–112**
- MHC class I-deficient, **55:381–383**,  
 415–417; **58:313**  
 autoimmune disease, **55:415**  
 bacterial infection, response to,  
**55:412–413**  
 cell surface expression, **55:385–387**  
 development, **55:384–385**  
 functional class I molecules on  $\beta_2m$ -  
 deficient cells, **55:386–387**  
 hematopoietic cell grafts, **55:388**  
 human filarial parasites, response to,  
**55:415**  
 impaired NK cell activity, **55:404–405**  
*Leishmania major* infection, response to,  
**55:414–415**  
 liver cell grafts, **55:391**

- lymphocytes, deficient development of, **55:393–404**
- NK cells, target cell susceptibility, **55:392–393**
- pancreatic islet grafts, **55:390**
- pathogens, responses to, **55:405–406**
- production, **55:383–384**
- serological analysis, **55:385–386**
- skin grafts, **55:388–390**
- transplantation studies, **55:387–391**
- Trypanosoma cruzi* infection, response to, **55:413–414**
- viral infections, response to, **55:406–412**
- MHC class II-deficient, **55:423–424**
- B cells, **55:429–430**
- CD4<sup>+</sup> T cells, **55:424–427**
- CD8<sup>+</sup> T cells, **55:427–428**
- double deficient mouse, **55:435–436**
- E-only mouse, **55:434–435**
- immune system, peripheral compartment, **55:424–430**
- $\gamma\delta$  T cells, **55:428–429**
- thymus, **55:433**
- reconstituted, **55:433–434**
- single-positive compartment, **55:430–433**
- motheaten, CD5 B cell expression in, **55:314**
- MRL/Mp-lpr/lpr, recombinant IL-2/vaccina virus construct on, **50:193–203**
- Mtv-7<sup>+</sup> and Mtv-7<sup>-</sup>, **58:222**
- mutations affected by stem cell factor or SCF receptor, **55:17–23**
- neonatally thymectomized, effect of IL-2.VV, **50:205–208**
- Nu/nu*, effect of IL-2.VV on, **50:204–206**
- p53-deficient, **58:169**
- perforin gene mutation, **60:292–296**
- retention of Vbse sequences, **50:41–42**
- scid*, **60:341–343**
- and DSB repair and V(D)J recombination, **58:45–51**
- genetic reconstitution experiments, **58:142–143**
- lymphocytes, **58:317**
- rearrangement-deficient, **58:155–156**
- thymocytes, **58:37–38**
- SEB shock model, **60:348–349**
- self-reactive T cells, **58:274–277**
- with severe combined immune deficiency, *see* Severe combined immunodeficiency, SCID mouse
- T cell activation, **41:1**
- cell surface molecules, **41:10, 11, 13, 14**
- receptor-mediated signal transduction, **41:23, 25**
- T cell development stages in, **51:118–119**
- T cells, tumorigenesis, **54:88–93**
- transgenic
- bcl2/scid*, **58:48–49**
- for given Mtv, **50:40**
- H-2<sup>b</sup> and H-2<sup>d</sup>, **58:313–316**
- IL-5 production models, **57:169–170**
- with knockout mutations, **58:30–33, 41, 89**
- RAG<sup>-/-</sup>, **58:143–145**
- TAP-1<sup>-/-</sup>, **58:162–163**
- TCR- $\alpha$ , - $\beta$ , - $\gamma$ , and - $\delta$  loci, **58:118–119**
- transgenic spleen cells, *in vitro* studies with, **54:414–415**
- Vbse not stimulating primary T cell response, **50:11–13**
- X-linked immunodeficient, **60:41–42**
- IL-5 production models, **57:171–172**
- Mouse mammary tumors, **65:139**
- induction of, **65:153–155**
- Mouse mammary tumor virus, **50:39; 65:139–141, 211–212**
- endogenous
- immune stimulation by superantigens, **65:196–203**
- superantigen expression, **65:152–153**
- tolerance induction, superantigens and, **65:203–208**
- virology, **65:141–146**
- exogenous
- adult T cell response, **65:175–178**
- neonatal response, **65:171–175, 203**
- T cell-dependent B cell differentiation and, **65:178–180**
- virology, **65:141–146**
- immune response to, **65:167–168, 212**
- adult T cell response, **65:175–178**
- cellular response, **65:192–194**
- humoral response, **65:188–192**
- neonatal response, **65:171–175, 203**
- receptors for, **65:194–196**
- superantigen-dependent, **65:171–194**



- Mouse mammary tumor virus (*continued*)  
 superantigens and T cell-independent,  
**65:168–171**  
 T–B interaction, **65:180–188**  
 T cell-dependent B cell differentiation,  
**65:178–180**
- superantigens, **65:140, 152–153**  
 cellular expression of antigens,  
**54:106–107**  
 expression, **65:152–153**  
 immune stimulation by, **65:140, 141,**  
**171–194, 196–203**  
 MHC class II molecules, interaction  
 with, **65:164–165**  
 MIs identification as product,  
**54:100–102**  
 protein structure, **65:157–164**  
 role in life cycle of virus and host,  
**54:107–108**  
 structure–function studies, **54:103–106**  
 TCR V $\beta$ , interaction with, **65:165–167**  
 tumor formation and, **65:152, 155**
- virology, **65:141–145**  
 amplification and spread, **65:180–188**  
 infection and transmission, **65:148–151**  
 life cycle, **65:211**  
 structure, **65:146–148**  
 tissue distribution, **65:151–152**  
 transcriptional regulation, **65:148**
- Mouse mammary tumor virus receptors,  
**65:194–196**
- MPL units, aPL antibodies and, **49:203–204**  
 mRNA, *See* Messenger RNA  
 $\alpha$ -MSH, *in vitro* IgE synthesis, **61:371–372**  
 mTOR, **61:181, 188–190**  
*mtp* genes, **65:49**
- MUC-1, **62:223, 229, 238–239**  
 $\mu$  chains, **43:238–239**
- Mucins, **62:222–223, 238–239**  
 lymphocyte–HEV interaction, **65:360–361**  
 tumor antigen recognition of, **57:302–303**
- Mucosa  
 addressin, **62:257**  
 associated lymphoid tissue  
 functional anatomy of Peyer's patches,  
**40:192–195**  
 studies on disassociated Peyer's patches  
 cells, **40:195–197**  
 and immunity, **58:297–298; 59:372**  
 lymphocyte homing into, **64:175–177**
- Mucosal immunity, immunosenescence and,  
**46:221, 251–253**
- Mucosal inflammatory infiltrate, in IBD,  
**42:298**
- Mucosal organs, lymphocyte homing and,  
**44:323, 327–330, 334–336**
- Mucosal tissues, mechanisms of homing of  
 plasma cell precursors to, **40:204–207**
- Mucosal vascular addressin, lymphocyte–HEV  
 interaction, **65:362–363**
- Mu heavy chain  
 allelic exclusion, **63:2, 19–21**  
 B cell development, **63:1–4, 11–15,**  
**16–25, 31**  
 ligand for PreB cell receptor, **63:25–26**  
 signal transduction through PreB cell  
 receptors, **63:26–29**
- Muller cells, **48:218–219**
- Multicatalytic protease complex, **52:26**
- Multichain immune recognition receptors,  
**61:154**
- Multi-CSF, *see* Interleukin-3
- Multidrug resistance gene, mammalian,  
**65:51**
- Multimeric–Synthetic Peptide Combinatorial  
 Library, **60:139**
- Multiple antigen peptides  
 as antigens, **60:137–139**  
 based on schistosome antigens, **60:125–128**  
 definition, **60:105–106**  
 design and synthesis, **60:106–108**  
 in helminthic diseases, **60:124–128**  
*mono-, di-, and triepitope*, **60:120–123**  
 [(NAAG) $_n$ ] $_k$ , MAP, immunized mouse, for  
*P. malariae*, **60:123**  
 in protozoan diseases, **60:108–124**  
 sporozoite malaria vaccine and, **45:321**  
 (T1B) $_1$  MAP construct, immunogenicity,  
**60:114–120**  
 for viral and bacterial diseases, **60:128–136**
- Multiple myeloma, **42:224; 64:219, see also**  
 Myeloma  
 adhesion molecules, **64:246–249**  
 CD40, **61:12, 39**  
 cell identification, **64:242–246**  
 chromosome and oncogene abnormalities  
 in, **64:250–251**  
 cytokines, **64:252–260**  
 IL-6 signal transduction therapies,  
**64:260–263**

- immunophenotype, **64:242**  
 oncogenic transformation, **64:249–251**
- Multiple sclerosis, **49:357**  
 antibodies, **49:368–374**  
 aPL antibodies and, **49:209**  
 DP  $\alpha$ -DQ  $\beta$ , **48:149**  
 DPw4, **48:149–150**  
 DQ  $\alpha$ -DQ  $\beta$ , **48:149**  
 DQ  $\alpha$  gene polymorphism, **48:149**  
 DQR2-6, **48:148–149**  
 DQw1, **48:148**  
 DQw1a, **48:148**  
 DQw1b, **48:148**  
 DR2, **48:148–150**  
 DR  $\alpha$ -DQ  $\beta$ , **48:149**  
 Dw2 subtype, **48:148–150**  
 HLA-A3, **48:148–150**  
 HLA-B7, **48:148–150**  
 HLA class II peptide binding and, **66:88–91**  
 IFN- $\gamma$  and, **62:75, 91**  
 myelin basic protein and, **49:362–363**  
 NK cells and, **47:301, 302**  
 pituitary hormones, **63:425**  
 T cell response, **48:150**  
 TCR usage restriction and, **49:367–368**  
 vaccination to TCR V regions, **49:374–375**
- MUM-1, **62:229, 237**
- Murine acquired immunodeficiency syndrome, **52:432**
- Murine colony-stimulating factor, **48:73**
- Murine cytomegalovirus, hybrid resistance and, **41:389**
- Murine encephalomyocarditis virus, resistance to infection, **65:31**
- Murine hepatitis virus, hybrid resistance and, **41:375, 376**
- Murine leukemia virus, **52:432–434**  
 antinuclear antibodies and, **44:130**  
 plasmacytomagenesis, **64:230**
- Murine mammary tumor virus, *see* Mouse mammary tumor virus
- Muscle, AChR, **42:239**  
 autoantibody effects on, **42:260–263**
- Muscle cells, cachectin and, **42:223**
- Mutagenesis  
 CD4 molecules and, **44:295**  
 genetically engineered antibody molecules and antigen-combining sites, **44:84**  
 biological properties, **44:83**  
 cloning, **44:75**  
 expression, **44:77, 79**  
 production, **44:68**  
 HIV infection and, **47:386**  
 spontaneous autoimmune thyroiditis and, **47:464**  
 Stat4, **60:20**
- Mutants  
 GPI anchor-deficient, **60:65–67**  
*PIG-A*, clonal dominance, **60:90–91**  
 V(D)J recombination/DSB repair and cell cycle arrest, **58:71–72**  
 leading to chromosome errors, **58:72–74**
- Mutations, *see also* Deletion; Hypermutation; Somatic mutation  
 adoptive T cell therapy of tumors and, **49:320, 327, 332, 334**  
 affected by stem cell factor or SCF receptor  
 human, **55:23–24**  
 mouse, **55:17–23**  
 rat, **55:23**  
 antigen-presenting cells and, **47:80, 103**  
 autoimmune thyroiditis and, **46:263, 286**  
 autoreactive T cells and, **45:417, 420, 424, 427**
- B cell formation and, **41:185**  
 B cell precursors, **41:195, 198**  
 genetically determined defects, **41:224, 226, 228, 231, 232**
- B cells, **59:300**  
 box1 motif, **60:12**  
*Btk* genes, **59:185–192, 195**  
 CD4 molecules and, **44:291, 296**  
 CD5 B cell and, **47:132, 146, 154, 155**  
 CD5<sup>+</sup> B cell lines, **55:330**  
 CD23 antigen and, **49:163–164**  
 cell cycle checkpoints, **58:29**  
 complement receptor 1 and, **46:193, 194, 196**  
 complement receptor 2 and, **46:211**
- CTL and, **41:138, 169, 170**  
 $\beta_2$ -microglobulin, **41:155**  
 amino acid, **41:158–163, 165**  
 carbohydrate moieties, **41:153, 154**  
 exon shuffling, **41:141, 142, 145, 148**  
 mAbs, **41:156, 157, 165, 166**

Mutations (*continued*)

## Fas gene

loss of function, **57**:139*lpr* mouse, **57**:132–133genetically engineered antibody molecules and, **44**:79, 84grooves of MHC molecules, **58**:161HIV genome, **65**:311–317

## HIV infection and

etiologically agent, **47**:381, 383immune response, **47**:408immunopathogenic mechanism, **47**:388, 400*hopscotch*, **60**:3hybrid resistance and, **41**:343, 368, 374, 397IgE biosynthesis and, **47**:16, 38Ig gene superfamily and, **44**:18, 27, 28Ig heavy-chain variable region genes and, **49**:6, 22, 32, 43, 53IL-1 and, **44**:158, 182IL-2R $\gamma$ , **59**:246–253immunosenescence and, **46**:222, 234I region, *I $\rho$*  genes and, **38**:84–91cytotoxic T cells, **38**:163, 164gene function, **38**:92, 93H-Y antigens, **38**:176immunodominance, **38**:180T cells, **38**:130, 131, 144tolerance, **38**:126kinase domain of XLA patients, **60**:40–41leukocyte integrins and, **46**:160, 171, 172, 174–176*lpr*, **60**:294maps of Ig-like loci and, **46**:3, 12murine lupus models and, **46**:99Ig germline, **46**:65, 66, 69, 76–78lupus strains, **46**:63, 64T cell antigen receptor, **46**:83, 94, 98natural and artificial, **58**:90–101NK cells and, **47**:225p53 protein-derived tumor antigens, **57**:295–296*scid*, **58**:45–51; **61**:299–301, 317SCID and, **49**:383sporozoite malaria vaccine and, **45**:298, 311, 312switch recombination, **61**:108*sxl1*, **58**:54–55synthetic T and B cell sites and, **45**:217, 228, 229, 261T cell activation and, **41**:5, 8, 12, 20

## T cell receptor and

alloreactivity, **45**:150–152, 154, 156, 157homogeneity, **45**:128, 129structure-function relationships, **45**:135, 139–142T cell repertoire, **45**:164, 165T cell subsets and, **41**:42, 46H-2 alloantigen recognition, **41**:81, 82, 85, 86, 88, 93and transgenes, **58**:147–149V-3, **58**:51–52virus-induced immunosuppression and, **45**:349–351W, allelism with *c-kit*, **55**:6–7Xid mutation, **59**:174–176, 317–318, 328*XR-1*, **58**:52–53*xrs*, **58**:53–54MW, *see* Maedi-visna virusMyasthenia gravis, *see also* Acetylcholine receptor; Experimental autoimmune myasthenia gravisanti-Id antibody as mediator of, **39**:279aPL antibodies and, **49**:209diagnosis of, **42**:254–256, 272discovery of autoimmune nature of, **42**:233–234etiology of, **42**:250–253experimental approaches to, **42**:233–235fatigue and, **42**:237future prospects for, **42**:272–274genetic factors in, **42**:259Ig heavy-chain variable region genes and, **49**:46, 50–51incidence of, **42**:255–256murine lupus models and, **46**:79pathology of, **42**:272autoantibody effects, **42**:260–263autoantibody production, **42**:256–260penicillamine and, **42**:235therapy for, **42**:235, 269–274transient neonatal, **42**:252, *see also*

Myasthenia gravis

## Myb

B cell genesis, **63**:220–221, 238–239interaction with NF-IL6, **65**:22

- myb*, **65:22**  
retrovirus-induced B cell neoplasia in bursa  
of fabricius, role in, **56:477–478**
- myc*, **63:161, 162**  
antisense, blocking of negative signaling,  
**54:413–415**  
retrovirus-induced B cell neoplasia in bursa  
of fabricius  
deregulation of expression, **56:480**  
role in, **56:472–478, 481**  
TGF- $\beta$  anf pRB, **54:411–413**
- Mycobacteria  
CD1-restricted antigens, **59:82–85, 89**  
reactivity, **58:321–322**
- Mycobacterium avium*, **50:162, 54:36**
- Mycobacterium bovis*, and diabetes, **51:294**
- Mycobacterium paratuberculosis*, IBD and,  
**42:319**
- Mycobacterium tuberculosis*, **54:36**  
infection, **59:398–402**  
pneumonia, **59:379, 383, 398–402**  
responses in MHC class I-deficient mouse,  
**55:412–413**
- Mycolic acid, **59:82–85, 90**
- Mycophenolic acid, genetically engineered  
antibody molecules and, **44:70–72**
- Mycoplasma, infections, X-linked  
agammaglobulinemia, **59:146**
- Mycoplasma arthritides*, mitogens, **54:113, 141**
- Myelin, Ig gene superfamily and, **44:37, 38**
- Myelin-associated glycoprotein, **46:171, 172**  
Ig gene superfamily and, **44:37, 38, 44, 45, 48**
- Myelin basic protein, **48:162, 163–166**  
 $\alpha$ -acetylated amino-terminal peptide,  
**48:167**  
autoimmune demyelinating disease and,  
**49:357–363**  
multiple sclerosis, **49:369–370, 372–374**  
TCR usage restriction, **49:363–366**  
autoimmune thyroiditis and, **46:289**  
dominant epitope, **48:164–165**  
multiple sclerosis and, **66:88, 90**  
murine lupus models and, **46:79**  
specific tolerance induction, **48:167**  
synthetic T and B cell sites and, **45:209, 235–237**
- Myeloablative therapy, multiple myeloma,  
**64:205**
- Myeloblasts, leukocyte integrins and, **46:166**
- Myelocytes, eosinophil, morphology,  
**60:155–158**
- Myeloid cells  
B cell formation and, **41:237**  
B cell precursors, **41:189–191**  
bone marrow cultures, **41:209, 210, 212, 213, 219, 220**  
cyclic neutropenia, **41:229, 230**  
inducible cell line, **41:220**  
lymphohemopoietic tissue organization,  
**41:87**  
NZB mice, **41:229**  
SCID mice, **41:225**  
soluble mediators, **41:232, 233**  
W/W anemic mice, **41:224**  
CD1 protein distribution, **59:56**  
chemotactic molecules attracting,  
**58:380–381**  
cytolysis and, **41:285**  
helper T cell cytokines and, **46:114, 115, 117**  
hybrid resistance and, **41:373, 376**  
leukocyte integrins and, **46:150, 163, 165**  
surface antigens of human leukocytes and,  
**49:92, 111–112, 116**
- Myeloid-specific enzymes, **60:25–26**
- Myeloid zinc finger, **63:1, 239**
- Myeloma  
CD23 antigen and, **49:168**  
genetically engineered antibody molecules  
and, **44:89**  
antigen-combining sites, **44:84, 85**  
chimeric antibodies, **44:79, 80, 82, 87**  
expression, **44:70, 71, 75–79**  
fusion proteins, **44:85**  
lymphoid mammalian cells, **44:69, 70**  
production, **44:68, 69**  
human, **48:16–18**  
IgM, **48:16–18**  
human B cell neoplasia and  
chromosomal translocations, **38:247, 248, 254, 257, 259**  
*c-myc* gene expression, **38:260**  
t(11;14) chromosomal translocation,  
**38:264, 272**
- hybridomas  
genetically engineered antibodies and,  
**38:305**

- Myeloma (*continued*)
- human-human, **38**:292, 293, 296, 297, 300
  - human-mouse heterohybridomas, **38**:300, 301
  - human-murine, **38**:290-292
  - mAbs and, **38**:306
  - IgE, ESR spectra, **48**:30-31
  - Ig heavy-chain variable region genes and, **49**:1-2
    - D segments, **49**:33
    - V<sub>H</sub> families, **49**:6-7
    - V<sub>H</sub> gene expression, **49**:39-40, 46, 48-49
  - IgM, ESR spectra, **48**:30-31
  - surface antigens of human leukocytes and, **49**:98
- Myeloma cells
- adhesion molecules in, **64**:246-249
  - autocrine and/or paracrine growth, **64**:257
  - B cell formation and, **41**:220
  - FAS/APO-1 in, **64**:259-260
  - hybrid resistance and, **41**:378
  - identification of, **64**:242-246
  - IL-6 production, **64**:252-253
  - precursors, **64**:249-250
  - tumors in idiotype immune mice and, **40**:136-137
- Myeloma protein, **48**:2
- Ir* genes and, **38**:45, 68
- Myelopathy, HTLV-I associated, **50**:182
- Myelopoiesis, **62**:92-93
- B cell formation and, **41**:186, 187, 213, 219
  - pituitary hormones, **63**:404-405, 410-411
- Myelosuppression
- colony-stimulating factor, **48**:93
  - IL-6 treatment, **54**:48
- Myocardial infarction, aPL antibodies and, **49**:219-220
- Myoglobin
- antigenic structure, **43**:118
  - epitopes, **43**:51-52, 55
  - humoral immune response and, **45**:19
  - synthetic T and B cell sites and
    - globular protein antigens, **45**:204, 211, 212, 215
    - peptides, **45**:203, 240, 250
  - T cell receptor and, **45**:123, 131, 134
- Myohemerythrin
- antibody-antigen interaction, **43**:42
  - antigenic response, **43**:29-31, 47
  - antigenic sites, **43**:80
  - critical residues, stereochemical relationships, **43**:43
  - crystallographic structure, **43**:21
  - electrostatic potential, **43**:35
  - epitopes, **43**:51, 53
  - features, **43**:28
  - hexapeptide homologs, **43**:32
  - hydrophilicity, **43**:35
  - immune response, **43**:28-29, 44-46, 75
  - mobility, **43**:33-35
  - molecular surface chemistry and
    - immunological reactivity, **43**:33-34
  - monoclonal anti-MHr antibody affinity, **43**:61-62
  - packing density, **43**:33-35
  - peptides, monoclonal anti-MHr antibody affinity, **43**:61-62
  - protein fold, **43**:28
  - reactive sites, **43**:29
  - secondary structure, **43**:38
  - sequential epitopes, **43**:36, 38-40
  - shape accessibility and exposed surface area, **43**:35-36
  - side-chain contributions, **43**:36-38
  - site 4-9, **43**:37, 40, 43, 45
  - site 90-95, **43**:45-46
- Myosin
- cytolysis and, **41**:275
  - hybrid resistance and, **41**:378
- Myositis, antinuclear antibodies and, **44**:118, 119
- MZ2-E, **62**:228, 231-232

## N

- [(NAAG)<sub>6</sub>]<sub>s</sub> MAP, immunized mouse, for *P. malariae*, **60**:123
- Na<sup>+</sup>/H<sup>+</sup> antiporter, intracellular pII, **48**:288
- L-NAME, *see* N<sup>C</sup>-Nitro-L-arginine methyl ester
- NAP-2, conversion of CTAP III to, **50**:242-243
- Naproxen, **62**:184, 186
- Nasal polyps, endothelium, eosinophil adhesion to, **60**:167-168
- Natural cytotoxic cells, **47**:213, 286
  - hybrid resistance and, **41**:373, 374

- Natural killer cell colony inhibiting activity, cachectin and, **42:220**
- Natural killer cell cytotoxic factor, **47:241**, 250, 251, 253, 262, 302
- Natural killer cell receptors  
activation, mediation, **55:367–369**  
hybrid resistance, **55:367**  
for MHC class I molecules, **55:356**, 358–360, 372  
murine, **55:364**, 366–367  
p58 dimers, **55:358**, 361–362  
murine, **55:364**, 366–367
- Natural killer cells, **47:187–189**  
adaptive immunity  
  B cell response, **47:291–294**  
  T cell response, **47:294**, 295  
adoptive T cell therapy of tumors and, **49:302**, 315–319, 333  
alterations, **47:300–303**  
anti-CD2 mAb, **48:236**  
antimicrobial activity  
  antiviral activity, **47:282–288**  
  infection, **47:288–291**  
antitumor activity  
  cancer patients, **47:297–300**  
  experimental animals, **47:295**, 296  
apoptosis, **58:227**  
autoimmune thyroiditis and, **46:279**, 288, 289, 295  
B cell formation and, **41:192**, 199, 225, 231, 236, 237  
CD23 antigen and, **49:155**  
cell-mediated cytotoxicity, **47:189–196**  
clonal human cell lines of, **42:184–186**  
CNS, **47:266–269**  
congenital defects, **47:224–226**  
cytotoxicity, **41:269–273**; **60:289–291**  
  cytolysis, **41:275–277**, 280–286  
  granule proteins, **41:286**, 287, 289, 291, 297, 298  
  membrane attack complex of complement and, **41:309**  
defined allospecificities, genetic analysis, **55:348–349**  
differentiation, **47:229–234**  
effector mechanisms, **47:234**, 235  
  cytotoxicity, **47:248–254**  
  lymphocyte production, **47:262–266**  
  receptors, **47:242–248**  
  regulation, **47:254–262**  
  target cells, **47:235–242**  
  effects of MHC class I-deficiency, **55:392–393**  
  functions of, **42:181–182**  
  genetic control, **47:222–224**  
  granules in, **42:183**  
  helper T cell cytokines and, **46:114**, 116  
  hematopoiesis, **47:272**, 273  
  graft-versus-host reaction, **47:280–282**  
  inhibition, **47:276**, 277  
  regulation, **47:273–276**  
  soluble factors, **47:277–280**  
heterogeneity of, **42:182–183**, 186, 188  
HIV infection and, **47:411**  
human, **55:341–342**, 370–373  
  allospecificity, genetic analysis of, **55:348–349**  
  CD3 gene expression during maturation, **55:346**  
  class I molecules, **55:349–353**  
  cytolysis, p58 in, **55:354–357**  
  MHC recognition by, **55:363–365**  
  ontogeny of, **55:342–346**  
  p58 modulation, **55:362–363**  
  repertoire, **55:347–348**  
  specificity, **55:347**  
human clonal cell lines, **42:184–186**  
humoral immune response and, **45:68**, 70, 83, 84  
hybrid resistance and, **41:334**  
antibodies, **41:376–380**  
antigen expression, **41:402–410**  
bone marrow cells, **41:336**, 338, 340, 351  
effector mechanisms, **41:372–376**  
leukemia/lymphoma cells, **41:361**, 363–369  
lymphoid cells, **41:354**, 357  
macrophages, **41:371**, 372  
marrow engraftment, **41:386–388**  
marrow microenvironment, **41:390–393**  
syngeneic stem cell functions, **41:388–390**  
T cells, **41:382**  
IBD and, **42:294–296**  
identification, **47:196–199**  
IFN- $\gamma$  production, **62:63–66**, 105, 106–107  
IL-1 and, **44:164**, 166, 178  
IL-10 biological effects, **56:10**

- Natural killer cells (*continued*)
- impaired activity in MHC class I-deficient mouse, **55**:404–405
  - leukocyte integrins and, **46**:161, 163, 169
  - lineage derivation of, **42**:186–188
  - lymphocyte homing and, **44**:349, 350
  - malignant expansion, **47**:226–229
  - morphology, **47**:214–218
  - murine splenic, perforin expression, **51**:220, 221
  - pituitary hormones, **63**:416–417
  - prolactin receptor, **48**:180
  - regulators of complement activation and, **45**:395, 396
  - reproduction, **47**:269–272
  - SCID and, **49**:382, 396–397
  - self-MHC class I recognition in tumor cells, **57**:315–317
  - specificity, **42**:181
  - specificity of, **42**:181
  - stem cell factor receptor
    - lymphohematopoietic effect, **55**:48–51
  - stimulation by IL-2, **58**:426–429
  - sulfasalazine and, **42**:317–318
  - surface antigens, **42**:187, 204–206
    - CD2, **42**:187, 194–198, 205
    - CD3, **42**:187, 198–201, 205–206
    - CD11a, **42**:187, 192–194
    - CD16, **42**:187, 190–191
    - HNK-1, **42**:187, 191–192
    - NKH1 antigen, **42**:187, 188–190
    - phenotype, **42**:185–186, 188
    - TCR<sub>TAR</sub>, **42**:198–204, 205
    - TNK<sub>TAR</sub>, **42**:201–202
  - surface antigens of human leukocytes and, **49**:90, 94, 114–115
    - adhesion molecules, **49**:83, 88
    - antigen-specific receptors, **49**:79
    - MHC glycoproteins, **49**:81–82
  - surface phenotype, **47**:199–201, 207, 208
    - experimental animals, **47**:210–214
    - FcR antigen, **47**:201–205
    - HNK-I, **47**:206, 207
    - NKH-I antigen, **47**:205, 206
    - T cell-associated antigens, **47**:208–210
  - T cell activation and, **41**:9, 10, 24
  - T cell subsets and, **41**:49
  - tissue distribution, **47**:219–221
  - virus-induced immunosuppression and, **45**:341, 357, 358, 360, 363
- Natural killer cell stimulating factor, **62**:105
- Natural killer cytotoxic factor, **41**:285, 296
- Natural resistance, hybrid resistance and, **41**:334
- NBD, *see* Nucleotide-binding domain
- NC41, **43**:21, 123–125
- N-CAM, *see* Neural cell adhesion molecule
- NDP52, **63**:202
- Necrosis, vs apoptosis, **58**:240
- nef* gene, HIV-1 disease, **63**:85–86, 94, 105–106
- Negative regulators, growth and differentiations of human basophils and mast cells, **52**:355–357
  - interferons, **52**:355–356
  - transforming growth factors, **52**:356–357
- Negative regulatory element, HIV infection and, **47**:381, 382
- Negative selection
  - inhibition by FK-506, **58**:261–262
  - T cells, **51**:165–175; **58**:166–168
    - intrathymic clonal deletion, **51**:165–173
      - cell biology of, **51**:165–170
      - search for mechanism, **51**:170–173
      - other mechanisms, **51**:173–175
    - vs positive selection, **51**:180–183
  - thymocytes, **58**:165–174, 171–174; **59**:105–107
  - transgenic T cells, **58**:316
- Negative signaling
  - blocking with antisense myc, **54**:413–414
  - CD4 and, **53**:61
  - CD8 and, **53**:61
- Neisseria meningitidis*, MAP vaccines, **60**:134–135
- neo*, **62**:36–38
- Neolactosylceramides, sulfoglucuronyl-containing, **58**:358
- Neonatal development
  - anti-Id antibodies and, **42**:52–54
  - B cells and, **42**:76
  - clonotype repertoire acquisition and, **42**:26–30
  - MC and, **42**:263
  - preferential utilization of gene segments in mice and, **42**:132–133
- Neoplasia
  - B cell, retrovirus-induced, in avian bursa of fabricius, **56**:467–481
  - CD5<sup>+</sup> B cell, V gene usage, **55**:323

- etiology, stem cell factor role, **55:71–78**  
 hybrid resistance and, **41:387**  
 immune regulation, **48:212**  
 and reactive hypereosinophilia, **60:225**  
 spontaneous, immune regulation, **48:212**  
 Neoplastic cells, CD1 proteins, **59:69**  
 Neostigmine, for MG, **42:269–270**, **271**  
 Nephritic factors, **61:245–247**  
 Nephritis, *see also* Interstitial nephritis  
 murine lupus models and, **46:64**  
 regulators of complement activation and,  
**45:389**  
 virus-induced immunosuppression and,  
**45:338**  
 Nerve growth factor, **48:173–174**; **61:5**  
 Nerve growth factor receptor, family  
 members, **52:156**  
 Nervous system  
 allergic reactions, **61:364–368**, **375**  
 autoimmune reaction, T cell component,  
**48:163–167**  
 IL-1ra in, **54:211–213**  
 stem cell factor receptor in, **55:69–71**  
 Neural autoantigen, dominant epitope,  
**48:164–165**  
 Neural cell adhesion molecule, **46:171**  
 CD4 molecules and, **44:288**  
 Ig gene superfamily and, **44:36–38**,  
**43–45**, **48**  
 lymphocyte homing and, **44:365**  
 multiple myeloma, **64:247**  
 surface antigens of human leukocytes and,  
**49:88**, **114**  
 Neural cells  
 Ig gene superfamily and, **44:30**, **35–38**, **49**  
 immunological mediation, **48:173–174**  
 Neuraminidase  
 B cell antigen-presenting capacity and,  
**39:74**  
 humoral immune response and, **45:42**, **44**  
 hybrid resistance and, **41:400**  
 la structure and, **39:74**  
 T cell subsets and, **41:64**, **91**  
 Neuroblastoma, structure and functional  
 properties of associated gangliosides,  
**40:355–357**  
 Neuroendocrine mediators, *see also*  
 Neuromediators  
 acute inflammation, **48:175–176**  
 chronic inflammation, **48:177–179**  
 immediate hypersensitivity, **48:175–176**  
 immunological effects, **39:301**; **48:**  
**175–179**  
 immunological generation, **48:169–173**  
 lymphocyte function, **48:177–179**  
 Neuroendocrine peptides, *in vitro* IgE  
 synthesis, **61:371–374**  
 Neuroendocrine system, **54:30–31**  
 Neuroimmunology, **48:161–184**  
 antigens and, **39:299–300**  
 interleukins and, **39:301**  
 neuroendocrine mediators and, **39:300–301**  
 neuropeptides and, *see* Neuropeptides  
 Neurological abnormalities, HIV infection  
 and, **47:377**, **413**  
 Neuromediators, **48:162**, *see also*  
 Neuroendocrine mediators  
 cellular source, **48:170–172**  
 identification method, **48:170–172**  
 immunological sources, **48:170–172**  
 lymphocyte receptors, **48:167**, **179–184**  
 structure, **48:170–172**  
 Neuromuscular transmission, MG and,  
**42:233–234**, **236–237**, **263**, *see also*  
 Acetylcholine receptor  
 Neuronal cells  
 IL-6 effect, **54:30–31**  
 TE671 cell line, human, **42:239**  
 Neuropeptidase  
 cellular localization, **48:167**  
 specificity, **48:167**  
 Neuropeptide receptors  
 immune cell, **39:311–313**  
 lymphocyte, **48:180**  
 Neuropeptides  
 effects on nonneural tissues, **39:301–304**  
 future research, **39:318–319**  
 human lymphocyte receptor, **48:180**  
 IL-1, **48:178**  
 immediate hypersensitivity and,  
**39:304–307**  
 immunopathogenic role, **39:317–318**  
 inflammation and, **39:307**  
 leukocyte chemotaxis and, **39:307–308**  
 leukocyte-derived, **39:315–317**  
 lymphocyte, **48:177**  
 differentiation, **48:178**  
 immunological functions, **48:178**  
 tissue cycles, **48:178**  
 tissue homing, **48:178**



- Neuropeptides (*continued*)  
 lymphocyte functions and, **39**:309–311  
 macrophage, **48**:177  
 mediation by, immunological cell, **48**:176, 177  
 similarity to thymic factors, **39**:314–315  
 structure, **48**:167  
 tissue repair and, **39**:308–309
- Neuropsychiatric manifestations, HIV infection, **47**:395, 403–405
- Neurotoxin, eosinophil-derived, *see* Eosinophil-derived neurotoxin
- Neurotransmitter receptors, surface antigens of human leukocytes and, **49**:101, 111
- Neurotrophic virus, **48**:165
- Neurotrophin-3, LNGFR recruitment of, **61**:5
- Neurotrophin-4, LNGFR recruitment of, **61**:5
- Neutralization  
 aPL antibodies and, **49**:244  
 apoptosis-inducing stimuli, **58**:242–243  
 virus-induced immunosuppression and, **45**:365
- Neutralizing antibodies  
 colony-stimulating factor, **48**:95–96  
 HIV infection and, **47**:407, 408, 410, 413
- Neutropenia  
 agammaglobulinemia, **59**:146  
 cyclic, B cell formation and, **41**:222, 228–230, 234, 237  
 hybrid resistance and, **41**:376
- Neutrophil-activating factor, **46**:115
- Neutrophil-activating peptide-1, **66**:135
- Neutrophil elastase, **62**:266
- Neutrophil receptors  
 characteristics, **39**:96–98  
 ligand interaction  
 dynamics at 4°C, **39**:99–101  
 dynamics at 15–25°C, **39**:101–102  
 free radical production, **39**:105  
 in permeabilized cells, **39**:109–110, 115  
 pulse response analysis at 37° C  
 antibody to ligand and, **39**:103–104  
 occupancy response, **39**:102–104, 106  
 static model of, **39**:98–99  
 transiently active  
 Ca<sup>2+</sup> release and, **39**:126, 132–135  
 cell signal generation and, **39**:110–111
- G protein interaction, **39**:113–116  
 amplification during transduction and, **39**:116–117  
 cAMP elevation and, **39**:113–116, 118  
 model of, **39**:115–116  
 termination of, **39**:117–118  
 potential functions, **39**:110–112
- Neutrophils, **51**:336  
 adoptive T cell therapy of tumors and, **49**:328  
 arachidonic acid metabolism, human dietary EPA and, **39**:166–167  
 esterified and nonesterified EPA and, **39**:167–168  
 B cell formation and, **41**:229, 230  
 cachectin and, **42**:223  
 chemotaxis, SP and, **39**:308  
 complement receptor 1 and, **46**:190–193, 198–200  
 CXC proteins as activators, **55**:115–116  
 cytotoxicity and, **41**:269  
 decay-accelerating factor-deficient, **60**:79  
 Fc receptors on, **40**:68  
 FcRIII expression, **60**:179–181  
 function, IBD and, **42**:307–308  
 IBD and, **42**:285, 286, 287, 307, 308  
 complement pathway products, **42**:309  
 LTB<sub>4</sub>, **42**:314–315  
 IL-1ra production, **54**:189–190  
 IL-8 as agonist, **55**:112–113  
 adhesion, **55**:114  
 exocytosis, **55**:113  
 lipid formation, **55**:114  
 receptor up-regulation, **55**:113–114  
 respiratory burst, **55**:114–115  
 shape change, **55**:113  
 immune reconstitution and, **40**:416–417  
 interactions with endothelium, **60**:331–332  
 interaction with IgA, **40**:169  
 leukocyte integrins and, **46**:151, 177  
 inflammation, **46**:160, 161, 163–169  
 ligand molecules, **46**:173  
 structure, **46**:154  
 LTA hydrolase-containing, **60**:189  
 neuropeptide production, **39**:317  
 NK cells and, **47**:189, 190, 194, 201–204, 260  
 NO generation, **60**:352  
 PNH, PIG-A abnormalities, **60**:81

- polymorphonuclear  
 interactions with endothelium,  
**60:331–332**  
 as source of iNOS, **60:329**  
 recruitment by chemokines, **60:339**  
 regulators of complement activation and,  
**45:389, 390, 403, 410**  
 rolling, selectin-mediated, **60:165–167**  
 senescent, **58:270**  
 as source of chemokines, **55:106–107**  
 as source of iNOS, **60:329**  
 surface antigens of human leukocytes and,  
**49:86, 88, 93, 112**  
 TNF and IL-1 and, **66:111**  
 upregulation of CR3 expression, **60:182**
- Neutrophils, activation  
 amplification  
 Ca<sup>2+</sup> release and, **39:132–135**  
 ligand binding rate and, **39:133–134**  
 oxidase activation, **39:132**  
 phospholipase C lifetime and, **39:124, 132–134**  
 sequence of events, **39:131**  
 termination steps, **39:133–134**  
 transient responses, **39:132–133**  
 branchpoints, of, **39:134–135**  
 Ca<sup>2+</sup> release, **39:124–127**  
 future research, **39:136**
- G proteins, linkage to  
 phosphatidylinositol turnover, **39:119**  
 phosphoinositide metabolism,  
**39:119–121**  
 phospholipase C, **39:119–120, 122**  
 GTP and, **39:99–100, 116, 120–121, 132**  
 leukotriene low effects, **39:135–136**  
 phospholipase C role, **39:119–120, 122, 124–125, 132–134**  
 protein kinase C role, **39:127–131**  
 transduction sequence, **39:111, 120–121**
- Neutrotrophic coronavirus, **48:141**  
 Newcastle disease virus, **41:166, 167, 389**  
 lymphocyte homing and, **44:366**  
 NF-AT, **63:166–167**  
 role in CD40L gene expression, **60:47–48**
- NFAT family, **65:120**  
 NF-IL6, **58:12–14, 65:3–8**  
 activation of, **65:2–3**  
 CYP2DG gene and, **65:23**  
 gene, **65:2**  
 gene regulation, **65:8–9**  
 AP-1, interaction with, **65:18–19**  
 CREB, interaction with, **65:19**  
 cytokine induction, **65:29–30**  
 glucocorticoid receptors, interaction with,  
**65:21–22**  
 Myb, interaction with, **65:22**  
 NF- $\kappa$ B, interaction with, **65:16–18**  
 PU.1, interaction with, **65:21**  
 STAT family, interaction with, **65:19–21**  
 knockout mice studies, **65:29–30**  
 structure and function of, **65:1–2**  
 transcriptional regulation, **65:1–3, 8–11, 16–18**  
 in viral infection, **65:9–11**
- NF-IL6 $\beta$ , **65:3–6**  
 NF-IL-6/C/EB $\beta$  response elements, **62:194**  
 NF- $\kappa$ B, **43:250–251; 48:298; 52:271–272; 63:157–160; 65:1, 111**  
 activation, **58:4–6; 65:16–18, 130**  
 inappropriate, **58:14–18**  
 by lipopolysaccharide, **60:335**  
 role of Fas, **60:300**
- antiinflammatory/immunosuppressive  
 molecule target, **65:128–132**  
 antioxidants, **65:122–123**  
 anti-TNF- $\alpha$  antibodies, **65:123–124**  
 cAMP, **65:124–125**  
 cyclosporin A and FK506, **65:120**  
 deoxyspergualin, **65:125–126**  
 gliotoxin, **65:126**  
 glucocorticoids, **65:118–120**  
 gold compounds, **65:123–124**  
 rapamycin, **65:121**  
 rheumatoid arthritis drugs, **65:123–124**  
 ROI-generating molecules, **65:122–123**  
 salicylates, **65:121–122**  
 spergualin, **65:125–126**  
 steroids, **65:118–120**
- description, **58:2–4**  
 disease and, autoimmune and  
 inflammatory, **65:117–118**  
 family, transcriptional regulation, **65:11–12, 15–22, 30–32**  
 gene regulation, **65:1, 26, 32, 111**  
 cytokine induction, **65:30–32**  
 interaction with NF-IL6, **65:16–18**  
 glucorticoid-mediated repression, **65:23**  
 induction, **65:111**  
 endogenous, **65:114**  
 exogenous, **65:112–113**

- NF- $\kappa$ B (*continued*)  
 as inflammatory mediator, **58**:14  
 inflammatory process, **65**:111–118  
 inhibition, **58**:19–20  
 in innate immunity in vertebrates, **58**:1–27  
 knockout mouse studies, **65**:30–32  
 physiologic inducers, **58**:6–9  
 structure and function of, **65**:11–12  
 target genes for, **65**:115–116  
 viruses and, **65**:112, 127–128
- NF- $\kappa$ B box, TAP genes, **65**:60
- NF- $\kappa$ B/p50, binding site, switch recombination, **61**:117
- NF-M, **65**:2–3, 7
- NF-S $\mu$ , binding site, **61**:119
- Nicotinic AChR, *see* Acetylcholine receptor
- Nijmegen breakage syndrome, chromosome 7 and 14 translocations, **58**:69
- Nippostrongylus brasiliensis*, **54**:94–95  
 helper T cell cytokines arc, **46**:137  
 infections, IL-4 production by Fc $\epsilon$ R<sup>+</sup> cells in, **53**:15–17
- Nitrate, urine  
 L-NMMA effect, **60**:343  
 production in septic trauma patients, **60**:351
- Nitric oxide  
 in biological systems, **62**:72–76, 99, 105, 264–265  
 in immunoregulation, **60**:348–349  
 in inflammation  
 effector molecule, **60**:332–346  
 protective molecule, **60**:346–348  
 in leukocyte adhesion and migration, **60**:330–332  
 in pain mediation, **60**:349–350  
 in vascular leak syndromes, **60**:327–330  
 in wound healing, **60**:350–351
- Nitric-oxide synthase, **62**:72–73  
 constitutive, **62**:72–73  
 expression, role of IRF-1, **60**:17  
 inducible  
 in human macrophages, **60**:353–354  
 regulation, **60**:333–341  
 isoforms  
 in edema formation, **60**:328–329  
 expression in human tissues, **60**:351–354  
 in inflammation, **60**:323–326
- Nitrite  
 inhibition by L-NMMA, **60**:353  
 production by RAW 264.7 cells, **60**:349–350
- N<sup>G</sup>-Nitro-L-arginine methyl ester  
 in conjunction with SEB, **60**:348–349  
 effect on aortic ring reactivity, **60**:336–337  
 infusion, and lymph flux increase, **60**:329–330  
 inhibition of F-BSA extravasation, **60**:328
- Nitrogen, lymphocyte homing and, **44**:354
- NK cells, *see* Natural killer cells
- NK-C1A, cachectin and, **42**:220
- NKH-1, **42**:188–190  
 NK cells and, **47**:188, 293, 294, 302  
 CNS, **47**:266, 267  
 differentiation, **47**:233, 234  
 effector mechanisms, **47**:261  
 reproduction, **47**:271  
 surface phenotype, **47**:205, 206  
 tissue distribution, **47**:219, 220
- NLDC-145, **59**:379
- L-NMMA, *see* N<sup>G</sup>-Monomethyl-L-arginine
- N-myc*, **64**:232–233
- NOD mouse, *see* Nonobese diabetic mouse
- Nonclustered antigens, B cell, **52**:164–174  
 adhesion molecules, **52**:166–168  
 activation of, **52**:168  
 Ig superfamily, **52**:167  
 integrin family, **52**:166  
 selection family, **52**:167–168  
 B7/BB1, **52**:168–169  
 cytokine receptors on B cells, **52**:169–173  
 IL-1, **52**:169–171  
 IL-2, **52**:171–172  
 IL-4, **52**:172  
 IL-6, **52**:172  
 other cytokines, **52**:173  
 TNF- $\alpha$ , **52**:172–173  
 transforming growth factor  $\beta$ , **52**:173
- HLA class II molecules, **52**:164–166  
 other antigens of B cells, **52**:173–174  
 Bgp 95, **52**:173  
 CK226 antigen, **52**:173  
 IgM-binding protein (Fc $\mu$  receptor), **52**:173
- Noncovalent bimolecular IL-2 receptor structure, **42**:176
- Nongermline elements, as V(D)J recombination products, **56**:54–56
- Nonlymphoid cells, interaction with IgA, **40**:168–184

- Nonobese diabetic mouse, **51:286**, *see also*  
 Autoimmune diabetes, murine model  
 IDDM-prone, **48:139**  
 NOD.SCID, **63:80**  
 strain development, **51:287–289**
- Nonobese nondiabetic mouse, **51:288**
- Non-self antigens, **64:1, 2**  
 antibodies  
 allergens, **57:228**  
 bacteria, **57:228**  
 Epstein–Barr-virus-transformed cell  
 lines, **57:229–230**  
 HuSCID mouse, **57:230–231**  
 hybridomas, **57:229–230**  
 overview, **57:208–209**  
 primates, **57:231–232**  
 staphylococcal protein A, **57:229**  
 study of responses, **57:232–242**  
 viruses, **57:209–228**
- Nonspecific immune system, pituitary  
 hormones, **63:407–408**
- Nonspecific inflammation, IFN- $\gamma$  and,  
**62:103–104**
- Nonsteroidal antiinflammatory drugs  
 IBD and, **42:313**  
 PGHS and, **62:167, 184–187**  
 class I NSAIDs, **62:184, 185–186,**  
**201**  
 class II NSAIDs, **62:184, 185, 186**  
 class III NSAIDs, **62:185**
- Normal rabbit gamma globulin, presentation  
 by B cells, **39:55–56**
- Northern blot analysis  
 Ig gene rearrangements, **40:269**  
 T cell receptor genes, **38:11**
- NOS, *see* Nitric-oxide synthase
- NPb, secondary B cell lineage and, **42:70**
- N region diversity, T cell receptor,  
**58:301–303**
- NRGG, *see* Normal rabbit gamma globulin
- NRI, concentration, **43:265**
- NS398, **62:186**
- NSAIDs, *see* Nonsteroidal antiinflammatory  
 drugs
- Nuclear factors, protein-binding sites, **43:255**
- Nuclear matrix, **63:201**
- Nuclease  
 B cell-associated, as truncation factor in  
 V(D)J joining, **56:80**  
 sequence, **43:209**
- Nucleic acids  
 antinuclear antibodies and, **44:119, 132,**  
**134**  
 murine lupus models and, **46:76**
- Nucleolus, antinuclear antibodies and,  
**44:122–125, 133**
- Nucleoprotein  
 synthetic T and B cell sites and, **45:261,**  
**263**  
 antigens, **45:234**  
 bacterial antigens, **45:230**  
 viral antigens, **45:217, 218**
- T cell receptor and  
 antigen processing, **45:119, 125**  
 homogeneity, **45:128**  
 peptides, **45:137**  
 structure-function relationships,  
**45:139**
- Nucleosomes, antinuclear antibodies and,  
**44:98–100**
- Nucleotide binding, TAP, **65:86**
- Nucleotide-binding domain, **65:56**
- Nucleotides  
 antinuclear antibodies and, **44:98, 119, 130,**  
**135**  
 autoimmune demyelinating disease and,  
**49:386**  
 B cell formation and, **41:191, 194, 197,**  
**203**  
 CD4 molecules and, **44:285, 288**  
 CD5 B cell and, **47:144**  
 CD8 molecules and, **44:274, 276**  
 complement receptor 2 and, **46:201**  
 conjugate, **58:322**  
 CTL and, **41:159**  
 in gene rearrangements, **58:32**  
 genetically engineered antibody molecules  
 and, **44:70, 73, 79**  
 HIV infection and, **47:383, 384**  
 IgE biosynthesis and, **47:16, 20**  
 Ig gene superfamily and, **44:16–18, 48**  
 Ig heavy-chain variable region genes and  
 D segments, **49:28–29, 31, 33**  
 J<sub>H</sub> segments, **49:34**  
 polymorphism of V<sub>H</sub> gene segments,  
**49:22–27**  
 regulation, **49:57**  
 V<sub>H</sub> families, **49:7–9, 16, 19**  
 V<sub>H</sub> gene expression, **49:39, 43, 48–49, 51**  
 immunosenescence and, **46:223, 226, 227**

Nucleotides (*continued*)

- maps of Ig-like loci and MHC, **46:31, 32**
- structure, **46:13, 15, 17, 20, 21, 25, 27, 28**
- T cell receptor, **46:36, 39**
- mismatched, **58:44**
- murine lupus models and, **46:67**
- NK cells and, **47:202, 252**
- nontemplated, **58:308**
- P (palindromic), **58:36–38**
- as V(D)J recombination product, **56:56–58**
- SCID and, **49:383**
- T cell activation and, **41:18, 26**
- T cell receptor, **45:109**
- $\gamma$  V-J junction sequences, **43:145**
- T cell subsets and, **41:42, 43, 46, 47**
- two, overlap internal to coding end, **58:42**
- Nucleotide sequence
  - A/J *FLI6.1 D<sub>H</sub>* gene segment, **42:105–106**
  - ArS A response and, **42:101, 143**
  - Ig heavy-chain variable region genes
    - D<sub>H</sub> genes, **49:28–33, 30**
    - J<sub>H</sub> gene segments, **49:35**
    - V<sub>H</sub>J germline gene sequences, **49:10–11**
    - V<sub>H</sub>III germline gene sequences, **49:12–13**
    - V<sub>H</sub>IV gene segments, **49:16–17**
    - V<sub>H</sub>V gene segments, **49:18**
    - V<sub>H</sub>VI gene segments, **49:20**
  - J558 V<sub>H</sub> gene segments, **42:112–113, 115**
  - surface antigens of human leukocytes and, **49:77, 90**
  - V<sub>H</sub> gene segments, **42:102–105**
- Nucleus, signal transduction, **48:311**
- nur-77*, encoding orphan steroid receptor, **58:229**
- Nur-77*, nuclear hormone receptor, **58:137**
- Nylon fibers, IBD and, **42:309**

## O

- Obese strain chicken, autoimmune cellular immune responses, **46:298**
- experimental models, **46:273–276, 279**
- genetic control, **46:282–284**
- humoral responses, **46:301, 303**
- prevention, **46:310**
- thyroiditis and antigens, **46:269, 270**
- Obese strain chicken, spontaneous autoimmune thyroiditis, *see* Spontaneous autoimmune thyroiditis
- oct-1, **63:243**
- oct-2, B cell genesis, **63:220–221, 243–244**
- Octameric sequence, V<sub>H</sub> gene, **42:113**
- Oil granulomas, **64:224–225**
- Oligomeric proteins, buried surfaces, **43:101**
- Oligomerization, cytotoxicity and, **41:306, 315, 317, 318**
- Oligonucleotide capture, in V(D)J joining of antigen receptor genes, **56:62–63**
- Oligonucleotides
  - antinuclear antibodies and, **44:108, 119, 130**
  - antisense, **58:249–250**
  - CD23 antigen and, **49:162**
  - Ig heavy-chain variable region genes and, **49:23, 27**
  - in ligation reactions, **58:33**
  - synthesis, complement components and
    - C1q B chain, **38:232**
    - C4 genes, **38:228**
    - Factor B and C2 cDNA, **38:209**
- Oligosaccharide rotation, **48:26–27**
- Oligosaccharides
  - complement receptor 1 and, **46:187, 192**
  - complement receptor 2 and, **46:202, 204**
  - CTL and, **41:135, 152, 153**
  - IgE biosynthesis and, **47:16, 18, 19, 23**
  - leukocyte integrins and, **46:154**
- Omenn's syndrome, with V(D)J recombination defects, **58:63–64**
- Onchocerca volvulus*, major basic protein in patient tissues and, **39:213**
- Onchocerciasis, human, eosinophilic infiltrate, **60:213–214**
- Oncogenes
  - adjacent, effects of chromosomal abnormalities, **50:124–132**
  - c-myc* in Burkitt's lymphoma translocations, **50:124–128**
  - gene fusion resulting from chromosome translocation, **50:128–129**
  - helix-loop-helix oncogenes in chromosome translocations, **50:129–130**
  - oncogene location after translocation, **50:131–132**

- transcriptional disruption of LIM domain  
 oncogenes by translocation,  
**50:130–131**
- cellular  
*c-myb*, rearrangement in myeloid  
 leukemia, **39:36–37**  
*c-myc*, expression in IL-3-dependent  
 cells, **39:40, 42**
- complement receptor 1 and, **46:187**  
 complement receptor 2 and, **46:210**  
 derived tumor antigens, **57:296–299**  
 Ig gene superfamily and, **44:39**  
 LIM domain, by translocation,  
 transcriptional disruption of,  
**50:130–131**
- location after translocation, **50:131–132**  
 regulators of complement activation and,  
**45:395**
- synthetic T and B cell sites and, **45:248,**  
**249**
- translocation, differentiation-related,  
**50:139**
- viral  
*v-abl*, cell response to  
 IL-2 and, **39:41**  
 IL-3 and, **39:40–41**  
*v-myc*, cell response to IL-3 and,  
**39:40**
- virus-induced immunosuppression and,  
**45:348**
- Oncogenic proteins, **62:237–238; 64:65**  
 recognition by T cells, **58:420–421**
- Oncostatin M, **54:15–16; 61:151; 64:256**  
 amino acid sequence, **53:40**  
 binding to high-affinity LIF receptor,  
**53:41–43**  
 and CNTF, **53:44–47**  
 and LIF, **53:44–47**  
 pleiotropic nature of, **53:46**
- One-dimensional isoelectrofocusing, HLA  
 class II, **48:114–116**
- Ophthalmia, sympathetic, **48:216, 217**
- Ophthalmopathy, antibodies to self-antigens  
 from human donors, **57:245**
- Opioid receptor  
 human granulocyte, **48:180**  
 human lymphocyte, **48:180**  
 human monocyte, **48:180**  
 monocyte, **48:180**
- Opioids, NK cells and, **47:268, 269**
- Opsonic effects, fibronectin  
 fragment, **38:389–391, 393**  
 intact, **38:388, 389, 393**
- Opsonins, phagocytosis and, **38:362, 392**
- Oral tolerance, IgA and, **40:223–226**
- Organ transplantation, graft-versus-host  
 disease, **59:420–426**
- Ornithine decarboxylase  
 half-life, **48:289**  
 polyamine metabolism, **48:289–290**
- Orphans, **62:10–12, 20, 22–24**
- Orthogonal field electrophoresis, **38:205**
- OSM, *see* Oncostatin M
- Osteoarthritis, **54:187**  
 cartilage destruction in, **64:297**
- Osteoblasts, LIF effects, **53:36–37**
- Osteoclasts, IL-1 and, **44:154, 168, 195**
- Osteopetrosis  
 B cell formation and, **41:232**  
 hybrid resistance and, **41:374, 390, 392,**  
**393**
- Ouabain, hybridomas and  
 human-human, **38:293–295**  
 human-mouse heterohybridomas, **38:300**  
 human-murine, **38:289**
- Ouabain resistance, hybridomas and, **38:280,**  
**286, 301**
- Outer membrane protein, *Chlamydia*,  
**60:136**
- Ovalbumin  
 17 amino acid peptide, binding to B cells,  
**39:72–73**  
 CTL and, **41:167, 168**  
 humoral immune response and, **45:11**
- IgE biosynthesis and  
 antibody response, **47:8**  
 antibody response suppression, **47:29,**  
**30, 32–37, 39**
- binding factors, **47:27**
- Ir* genes and, **38:49, 55, 86**  
 antigen processing, **38:95**  
 competitive inhibition, **38:109**
- synthetic T and B cell sites and  
 globular protein antigens, **45:204, 210,**  
**214–216**  
 immunological considerations, **45:200**  
 viral antigens, **45:228**
- T cell receptor and, **38:49, 55, 86**  
 alloreactivity, **45:153**  
 antigen processing, **45:123, 125**

- Ovalbumin (*continued*)  
 experimental systems, **45**:131  
 peptides, **45**:133  
 T cell subsets and, **41**:55, 70  
 urea-denatured, IgE biosynthesis and, **47**:29, 30, 33
- Ox40, **61**:7, 9  
 OX40 gene, **61**:9  
 Ox40-L, **61**:24–26  
 OX62, **59**:380  
 Oxidant formation, **62**:262–267  
 Oxidation, periodate, as strategy for  
 chemioimmunoconjugation, **56**:315–316  
 Oxidative burst, surface antigens of human  
 leukocytes and, **49**:111  
 Oxygen radicals, **62**:72, 262–264
- P**
- P3C-MAP construct, HIV, **60**:133–134  
 p21<sup>ras</sup>, B cell antigen receptor-induced  
 activation, **55**:238–240  
 p50, **65**:15  
 B cell genesis, **63**:220–221, 245–246  
 and p52, **58**:3  
 p50 knockout mouse, cytokine induction,  
**65**:30–31  
 p53  
 association with apoptosis, **58**:138  
 BCL-2, **63**:164  
 dependent pathways in immunodeficiency  
 syndromes, **58**:66–67  
 role in PCD regulation, **58**:258  
 p53, **62**:226–227, 237–238; **64**:251  
 regulation, **65**:25  
 p53/56<sup>lyn</sup>, CD45 and, **66**:24, 37, 39, 44  
 p55, transcriptional regulation, **48**:294–295,  
 297–299  
 p56<sup>lck</sup>, **64**:69  
 binding to CD4 and CD8 cytoplasmic tails,  
**53**:61–64  
 CD45 and, **66**:11, 12, 19–21, 26, 37–39,  
 39–44, 53  
 interaction with CD4 and CD8  
 coreceptors, **58**:129–131  
 phosphorylation of TAM, **58**:127–128, 130  
 role in signaling through pre-TCR, **58**:150  
 role in T cell activation, **53**:78–82  
 structure, **53**:62–64
- T cell signaling by  
 CD4 association, **56**:160–161  
 CD8 association, **56**:160–161  
 cell-surface receptor interactions,  
**56**:157–159  
 cellular targets, **56**:159–160  
 function, **56**:151  
*lck* expression regulation  
 restricted accumulation of transcripts,  
**56**:151–152  
 transcription, **56**:152–153  
 regulation  
 post-translational modification,  
**56**:156–157  
 structure as factor, **56**:153–156  
 T cell receptor interactions, **56**:161–162  
 thymocyte development control  
 allelic exclusion, **56**:164–166  
 differentiation, **56**:162–163  
 maturation, **56**:164–166  
 modes of action, **56**:167–168  
 T cell receptor  $\beta$ -chain, **56**:163–164  
 and TCR-mediated signaling, **53**:85–91
- p58  
 dimers, **55**:358, 361–362  
 in modulation of NK-mediated cytotoxicity,  
**55**:354–357, 362–363  
 as NK receptor for MHC class I molecules,  
**55**:356, 358–360, 372  
 p59<sup>lyn</sup>, CD45 and, **66**:19–21, 37, 38, 39–43  
 p70<sup>kat</sup>, located on human chromosome 22,  
**58**:57  
 p70<sup>s6k</sup>, mTOR and, **61**:188–190  
 p70<sup>zap</sup>, CD45 and, **66**:21–22, 26  
 p72<sup>nk</sup>, CD45 and, **66**:21, 23–24, 26, 45  
 p75 LNGFR, **61**:2, 4–5  
 p95<sup>cat</sup>, B cell antigen receptor-induced  
 tyrosine phosphorylation, **55**:243–244  
 p105, **65**:15–16  
 p150,95, leukocyte integrins and, **46**:149–153  
 chromosomal localization, **46**:160  
 inflammation, **46**:164, 167  
 ligand molecules, **46**:173  
 structure, **46**:153, 156, 158, 159  
 PA28, **64**:21  
 PA28 $\alpha$ , **64**:21–24, 30  
 PA28 $\beta$ , **64**:21–24  
 PAC-1, **63**:167  
 Packaging cells, development, **58**:424  
 Packing density, **43**:33–35

- PAF, *see* Platelet-activating factor
- Pain, mediation with NO, **60**:349–350
- Palmylation, **52**:61–62
- PALS, *see* Periaarteriolar lymphoid sheath
- pan*, **63**:232
- Pancreas  
   IFN- $\gamma$  and, **62**:100–101  
   rat adenocarcinoma cell line, **54**:324
- Pancreatic islets, grafts in MHC class I-deficient mouse, **55**:390
- Pancreatitis, autoimmune, **62**:98
- Pannus, **64**:287–288
- Papillomavirus, *see also* Human papillomavirus  
   tumor antigen induction, **57**:292–293
- Paracrine effects, IL-1, **54**:201–202
- Parallel tubular arrays, NK cells and, **47**:216, 218, 256, 281
- Paralysis, autoimmune demyelinating disease and, **49**:371–372
- Paramecium*  
   antigenic variation in, **38**:340  
   maternally transmitted antigen and, **38**:315
- Paraprotein  
   aPL antibodies and, **49**:242  
   Ig heavy-chain variable region genes and, **49**:35, 43, 46–48
- Parasites  
   cytotoxicity and, **41**:269  
   and eosinophils, **60**:210–216  
   helper T cell cytokines and, **46**:137–139  
   human filarial, responses in MHC class I-deficient mouse, **55**:415  
   humoral immune response and, **45**:84, 85  
   infection  
     IL-5 production in animal models, **57**:172–173  
     and IL-6, **54**:36–37  
   Parasitic antigens, synthetic T and B cell sites and, **45**:228–230, 245
- Paratope, *see also* Complementarity-determining region  
   *Ir* genes and, **38**:107
- Paroxysmal nocturnal hemoglobinuria, **61**:201, 253  
   decay-accelerating factor and CD59 deficiencies, **60**:75–78  
   defective GPI synthesis, **60**:78–80  
   genetic basis, **60**:80–91  
   monoclonal or oligoclonal, **60**:89  
   regulators of complement activation and, **45**:387, 400
- Partial lipodystrophy, **61**:245
- Partial thromboplastin time, aPL antibodies and, **49**:200
- Partial thromboplastin time with kaolin, aPL antibodies and, **49**:201
- Particulate activators  
   alternative complement pathway, **38**:384–386  
   monocyte ingestion, **38**:366  
   phagocytosis, **38**:361, 362, 392, 393  
   by human monocytes, **38**:380–382  
   by nonelicited murine macrophages, **38**:383, 384
- Passive transfer  
   AChR and  
     B cell line, **42**:260  
     T cell clones, **42**:258  
   with Ig, **42**:262  
   MG, **42**:234
- Pathogenesis  
   aPL antibodies and, **49**:193, 227, 238, 252–257  
   autoimmune demyelinating disease and, **49**:360, 370, 357–358, 368, 374  
   CD23 antigen and, **49**:174  
   Ig heavy-chain variable region genes and, **49**:49–50  
   surface antigens of human leukocytes and, **49**:81
- Pathogenicity, SIVmac and SIVsm molecular clones, **52**:448
- Pathogens, responses in MHC class I-deficient mouse, **55**:405–415
- Paw edema model, NO role, **60**:328–329
- pax5*, B cell genesis, **63**:218–219, 228–232
- Pax-5/BSAP, binding site, **61**:120–121
- PBMC, *see* Peripheral blood mononuclear cells
- PC-1, a plasma cell threonine-specific protein kinase, **52**:174
- PCD, *see* Apoptosis
- Peanut agglutinin  
   antigen-presenting cells and, **47**:86  
   IgE biosynthesis and, **47**:15, 18  
   T cell subsets and, **41**:97
- PEBP2 family, **65**:24
- PEL-CTLs, Perforin expression in murine splenic, **51**:220, 221



- Pemphigus foliaceus**  
 antigen  
 cadherin gene superfamily, **53:310–312**  
 cDNA cloning, **53:310–312**  
 desmosomal localization, **53:300–303**  
 relationship to PVantigen, **53:312–314**  
 clinical presentation, **53:295–297**  
 histology, **53:295–297**  
 immunopathology, **53:295–297**
- Pemphigus vulgaris**  
 antigen  
 characterization, **53:303–305**  
 identification as PF antigen-related  
 cadherin, **53:312–314**  
 sequence homologies and conserved sites  
 with desmoglein, **53:314**  
 clinical presentation, **53:295–297**  
 histology, **53:295–297**  
 HLA class II peptide binding and, **66:87**  
 immunopathology, **53:295–297**
- Penicillamine**, MG and, **42:235, 251–252, 253, 272**
- Pentanoysalicylate**, **62:187**
- Pentoxifylline**, sepsis and, **66:130**
- Peptide**  
 B cell formation and, **41:215**  
 CTL and, **41:136, 137, 167–169**  
 amino acid, **41:162**  
 exon shuffling, **41:148**  
 HLA antigens, **41:152**  
 cytotoxicity and, **41:279, 280, 309, 313**  
 pore formation and, **41:313–319**  
 epitope vaccines, **43:77–78**  
 $\alpha$ -helical conformation, **43:203–204**  
 MHC interaction, rate constants for  
 binding reaction, **43:211**  
 monoclonal anti-MHr antibody affinity,  
**43:61–62**  
 synthesis, **43:77**  
 T cell activation and, **41:3**  
 T cell subsets and, **41:41, 47, 110**  
 H-2-restricted antigen recognition,  
**41:52–55, 57, 58, 74, 75, 77**
- Peptide add-back experiments**, **59:123**
- Peptide antigens**  
 T cell specificity for, **43:197–206**  
 in trimolecular complex  
 features, **56:239, 250–251**  
 MHC blockers, **56:244–247**  
 peptide determinant as tolerogen,  
**56:240–244**  
 T cell antagonists, **56:244–247**
- Peptide antigen X**, RA susceptibility role,  
**56:455**
- Peptide binding**  
 to cell surface-associated class I molecules,  
 mechanism, **52:81–84**  
 to TAP, **65:84–86**
- Peptide-binding motifs**, HLA class II  
 molecules, **66:69–71**
- Peptide mapping**, **43:3**  
 blind study, **43:26**  
 critical residue, **43:74**  
 reconciling data, **43:23–27**  
 sites mapped into conformational epitopes,  
**43:38–39**  
 T cell receptor  $\gamma\delta$  subunits, **43:150**
- Peptide–MHC complexes**, **64:2**
- Peptide receptors**, functionally active,  
 expression on basophils and mast cells,  
**52:367**
- Peptides**  
 adoptive T cell therapy of tumors and,  
**49:283, 319, 321–323, 334**  
 antigen-presenting cells and, **47:87, 104**  
 antigen presentation, **47:64, 66, 71, 74, 76, 77, 79, 81**  
 antigen processing, **47:87, 88, 90–92**  
 T cells, **47:82, 96, 97, 99, 101**  
 antinuclear antibodies and, **44:106, 129, 134, 135**  
 autoimmune demyelinating disease and,  
**49:357**  
 multiple sclerosis, **49:369–371, 373–375**  
 myelin basic protein, **49:357–361**  
 TCR usage restriction, **49:363, 366**  
 autoreactive T cells and, **45:425, 426**  
 bacterial formyl, attracting myeloid cells,  
**58:381**  
 biologically active, from Fc region of Ig,  
**40:111–119**  
 branched, synthesized on polylysine core,  
**60:105–108**  
 CD4 and CD8 molecules and, **44:269**  
 CD4 molecular biology, **44:285, 286, 289, 295, 296**  
 CD8 molecular biology, **44:272, 274–276**  
 CD23 antigen and, **49:156**

- exogenous, association with class I molecules, **52:78–86**  
 physiological relevance, **52:85–86**  
 site of, **52:79–81**
- fMLP  
 eosinophil response to, **60:185–186**  
 induced eosinophil degranulation, **60:173**
- fusogenic, **58:423**
- genetically engineered antibody molecules and, **44:67**
- HIV infection and  
 immune response, **47:406, 410**  
 immunopathogenic mechanism, **47:389, 391, 392**  
 neuropsychiatric manifestations, **47:404**
- humoral immune response and, **45:7, 18–21**
- IgE biosynthesis and  
 antibody response, **47:39**  
 binding factors, **47:15–17, 20, 23, 25**
- Ig gene superfamily and  
 MHC complex, **44:24, 26, 29**  
 nonimmune receptor members, **44:32–34, 36, 42**
- IL-1 and, **44:164, 173, 190**  
 gene expression, **44:160, 163**  
 receptor, **44:179, 181**  
 structure, **44:155, 157, 158**
- immunogenic, conformation, **43:63**
- MHC class I molecules  
 anchoring, **64:124–127**  
 binding, **64:114–115, 118, 127–128**  
 loading, **64:105–128**
- Multimeric–Synthetic Peptide Combinatorial Library, **60:139**
- multiple-antigen, *see* Multiple antigen peptides
- neuroendocrine, *in vitro* IgE synthesis, **61:371–374**
- neuroendocrine, *in vitro* IgE synthesis, **61:371–374**
- NK cells and, **47:202, 204, 268, 303**
- P2 and P30, **60:110–111, 121–122**
- P12 and P14, **60:127**
- P30, purified from *T. gondii*, **60:124**
- positive selection, **59:122–128**
- precursor, to be GPI anchored, **60:61–63**
- production in cytosol, functional evidence, **52:28–29**
- regulators of complement activation and, **45:389, 394, 399, 400**
- role in positive selection, **58:161–164**
- SCID and, **49:387**
- sporozoite malaria vaccine and, **45:320–322**
- antibodies, **45:304, 305**
- CS proteins, **45:296**
- CS-specific T cells, **45:307, 308, 310, 311**
- human trials, **45:314, 315**
- immunity, **45:287**
- surface antigens of human leukocytes and, **49:80–82, 112**
- switch, **43:113**
- synthetic  
 extracellular processing, **52:84–85**  
 recognition sites defined by, *see* Recognition sites, synthetic  
 technology, applications, **43:59**
- T cell development and, **44:209, 218, 233, 253**
- T cell receptor and, **45:107, 108**  
 alloreactivity, **45:148–157**  
 antigen processing, **45:118–123, 125, 127, 128**  
 binding, **45:132–134**  
 epitopes, **45:142–148**  
 experimental systems, **45:131, 132, 137**  
 homogeneity, **45:129–131**  
 MHC molecules, **45:112, 115, 116**  
 polymorphic residues, **45:158–161**  
 selection, **45:137–139**  
 structure-function relationships, **45:135, 139–142**  
 T cell repertoire, **45:162, 163, 165–167**
- tumor-specific, T cell recognition, **57:288–290**
- virus-induced immunosuppression and  
 human immunodeficiency virus, **45:350, 351, 362, 363, 366–368**  
 measles, **45:337**
- Peptide supply factor gene, **65:50**
- Peptidoleukotrienes, and asthma, **51:341**
- Peptons, or proteins, in entry of proteins into class I processing pathway, **52:13–19**
- Percoll density gradients, NK cells and, **42:182, 184**
- Perforin, **62:43, 52–53; 64:1, 69**  
 in cytolysis, **51:215–216, 224–232**  
 perforin-independent mechanisms, **51:231–232**

- Perforin (*continued*)  
 verification in cell lines, **51:224–227**  
 verification by genetic approach,  
**51:227–231**  
 cytotoxicity and, **41:269, 270, 280, 281,**  
**291, 305, 307–309, 319**  
 cell-mediated killing, **41:291–299**  
 cytolytic, **41:311–319**  
 membrane attack complex of  
 complement, **41:299, 305, 307–309,**  
**311**  
 effector molecule in cytotoxicity,  
**60:290–292**  
 in lymphocyte-mediated cytotoxicity  
 expression of, **51:219–224**  
 in human leukocyte, **51:222–223**  
 regulation of, **51:223–224**  
 perspectives, **51:232–233**  
 structure of, **51:216–219**  
 NK cells and, **47:251–254, 262, 291**  
 pathway of CTL-mediated cytotoxicity,  
**60:292–296**  
 verification by genetic approach,  
**51:227–231**
- Perforin-independent mechanisms,  
**51:231–232**
- Periarteriolar lymphoid sheath  
 associated foci, **60:270–271**  
 B cell activation in, **60:276**  
 containing interdigitating cells, **60:268–269**  
 T cells, **63:48, 71**
- Periodate oxidation, as strategy for  
 chemoimmunoconjugation, **56:315–316**
- Peripheral blood  
 CD5 B cell and, **47:122, 131**  
 autoimmune diseases, **47:150**  
 marker for activation, **47:127**  
 surface antigen, **47:147**  
 eosinophil counts, **60:216–218**  
 HIV infection and  
 immune response, **47:411**  
 immunopathogenic mechanism, **47:394,**  
**397, 400, 402, 403**  
 NK cells and, **47:289, 293, 298, 300, 303**  
 CNS, **47:266**  
 differentiation, **47:232–234**  
 effector mechanisms, **47:252, 254, 258,**  
**264**  
 hematopoiesis, **47:275, 277, 279**  
 identification, **47:199**  
 malignant expansion, **47:226**  
 morphology, **47:216**  
 surface phenotype, **47:201, 205, 206**  
 spontaneous autoimmune thyroiditis and,  
**47:447**  
 cellular immune reactions, **47:449, 451**  
 disturbed immunoregulation, **47:471,**  
**473, 474**
- Peripheral blood lymphocytes  
 adoptive T cell therapy of tumors and,  
**49:16**  
 aPL antibodies and, **49:245**  
 autoimmune thyroiditis and, **46:287, 289,**  
**299, 300**  
 CD5 B cell and, **47:144, 149**  
 CD23 antigen and, **49:166**  
 HIV infection and, **47:388**  
 in IBD, IBD and; **42:288–290, see also**  
 Lymphocytes  
 immunosenescence and  
 lymphocyte activation, **46:224, 226–230**  
 lymphocyte subsets, **46:238, 239**  
 stem cells, **46:239, 240**  
 in MG, **42:259**  
 NK cells and, **47:187, 294, 297, 301, 302**  
 antimicrobial activity, **47:286–289**  
 cell-mediated cytotoxicity, **47:195**  
 CNS, **47:267**  
 cytotoxicity, **47:254, 258–261**  
 differentiation, **47:234**  
 effector mechanisms, **47:234, 240, 243,**  
**246**  
 genetic control, **47:222**  
 hematopoiesis, **47:275, 276**  
 lymphokines, **47:264, 265**  
 morphology, **47:214, 217, 218**  
 reproduction, **47:270**  
 surface phenotype, **47:205–209**  
 tissue distribution, **47:219**  
 SCID and, **49:385**  
 spontaneous autoimmune thyroiditis and,  
**47:492**  
 cellular immune reactions, **47:452, 453,**  
**456**  
 disturbed immunoregulation, **47:471,**  
**472, 475, 479**  
 effector mechanisms, **47:469**  
 genetics, **47:487, 488**  
 humoral immune reactions, **47:447,**  
**449**

- Peripheral blood mononuclear cells, **61:214**  
 CD23 antigen and, **49:152, 157, 174**  
 HIV infection and  
 activation, **47:398, 400, 403**  
 immune response, **47:411**  
 immunopathogenic mechanism,  
**47:390–392**  
 human immunodeficiency virus and,  
**45:350, 352, 354–362, 367**  
 IBD and, **42:289, 294–297, 302**  
 IgE biosynthesis and  
 antibody response, **47:6, 7, 9, 12, 38**  
 binding factors, **47:21, 22**  
 measles and, **45:338, 340, 342, 346**  
 NK cells and, **42:181–184**  
 PGE, IBD and, **42:311–312**  
 PGE<sub>2</sub>, corticosteroids and, **42:316, 318–319**  
 phagocytic invasion, MG and, **42:261**  
 phagocytosis, IBD and, **42:307**  
 C3b and, **42:308**
- Peripheral immune system  
 compartmentalization  
 anatomic localization of colonizing  
 lymphocytes, **53:159**  
 B cells  
 CD5<sup>+</sup>/CD5<sup>-</sup> dichotomy, **53:178–183**  
 in lymph follicles, **53:185–186**  
 in peritoneum, **53:183–185**  
 generation of compartments, **53:187–194**  
 significance of, **53:199–203**  
 site-dependent tolerance, **53:201–203**  
 specialized functions of, **53:199–201**  
 T cells  
 intestinal intraepithelial, **53:163–167**  
 $\gamma/\delta$  invariant intrac epithelial cells,  
**53:167–169**  
 in liver, **53:169–171**  
 in lymph nodes, **53:161–163**  
 in peritoneum, **53:173–177**  
 in spleen, **53:161–163**  
 IL-2 effects and toxicity, **50:160–163**
- Peripheral lymph nodes  
 lymphocyte homing, **58:390–391**  
 carbohydrate, **44:354–359, 362–367,**  
**369, 371**  
 molecules, **44:342–348, 350, 351, 353**  
 regional specificity, **44:327, 328, 331,**  
**334–341**  
 selective homing model, **44:323–325**  
 lymphocyte migration into, **64:174–175**  
 lymphocyte recirculation, **64:141, 142**
- Peripheral node vascular addressins  
 expression, **64:149**  
 lymphocyte–HEV interaction, **65:361–363**  
 ontogenesis, **64:164**  
 in PLNs, **64:174**  
 properties, **64:147**
- Peripheral T cells, *see* T cells, peripheral
- Peripoleosis, spontaneous autoimmune  
 thyroiditis and, **47:442, 447, 469**
- Peritoneal cavity, localization of CD5 B cells,  
**55:299–300**
- Peritoneum  
 B cells, **53:183–185**  
 forbidden  $\alpha/\beta$  T cells, **53:166**  
 IL-1ra injection, **54:212**  
 IL-1ra production by macrophages, **54:188**  
 lymphokine production by Fc $\epsilon$ RI<sup>+</sup> cells  
 (murine), **53:9–14**  
 T cells, characterization, **53:173–177**
- Peroxidase, eosinophil, *see* Eosinophil  
 peroxidase
- Peroxidase active site, PHGS-2, **62:176–177,**  
**187–188**
- Pertussis toxin, **43:291–292**  
 autoimmune side effects, **58:278**  
 and G protein-mediated regulation,  
**58:260–261**  
 suppression of cell death, **58:246–248**
- PERUN (software), T cell epitope prediction,  
**66:82**
- Peyer's patches  
 disassociated cells, studies with,  
**40:195–197**  
 functional anatomy of, **40:192–195**  
 immunosenescence and, **46:236, 237, 251,**  
**252**  
 lymphocyte homing  
 carbohydrate, **44:362–371**  
 high endothelial venules, **44:315, 317,**  
**318**  
 molecules, **44:342–347, 353**  
 into mucosa, **64:175–177**  
 regional specificity, **44:322, 324–329,**  
**334–338, 341**
- PF, *see* Pemphigus foliaceus
- Pf322, *P. falciparum* blood stage, **60:120–121**
- PGHS, *see* Prostaglandin endoperoxide H  
 synthase
- P-glycoprotein, surface antigens of human  
 leukocytes and, **49:114–115**

## pH

- antigen-presenting cells and, **47:88**
- IgE biosynthesis and
  - antibody response, **47:8, 33, 34, 36**
  - binding factors, **47:12**
- Na<sup>+</sup>/H<sup>+</sup> antiporter, **48:288**
- NK cells and, **47:263**
- spontaneous autoimmune thyroiditis and, **47:446**
- Phagocytes, mononuclear, IFN- $\gamma$  and, **62:78–80**
- Phagocytic cells, interaction with IgA, **40:168–174**
- Phagocytosis, **38:361, 392, 393**
  - adoptive T cell therapy of tumors and, **49:319, 323, 328**
  - B cell formation and, **41:212, 213**
  - CD23 antigen and, **49:167**
  - complement receptor 1 and, **46:183, 186, 198, 199**
  - by eosinophils, **39:208**
  - hybrid resistance and, **41:340, 357, 370**
  - Ir* genes and, **38:94**
  - leukocyte integrins and, **46:151, 161, 163, 168**
  - by mononuclear cells, **38:363**
  - of particulate activators
    - by human monocytes, **38:380–382, 392**
    - by nonelicited murine macrophages, **38:383, 384**
  - pore-forming proteins and, **41:313**
  - surface antigens of human leukocytes and, **49:89**
  - surface changes resulting in, **50:62–63**
  - zymosan
    - by human monocytes, **38:363–376**
    - by nonelicited murine macrophages, **38:376–380**
- Phenothiazine, aPL antibodies and, **49:212, 227**
- Phenotype
  - adoptive T cell therapy of tumors and, **49:325, 333**
  - mechanisms, **49:299–300, 316**
  - principles, **49:290, 297**
- antinuclear antibodies and, **44:109, 110**
- autoimmune demyelinating disease and, **49:362–363**
- autoimmune thyroiditis and
  - cellular immune responses, **46:287, 288, 290**
  - experimental models, **46:274, 275**
  - genetic control, **46:282**
  - prevention, **46:311**
- B cell, developmentally regulated generation, **55:301**
- B cell formation and
  - B cell precursors, **41:192, 201**
  - Ig genes, **41:204, 205**
  - lymphohemopoietic tissues, **41:187**
  - NZB mice, **41:227, 229**
  - W/W anemic mice, **41:2a4**
- CD4 and CD8 molecules and, **44:266, 277, 279**
- CD5 B cell and, **47:120, 122**
  - malignancies, **47:124**
  - physiology, **47:132, 135, 140, 142**
- cytotoxicity and, **41:273, 287**
- genetically engineered antibody molecules and, **44:70, 72**
- helper T cell cytokines and, **46:111, 123, 126–128, 139**
- HIV infection and, **47:384**
- human B cell, **52:129–174**
  - B cell antigen receptor, **52:136–138**
  - Ig complex, **52:136–138**
  - proteins associated with Ig complex, **52:138**
- non-Ig B cell surface antigens, **52:138–174**
  - antigens of plasmacytes, **52:174**
  - clustered antigens of B cells, **52:140–164**
- non-Ig nonclustered antigens, **52:164–174**
  - adhesion molecules, **52:166–168**
  - B7/BB1, **52:168–169**
  - cytokine receptors on B cells, **52:169–173**
  - HLA class II molecules, **52:164–166**
  - plasmacyte, **52:174**
- non-Ig nonclustered antigens, other, **52:173–174**
  - Bgp 95, **52:173**
  - CK226 antigen, **52:173**
  - IgM-binding protein (Fc $\mu$  receptor), **52:173**

- hybrid resistance and, **41**:338, 374, 382, 400, 401
- IgE biosynthesis and, **47**:10, 12
- Ig gene superfamily and, **44**:24, 29, 48
- Ig heavy-chain variable region genes and, **49**:24
- immunosenescence and, **46**:252
- Ir* genes and, **38**:61–64
- antigen binding, **38**:115
- cross-reactive lysis, **38**:186, 187
- immunodominance, **38**:181
- T cells
- cytotoxic, **38**:163, 165, 167, 178
- interaction, **38**:159
- repertoire suppression, **38**:151, 152
- tolerance, **38**:125
- leukocyte integrins and, **46**:174–176
- lymphocyte homing and, **44**:321
- murine lupus models and, **46**:64, 82, 94
- NK cells and, **47**:292, 298, 302
- cell-mediated cytotoxicity, **47**:195
- differentiation, **47**:229, 231–233
- effector mechanisms, **47**:246, 260, 264
- genetic control, **47**:223
- hematopoiesis, **47**:274–277
- identification, **47**:197–199
- malignant expansion, **47**:226–228
- reproduction, **47**:271
- surface, **47**:199–214
- tissue distribution, **47**:220
- SCID and, **49**:381–385, 387, 391
- lack of stem cell engraftment, **49**:396–397
- posttransplant immunocompetence, **49**:400
- T cell-depleted bone marrow, **49**:394–395
- spontaneous autoimmune thyroiditis and, **47**:435–437
- disturbed immunoregulation, **47**:470
- genetics, **47**:484, 488
- surface, murine CD5 B cell, **55**:306, 308–309
- surface antigens of human leukocytes and, **49**:101
- T cell activation and, **41**:1, 7, 28
- T cell development and cellular selection within thymus, **44**:254
- ontogeny, **44**:220, 221
- thymocyte subpopulation, **44**:225, 229–232, 235, 237–244
- T cell subsets and
- cell surface molecules, **41**:49, 50
- H-2 alloantigen recognition, **41**:84, 87, 88
- H-2 molecules in thymus, **41**:96
- H-2-restricted antigen recognition, **41**:60, 69, 73
- Phenotypic selection, germinal centers, **60**:280
- Phenylalanine, CTL and, **41**:162, 166
- Phenylbutazone, **62**:186
- Phenylenediamine mustard, in cancer treatment, **56**:329, 331
- 2-Phenyl-4,4,5,5-tetramethylimidazoline-3-oxide-1-oxyl, interaction with NO, **60**:340
- Philadelphia chromosome, **38**:245
- Phorbol esters
- adoptive T cell therapy of tumors and, **49**:307
- B cell formation and, **41**:22a
- CD4 molecules and, **44**:296
- CD23 antigen and, **49**:151, 172
- cell-mediated killing and, **41**:14–19, 24, 26
- complement receptor 1 and, **46**:199
- complement receptor 2 and, **46**:208
- Ig gene superfamily and, **44**:34, 41
- IL-1 and, **44**:174–176
- leukocyte integrins and, **46**:162, 163, 165–169
- T cell activation, **48**:258–260
- T cell development and, **44**:236, 243
- Phorbol myristate acetate, **48**:234
- autoimmune thyroiditis and, **46**:296
- CD4 and CD8 molecules and, **44**:268, 269, 298, 301
- CD5 B cell and, **47**:125, 126, 141
- immunosenescence and, **46**:224, 226, 228, 230
- leukocyte integrins and, **46**:168
- T cell activation and, **41**:8, 9, 11, 12, 14, 19
- gene regulation, **41**:28, 30
- receptor-mediated signal transduction, **41**:20, 22, 23, 25
- T cell development and, **44**:226, 227, 229, 237, 241
- Phosphatases
- hematopoietic cell, role in cytokine signaling, **60**:25–26
- T cell, signal transduction, **48**:284

- Phosphates  
 CTL and, **41**:153  
 T cell activation and, **41**:16, 24
- Phosphatidic acid, aPL antibodies and, **49**:194, 236–237, 242, 248
- Phosphatidylcholine  
 aPL antibodies and, **49**:259  
 biochemistry, **49**:194, 196–197  
 LA antibodies, **49**:242–246  
 specificity, **49**:234–237, 248, 251  
 cytotoxicity and, **41**:275, 276  
 IL-1 and, **44**:175, 176, 185
- Phosphatidylethanolamine, aPL antibodies and  
 biochemistry, **49**:194, 196–197  
 clinical aspects, **49**:202  
 LA antibodies, **49**:242–248  
 specificity, **49**:236–237, 251–252
- Phosphatidylinositol  
 aPL antibodies and, **49**:194, 229, 251  
 LA antibodies, **49**:242–243, 246  
 specificity, **49**:236–237  
 B cell formation and, **41**:197, 198, 202, 222, 239  
 bone marrow cultures, **41**:215, 216  
 leukocyte integrins and, **46**:171  
 neutrophil  
 cell activation and, **39**:122–124, 130  
 G proteins and, **39**:119–120  
 transfer of GlcNAc from UDP-GlcNAc, **60**:64–70
- Phosphatidylinositol biphosphate, T cell activation and, **41**:15, 16, 23, 25
- Phosphatidylinositol 4,5-biphosphate, **48**:228  
 neutrophil  
 amplification and, **39**:123–124  
 metabolism, **39**:122–123  
 phospholipase C and, **39**:122, 124–125  
 T cell antigen receptor-CD3 complex  
 Ca<sup>2+</sup> response, **48**:262–265  
 hydrolysis, **48**:262–265
- Phosphatidylinositol-4,5-biphosphate kinase, **48**:253
- Phosphatidylinositol 3-kinase, **54**:368–369, **61**:167; **63**:144, 149–154, 171  
 activation, **61**:168–171  
 B cell antigen receptor-induced activation, **55**:241–243  
 cytokine-induced activity, **60**:15  
 downstream effectors, **61**:171–173  
 pathway, IR-2R-induced activation, **61**:167–173  
 phosphorylation, **61**:28  
 signal transduction, **59**:263
- Phosphatidylinositol 4-kinase, as p56<sup>lck</sup> target in T cell signaling, **56**:160
- Phosphatidylinositol phospholipase C  
 bacterial, **60**:60  
 resistance of GPI anchor, **60**:61
- Phosphatidylinositol-specific phospholipase, B cell formation and, **41**:198, 214, 215
- Phosphatidylinositol-specific phospholipase C  
 bacterial, **60**:60  
 regulators of complement activation and, **45**:399  
 resistance of GPI anchor, **60**:61
- Phosphatidylserine, aPL antibodies and, **49**:194, 259  
 affinity purification, **49**:229–231  
 antibody subsets, **49**:232  
 clinical aspects, **49**:201, 204  
 specificity, **49**:236, 240, 242–248, 251
- Phosphodiesterase type IV inhibitors, **64**:331
- Phosphodiester groups, aPL antibodies and, **49**:235, 237, 240, 248
- Phosphoinositide, **48**:228  
 hydrolysis, **48**:253–254  
 mast cell-specific receptor, **43**:290–293  
 G protein role, **43**:291–292  
 inositol phosphate role, **43**:292  
 protein kinase role, **43**:292–293  
 role in signal transduction, **54**:418–419  
 turnover, T cell, **48**:258–265  
 direct measurements, **48**:260  
 secondary messenger formation, **48**:253–265
- Phosphoinositide cycle, **48**:253–255
- Phosphoinositide 3-kinase, **62**:133–135
- Phosphoinositide kinase type I, **48**:253
- Phosphoinositide kinase type II, **48**:253
- Phosphoinositide-specific phospholipase, **48**:256–258  
 function, **48**:256–257  
 G protein, **48**:266  
 inositol 1-monophosphate, **48**:253  
 lymphocyte, **48**:256  
 multiple forms, **48**:256  
 regulation, **48**:257–258  
 structure, **48**:256–257

- Phospholipase  
 action of, **65**:122  
 aPL antibodies and, **49**:235, 239, 246, 251  
 B cell antigen receptor-induced activation of, **55**:234–238  
 B cell formation and, **41**:198, 216, 239  
 cytotoxicity and, **41**:300, 314  
 IgE biosynthesis and  
 antibody response, **47**:39  
 binding factors, **47**:18, 24–26, 28  
 NK cells and, **47**:249  
 SCID and, **49**:386  
 surface antigens of human leukocytes and, **49**:111
- Phospholipase A, cytolysis and, **41**:275, 276
- Phospholipase A2, pore formers and, **41**:314–316
- Phospholipase C  
 activation, **54**:365–367  
 IgR complex to, **54**:366  
 immunosenescence and, **46**:223  
 leukocyte integrins and, **46**:171  
 neutrophil  
 amplification and, **39**:124, 132–134  
 G proteins and, **39**:119–120, 122  
 phosphoinositide turnover and, **39**:124  
 PIP<sub>2</sub> content and, **39**:122, 124–125
- Phospholipase Cγ1, as p56<sup>lck</sup> target in T cell signaling, **56**:159
- Phospholipase Cγ2, phosphorylation, **61**:28
- Phospholipids  
 aPL antibodies and, *see* Antiphospholipid antibodies  
 cytotoxicity and, **41**:276, 300, 302, 303  
 pore formation, **41**:314, 315, 318  
 IgE biosynthesis and, **47**:26  
 immunosenescence and, **46**:223  
 T cell activation and, **41**:15–19
- Phosphomannan polysaccharide, **65**:356
- Phosphoprotein phosphatases, **63**:164–167
- Phosphorylation, **52**:62. *see also* Tyrosine phosphorylation  
 antigen-presenting cells and, **47**:101  
 antinuclear antibodies and, **44**:115, 120, 124  
 autoimmune thyroiditis and, **46**:267  
 CD4 and CD8 molecules and, **44**:269, 296, 300  
 CD23 antigen and, **49**:156  
 CD45, **66**:53–54  
 complement receptor 1 and, **46**:187, 199  
 complement receptor 2 and, **46**:202, 208, 209  
 CTL and, **41**:135, 148  
 cytoplasmic tail of CD44, **54**:281  
 cytotoxicity and, **41**:273  
 in Fc receptor-mediated signal transduction  
 FcγR, **57**:74–77  
 FcεRI, **57**:79–81  
 IκB by TNFα, **58**:8  
 IgE biosynthesis and, **47**:24  
 IL-1 and, **44**:163, 184  
 immunosenescence and, **46**:222  
 involvement, **52**:90–92  
 leukocyte integrins and, **46**:155, 169  
 lymphocyte homing and, **44**:356–358  
 NF-κB, **65**:15–16  
 NF-IL6 activation, **65**:2–3  
 possible role, **54**:311–313  
 protein kinases, in Fas ligand expression, **60**:298–299  
 protein tyrosine, B cell antigen receptor-induced, **55**:231–233  
 SCID and, **49**:383  
 serine, **48**:270–277  
 Src family kinases, **66**:40–41  
 surface antigens of human leukocytes and, **49**:117  
 adhesion molecules, **49**:86  
 antigen-specific receptors, **49**:76–77  
 complement components, **49**:92  
 receptors, **49**:98–100  
 TAM, by Src family protein tyrosine kinases, **58**:127–128, 130  
 T cell activation, **41**:4, 16, 18, 19, 23, 24, **48**:269–285  
 threonine, **48**:270–277  
 transcription factors by DNA-PK, **58**:60–62
- Phosphorylcholine  
 electrostatic complementarity with antibody McPC603, **43**:10  
 immunosenescence and, **46**:248
- Phosphorylcholine response, **42**:131
- B cells  
 BALB/c mice, **42**:31  
 level, **42**:65  
 secondary B cell lineage, **42**:70  
 bone marrow isolates, **42**:23–26
- Phosphotyrosine-binding domain, **61**:161–162
- Ras/MAP kinase cascade, **61**:161–162



- Photoactivation, linkage procedure for chemioimmunoconjugates in cancer treatment, **56:323**
- Photochemical crosslinking, for lipid A receptor identification, **53:274–279**
- PhOX, B cell repertoire and, **42:71**
- Physical mapping,  $V_H$  locus, **62:4–7**
- Physiological abnormalities, IL-1ra blocking, **54:205**
- Physiological experiments, implying role for CD44, **54:296–302**
- in hematopoiesis *in vitro*, inhibition by CD44-specific Abs, **54:299–300**
- inhibition of thymocyte progenitor migration, **54:299**
- in lymphocytic migration *in vivo*, **54:298–299**
- relationship to hermes antigen mediating PLN adhesion, **54:296–298**
- signaling through CD44-ligand interactions, **54:300–302**
- Phytohemagglutinin, **48:233; 54:85**
- autoimmune thyroiditis and, **46:293, 310**
- B cell formation and, **41:198**
- CD23 antigen and, **49:150, 171**
- CTL and, **41:50**
- HIV infection and, **47:390, 398, 399, 401**
- hybrid resistance and, **41:359, 361**
- polyclonal growth of human T cells, **42:165**
- SCID and, **49:386**
- spontaneous autoimmune thyroiditis and, **47:492**
- cellular immune reactions, **47:452, 455**
- disturbed immunoregulation, **47:470, 471, 473**
- genetics, **47:487**
- potential effector mechanisms, **47:467**
- T cell activation and, **41:8, 14, 22, 26–28**
- T cell subsets and, **41:60, 63**
- virus-induced immunosuppression and human immunodeficiency virus, **45:356–358, 361–363**
- measles, **45:338**
- PI, *see* Phosphatidylinositol
- PID, Ras/MAP kinase cascade, **61:161**
- PIG-A, **60:67–71**
- PIG-A, **60:57, 67–72, 80–91**
- human class A gene, **60:57, 67–72**
- mutant cells, clonal dominance, **60:90–91**
- and *Pig-a*, **60:67–72, 93**
- responsible for PNH, **60:80–82**
- somatic mutations, **60:82–89**
- PIG-B, **60:73**
- Pigeon cytochrome c, *see* Cytochrome c
- PIG-F, **60:73**
- pin-1*, and PCD, **58:258**
- Pinocytosis, B cell formation and, **41:212, 213**
- PIP<sub>2</sub>, *see* Phosphatidylinositol 4,5-bisphosphate
- Piroxicam, **62:184, 186, 201**
- Pit-1, **63:381**
- Pituitary adenoma, **63:380**
- Pituitary cells, thymic factor effects on secretion of
- ACTH, **39:315**
- LH, **39:315**
- Pituitary gland
- anatomy, **63:379**
- immune system, **63:377, 433**
- Pituitary hormone receptors, **63:393–404, 426–427, 431–432**
- Pituitary hormones, **63:379–380, 459, see also specific hormones**
- assays, **63:429–430**
- autoimmune disease, **63:420, 425–426, 433**
- depletion, chemical, **63:430**
- hyperprolactinemia, **63:409–410, 430**
- immune system, **63:377–378, 407–408, 433**
- in vitro* effects, **63:410–417**
- in vivo* effects, **63:404–410**
- knockout animals, **63:430–431**
- lymphohemopoietic system
- growth hormone, **63:386–388, 431–432**
- growth hormone receptor, **63:396–397**
- IGF-I, **63:389–393, 402–404, 431–432**
- IGF-II, **63:417–419**
- as lymphohemopoietic growth factors, **63:431–432**
- prolactin, **63:382–384, 431–432**
- prolactin receptor, **63:394–396**
- lymphoproliferative diseases, **63:426–429**
- mutant animals, **63:430–431**
- production, **63:430**
- secretion, **63:382**
- as therapeutic agents, **63:408, 433**
- transgenic animals, **63:430–431**
- Placenta
- development, role of IL-6, **54:32**
- major basic protein production, human, **39:188, 228**

- Placental lactogens, **63**:379
- Plakoglobin, 130-kDa glycoprotein complexed with, **53**:303–305
- Plaque-forming cells  
 anti-BrMRBC, **55**:315–316  
 autoimmune thyroiditis and, **46**:299, 301  
 CD5 B cell and  
   physiology, **47**:130–132, 137, 139  
   surface antigen, **47**:144  
 hybrid resistance and, **41**:352  
 immunosenescence and, **46**:247, 248, 251  
 spontaneous autoimmune thyroiditis and, **47**:446
- Plasma  
 antigen-presenting cells and, **47**:45, 52, 53  
 aPL antibodies, **49**:259  
   antibody subsets, **49**:232  
   binding to cell membrane, **49**:252  
   clinical aspects, **49**:200–202, 206, 224  
   isotype, **49**:227  
   pathogenic potential, **49**:253–254, 257  
   specificity, **49**:240–242, 244–245, 247–248  
 CD5 B cell and, **47**:132  
 genetically engineered antibodies, **44**:76  
 HIV infection and, **47**:408  
 IgE biosynthesis and, **47**:4–6, 9, 13  
 NK cells and, **47**:267, 268  
 regulators of complement activation, **45**:387, 388, 397  
 spontaneous autoimmune thyroiditis and  
   clinical symptoms, **47**:440  
   disturbed immunoregulation, **47**:476, 479–481  
   genetics, **47**:488  
   humoral immune reactions, **47**:446, 447  
   potential effector mechanisms, **47**:467, 469
- Plasmablasts, *In vivo* activated, **52**:213–215
- Plasma cell dyscrasias  
 amyloidosis, **64**:219, 220–221  
 defined, **64**:219  
 heavy chain diseases, **64**:219, 220  
 MGUS, **64**:219, 220  
 multiple myeloma, **64**:219, 242  
   adhesion molecules, **64**:246–249  
   cell identification, **64**:242–246  
   cytokines, **64**:252–260  
   IL-6 signal transduction therapies, **64**:260–263  
   oncogenic transformation, **64**:249–251  
 plasmacytomagenesis, **64**:221–242  
   chromosomal translocation, **64**:227–229  
   pristane-induced, **64**:222–227  
   spontaneous, **64**:229–230  
   susceptibility and resistance to, **64**:238–242  
   transgenic studies, **64**:232–238  
   virus infection induced by, **64**:230–232  
 Waldenström's macroglobulinemia, **64**:219–220
- Plasma cells  
 distribution, **40**:184–185  
 humoral immune response and, **45**:81–83  
 lymphocyte homing and, **44**:326, 327, 335, 336  
 migration, **53**:247–248  
 precursors, mechanisms of homing to  
   mucosal tissues and secretory glands, **40**:204–207  
 surface antigens of human leukocytes and, **49**:77, 98, 116
- Plasmacyte foci, PALS-associated, **60**:270–271
- Plasmacytes, antigens, **52**:174  
 PC-1: threonine-specific protein kinase, **52**:174
- Plasmacytoma, **64**:219  
 adoptive T cell therapy of tumors and, **49**:301, 305  
 CD23 antigen and, **49**:153  
 cell line, dysregulated expression, **54**:15  
 helper T cell cytokines and, **46**:116  
 humoral immune response and, **45**:74, 75  
 hybrid resistance and, **41**:367, 368  
 IL-1 and, **44**:178, 189  
 plasmacytoma/hybridoma growth factor, **54**:3
- Plasmacytomagenesis, **64**:221–242  
 chromosomal translocation, **64**:227–229  
 pristane-induced, **64**:222–227  
 spontaneous, **64**:229–230  
 susceptibility and resistance to, **64**:238–242  
 transgenic studies, **64**:232–238  
 virus infection induced by, **64**:230–232
- Plasmacytosis, polyclonal, Castleman's disease patients, **54**:40–41
- Plasma membrane  
 antigen-presenting cells and, **47**:51, 68  
 antinuclear antibodies and, **44**:109

- Plasma membrane (*continued*)  
 aPL antibodies and, **49**:193, 197, 204, 212–213  
 CD8 molecules and, **44**:273  
 complement receptor 1 and, **46**:191, 192, 197, 199  
 complement receptor 2 and, **46**:204, 209  
 HIV infection and, **47**:393  
 IL-1 and, **44**:163, 166, 175, 182, 184, 185  
 immunosenescence and, **46**:224, 226, 235  
 lymphocyte homing and, **44**:319, 368  
 NK cells and, **47**:253  
 P-selectin translocation, **58**:356  
 Plasma membrane glycoprotein, **48**:161–162  
 Plasmapheresis, for MG, **42**:271  
 Plasmids, maps of Ig-like loci and, **46**:4  
 Plasmin, lymphocyte homing and, **44**:347, 348, 358  
 Plasminogen, activation, **66**:241  
 Plasminogen activator  
 NK cells and, **47**:254  
 tissue PA, **46**:166  
*Plasmodium*, sporozoite malaria vaccine and, **45**:296, 297, 299  
*Plasmodium berghei*, **54**:36  
 rodent malaria model, **60**:108–111  
 sporozoite malaria vaccine and  
 CS-specific T cells, **45**:308, 309  
 immunity, **45**:285–290  
 interferon- $\gamma$ , **45**:302, 306  
*Plasmodium falciparum*, **54**:36  
 CS-specific T cells, **45**:308–311  
 endemic areas, **45**:315, 316  
 human trials, **45**:313  
 immunity, **45**:285, 286, 288, 290, 292  
 interferon- $\gamma$ , **45**:306  
 MAP candidate vaccines, **60**:112–122  
 sporozoite malaria vaccine and, **45**:283, 317, 320–322  
 synthetic T and B cell sites and, **45**:229, 258  
 T cell receptor and, **45**:143  
*Plasmodium malariae*  
 response to MAP [(NAAG)<sub>6</sub>]<sub>8</sub>, **60**:123  
 sporozoite malaria vaccine and, **45**:283, 293, 294, 297  
*Plasmodium vivax*  
 circumsporozoite protein-based vaccines, **60**:122–123  
 sporozoite malaria vaccine and, **45**:283  
 CS proteins, **45**:297–299, 317, 318  
 CS-specific T cells, **45**:308–310, 313  
 immunity, **45**:286, 288, 292  
 interferon- $\gamma$ , **45**:302  
*Plasmodium yoelii*, **54**:36  
 MAP immunogenicity, **60**:111–112  
 Plasmocytosis, polyclonal, in patients with Castleman's disease, **54**:40–41  
 Platelet-activating factor, **51**:352  
 attracting myeloid cells, **58**:381  
 CD23 antigen and, **49**:154, 159–161  
 as eosinophil-derived lipid mediator, **60**:190–191  
 eosinophil receptors for, **60**:185–186  
 IL-1 and, **44**:166, 171, 187  
 induced neutrophil infiltration, **60**:176  
 inducing granule protein release, **60**:207  
 as neutrophil receptor, **39**:96–98  
 Platelet-derived growth factor, **48**:308; **62**:268  
 Ig gene superfamily and, **44**:39, 44, 45  
 IL-1 and, **44**:153, 158, 164, 168, 169  
 IL-6 production and, **66**:128  
 Platelet-derived growth factor receptor, genes, and *c-kit*, evolutionary relationship, **55**:9–10  
 Platelet factor 4  
 biological effects on neutrophils, **55**:115  
 chemical properties, **55**:97, 99–100  
 Platelet neutralization procedure, aPL antibodies and, **49**:202, 244  
 Platelets  
 aggregation, PGHS-1, **62**:200–201  
 aPL antibodies and, **49**:193, 197  
 affinity purification, **49**:231  
 binding to cell membranes, **49**:251–252  
 clinical aspects, **49**:200, 202–203, 213  
 pathogenic potential, **49**:254–257  
 specificity, **49**:239, 241–242, 244–246  
 CD23 antigen and, **49**:161, 167  
 contact activation system, **66**:244  
 Fc receptors on, **40**:68  
 gpIIb-IIIa integrin, **54**:309  
 IgE, **43**:306–307  
 IL-1 and, **44**:153, 167  
 SCID and, **49**:382  
 surface antigens of human leukocytes and, **49**:85–86, 88  
*cis*-Platinum, *see* Cisplatin  
 Platinum compounds, in cancer treatment, **56**:329, 332

- Pleckstrin homology domain, Btk,  
**59**:182–183, 185, 187–189, 191
- Pleiotropic effects, TGF- $\beta$   
 IL-4, **52**:179–181  
 IL-6, **52**:184  
 IL-10, **52**:181–182
- Pleiotropy  
 LIF, OSM, CNTF, and IL-6, **53**:44–47  
 reduction by compartmentalization,  
**50**:163–165  
 IL-2 bioavailability, **50**:164  
 IL-2 production, **50**:163–164  
 IL-2 responsiveness, **50**:164–165
- PLNs, *see* Peripheral lymph nodes
- Pmel17, **62**:229, 235
- PML domains, **63**:202
- pml* gene, **63**:202, 203
- PMN leukocytes, *see* Neutrophils
- Pneumococcus* polysaccharide, **48**:28
- Pneumonia, **59**:397–398  
 bacterial  
*Legionella pneumophila*, **59**:398  
*Listeria monocytogenes*, **59**:398  
*Mycobacterium tuberculosis*, **59**:379,  
 383, 398–402  
*Streptococcus pneumoniae*, **59**:395–396  
 fungal, **59**:397–406  
*Cryptococcus neoformans*, **59**:402–405  
 streptococcal, **59**:395–396  
 viral  
 influenza virus, **59**:406–408  
 respiratory syncytial virus, **59**:406–408
- PNH, *see* Paroxysmal nocturnal  
 hemoglobinuria
- P nucleotides, **58**:36–38  
 as V(D)J recombination product, **56**:56–58
- Pocket specificity profiles, quantitative  
 matrices and, **66**:74–76
- Pokeweed mitogen  
 activation of B cells and, **40**:13  
 B cells responsive to, **40**:20, 23–29  
 complement receptor 1 and, **46**:200, 201  
 hybridomas and, **38**:297, 298  
 virus-induced immunosuppression and  
 HIV, **45**:356, 362  
 measles, **45**:340–342, 346
- pol $\beta$* , **61**:303–304
- Polarity  
 cytolytic mechanisms and, **41**:273–275, 282  
 T cell subsets and, **41**:41
- Poliovirus type II, mouse infection, anti-Id  
 antibodies as vaccines against, **39**:283
- Polyacrylamide gel electrophoresis, two-  
 dimensional, HLA class II, **48**:114–116  
 silver staining, **48**:116  
 theoretical limitations, **48**:116
- Polyadenylation  
 complement receptor 1 and, **46**:184  
 regulators of complement activation and,  
**45**:407, 408
- Poly(ADP-ribose) polymerase, switch  
 recombination, **61**:110
- Polyamine metabolism, **48**:288–290  
 ornithine decarboxylase, **48**:289–290
- Polyarthritis, agammaglobulinemia, **59**:146
- Polyclonal activators, **52**:195–199  
 IL-2, **52**:195–196, 196–198  
 other stimulatory cytokines, **52**:198–199  
 transforming growth-factor is, **52**:199
- Polyclonal B cell activation, **52**:185–195  
 activated T cell induction of, **52**:191–193  
 anti-CD40, **52**:188–191  
 antigen receptor, **52**:185–188  
 anti-Igs, **52**:185–188  
 inhibitory effects, **52**:186–187  
 stimulatory effects, **52**:185–186  
*Branhamella catarrhalis* and others,  
**52**:188  
*Staphylococcus aureus* Strain Cowan,  
**52**:187–188
- Epstein-Barr virus, **52**:193–195  
 virus-induced immunosuppression and,  
**45**:356, 357, 362
- Polyclonal plasmacytosis, in patients with  
 Castleman's disease, **54**:40–41
- Polyclonal stimulation, **42**:19–22
- Polycomb* group, **63**:241
- Polyglutamic acid, anthracycline–antibody  
 conjugation role in cancer treatment,  
**56**:338
- Polyinosinic:polycytidylic acid, hybrid  
 resistance and, **41**:371–372, 388–390
- Poly(l-lysine), synthetic T and B cell sites  
 and, **45**:198, 199
- Polymerase chain reaction  
 autoimmune demyelinating disease and,  
**49**:357, 368  
 Ig heavy-chain variable region genes and,  
**49**:27, 35–36  
 leukocyte integrins and, **46**:175, 176  
 quantitative techniques, **54**:137

- Polymeric antigens, and IgE responses, **52:289–290**
- Polymeric Ig receptor, **65:249**
- Polymerization  
 aPL antibodies and, **49:230**  
 CD23 antigen and, **49:168**  
 cell-mediated killing and, **41:290, 292–295, 298**  
 complement components and, **38:234**  
 genetically engineered antibody molecules and, **44:79**  
 IL-1 and, **44:179, 183**  
*Ir* genes and, **38:35, 37**  
 membrane attack complex of complement and, **41:304, 305, 309, 311**
- Polymers, size-fractionated: Dintzis model, **52:288–289**
- Polymorphism  
 autoimmune demyelinating disease and, **49:365, 368–369**  
 B cell formation and, **41:193, 197, 223, 224, 229**  
 CD1 proteins, **59:46–47**  
 complement components and, **38:206, 236**  
   of C2, **38:208, 209**  
   of C4, **38:223, 225, 229–231**  
   of C4b-binding protein, **38:204**  
   of Factor B, **38:207–209, 227**  
   restriction fragment length, **38:215, 216**  
 CTL and, **41:135–137, 169**  
   amino acid, **41:158–163, 165**  
   exon shuffling, **41:141, 142**  
   HLA class I antigens, **41:151**  
   mAbs, **41:158, 165**  
 hybrid resistance and, **41:367, 400, 401, 405**  
 Ig heavy-chain variable region genes and, **49:1–3**  
   J<sub>H</sub> Segments, **49:34**  
   V<sub>H</sub> families, **49:9, 17–18, 20–21**  
   V<sub>H</sub> gene expression, **49:41, 48**  
   V<sub>H</sub> gene segments, **49:21–28**  
*Ir* genes and, **38:190**  
 cytotoxic T cells, **38:169**  
 gene function, **38:93**  
 Ia molecules, **38:68**  
 T cell repertoire, **38:145**  
 maternally transmitted antigen, **38:336, 347**  
 regulators of complement activation and, **45:388, 396, 407**  
 sporozoite malaria vaccine and, **45:311–313**  
 surface antigens of human leukocytes and, **49:80–81, 92**  
 synthetic T and B cell sites and, **45:229**  
 TAP, **65:71–75**  
 T cell receptor, **38:16; 45:108**  
   alloreactivity, **45:149, 154, 156**  
   homogeneity, **45:129**  
   MHC molecules, **45:112, 115–117**  
   peptides, **45:132**  
   residues, **45:157–162**  
   structure-function relationships, **45:140**  
   T cell repertoire, **45:162, 167**
- T cell subsets and  
 cell surface molecules, **41:41, 44–47**  
 H-2 alloantigen recognition, **41:182, 183**  
 H-2-restricted antigen recognition, **41:58, 59, 62**
- V<sub>H</sub> gene segments, **49:22–27**  
 V<sub>H</sub> locus, **62:8–9**
- Polymorphism analysis, **48:114**
- Polymorphonuclear leukocytes, *see* Neutrophils
- Polymyositis, antinuclear antibodies and, **44:118–120**  
 autoantibodies, **44:137**  
 autoimmune response, **44:131, 132**  
 mixed connective tissue disease, **44:111**  
 scleroderma, **44:124**  
 Sjögren's syndrome, **44:112, 113**  
 SLE, **44:97, 109**
- Polypeptide chain, AChR, **42:238**
- Polypeptides  
 antigen-presenting cells and, **47:82, 88**  
 antinuclear antibodies and, **44:120**  
 autoantibodies, **44:127**  
 autoantigen, **44:129, 131**  
 autoimmune response, **44:135**  
 scleroderma, **44:121, 123, 124**  
 SLE, **44:101**  
 autoimmune thyroiditis and, **46:272**  
 B cell formation and, **41:190**  
 CD4 and CD8 molecules and, **44:298**  
   CD4 molecular biology, **44:284–287**  
   CD8 molecular biology, **44:270–275, 277–280, 284**  
 CD5 B cell and, **47:142**

- cell-mediated killing and, **41**:291, 292, 298, 313
- complement receptor 1 and, **46**:184
- complement receptor 2 and, **46**:204
- CTL and, **41**:168
- cytolysis and, **41**:276, 279, 285
- cytotoxicity and, **41**:309, 319
- genetically engineered antibody molecules and
- cloning, **44**:73
  - expression, **44**:79
  - fusion proteins, **44**:85, 86
  - production, **44**:67–69
- helper T cell cytokines and, **46**:124
- IgE biosynthesis and, **47**:17–19, 34
- IL-1 and, **44**:153
- human disease, **44**:193
  - receptor, **44**:180, 183
  - structure, **44**:155
  - TNF, **44**:185, 186
- IL-5, molecular structure, **57**:149–151
- immunosenescence and, **46**:229, 230
- Ir* gene control and, **38**:46–50
- leukocyte integrins and, **46**:153, 156
- lymphocyte homing and, **44**:342, 371
- maps of Ig-like loci and, **46**:2, 46
- structure, **46**:7, 12, 20
  - T cell receptor, **46**:35, 41–43
- NK cells and, **47**:202, 203, 208, 213
- pore formers and, **41**:316, 317
- regulators of complement activation and, **45**:392, 405
- sporozoite malaria vaccine and
- CS proteins, **45**:294, 295, 300
  - human trials, **45**:315
  - Plasmodium vivax*, **45**:318
- surface antigens of human leukocytes and, **49**:92, 94, 101, 112–113, 115
- synthetic T and B cell sites and
- bacterial antigens, **45**:238
  - prediction, **45**:251
  - vaccine, **45**:253, 255
  - viral antigens, **45**:221, 224
- T cell activation and, **41**:10, 17, 23
- T cell receptor and
- accessory molecules, **45**:109
  - antigen processing, **45**:120
  - homogeneity, **45**:130
  - MHC molecules, **45**:112
  - T cell repertoire, **45**:165
- T cell subsets and, **41**:41, 43, 50, 51, 75
- Polyperforin 1, cytotoxicity and, **41**:280, 289
- Polyperforin 2, cytotoxicity and, **41**:280
- Polyphosphomonooester, lymphocyte homing and, **44**:356–363, 370
- Polyps, nasal, endothelial adhesion of eosinophils, **60**:167–168
- Polyribosomes, B cell formation and, **41**:183
- Polysaccharides
- CD23 antigen and, **49**:162
  - lymphocyte homing and, **44**:320, 356, 357, 362
  - surface antigens of human leukocytes and, **49**:87
- Poly-2-vinylpyridine-*N*-oxide, hybrid resistance and, **41**:371
- POMC, **61**:371
- Population dynamics, B cell formation and, **41**:205–208
- Population studies, RA susceptibility, **56**:425–427
- Pore formation, cytotoxicity and, **41**:313–320
- Pore-forming protein, *see* Perforin
- Positional cloning, X-linked
- agammaglobulinemia gene, **59**:165–169
- Position-specific antigens, leukocyte integrins and, **46**:153
- Positive selection
- CD4<sup>+</sup>8<sup>+</sup> cells, **58**:158–159
  - definition, **59**:105, 110
  - discovery, **59**:109–113
  - epithelial cells, **59**:120–121
  - genetically manipulated animals, **59**:113–118
  - inducing cells, **58**:164–165
  - ligand for, **59**:122–128
  - ligands, **58**:160–164
  - mechanism, **51**:175–189
  - functional divergence, **51**:186–189
  - ligands and receptors in positive selection, **51**:178–180
  - molecular basis of four-way CD4 vs CD8 down-regulation, **51**:185–186
  - developmental choice, **51**:180–186
  - positive vs negative selection, **51**:180–183
  - signaling pathways that control positive selection, **51**:183–185
  - vs two kinds of death, **51**:175–177

- Positive selection (*continued*)  
 thymocytes, **59:99–129**  
 vs negative selection, **51:180–183**  
 vs two kinds of death, **51:175–177**
- Post-translational modification  
 antinuclear antibodies and, **44:131**  
 lymphocyte homing and, **44:370**  
 role in class I assembly and transport,  
**52:59–62**  
 glycosylation, **52:59–61**  
 palmylation, **52:61–62**  
 phosphorylation, **52:62**  
 T cell development and, **44:241**
- Post-translational processing event, **48:123**
- Post-transplant lymphoproliferative disorder,  
**54:35–36**
- Potassium, cytotoxicity and, **41:294, 318**
- Potassium channels, **48:287–288**
- Poxviruses  
 homologs, **61:10**  
 virulence factors, **63:308–309**
- Praomys*, autoimmune thyroiditis and, **46:273, 275**
- Prasnitz-Kustner reaction, genetically engineered antibody molecules and,  
**44:68**
- PRE2*, **64:20**
- PRE3*, **64:20**
- Pre-B cells, *see* B cells, pre-B cells
- Precipitation  
 epitope, **48:23**  
 segmental flexibility, **48:23–24**
- Precursor cells, HIV infection and,  
**47:395–397**
- Precursor peptides, to be GPI anchored,  
**60:61–63**
- Prednisolone, IBD and, **42:318–319**
- Prednisone  
 aPL antibodies and, **49:223**  
 MG and, **42:272**  
 prostaglandin synthesis and, **42:312–313**
- Pregnancy  
 alloimmunization, human, anti-HLA antibodies and, **39:281–282**  
 idiotypic network, **39:281–282**  
 and IL-10, **56:17**  
 and preterm delivery, IL-1ra effects,  
**54:216–217**  
 rheumatoid arthritis remission during,  
**56:431**
- Pregnancy zone protein, **38:234, 236**
- PRE-I, **65:18–19**
- Preimmune repertoire, self-tolerance checkpoints, **59:281–319**
- Prekallikrein, **66:225**  
 activation, **66:249**  
 function, **66:236**  
 properties, **66:226, 229**  
 structure, **66:229**
- Pre-pre B cells, **43:237**
- Preproenkephalin, helper T cell cytokines and, **46:112, 116**
- Pre-T cell receptor  $\alpha$ , **62:42, 44**
- Pre-T cells, endothelium and migration of to thymus, **50:275**
- Preterm delivery, IL-1ra effects, **54:216–217**
- Primary amyloidosis, **64:219, 220–221**
- Primary antiphospholipid syndrome,  
**49:257–259**  
 clinical aspects, **49:209, 219, 221–222**  
 isotype, **49:225–226**
- Primary B cell repertoire, antiidiotypic recognition and, **42:51–62, see also** B cell repertoire expression
- Primary biliary cirrhosis, antibodies to self-antigens from human donors,  
**57:244–245**
- Primate lentiviruses, phylogenetic tree,  
**52:444**
- Primates, antibodies derived from,  
**57:231–232**
- Priming  
 adoptive T cell therapy of tumors and,  
**49:308–310, 321, 325, 329–332**  
 antigen-presenting cells and, **47:65, 68, 71–73, 75, 80**  
 T cells, **47:82, 83, 85, 86, 94**  
 tissue distribution, **47:56**  
 autoimmune demyelinating disease and,  
**49:370**  
 CD5 B cell and, **47:137, 139**  
 hybrid resistance and, **41:370**  
 IgE biosynthesis and  
 antibody response, **47:6, 29, 30, 32, 33, 36–39**  
 binding factors, **47:14, 22–24, 26, 28**  
 T cell subsets and, **41:72, 74, 100**
- Primordial germ cells, LIF effects, **53:34–35**

- Pristane  
 arthritis induction by, **64:289**  
 plasmacytoma induction by, **64:222–227**
- Pro-B cells, *see* B cells, pro-B cells
- Probes, of T cell proliferations, **40:268–269**
- Procainamide, antinuclear antibodies and, **44:109, 111**
- Procarbazine serum, hybrid resistance and, **41:350**
- Programmed cell death, *see* Apoptosis
- Proinflammatory cytokines, **64:291–294**  
 IL-6 effects, **54:27–28**
- Prokaryotes, maternally transmitted antigen and, **38:348**
- Prolactin, **63:379–380**  
 activation of Jak2, **60:7**  
 expression, **63:381–384**  
 gene regulation, **63:400**  
 hyperprolactinemia, **63:380, 430**  
 immune system, **63:377–378**  
 lymphohemopoietic system, **63:382–384, 431–432**  
 regulation, **63:381–384**  
 secretion, **63:382**  
 structure and physiology, **63:380–381**  
 in women, **63:380, 400, 409**
- Prolactinoma, **63:380**
- Prolactin receptor, **48:180–181; 63:394–396, 396–401**  
 NK cell, **48:180**
- Proliferating cell nuclear antigen, antinuclear antibodies and, **44:94**  
 autoantigen, **44:130**  
 autoimmune response, **44:131, 134, 135**  
 SLE, **44:95–97, 106–108**
- Proliferation  
 adoptive T cell therapy of tumors and, **49:283, 334–335**  
 antigen recognition, **49:319, 321**  
 expression of antitumor responses, **49:325–330**  
 mechanisms, **49:300, 302, 304**  
 principles, **49:289–290, 294, 298**  
 autoimmune demyelinating disease and, **49:359–360, 362, 364–366, 370**
- B cell formation and, **41:183, 184, 186, 187**  
 B cell precursors, **41:192, 200, 202**  
 bone marrow cultures, **41:210, 212**  
 genetically determined defects, **41:225, 229, 231, 232, 234**  
 inducible cell line, **41:220**  
 population dynamics, **41:205–207**
- B cells, **40:6**  
 antibody response and, **40:7–12**  
 B cell subpopulations, **53:127–130**  
 cytotoxicity and, **41:269**  
 hybrid resistance and, **41:384, 390, 391, 397**  
 bone marrow cells, **41:335, 336, 338, 340, 349**  
 lymphoid cells, **41:352, 353**  
 long-term, pro- and pre-B cells, **53:131–136**  
 SCID and, **49:384–387, 390–391, 400**  
 stem cell factor receptor–ligand interaction in, **55:39–40**
- T cell activation and, **41:1, 6, 7, 9, 10, 12–15, 26**
- T cell clone, **58:126–127**
- T cells, **51:106–110**  
 anergy, **51:109–110**  
 growth, **51:106–109**
- T cell subsets  
 H-2 alloantigen recognition, **41:85, 86, 88, 92**  
 H-2-restricted recognition of antigen, **41:51, 52, 60, 62–66, 70, 72**
- Pro-MCP, **61:216**
- Promonocytes, hybrid resistance and, **41:371**
- Promoters  
 CD23 antigen and, **49:166–167**  
 Ig heavy-chain variable region genes and, **49:53–56, 61**  
 OTF2, **49:55**  
 PGHS-1 and PGHS-2, **62:192–196**
- Promyelocytic leukemia cells, hybrid resistance and, **41:348**
- Proopiomelanocortin, **48:172–173**
- Properdin, **61:207, 241–245**  
 sporozoite malaria vaccine and, **45:296**
- Propionylsalicylate, **62:187**
- Prostacyclin  
 aPL antibodies and, **49:253, 255**  
 IL-1 and, **44:160**
- Prostaglandin binding sites, **52:399–401**
- Prostaglandin E, release, Fc fragments and, **40:103–106**
- Prostaglandin E<sub>2</sub>, **59:376; 62:198; 63:57–58**  
 action of, **65:124–125**  
 CD40 expression, **61:98**



- Prostaglandin E<sub>2</sub> (*continued*)  
 production by RAW 264.7 cells,  
**60:349–350**
- Prostaglandin endoperoxide H synthase,  
**62:192**  
 cellular and physiologic action of PGHS,  
**62:196–200**  
 future work, **62:201–202**  
 membrane-binding domain, **62:172–173**  
 NSAIDs, **62:184–187**  
 pathophysiologies, **62:200–201**  
 regulation of gene expression, **62:188–196**  
 structure–function relationships,  
**62:169–178**
- Prostaglandin endoperoxide H synthase-1  
 catalysis by, **62:178–188**  
 cellular and physiologic action, **62:196–200**  
 future work, **62:201–202**  
 gene structure, **62:192**  
 mangano-heme PGHS-1, **62:188**  
 NSAIDs, **62:184–187**  
 pathophysiology, **62:200–201**  
 platelet aggregation, **62:200–201**  
 promoters, **62:192–196**  
 prostanoid production, **62:196–199**  
 regulation of gene expression, **62:188–189**  
 structure–function relationship,  
**62:169–178**
- Prostaglandin endoperoxide H synthase-2  
 catalysis by, **62:178–188**  
 cellular and physiologic action, **62:196–200**  
 cyclooxygenase active site, **62:174–176**  
 future work, **62:201–202**  
 gene structure, **62:192**  
 inflammation, **62:201**  
 NSAIDs, **62:184–187**  
 pathophysiology, **62:200, 201**  
 peroxidase active site, **62:176–177,**  
**187–188**  
 promoters, **62:192–196**  
 prostanoid production, **62:199–200**  
 regulation of gene expression, **62:188–196**  
 structure–function relationship,  
**62:169–178**  
 trypsin cleavage sites, **62:174**
- Prostaglandin E synthase, **62:198**
- Prostaglandin C, **62:174**
- Prostaglandin H<sub>2</sub>, **62:198**
- Prostaglandin I<sub>2</sub> synthase, **62:200**
- Prostaglandins  
 adoptive T cell therapy of tumors and,  
**49:287**  
 B cell formation and, **41:208, 236**  
 CD23 antigen and, **49:160**  
 hybrid resistance and, **41:360, 387**  
 IBD and, **42:310–315**  
 IL-1 and  
   biological effects, **44:165, 166, 168**  
   gene expression, **44:160, 161**  
   human disease, **44:193, 195**  
   TNF, **44:186–188**  
 NK cells and, **47:250, 257**  
 production by IL-1ra, **54:201**  
 SCID and, **49:384**  
 and thromboxane, **51:347–352**  
   biological activities, **51:347**  
   measurements of prostanoids in  
     biological fluids, **51:349**  
   pharmacological modulation  
     airway hyperresponsiveness,  
       **51:351–352**  
     airway tone and acute asthmatic  
       response, **51:350–351**  
     prostanoid action, **51:350–352**  
   potency, **51:347–349**  
   prostanoids and airway  
     hyperresponsiveness, **51:349**  
     synthesis and metabolism, **51:347**
- Prostanoids, **62:167, 168, 196–200**  
 action, pharmacological modulation,  
**51:350–352**  
 airway hyperresponsiveness, **51:351–352**  
 airway tone and acute asthmatic  
 response, **51:350–351**  
 and airway hyper-responsiveness, **51:349**  
 measurements of in biological fluids,  
**51:349**
- Prostate-specific antigen, **62:224–225**
- Protease inhibitors, prevention of DNA  
 fragmentation, **58:252**
- Proteases, cytotoxicity and, **41:282, 298**
- Proteasome inhibitors, **64:11–12**
- Proteasomes, **64:1–3, 8; 65:15**  
 20S, **64:9, 11, 12, 20, 24–25, 30, 105**  
 26S, **64:9–11, 21, 25–26, 30, 105–107**  
 activator protein, **64:21–24**  
 cleavage properties, **64:24–26**  
 in cytosolic degradation pathway,  
**52:25–28**

- genes, evolution, **64**:19–21  
inhibitors, **64**:11–12  
LMP and IFN- $\gamma$  regulation, **64**:12–14  
molecular adaptation, **64**:19–21  
structural and catalytic features, **64**:8–11  
subunits XY, **64**:14–16  
subunits Z and MECL1, **64**:16–18  
threonine residues, **64**:18–19  
Protective immunity, HIV-1 disease,  
**63**:95–98  
Protein antigen presentation, by cultured  
endothelial cells, **50**:265–266  
Protein antigens, **62**:221–225  
Proteinases, pulmonary inflammation,  
**62**:266–267  
Protein-binding sites  
  B cell-specific, **43**:256  
  enhancers containing, **43**:264  
  fibroblast-specific site, **43**:256  
  heavy and  $\kappa$  chain enhancers, **43**:243–244  
  IgE, **43**:281–282  
  multiple  
     $\kappa$  enhancer, **43**:250–251  
    required, **43**:245–247  
    *in vitro* mapping, **43**:244–245  
  NF- $\kappa$ B, **43**:250–251  
  nuclear factors, **43**:255  
  protein purification, **43**:247  
  sequences, **43**:246  
  site A, **43**:248  
  site B/ $\mu$ E1, **43**:247  
  site D, **43**:248  
  site E, **43**:247  
  switch recombination, **61**:117, 120  
    E47/E12, **61**:117  
    LR1, **61**:120  
    NF- $\kappa$ B/p50, **61**:117, 118–119  
    NF-S $\mu$ , **61**:119  
    Pax5, **61**:120–122  
    Sy3 regions, **61**:117–118  
    S $\mu$ bp-2, **61**:119  
  switch regions, at or near, **61**:117–122  
  *in vivo*, **43**:243–244  
  V $\beta$  promoter, **43**:268–269  
Protein C, aPL antibodies and, **49**:253–256  
Protein–DNA complexes, **58**:56–57  
Protein electrophoresis, complement  
components and, **38**:225  
Protein export, mitochondrial, maternally  
transmitted antigen and, **38**:315  
Protein interaction domain, Ras/MAP kinase  
cascade, **61**:161  
Protein kinase, **48**:228  
  antigen-presenting cells and, **47**:101  
  Ca<sup>2+</sup>-dependent, **48**:274–275  
  CaM-dependent, **48**:274–275  
  cAMP-dependent, VIP effect, in  
  lymphocytes, **39**:311  
  CD4 molecules and, **44**:296  
  CD5 B cell and, **47**:125  
  cyclic nucleotide-dependent, **48**:  
  275–277  
  DNA-dependent, *see* DNA-dependent  
  protein kinase  
  in Fc receptor-mediated signal transduction  
  Fc $\gamma$ R, **57**:74–77  
  Fc $\epsilon$ RI, **57**:79–81  
  HIV infection and, **47**:382  
  IgE biosynthesis and, **47**:26  
  IL-1 and, **44**:175, 176, 179, 185  
  mitogen-activated, *see* MAP kinase  
  NK cells and, **47**:249, 271  
  p34<sup>cdc</sup>, cell cycle regulatory, blockade,  
  **58**:267  
  stress-activated, **63**:148  
  surface antigens of human leukocytes and,  
  **49**:77, 81, 83, 113  
  T cell, signal transduction, **48**:284  
  T cell development and, **44**:214, 226  
Protein kinase Ia, interaction with CD3/TCR  
complex, **58**:232  
Protein kinase A, inhibition, **63**:51  
Protein kinase B, **63**:153–154  
Protein kinase C, **48**:79, 270–274;  
**63**:154–157  
  autoimmune thyroiditis and, **46**:296  
  B cell formation and, **41**:222  
  CD45, **63**:165  
  cell-mediated killing and, **41**:296, 297  
  complement receptor 1 and, **46**:187, 199  
  complement receptor 2 and, **46**:202, 208,  
  211  
  growth hormone, **63**:399  
  humoral immune response and, **45**:43  
  IL-2 signaling, **63**:171, 172  
  in IL-3-dependent cells, **39**:39  
  immunosenescence and, **46**:222–227, 230,  
  235  
  isozymes, **54**:371  
  leukocyte integrins and, **46**:169

- Protein kinase C (*continued*)
- neutrophil activation
    - Ca<sup>2+</sup> and, **39**:130–135
    - DAG and, **39**:130–135
    - termination of, **39**:131
    - metabolism activation by, **39**:128–129
    - protein targets of, **39**:129
    - translocation, **39**:127–128
    - Ca<sup>2+</sup> role, **39**:128–130
  - plasma membrane kinase, **54**:370
  - role in phosphoinositide hydrolysis, **43**:292–293
  - role in thymocyte apoptosis, **58**:245–246
  - signal transduction, **59**:263–264
  - T cell activation and, **41**:8, 31
    - Ca<sup>2+</sup>, **41**:15–19
    - gene regulation, **41**:28–30
    - receptor-mediated signal transduction, **41**:19, 20, 23, 25, 26
  - T cell subsets and, **41**:65
  - tyrosine kinase, role in IgR-associated transmembrane signaling, **54**:359–364
- Protein phosphatase, **48**:283–285
- Protein–protein interactions, **43**:81, 265
- buried surfaces, **43**:100–101
  - complementarity, **43**:101–103
  - conformational changes, **43**:103–105
  - free energy, **43**:100
  - structural complementarity, **43**:104–105
  - thermodynamics, **43**:100
- Protein S, **61**:237
- Proteins
- adoptive T cell therapy of tumors and, **49**:283, 334–335
    - antigen recognition, **49**:319–324
    - expression of antitumor responses, **49**:324, 331–332
  - antigen-presenting cells and, **47**:46, 64–73, 77
    - antigen processing, **47**:87, 88, 90, 91
    - cell surface, **47**:60
    - immunogenicity, **47**:104
    - T cells, **47**:86, 94, 99, 101
  - antinuclear antibodies and, **44**:93, 94
  - autoantibodies, **44**:125, 127, 137, 138
  - autoantigen, **44**:127–131
  - autoimmune response, **44**:137, 138
  - dermatomyositis, **44**:118–120
  - mixed connective tissue disease, **44**:111
  - scleroderma, **44**:121, 122, 124, 125
  - Sjögren's syndrome, **44**:112, 113, 115
  - SLE, **44**:98, 100–106, 108, 109
  - aPL antibodies and, **49**:195, 259
    - affinity purification, **49**:229–230
    - clinical aspects, **49**:200, 203, 213
    - pathogenic potential, **49**:253–254, 256–257
    - specificity, **49**:239–240, 247–248, 250–252
  - autoimmune demyelinating disease and, **49**:369
  - autoimmune thyroiditis and, **46**:265, 266, 315, 316
    - antigens, **46**:268, 272
    - cellular immune responses, **46**:294
    - experimental models, **46**:276
  - B cell formation and, **41**:205, 216, 239
    - B cell precursors, **41**:191, 197, 198
    - inducible cell lines, **41**:221, 222
  - biosynthesized, targeting to class I processing pathway, **52**:19–21
  - CD4 and CD8 molecules and, **44**:265, 266, 297, 298, 303
    - CD4 molecular biology, **44**:285, 288–291, 297
    - CD8 molecular biology, **44**:271–274, 276–280, 284
  - CD5 B cell and, **47**:126
    - Ig gene expression, **47**:150, 153, 154, 157
    - physiology, **47**:131, 134
    - primordial immune network, **47**:160
    - surface antigen, **47**:146
  - CD23 antigen and, **49**:176
    - biological activity, **49**:169, 171
    - cellular expression, **49**:152–154
    - cleavage regulation, **49**:158
    - expression regulation, **49**:160
    - FcεRII, **49**:162–165, 167
  - complement receptor 1 and, **46**:185, 186, 190, 194, 197, 199
  - complement receptor 2 and, **46**:201–203
  - CTL and, **41**:135, 148, 153, 154, 159, 165, 168
  - cytotoxicity and, **41**:269, 270, 320
    - cell-mediated killing, **41**:289–295, 297, 311, 312
  - cytolysis, **41**:277–281, 316–319
  - mediation, **41**:270–273

- membrane attack of complement and,
  - 41:299, 301, 303, 307, 309–311
  - small peptides, 41:314
- degradation mediated by ubiquitin-proteasome system, 64:6–8
- entry into class I processing pathway,
  - 52:13–14
- epitopes, 43:2–4
- extracellular matrix, interaction of CD44,
  - 54:290–291
- folding, 43:83, 100
- fusion
  - expressing B cell lymphoma and GM-CSF, 58:435
  - L-selectin-IgG, 58:353, 358–359
- genetically engineered antibody molecules and, 44:89
  - antigen-combining sites, 44:84, 85
  - chimeric antibodies, 44:79, 80, 82, 87
  - cloning, 44:75
  - expression, 44:76, 78
  - fusion, 44:85, 86
  - lymphoid mammalian cells, 44:70
  - production, 44:66–68
- GPI-anchored, 60:57–74, 79
- granule
  - eosinophil, 60:191–194, 205–208, 221
  - role in DNA fragmentation, 60:300–301
- helper T cell cytokines and, 46:115, 116, 123
- HIV infection and
  - activation, 47:398–402
  - etiological agent, 47:378–382, 384, 385
  - immune response, 47:405–407, 409, 411
  - immunopathogenic mechanism, 47:387, 392, 395
- human counterpart of IgR-associated,
  - 54:356–357
- human T cell activation and, 41:1, 4, 8, 18, 23
  - gene regulation, 41:29, 30
  - IL-1 receptor, 41:13, 14
- humoral immune response and
  - antigens, 45:10, 14, 15, 17, 18
  - helper T cells, 45:35
  - interleukins, 45:72, 74, 75
- hybrid resistance and, 41:393
- Ig complex-associated, 52:138
- IgE biosynthesis and, I
  - antibody response, 47:2, 3, 11
  - antibody response suppression, 47:31, 32, 34, 39
  - binding factors, 47:16–18, 20, 22, 24–27
- Ig gene superfamily and
  - evolution, 44:43, 44
  - homology unit, 44:5, 6, 8
  - MHC complex, 44:24, 26, 28
  - nonimmune receptor members, 44:30, 31, 34–37, 39–41
  - receptors, 44:10, 11, 14, 16, 17, 21
- Ig heavy-chain variable region genes and,
  - 49:1–3
  - D segments, 49:33
  - regulation, 49:53–57
  - V<sub>H</sub> families, 49:6–9, 11, 15, 18
  - V<sub>H</sub> gene expression, 49:39, 41, 43, 46, 51
- IL-1 and, 44:154, 155
  - biological effects, 44:164–166
  - gene expression, 44:159–161, 163
  - human disease, 44:192, 194
  - immunocompetent cells, 44:173, 177, 178
  - receptor, 44:179, 182–184
- IL-10-related, properties, 56:3
- immunogenicity, 43:2
- immunosenescence and, 46:222, 223, 227–230, 234
- interaction with Ig conserved octanucleotide, 43:254–255
- isoform-specific TGF- $\beta$ -binding,
  - 55:199
- $\kappa$ B-dependent, inappropriate expression,
  - 58:17–18
- leukocyte integrins and
  - inflammation, 46:164, 165, 169
  - leukocyte adhesion deficiency disease, 46:174, 175
  - ligand molecules, 46:171
  - structure, 46:153, 154, 158, 159
- lymphocyte homing and
  - carbohydrate, 44:354, 356, 364, 369, 370
  - molecules, 44:342, 345–349, 351, 353
- maps of Ig-like loci and
  - MHC, 46:28–30, 32
  - structure, 46:8, 10, 12, 13, 15, 17, 19
  - T cell receptor, 46:45
- molecule, 43:118
- murine lupus models and, 46:69

Proteins (*continued*)

naturally occurring, T cell specificity for  
 liner sequences, **43:198–201**

NK cells and, **47:284, 287, 291**

cytotoxicity, **47:252, 255**

effector mechanisms, **47:241, 242,**  
**244–246**

lymphokines, **47:263, 265**

surface phenotype, **47:203, 205**

octanucleotide, **43:254–255**

oligomeric, buried surfaces, **43:101**

oncogenic, **62:237–238; 64:65**

recognition by T cells, **58:420–421**

outer membrane, *Chlamydia*, **60:136**

posttranslational modification, **64:169**

regulators of complement activation and,  
**45:381–383, 410, 411**

expression, **45:394–403**

genes, **45:403, 405, 408**

interactions, **45:383, 384**

roles, **45:384–390**

short consensus repeat, **45:391–394**

utilization, **45:409, 410**

retroviral, IgE-binding factor, **43:304**

SCID and, **49:387**

soluble TGF- $\beta$ -binding, **55:199–200**

spontaneous autoimmune thyroiditis and,  
**47:462, 476, 479**

sporozoite malaria vaccine and, **45:319–322**

antibodies, **45:300**

CS proteins, **45:292–300**

CS-specific T cells, **45:306–313**

immunity, **45:291, 292**

interferon- $\gamma$ , **45:306**

*Plasmodium vivax*, **45:317, 318**

surface antigens of human leukocytes and,  
**49:85, 90, 115–117, 125**

antigen-specific receptors, **49:76–77, 79**

MHC glycoproteins, **49:80, 82**

in switch recombination, **54:239–240**

synthetic T and B cell sites and, **45:195,**  
**197, 259–264**

antigens, **45:234**

globular protein antigens, **45:203–216**

immunological considerations, **45:201,**  
**202**

parasitic antigens, **45:228–230**

peptides, **45:203, 230–232, 237–239**

prediction, **45:250–252**

vaccine, **45:255–258**

viral antigens, **45:218, 219, 221, 223,**  
**227, 228**

T cell development and, **44:232, 234, 241**

T cell receptor and, **45:107**

accessory molecules, **45:110**

alloreactivity, **45:149**

antigen processing, **45:118, 119, 124,**  
**125, 127**

epitopes, **45:143–148**

experimental systems, **45:131, 132, 137**

homogeneity, **45:128, 129**

MHC molecules, **45:117**

peptides, **45:138, 139**

polymorphic residues, **45:160**

structure-function relationships,  
**45:139**

T cell repertoire, **45:165, 166**

T cell subsets and, **41:90, 97, 99**

cell surface molecules, **41:45–47, 50**

H-2-restriction antigen recognition,  
**41:52, 54, 56–58, 62, 70, 74, 75**

T cell receptor, **41:41–43**

tumor antigens derived from

abl oncogenes, **57:296–297**

bc1 oncogenes, **57:296–297**

mutated p53, **57:295–296**

overexpression role, **57:299–302**

ras oncogenes, **57:297–299**

tum<sup>-</sup>, **57:293–295**

tyrosine phosphorylation, B cell antigen  
 receptor-induced, **55:231–233**

as V(D)J joining factors

nonamer-binding, **56:69–70**

RBP-J $\kappa$ , **56:70–71**

recognition protein, **56:71**

signal-binding, **56:69**

V(D)J joining protein, **56:72**

virus-induced immunosuppression and

HIV, **45:348, 349, 361–363,**

**365–367**

measles, **45:337–339, 346**

virus-produced, **58:16–17**

$\zeta$  and  $\epsilon$

invariant chains, **58:127–128**

and structure and assembly of TCR  
 complexes, **58:121–124**

## Protein synthesis

hepatic, cachectin and, **42:225**

maternally transmitted antigen and,  
**38:348**

- Protein-tyrosine kinase, **59**:178–185,  
259–261, 265–266; **63**:51  
activation by B cell antigen receptor  
components, **55**:248, 250–253  
coreceptors, **55**:259–261  
functions, **55**:255–256  
signal initiation model, **55**:256–259  
*src* family, regulation, **55**:253–255  
adaptor molecules, **63**:134, 141–143  
CD23 antigen and, **49**:169  
complement receptor 1 and, **46**:202  
cytoplasmic, **59**:176–185  
developmental expression, **54**:362  
IL-2R activation, **61**:153–159  
lymphoid tissue, **48**:277–280  
phosphorylation, in Fas ligand expression,  
**60**:298–299  
protein expression, **54**:416  
regulate lymphocyte function, **59**:176–178  
signal transduction, **59**:259–261  
surface antigens of human leukocytes and,  
**49**:78, 99–100, 113  
T cell, **48**:277–280  
substrates, **48**:281–283  
transforming protein, properties of *v-2bl*  
and, **37**:76–77
- Protein-tyrosine-phosphatase, **63**:164, 198  
calcineurin, **63**:166–167  
CD45, **63**:164–165  
CD45R(0), and T cell apoptosis, **58**:246  
negative regulation of cytokine signaling,  
**60**:25–26  
PAC-1, **63**:167  
SHPTP2, in cytokine signaling, **60**:26
- Protein-tyrosine-phosphatase 1C, **59**:299–300,  
308–309; **63**:165–166
- Proteoglycans  
cachectin and, **42**:224  
CD44  
binding to  $\beta$ -chemokine, **58**:383  
role in leukocyte–endothelial adhesion,  
**58**:376–377  
cell-mediated killing and, **41**:298
- Proteolipid protein  
autoimmune demyelinating disease and,  
**49**:362, 374  
multiple sclerosis and, **66**:88, 90
- Proteoliposomes, cytotoxicity and, **41**:274,  
278, 303
- Proteolysis, **52**:22–35; **64**:3  
additional factors in selectivity, **52**:34–35  
antigen-presenting cells and, **47**:66, 87, 88  
in antigen processing, functional evidence,  
**52**:24–25  
antinuclear antibodies and, **44**:132, 135  
background information, **52**:22–24  
CD5 B cell and, **47**:130, 161  
CD23 antigen and, **49**:156–158, 173  
chemokines, **55**:102–103  
cytotoxicity and, **41**:275, 276, 301, 305  
functional evidence for peptide production  
in cytosol, **52**:28–29  
functional evidence for proteolysis in  
antigen processing, **52**:24–25  
genetically engineered antibody molecules  
and, **44**:66, 86  
IgE biosynthesis and, **47**:16, 17, 20  
IL-1 and, **44**:158, 162, 164, 188, 192  
IL-8, **55**:102–103  
lymphocyte homing and, **44**:320, 354  
NK cells and, **47**:203, 250, 254  
proteasomes in pathway, **52**:25–28  
proteolytic machinery demonstrating  
selectivity, **52**:30–34  
*ras*GAP, B cell antigen receptor-induced  
activation, **55**:239–240  
role of class I molecules, **52**:29–30  
spontaneous autoimmune thyroiditis and,  
**47**:461  
surface antigens of human leukocytes and,  
**49**:90, 93, 112  
T cell activation and, **41**:18  
T cell subsets and, **41**:53
- Prothrombin, aPL antibodies and, **49**:231,  
242–243, 248
- Prothrombin activator complex, aPL  
antibodies and, **49**:199, 241
- Prothrombin time, aPL antibodies and,  
**49**:200
- Protooncogene, T cell activation, **48**:291–294
- Prototypic sequences, Ig heavy-chain variable  
region genes and, **49**:6–7
- Protozoan diseases, **60**:108–124  
multiple antigen peptides as immunogens,  
**60**:108–124
- Protozoan infections, X-linked  
agammaglobulinemia, **59**:146
- Proviruses, **65**:143  
Mtv, **65**:142–146

- Provoked immunity, **62:244**
- Proximal tubular epithelial cells, CD40 expression, **61:14**
- 4PS, **63:168**  
phosphorylation, **60:15–16**
- Psc* (posterior sex combs), **63:241**
- P-Selectin, **59:383; 62:276; 64:144, 145; 65:354, 355, 363, 367**  
cooperative ligand binding site, **58:354–357**  
expression, **64:148, 167**  
genetic studies, **64:194**  
ligands, **58:360; 64:150–152**  
120-kDa, **58:361**  
PSGL-1, **58:360–361**  
properties, **64:147**  
redistribution, **64:166**  
shedding, **64:171**  
synthesis, induction by alarm cytokines, **58:394**  
upregulation, **64:165, 166**
- Pseudoallelism, Ig heavy-chain variable region genes and, **49:14**
- Pseudogenes, **42:138; 62:16–17, 24–26**  
conserved, **62:16, 24**  
diverged, **62:16**  
Ig gene superfamily and, **44:20, 30**  
Ig heavy-chain variable region genes and, **49:57, 61**  
D segments, **49:29**  
J<sub>H</sub> segments, **49:33–34**  
organization, **49:3, 6, 8–9, 14–15, 17**  
V<sub>H</sub> gene expression, **49:39, 52**  
*J558 V<sub>H</sub>*, **42:115**  
V<sub>H</sub>, **42:113**
- Pseudogout, inflammation in, **66:260**
- Pseudo-light chain, **63:2**
- Pseudomonas* exotoxin A, **54:114**
- Pseudo T cell lymphoma, gene rearrangement and, **40:294–295**
- PSF1/2, **64:4**  
*psfl* gene, **65:50, 51**
- PSGL-1, **64:146, 150–151, 173**
- Psoriasis, and IL-6, **54:41**
- P/STEL sequences, PHCS-2, **62:177**
- Psychological factors, allergic reactions, **61:368–369, 374–375**
- pTα, **62:42, 44**
- PTB domain, Ras/MAP kinase cascade, **61:161–162**
- Pteridin metabolism, IFN-γ, **62:72**
- PUL1*, **64:86**
- PU.1  
B cell genesis, **63:217, 218–219, 222–224**  
binding sites, **64:76–77**  
domains, **64:76–77**  
expression, **64:85, 89**  
gene targeting, **64:86–87**  
interaction with NF-IL6, **65:21**  
oncogenic potential, **64:65**  
structure, **64:79**  
structure–function studies, **64:85–86**
- PU.1P*, **63:217, 222**
- Pulmonary disease, *see* Lung disease
- Pulmonary embolism, aPL antibodies and, **49:219**
- Pulmonary eosinophilia, including Churg–Strauss syndrome, **60:226**
- Pulmonary fibrosis, bleomycin, **59:418–419**
- Pulmonary hypersensitivity, **59:387, 412–420**
- Pulmonary immunity, **59:369–427**  
hypersensitivity lung diseases, **59:387, 412–420**  
transplantation, **59:420–426**  
vaccination, **59:409–412**
- Pulmonary inflammation, **62:257–260, 290**  
adhesion molecules, **62:267, 288**  
allergic, **62:283–285**  
animal models, **62:271–285**  
complement cascade, **62:260–262, 271, 286–288**  
cytokines, **62:267–271, 280, 288**  
and eosinophil increase, **60:219–220**  
granuloma formation, **62:280–283, 290**  
immune-complex mediated, **62:277–279**  
ischemia/reperfusion, **62:275–277**  
oxidant formation, **62:262–267**  
proteinases, **62:266–267**  
sepsis, **62:271–275**  
therapeutic interventions, **62:259, 285–290**
- Pulps, white and red, splenic, **60:268–269**
- Pulsed-field gel analysis, Ig heavy-chain variable region genes and, **49:4–5**
- PUP1* gene, **64:20**
- Purified protein derivative  
autoreactive T cells and, **45:419**  
humoral immune response and, **45:16**  
virus-induced immunosuppression and, **45:355, 356**
- Purine nucleotide phosphorylase deficiency, **59:246**

- Putrescine, **48:288**  
*PV*, *see* *Pemphigus vulgaris*  
 Pyridostigmine, for *MG*, **42:269–270, 271**  
 Pyrogen, endogenous, cachectin as, **42:224**  
 Pyrrolidine dithiocarbamate, **65:123**
- Q**
- Q10, **52:94–95**  
 Qa-2, **52:95–98**  
 QKRAA, Epstein-Barr virus  
   Dw4 peptide, **48:130**  
   gp 110 peptide, **48:130**  
 Q region gene products, **52:94**  
 Q10, **52:94–95**  
 Qa-2, **52:95–98**  
 Quantitative matrices  
   algorithms based on, **66:81–82**  
   peptide binding motifs by, **66:72–76**  
 Quantitative regulatory mechanism, **48:123**
- R**
- RA, *see* Rheumatoid arthritis  
 Rabbit, infection with HIV-1, **52:461–463**  
 Rabbit anti-mouse Ig, *see* Immunoglobulin,  
   rabbit anti-mouse  
 Rabies, synthetic T and B cell sites and,  
   **45:226, 244**  
 Rabies virus  
   AChR and, **42:272**  
   nucleocapsid, **54:116–117**  
 Race, *see also* Ethnicity  
   as RA susceptibility factor, **56:427–429**  
 Radiation chimeras, **59:106, 109–111**  
 Radioautoautography, B cell formation and,  
   **41:205**  
 Radioactive antigen suicide, **42:268**  
 Radioactivity, hybrid resistance and, **41:349**  
 Radioimmunoassay  
   IgE biosynthesis, **47:1, 20**  
   IL-1 and, **44:160, 163, 192**  
 Radioreceptor assay, IL-2, **42:166–167**  
 Radioreistance, hybrid resistance and,  
   **41:365, 376, 380, 383, 390, 393, 409**  
 Radiosensitivity, hybrid resistance and,  
   **41:350, 368**  
 Raf, **63:144, 147, 399**  
 Raf-1 kinase, signal transduction, **59:262–263**  
 RAFT1, **61:181**  
 RAG, **64:46**  
   B cell development, **63:20–21**  
 RAG1, **64:46, 48**  
 RAG1  
   aging and, **63:215**  
   in rabbit B lymphopoiesis, **56:184, 186**  
   as V(D)J joining agent, **56:64–67**  
   V(D)J recombination, **64:45–47, 52–54, 59**  
 RAG1/2, **61:123**  
   active in immature lymphocytes, **58:311**  
   mutations, **61:293–296, 317**  
   SCID, **61:308–310**  
   and signal joint product formation, **58:48**  
   transcription by CD44<sup>25+</sup> cells, **58:141**  
   transfection into *XR-1* G12 cells, **58:53**  
   transient transfection  
     into Bloom syndrome cells, **58:65**  
     into nonlymphoid cells, **58:51**  
     and V(D)J recombination, **58:32–33**  
     V–D–J recombination, **61:291–296**  
 RAG2, **64:46, 48**  
 RAG2  
   deficient blastocyst complementation,  
     **62:31–41**  
   in rabbit B lymphopoiesis, **56:184, 186**  
   as V(D)J joining agent, **56:66–67**  
   V(D)J recombination, **64:46–48, 52–54, 59**  
 Raji cells, complement receptor 2 and,  
   **46:201–203, 206, 207, 209, 210**  
 RaIGDS, **63:144**  
 RAMIG, *see* Immunoglobulin, rabbit  
   anti-mouse  
 RANTES, **62:285; 64:154**  
   composed of basophil chemotaxins,  
     **60:177–178**  
   HIV and, **65:282**  
 Rapamycin, **61:180–187, 182–183; 63:154**  
   effect on eosinophil survival, **60:197–198**  
   NF- $\kappa$ B and, **65:121**  
 RAP1, **61:181**  
 Ras, **62:42, 46; 63:143–147**  
   GTP-bound, **60:209**  
   IL-2 signaling, **63:171, 172**  
   mutant, **58:417**  
   prolactin signaling, **63:399**  
   signaling pathway, activation by cytokine  
     receptors, **60:12–14**  
   signal transduction, **59:261–262**



- ras*, tumor antigens derived from, **57:297–299**
- ras*-GAP, as p56<sup>lck</sup> target in T cell signaling, **56:159–160**
- ras*GAP-associated proteins, B cell antigen receptor-induced activation, **55:240–241**
- Ras-GTP, **63:147**
- Ras/MAP kinase, pathway, IL-2R initiation, **61:161–167, 190**
- Rat
- arthritis model, **60:343–344**
  - chloroleukemia cell line, observation, **50:73**
  - IL-6 administration *in vitro*, **54:25–26**
  - mutations affecting stem cell factor or SCF receptor, **55:23**
  - paw edema model, **60:328–329**
  - RT-6 alloantigen, **48:241**
  - wound healing model, **60:350–351**
- Rat basophilic leukemia tumor, **43:282–283**
- RAW 264.7 cells
- lipid A binding sites, **53:278–279**
  - LPS-stimulated, **60:349–350**
- RB, **65:25**
- Rb, **62:42, 48–49**
- Rb gene, **62:42, 48–49**
- Rch1, **64:48**
- Reactive hypereosinophilia, and neoplasms, **60:225**
- Reactive oxygen intermediates
- cytolysis and, **41:286**
  - NF- $\kappa$ B and, **65:122–123**
- Reactive oxygen species
- generation, inhibition by Bcl-2, **58:256**
  - IFN- $\gamma$ , **62:72**
  - induction of NF- $\kappa$ B, **58:6–7**
  - pulmonary inflammation, **62:262, 263**
  - role in PCD, **58:250**
  - scavenging by acute-phase proteins, **58:9**
- Reactive site
- association with electrostatic regions and surface grooves, **43:79**
  - MHr, **43:29**
  - stereochemistry, **43:32–39**
    - electrostatic potential, **43:35**
    - hydrophilicity, **43:35**
    - mobility and packing density, **43:33–35**
    - secondary structure, **43:38**
    - shape accessibility and exposed surface area, **43:35–36**
    - side-chain contributions, **43:36–38**
    - sites mapped by peptides cluster into conformational epitopes, **43:38–39**
    - superassemblies, **43:74–75**
- Reading frames, preB cells expressing D $\mu$  protein, **63:22**
- Reaggregate cultures, thymocyte maturation, **59:109**
- Reagin, aPL antibodies and, **49:258**
- biochemistry, **49:198**
  - specificity, **49:234–236, 240, 249–250**
- Rearrangement
- human B cell neoplasia and
    - Burkitt lymphoma cells, **38:257**
    - chromosome translocation, **38:267–269, 271**
    - c-myc* gene, **38:249**
    - c-myc* oncogene, **38:264**
  - Ir* genes and, **38:96**
  - maternally transmitted antigen and, **38:331, 339**
  - V $\alpha$ 11, **60:278–280**
  - V(D)J region, **60:38, 268**
  - V $\text{H}8$  gene, **60:47**
- Receptor affinity, B cell development and, **59:305–306**
- Receptor antagonists
- cytokines, **63:277**
  - function of IL-1ra as, **54:197–200**
- Receptor desensitization, **59:324–328**
- Receptor editing, B cells, **59:300–302**
- Receptor-mediated signal transduction, T cell activation and, **41:19–26**
- Receptors
- for activating peptides, **52:366–375**
    - formyl-methionine peptides and related compounds, **52:371–372**
    - IL-8 and related intercrines, **52:367–371**
    - substance P and other neuropeptides, **52:372–375**
  - auxiliary signaling, **51:157–160**
  - for growth and differentiating factors, **52:339–355**
  - and ligands/counterreceptors, promiscuity in interactions between, **52:138**
  - for low-molecular-weight regulators and pharmacological compounds, **52:396–404**
    - adenosine, **52:396–398**
    - antiinflammatory drugs, **52:402–404**

- arachidonic acid metabolites, **52:398–402**  
   other arachidonic acid derivatives,  
     **52:401–402**  
   prostaglandin binding sites,  
     **52:399–401**  
   histamine, **52:402**
- Receptor shedding, **63:280**
- Receptor subunit oligomerization, ligand-  
 triggered, **61:151**
- Receptor tyrosine kinases, **52:351–355**  
   other receptors of RTK family, **52:354–355**  
   stem cell factor receptor: c-kit, **52:352–354**
- Recognition, **58:124–128**  
   antigen-specific, T cell cultures for,  
     **42:165–166**  
   antiidiotypic, B cell repertoire expression  
     and, **42:51–62**  
   leukocyte–endothelial cell, models,  
     **58:381–389**  
   target, TCRs and, **38:22–24**
- Recognition molecules, Ig superfamily,  
**52:364**
- Recognition phase, T cell activation,  
**63:43–44**
- Recognition sites, synthetic, T and B cell,  
**45:159–164, 195–197**  
   B cell sites, synthetic peptides and,  
     **45:237–250**  
   candidate synthetic peptide vaccines,  
     **45:252–259**  
   immunological considerations, **45:197–202**  
   prediction  
     B cell, **45:250, 251**  
     T cell, **45:251, 252**  
   T cell sites, synthetic peptides and, **45:202,**  
     **203**  
     antigens, **45:232–237**  
     bacterial antigens, **45:230–232**  
     globular protein antigens, **45:203–216**  
     parasitic antigens, **45:228–230**  
     viral antigens, **45:216–228**
- Recombinant DNA  
   and carcinogenesis, **58:417**  
   mAbs and, **38:304**
- Recombinase activating gene, *see* RAG
- Recombination  
   complement components and, **38:229,**  
     **230**  
   deletional switch, in B cells, **60:38–39**  
   double-homologous, **48:56**  
   experiments, Ars A response and, **42:141**  
   frequency,  $V_{H1}$  complex and, **42:137**  
   gene inactivation, **59:108**  
   homologous, *see* Homologous  
     recombination  
   Ig heavy-chain variable region genes and,  
     **49:3, 6, 9**  
     D segments, **49:28, 30–32**  
     polymorphism of  $V_{H1}$  gene segments,  
       **49:22, 24, 26**
- Ir* genes and  
   antigen binding, **38:98**  
   complementation, **38:79, 80**  
   cytotoxic T cells, **38:166**  
   immunodominance, **38:180**  
   I region mutations, **38:86**  
   MHC, **38:45, 73**  
   T cell suppression, **38:145, 148**  
   maps of Ig-like loci and, **46:3, 4, 47**  
   structure, **46:19–21, 23**  
   mechanisms, joining of segments of Ig  
     variable region and, **40:253–256**  
   murine lupus models and, **46:87**  
   nonhomologous, and end-joining,  
     **58:43–45**  
   switch, *see* Switch recombination  
   tolerance, **38:129**
- V(D)J, *see* V(D)J joining, antigen receptor  
 genes; V(D)J recombination
- XLA, **59:161–162**  
 X-linked agammaglobulinemia, **59:161–162**
- Recombination recognition sites, in V(D)J  
 joining of antigen receptor genes, **56:86**
- Recombination signal sequences, **64:39**  
   junctions, and coding junctions, **58:42, 46,**  
     **53–55**  
   in V(D)J recombination, **58:31–36**
- Reconstitution, *see also* Immune  
 reconstitution  
   IL-2 receptors, **59:231–234, 254**
- Recruitment  
   neutrophils, by chemokines, **60:339**  
   ras exchange factor, by GRB2, **60:13**  
   Stats, to cytokine receptor complexes,  
     **60:22–23**
- Rectal dialysis, lipoxygenase products and,  
**42:314–315**
- Rectal mucosa, estimate of prostaglandin  
 syntheses by, **42:311–312**
- Red blood cells, *see* Erythrocytes

- Redundancy  
 functional, defined, **63**:173  
 killing mechanisms, **60**:303, 311  
 LIF, OSM, CNTF, and IL6, **53**:44–47
- Reed Sternberg cells, CD40 expression, **61**:12, 39
- Regulation of complement activation  
 complement receptor 1 and, **46**:189  
 complement receptor 2 and, **46**:202
- Regulators of complement activation, **45**:381, 410, 411; **61**:207  
 complement pathways, **45**:381–383  
 genes  
 divergent function, **45**:408, 409  
 exon structure, **45**:404, 405  
 gene duplication, **45**:405  
 intragenic duplication, **45**:406, 407  
 organization, **45**:403, 404  
 polyadenylation, **45**:407, 408  
 protein expression  
 alternate RNA processing, **45**:398, 399  
 anchoring systems, **45**:399, 400  
 differential glycosylation, **45**:400–403  
 tissue-specific, **45**:394–398  
 protein interactions, **45**:383, 384  
 protein roles  
 autologous tissue, **45**:386, 387  
 history, **45**:384, 385  
 immune complexes, **45**:388, 389  
 plasma, **45**:387, 388  
 transmembrane functions, **45**:389, 390  
 RCA-like protein utilization, **45**:409, 410  
 short consensus repeat  
 common structural motif, **45**:391, 392  
 localization, **45**:392–394
- Regulatory DNA sequences, in type I interferon genes, **52**:265–267
- Reiter's syndrome, HLA-B27 and, **65**:94
- REKS, **63**:144
- rel*, retrovirus-induced B cell neoplasia in bursa of fabricius, role in, **56**:477–478
- Rel  
 and ankyrin repeats, **58**:3–4  
 B cell genesis, **63**:245–248  
 in innate immunity in vertebrates, **58**:1–27  
 subunits, and promotion of HIV-1 transcription, **58**:15  
*relA*, **63**:159–160  
 RelA/p65 knockout mouse, cytokine induction, **65**:31
- Rel-B  
 B cell genesis, **63**:220–221, 246–248  
 deficiency, **63**:159
- RelB knockout mouse, cytokine induction, **65**:31–322
- REL family, **65**:12–13  
 transcriptional regulation, **65**:12–13
- Repair, double-strand break, *see* DNA, double-strand break repair
- Repair synthesis, across double-strand gap, **58**:44
- Reperfusion  
 injury due to, antiadhesion therapy, **64**:196  
 leukocyte integrins and, **46**:165, 166, 177  
 pulmonary inflammation, **62**:275–277  
 therapeutic complement inhibition using soluble CR1, **56**:282–284
- Repetitive amino acid interchanges, Ars A response and, **42**:110–111
- Replacement therapy, intravenous Ig, **60**:40
- Replication  
 B cell formation and, **41**:183–185, 236  
 B cell precursors, **41**:200  
 bone marrow cultures, **41**:210, 213, 216, 217  
 genetically determined defects, **41**:228, 231  
 population dynamics, **41**:206, 207  
 soluble mediators, **41**:232–234  
 genetically engineered antibody molecules and, **44**:72  
 maps of Ig-like loci and, **46**:4  
 and V(D)J joining of antigen receptor genes, **56**:80–81
- Reproduction  
 clusterin, **61**:250–251  
 membrane cofactor protein, **61**:219–220  
 NK cells and, **47**:269–272  
 PGHS-1, **62**:191
- Reproductive tract, female  
 invariant intraepithelial  $\gamma/\delta$  T cells, **53**:167–169  
 invariant  $\gamma\delta$  T cell receptors, **58**:303
- Rescue  
 CD4<sup>+</sup>8<sup>-</sup> cells, **58**:158  
 cells in thymic cortex, **58**:154–155  
 IL-2-dependent cells, **58**:244  
*scid* coding junction products, **58**:48–49  
 signal, **58**:241  
 thymocytes, from PCD, **58**:165

- Reshaped antibody, human PM-1, construction, **64:261**
- Resistance, to retrovirus-induced B cell neoplasia, **56:470–471**
- Respiratory burst, induction by IL-8 in neutrophils, **55:116–117**
- Respiratory syncytial virus, **59:406–408**  
antibodies from combinatorial libraries, **57:217–219**
- Respiratory tract  
immunity mechanisms, **59:371–373**  
lung diseases  
bacterial pneumonia, **59:379, 383, 395–402**  
fungal pneumonia, **59:402–406**  
graft-versus-host disease, **59:420–426**  
hypersensitivity diseases, **59:387, 412–420**  
viral pneumonia, **59:406–409**  
lung transplantation, **59:420–426**
- Responding cells, **50:29–31**
- Response genes, **51:98–105, 146–157**  
characteristics of, as defined by cloned lines, **51:100**  
combinatorial regulation of, **51:105**  
IL-2 gene regulation, case study, **51:103–105**  
inducibility, **51:151–157**  
cortical loss of responsiveness in, **51:153–156**  
emergence from paralysis to functional maturity, **51:156–157**  
immature thymocytes, early inducibility of responsive genes in, **51:151–153**  
proliferation, **51:146–151**  
T cell subsets, **51:98–103**
- Restitope, *Ir* genes and, **38:107**
- Restriction enzymes, maps of Ig-like loci and, **46:3, 4**
- Restriction fragment length polymorphism, **48:117–119**  
–allele-specific oligonucleotide, **48:117–119**  
analysis, pitfalls, **48:117**  
Ars A response and, **42:107**  
autoimmune thyroiditis and, **46:284**  
complement receptor 1 and, **46:191**  
Ig heavy-chain variable region genes and, **49:4, 22–23, 25, 27, 43**  
leukocyte integrins and, **46:160**  
maps of Ig-like loci and, **46:23**  
murine lupus models and, **46:66, 67**  
*Taq1* fragment, **48:139**
- Restriction mapping, Ars A response and, **42:106**  
*A/J J558 V<sub>H</sub>* gene segments and, **42:101–102**
- Reticular cells, lymphocyte homing and, **44:316**
- Reticular dysgenesis, SCID and, **49:382, 389**
- Reticuloendothelial hyperplasia, cachectin and, **42:222**
- Reticuloendotheliosis virus-induced tumors, **50:107–108**
- Retina, organ-resident nonlymphoid cell, **48:218**
- Retinal antigen  
autoimmuneresponse, **48:217**  
specific T cell clone, deletion, **48:217, 218**
- Retinal glial cell, T helper lymphocyte, **48:218**
- Retinoblastoma gene, **62:42, 48–49**
- 9-*cis*-Retinoic acid  
PCD inhibition, **58:245**  
targeted to steroid receptor family, **58:259**
- all-*trans*-Retinoic acid, IL-6 signal transduction modulation, **64:261–262**
- Retinol, *see* Vitamin A
- Retroviral protein, IgE-binding factor, **43:304**
- Retroviral switch recombination vector, **61:123–124**
- Retroviruses, **50:40–41**  
adoptive T cell therapy of tumors and, **49:282, 320, 335**  
mechanisms, **49:313–314**  
principles, **49:292, 295**  
antinuclear antibodies and, **44:130**  
autoimmune thyroiditis and, **46:275**  
B cell formation and, **41:195, 233**  
CD4 and CD8 molecules and, **44:269, 284, 290, 291**  
endogenous, insertions, inseparable from *Vbse*, **50:38–39**  
endogenous or extrinsic, **50:37–42**  
endogenous retroviral insertions  
inseparable from *Vbse*, **50:38–39**  
expressions of *Mtv* in B cells with *Vbse* expression, **50:39**  
mice transgenic for given *Mtv*, **50:40**  
mouse mammary tumor virus (MMTV), **50:39**

- Retroviruses (*continued*)
- mouse retention of Vbse sequences, **50:41–42**
  - Mtv transcripts expressed in activated B cells, **50:40**
  - other retroviruses, **50:40–41**
  - retroviral sequences bearing no homology to bacterial toxic mitogen, **50:41**
  - genetically engineered antibody molecules and, **44:68**
  - hybrid resistance and, **41:378, 400, 403**
  - IgE biosynthesis and, **47:17**
  - induction of B cell neoplasia in avian bursa of fabricius, *see* Bursa of fabricius
  - infection, as substrate introduction method in V(D)J joining, **56:50–51**
  - integration of viral DNA, **65:168**
  - NK cells and, **47:303**
  - origin of endogenous superantigens, **54:101–102**
  - SCID and, **49:400**
  - surface antigens of human leukocytes and, **49:99**
  - transformed tumors, adoptive T cell therapy of tumors and, **49:281, 295**
  - virus-induced immunosuppression and
    - HIV, **45:348, 349, 361, 365**
    - measles, **45:344**
- Reverse-phase high-performance liquid chromatography, leukemia inhibitory factor, **53:32**
- Reverse transcriptase, virus-induced immunosuppression and, **45:358, 360, 361, 366**
- RF, *see* Rheumatoid factor
- RFX, **61:334–336**
- RGD sequence, leukocyte integrins and, **46:153**
- ligand molecules, **46:171–173**
  - structure, **46:158, 159**
- RGL, **63:144**
- Rhe, **43:112–113**
- Rhesus monkey, complement components and, **38:207–209**
- Rheumatoid arthritis, **38:284, 298; 54:137–140, 187; 59:146, 343; 61:367**
- 109 D6 mAb, **48:128**
  - anemia in, **64:321–322**
  - animal models, **64:288, 298**
  - antinuclear antibodies and, **44:99, 111**
  - anti-TNF- $\alpha$  antibodies and gold compounds and, **65:123–124**
  - anti-TNF- $\alpha$  therapy, **64:289, 293, 333–334**
    - animal models, **64:298**
    - clinical studies, **64:299–307**
  - aPL antibodies and, **49:208–210**
  - autoimmune response in, **64:288**
    - future prospects, **64:330–333**
    - mode of action, **64:311–323**
    - problems in, **64:323–330**
  - cardiovascular disease and, **64:322**
  - CD5 B cell and, **47:136, 147, 148–150**
  - CD23 antigen and, **49:174**
  - conformational epitope three-dimensional structure, **48:129**
  - cytokines in, **64:290–298**
  - DR  $\beta$  gene, **48:131**
  - DRw53 molecule, **48:128**
  - Dw4, **48:126–127**
  - DW14, **48:126–127**
  - DwlO, **48:126–127**
  - etiology, **48:126–132; 64:283**
  - HLA, **48:126**
  - HLA-B27 and, **65:94**
  - HLA class II peptide binding and, **66:85, 87**
  - Ig heavy-chain variable region genes and, **49:43, 46–47**
  - IL-1 and, **44:191, 193–195**
  - and IL-6, **54:40**
  - infections, **64:288–289**
    - susceptibility and outcome, **64:326**
  - juvenile
    - DR4, **48:131**
    - DR5, **48:131**
    - DRw8, **48:131**
  - kallikrein in, **66:260**
  - lymphocyte homing and, **44:315, 338, 344**
  - MCI, **48:128**
  - molecular basis of susceptibility alleles
    - properties as factor in determination, **56:444–446**
    - risk of severe disease associated with, **56:441–444**
  - blacks, incidence of disease in, **56:427–429**
  - characteristics of disease process, **56:389–390**

- epitope, shared  
 concept, **56:403–404**, 416–418  
 haplotype encoding, **56:438–440**  
 identification by mAbs, **56:422–425**  
 mapping, **56:410–416**
- ethnic differences, **56:408–410**
- genetic studies  
 early knowledge, **56:400–401**  
 family, **56:433–435**  
 female sex, **56:434**  
 number of genes, **56:433–438**  
 twins, **56:433–435**, 446–449
- HLA polymorphism, actions of  
 remission during pregnancy, **56:431**  
 testing, **56:432–433**  
 toxicity, **56:431–432**
- immune response, **56:455–456**
- incidence, **56:399–400**
- inheritance mode, **56:440–441**
- mapping  
 in region facing antigen-binding  
 groove, **56:418–419**  
 into sequence motif, **56:410–416**
- MHC associated with  
 class II molecules, **56:429–430**  
 concepts, **56:390–397**  
 determinants, **56:400–402**  
 DR1, **56:420–422**, 426  
 DR4, **56:404–408**, 422–426  
 DR6, **56:419–420**  
 DR10, **56:424–427**, 429  
 Dw determinants, **56:407–408**  
 function of molecules, **56:449–450**  
 haplotype interactions, **56:438–446**  
 polymorphism, **56:398–399**  
 terminology, **56:390–397**
- MHC class II molecules, serologic  
 identification, **56:402–404**
- monoclonal antibody 109d6 associated  
 with, **56:422–425**
- peptide antigen X role, **56:455**
- population studies, **56:425–427**
- serologic association, **56:406–407**
- structural determinants, **56:455–456**
- T cell repertoire  
 exogenous events, **56:452–455**  
 formation, **56:450–452**  
 therapeutic directions, **56:456**
- mortality, **64:286**
- NK cells and, **47:300**
- pathogenesis, **64:283–288**
- pituitary hormones, **63:421–422**
- rat, dietary fish oil and, **39:163**, 165
- TNF- $\alpha$ , **64:293**, 296–298, 315, 316  
 cell trafficking, **64:317–319**  
 joint destruction mechanism,  
**64:320–321**  
 neovascularization, **64:319–320**
- Rheumatoid factor, **38:278**, 284; **39:263**  
 murine lupus models and, **46:72**, 75, 77, 78
- Rheumatoid factors  
 aPL antibodies and, **49:210**  
 Ig heavy-chain variable region genes and,  
**49:31**, 43, 46–47, 52
- Rheumatoid synovial fibroblast-like cells,  
**54:193**
- Rheumatoid synovial tissue, **54:170**
- Rhinitis  
 allergic, **60:221**  
 seasonal allergic and perennial, **60:172–173**
- Rho, **63:149**, 171
- RIBI adjuvant, with MAP, **60:131–132**
- Ribonucleic acid, in suppressed cells,  
**40:140–141**
- Ribonucleoprotein, antinuclear antibodies  
 and, **44:93**, 94  
 autoantibodies, **44:138**  
 autoantigen, **44:129–131**  
 autoimmune response, **44:131–134**, 136  
 mixed connective tissue disease, **44:111**  
 SLE, **44:96**, 97, 100–102, 104–106
- Ribosomes  
 antinuclear antibodies and, **44:120**, 128  
 autoimmune response, **44:132**, 133  
 SLE, **44:96**, 97, 105, 106  
 genetically engineered antibody molecules  
 and, **44:70**  
 lymphocyte homing and, **44:317**
- Ricin A chain, MC and, **42:265**
- Rigin, **40:115**  
 potency of, **40:112**
- Rin1, **63:144**
- RING4, **65:50**, 51
- RING4/11, **64:4**
- RING11* gene, **65:50**, 51
- RIP, **61:31**; **65:117**
- RNA, *see also* Messenger RNA  
 antinuclear antibodies and, **44:120**  
 autoantigen, **44:129**, 130  
 autoimmune response, **44:132**, 133

RNA (*continued*)

- mixed connective tissue disease, **44:111**
- scleroderma, **44:124, 125**
- Sjögren's syndrome, **44:113, 118**
- SLE, **44:100, 101, 104**
- B cell formation and, **41:191, 198, 221**
- double-stranded, induction of NF- $\kappa$ B, **58:6, 11–12**
- HIV infection and, **47:403**
  - etiological agent, **47:378, 380**
  - immunopathogenic mechanism, **47:387, 395**
- hybrid resistance and, **41:80, 377**
- IgE biosynthesis and, **47:21**
- Ig gene superfamily and, **44:10, 12, 34, 39, 44, 46**
- Ig heavy-chain variable region genes and, **49:33, 38, 55**
- Ig-like loci, maps, **46:8, 13, 25**
- IL-1 and, **44:156, 159–161**
- immunosenescence and, **46:227**
- leukocyte integrins and, **46:174–176**
- murine lupus models and
  - Ig germline, **46:74**
  - T cell antigen receptor, **46:86–88, 90–92, 95**
- negative strand transcript, **58:15–16**
- NK cells and, **47:203, 241, 242, 284**
- regulators of complement activation and, **45:396, 398, 399, 407**
- SCID and, **49:383, 385**
- sporozoite malaria vaccine and, **45:302**
- T cell activation and, **41:27**
- T cell development and, **44:217**
- T cell receptor and, **45:116**
- translation inhibition, **58:240**
- virus-induced immunosuppression and
  - HIV, **45:348, 354, 355, 366**
  - measles, **45:336, 344, 346**
- RNA colony blot hybridizations, Ars A response and, **42:132–133**
- RNA–duplex DNA complex, **61:114–116**
- RNA polymerases, antinuclear antibodies and, **44:93, 94**
  - autoantigen, **44:127, 129**
  - autoimmune response, **44:133, 134**
  - scleroderma, **44:122–125**
  - Sjögren's syndrome, **44:113**
  - SLE, **44:104**

## RNase

- complement receptor 2 and, **46:202**
- murine lupus models and, **46:86–88, 91**
- RNA splicing, switch recombination, **61:101–102**
- RNA viruses, in IBD, **42:291**
- Rolipram, **64:331**
- Rolling
  - eosinophils and neutrophils, **60:165–167**
  - high endothelial venules, **65:367, 368**
  - leukocytes, **58:382–383**
- RPMI 8866, **43:298–300**
- RSal class II fragment, 4-kDa, celiac disease, **48:145**
- RSS, *see* Recombination signal sequences
- RT-6, **48:241**
- RU-38486, effect on CD4<sup>+</sup>8<sup>+</sup> thymocyte deletion, **58:259**
- Runt domain, AML1, **65:24, 25**

## S

- Sy3 regions, binding site, switch recombination, **61:117–118**
- S6 kinase, signal transduction, **59:264**
- Saccharomyces cerevisiae*, cytolysis, **41:319**
- SAGs, *see* Superantigens
- Salicylates
  - NF- $\kappa$ B and, **65:121–122**
  - PGHS, **62:187**
- Salicylic acid, **62:184–187**
- Saliva, S-IgA antibodies in, **40:201–202**
- Salmonella adelaide*, **54:395**
- Salmonella paratyphi*, flagella, and human antibody effector function, **51:16–17**
- Salmonella typhimurium*, secondary B cells and, **42:71–72**
- Salt, cytotoxicity and, **41:290, 301**
- S antigen, **48:215–216**
  - anterior chamber-associated immune deviation, **48:219**
  - experimental autoimmune uveitis, **48:219**
- Saporin, MG and, **42:265**
- Sarcoidosis, **62:267, 281**
  - and TCR junctional regions, **58:328–329**
- Sarcoma
  - adoptive T cell therapy of tumors and, **49:286, 291, 297, 301, 305**
  - hybrid resistance and, **41:358, 359, 363**

- SASD, identification of lipid A-binding membrane proteins, **53**:274–275
- SC58125, **62**:186
- Scatter factor, *see* Hepatocyte growth factor
- Schistosoma mansoni*, **54**:37
- anti-Id antibodies as vaccines against, rat, **39**:284
  - eosinophil-activating substance production, **39**:217
  - eosinophil-mediated killing of
    - AES and, **39**:209
    - C3 and, **39**:210
    - ECP and, **39**:106, 213
    - F(ab') of anti-GFA-2 and, **39**:184
    - IgE receptor and, **39**:180–181
    - IgG antibodies and, **39**:209–212
    - major basic protein and, **39**:188–190, 209, 212–213
  - infections, lymphokine production in, **53**:16
- Schistosomiasis, immunogen selection, **60**:124–125
- Schizosaccharomyces pombe*, maps of Ig-like loci and, **46**:5
- Schlepper experiment, *Ir* genes and, **38**:39, 40, 42, 51
- SCID, *see* Severe combined immunodeficiency
- Scleroderma
  - antinuclear antibodies and, **44**:94, 114, 119–121
  - autoantibodies, **44**:125, 136, 137
  - autoimmune response, **44**:131–133
  - centromere antigens, **44**:121, 122
  - mixed connective tissue disease, **44**:111
  - nuclear antigens, **44**:122–125
  - Sjögren's syndrome, **44**:112
  - SLE, **44**:97, 105
  - IL-1 and, **44**:193
- Scleroderma–polymyositis overlap syndrome, **61**:301–302
- Sclerosing panencephalitis, virus-induced immunosuppression and, **45**:346
- SCMC assays, IBD and, **42**:295
- SDF-1, **65**:283
- 20 $\alpha$ SDH, *see* 20 $\alpha$ -Hydroxysteroid dehydrogenase
- SDS-PAGE, **42**:166–168, 167–172, 172, 188
- T cell receptor, **43**:150
- SEB, *see* Staphylococcal enterotoxin B
- Secondary B cell lineage, **42**:83, *see also* B cell repertoire expression environment and, **42**:68–79
- Secondary B cell repertoire expression, somatic mutation and, **42**:9–12, *see also* B cell repertoire expression
- Secondary immune response, regulation, **51**:271–272
- Secondary structure
  - antigenicity and, **43**:76
  - antigenic recognition and, **43**:38
- Second messengers
  - B cell formation and, **41**:197
  - in Fc receptor-mediated signal transduction
    - Fc $\gamma$ R, **57**:72–74
    - Fc $\epsilon$ RI, **57**:77–79
  - T cell antigen receptor and, **41**:2, 26, 27
- Secretion, helper T cell cytokines, **46**:111–114, 127, 136
- Secretory antibodies, **65**:249, 250
- Secretory component, IgA
  - binding of, **40**:165–166, 167, 186
  - epithelial cells and, **40**:175–177
  - hepatocytes and, **40**:179–180, 182
  - structure and function, **40**:160–163
- Secretory glands, mechanisms of homing of plasma cell precursors to, **40**:204–207
- Secretory leukoprotease inhibitor, **62**:287–288
- Segmental flexibility
  - agglutination, **48**:23–24
  - antidansyl antibody, **48**:13, 14
  - cell receptor binding, **48**:24–26
  - complement activation, **48**:24–26
  - complement binding activity, **48**:13, 15, 22
  - domain structure, **48**:14, 16, 22
  - evolution, **48**:26
  - functional implications, **48**:23–26
  - genetically engineered antibody, **48**:14, 16, 22
  - hinge region structure, **48**:13, 15, 22
  - Ig, **48**:5–19
    - electron microscopy, **48**:2–3
    - fluorescence polarization, **48**:3–5
    - hydrodynamic study methods, **48**:2
    - nanosecond, **48**:4–5
    - spin-label approach, **48**:5
    - steady state, **48**:4
    - study methods, **48**:1–34
    - X-ray crystallography, **48**:3



Segmental flexibility (*continued*)

- IgA, **48**:14–18
- IgE, **48**:18–19
- IgG, **48**:5–19
  - early studies, **48**:5–6
  - fluorescence polarization, **48**:6–10
  - hinge region structure, **48**:21–23
  - IgG subclasses, **48**:11–14
  - spin-label method, **48**:10–11, 12
  - X-ray crystallography, **48**:11
- IgM, **48**:14–18
- mouse monoclonal antibody, **48**:13, 14
- precipitation, **48**:23–24
- SEK1, **63**:148
- Selectin ligands, **64**:168, 172, 194
- Selectins, **52**:167–168; **59**:383–385;
  - 62**:257–258, 259, 267, 276, 277; **64**:144, 148; **65**:352; 367, *see also* E-Selectin; L-Selectin; P-Selectin
  - CD23 antigen and, **49**:163
  - characterization, **60**:165–167
  - genetic studies, **64**:193–195
  - interactions with eosinophils, **60**:167–169
  - monospecific ligands, **58**:362
  - multistep adhesion cascades, **64**:183–184 and related recognition molecules, **52**:364–366
  - surface antigens of human leukocytes and, **49**:88
- Selection, *see also* Negative selection; Positive selection
  - extrathymic, **58**:315–316
  - Ig heavy-chain variable region genes and, **49**:22, 25, 40
  - intracellular, **58**:120–121
  - intrathymic, T cells, **58**:139–174
  - phenotypic, in germinal centers, **60**:280
  - T cell, processes, **51**:164–189
    - negative selection, **51**:165–175
      - intrathymic clonal deletion, **51**:165–173
    - positive selection, **51**:175–189
      - functional divergence, **51**:186–189
      - ligands and receptors in positive selection, **51**:178–180
      - vs two kinds of death, **51**:175–177
  - positive selection, molecular basis of
    - four-way
      - CD4 vs CD8 down-regulation, **51**:185–186
      - developmental choice, **51**:180–186
      - positive vs negative selection, **51**:180–183
      - signaling pathways that control positive selection, **51**:183–185
    - thymic, **58**:311–315
- Self-antigens
  - autoimmune thyroiditis and, **46**:263, 265, 305, 307, 319
  - B cell repertoire and, **42**:43–51 and foreign, **58**:297–298
  - from human donors, antibodies to
    - Graves' ophthalmopathy, **57**:245
    - HIV-1, **57**:246–250
    - primary biliary cirrhosis, **57**:244–245
    - thyroid disease, **57**:242–244
  - Ir* genes and
    - cytotoxic T cells, **38**:162
    - T cell suppression, **38**:152
    - tolerance, **38**:120, 123–125, 127, 128
  - murine lupus models and, **46**:65
  - recognition, **58**:319–320
  - self-Ia, **38**:120, 123, 127, 132, 134
  - self-MHC, **38**:119, 120
  - sequestration, **48**:217
- Self-nonsel self discrimination, **59**:280
  - in complement system, **60**:75–76
- Self-peptides, positive selection, **59**:122–128
- Self-reactive cells, elimination, **59**:288–295
- Self-reactive clones, **58**:213
- Self-reactive immune cells, clonal deletion, **48**:216, 217
- Self-tolerance
  - experimental autoimmune uveitis, **48**:216–219
  - eye, strategies, **48**:217
  - germinal center B cells, maintenance, **60**:280–283
  - idiotypic network and, **39**:276–277
  - immunological memory and, **53**:249–251
  - lens, **48**:220
- Self-tolerance checkpoints, **59**:279–281, 342–344
  - immune repertoire, **59**:319–342
  - preimmune repertoire, **59**:281–319
- Sendai virus
  - cachectin, **42**:220
  - cytotoxic T cells and, **38**:163, 164, 167
  - responses in MHC class I-deficient mouse, **55**:408–409

- Sepsis  
 anticytokine therapies, **66:151**  
 anti-TNF- $\alpha$  therapy, **64:310–311, 326**  
 chemokines and, **66:104**  
   IL-8, **66:104, 135–141**  
   MCP-1, **66:141–142**  
 cytokines and, **66:101–102, 103–104, 104**  
   G-CSF, **66:149–150**  
   GM-CSF, **66:150**  
   IFN- $\gamma$  and, **66:145–146**  
   IL-2, **66:104, 150–151**  
   IL-4, **66:144–145**  
   IL-10, **66:142–145**  
   IL-12, **66:146–147**  
   LIF, **66:147–148**  
   measurement, **66:104–105**  
   MIF, **66:147–148**  
   TNF and IL-1, **66:104, 117–127, 150**  
 defined, **66:101**  
 and IL-1ra  
   animal models, **54:204–207**  
   in human infections, **54:207–209**  
 immunointervention, **66:150–151**  
 models, **66:102–103, 117–121**  
 pathogenesis, **66:150–151**  
   chemokines, **66:135–142**  
   cytokines, **66:104, 105–135, 142–151**  
   pulmonary inflammation, **62:271–275**  
   therapeutic regulation of complement system in, **56:281–282**
- Septic shock  
 complement cascade, **62:271**  
 contact cascade in, **66:235**  
 experimental treatment, **58:280–281**  
 IFN- $\gamma$  and, **62:103, 104**  
 NO role, **60:337**  
 therapeutic regulation of complement system in, **56:281–282**
- Sequential epitope, **43:25, 72**  
 amino acid, **43:39, 66–67**  
 collective responses of different species, **43:48**  
 critical residue, **43:64**  
 DFLEKI, **43:63–64**  
 EVVPH, **43:63–64**  
 individual side chain role, **43:40**  
 replaceability matrix, **43:77–78**  
 superassemblies, **43:36, 38**
- Sequential switching, switch recombination, **61:105–107**
- Ser530, cyclooxygenase active site, **62:175**
- Serine  
 antinuclear antibodies and, **44:115**  
 Ars A response and, **42:111–112, 155**  
 CD4 and CD8 molecules and, **44:269**  
 CTL and, **41:135, 148**  
 genetically engineered antibody molecules and, **44:84**  
 IL-1 and, **44:184**  
 phosphorylation, **48:270–277**  
 Serine esterases, cytotoxicity and, **41:267, 288, 297, 298, 310**  
 Serine proteinase inhibitor, **61:202**  
 Serine proteinases, **64:297**  
 complement components and  
   C2, **38:213, 214**  
   Factor B, **38:209, 211, 214**  
 cytotoxicity and, **41:277, 297, 310**  
 IL-1 and, **44:157, 158, 163**  
 Serine/threonine kinase inhibitors, **54:18–19**  
 Serine/threonine kinase receptors, in TGF- $\beta$  signal transduction, **55:188, 194–195**  
 binding of isoforms, **55:194**  
 cDNA cloning, **55:188, 192**  
 structure, **55:190–193**  
 Serine/threonine phosphatases, **63:166**  
 as p56<sup>lck</sup> targets in T cell signaling, **56:160**
- Serology  
 in analysis of MHC class I-deficient cells, **55:385–386**  
 CD1, **59:37–44**  
 CTL and, **41:139–141**  
 HLA class II, **48:112–114**
- Serpins, **61:202, 205**
- Serratia*, tumor necrosis and, **42:215**
- Serum  
 antibodies, IBD and, **42:291–292**  
 antithymocyte, hybrid resistance and, **41:350**  
 IL-6 levels, **54:30**  
 Serum amyloid A, lymphocyte adhesion and, **64:153**  
 Serum sickness, IFN- $\gamma$  and, **62:103**  
 Servomodulator, regulating functional tolerance, **50:167–170**
- Severe combined immunodeficiency, **49:381–388, 402; 59:227, 235, 246–253, 247, 318–319; 61:306–311**  
 B cell formation and, **41:224–226, 237**  
 DNA repair defects, **61:310–311**

- Severe combined immunodeficiency  
*(continued)*  
 graft-versus-host disease, **49:397–398**  
 histocompatible bone marrow  
 transplantation, **49:392**  
 hybrid resistance and, **41:351, 365, 366, 384, 379–381**  
 antigen expression, **41:404, 405, 408, 409**  
 ontogeny, **49:398–400**  
 posttransplant immunocompetence,  
**49:399–402**  
 RAG1/2 mutations, **61:308–310, 311**  
 SCID.Beige mouse, **63:80**  
 SCID defect, V(D)J recombination and,  
**64:49–50**  
 SCID-hu mouse, HIV infection in,  
**52:463–466**  
 SCID-hu thy/iv xenograft model, **63:79**  
 HIV-1 infection, **63:89–90, 99–107**  
 T cells, **63:82–83**  
 SCID mouse, **50:303**  
 EBV-associated lymphoproliferative  
 disease in hu-PBL-SCID mice,  
**50:310–313**  
 expression of defective B lineage cells,  
**53:146**  
 HIV-infection of hu-PBL-SCID mice,  
**50:314–317**  
 other tumor models in SCID mice,  
**50:313–314**  
 transfer of normal or autoimmune  
 human cells to, **50:304–310**  
*scid* mutation, **61:299–301, 317**  
 Scid syndromes, with V(D)J recombination  
 defects, **58:62–63**  
 stem cell engraftment, **49:388–392**  
 lack of, **49:396–397**  
 tolerance, **49:398–399**  
 transplantation  
 with fetal tissue, **49:392–393**  
 with T cell-depleted bone marrow,  
**49:393–396**  
 and V(D)J joining of antigen receptor  
 genes, **56:73–78**  
 Sex-limited protein, **46:29**  
 Sex steroids, spontaneous autoimmune  
 thyroiditis and, **47:480, 481**  
 SGP2, **61:204, 249–251**  
 SH1 domain, BTK, **59:179, 185–186, 188–191**  
 SH2 domain  
 BTK, **59:179, 182, 186, 188–190**  
 lacking in Jaks, **60:4**  
 in ras pathway activation, **60:13–14**  
 Stat activation specificity in, **60:23**  
 Stat proteins, **60:18–20**  
 SH2 and IRS1 NPXY (SAIN)-binding  
 domain, **61:161**  
 SH2-PTP, **63:165–166**  
 SH3 domain, Btk, **59:179, 182, 184–187**  
 Shape accessibility, MHR, **43:35–36**  
 Shared epitope, **64:283–285**  
 Shc, **63:143, 146**  
 IL-2-induced Ras activation, **61:161–163, 164–166**  
 signal transduction, **59:262**  
 SHC, tyrosine phosphorylation, **60:13–14**  
 Shedding  
 lymphocytes, **64:170**  
 in regulation of CD44 receptors,  
**54:317–318**  
 Sheep red blood cells  
 cytotoxicity and, **41:293**  
 humoral immune response and, **45:1, 2, 68, 70, 72**  
 hybrid resistance and, **41:352**  
 T cell subsets and, **41:67–71, 77, 90, 92**  
 Sheet-sheet interactions, **43:102–103, 110**  
 Sheet-sheet packing, schematic, **43:102–103**  
 Shock, **42:213**, *see also* Cachectin  
 Shope fibroma virus, T2 ORF product  
 resemblance to TNF-R domain, **61:10**  
 Short consensus repeats  
 complement receptor 1 and, **46:184–186, 188–190, 194, 195**  
 complement receptor 2 and, **46:202, 203, 211**  
 regulators of complement activation and  
 common structural motif, **45:391, 392**  
 genes, **45:404–408**  
 localization, **45:392–394**  
 protein expression, **45:399**  
 protein utilization, **45:409, 410**  
 SHPTP2, in cytokine signaling, **60:26**  
 Sialic acid, **64:162, 168**  
 CD23 antigen and, **49:155–156**  
 lymphocyte homing and, **44:354, 355, 363, 367–369, 371**  
 Sialidases, lymphocyte homing and,  
**44:364–368, 371**

- Sialomucins, **64**:144, 146–152  
 CD34, and selectin ligand, **58**:359–360
- Sialophorin, **48**:248
- Sialyl Lewis X, selectins and, **60**:166–167;  
**65**:363
- Sialyltransferases, **64**:168
- Sicca-CD8<sup>+</sup> lymphocytosis syndrome, **65**:286
- Side chain  
 contribution to solvent-exposed surface  
 area, **43**:36–38  
 hydrophobic, **43**:42, 80–81  
 sequential epitope role, **43**:40
- Signal binding proteins, recombination,  
**61**:303–304
- Signaling, *see also* Negative signaling  
 abortive, and second signals in adult B  
 cells, **54**:407–410  
 antigenic, constraints to biochemical study  
 of, **52**:294–295  
 cytokines in, **58**:369  
 differential, between CD4 and CD8,  
**53**:91–94  
 in IL-4 production, mechanisms, **53**:  
 17–22  
 mitogenic, Ig, **59**:326–328  
 in naive and memory T cells, **53**:228–229  
 pathways, controlling positive selection,  
**51**:183–185  
 TCR-mediated  
 and CD4, **53**:85–91  
 and CD8, **53**:85–91  
 and p56<sup>lck</sup>, **53**:85–91  
 transmembrane, **48**:227
- Signal joints, V(D)J recombination, **64**:40, 41
- Signal sequence recognition, V(D)J  
 recombination, **64**:54
- Signal transducers and activators of  
 transcription, **59**:261; **60**:17–25, *see also*  
 Stat  
 activation by ECF, **60**:27  
 in cytokine signaling, **60**:19–22  
 in IFN signaling, **60**:17–19  
 phosphorylation by Jak2, **60**:210  
 recruitment, **60**:22–23
- Signal transduction, **59**:176–177  
 adoptive T cell therapy of tumors and,  
**49**:287, 289, 302, 313, 316  
 B7-1 and B7-2, **62**:138  
 Btk, **59**:184–185; **60**:42  
 cachectin and, **42**:226  
 CD4 and CD8 molecules and, **44**:267, 270,  
 299, 300, 302  
 CD23 antigen and, **49**:156  
 CD28, **62**:134  
 CD40, **60**:45–46; **61**:32–38; **63**:50–52  
 B cell proliferation, **63**:53–54  
 B cell receptor pathway, **61**:37–38  
 B cells, **61**:32–35  
 CD28–CD80/CD86 pathway, **61**:36–37  
 Fas-Fas-L pathway, **61**:37  
 Ig production, **63**:58–70  
 CD44–ligand interactions, **54**:300–302  
 CD45 and, **66**:1–56  
 and cytokine receptor superfamily, **60**:1–2  
 cytokines  
 adapter molecules, **63**:134, 141–143  
 calcineurin, **63**:166–167  
 CD45, **63**:164–165  
 Jak–Stat pathway, **63**:138–141  
 MAPK family, **63**:148–149  
 negative regulation, **60**:25–26  
 nuclear transcription factor NF- $\kappa$ B,  
**63**:157–160  
 Pac-1, **63**:167  
 phosphatidylinositol 3-kinase,  
**63**:149–154  
 phosphoprotein phosphatases,  
**63**:164–167  
 protein kinase C, **63**:154–157  
 protein-tyrosine kinases, **63**:133–143  
 protein-tyrosine-phosphatase 1C,  
**63**:165–166  
 Raf kinase, **63**:147–148  
 Ras, **63**:143–147  
 Rho protein, **63**:149  
 Src family, **63**:133–137  
 Stats role, **60**:19–22  
 Syk family, **63**:134, 137–138  
 eosinophil, **60**:208–210  
 Fas-mediated, **57**:134–135, 139  
 Fc receptor-mediated  
 antigen receptor homology motif,  
**57**:81–83  
 Fc $\gamma$ R, mechanisms of activity, **57**:72–77  
 Fc $\gamma$ R, structural factors, **57**:82, 84–89  
 Fc $\epsilon$ RI, **57**:77–81, 89–90  
 mechanism, **57**:71–81  
 phosphorylation, **57**:74–77, 79–81  
 protein kinase involvement, **57**:74–77,  
 79–81

- Signal transduction (*continued*)  
 second messenger interactions,  
 57:72–74, 77–79  
 structural factors, 57:81–90  
 GPI hydrolysis, 59:264–265  
 Grb2, 59:262  
 IFN- $\gamma$  binding, 62:67–71, 106  
 Ig gene superfamily and, 44:31, 36  
 IgR-mediated cascade  
 functional molecules, 54:351, 352  
 stimulation, 54:378–379  
 IL-1 and, 44:183  
 IL-2/IL-2R system, 63:127, 173–176  
 signaling pathways, 63:169–173  
 signal molecules, 63:167–169  
 target genes, 63:160–164  
 three-channel model, 63:171–173  
 IL-2-induced, 59:253–259, 265–266  
 IL-2R, 42:178  
 IL-2R $\gamma$ , 59:227  
 IL-2R-triggered proximal signaling events,  
 61:153–161  
 IL-6R complex chain, 54:14, 18  
 IL-9 receptors and, 54:83  
 lymphocyte, 62:42, 44–47  
 lymphokine-mediated, 48:310  
 MAP kinase, 59:262–263  
 MB-1 molecule and, 54:351–355  
 mechanism of IL-2R-mediated, 50:152  
 in neutrophil regulation by IL-8,  
 55:140–142  
 new molecules, 61:29–32  
 NF- $\kappa$ B, 58:5  
 nucleus, 48:310–311  
 PI3-K, 59:263  
 pituitary hormones, 63:397–399, 401–402  
 preB cell receptor and, 63:26–29  
 pre-TCR, 58:145–146  
 protein kinase C, 59:263–264  
 Raf-1 kinase, 59:262–263  
 Ras, 59:261–262; 60:12–14  
 regulators of complement activation and,  
 45:384, 410  
 S6 kinase, 59:264  
 SCID and, 49:386  
 Shc, 59:262  
 SOS, 59:262  
 surface antigens of human leukocytes and,  
 49:113, 125  
 adhesion molecules, 49:87  
 antigen-specific receptors, 49:76–78  
 MHC glycoproteins, 49:81  
 receptors, 49:98, 100  
 T cell development and, 44:212  
 T cell receptor and, 45:110  
 $\alpha\beta$  TCR complex, 58:124–128  
 TGF- $\beta$   
 endoglin functions, 55:203–204  
 formation of complexes, 55:200–202  
 intracellular, 55:204–205  
 type III receptor functions, 55:203–204  
 TNF-R superfamily, CD40, 61:26  
 tyrosine kinases, 59:259–261  
 Signal transduction pathways  
 artificial inducers, 58:269  
 artificial triggering, 58:230–232  
 Bcl-2 effects, 58:256  
 biochemical analysis, 54:415–420  
 direct analysis, 54:418  
 identification of IgG complex and  
 associated second messengers,  
 54:419–420  
 use of inhibitors to block *in vitro*  
 tolerance, 54:415–418  
 DNA damage, 58:29  
 via IgR transmembrane signaling,  
 54:359–378  
 and intervention of apoptosis, 58:245–247  
 leading to NF- $\kappa$ B activation by TNF $\alpha$ ,  
 58:7–9  
 and p53, 58:67  
 TCR-mediated, relation of Apo-1/Fas,  
 58:136  
 SIINFEKL, 59:122, 124  
 SIIRFEKL, 59:125  
 Silica, hybrid resistance and, 41:350, 368,  
 395, 371–373  
 Simian immunodeficiency virus, 63:79  
 HIV infection and, 47:378, 385, 404  
 infection of macaques, 52:442–452  
 pathogenesis, 52:443–452  
 genetic drift of SIV molecular clones  
*in vivo*, 52:451–452  
 natural history, 52:443–448  
 viral determinants, analysis with SIV  
 molecular clones, 52:448–451  
 phylogeny of nonhuman primate  
 lentiviruses, 52:442–443  
 for vaccine testing, 52:452–454  
 vaccines, 65:321–322

- Simian immunodeficiency virus type 1, **63:79, 85**
- Simian virus 40  
early promoter, **43:268**  
Ig heavy-chain variable region genes and, **49:56–57**
- Sindbis virus, cytotoxic T cells and, **38:162**
- Single strand annealing model, **61:111**
- sis-inducible element, in *c-fos* gene, **60:24**
- Sister chromatid exchange, **54:234–235**
- Site-specific tolerance, peripheral lymphocytes, **53:201–203**
- Sjögren's syndrome, **62:76–77**  
antinuclear antibodies and, **44:111–113, 115–118**  
autoantibodies, **44:127, 136**  
SLE, **44:93, 95, 102, 104**  
aPL antibodies and, **49:209–210**
- Skin  
allergic reaction, contact activation, **66:259**  
homing, **58:392**  
IL-6 effects, **54:28–29**  
infections, immunity, **58:326–328**  
invariant intraepithelial  $\gamma/\delta$  T cells, **53:167–169**  
invariant  $\gamma\delta$  T cell receptors of murine IEL, **58:301–303**  
suppressor antigen-presenting cell, **48:206**
- Skin disease, IL-8 role, **55:142–143**
- Skin grafts  
allografts, T cell subsets and, **41:86, 88, 93**  
B cell formation and, **41:225**  
CTL and, **41:158**  
hybrid resistance and, **41:369, 376, 383**  
in MHC class I-deficient mouse, **55:388–390**  
rejection  
CTL and, **41:159, 165**  
T cell subsets and, **41:71, 88, 93, 94**
- Skin test antigens, Crohn's disease and, **42:289**
- Skin window chamber technique, **42:307**
- SLE, *see* Systemic lupus erythematosus
- Sl* locus, kit ligand encoded at, **55:10–12**
- Smoking, related lung disease, **60:220–221**
- Smooth muscle cells, cachectin and, **42:220**
- $S\mu$ bp-2, binding site, switch recombination, **61:119**
- Snake venom toxin, MG and, **42:237**
- Sodium azodisalicylate, **42:318**
- Sodium dodecyl sulfate, denatured AChR subunits, **42:257, 258**
- Sodium dodecyl sulfate–polyacrylamide gel electrophoresis, *see* SDS–PAGE
- Sodium salicylate, inhibition of NF- $\kappa$ B activation at high doses, **58:19–20**
- Solid-phase immunoassay, aPL antibodies and, **49:193, 199, 258–259**  
affinity purification, **49:230–231**  
antibody subsets, **49:232**  
clinical aspects, **49:200, 203–206**  
isotype, **49:227**  
specificity, **49:235, 243, 249**
- Solid-phase synthesis, multiple antigen peptides, **60:106–108**
- Soluble costimulators, EC production of, **50:272–274**
- Soluble mediators, in IBD, **42:310–315, 322**
- Solvation energy, estimating, **43:101**
- SOM28, **48:172**
- Somatic cell genetics  
complement components and, **38:204, 233**  
human B cell neoplasia and, **38:247**  
maternally transmitted antigen and, **38:320**
- Somatic cell hybridization  
human B cell neoplasia and  
Burkitt lymphoma cells, **38:257, 259**  
chromosomal translocation, **38:248, 265**  
*c-myc* activation, **38:263**  
*c-myc* oneogene, **38:248, 249, 259**  
lymphoblastoid cells, **38:260**  
lymphocyte hybridomas and, **38:275**  
B cell immortalization, **38:306**  
genetically engineered antibodies, **38:305**  
human-human, **38:293, 297, 298**  
human-mouse, **38:287–289**  
mAbs, **38:277, 282, 302**
- Somatic diversification  
Ig gene superfamily and, **44:12–20**  
Ig VL gene, **48:60–62**
- Somatic fusion, B cell hybridization and, **38:279**
- Somatic hypermutation  
in germinal centers, **53:233–234**  
T cell subsets and, **41:42, 88, 106**
- Somatic mutation, **42:96, 138**  
adoptive T cell therapy of tumors and, **49:282**  
and antibody repertoire generation in rabbit, **56:201, 203**

- Somatic mutation (*continued*)  
 antigen and, **42:34**  
 Ars A response and, **42:108**  
 B cell repertoire expression and  
   junctional diversity, **42:15–18**  
   primary, **42:12–15**  
   random vs nonrandom V region segment  
     selection, **42:18–19**  
     age factor, **42:30–32**  
     antigen responsive cell populations,  
       **42:19–22**  
     fetal and neonatal development,  
       **42:26–30**  
     predominant clonotype expression,  
       **42:22–26**  
   secondary, **42:9–12, 69–71**  
 Ig heavy-chain variable region genes and,  
**49:2, 7, 26**  
 D segments, **49:28, 32**  
 V<sub>H</sub> gene expression, **49:37, 39, 41, 46,**  
**49, 52**  
 neonatal hybridoma and, **42:67**  
*PIG-A* gene, **60:82–89**  
 secondary B cells and, **42:79**  
 and terminal differentiation, apoptosis and,  
**50:65–66**
- Somatic variation, T cell receptors and, **38:16**
- Somatostatin, **48:169; 63:385, 386–387**  
 cells of origin, **39:317**  
 histamine release by mast cells and,  
**39:305–306**  
 immunosuppressive properties, **39:310–311**  
 secretion regulation by, **39:302–303**
- Sos, **63:143, 144, 146**
- SOS, signal transduction, **59:262**
- Southern blot analysis  
 autoimmune demyelinating disease and,  
**49:363**  
 clonally rearranged genes, **40:267–268**  
 complement components, **38:212, 215, 229,**  
**237**  
 human B cell neoplasia, **38:248, 266, 267**  
 hybridomas, **38:299**  
*Ir* genes, **38:117**  
 SCID and, **49:385–386**  
 T cell receptors, **38:11, 13, 15, 16**
- Southern filter hybridization analysis  
 Ars A V<sub>H</sub> gene segment and, **42:101**  
 of BALB/c liver, **42:121**  
 of V<sub>H</sub> complex, **42:130**  
 V<sub>κ</sub>10 family of germline genes and, **42:144**
- sox-4*, B cell genesis, **63:218–219, 226–228**
- Soybean agglutinin, SCID and, **49:394–396**
- SP, *see* Substance P
- SP-40,40, **61:204, 249–251**
- Sp100/ND, **63:202**
- Spacer sequences, Ars A response and,  
**42:116**
- Specific unresponsiveness, hybrid resistance  
 and, **41:384–386**
- Spectrotyes, autoimmune thyroiditis and,  
**46:301, 304, 306**
- Spergualin, **65:125–126**
- Spermidine, **48:288**
- Spermine, **48:288**  
 depletion, induction of DNA  
 fragmentation, **58:252**
- Sphingomyelin, turnover, role of Fas,  
**60:299–300**
- Spi-B  
 binding sites, **64:76–77**  
 domain, **64:76–77**  
 expression, **64:87–88**  
 gene targeting, **64:88**  
 structure, **64:79**  
 structure–function studies, **64:88**
- Spleen  
 adoptive T cell therapy of tumors and  
 antigen recognition, **49:321**  
 expression of antitumor responses,  
**49:331–332**  
 mechanisms, **49:300, 309**  
 principles, **49:293, 295–298**  
 anterior chamber-associated immune  
 deviation, **48:206, 211**  
 antigen-presenting cells and, **47:69–72,**  
**74–76, 78–81**  
 antigen processing, **47:92**  
 immunogeneity, **47:102**  
 T cells, **47:83, 85**  
 tissue distribution, **47:47, 50–52, 56**  
 antinuclear antibodies and, **44:102**  
 architecture, **60:268–269**  
 autoimmune thyroiditis and, **46:280, 281,**  
**306, 310–312**  
 autoreactive T cells and  
 activation, **45:421, 422**  
 physiology, **45:428**  
 regulation, **45:432, 433**  
 B cell formation and, **41:181, 182, 184, 238**  
 B cell precursors, **41:198, 200–202**

- genetically determined defects, **41:229**  
 inducible cell line, **41:223**  
 population dynamics, **41:207, 208**
- B cells, **42:74, 75**  
 adult, **42:68**  
 CD5<sup>+</sup> and CD5<sup>-</sup>, **53:180–181**  
 neonatal, **42:65–67**
- CD4 molecules and, **44:288**
- CD5 B cell and, **47:120–123**  
 genetic influence, **47:147**  
 Ig gene expression, **47:152, 157**  
 lineage, **47:128**  
 physiology, **47:130, 132, 133**  
 primordial immune network, **47:159**
- CD8 molecules and, **44:271, 282**
- complement receptor 2 and, **46:204–206**
- CTL and, **41:138**
- delayed-type hypersensitivity, **48:211–212**
- FcεRI<sup>+</sup> cells, lymphokine production by, **53:9–14**
- forbidden α/β T cells, **53:166**
- helper T cell cytokines and, **46:122, 123, 128, 129, 137, 138**
- histology, **60:268–272**
- humoral response and, **45:2**  
 antigens, **45:11, 16, 17**  
 helper T cells, **45:27, 34**  
 physical interaction, **45:40, 53**
- hybrid resistance and, **41:334**  
 antigen expression, **41:397, 402, 404, 408**  
 bone marrow cells, **41:336, 338–340, 342, 345, 347, 348**  
 effector mechanisms, **41:370**  
 leukemia/lymphoma cells, **41:358, 361–368**  
 lymphoid cells, **41:351–356**  
 marrow, **41:384–388, 391, 393**  
 NK cells, **41:372, 373, 375**  
 syngeneic stem cells, **41:388–390**  
 T cells, **41:380–384**  
*in vitro* assays, **41:394–396**
- IgE biosynthesis and  
 antibody response, **47:5, 8, 11**  
 antibody response suppression, **47:29, 32–34, 36, 37**  
 binding factors, **47:13–15, 22–26, 28**
- IGF-I, **63:391–392**
- immunosenescence and  
 lymphocyte activation, **46:226, 228, 232**  
 lymphocyte subsets, **46:237, 238**  
 marker density, **46:239**  
 mucosal immunity, **46:251, 253**  
 regulatory changes, **46:247–251**  
 stem cells, **46:240, 241, 244, 245**
- lymphocyte homing  
 high endothelial venules, **44:315**  
 molecules, **44:344, 351, 353**  
 regional specificity, **44:328, 335**
- lymphocyte migration, **58:346–347**
- lymphocyte recirculation, **58:350; 64:177–178**
- murine lupus models and, **46:64, 91, 92, 98**
- NK cells and, **47:187, 283, 289, 290, 292, 300**
- CNS, **47:268**
- congenital defects, **47:226**  
 differentiation, **47:229, 230**  
 effector mechanisms, **47:234, 260, 262**  
 genetic control, **47:223**  
 hematopoiesis, **47:274, 276**  
 identification, **47:199**  
 malignant expansion, **47:228**  
 surface phenotype, **47:210, 211, 213**  
 tissue distribution, **47:220, 221**
- regulators of complement activation and, **45:384, 388, 389, 410**
- spontaneous autoimmune thyroiditis and  
 cellular immune reactions, **47:450, 452, 454, 456**  
 disturbed immunoregulation, **47:471, 473–476, 481**  
 humoral immune reactions, **47:446, 447**
- sporozoite malaria vaccine and, **45:287, 305, 306**
- synthetic T and B cell sites and, **45:199**
- T cell development and, **44:250, 251**
- T cell populations, **53:161–163**
- T cell receptor and, **45:134**
- T cell subsets and  
 H-2 alloantigen recognition, **41:78, 86, 89, 91, 92**  
 H-2 molecules in thymus, **41:95, 102**  
 H-2-restricted antigen recognition, **41:67, 69, 72**
- virus-induced immunosuppression and, **45:354**
- Spleen cells  
 NZB, IgM secretion, **55:313–314**  
 transgenic, preliminary *in vitro* studies, **54:414–415**



- Spleen colony formation, hybrid resistance and  
 antigen expression, **41:402, 404**  
 bone marrow cells, **41:337, 347**  
 syngeneic stem cells, **41:388–390**  
 T cells, **41:382**
- Spliceosomes, antinuclear antibodies and, **44:102, 131**
- Splicing  
 CD1 genes, **59:9–10**  
 events, abnormal, in *PIG-A* gene, **60:88–89**
- Splicing domains, **63:201**
- Spondyloarthritic diseases, TAP and, **65:93**
- Spontaneous autoimmune thyroiditis  
 antigens, **46:269, 270**  
 cellular immune responses, **46:287**  
 experimental models, **46:273–276, 279**  
 genetic control, **46:282–284**  
 humoral responses, **46:298, 305, 306**  
 obese strain chicken, **47:433–435, 491–494**  
 altered thyroid function, **47:456–465**  
 breeding, **47:435–438**  
 cellular immune reactions, **47:449–456**  
 clinical symptoms, **47:438–440**  
 disturbed immunoregulation, **47:470, 476, 477, 479**  
 genetics, **47:484**  
 dysfunctions, **47:487–491**  
 MHC, **47:481–486**  
 target organ, **47:485, 487**  
 histopathology, **47:440–444**  
 humoral immune reactions, **47:444–449**  
 immunoregulation, **47:469**  
 extrinsic, **47:476–481**  
 intrinsic, **47:470–476**  
 potential effector mechanisms, **47:465–469**  
 prevention, **46:310, 311**
- Spontaneous cell-mediated cytotoxicity, assays, IBD and, **42:295**
- Spontaneous cellular cytotoxicity, **47:451, 452**
- Spontaneous neoplasm, immune regulation, **48:212**
- Sporozoite malaria vaccine, **45:283, 284**  
 antibodies, **45:300, 301**  
 CS proteins, **45:292–294**  
 cloning, **45:294–296**  
 evolution of repeats, **45:296–299**  
 function of repeats, **45:299, 300**  
 CS-specific T cells, **45:306–308**  
 epitopes, **45:310–313**  
 Ir gene control, **45:308–310**  
 endemic areas, **45:315–317**  
 human trials, **45:313–315**  
 immunity, **45:285, 286**  
 specificity, **45:287–292**  
 viability, **45:286, 287**  
 interferon- $\gamma$ , **45:301–306**  
 perspectives, **45:319–322**  
*Plasmodium vivax*, **45:317, 318**
- Sporozoites, *Plasmodium*, antibodies, **60:112–124**
- S protein, **61:204, 247–249**
- 11S protein, **64:21, 25**
- SPT14*, **60:72**
- Src family, **55:253–255; 61:153–158; 63:133–137**  
 in cytokine signaling, **60:5–9**  
 src homology 2, *see* SH2 domain  
 Src tyrosine kinases, **63:133–137**  
 activation by B cell antigen receptor, **55:253–255**  
 in cytokine signaling, **60:5–9**  
 IL-2R coupling, **61:153–158**  
 regulation by CD45, **66:4, 23, 39–45**
- S region, **54:236**
- SRP1, **64:48**
- Stamper–Woodruff assay, **60:167–168**
- Staphylococcal  $\alpha$ -toxin, cytolysis and, **41:317**
- Staphylococcal  $\delta$ -toxin, cytolysis and, **41:315, 316**
- Staphylococcal enterotoxin A  
 action on TCR, **58:323**  
 deletion of  $V\beta 3^+$  and  $V\beta 11^+$  R lymphocytes, **58:222**
- Staphylococcal enterotoxin B  
 beneficial effect, **58:274–275**  
 induction  
 cytokines, **58:271–272**  
 thymocyte apoptosis, **58:216**  
 $V\beta 8^+$  thymocyte depletion, **58:259–260, 262**  
 with L-NAME, **60:348–349**  
 pleiotropic effects *in vivo*, **58:219–224**
- Staphylococcal enterotoxins, **52:165**
- Staphylococcal protein A, antibodies from combinatorial libraries, **57:229**

- Staphylococcus aureus*, **52:160**; **54:108**, 109  
 antinuclear antibodies and, **44:115**, 118,  
 135  
 autoimmune thyroiditis and, **46:299**  
 Cowan I strain, CD23 antigen and, **49:151**  
 Cowan strain, **52:187–188**  
 and anti-CD40 results in T-independent  
 B cell differentiation, **52:191**  
 and food poisoning, **54:128**  
 genetically engineered antibody molecules  
 and, **44:78**, 85  
 infection-associated autoimmune disease,  
**54:140–141**  
 pulmonary infection, **59:397**
- Staphylococcus aureus* B  
 B cells responsive to, **40:20**, 21  
 cell response and, **40:14–15**, 16,  
 41–44
- Stat1, **59:261**; **62:69**; **63:141**  
 Stat2, **59:261**; **62:69**  
 STAT3, **65:19**  
 Stat3, **59:261**; **61:177**; **63:141**, 399  
 STAT5, **65:20**  
 Stat5, **63:141**, 399  
 IL-2 activation, **61:177**, 178  
 STAT6, **65:20**  
 Stat6, **61:177**  
 Stat48, **62:69**  
 Stat91, **62:68**  
 STAT family, interaction with NF-IL6,  
**65:19–21**
- Stat proteins, **59:261**; **62:68**, 69; **63:140**, 398,  
*see also* Signal transducers and activators  
 of transcription  
 IL-2R coupling, **61:162**, 174–179
- Stem cell factor, **55:1–2**, 81–84; **62:189**  
 chromosomal location, **55:13–15**  
 effect on secretion in SCFR<sup>+</sup> cells, **55:43**  
 expression regulation, **55:31–33**  
 genomic organization, **55:13–15**  
 germ cell development, **55:66–69**  
 identification, **55:10–12**  
 kit ligand, identification, **55:10–12**  
 lymphohematopoiesis effects  
 hematopoiesis, **55:43–48**  
 lymphocytes, **55:48–51**  
 NK cells, **55:48–51**  
 in mast cell biology  
 development, **55:52–60**  
 function, **55:60–64**  
 in melanocyte biology, **55:64–66**  
 mutations affecting  
 human, **55:23–24**  
 mouse, **55:17–23**  
 rat, **55:23**  
 neoplasia, **55:71–72**  
 brain tumors, **55:77**  
 breast cancer, **55:78**  
 gonadal tumors, **55:76–77**  
 hematopoietic tumors, **55:72–74**  
 lung cancer, **55:77–78**  
 mast cell leukemia, **55:74**  
 melanoma, **55:74–76**  
 nervous system, **55:69–71**  
 as therapeutic agent, **55:78–81**  
 tissue distribution, **55:15–17**
- Stem cell factor receptor  
 c-kit gene encoding, **55:3–10**  
 allelism with W, **55:6–7**  
 and c-fms, evolutionary relationship,  
**55:9–10**  
 chromosomal location, **55:7–9**  
 genomic organization, **55:7–9**  
 and PDGFR genes, evolutionary  
 relationship, **55:9–10**  
 expression regulation, **55:24–31**  
 germ cell development, **55:66–69**  
 interaction with ligand, consequences  
 adhesion, **55:37**  
 chemotaxis, **55:37–38**  
 differentiation, **55:40–42**  
 haptotaxis, **55:37–38**  
 maturation, **55:40–42**  
 proliferation, **55:39–40**  
 secretion, **55:43**  
 survival, **55:38–39**
- lymphohematopoiesis effects  
 hematopoiesis, **55:43–48**  
 lymphocytes, **55:48–51**  
 NK cells, **55:48–51**  
 mast cells bearing, secretion, SCF effects,  
**55:43**  
 melanocyte biology, **55:64–66**  
 mutations  
 human, **55:23–24**  
 mouse, **55:17–23**  
 rat, **55:23**  
 neoplasia, **55:71–78**  
 signal transduction through, **55:33–36**  
 tissue distribution, **55:15–17**

- Stem cell factor receptor/c-kit, **52**:352–354, 363–364
- Stem cells
- B cell formation and, **41**:181, 182, 184, 187, 206, 237
  - B cell precursors, **41**:188, 191, 195, 199, 200
  - bone marrow cultures, **41**:209, 217, 219
  - genetically determined defects, **41**:220, 224, 225
  - soluble mediators, **41**:232–234
  - embryonic, *see* Embryonic stem cells
  - hematopoietic, *see* Hematopoietic stem cells
  - hybrid resistance and, **41**:352, 362, 367
    - antigen expression, **41**:402–407
    - bone marrow cells, **41**:336–340, 344, 346
    - effector mechanisms, **41**:370–373, 377–380, 383, 386, 388–391
  - lymphoid, *see* Lymphoid stem cells
  - self-renewal, **58**:422
  - switching, developmentally programmed, **58**:308–309
  - syngeneic stem cell functions, hybrid resistance and, **41**:388–390
- Steroids
- aPL antibodies and, **49**:223, 232
  - B cell formation and, **41**:209, 219, 236, 238
  - hybrid resistance and, **41**:348, 387
  - NF- $\kappa$ B and, **65**:118–120
  - spontaneous autoimmune thyroiditis and, **47**:480, 481
  - virus-induced immunosuppression and, **45**:338
- Steroid therapy, IBD and, **42**:286, 289, 316–319
- Stimulating cells, **50**:31–32
- B cells, role in V $\beta$  selective element action, **50**:31
  - dendritic cells, role in V $\beta$  selective element action, **50**:31
  - transfer of Vbse among cells, **50**:32
- Stochastic processes, maternally transmitted antigen and, **38**:324, 326, 327, 341
- Stomach cancer, X-linked agammaglobulinemia, **59**:147
- Streptococcal M proteins, **54**:114–115
- Streptococcal pneumonia, **59**:395–396
- Streptococcal toxins, **54**:108–113
- Streptococcus*
- infection, membrane cofactor protein, **61**:221
  - tumor necrosis and, **42**:215
- Streptococcus mutans*, subunit vaccines, **60**:135–136
- Streptococcus pneumoniae*, mouse infection anti-Id antibodies as vaccines against, **39**:283
- Streptococcus pyogenes*, **54**:109, 114
- v $\beta$  specificity for, **54**:109, 110–112
- Streptococcus zooepidemicus*, and Fc of IgG, **51**:61
- Streptolysin O. 317, **41**:318
- Streptomyces tsukobaensis*, **52**:403
- Streptozotocin, diabetes induced by, **62**:100
- Stress-activated protein kinases, **63**:148
- Stroke, aPL antibodies and, **49**:218, 221, 258
- Stroma, hybrid resistance and, **41**:336, 404
- Stromal cells
- B cell formation and, **41**:184, 185, 237, 238
  - B cell precursors, **41**:198, 200, 203
  - bone marrow cultures, **41**:209, 210, 212–216, 219, 220
  - genetically determined defects, **41**:223, 227, 229, 231, 232
  - lymphohematopoietic tissue organization, **41**:186–188
  - soluble mediators, **41**:234
  - contacts with pre-B cells, **53**:133–134
  - immunosenescence and, **46**:241
  - pre-B cell nonproliferation on, **53**:134–135
  - pro- and pre-B cells reactive to, **53**:131–136
  - thymic, autoreactive T cells and, **45**:421–425
  - uterine, IL-1ra production, **54**:188
- Stromelysins, **62**:288; **64**:297
- Structural complementarity, protein-protein interactions, **43**:104–105
- Structure–function studies, MMTV superantigens, **54**:103–106
- Subclones
- B cell formation and, **41**:210
  - CTL and, **41**:139
- Subcloning, hybridomas and, **38**:291
- Submucosa, Crohn's disease specimens, **42**:298
- Substance P, **61**:372–373
- arthritis and, **39**:317–318

- bronchospasm induction and, **39:318**  
 effects on  
   secretory functions, **39:302–303**  
   smooth muscle and vasculature,  
     **39:302–303**  
 histamine release by mast cells and,  
   **39:305–306**  
 immunostimulatory properties,  
   **39:311**  
 leukocyte chemotaxis and, **39:308**  
 lymphocyte adhesion and, **64:153**  
 in nasal secretion, **39:304**  
 and other neuropeptides, receptors for,  
   **52:372–375**  
 tissue repair and, **39:308–309**
- Substance P receptors  
 lymphocyte, **39:313**  
 recovery from IM-9 cells, **39:313**  
 T cell, **39:313**
- Subtilisin, site-directed mutants, **43:23**
- Subtractive hybridization, **43:135**
- N*-Succinimidyl 3-(2-pyridyldithio) propionate,  
 in crosslinking for chemoimmuno-  
 conjugates in cancer treatment,  
   **56:319–320**
- Sucrose, cytotoxicity and, **41:290, 304**
- Sugars  
 immunosenescence and, **46:234**  
 lymphocyte–HEV interaction, **65:360–361,**  
   **363–365**  
 as selectin ligands, chemical structure,  
   **58:355**
- Sulfapyridine, **42:317, 318**, *see also*  
 Sulfasalazine
- Sulfasalazine, **42:311**  
 IBD and, **42:289, 296, 316–318**  
 prostaglandin synthesis and, **42:312–313**
- Sulfated glycoprotein 2, **61:204, 249–251**
- Sulfidoleukotrienes, IBD and, **42:314, 315**
- Sulfosuccinimidyl-2-(*p*-azidosalicylamino)-1,3'-  
 dithiopropionat identification of lipid A-  
 binding membrane proteins, **53:274–275**
- Sulfotransferases, **64:168**
- Sulindac, **62:184, 186, 201**
- SUN1*, **64:20, 21**
- Superantigens, *see also* Staphylococcal  
 enterotoxin A; Staphylococcal  
 enterotoxin B  
 bacterial, **65:14, 208–210**  
 classes, **54:99–100**  
 endogenous murine, **54:100–108**  
 cellular expression of MMTV antigens,  
   **54:106–107**  
 identification of MIs antigens as MMTV  
 products, **54:100–102**  
 role in life cycle of MMTV and host,  
   **54:107–108**  
 structure–function studies, **54:103–106**  
 exogenous, **54:108–117**  
   bacterial products with related function  
   as superantigen, **54:113–115**  
   produced by infectious viruses,  
     **54:115–117**  
   staphylococcal and streptococcal toxins,  
     **54:108–113**  
 and human disease, **54:128–145**  
   autoimmune disease associated with  
   streptococcal infection, **54:140–141**  
   food poisoning, **54:128**  
   immunodeficiency disease, **54:142–143**  
   Kawasaki syndrome, **54:133–137**  
   lymphoproliferative diseases, **54:143–145**  
   rheumatoid arthritis, **54:137–140**  
   systemic lupus-like autoimmune disease,  
     **54:141–142**  
   toxic shock syndrome, **54:128–133**
- immune responses  
 binding to major histocompatibility  
 complex, **54:117–120**  
 direct non-T cell effects, **54:127**  
 involvement of accessory CD4 or CD8  
 molecules, **54:124–125**  
 recognition by T cell receptors,  
   **54:121–124**
- T cell deletion and anergy in adult  
 animals injected with superantigens,  
   **54:125–127**
- T cell signaling in response to  
 superantigens vs conventional  
 antigens, **54:127**
- induced deletion and anergy, differential  
 regulation, **58:272**
- MMTV, **65:140, 152–153**  
 expression, **65:152–153**  
 immune stimulation by, **65:140, 141,**  
   **171–194, 196–203**  
 MHC class II molecules, interaction  
 with, **65:164–165**  
 protein structure, **65:157–164**  
 TCR V $\beta$ , interaction with, **65:165–167**  
 tumor formation and, **65:155, 156**

- Superantigens (*continued*)  
 mycobacterial, **58**:321–323  
 T cells stimulated by, **58**:260–262
- Supergenes, cytotoxicity and, **41**:310
- Supernatants, humoral immune response and, **45**:5  
 antigens, **45**:15  
 interleukins, **45**:62, 65, 67, 69, 70  
 physical interaction, **45**:54
- Superoxide  
 interaction with NO, **60**:324–325  
 relation to P-selectin, **58**:355
- Suppression  
 allotypic and anti-idiotypic, Fc region and, **40**:73  
 hybrid resistance and, **41**:380, 381, 384, 387, 389, 395  
 IDDM, **48**:143–144  
*in vitro*, induced by V $\beta$  selective elements, **50**:37  
 T cell-mediated  
*Ir* genes and, **38**:188  
 GAT, **38**:134–141  
 GT, **38**:144–149  
 H-Y antigen, **38**:175, 179  
 immunodominance, **38**:182–184  
 insulin, **38**:142–144  
 lactate dehydrogenase B, **38**:149–152  
 lysozymes, **38**:140–142  
 tolerance, **38**:129  
 malignant B cell proliferation, **40**:144–145
- Suppressor antigen-presenting cell, **48**:206
- Suppressor cells, *see also* Suppression, T cell-mediated; Suppressor T cells  
 hybrid resistance and, **41**:340, 368, 410  
 marrow, **41**:385–387, 391, 392  
 in IBD, **42**:299  
 immunosenescence and, **46**:249–251  
 in MG, **42**:260
- Suppressor macrophages, **50**:176
- Suppressor T cells, **43**:266; **50**:176–177, *see also* Suppression, T cell-mediated  
 AChR-specific, **42**:258–259  
 adoptive T cell therapy of tumors and, **49**:287–289, 293  
 antigen-specific inhibition of MOPC-315 by, **40**:143–144  
 autoreactive T cells and, **45**:431, 432  
 covert, in Crohn's disease, **42**:300, 301  
 historical background, **40**:135–136  
 hybrid resistance and, **41**:379, 386, 410  
 idiotype-specific inhibition of B cells by, **40**:136–143  
 immunosenescence and, **46**:251, 252  
 isotype-specific inhibition of B cells by, **40**:145–148  
 lymphocytotoxic antibodies and, **42**:291–292  
 MG therapy and, **42**:269  
 T cell subsets and, **41**:102, 107, 110
- Surface area, exposed, MHR, **43**:35–36
- Surface markers, for memory B cells, **53**:235
- Surface receptors, alternative, death induction by, **58**:224–227
- Surface variability analysis, **43**:11, 14
- Surrogate heavy chain, **63**:8, 25
- Surrogate light chain  
 B cell development, **63**:2–4, 15–25, 29–31  
 expression, **63**:5–12, 13–15  
 genes, **63**:4–5  
 transduction in complex, **63**:25–29
- Switched memory B cells, **59**:340–341
- Switch peptides, **43**:113
- Switch recombination  
 B cells, **61**:83  
 CD40 signaling, **61**:92–98  
 comparisons between VJD and switch recombination, **54**:235–237  
 control during cell cycle, **61**:116–117  
 in DNA replication, **54**:237–238  
 experimental systems for studying, **54**:237  
 fine sequence specificity, **61**:107–108  
 germline transcripts, **61**:111–116  
 homeologous recombination similarity, **61**:110–111  
 Ig production, **63**:58–59  
 illegitimate priming model, **61**:108–111  
 intrachromosomal deletion, **61**:99  
 looping out and deletion, **54**:234  
 mutations, **61**:108  
 poly(ADP-ribose) polymerase, **61**:110  
 protein-binding sites, **61**:117, 120  
 E47/E12, **61**:117  
 LR1, **61**:120  
 NF- $\kappa$ B/p50, **61**:117, 118–119  
 NF- $\Sigma$ , **61**:119  
 Pax5, **61**:120–122

- sy3 regions, **61**:117–118  
*subp-2*, **61**:119  
 proteins involved in switch recombination, **54**:239–240  
 RNA splicing, **61**:101–102  
 sequential switching, **54**:238–239;  
**61**:105–107  
 sister chromatoid exchange, **54**:234–235  
 sites, **61**:102–105  
 substrates, **61**:123–129  
 transchromosomal switching, **61**:100–102  
 vectors, **61**:123–129  
 Syk, **59**:261, 324  
   IL-2R coupling, **61**:159–160, 190  
 Syk kinase, **59**:261, 324  
 Syk tyrosine kinase, **63**:28, 134, 137–138  
 Sympathetic ophthalmia, **48**:216, 217  
 Synctium formation, virus-induced  
   immunosuppression and, **45**:349, 350,  
   358, 359  
 Synergy  
   anti-TNF- $\alpha$  therapy, **64**:331–333  
   B cell formation and, **41**:222, 234  
   cytotoxicity and, **41**:284, 296  
   hybrid resistance and, **41**:406  
   T cell activation and, **41**:20, 23, 28, 30  
     Ca<sup>2+</sup> ionophores, **41**:15–19  
     cell surface molecules, **41**:2, 12, 14  
 Syngeneic mixed lymphocyte responses,  
   autoreactive T cells and  
   activation, **45**:426  
   origin, **45**:418–420  
   regulation, **45**:432, 433  
 Syngeneic preference, hybrid resistance and,  
   **41**:334, 358  
 Syngeneic stem cell functions, hybrid  
   resistance and, **41**:388–390  
 Synovial cells  
   HLA class II molecule, **48**:132  
   as source of chemokines, **55**:111  
 Synoviocytes, **64**:288  
   CD40 expression, **61**:15, 41  
 Synovitis, lymphocytes, **64**:191  
 Synovium  
   IL-1ra production in macrophages,  
     **54**:187–188  
   lymphocyte homing and, **44**:344  
   normal, **64**:287  
   rheumatoid, **64**:287–288, 291, 315  
     joint destruction mechanism, **64**:320–321  
     neovascularization, **64**:319–320  
 Synthetic peptides  
   defined recognition sites, *see* Recognition  
     sites, synthetic  
   extracellular processing, **52**:84–85  
   technology, applications, **43**:59  
 Syphilis, *see also* Biological false positive  
   serological test for syphilis  
   aPL antibodies and antibody subsets,  
     **49**:232  
   history, **49**:198–199  
   specificity, **49**:234–236, 240, 249–250  
 Systemic inflammatory response syndrome,  
   **63**:310  
   criteria for, **66**:101, 123  
 Systemic lupus erythematosus, **46**:196, 200  
   antinuclear antibodies and, **44**:94–97  
   autoantibodies, **44**:125, 136  
   autoimmune response, **44**:131, 132  
   DNA, **44**:97, 98  
   drug-induced autoimmunity, **44**:109  
   histones, **44**:98–100  
   ku, **44**:104, 105  
   mixed connective tissue disease, **44**:111  
   PCNA, **44**:106–109  
   ribosomal RIP, **44**:105, 106  
   RNP, **44**:100–102  
   scleroderma, **44**:120, 124  
   Sjögren's syndrome, **44**:112  
   subcellular particles, **44**:102–104  
   aPL antibodies and, **49**:193, 198, 209, 212,  
     219, 250, 257, 259  
   affinity purification, **49**:229  
   anybody subsets, **49**:231  
   binding, **49**:251–252  
   clinical aspects, **49**:206–209, 212  
   isotype, **49**:225–227  
   LA antibodies, **49**:245–246  
   pathogenic potential, **49**:252–255, 257  
   specificity, **49**:234–236, 238–239,  
     248–249  
   syndromes, **49**:213–216, 218–222  
 CD23 antigen and, **49**:174–175  
 human idiotypic network and, **39**:277–278  
 Ig heavy-chain variable region genes and,  
   **49**:46–50  
 IL-1 and, **44**:193  
 and IL-6, **54**:41–42  
 lymphocytotoxic antibodies and,  
   **42**:291–292  
 NK cells and, **47**:300, 301

- Systemic lupus erythematosus (*continued*)  
 overexpression of Fas variant, **58:274**  
 patients, low IL-1 production in,  
**50:175–176, 186–187**  
 pituitary hormones, **63:420–421**  
 transfer to hu-PBL-SCID mouse, **50:307**
- Systemic lupus erythematosus, murine, **46:61**,  
 62, 65, 71, 99, 100, *see also* Lupus  
 mouse
- aPL antibodies and, **49:219, 248**
- EPA and docosahexaenoic acid in diet and,  
**39:163–164**
- fish oil in diet and, **39:163–165**
- functional abnormalities in  
 B cells, **37:309–316**  
 macrophage defects, **37:324–326**  
 natural killer cells, **37:327**  
 other cellular and humoral abnormalities,  
**37:327–330**
- T cells, **37:316–324**
- genetics, **37:336–337**  
 complementarity of genetic backgrounds  
 among lupus mice and role of  
 accelerator and other autosomal  
 genes, **37:341–345**
- inheritance of autoimmune traits,  
**37:337–338**
- relationship among autoimmune traits  
 and their association with disease,  
**37:338–341**
- relationship between the traits, H-2 and  
 Ig genes, **37:345–346**
- Ig germline, **46:65, 66**  
 autoantibodies, **46:71–76**  
 inducing agent, **46:78**  
 murine lupus, **46:66–71**  
 somatic mutation, **46:76, 77**
- influence of sex and sex hormones on  
 pathogenesis of, **37:346–348**
- lupus strains, **46:61–65**
- morphologic manifestations  
 arthritis, **37:282–283**  
 glomerulonephritis, **37:276–278**  
 lymphoid hyperplasia, **37:279–282**  
 neoplasia, **37:282**  
 other significant histopathologic  
 characteristics, **37:283–284**
- thymic atrophy, **37:278**
- vascular disease and myocardial  
 infarction, **37:278–279**
- recombinant IL-2/vaccinia virus construct  
 on, **50:193–203**
- serologic manifestations  
 antierythrocyte antibodies, **37:**  
**295–297**  
 antiretroviral gp70 autoantibodies,  
**37:293–295**  
 autoantibodies to IgG, **37:298–300**  
 autoantibodies to nuclear antigens,  
**37:286–293**  
 complement levels, **37:295**  
 cryoprecipitates, **37:295**  
 Igs, **37:284–286**  
 natural thymocytotoxic antibody,  
**37:297–298**
- T cell antigen receptor, **46:78, 79**  
 autoimmune strains, **46:83–86**  
 expression, **46:86–99**  
 gene diversity, **46:79–83**  
 treatment of, **37:350–355**  
 viruses in, **37:348–349**
- Systemic lupus erythematosus-like  
 autoimmune disease, **54:141–142**  
 B/WF1 mouse, **53:144–147**

## T

- T3, T cell receptor and, **38:18, 22**
- T3 membrane proteins, **43:116**
- T9, positive lymphocytes, in Crohn's disease,  
**42:290**
- T11, *see* CD2
- T15' B cells in mice, **42:72**
- Tac antigen, **59:228**
- Tachykinin receptor, **48:181**
- Tachyzoite antigen, **65:208**
- Talin, leukocyte integrins and, **46:169**
- T-ALL cell line (YT), **42:171**
- TAM, *see* Tyrosine-containing sequence  
 motifs
- TAP, **64:4**
- TAP, **65:47–96, 96**  
 background, **65:47–56**  
 disease and  
 autoimmune disease and, **65:92–94**  
 dysfunction in tumors, **65:94–95**  
 polymorphism, **65:92–94**  
 viral inhibitors, **65:95**

- gene structure, **65:58**, 59–61  
intracellular localization, **65:62–63**  
MHC class I assembly and, **65:87–92**  
polymorphism, **65:71–75**, 92–94  
protein structure  
  as heterodimer, **65:61–62**, 79, 81  
  intracellular localization, **65:62–63**  
  subcellular localization, **65:63**, 65  
  topology, **65:64**, 65–71  
  subcellular localization, **65:63**, 65  
TAP1, **64:4**; **65:50**, 85  
TAP1, structure, **65:58**, 60–61  
TAP1/TAP2, **64:4**, 112  
  function, **64:112**  
  MHC class I molecules and, **64:113–115**,  
  117–119  
  peptide binding, **64:114–115**  
  peptide transport, **64:112–113**  
TAP2, **64:4**; **65:51**, 85  
TAP2, structure, **65:58**, 60–61  
Tapasin, **65:91**  
TAP complex, **65:75–76**  
  length specificity, **65:78**  
  peptide and nucleotide binding, **65:84–86**  
  sequence specificity, **65:78–84**  
  transport assays, **65:76–78**  
  transport model, **65:86–87**  
TAP system, **64:3–5**, 30–31  
Target-binding cells, NK cells and, **47:230**,  
269  
Target cell–effector cell interaction, mediated  
  by leukocyte Fc receptors, **51:51–54**  
Target cells  
  CTL and, **41:137**, 158, 162, 168  
  carbohydrate moieties, **41:153**, 154  
  exon shuffling 142, **41:144**, 149  
  HLA class I antigens, **41:149–152**  
  cytotoxicity and, **41:269–272**, 300, 319, 320  
  cell-mediated killing 294, **41:296–298**,  
  312  
  cytolysis, **41:273–284**  
  cytotoxic T cells and, **38:173**  
  HIV infection and  
  etiologic agent, **47:378**, 384  
  immune response, **47:409**, 411  
  immunopathogenic mechanism, **47:400**  
  hybrid resistance and, **41:363**, 369, 372,  
  373, 383  
  antibodies, **41:376–378**  
  antigen expression, **41:400**, 404  
  marrow, **41:387**, 391, 392  
  *in vitro* assays, **41:393–396**  
  NK cells and, **47:292**, 294  
  antimicrobial activity, **47:285–288**  
  cytotoxicity, **47:249–256**, 259  
  effector mechanisms, **47:234–242**  
  hematopoiesis, **47:280**  
  lymphokines, **47:262–264**  
  receptors, **47:242–248**  
  spontaneous autoimmune thyroiditis and,  
  **47:451**  
  T cell activation and, **41:1**, 14, 30  
  T cell subsets and, **41:76**, 94, 95  
  Targeted chemotherapy, concept of,  
  **56:301–303**  
Target organ, spontaneous autoimmune  
  thyroiditis and  
  defect, **47:456–465**  
  genetics, **47:482**, 485, 487  
Target recognition, T cell receptors and,  
**38:22–24**  
TATA box, TAP genes, **65:60**  
Tax, **65:29**  
  HTLV-I, activation of NF- $\kappa$ B, **58:17–18**  
TBAM, **63:47**  
T cell-activating protein, **48:240–241**  
T cell activation, **41:1**, 4, 8, 10, 17, 19, 21,  
22, 24, 25, 30, 31; **58:18–19**;  
**61:148–149**; **62:131**  
  accessory activation molecule, **48:304–306**  
  alternative activation molecule, **48:304–306**  
  alternative pathway, **48:235**  
  calcium ionophore, **48:258–260**  
  CD8a role, **53:84–85**  
  cell cycle progression, **48:290**  
  cell surface molecules, **41:1–15**  
  *c-fos*, **48:291–292**  
  *c-myb*, **48:293–294**  
  *c-myc*, **48:292–293**  
  de novo-induced genes, **48:290**  
  gene products, **48:290**  
  gene regulation, **41:26–30**  
  IL-1 receptor, **48:250–253**  
  intracellular signals, **41:26**  
  *in vivo*, **63:71**  
  *Ir* genes and, **38:106**, 107, 189  
  antigen binding, **38:104–108**  
  competitive inhibition, **38:110**  
  complementation, **38:79**  
  cytotoxic T cells, **38:165**, 171



- T cell activation (*continued*)  
 expression, **38:58**  
 gene function, **38:91**  
 H-Y antigen, **38:177**  
 I region mutations, **38:91**  
 selection, **38:132**  
 suppression, **38:135, 152**  
 molecular events mediating, **48:227–311**  
 murine system, **41:1**  
   cell surface molecules, **41:10, 11, 13, 14**  
   receptor-mediated signal transduction, **41:23, 25**  
 nuclear events, **48:290–299**  
 phorbol ester, **48:258–260**  
 protooncogene, **48:291–294**  
 Ras proteins, **63:144–145**  
 receptor-mediated signal transduction, **41:19–26**  
 recognition phase, **63:43–44**  
 signal transduction, **48:251–252**  
 synergy, **41:15–19**  
 T cell antigen receptor-CD3 complex, **48:232–235**  
 two stages of, **51:107**  
 tyrosine kinase p56<sup>lck</sup> role, **53:78–82**  
 T cell antigen receptor, *see* T cell receptor  
 T cell–B cell collaboration, antigens and, **42:75**  
 T cell–B cell interaction, **60:282–283; 63:44, 46, 71–72, 71–72**  
 T cell clones, **38:3, 22; 43:134; 48:78**  
 activation, **43:216**  
 alloreactive, **38:3**  
 antigen binding, **38:99, 105, 106**  
 antigen dose-response curves, **43:202**  
 colony-stimulating factor gene differential expression, **48:89–92**  
 competitive inhibition, **38:109, 110**  
 cross-reactive lysis, **38:187**  
 cytotoxic T cells 165, **38:170**  
 gene dosage, **38:81**  
 gene function, **38:92**  
 germline repertoire, **38:116–118**  
 GM-CSF preferential synthesis, **48:91**  
 immunizing, **38:3**  
 immunodominance, **38:184, 185**  
 lines, **43:196**  
 lymphokine mRNA expression, **48:87–88**  
 macrophages, **38:111–114**  
 reactivity, HLA-Dw14, **48:129**  
 suppression, **38:134, 143, 152**  
 T cell selection, **38:131, 134**  
 T cell–T cell interactions, **38:160**  
 tolerance, **38:119–121, 124, 126, 129**  
 T cell cytokines, *see* T helper cells, cytokines  
 T cell development, **44:207, 255; 58:90–101; 63:1**  
 antigen recognition, **44:209–214**  
 avian, experimental manipulation, **50:102–105**  
   cyclosporin treatment, **50:104–105**  
   embryonic treatment with antibodies, **50:103**  
   thymectomy, **50:102**  
 CD4 vs. CD8, **53:108–113**  
 cellular selection within thymus, **44:245**  
   negative selection, **44:245–252**  
   positive selection, **44:252–255**  
 four-way developmental choice, **51:180–186**  
   CD4 vs CD8 down-regulation, **51:185–186**  
   positive selection vs two kinds of death, **51:175–177**  
   positive vs negative selection, **51:180–183**  
   signaling pathways that control positive selection, **51:183–185**  
 functionally responsible  
   intrathymic transitions, **51:117–139**  
     ontogeny of major thymic lineages, **51:133–138**  
     ontogeny of minor thymic lineages, **51:138–139**  
   summary, **51:139**  
   TCRa,B lineage, **51:118–124**  
   TCR $\gamma\delta$  lineage, **51:124–133**  
 mature T cells, properties, **51:85–110**  
   proliferative response, **51:106–110**  
   recognition/auxiliary coreceptors, **51:91–92**  
   recognition structures, **51:86–91**  
   response genes, **51:98–105**  
   signalling through TCR/CD3 and coreceptors, **51:92–98**  
 selection, and mechanism, **51:164–189**  
   negative selection, **51:165–175**  
   positive selection, **51:175–189**  
 summary, **51:189–194**

- thymocytes, functional maturation, **51**:139–164  
 auxiliary signaling receptors, **51**:157–160  
 functional maturation vs commitment to T cell lineage, **51**:162–164  
 mature vs immature characteristics, history, **51**:139–140  
 postthymic maturation, **51**:160–162  
 response genes, **51**:146–157  
 TCR/CD3 complexes and signaling mediators, **51**:140–146  
 thymus and its seeding, **51**:110–117
- ontogeny, **44**:214, 215, 221–225  
 accessory molecules, **44**:219–221  
 function, **44**:221  
 receptor expression, **44**:218, 219  
 thymocyte, **44**:215–218  
 thymocyte subpopulation, **44**:225–245  
 in thymus, **51**:112
- T cell epitopes, **43**:4, 60, 73, 78  
 autoimmune diseases and, **66**:88–91  
 circumsporozoite protein-derived, **60**:106–120  
 computational identification, **66**:77–84  
 nonmalarial protein-derived, **60**:110–112
- T cell growth factor, **46**:112, 114; **61**:147
- T cell hybridomas, *I $\tau$*  genes and, **38**:40  
 antigen binding, **38**:99, 107  
 antigen processing, **38**:95  
 competitive inhibition, **38**:109, 110  
 germline repertoire, **38**:116  
 suppression, **38**:151  
 T cell–T cell interactions, **38**:156, 157, 160
- T cell hybrids  
 alloreactive responses to  
 B cells, **39**:85–87  
 macrophages/dendritic cells, **39**:85–86  
 hapten-specific B cells and, **39**:56–57
- T cell leukemias, **38**:18  
 anti-Id antibody therapy, **39**:288  
 development, **50**:141–142  
 mature, receptor gene rearrangements in, **40**:276–284
- T cell lymphocytopenia, steroid therapy and, **42**:289
- T cell lymphoma  
 depletion, **58**:272–275  
 murine, **54**:289
- T cell receptor, **41**:2–8; **43**:105, 114–117; **45**:107, 108, 131; **48**:78–81; **58**:119–120; **63**:43–44, *see also* Antigen–MHC determinant; T cell development  
 $\alpha$ , **64**:69  
 and  $-\beta$  and  $-\gamma$  and  $-\delta$   
 generation of diversity, **58**:115–116  
 genomic organization, **58**:114–115  
 rearrangement and expression, **58**:116–119  
 rearrangement, **58**:150–152; **61**:305–306  
 transcription inhibition, **58**:243  
 $\alpha$  enhancer, **43**:268  
 $\alpha\beta$ , **43**:115; **59**:100–105  
 antigen receptor dimer, **43**:116–117  
 CD3 complex, **43**:135  
 chain alignment, **43**:221  
 compared to T cell receptor Ad, **43**:175  
 developmental control, **58**:157  
 expression, **43**:146–147, 165  
 genes, **43**:136  
 heterodimers, **43**:221, 266  
 induction of CD8<sup>+</sup> T cell apoptosis, **58**:223  
 loci, **43**:140  
 lymphocytes, ontogeny, **43**:169  
 molecules, **43**:134  
 mRNA, **43**:146–147  
 protein complex, **43**:134–135  
 role in signal transduction, **58**:125–127  
 specificity, **58**:124–125, 174  
 transcripts, **43**:168  
 variable region sequences, **43**:221  
 $\alpha\beta$  and  $\gamma\delta$   
 complexes, **58**:113–128  
 diversified  
 in human, **58**:305–306  
 in mouse, **58**:304–305  
 $\alpha\beta$  lineage, **51**:118–124  
 $\beta$ , **43**:136  
 germ-line genes, **43**:267  
 induction of development, **58**:142–144  
 primary structure, **43**:220  
 rearrangement, **61**:305–306  
 signal mediation, and p56<sup>lck</sup> control, in thymocyte development, **56**:163–164  
 transcription, **43**:268  
 $\beta$  enhancer, **62**:43, 51–52

- T cell receptor (*continued*)
- epitopes, **45:142**
    - conformation, **45:145, 146**
    - helical conformation, **45:142-144**
    - location, **45:146-148**
  - $\gamma$  gene
    - disulfide-linked form, **43:148**
    - human, **43:140-143**
    - IDP2 transcript organization, **43:154**
    - mRNA transcripts, **43:167**
    - murine genes, **43:136-140**
    - puzzle, **43:144-145**
    - rearrangement and diversity, **43:143-144**
    - role in fetal life, **43:144**
  - $\gamma\delta$ , **43:175-176**
    - expression by fetal CD44<sup>+</sup>CD25<sup>+</sup> cells, **58:141**
    - heterodimers, **43:266**
    - importance, **43:177-178**
    - invariant, **58:301-304**
      - lung, **58:303-304**
      - skin, **58:301-303**
      - tongue and female reproductive tract, **58:303**
    - ontogeny, **43:165-171, 177**
      - gene expression, **43:266**
      - protein structure, **43:174-175**
      - thymic ontogeny, **43:177**
    - V3, **64:69**
  - $\gamma$ - $\gamma$  homodimers, **43:150**
  - $\gamma\delta$  lineage, **51:124-133**
  - $\gamma\delta$  lymphocytes
    - activation, **43:171-172**
    - allogenic target cell recognition, **43:173-174**
    - anti-CD3 mAb, **43:172**
    - cell surface expression, **43:162**
    - cytolysis, **43:172-174**
    - functional studies, **43:174**
    - peripheral blood and thymic, **43:161-164**
    - skin, **43:164-165**
  - $\gamma\delta$  proteins, **43:146**
    - CD3 polypeptides, **43:150-152**
    - cytofluorographic analysis, **43:146-147**
    - forms, **43:148-149**
    - human subunit structure, **43:148-152**
    - identification, **43:146-148**
    - mobility, **43:150**
    - murine subunit structure, **43:152-153**
    - peptide mapping, **43:150**
    - SDS-PAGE, **43:150**
    - two-color cytofluorographic analysis, **43:146-147**
  - $\delta$ , **43:150**
    - hairpin accumulation at, **58:48**
  - $\delta$  gene
    - breakpoints, **43:160**
    - C $\delta$ -C $\alpha$  locus organization, **43:155-156**
    - C6 gene segment, **43:156-157**
    - chromosomal translocation, **43:160-161**
    - genomic organization, **43:155-156**
    - identification, **43:153-155**
    - IDP2 transcript organization, **43:154**
    - rearrangement and diversity, **43:158-160, 167**
  - accessory molecules, **45:108, 109**
    - CD3 complex, **45:109, 110**
  - adoptive T cell therapy of tumors and, **49:299**
  - allelic exclusion, **38:17, 18**
  - alloreactivity, **45:148-157**
  - amino acid conservation, **43:221-222**
  - amphipathicity, **43:204**
  - antigen, **38:2**
    - conformation and recognition, **43:194, 223-225**
    - MHC interaction model, **43:201**
    - processing, **43:196-197**
    - specificity, **43:193-194**
  - antigen binding, **38:98, 99, 104-107**
  - antigen processing
    - class II molecules, **45:117, 118**
    - class I molecules, **45:118, 119**
    - exceptions, **45:119, 120**
    - factors, **45:122-124**
    - molecular mechanisms, **45:127, 128**
    - pathways, **45:124-127**
    - peptides, **45:120, 121**
    - recycling, **45:121, 122**
  - antigen-specific, **38:115-117**
  - autoimmune demyelinating disease and, **49:357**
    - myelin basic protein, **49:358-360**
    - usage restriction, **49:363-366**
  - autoimmune thyroiditis and, **46:265, 318, 319**
    - cellular immune responses, **46:291**
    - humoral responses, **46:307**
    - prevention, **46:312, 314-316**
  - autoreactive T cells and, **45:417, 419**

- B cell formation and, **41**:194, 199, 225, 226, 237
- $C_\alpha$  domain, **43**:221
- CDR, diversity, **43**:222
- chromosomal mapping, **38**:16, 17
- class I and class II-specific, **43**:205
- $C_\delta$  locus deletion, **43**:170
- combining site
- antigens bound to MHC, **43**:215–220
  - selections based on receptor specificity, **43**:218–219
  - shape, **43**:222
  - T cell receptor structure, **43**:220–222
- complex, **58**:128–136
- CTL and, **41**:136, 137, 139, 152, 167, 168, 170
- cytotoxic, **38**:170, 173
- cytotoxicity and, **41**:271, 272, 274
- defined, **64**:1
- encoding, **38**:5–9
- evolution, **52**:110–111
- experimental systems, **45**:131, 132, 137
- expression, peripheral T cells, **38**:13–15
- expression at different anatomical sites, **58**:300–306
- gene defects, in hereditary primary immunodeficiency disorders, **40**:306–309
- gene expression, **43**:135
- peripheral T cells, **38**:13–15
  - putative transcription signals, **43**:267
  - during T cell ontogeny, **43**:266–267
  - tissue specific, **43**:235
  - trans-acting negative regulation, **43**:267
  - transcriptional regulatory elements, **43**:267–269
- gene organization, **40**:259–262
- gene rearrangements, **58**:31, 36–41, 63, 68–69
- applications to clinical medicine, **40**:264–270
  - definition of clonality based on, **40**:295–305
  - developmentally programmed, **58**:308–309
  - and expression, thymus, **38**:10–13
- genes
- allelic exclusion, **38**:17–18
  - $\alpha$  enhancer, **43**:268
  - avian, **50**:108–112
  - conserved structural features, **50**:111–112
  - genomic organization, **50**:108–109
  - TCR $\beta$  diversity, **50**:109–111
  - hypermutation, **60**:278–280
  - germline repertoire, **38**:118
  - homogeneity
    - peptidic self model, **45**:128, 129
    - self-component, **45**:128
    - self-peptides, **45**:129–131  - humoral immune response and, **45**:5, 6
    - antigens, **45**:18, 19
    - physical interaction, **45**:36, 38, 41, 44–46, 52–54  - Ia molecules, **38**:68
  - Ig fold, **43**:221
  - Ig heavy-chain variable region genes and, **49**:5
  - IL-2 and, **42**:173–174
  - mediate responses, mediators for, **51**:143–146
  - interaction with antigen bound to MHC, **43**:222
  - intracellular selection, **58**:120–121
  - J gene segment, **43**:115
  - ligands inducing deletion of thymocytes, **58**:170–171
  - mAb,SFI, **43**:161
  - male-specific, CD4 $^+$ 8 $^+$  thymocytes expressing, **58**:261
  - maps of Ig-like loci and, **46**:1, 5, 34–45
    - chromosomal locations, **46**:6
    - mechanisms, **46**:46, 47  - mediated induction of T cell death, **58**:215–224
  - mediated signaling
    - and CD4, **53**:85–91
    - and CD8, **53**:85–91
    - in naive and memory T cells, **53**:228–229
    - and p56<sup>lck</sup>, **53**:85–91  - membrane proximal domains, **43**:221
  - methodological breakthroughs in discovery, **58**:88–89
  - MHC molecules, **45**:110, 111
    - antigen presentation, **45**:115–117
    - class II molecules, **45**:112–115
    - HLA-A2, **45**:111
    - models, **45**:111, 112

T cell receptor (*continued*)

- MHC-restricted, **38:2**
  - peripheral T cells, **38:14, 15**
  - protein properties, **38:3–5**
  - specific binding, **38:19–21, 23, 24**
  - target recognition, **38:22, 23**
  - thymus, **38:10**
  - V region genes, **38:15**
- molecule recognition, **43:194–196**
- murine lupus models and, **46:61, 65, 78, 79**
  - autoimmune strains, **46:83–86**
  - expression, **46:86–99**
  - gene diversity, **46:79–83**
- NK cells and, **42:198–204, 205**
- oligoclonal expansion, **58:327**
- p56<sup>lck</sup> interactions, **56:161–162**
- peptides
  - binding, **45:132–134**
  - selection, **45:137–139**
- peptide vaccination in trimolecular complex, **56:236–239**
- peripheral T cells, **38:13–15**
- polymorphic residues, **45:157–160**
  - modeling, **45:160, 161**
  - recognition, **45:161, 162**
- polymorphism recognition, **43:214–215**
- precursors, structure and function, **58:144–151**
- pre-T cell receptor  $\alpha$ , **62:42, 44**
  - properties, **38:3–5**
- recognition of superantigens, **54:121–124**
  - models, **54:122–123**
  - modifications of  $v\beta$  rule, **54:123–124**
- restricted recognition, **43:202–203, 216**
- restriction, **43:195–196**
- SCID and, **49:384, 386–388, 396, 400**
- signaling in CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58:173–174**
- signalling through TCR/CD3 and coreceptors, **51:92–98**
- specific, **43:193**
- specific binding, **38:19–21., 23, 24**
- structure, **40:258–259; 43:220–222**
- structure–function relationships, **45:135, 136, 139–142**
- surface antigens of human leukocytes and, **49:77–79, 81–83, 86–87**
- synthetic T and B cell sites and
  - antigens, **45:233, 234, 236**
  - globular protein antigens, **45:210, 211, 213, 216**

- immunological considerations, **45:200, 201**
- prediction, **45:252**
- viral antigens, **45:219**
- T3, **38:18, 19**
- T cell repertoire, **45:162**
  - positive selection in thymus, **45:163–167**
  - recognition, **45:167, 168**
- T cell subsets and, **41:40–43, 46, 111**
  - H-2 alloantigen recognition, **41:79–81, 88**
  - H-2 molecules in thymus, **41:97, 99, 106, 107**
  - H-2-restricted antigen recognition, **41:51–54, 56, 60–65**
- TCR1, functional capabilities, **50:101–102**
  - antibodies, embryonic treatment, **50:103–105**
  - migration of subpopulations, **50:96**
- TCR2, functional capabilities, **50:101–102**
  - antibodies, embryonic treatment, **50:103–105**
  - migration of subpopulations, **50:96**
- TCR3, functional capabilities, **50:101–102**
  - antibodies, embryonic treatment, **50:103–105**
  - migration of subpopulations, **50:96**
- TCR/CD3 complexes and signaling mediators, **51:140–146**
- TCR $\gamma\delta$  lineages, **51:124–133**
- TH cell
  - experimental autoimmune encephalomyelitis, **48:166**
  - T cell receptor V gene, **48:166**
- thymus, **38:10–13**
- tolerance, **38:127**
- transgenes, **59:107–108, 113–116, 124–127**
- transgenic, **58:154–156, 159, 166–167**
- triggered CTL-mediated killing, **60:291**
- triggering, coreceptor molecules
  - modulation of adhesiveness during, **53:83–84**
- tumor antigen interactions
  - costimulatory pathway-determined immunogenicity, **57:288–290**
  - early evidence of recognition, **57:285–288**
  - tumor-specific peptide recognition, **57:288–290**
- tumor antigens defined by, **62:227–231**

- tyrosine protein kinase, **48:277-280**
- V $\beta$ , interaction with MMTV superantigen, **65:165-167**
- V $\beta$ 2, **64:69**
- V $\beta$ 8<sup>+</sup>, SEB effects, **58:275**
- V $\beta$  selective elements, **50:2-3, 6-16**  
 bacterial toxic mitogens, **50:15-16**  
 cellular basis of action, **50:29-32**  
 B cell role, **50:31**  
 dendritic cell role, **50:31**  
 responding cells, **50:29-31**  
 stimulating cells, **50:31-32**  
 transfer of Vbse between cells, **50:32**
- in intrathymic development, **50:33**  
 negative selection, **50:34-35**  
 positive selection, **50:34**
- MIs, **50:7-10**  
 definition, **50:7-9**  
 multiple loci, **50:9-10**  
 molecular basis of action, **50:16-22**  
 non-MIs, in murine genome, **50:11-14**  
 general nomenclature, **50:13-14**  
 not stimulating primary T cell response, **50:11-13**  
 null alleles, **50:14**  
 questions, **50:42-47**  
 biological function, **50:45**  
 distribution, **50:44-45**  
 molecular nature, **50:44**  
 validity, **50:42-44**
- V $\gamma$ 5 and V $\gamma$ 6 subsets, **58:103-104**
- variable region gene recombination  
 diversity and, **40:262-264**
- variable regions  
 autoimmune demyelinating disease and, **49:357**  
 usage restriction, **49:363-364, 366-367**  
 multiple sclerosis and, **49:372-375**
- V and C domains, **43:115**
- V(D)J joining of antigen receptor genes  
 endogenous substrate, **56:34-37**  
 gene assembly, **56:28-32**  
 resulting in rearrangement, **56:47, 49**
- V gene  
 experimental autoimmune encephalomyelitis, **48:166**  
 TH cell receptor, **48:166**
- V region repertoire and variability, **38:15-16**
- retroviruses, endogenous or extrinsic, **50:37-42**  
 endogenous retroviral insertions  
 inseparable from Vbse, **50:38-39**  
 expressions of Mtv in B cells with  
 Vbse expression, **50:39**  
 mice transgenic for given Mtv, **50:40**  
 mouse mammary tumor virus, **50:39**  
 mouse retention of Vbse sequences, **50:41-42**  
 Mtv transcripts expressed in activated  
 B cells, **50:40**  
 other retroviruses, **50:40-41**  
 retroviral sequences bearing no  
 homology to bacterial toxic  
 mitogen, **50:41**
- role of MHC molecules, **50:17-22**  
 I-A molecules, **50:20-21**  
 I-E molecules, **50:18-19**  
 incompetent class II, **50:22**
- role of T cell receptors and coreceptors, **50:23-28**  
 coreceptors, **50:27-28**  
 mapping relevant sites on region, **50:25-27**  
 T cell receptor, **50:23-24**  
 V $\beta$  region of TCR, **50:24-25**
- T cell development and function, **50:32-37, 35-37**
- T cell development and function in  
 periphery, **50:35-37**  
 clonal inactivation, **50:35-36**  
 enhancement of responses to antigen, **50:36-37**  
 suppression induced *in vitro*, **50:37**  
 working model, **50:4-6**  
 working model, evidence, **50:28-29**
- V $\beta$ -specific antibodies, **58:275**
- V-V interface edge strands, **43:115-116**
- V-V pairings, **43:116**  
 what it sees, **52:10-11**
- X-linked severe combined  
 immunodeficiency, **59:248-252**
- X phage repressor protein response, **43:209-210**
- zone for, **59:312-315, 338-339**

- T cell receptor-CD3 complex, **43**:171  
*chains*, **48**:229-232  
 and coreceptors, signaling through, **51**:92-98  
 G protein, **48**:306-307  
 heterodimers, **48**:229  
 phosphatidylinositol 4,5-bisphosphate2  
   Ca<sup>2+</sup> response, **48**:262-265  
   hydrolysis, **48**:262-265  
 polymorphic proteins, **48**:229  
 and signaling mediators, **51**:140-146  
   mediators for immediate TCR responses, **51**:143-146  
   TCR/CD3 complex, **51**:140-143  
 structure, **48**:229-232  
 synthesis, **48**:232  
 T cell activation, **48**:232-235
- T cell receptor I, **43**:169
- T cell replacement factors, humoral immune response and, **45**:65, 66, 68
- T cell-replacing factor, interfering and, **40**:38
- T cells, **43**:134; **48**:70, 71  
 $\alpha\beta$   
 CD4<sup>-</sup>8<sup>-</sup>, expression of V $\beta$ 8 TCR chains, **58**:109-110  
 CD4<sup>+</sup>8<sup>-</sup>, heterogeneity, function, and specificity, **58**:105-108  
 CD4<sup>-</sup>8<sup>+</sup>, heterogeneity, function, and specificity, **58**:108-109  
 extrathymically derived, **58**:111-112  
 negative and positive selection, **58**:311  
 reactivities, **58**:318-319  
 $\alpha\beta$  and  $\gamma\delta$   
 differences, **58**:300  
 lineage divergence, **58**:141  
 $\gamma\delta$   
 extrathymically derived, **58**:110-111  
 function, **58**:104-105  
 heterogeneity, **58**:102-103  
 murine, properties of classes of, **51**:128  
 reactivities, **58**:319-324  
 self-tolerance, **58**:313  
 specificity, **58**:103-104
- 20 $\alpha$ SDH expression  
 differentiation and, **39**:26-31  
 IL-3-i induced 2, **39**:5, 18-19, 23-24  
 in Thy-1<sup>+</sup>, **39**:21-22, 24, 26-29
- AChR and, **42**:256-260  
 activated  
   CD44 expression, **54**:294-296  
   cytokine and B cell differentiation, **52**:212-213  
   cytokines and B cell growth, **52**:203  
   defective CD40L expression in, **60**:44-48  
   inducing resting B cells to proliferate and differentiate, **52**:191-193  
   T cell subsets and, **41**:52-59  
 activation, *see* T cell activation  
 adjuvant action and, **40**:92-94  
 allogeneic, *Ir* genes and, **38**:125, 126  
 alternative transmembrane signaling pathways, **48**:307-309  
 antagonists, in trimolecular complex, **56**:244-247  
 antigen-independent recruitment into tissues by endothelial cells, **50**:274-287  
 endothelium and tissue-specific homing of lymphocytes, **50**:284-285  
 extravasation of T cells, **50**:285-287  
 migration of memory T cells to inflammatory sites, **50**:278-284  
 endothelial leukocyte adhesion molecules, **50**:279-281  
 expression of endothelial leukocyte adhesion molecules *in vivo*, **50**:283-284  
 role of endothelial leukocyte adhesion molecules in lymphocyte binding *in vitro*, **50**:281-283  
 migration of naive T cells to lymph nodes, **50**:275-278  
 migration of pre-T cells to thymus, **50**:275  
 antigen-presenting cells and, **47**:47, 64-74, 76, 77  
 antibody responses, **47**:81-86  
 antigen presentation, **47**:78-81  
 antigen processing, **47**:87, 90-92  
 APC-T cell binding, **47**:95-99  
 cell surface, **47**:57, 59, 61-63  
 immunogeneity, **47**:102-104, 103  
 T cell growth, **47**:99-101  
 T cells, **47**:86, 96, 99  
 tissue distribution, **47**:48, 49, 50, 52-57, 54  
 antigen recognition, **43**:134, 223  
 antigens, **38**:2  
   conformation, **43**:203

- antinuclear antibodies and, **44**:134
- apoptosis, pharmacology, **58**:211–296
- autoimmune demyelinating disease and  
 multiple sclerosis, **49**:369–375  
 myelin basic protein, **49**:358, 360–362  
 TCR usage restriction, **49**:363–366
- autoimmune thyroiditis and, **46**:263, 265, 266, 317–319
- antigens, **46**:270
- cellular immune responses, **46**:287–291, 293–298
- experimental models, **46**:273, 275–282
- genetic control, **46**:283
- humoral responses, **46**:299, 302–304, 306–308
- prevention, **46**:308, 310–312, 314–316
- autoimmunity, theories, **56**:453
- autoreactive, *see* Autoreactive T cells
- BALU, **59**:386
- B cell activation, **40**:2–4, 12–13; **63**:43, 46
- B cell differentiation and, **40**:31–35
- B cell formation and, **41**:205, 212, 225, 236
- B cell precursors, **41**:189, 191, 192, 198, 199
- genetically determined defects, **41**:226, 227, 230, 231
- Ig genes, **41**:204
- soluble mediators, **41**:233–235
- B cell interactions
- antigen bridging, **39**:51
- antigen presentation by B cells, *see* B cells
- and B cells, interphase death and  
 nonspecific damage, **50**:69–70
- bone marrow, characterization, **53**:171–173
- cachectin and, **42**:220, 222
- CD1 proteins, **59**:76–90
- CD3, T cell receptor and, **45**:109, 110
- CD4<sup>+</sup>, **48**:84–86, 198; **60**:38–39, 114, 271–272, 294–296
- antigen-presenting cells and  
 antigen presentation, **47**:64, 75, 80  
 cell surface, **47**:57  
 immunogeneity, **47**:102  
 interaction with T cells, **47**:93, 94  
 T cell-dependent antibody responses, **47**:83, 84, 86  
 tissue distribution, **47**:50
- CD5 antigen, NK cells and, **47**:227
- CD5 B cell, **47**:117, 118, 161, 162
- aging, **47**:122, 123
- anatomic localization, **47**:120, 121
- autoimmune diseases, **47**:148–150
- bone marrow transplantation, **47**:129, 130
- definition, **47**:118–120
- genetic influence, **47**:147, 148
- CD5 cells, antigen-presenting cells and, **47**:47, 55, 63
- CD8<sup>+</sup> antiviral effect, **66**:274–275, 282–283, 292–294
- CD8 cells, antigen-presenting cells and  
 antigen presentation, **47**:64, 75, 80, 81  
 antigen processing, **47**:92  
 immunogeneity, **47**:102
- CD11 antigen, NK cells and, **47**:291
- congenital defects, **47**:224
- differentiation, **47**:234
- effector mechanisms, **47**:245, 246
- hematopoiesis, **47**:281
- malignant expansion, **47**:226
- surface phenotype, **47**:207, 208
- CD16 antigen, NK cells and, **47**:188, 189
- adaptive immunity, **47**:291, 295
- alterations, **47**:302
- antimicrobial activity, **47**:288, 289
- antitumor activity, **47**:298
- CNS, **47**:267
- congenital defects, **47**:224
- cytotoxicity, **47**:249, 257, 258, 261
- differentiation, **47**:233, 234
- effector mechanisms, **47**:237, 242, 244, 247
- genetic control, **47**:222, 223
- hematopoiesis, **47**:275, 279
- lymphokines, **47**:265
- morphology, **47**:218
- reproduction, **47**:271
- surface phenotype, **47**:201–206, 208
- tissue distribution, **47**:219, 220
- CD18 antigen, NK cells and, **47**:207, 224
- CD45 and, **66**:18, 26, 35–36
- clone, **48**:197
- development models, **53**:108–113
- HIV infection and  
 depletion, **47**:386–389



T cells (*continued*)

- etiologic agent, **47:379, 382, 384, 385**
- immune response, **47:405, 408**
- immunopathogenic mechanism, **47:385, 386, 389–392, 394**
- neuropsychiatric manifestations, **47:405**
- humoral immune response and, **45:20, 44, 45**
- Ig gene expression
  - lymphomas, **47:150–152**
  - malignancies, **47:152–159**
- lineage, **47:128, 129**
- lymphokine-producing phenotypes, **53:17–19**
- lymphokine production patterns, **48:85–86**
- malignancies, **47:123–125**
- marker for activation, **47:125–128**
- ontogeny, **47:121, 122**
- physiology
  - autoantibody production, **47:130–136**
  - helper B cells, **47:137–141**
  - monocytoid features, **47:141–143**
- primordial immune network, **47:159–161**
- role in V $\beta$  selective element action, **50:30**
- sporozoite malaria vaccine and, **45:303, 304, 319**
- surface antigen, **47:143–147**
- T cell receptor and, **45:109, 110, 127**
- T helper, **48:163**
- virus-induced immunosuppression and, **45:349–358, 360–363, 366**
- CD4 and CD8 molecules and, **44:265–270, 298–303**
- CD4 molecular biology, **44:285, 286, 288–293, 295, 297**
- CD8 molecular biology, **44:271–273, 278–280, 282, 284**
- CD5 B cell and, **47:118, 126, 162**
- bone marrow transplantation, **47:130**
- lineage, **47:129**
- marker for activation, **47:125, 126**
- physiology, **47:131, 137, 140–142**
- primordial immune network, **47:160, 161**
- surface antigen, **47:143–147, 144, 147**
- CD8<sup>+</sup>, **48:84–86, 197, 198**
- CD45 and, **66:18, 26, 35–36**
- development models, **53:108–113**
- in HIV-1 infection, **66:283–291, 297–298**
- antiviral activity, **66:274–275**
- antiviral therapy, **66:295–297**
- HIV-1-specific lytic activity, **66:275–277**
- viral inhibition, mechanism, **66:280–291**
- humoral immune response and, **45:20**
- lymphokine production patterns, **48:85–86**
- role in V $\beta$  selective element action, **50:30–31**
- sporozoite malaria vaccine and, **45:319**
- CS-specific T cells, **45:312**
- interferon- $\gamma$ , **45:303–306**
- T cell receptor and, **45:109, 110**
- TH responses, **61:358–360**
- virus-induced immunosuppression and HIV, **45:352, 353, 356–358, 366**
- measles, **45:339**
- what it recognizes, **52:6–11**
- CD23 antigen and, **49:149, 151–153, 176**
- biological activity, **49:167, 169–170**
- cellular expression, **49:151–153, 155**
- cleavage regulation, **49:158**
- expression regulation, **49:159**
- Fc $\epsilon$ R11, **49:164**
- CD40 expression, **61:13, 39–40**
- CD40-L expression, **61:20**
- CD45 and, **66:32–36**
- monoclonal antibody studies, **66:6–12**
- CD45-deficient, **66:18–22**
- CD45R<sup>-</sup>, life span, **53:240**
- CD45RA<sup>+</sup>, functional and phenotypic properties, **53:225–227**
- CD45RO<sup>+</sup>, functional and phenotypic properties, **53:225–227**
- circulating, functions, **53:199–201**
- clonal proliferation, **63:127**
- clones, *see* T cell clones
- colony-stimulating factor
  - studies *in vitro*, **48:77–78**
  - studies *in vivo*, **48:92–98**
  - synthesis, **48:96–98**
  - antigen-presenting cell, **48:97**
  - local polarization secretion, **48:97**
  - local response, **48:96**
  - target cells, **48:97**

- complement receptor 1 and, **46:183, 200, 201**
- complement receptor 2 and, **46:203, 205–207, 213**
- costimulation, molecules involved in, **58:132–134**
- costimulator activities of vascular endothelial cells, **50:267–274**
- EC costimulator in polyclonal CD4+ T cell activation, **50:268–270**
- EC costimulator in polyclonal CD8+ T cell activation, **50:270–271**
- EC costimulators in alloantigen responses, **50:271–272**
- EC production of soluble costimulators, **50:272–274**
- cross-reactivity, **43:200**
- CTL and, **41:165**
- cytotoxic, *see* Cytotoxic T cells
- cytotoxicity, islet beta cell, **48:142**
- cytotoxicity and, **41:271–273, 277, 297**
- dependent autoimmunity, **51:294–296**
- dependent B cell responses, **62:131–157, 144–148**
- B7-1/B7-2 ligand family, **62:135–138, 140–142**
- CD28–B7 costimulation, **62:142–144, 148–157**
- CD28/CTLA-4 receptor family, **62:132–135, 138–140**
- costimulation, **62:138–144, 148–154**
- two-signal model, **62:131–132**
- dependent isotype switching, role of IL-4, **54:249–252**
- depleted haploidentical bone marrow, SCID and, **49:393–396**
- depletion, immune reconstitution and, **40:417–419**
- derived colony-stimulating factor, **48:69–98**
- derived lymphokine, *in vivo* studies, **48:94–95**
- development, *see* T cell development
- differentiation, CD4 and CD8 roles, **53:94–113**
- in negative selection, **53:101–103**
- in positive selection, **53:97–100**
- DR antigens and, **42:293, 294**
- effector
- functional differences with memory and naive cells, **53:227–228**
- maturation into, **53:229–230**
- migration pattern, **53:242–244**
- primary and secondary, **53:227–228**
- tissue-specific migration, **53:244–247**
- epithelial, clonotype dominance, **58:298**
- epitopes, *see* T cell epitopes
- experimental autoimmune uveitis, **48:216**
- expressing Epo receptor, **60:14**
- facilitation of hematopoietic engraftment by, **40:391–392**
- factors, Ig-secreting cell differentiation and, **40:11–12**
- Fas effects
- development role, **57:137**
- expression in cytotoxic T cells, **57:138**
- fate determination, **58:136–139**
- Fcε receptors, **43:301, 303**
- Fc receptors on, **40:67–68**
- isotype response and, **40:212–216**
- forbidden, in peripheral immune system, **53:164–166**
- fusion, **38:283, 286**
- genetically engineered antibody molecules and, **44:86**
- G protein, **48:267–269**
- in graft-versus-host diseases, rat, **39:280–281**
- idiotypic network and, **39:281**
- and growth requirements, **53:167**
- helper, *see* T helper cells
- heterogeneity, **48:83–92**
- high-affinity self-reactive, deletion, **43:219**
- HIV-1 disease, **63:87–89, 90**
- SCID-hu thy/liv xenograft model, **63:99–107**
- HIV infection and, **47:379**
- activation, **47:398–400, 402**
- etiological agent, **47:378, 379, 382**
- immune response, **47:405, 409, 410**
- immunopathogenic mechanism, **47:385, 386, 387–392, 388, 390, 391, 394, 397**
- neuropsychiatric manifestations, **47:405**
- human
- interactions with rabbit anti-Id antibodies
- binding to, **39:265–267**
- suppression by, **39:267–269**
- met-enkephalin receptors, **39:312**
- SP receptors, **39:313**
- T8<sup>+</sup>, Id determinants, **39:266–267**

T cells (*continued*)

## human, IL-9

characterization and cloning, **54:80–82**

expression, **54:85**

growth-stimulating activity, **54:85–88**

response to, **54:86, 87**

human leukemia, **38:5, 8**

hybridomas, *see* T cell hybridomas

hybrid resistance and, **41:337, 353, 364–366, 368**

antigen expression, **41:402–405, 408–410**

effector mechanisms, **41:372–374, 392, 395, 376–388**

hybrids, **48:78**

hyperprolactinemia, **63:409–410**

IBD and, **42:297, 300–301**

subsets, **42:298**

IELs as, **58:298–300**

IFN- $\gamma$  production, **62:63–66, 105**

IgE-binding factors, **43:301–303**

IgE biosynthesis and, **47:1, 28–30, 32–39**

antibody response, **47:4–12**

binding factors, **47:12, 13, 15–24, 26–28**

IGF-I, **63:406**

IGF-I-R, **63:402**

Ig gene superfamily and

evolution, **44:43, 47**

MHC complex, **44:24, 26, 28, 29**

nonimmune receptor members,

**44:31–37, 41, 42**

receptors, **44:9–12, 14, 16, 17, 20–24**

Ig heavy-chain variable region genes and, **49:52, 54**

IL-1 and, **44:154, 156, 164, 190**

human disease, **44:193**

immunocompetent cells, **44:172, 173, 175–178**

receptor, **44:179, 181–183**

TNF, **44:185, 186**

IL-2 receptor and, **42:165–166, 177, *see also* Interleukin-2 receptor**

IL-6 effects, **54:21–22**

IL-10 biological effects, **56:8–10**

immune, transfer of idiotypic-suppression by, **40:139**

immunosenescence and, **46:221**

lymphocyte activation, **46:221, 222, 224–232, 234, 236**

lymphocyte subsets, **46:236–239**

regulatory changes, **46:250–252**

stem cells, **46:240, 243–247**

intermitotic life span of, **53:237–241**

intestinal intraepithelial lymphocytes, **53:163–167**

intrathymic development, **58:139–174**

control of apoptosis during, **58:168–174**

pre-T cell receptor control, **58:142–151**

role of V $\beta$  selective elements in, **50:33**

negative selection, **50:34–35**

positive selection, **50:34**

and selection, **58:139–174**

$\alpha\beta$  TCR control, **58:151–165**

intrathymic transitions, **51:117–139**

ontogeny of major thymic lineages,

**51:133–138**

ontogeny of minor thymic lineages,

**51:138–139**

summary, **51:139**

TCR $\alpha\beta$  lineage, **51:118–124**

TCR $\gamma\delta$  lineage, **51:124–133**

invariant intraepithelial  $\gamma\delta$  T cells (skin, female reproductive tract), **53:167–169**

ion channel, **48:285–288**

*Ir* genes and

antigen binding, **38:98–103**

antigen processing, **38:93, 94, 95, 96, 97**

competitive inhibition, **38:109**

complementation, **38:74–78**

expression, **38:40–43, 46, 50–63, 188–190**

gene function, **38:91–93**

gene function H-Y antigen, **38:178**

Ia molecules, **38:68, 69, 70–72, 89**

I region mutations, **38:86, 89**

macrophages, **38:111–115**

MHC restriction, **38:64–67**

T cell-T cell interactions, **38:158**

tolerance, **38:124**

lamina propria, IBD and, **42:300–301**

leukocyte integrins and, **46:154, 169, 172** lineages, **58:87–88**

extrathymically derived, **58:110–112**

thymus-derived, **58:102–110**

in lymph nodes, **53:161–163**

lymphocyte homing and

carbohydrate, **44:362**

high endothelial venules, **44:315**

molecules, **44:349–351**

regional specificity, **44:325, 329, 330, 334, 335, 339**

- lymphocytes and, **38:283, 286**  
 lymphogenesis in liver, **53:169–171**  
 from lymphoid compartment, origins,  
**53:164**  
 and lymphokine production, **53:167**  
 maps of Ig-like loci and, **46:1, 28, 29, 31**  
 maternally transmitted antigen and, **38:313, 329, 334**  
 mature, properties, **51:85–110**  
   proliferative response, **51:106–110**  
   anergy, **51:109–110**  
   growth, **51:106–109**  
   recognition/auxiliary coreceptors,  
   **51:91–92**  
   recognition structures, **51:86–91**  
   response genes, **51:98–105**  
     combinatorial regulation of, **51:105**  
     IL-2 gene regulation, case study,  
     **51:103–105**  
     T cell subset characteristics, **51:100**  
     T cell subsets, **51:98–103**  
     signaling via TCR/CD3 and coreceptors,  
     **51:92–98**  
 mediated suppression, *see* Suppression, T  
 cell-mediated  
 memory, *see* Memory T cells  
 MG and, **42:241–245, 273**  
 MHC class I-deficient mouse  
   CD4<sup>+</sup>, **55:393–394**  
   TCR $\alpha\beta$ <sup>+</sup> CD4<sup>-</sup> CD8<sup>-</sup> T cells,  
   **55:401–403**  
   TCR $\alpha\beta$ <sup>+</sup> CD8<sup>+</sup> CD4<sup>-</sup> T cells,  
   **55:394–401**  
   TCR $\gamma\delta$ <sup>+</sup> T cells, **55:403–404**  
 MHC class II-deficient mouse  
   CD4<sup>+</sup>, **55:424–427**  
     single-positive compartment,  
     **55:430–433**  
   CD8<sup>+</sup>, **55:427–428**  
    $\gamma\delta$ , **55:428–429**  
 MHC class I-restricted, antigen processing  
 and presentation to, *see* Antigen  
 processing and presentation  
 MHC class II-restricted, **60:305–306**  
 MHC recognition, **43:224, 55:364**  
 MHC-restricted recognition, **59:100**  
 migration to periphery, avian, **50:96–101**  
   homing preferences, **50:96–97**  
   interstitial T cell surface glycoprotein,  
   **50:97–101**  
   migration of TCR1, TCR2 and TCR3  
     sub-populations, **50:96**  
 murine, **54:88–93**  
   deletion and anergy in adult animals  
     injected with superantigens,  
     **54:125–127**  
 murine lupus models and, **46:64, 66, 67, 99, 100**  
 naive  
   adhesion molecules affecting migration,  
   **53:248–249**  
   endothelium and migration of to lymph  
     nodes, **50:275–278**  
   functional differences with memory and  
     effector cells, **53:227–228**  
   migration  
     adhesion molecules and, **53:248–249**  
     basic pattern, **53:242–244**  
     tissue topic subsets, **53:244–247**  
     migration pattern, **53:242–244**  
     TCR and signal transduction,  
     **53:228–229**  
 negative selection, **58:166–168**  
 networks in secretory immune system,  
**40:217–218**  
 NK cells and, **47:188, 190, 197, 294**  
 adaptive immunity, **47:291–296**  
 antimicrobial activity, **47:289**  
 CNS, **47:266**  
 congenital defects, **47:225, 226**  
 cytotoxicity, **47:248, 255, 257–262**  
 differentiation, **47:232**  
 effector mechanisms, **47:240, 244, 245, 247, 248, 257, 265**  
 genetic control, **47:222**  
 hematopoiesis, **47:272–275, 277–281**  
 identification, **47:196, 198, 199**  
 lymphokines, **47:264, 265**  
 malignant expansion, **47:227, 228**  
 morphology, **47:218**  
 reproduction, **47:271**  
 surface phenotype, **47:200, 204–213**  
 tissue distribution, **47:219–221**  
 ontogeny, avian  
   development, interest, **50:87**  
   differentiation antigens, **50:88–89**  
 T cell development, experimental  
 manipulation, **50:102–105**

T cells (*continued*)

- embryonic treatment with anti-TCR1, -TCR2, -TCR3 antibodies, **50:103–105**
- thymectomy, **50:102**
- T cell migration to periphery, **50:96–101**
  - homing preferences, **50:96–97**
  - interstitial T cell surface glycoprotein, **50:97–101**
  - migration of TCR1, TCR2 and TCR3 sub-populations, **50:96**
- T cell tumors, **50:105–108**
  - Marek's disease (MDV) virus-induced tumors, **50:105–107**
  - reticuloendotheliosis virus-induced tumors, **50:107–108**
- TCR1, TCR2, TCR3 cells, functional capabilities, **50:101–102**
- TCR genes, **50:108–112**
  - conserved structural features, **50:111–112**
  - genomic organization, **50:108–109**
  - TCR $\beta$  diversity, **50:109–111**
  - thymic attraction and origin, **50:89–90**
  - thymus, diversification in, **50:90–96**
    - embryonic waves of thymocyte development, **50:95–96**
    - intrathymic clonal selection, **50:94**
    - ontogeny of TCR1, TCR2, and TCR3, **50:91–94**
- ontogeny, T cell receptor gene expression, **43:266**
- oral tolerance and, **40:224–226**
- p56<sup>lck</sup>, signaling role, *see* p56<sup>lck</sup>
- paracortical area, **58:431**
- perforin-negative, **60:293, 303**
- peripheral
  - classification, **53:159–161**
  - gene expression in, **38:13–15**
  - phenotype and function, immune reconstitution and, **40:412–414**
  - target recognition, **38:22**
  - V region genes, **38:16**
- in Peyer's patches, **40:194, 195–197, 206, 210–212**
- phosphatase, signal transduction, **48:284**
- phosphoinositide turnover, **48:258–265**
  - direct measurements, **48:260**
  - secondary messenger formation, **48:253–265**
- phosphorylation, activation-associated, **48:269–285**
- pituitary hormones, **63:414–416**
- plasmacytoma development, **64:240**
- polyclonal CD4+, activation, EC costimulator in, **50:268–270**
- polyclonal CD8+, activation, EC costimulator in, **50:270–271**
- potential effector mechanisms, **47:465–469**
- precursors, migration to thymus, **58:347, 392–394**
- pre-T cells, endothelium and migration of to thymus, **50:275**
- production of
  - EAF, **39:216–217**
  - GM-CSF, **39:2, 3, 10–15**
  - IL-2, **39:1, 3, 10–15**
  - IL-3 2-3, **39:10–15**
- programmed cell death, **50:66–69**
  - CTL targets, death, **50:69**
  - deprived of growth factors, **50:68–69**
  - hybridomas, activation-induced death, **50:67**
  - non-selected thymocyte, death, **50:67–68**
  - thymus, negative selection, **50:66**
- proliferation
  - IL-2-independent, **48:302–304**
  - immune complexes and, **40:77–78**
- Ir* genes and
  - antigen binding, **38:103**
  - antigen processing, **38:94, 97**
  - competitive inhibition, **38:110**
  - complementation, **38:73, 79, 80**
  - cytotoxic T cells, **38:172**
  - H-Y antigen, **38:176**
  - immunodominance, **38:184, 185**
  - inhibition, **38:68, 69**
  - I region mutations, **38:86, 88**
  - macrophages, **38:111, 113, 114**
  - suppression, **38:136, 138, 141, 147, 149–152**
  - tolerance, **38:125, 126**
- protein kinase, signal transduction, **48:284**
- pulmonary, resident
  - CD4 and CD8 antigens, **58:306**
  - $\gamma\delta$  lineage, **58:303–304**
- pulmonary hypersensitivity, **59:417–420**
- pulmonary immunity, **59:389–391**
- Ras proteins, **63:144–145**
- receptor-like genes and, **38:10**

- recognition, antigen processing for, **58:420**
- recognition and function, overview, **52:1-4**
- regulation, **48:285, 286**
- regulation of IgA response and, **40:209-212**
- regulatory potential, **61:344-360**
- CD8<sup>+</sup>, **61:358-360**
  - cytokines, **61:347-355**
  - extrinsic factors, **61:357-358**
  - surface molecules, **61:355-357**
  - TH-1-TH-2 concept, **61:346-347**
- repertoire, constraints
- germline limitations, **38:115-118**
  - positive T cell selection, **38:130-134**
  - suppression, **38:134-152**
  - tolerance, **38:119-130**
- repertoire, and RA susceptibility
- exogenous events, **56:452-455**
  - formation, **56:450-452**
- response
- cytotoxic T cells and, **65:279-280**
  - to MMTV
    - adult, **65:175-178**
    - endogenous Mtv, **65:196-208**
    - neonatal, **65:171-175**
    - T-B cell interaction, **65:180-188**
- resting, accessory signal, **48:247-248**
- SCID and, **49:381-388**
- graft-versus-host disease, **49:397-398**
  - lack of stem cell engraftment, **49:396**
  - posttransplant immunocompetence, **49:399-402**
  - stem cell engraftment, **49:388-391**
  - tolerance, **49:398-399**
  - transplantation, **49:393-396**
- SCID-hu thy/liv xenograft model, **63:82-83**
- secondary B cell lineage and, **42:73**
- selection, **43:217; 51:164-189**
- negative selection, **51:165-175**
    - intrathymic clonal deletion, **51:165-173**
  - positive selection, **51:175-189**
    - functional divergence, **51:186-189**
    - ligands and receptors in positive selection, **51:178-180**
    - vs two kinds of death, **51:175-177**
- positive selection, four-way
- CD4 vs CD8 down-regulation, **51:185-186**
  - developmental choice, **51:180-186**
  - positive vs negative selection, **51:180-183**
  - signaling pathways controlling, **51:183-185**
- selective defect, **59:247**
- self-MHC class I recognition by cytotoxic T cell effector cells, **57:314-315**
- self- vs nonself-discrimination, **43:223**
- signaling response to superantigens and conventional antigens, **54:127**
- signal transduction
- calcineurin, **63:166-167**
  - GTP-binding protein, **48:265-269**
  - PTPs, **63:166**
- site-dependent tolerance, **53:201-203**
- soluble factors, B cell responses and, **40:13-14, 15, 26-29**
- specific antigen presentation by vascular EC, **50:261-267**
- alloantigen presentation, **50:266-267**
  - protein antigen presentation, **50:265-266**
  - regulation of MHC molecule expression, **50:262-265**
- specific for foreign antigens, **43:219-220**
- specificity for peptide antigens, **43:197-206**
- approaches, **43:197-198**
  - cytochrome c, **43:198-200**
  - hen egg lysozyme, **43:201**
  - liner sequences, naturally occurring proteins, **43:198-201**
  - minimum fragment size, **43:197**
- specific tyrosine protein kinase, CD4, **48:243-244**
- splenic, **53:161-163**
- spontaneous autoimmune thyroiditis and, **47:434, 491, 492, 494**
- altered thyroid function, **47:461, 462**
  - cellular immune reactions, **47:449-452, 454-456, 455**
  - disturbed immunoregulation, **47:470-472, 472-474, 475, 477, 481**
  - genetics, **47:488-490**
  - histopathology, **47:442, 444**
  - humoral immune reactions, **47:445, 446**
  - potential effector mechanisms, **47:466-469**
- stimulation by
- B cells, **39:83-85**
  - B cell tumors, **39:84**

- T cells (*continued*)
- macrophages, **39:84**
  - TT-specific B cells, **39:57–58**
  - subsets, **41:44**; **51:98–103**
    - characteristics defined by cloned lines, **51:100**
    - dietary EPA and, **39:167**
    - insulinitis and overt diabetes, **51:296–298**
    - MHC molecules, **59:75–76**
    - subsets in mouse, **41:39**, 110–113
    - cell surface molecules, **41:40–50**
    - H-2 alloantigen recognition, **41:78**
    - alloreactivity, **41:78–83**
    - antigen-presenting cells, **41:88–92**
    - effector phase, **41:92–95**
    - resting T cells subsets, **41:83–88**
    - H-2 molecules in thymus, **41:95**, 96
    - development, **41:96–99**
    - restricted T cells, **41:99–107**
    - tolerance induction, **41:107–110**
    - H-2-restricted antigen recognition, **41:51**, 52
    - effector phase, **41:75–77**
    - T accessory molecule function, **41:59–62**
    - triggering of activated T cells and hybridomas, **41:52–59**
    - triggering of unprimed and resting T cells, **41:62–75**
  - substrates, **48:281–283**
  - supernatants, **54:247**
  - suppressor, *see* Suppressor T cells
  - surface activation molecule, **48:228–253**
  - surface antigens of human leukocytes and, **49:86**, 98, 112, 114, 116–117, 125
  - adhesion molecules, **49:83**, 85, 87, 89
  - antigen-specific receptors, **49:76**, 78–79
  - Igs, **49:91**
  - membrane enzymes, **49:112–114**
  - MHC glycoproteins, **49:80–81**
  - receptors, **49:98**, 101–110
  - surface molecules, in communication with APCs, **58:112–139**
  - target, specific binding and, **38:20**
  - target interaction, **38:21–23**
  - as target molecules in trimolecular complex
    - anti-CD3 antibody, **56:220–223**
    - anti-CD4 antibody, **56:223–228**
    - anti- $\alpha/\beta$  T cell receptor antibody, **56:228–229**
    - anti-T cell receptor V $\beta$  antibody, **56:229–233**
    - perspective, **56:219**
    - receptor peptide vaccination, **56:236–239**
    - vaccination, **56:233–236**
  - therapy of tumors, *See* Tumors, adoptive T cell therapy
  - T cell–T cell interactions, *Ir* genes and gene control, **38:189**
  - helper factors, **38:153–156**
  - Ia-like molecule expression, **38:156**, 157
  - MHC restriction, **38:157–160**
  - T cell tumors, avian, **50:105–108**
    - Marek's disease (MDV) virus-induced tumors, **50:105–107**
    - reticuloendotheliosis virus-induced tumors, **50:107–108**
  - TCR, *see* T cell receptor
  - T-dependent and T-independent B cells, **42:63–65**
  - TdT, *see* Terminal deoxynucleotidyltransferase
  - Tec, association with *c-kit*, **60:5–6**
  - Telencephalin, **64:157**
  - Tel protein, **64:65**
  - Temperature, and apoptosis, **58:237–240**
  - TEMPO-amine spin label, **48:27–28**
  - TEPITOPE (software), T cell epitope prediction, **66:82–84**, 86, 90–91
  - Terminal deoxynucleotidyltransferase, **58:117**; **62:43**, 52; **64:51**
    - in cortical thymocytes, **39:23**, 25
    - Ig heavy-chain variable region genes and, **49:31**
    - V–D–J recombination, **61:296–298**
    - as V(D)J recombination product
      - molecular genetics, **56:68–69**
      - structure, **56:54–56**
  - Ternary complex factors
    - binding sites, **64:76–77**
    - domain, **64:76–77**
    - expression, **64:93**
    - gene targeting, **64:94**
    - structure, **64:78**
    - structure–function studies, **64:93–94**
  - Testosterone
    - autoimmune thyroiditis and, **46:276**, 310

- depletion of CD4<sup>+</sup>8<sup>+</sup> thymocytes, **58:227-229**
- spontaneous autoimmune thyroiditis and, **47:480, 481**
- Tetanus toxoid
- B cell specificity for, **39:57-58**
  - antigen-presenting capacity and, **39:57-58**
  - immunization, human
    - auto-anti-Id antibodies and, **39:269-275**
    - B- and T cell role, **39:264-269**
    - cross-reactive Id and, **39:263-264**
    - IgG response, **39:261-262**
  - as carrier for (NANP)<sub>3</sub> vaccine, **60:112-113**
  - derived epitopes, **60:121-122**
  - donor lymphocytes and, **38:283-285**
  - heterohybridoma antibodies, **38:288, 289**
  - human-human hybridomas, **38:293, 294, 303**
  - humoral immune response and, **45:13**
  - sporozoite malaria vaccine and antibodies, **45:300, 301**
  - human trials, **45:313-315**
  - synthetic T and B cell sites and, **45:229, 232, 255, 258**
  - virus-induced immunosuppression and, **45:355, 357, 361, 362**
- Tethering
- high endothelial venules, **65:367**
  - leukocytes, **58:382-383**
- Tetrahydrobiopterin, IFN- $\gamma$ , **62:72**
- Tetrahymena*, maternally transmitted antigen and, **38:315**
- TFIIIA, concentration, **43:266**
- TGF, *see* Transforming growth factor
- TH cell receptor
- experimental autoimmune encephalomyelitis, **48:166**
  - T cell receptor V gene, **48:166**
- TH domain, Btk, **59:183, 187, 190**
- Theiler's murine encephalomyelitis virus, **48:165**
- Theiler's virus, responses in MHC class I-deficient mouse, **55:409**
- T helper cell responses, **61:374-375**
- APCs, **61:361-364**
  - CD8<sup>+</sup> T cells, **61:358-360**
  - cell-surface molecules, **61:355-357**
  - cytokines, **61:347-348**
  - extrinsic factors, **61:357-358**
- T helper cells, **59:319-321, 343**
- adoptive T cell therapy of tumors and, **49:289-291**
  - expression of antitumor responses, **49:327-328, 332**
  - mechanisms, **49:299, 312**
- B cell antigen receptor-activated, **55:269-273**
- CD23 antigen and, **49:159**
- clones, **54:89**
- CTL and, **41:136, 137**
- cytokines, **46:111**
- cross-regulation of differentiation, **46:130-133**
  - differential induction, **46:127-130**
  - functions, **46:114-117**
  - DTH, **46:117**
  - helper, **46:117-120**
  - human clones, **46:121, 122**
  - isotype regulation, **46:120, 121**
  - macrophage activation, **46:122**
  - human subsets, **46:138, 139**
  - immune responses, **46:133-138**
  - precursors of differentiation states
    - antigen expression, **46:123-125**
    - bulk cultures, **46:122, 123**
    - clones, **46:123**
    - heterogeneity, **46:125, 126**
    - phenotypes, **46:126, 127**
    - secretion patterns, **46:111-114**
- cytolysis and, **41:276**
- cytotoxicity and, **41:274, 297**
- function, Crohn's disease and, **42:300, 301**
- in  $\beta$ -galactosidase-induced antibody response, **39:88-90**
- Id recognizing, **39:257-262**
- B cells and, **39:259-260**
- IL-2-dependent, *v-abl* effect, **39:41**
- Ir* genes and, **38:188**
- antigen binding, **38:105-107**
  - cross-reactive lysis, **38:187**
  - cytotoxic T cells, **38:165, 170-172**
  - expression, **38:58-60**
  - germline repertoire, **38:118**
  - H-Y antigen, **38:175-179**
  - immunodominance, **38:183**
  - macrophage factors, **38:111**



- T helper cells (*continued*)  
 suppression, **38**:137–139, 141–144  
 T cell-T cell interactions, **38**:154, 157–160  
 tolerance, **38**:124  
 leukocyte integrins and, **46**:163  
 surface antigens of human leukocytes and, **49**:77  
 T cell subsets and, **41**:40  
 H-2 molecules in thymus, **41**:101–103, 105  
 H-2-restricted antigen recognition, **41**:67, 70–72, 75, 77  
 TH0, TH1, and TH2, characterization, **58**:106–107  
 TH1, **48**:86–89  
 and IL-10 discovery, **56**:1–2  
 TH1 and TH2  
 CD4<sup>+</sup>, **52**:175–177  
 function roles and cross-regulation, **52**:176  
 TH1–TH2, allergic responses, **61**:341, 374–375  
 APCs, **61**:361–364  
 CD8<sup>+</sup>, **61**:358–360  
 cytokines, **61**:347–355  
 extrinsic factors, **61**:357–358  
 IgE, **61**:342–344, 369–374  
 mast cells, **61**:360–361  
 nervous system, **61**:364–368  
 neuroendocrine factors, **61**:366–367, 369–374  
 psychological factors, **61**:368–369  
 surface molecules, **61**:355–357  
 T cell regulatory potential, **61**:344–360  
 TH1–TH2 concept, **61**:346, 374–375  
 TH2, **48**:86–89; **62**:146  
 and IL-10  
 discovery, **56**:1–2  
 functional similarities to cytokines, **56**:12–13  
*in vitro* stimulations of primed cells, **56**:13–14  
*in vivo* expression correlated to TH2 responses, **56**:14–15  
 PCD induction, inhibition, **58**:243  
 T helper epitopes, pathogen-derived, **60**:140–141  
 Theophylline, IL-1 and, **44**:160  
 Therapy  
 for EAMG, **42**:263–269  
 for IBD, **42**:316–319  
 for MG, **42**:235, 269–272  
 Thermal injury, therapeutic regulation of complement system in, **56**:280–281  
 Thermodynamics, protein-protein interactions, **43**:100  
*Thermoplasma acidophilum*, proteasome from, **64**:105–106  
 Thioether, linkage procedure for chemoimmunoconjugates in cancer treatment, **56**:321–322  
 Thiol-activated lysins, **41**:317, 318  
 Thoracic duct lymphocytes, hybrid resistance and, **41**:356–358  
 Threonine  
 antinuclear antibodies and, **44**:115  
 genetically engineered antibody molecules and, **44**:84  
 phosphorylation, **48**:270–277  
 Threonine phosphatases, as p56<sup>lck</sup> targets in T cell signaling, **56**:160  
 Threonine protease, proteasome, **64**:18–19  
 Threonine/tyrosine phosphatase, PAC-1, **63**:167  
 Thrombin, aPL antibodies and, **49**:197  
 Thrombocytopenia  
 aPL antibodies and, **49**:199, 257–258  
 clinical aspects, **49**:209, 222  
 isotype, **49**:225–226  
 pathogenic potential, **49**:252, 254  
 specificity, **49**:250, 252  
 syndromes, **49**:213, 215–216, 218, 221  
 IL-6 treatment, **54**:48  
 Thrombomodulin  
 aPL antibodies and, **49**:254  
 cachectin and, **42**:224  
 downregulation, **66**:111  
 Thromboplastin, aPL antibodies and antibody subsets, **49**:232  
 clinical aspects, **49**:200–201, 205  
 specificity, **49**:243–245  
 Thromboplastin inhibition test, aPL antibodies and, **49**:202–203  
 Thrombosis  
 aPL antibodies and, **49**:194, 199, 257–258  
 antibody subsets, **49**:233  
 clinical aspects, **49**:204, 211–212  
 isotype, **49**:225–227

- pathogenic potential, **49**:252–254, 256–257  
 specificity, **49**:239, 250  
 syndromes, **49**:213–221, 223  
 venous, CD59-negative platelets in, **60**:91–92
- Thrombospondin, surface antigens of human leukocytes and, **49**:86
- Thrombospondin repeats, **61**:242
- Thromboxane  
 aPL antibodies and, **49**:254  
 and prostaglandins, **51**:347–352
- Thromboxane A<sub>2</sub>, **62**:198
- Thromboxane-A synthase, **62**:198, 200
- Thy-1, **48**:238–239  
 activation element, **48**:238  
 amino acid sequencing, **48**:238  
 dendritic epidermal cells, **43**:164–165  
 humoral immune response and, **45**:46, 74  
 independent signal-transducing molecule, **48**:239  
 isolation, **48**:238  
 surface antigens of human leukocytes and, **49**:117
- Thymectomy  
 adoptive T cell therapy of tumors and, **49**:288, 300  
 avian, **50**:102  
 helper T cell cytokines and, **46**:125  
 MG and, **42**:253, 259–260, 270–272  
 neonatal, autoimmune thyroiditis and, **46**:275, 301, 302
- Thymic attraction, thymocyte precursors, **50**:89–90
- Thymic factors  
 pituitary secretion induction, **39**:314–315  
 similarity to neuropeptides, **39**:314
- Thymic fragments, human postnatal, and SCID mice, **50**:309
- Thymic hormones, SCID and, **49**:384, 391
- Thymic hyperplasia, MG and, **42**:235, 259–260, 270
- Thymic lineages  
 major, ontogeny of, **51**:133–138  
 minor, **51**:138–139
- Thymic lymphomas, **54**:92
- Thymic nurse cells, spontaneous autoimmune, thyroiditis and, **47**:455, 456, 475, 491
- Thymic stroma, SCID and, **49**:384, 392–393
- Thymic stromal cells, autoreactive T cells and, **45**:421–425
- Thymidine, **38**:280  
 immunosenescence and, **46**:231–234, 243  
 T cell development and, **44**:236
- Thymidine kinase, expressing cells, killing, **58**:434
- Thymocyte-activating molecule, **48**:250
- Thymocytes  
 accumulation of TCR $\delta$  rearrangements, **58**:33  
 antinuclear antibodies and, **44**:108, 130  
 autoimmune thyroiditis and, **46**:274, 279  
 B cell formation and, **41**:198, 199  
 CD1 protein distribution, **59**:55–60  
 CD3<sup>-</sup>, anti-CD2 mAb, **48**:236  
 CD4<sup>+</sup>8<sup>+</sup>, **59**:101, 103  
 commitment to CD4 or CD8 lineages, **58**:156–160  
 deletion, blockade by cyclosporin A, **58**:267  
 depletion by testosterone and estradiol, **58**:227–229  
 generation and turnover, **58**:151–153  
 reduction in  $\zeta$ -deficient mouse, **58**:146–149  
 TCR signaling in, **58**:173–174  
 CD4<sup>+</sup>8<sup>-</sup>, **59**:101, 103  
 CD4<sup>+</sup>8<sup>+</sup>, mature, expressing male-specific TCR, **58**:261  
 CD4<sup>+</sup>8<sup>-</sup> and CD4<sup>+</sup>8<sup>+</sup>, generation from CD4<sup>+</sup>8<sup>+</sup> precursors, **58**:153–165  
 CD4 and CD8 molecules and, **44**:265, 298  
 CD8 molecular biology, **44**:270, 271, 278, 279  
 CD4 signaling role, **53**:82  
 cortical  
 TdT expression, **39**:23, 25  
 unaffected by IL-2 and IL-3, **39**:24–25  
 cytolysis and, **41**:276, 279  
 development and selection, CD4/CD8 roles, **53**:94–97  
 differentiation, and IL-2, **50**:158–160  
 functional maturation, **51**:139–164  
 auxiliary signaling receptors, **51**:157–160  
 CD2, **51**:157–159  
 CD2S, **51**:159–160  
 vs commitment to T cell lineage, **51**:162–164  
 mature vs immature characteristics, history, **51**:139–140

Thymocytes (*continued*)

- postthymic maturation, **51:160–162**
- response gene inducibility, **51:151–157**
  - cortical cells, loss of responsiveness in, **51:153–156**
  - early, in immature thymocytes, **51:151–153**
  - emergence from paralysis to functional maturity, **51:156–157**
  - response genes, **51:146–157**
  - proliferation, **51:146–151**
- TCR/CD3 complexes and signaling
  - mediators, **51:140–146**
  - mediators for immediate TCR responses, **51:143–146**
  - TCR/CD3 complex, **51:140–143**
- helper T cell cytokines and, **46:116**
- hybrid resistance and, **41:337, 376, 409**
- Ig gene superfamily and, **44:22, 30, 31, 35, 36, 41**
- IL-1 and, **44:173, 174, 189, 190**
- immature, early inducibility of responsive genes in, **51:151–153**
- Ir* genes and
  - expression, **38:54**
  - T cell suppression, **38:135**
  - T cell-T cell interactions, **38:154, 155, 158**
- irradiated, biochemical events in, **50:70**
- lymphocyte homing and, **44:345, 351, 352**
- maturation, **59:101–105, 108–109**
- mature vs immature characteristics, history, **51:139–140**
- mechanism of selection by CD4 and CD8, **53:104–108**
- medullary, **39:20erSDH** expression, **23**
- murine lupus models and, **46:82, 94–100**
- negative selection, **58:165–174**
- non-selected, death, **50:67–68**
- p56<sup>lck</sup> control of development
  - allelic exclusion, **56:164–166**
  - differentiation, **56:162–163**
  - maturation, **56:164–166**
  - modes of action, **56:167–168**
  - T cell receptor  $\beta$ -chain signaling, mediation, **56:163–164**
- phagocytosis and, **38:383, 384**
- positive selection, **59:99–129**
- precursor, **43:166**
- progenitors, inhibition of migration, **54:299**
- rodent, and DNA damage, **50:58–59**
- scid*
  - with broken DNA coding ends, **58:37–38**
  - hairpin accumulation at TCR $\delta$  coding ends, **58:48**
- single-positive, **59:101, 103**
- T cell development and, **44:208, 255**
  - antigen recognition, **44:213**
  - cellular selection, **44:245, 247–249, 252–255**
  - ontogeny, **44:214–221, 224, 225**
  - subpopulation, **44:225–245**
- T cell receptor and
  - gene expression, **38:14**
  - target recognition, **38:22**
  - V region genes, **38:15**
- T cell subsets and, **41:96–98, 105–108, 112**
- V $\beta$ 8<sup>+</sup>, SEB-induced depletion, **58:259–260**
- Thymoma, MG and, **42:235, 256, 259, 270, 272**
- Thymoma cells
  - CD4 and CD8 molecules and, **44:269**
  - IL-1 and, **44:179, 181, 194**
  - T cell development and, **44:215**
- Thymopoietin, **42:250**
- Thymus
  - antigen-presenting cells and, **47:47, 48, 81**
  - antinuclear antibodies and, **44:106, 107, 134, 136**
  - autoimmune thyroiditis and, **46:276, 286**
  - autoreactive T cells and, **45:417, 421, 423, 433**
  - B cell formation and, **41:191, 223, 236–238**
  - bone marrow cultures, **41:212, 214**
  - genetically determined defects, **41:231, 225–227**
  - population dynamics, **41:207, 208**
  - CD1 proteins, **59:67–72**
  - CD4 and CD8 molecules and, **44:265**
    - CD4 molecular biology, **44:288**
    - CD8 molecular biology, **44:272, 278, 279**
  - CD5 B cell and, **47:120, 121, 129**
  - CD23 antigen and, **49:169–171**
  - colonizing cells, and TCR $\beta$  cells, **58:139–142**
  - cortex, related cells, and rescue, **58:154–155**

- deletion of superantigen-reactive T cells, **65:203–204**
- dependent antigens, **60:272–277; 63:43**
- derived T cell lineages, **58:102–110**
- in development, waves of precursors populating, **51:137**
- diversification in, **50:90–96**
- embryonic waves of thymocyte development, **50:95–96**
  - intrathymic clonal selection, **50:94**
  - ontogeny of TCR1, TCR2, and TCR3, **50:91–94**
- endothelium and migration of pre-T cells to, **50:275**
- fetal, and synchronized thymocyte ontogeny, **50:158–159**
- HIV-1 infection, **63:88**
- humoral immune response and, **45:2, 3**
- cellular interactions *in vivo*, **45:83**
  - helper T cells, **45:32**
  - interleukins, **45:64**
- hybrid resistance and, **41:337, 352**
- effector mechanisms, **41:372–374, 384, 390–392**
- IGF-I, **63:391–392**
- Ig gene superfamily and, **44:9, 18, 22**
- Ig heavy-chain variable region genes and, **49:50**
- IL-2 receptor subunits, **59:235–236**
- immunosenescence and, **46:243–247**
- independent antigens, **60:272–277; 63:43**
- Ir* genes and
- cross-reactive lysis, **38:187**
  - cytotoxic T cells, **38:165, 167, 172**
  - expression in T cells, **38:60, 61, 63**
  - H-Y antigen, **38:177**
  - T cell repertoire, **38:117, 127, 130–134, 152**
  - T cell suppression T cell-T cell interactions, **38:166**
- lymphocyte homing, **64:177**
- MG and, **42:250–251, 253, 259–260**
- MHC class I-deficient mouse, TCR $\alpha\beta$ <sup>+</sup> CD8<sup>+</sup>CD4<sup>-</sup> T cell development, **55:394**
- MHC class II-deficient mouse, **55:430–434**
- negative selection, **50:66**
- NK cells and, **42:200–201; 47:187, 188, 273, 276**
- effector mechanisms, **47:239**
  - genetic control, **47:222**
  - malignant expansion, **47:228**
- prolactin, **63:382–383**
- prolactin receptor, **63:395**
- pro-T cell homing to, **58:392–394**
- repopulation, immune reconstitution and, **40:411–412**
- SCID and, **49:383–384, 392–393, 398, 400, 402**
- and seeding, **51:110–117**
- origins and alternatives, **51:115–117**
  - thymic environment, **51:110–114**
- spontaneous autoimmune thyroiditis and, **47:492**
- cellular immune reactions, **47:449–451, 454**
  - disturbed immunoregulation, **47:474–476**
  - histopathology, **47:434, 444**
  - humoral immune reactions, **47:445, 447**
  - potential effector mechanisms, **47:466, 468**
- surface antigens of human leukocytes and, **49:78–79, 81, 83, 114–117**
- synthetic T and B cell sites and, **45:197**
- T cell development and, **44:207, 208**
- antigen recognition, **44:213**
  - negative selection, **44:245–252**
  - ontogeny, **44:215, 216, 220, 221, 224**
  - positive selection, **44:252–255**
  - thymocyte subpopulation, **44:225, 228–238, 241, 243**
- T cell development and programming, **58:88**
- T cell receptor and, **45:115, 162–168**
- T cell receptor genes in, **38:11–13**
- T cell subsets and, **41:43, 44, 112**
- H-2 molecules, **41:95–110**
  - H-2-restricted antigen recognition, **41:51, 59, 69**
- V region genes, **38:16**
- Thyroglobulin, **46:263, 317–319; 47:491**
- altered thyroid function, **47:456, 459–461**
- antigens, **46:266–272**
- autoantibodies, **47:491, 492**
- altered thyroid function, **47:457, 459, 460, 462**
  - cellular immune reactions, **47:449, 451**
  - disturbed immunoregulation, **47:481**
  - effector mechanisms, **47:466–469**

- Thyroglobulin (*continued*)  
 genetics, **47:482, 484–487**  
 humoral immune reactions, **47:444–448**  
 cellular immune responses, **46:287, 288, 291, 297, 298; 47:450, 451**  
 experimental models, **46:274–278, 281–283, 285, 287**  
 genetics, **47:485**  
 humoral responses, **46:298, 299, 302–307, 309; 47:446, 447**  
 MG and, **42:265**  
 potential effector mechanisms, **47:466, 469**  
 prevention, **46:308, 310–312, 314, 315**
- Thyroid  
 antigen-presenting cells and, **47:76**  
 IFN- $\gamma$  effect on, **62:93**  
 spontaneous autoimmune thyroiditis and, *see* Spontaneous autoimmune thyroiditis
- Thyroid cells  
 autoimmune thyroiditis and, **46:293–295, 297**  
 target, **46:291–298**
- Thyroid disease, antibodies to self-antigens from human donors, **57:242–244**
- Thyroid epithelial cells, spontaneous autoimmune thyroiditis and, **47:493**  
 altered thyroid function, **47:458, 459, 461–463**  
 clinical symptoms, **47:440**  
 disturbed immunoregulation, **47:472**  
 effector mechanisms, **47:469**  
 genetics, **47:497**  
 histopathology, **47:442**
- Thyroid-infiltrating lymphocytes, **47:492**  
 effector mechanisms, **47:466, 467, 469**  
 immunoregulation, **47:473, 475**
- Thyroiditis, *see also* Autoimmune thyroiditis;  
 Experimental autoimmune thyroiditis;  
 Spontaneous autoimmune thyroiditis  
 allergic, murine lupus models and, **46:79**  
 goitrous, **46:284**  
 Hashimoto's, **46:317**  
 antigens, **46:268, 269, 271–275**  
 cellular immune responses, **46:287–291, 293**  
 genetic control, **46:284**  
 humoral 298–301, **46:303, 305, 306**  
 pituitary hormones, **63:424**
- Thyroid peroxidase, **46:272, 273, 298, 317**
- Thyroid-stimulating hormone, *see* Thyrotropin
- Thyrotropin, **47:457, 458, 461; 48:170–172**  
 antigens, **46:267–269, 272**  
 experimental models, **46:275, 278, 279, 294**  
 prevention, **46:311**
- Thyrotropin-releasing hormone, **46:279, 311**
- Thyroxine, **46:269, 278; 47:437, 439, 457, 470**
- TIA-1 granule proteins, polyadenylate binding motif, **60:301**
- Tissue edema, in IBD, **42:310**
- Tissue factor pathway inhibitor, **66:132**
- Tissue inhibitor of metalloproteinase-1, **62:267, 288; 64:297–298**
- Tissue inhibitor of metalloproteinase-2, **62:267, 288**
- Tissue plasminogen activator, **46:166**
- Tissues, stem cell factor and SCF receptor distribution, **55:15–17**
- Tissue-specific activator protein, B cell genesis, **63:228**
- Tissue specificity  
 Ig heavy-chain variable region genes and, **49:3, 52–56**  
 regulators of complement activation and, **45:394–398**
- Tissue transplantation, therapeutic complement inhibition using soluble CRI, **56:286–287**
- tk*, **62:36**
- T killer cells  
 cytolysis and, **41:280**  
 hybrid resistance and, **41:382, 383, 400**  
 T cell subsets and, **41:40, 54**
- TL region, gene products, **52:98–101**
- T lymphoblasts  
 antigen-presenting cells and, **47:76, 84, 102**  
 spontaneous autoimmune thyroiditis and, **47:467, 473**
- TMV coat protein, **43:54, 76**
- TNF, *see* Tumor necrosis factor
- TNF- $\alpha$ , *see* Cachectin; Tumor necrosis factor  $\alpha$
- Tobacco mosaic virus protein  
 secondary B cell lineage and, **42:68–69**  
 synthetic T and B cell sites and, **45:227, 244**  
 T cell receptor and, **45:132**
- Tocopherol, action of, **65:122**
- Tolerance, **59:279–281, 342–344**  
 B cell, *see* B cell tolerance

- early studies affecting antibody formation, **52:284–287**  
 dissection of T cell vs B cell tolerance, **52:285–287**  
 tolerance and antibody formation before T and B cell era, **52:284–285**
- immunological memory and, **53:249–251**
- Ir* genes and, **38:190**  
 antigen-specific clones, **38:121–123**  
 constraints, **38:127–130**  
 cytotoxic T cells, **38:172**  
 immunodominance, **38:184**  
 induction, **38:125–127, 188**  
 MHC restriction, **38:120**  
 neonatal, **38:183**  
 non-MHC-linked, **38:123–125**  
 self MHC, **38:119, 120**  
 T cell repertoire, **38:132, 133**
- monoclonal repertoires, **59:310–311**  
 perspectives including antigen presentation by B cells, **52:321–322**
- SCID and, **49:398–399**  
 self-tolerance checkpoints, **59:281–342**  
 site-specific, peripheral lymphocytes, **53:201–203**
- Tolerance induction, **42:48**  
 B cell repertoire expression and, **42:35, 82**  
 B cell subpopulations and, **42:77–78**  
 hybrid resistance and, **41:356, 361, 409**  
 Mtv superantigens in, **65:203–208**  
 murine lupus models and, **46:65**  
 T cell subsets and, **41:107–110**
- TOMS-1, **59:65**
- Tongue, invariant  $\gamma\delta$  T cell receptors of murine IEL, **58:303**
- Tonsils, human, isolation of highly purified FDC from, **51:245, 246**
- TOR1, **61:187**  
 TOR2, **61:187**
- Tor2, **63:154**
- Torpedo*, **42:249, 252, 257, 259, 260**
- Total body irradiation, SCID and, **49:397**
- Total lymphoid irradiation, hybrid resistance and, **41:386, 387**
- Toxic oil syndrome, with endothelial cell proliferation, **60:225**
- Toxic shock syndrome, **54:128–133**  
 clinical criteria used in classification, **54:128, 129**  
 fatal, **54:132–133**
- IFN- $\gamma$  and, **62:103**  
*Staphylococcus aureus* toxins, **54:129**  
 TSST-1, **54:129, 131**
- Toxoplasmosis, P30-induced IgG antibody, **60:123–124**
- Tp44, **48:244, 245–246**  
 Tp67, **48:246**  
 Tp90, **48:248**  
 Tpl35-45, **48:250**  
 TplO3, **48:244, 249**
- Trabecular meshwork, **48:206–207**
- Trachea, lymphocyte homing and, **44:330, 332, 333**
- TRADD, **61:31**
- TRAF1, **61:29; 63:50**  
 TRAF2, **61:29; 63:50**
- Transchromosomal switching, switch recombination, **61:100–102**
- Trans-complementation, HLA-DQ hybrid molecule, **48:119–120**
- Transcription, **42:176**  
 activation, Ig enhancers, **43:241–242**  
 antinuclear antibodies and, **44:94**  
 autoantibodies, **44:137**  
 autoantigen, **44:127–129**  
 scleroderma, **44:124, 125**  
 SLE, **44:104**  
 autoimmune demyelinating disease and, **49:368**  
 autoimmune thyroiditis and, **46:268, 295**  
 B cell formation and, **41:192, 198, 204, 205, 221, 222, 226**  
 CD1 genes, **59:7, 9–10**  
 CD4 molecules and, **44:288–291**  
 CD8 molecules and, **44:275, 277, 279**  
 CD23 antigen and, **49:165–167**  
 CD44 gene, multiple products, **54:278**  
 cytotoxicity and, **41:271, 276, 277, 297**  
 endogenous substrate activation in V(D)J joining of antigen receptor genes, **56:41–43**  
 genetically engineered Ab molecules and, **44:89**  
 cloning, **44:73–75**  
 expression, **44:77**  
 lymphoid mammalian cells, **44:70**  
 production, **44:66**  
 germline, *see* Germline,  $C_H$  transcription; Germline transcripts

Transcription (*continued*)

- HIV infection and, **47:380–382**, 399, 401
- human B cell neoplasia and, **38:257**, 260, 263, 264
- hybrid resistance and, **41:380**, 403
- IgE biosynthesis and, **47:21**
- Ig gene superfamily and, **44:43**, 46
- Ig heavy-chain variable region genes and, **49:15**, 33, 37, 53–56
- IL-1 and, **44:155**, 174, 195
  - gene expression, **44:159–161**
  - receptor, **44:179**, 181
- immunosenescence and, **46:223**, 228
- Ir* genes and, **38:82**
- $\kappa$ B-dependent, **58:3**
- in lymphocytes, **62:42**, 47–49
- lymphokine synthesis, **48:81**
- maps of Ig-like loci and
  - MHC, **46:30**, 34
  - structure, **46:18**, 19, 21, 27
  - T cell receptor, **46:43**, 44
- maternally transmitted antigen and, **38:340**, 342
- mRNA, **38:217**, 218
- murine lupus models and, **46:80**, 95
- NK cells and, **47:265**
- SCID and, **49:387**
- signal transducers and activators, *see* Signal transducers and activators of transcription
- spontaneous autoimmune thyroiditis and, **47:477**
- T cell activation and, **41:3**, 27–31
- T cell development and
  - ontogeny, **44:216–218**
  - thymocyte subpopulation, **44:229**, 233, 241
- T cell subsets and, **41:41**, 43, 48, 97
- Transcriptional factor
  - insulin gene, **48:142**
  - transgenic MHC, **48:142**
- Transcriptional regulation, **65:1**
  - C/EBP, **65:3–8**
  - chromatin structure, **63:200–201**
  - IFN-inducible genes, and potential role of
    - IRF-1 and IRF-2, **52:272–275**
  - I $\kappa$ B family, **65:14–15**
  - IL-2 gene, **48:294–297**
  - IL-2R  $\alpha$  gene, **48:294–295**, 297–299
  - in vivo*, **63:198–203**
  - lymphokine production by Fc $\epsilon$ RI<sup>+</sup> cells, **53:22**
  - NF- $\kappa$ B family, **65:11–12**, 15–22, 30–32
  - NF-IL6, **65:1–3**, 8–11, 16–18
  - nuclear scaffold, **63:201**
  - p55, **48:294–295**, 297–299
  - regulator proteins in nucleus, **63:201–203**
  - REL family, **65:12–13**
- Transcription complex, ISGF3, induction by IFN- $\alpha/\beta$ , **60:17**
- Transcription factors, **63:199–200**, *see also specific transcription factors*
  - assembly, role in gene rearrangements, **58:30–31**
  - B cell development, **63:5**
  - B cell development and function
    - c-fos, **63:220–221**, 248–250
    - EBF, **63:250**
    - EtS, **63:250**
    - hox-11, **63:220–221**, 244–245
    - oct-2, **63:220–221**, 243–244
    - p50, **63:220–221**, 246–248
    - Rel proteins, **63:245–248**
  - B cell genesis, **63:216**, 218–221
    - bmi-1, **63:220–221**, 241–243
    - c-myb, **63:220–221**, 238–239
    - E2A gene, **63:218–219**, 232–235
    - GATA-2, **63:217**, 218–219
    - hlx, **63:239–241**
    - homeodomain proteins, **63:239–241**, 243–245
    - Ikaros proteins, **63:218–219**, 224–226
    - pax-5* gene, **63:218–219**, 228–232
    - PU.1, **63:217**, 218–219, 222–224
    - sax-4* gene, **63:218–219**, 226–228
  - binding to regulatory elements of type I IFN genes
    - interferon regulatory factors 1 and 2, **52:267–271**
    - NF- $\kappa$ B, **52:271–272**
    - other factors, **52:272**
  - calcineurin-dependent, **60:47–48**
  - cloning, **43:269**
  - Dif, in rel family, characterization, **58:14**
  - phosphorylation, activation by DNA-PK, **58:60–62**
  - topography, **63:202**

- Transduction, in programmed cell death, **50:73–75**
- Transfectants, adhesion studies, **64:186**
- Transfection  
 adoptive T cell therapy of tumors and, **49:320–321, 329**  
 B cell formation and, **41:198, 205**  
 CD4 and CD8 molecules and, **44:266**  
   CD4 molecular biology, **44:292, 293**  
   CD8 molecular biology, **44:272–278, 280, 282, 283**  
 CD23 antigen and, **49:161, 169**  
 cell lines, positive and negative regulation of hyaluronan binding, **54:306, 307**  
 CTL and, **41:138, 139, 144, 149–152, 163**  
 cytotoxicity and, **41:272**  
 and expression of CD44 cDNA constructs, **54:286–287**  
 genetically engineered Ab molecules and, **44:89**  
   antigen-combining sites, **44:84**  
   chimeric antibodies, **44:81, 82**  
   expression, **44:70, 71, 75–77, 79**  
   fusion proteins, **44:85, 86**  
   lymphoid mammalian cells, **44:69, 70**  
 Ig heavy-chain variable region genes and, **49:53**  
 IL-1 and, **44:165**  
*I<sub>T</sub>* genes and, **38:91, 169**  
 $\kappa$  V gene promoter, **43:258**  
 T cell activation and, **41:3, 5, 8, 11, 25**  
 T cell development and, **44:210, 212**  
 T cell subsets and, **41:58, 59, 62, 80, 83**
- Transferrin  
 antigen-presenting cells and, **47:89**  
 B cell formation and, **41:193, 212**  
 immunosenescence and, **46:222, 227**  
 NK cells and, **47:209, 240**  
 SCID and, **49:385–386**  
 surface antigens of human leukocytes and, **49:115**  
 T cell receptor and, **45:124**  
 virus-induced immunosuppression and, **45:344, 356**
- Transfer RNA, antinuclear antibodies and, **44:119, 127, 131, 134–138**
- Transformation, malignant, p53, **62:226–227**
- Transformed producer cell line, **48:69**
- Transforming growth factor, IL-1 and, **44:153**  
 biological effects, **44:164, 168, 169**  
 human disease, **44:194**  
 structure, **44:155, 158**
- Transforming growth factor  $\alpha$ , mRNA, expression by eosinophils, **60:195**
- Transforming growth factor  $\beta$ , **48:169; 52:173, 199; 55:181–183, 205–206; 59:235, 418, 419; 61:86, 87–90, 353, 374; 62:84–85, 90, 105, 269**  
 adoptive T cell therapy of tumors and, **49:287**  
 B cell growth and differentiation, **52:182–184**  
 bioactivity effects  
   bifunctional, **55:185–186**  
   cytokine receptors, **55:187**  
   cytokines, **55:187**  
   extracellular matrix production, **55:186**  
   hematopoietic cells, **55:186–187**  
   immune functions *in vivo*, **55:188**  
   lymphocytes, **55:187**  
   macrophages, **55:187**  
   monocytes, **55:187**  
 CD23 antigen and, **49:160–161**  
 and IgA expression, **54:259, 262**  
 IgA synthesis, **63:54**  
 induced eosinophil apoptosis, **60:184**  
 inhibition of iNOS, **60:338**  
 and its receptor, sources and structure of, **52:183–184**  
 production by endothelial cells, **58:358**  
 signal transduction  
   formation of complexes, **55:200–202**  
   intracellular, **55:204–205**  
 sources and structure, **52:183–184**  
 structure, **55:183–184**  
 superfamily, **55:184–185**  
 synthesis by eosinophils, **60:196**  
 tumor immunogenicity affected by, **57:307–309**
- Transforming growth factor  $\beta$ 1, **61:86, 88–90, 353, 374**
- Transforming growth factor  $\beta$  receptor, **55:182–183, 195**  
 complex formation for intracellular signaling, **55:200–202**  
 endoglin, **55:198**  
 functions, **55:203–204**  
 serine/threonine kinase type, **55:188, 194–195**  
 binding of isoforms, **55:194**



- Transforming growth factor  $\beta$  receptor  
 (*continued*)  
 cDNA cloning, **55**:188–189, 192  
 structure, **55**:190–193  
 soluble TGF- $\beta$ -binding proteins,  
**55**:199–200  
 sources and structure, **52**:183–184  
 type I, **55**:195–196, 206  
 type II  
 binding of isoforms, **55**:194  
 cDNA cloning, **55**:190–192, 205  
 signal transduction, **55**:206  
 structural comparisons with actin  
 receptor II, **55**:192–193  
 type III, **55**:196–198  
 function, **55**:203–204  
 type IV, **55**:198  
 type V, **55**:194–195  
 Transforming retroviral protein, **48**:253  
 Transfusion effects, hematopoietic  
 engraftment and, **40**:386  
 Transgene  
 and mutations, effect on T cell  
 development, **58**:147–149  
 T cell receptors, **59**:107–108, 113–116,  
 124–127  
 Transgenic approaches, to B cell tolerance,  
**52**:303–317  
 advantages and disadvantages, **52**:303–305  
 anti-DNA transgenic model, **52**:314–315  
 anti-H-2Kk transgenic model, **52**:311–313  
 anti-transgenic models in which B cell  
 tolerance is absent or only partial,  
**52**:315–317  
 hen egg lysozyme model, clonal anergy  
 vindicated, **52**:305–311  
 Transgenic MHC, transcriptional factor,  
**48**:142  
 Transgenic spleen cells, preliminary *in vitro*  
 studies, **54**:414–415  
 Transglutaminase, and inhibition of apoptosis,  
**58**:253  
 Translation  
 antinuclear antibodies and, **44**:128  
 CD4 molecules and, **44**:289, 290  
 CD8 molecules and, **44**:275, 277, 279  
 IL-1 and, **44**:155, 159–162, 164, 195  
 IL-2 receptor and, **42**:176  
 T cell development and, **44**:241  
 Translocation, **52**:35–42  
 adoptive T cell therapy of tumors and,  
**49**:283, 320, 323  
 antinuclear antibodies and, **44**:120, 128  
 chromosomal, *see* Chromosomal  
 translocation  
*c-myc* gene, **64**:227–229  
 Ig heavy-chain variable region genes and,  
**49**:18  
 immunosenescence and, **46**:224, 225, 235  
 leukocyte integrins and, **46**:160  
 maps of Ig-like loci and, **46**:3, 26, 32, 45  
 MHC ABC protein function, **52**:38–42  
 MHC ABC protein genes, **52**:35–38  
 surface antigens of human leukocytes and,  
**49**:98  
 T cell activation and, **41**:17–19, 22, 23  
 V<sub>H</sub> and D<sub>H</sub> segments, **62**:11, 19  
 Transmembrane channel, cell-mediated  
 killing and, **41**:298  
 Transmembrane domain, **65**:56  
 CTL and, **41**:135, 146–148  
 Transmembrane signaling, **48**:227  
 Transmembrane spanning segments, TAP  
 protein, **65**:66–67  
 Transmigration, leukocyte–endothelial,  
**58**:388–389  
 Transplantation, *see also specific type*  
 antigen-presenting cells and, **47**:75, 76, 80  
 bone marrow, for SCID, *See* Severe  
 combined immunodeficiency  
 CD5 B cell and, **47**:128–130  
 graft-versus-host disease, **61**:47  
 haploidentical, SCID and, **49**:393–397,  
 399, 401  
 histocompatible bone marrow, **49**:392  
 lung, graft-versus-host disease, **59**:420–426  
 membrane cofactor protein, **61**:220  
 in MHC class I-deficient mouse,  
**55**:387–388  
 hematopoietic cell grafts, **55**:388  
 liver cell grafts, **55**:391  
 pancreatic islet grafts, **55**:390  
 skin grafts, **55**:388–390  
 murine lupus models and, **46**:64  
 NK cells and, **47**:187, 293, 302  
 differentiation, **47**:231, 232  
 hematopoiesis, **47**:273, 280–282  
 organ, graft-versus-host disease,  
**59**:420–426  
 spontaneous autoimmune thyroiditis and,  
**47**:457, 458  
 tissue, therapeutic complement inhibition  
 using soluble CR1, **56**:286–287

- Transplantation antigens, adoptive T cell therapy of tumors and, **49:281**
- Transplants  
 cytotoxic T cell, **48:197–198**  
 delayed-type hypersensitivity, **48:197**  
 rejection, graft-versus-host disease, **59:420–426**
- Transporter associated with antigen processing, *see* TAP
- Transporters, **65:47–56**  
 ABC transporters, **65:55, 56–57, 59**  
 antigen processing, *see* TAP  
 need for, **65:47–49**
- Transport proteins, surface antigens of human leukocytes and, **49:114–116**
- Transposase, V(D)J recombination, **64:57**
- Transverse myelitis, aPL antibodies and, **49:209**
- Transversions, Ars A response and, **42:125, 126**
- Trenimon, in cancer treatment, **56:329, 331–332**
- Trichinella spiralis*, **54:94**  
 killing  
 by eosinophils, **39:209–211**  
 by major basic protein, **39:190**
- Trichuris muris*, **54:94**
- Triggering, leukocytes, **58:383**
- Triglycerides, cachectin and, **42:214–215**
- Trimolecular complex  
 creation, **52:52–59**  
 immunotherapeutic strategies  
 components, **56:219–220**  
 MHC Ia molecule as target, **56:247–250**  
 peptide antigens as targets  
 analogs as MHC blockers, **56:244–247**  
 analogs as T cell antagonists, **56:244–247**  
 features, **56:239, 250–251**  
 peptide determinant as tolerogen, **56:240–244**
- T cell as target  
 anti- $\alpha/\beta$  T cell receptor antibody, **56:228–229**  
 anti-CD3 antibody, **56:220–223**  
 anti-CD4 antibody, **56:223–228**  
 anti-T cell receptor V $\beta$  antibody, **56:229–233**  
 perspective, **56:219**  
 receptor peptide vaccination, **56:236–239**  
 vaccination, **56:233–236**
- Trinitrophenyl  
 antigen-presenting cells and, **47:68, 69, 79, 80**  
 T cells, **47:86, 97**  
 tissue distribution, **47:49**  
 CD5 B cell and, **47:160, 161**  
 genetically engineered Abs and, **44:80, 81, 89**
- Trinitrophenyl-antigen-binding cells (TNP-ABCs)  
 helper T cells, **45:27, 33**  
 interleukins, **45:62–64, 66**  
 physical interaction, **45:37–40, 42, 44, 47, 50, 51, 53, 54**
- Trinitrophenylated polyacrylamide beads, **52:199**
- Trinitrophenyl-derived T cell, **48:212**
- Trinitrophenyl-keyhole limpet hemocyanin, sensitized B cells, **60:305–308**
- Trinitrophenyl-memory-antigen-binding cells (TNP-MABCs), **45:50, 51**
- trk receptors, **61:5**
- tRNA, antinuclear antibodies and, **44:119, 127, 131, 134–138**
- Trypanosoma cruzi*  
 infection, responses in MHC class I-deficient mouse, **55:413–414**  
 killing by major basic protein, **39:190**
- Trypanosoma rhodensiense*, mouse infection  
 anti-Id antibodies as vaccines against, **39:284**
- Trypanosomiasis, cachectin and, **42:214**
- Trypsin, **41:210, 227, 297, 298**  
 adoptive T cell therapy of tumors and, **49:301, 306**  
 aPL antibodies and, **49:239, 251**  
 autoimmune thyroiditis and, **46:271, 273, 277, 278, 302**  
 IgE biosynthesis and, **47:25**  
 IL-1 and, **44:157, 158**  
 lymphocyte homing and carbohydrate, **44:358, 362**  
 molecules, **44:345, 348**  
 regional specificity, **44:329**  
 site-directed mutants, **43:23**
- Trypsin cleavage sites, PGHS-2, **62:174**
- Tryptophan  
 Ig gene superfamily and, **44:34, 35, 41**  
 metabolism, IFN- $\gamma$ , **62:71–72**  
 L-Tryptophan, ingestion-induced eosinophilia myalgia syndrome, **60:224–225**

- TS1, **63**:174–176  
 TSG-6, **65**:18; **66**:111–112  
 TSH, *see* Thyrotropin  
 TSICSLYQLE (peptide), **66**:88  
 T suppressor cells, *see* Suppressor T cells  
 TT, *see* Tetanus toxoid  
 Tuberculosis, virus-induced  
   immunosuppression and, **45**:335, 336,  
   338, 339  
 Tubulin, **41**:275, 378  
   NK cells and, **47**:302  
 Tuftsin, biological activities of, **40**:111–112,  
   115  
 Tumor allografts  
   anterior chamber, **48**:204  
   anterior chamber-associated immune  
   deviation, intraocular, **48**:207–208  
   delayed-type hypersensitivity, **48**:208, 209  
 Tumor antigens, **58**:418–422; **62**:217–228,  
   240–245  
   B7, *see* B7  
   BAGE, **62**:229, 233  
   blood group antigens, **62**:220–221  
   carbohydrate antigens, **62**:219–221  
   carcinoembryonic antigen, **62**:221–222  
   monoclonal antibody recognition,  
   **56**:305  
   CD28, *see* CD28  
   *c-myb*, **62**:227  
   *c-myc*, *see* *c-myc*  
   costimulatory pathway, **57**:305–307  
   CTLA-4, *see* CTLA-4  
   defined by antibodies, **62**:218–229  
   defined by T cells, **62**:227–231  
   epithelial antigens, **62**:238–239  
   GAGE, **62**:229, 233  
   gangliosides, **62**:219–220  
   glycoproteins and  
   biosynthesis and intracellular transport,  
   **40**:337–341  
   immunochemical and molecular profiles,  
   **40**:328–337  
   immunological characterization,  
   **40**:324–328  
   preclinical models for immunotherapy  
   *in vitro* studies, **40**:341–345  
   *in vivo* reactions in animal model  
   systems, **40**:345–351  
   gp100, **62**:229, 235–236  
   HER-2/*neu*, **62**:223–224, 237–238  
   heterogeneity as barrier to antibody-  
   targeted chemotherapy, **56**:  
   352–354  
   HPV, **62**:229, 239–240  
   idiotypes, **62**:225  
   MAGE, **62**:228, 229, 231–232  
   MART-1, **62**:229, 235  
   MELAN-A, **62**:229, 235  
   melanocytic differentiation antigens,  
   **62**:233–236  
   monoclonal antibody use in identification,  
   **56**:305–306  
   mucin recognition, **57**:302–303  
   protein-derived  
   abl oncogenes, **57**:296–297  
   bcr oncogenes, **57**:296–297  
   mutated p53, **57**:295–296  
   overexpression resulting in, **57**:  
   299–302  
   ras oncogenes, **57**:297–299  
   *tum*<sup>r</sup>, **57**:293–295  
   serological detection, **57**:283–284  
   T cell recognition  
   early evidence, **57**:285–288  
   tumor-specific peptides, **57**:288–290  
   virus-induced tumors, **57**:290–293  
 Tumor cells  
   genetic modification, **56**:425–435  
   lysis, **43**:173  
   transfected, effect on preexisting tumor,  
   **58**:432–433  
 Tumor growth, NK cells and, **42**:182,  
   183  
 Tumorigenesis  
   anterior chamber, **48**:213–215  
   anterior chamber-associated immune  
   deviation, **48**:213  
   *pax* family, **63**:229–230  
   role of IL-9 and mouse T cells,  
   **54**:88–93  
   X-linked agammaglobulinemia,  
   **59**:147–148  
 Tumor immunology, **52**:104–106  
 Tumor immunotherapy, preclinical model  
   *in vitro* studies, **40**:341–345  
   *in vivo* reactions in animal model systems,  
   **40**:345–351  
 Tumor-infiltrating lymphocytes, **58**:437–438;  
   **64**:180, 197  
   adoptive T cell therapy and, **49**:284, 293

- Tumor necrosis factor, **41**:235–237, 285, 298, 374, 400, 401; **48**:70, 71  
 adoptive T cell therapy of tumors and 301, **49**:306–309  
 anti-TNF, **66**:124, 132, 150  
 antitumor effects in preclinical trials, **56**:354  
 autoimmune demyelinating disease and, **49**:360  
 autoimmune thyroiditis and, **46**:294, 295  
 biochemistry, **66**:105–107  
 cardiomyocytes and, **66**:114  
 circulating levels, **66**:104–107  
 complement receptor 1 and, **46**:192  
 in endotoxemia, **66**:114–116  
 eosinophil activation, **39**:216  
 helper T cell cytokines and, **46**:112, 114, 115  
 HIV infection and, **47**:394, 402–404  
 IL-1 and, **44**:153–155, 185–188  
   biological effects, **44**:165, 166, 168, 169  
   gene expression, **44**:161  
   human disease, **44**:192, 195  
   human joint fluid, **44**:191, 192  
   immunocompetent cells, **44**:178  
   structure, **44**:155, 157, 158  
   synergism, **44**:188, 189  
   systemic effects, **44**:170  
*in vitro* effects, **66**:110–112  
*in vivo* effects, **66**:112–114  
 leukocyte integrins and, **46**:170, 172  
 maps of Ig-like loci and, **46**:30, 33  
 mediated bystander killing, **60**:304  
 multiple myeloma pathogenesis, **64**:258  
 neutrophils and, **66**:111  
 NK cells and, **47**:286, 289, 290  
   differentiation, **47**:233  
   effector mechanisms, **47**:251, 262, 265, 266  
   hematopoiesis, **47**:278, 279, 281  
   reproduction, **47**:271  
   surface phenotype, **47**:213  
 regulation, **66**:108–110  
 regulators of complement activation and, **45**:397  
 sepsis and, **66**:104, 126–127, 150  
   animal models, **66**:117–121  
   clinical, **66**:121–124  
   treatment, **66**:124–126  
 signaling events, **65**:117  
 surface antigens of human leukocytes and, **49**:98  
 synergy between IFN- $\gamma$  and, **62**:81–82  
 vascular endothelial injury caused by, **56**:351  
 Tumor necrosis factor  $\alpha$ , **48**:169; **52**:172–173; **61**:5, 22, 24, 25–26; **62**:81, 86, 139; **63**:303–304, *see also* Cachectin  
 allergic airway inflammation, **62**:285  
 allergic inflammation, **60**:169–170  
 antibody pretreatment, **60**:336–337  
 anti-TNF- $\alpha$  therapy, *see* Anti-TNF- $\alpha$  therapy  
 and autoimmunity, **50**:211–212  
 B cell proliferation, **63**:55  
 cardiovascular risk factors and, **64**:322  
 cytokine regulation of, **64**:315, 316  
 granulomatous lesions, **62**:281, 282  
 IGF-I, **63**:390  
 IL-1, **64**:293, 316  
 IL-8, **64**:294, 295, 316  
 mRNA, eosinophils expressing, **60**:200  
 NF- $\kappa$ B induction, **58**:7–9  
 production  
   by crosslinkage of Fc $\epsilon$ R on peritoneal mast cells, **53**:9  
   by factor-dependent mast cell fines, **53**:8–9  
   by Fc $\epsilon$ RI<sup>+</sup> cells, **53**:9  
   by human mast cells, **53**:14–15  
 pulmonary inflammation, **62**:259, 260, 267, 273, 288–289  
   in hypersensitivity granuloma formation, **62**:280–281  
   regulation in IC-mediated inflammation, **62**:279  
   upregulation of vascular E-selectin and ICAM-1, **62**:276, 277  
 rheumatoid arthritis, **64**:293, 296–298, 316  
 cell trafficking, **64**:317–319  
 joint destruction mechanisms, **64**:320–321  
 neovascularization, **64**:319–320  
 systemic inflammatory response syndrome, **63**:310  
 TH responses, **61**:353  
 trimerization, **61**:26  
 Tumor necrosis factor  $\beta$ , **61**:5, 353; **63**:303–304  
 Tumor necrosis factor inhibitors, **63**:305

- Tumor necrosis factor receptor, **63:50**, 276, 284, 303–307, 313–314; **66:107–108**, 116  
 genes, **61:25**  
 p55, death domain, **58:135**  
 superfamily, **61:54**; **63:45**, 49  
 CD40 antigen, **61:2–4**  
 CD40-L, **61:17–22**  
 other members, **61:4–11**, 22–24  
 signal transduction, **61:26–27**  
 soluble forms, **61:15–17**, 25–26  
 viral homologs, **61:10**  
 TNF-R1, **61:5**, 7, 17; **63:276**, 305  
 gene, **61:8**  
 TNF-R2, **61:5**, 7, 8, 17; **63:276**, 305, 309  
 gene, **61:8**
- Tumor necrosis factor  $\alpha$  receptor, **42:225–226**
- Tumor necrosis factor receptor related protein, **61:7**, 8  
 gene, **61:8**
- Tumor necrosis serum, **41:406**
- Tumor rejection  
 adoptive T cell therapy of tumors and, **49:286**, 296, 318, 333  
 B cells, **49:312–315**  
 macrophages, **49:306–312**  
 mechanisms, **49:299–306**  
 NK cells, **49:315–318**  
 intraocular, *see* Intraocular tumor rejection
- Tumors, *see also* Cancer  
 adoptive T cell therapy, **49:281–286**, 332–335  
 antigen recognition, **49:318–324**  
 expression of antitumor responses, **49:324–325**  
 B cells, **49:330–332**  
 proliferation, **49:325–330**  
 mechanisms of tumor rejection, **49:299**  
 B cells, **49:312–315**  
 macrophages, **49:306–312**  
 NK cells, **49:315–318**  
 T cell subsets, **49:299–306**  
 principles, **49:286**  
 requirement, **49:294–299**  
 tumor burden, **49:286–294**  
 antigen-presenting cells and, **47:66**, 67, 100  
 autoreactive T cells and, **45:428–430**  
 barriers to antibody-targeted chemotherapy perfusion, **56:350–352**  
 tumor antigen-heterogeneity, **56:352–354**  
 vasculature, **56:350–352**
- B cell formation and, **41:186**, 204, 230, 233, 237  
 B cell precursors, **41:188**, 193, 194, 196  
 bone marrow cultures, **41:214**, 217  
 inducible cell line, **41:220**, 221  
 lineage fidelity, **41:195**, 196
- CD5 B cell and, **47:118**, 125  
 Ig gene expression, **47:150**, 151, 156  
 marker for activation, **47:126**
- CD8 molecules and, **44:271**, 273, 276
- CD44 expression and metastasis, **54:322–325**  
 cell migration, role of CD44 in metastasis, **54:318–325**  
 chimeric, and IL-6, **54:51**  
 CTL and, **41:135**, 138, 139, 154  
 cytotoxicity and, **41:270**, 284–286, 293, 313  
 defined by antibodies, **62:218–227**  
 defined by T cells, **62:227–240**  
 etiology, stem cell factor role  
 brain, **55:77**  
 gonadal, **55:74–76**  
 hematopoietic, **55:72–74**  
 lung cancer, **55:77–78**  
 mast cell leukemia, **55:74**  
 melanoma, **55:74–76**  
 ganglioside antigens and, **40:351–352**  
 properties of cell-associated gangliosides, **40:353–355**  
 properties of ganglioside antigens  
 associated with tumor cells,  
 colon cancer, **40:364–366**  
 melanoma, **40:357–364**  
 neuroblastoma, **40:355–357**  
 genetically engineered antibody molecules and, **44:87**, 88  
 hematopoietic, stem cell factor role in  
 etiology of, **55:72–74**  
 humoral immune response and, **45:7**, 24  
 hybrid resistance and, **41:338**  
 antigen expression, **41:397**, 402–404  
 effector mechanisms, **41:375**, 378, 380, 382, 387, 393, 394, 396  
 leukemia/lymphoma cells, **41:358–369**  
 IFN- $\gamma$  and, **62:96**, 101–103  
 Ig gene superfamily and, **44:39**

- Ig heavy-chain variable region genes and, **49:9, 11**
- IL-1 and, **44:166, 168, 178, 193**
- IL-5 effects, **57:177–178**  
rejection, **57:174**
- IL-5 role, **57:177–178**
- immune response, **57:281–326**  
antigens, *see* Tumor antigens  
B7-transfected cells, **57:320–321**  
cytokine genes in engineering of tumor cells, **57:321–323**  
escape mechanisms, **57:324–325**  
immunogenicity, factors contributing to low level  
antigen expression, low, **57:303–305**  
costimulatory molecules, lack of, **57:305–307**  
IL-10, **57:307–309**  
immune suppressive factors, **57:307–309**  
MHC class I expression, low, **57:303–305**  
TGF- $\beta$ , **57:307–309**  
tumor environment modification, **57:309–312**  
MHC expression increased by transfection  
allo-MHC, **57:312–313**  
self-MHC class I, **57:314–320**  
self-MHC class II, **57:313**  
tumor antigens, *see* Tumor antigens  
induction by MMTV, **65:153–156**  
leukocyte integrins and, **46:150**  
maps of Ig-like loci and, **46:8**  
metastasis and extracellular matrix, **54:318–322**
- NK cells and, **47:187–189, 295–300**  
CNS, **47:267**  
differentiation, **47:231, 234**  
effector mechanisms, **47:235, 238, 257, 259, 262**  
nonimmunogenic, **58:419**  
regulators of complement activation and, **45:395, 397, 402**  
reticuloendotheliosis virus-induced, **50:107–108**  
solid  
adoptive T cell therapy and, **49:284, 293**  
anti-Id antibody therapy, **39:291–292**  
spontaneous autoimmune thyroiditis and, **47:450**  
studies with B cell lines and, **52:219–220**  
surface antigens of human leukocytes and, **49:115**  
TAP dysfunction in, **65:94–95**  
T cell activation and, **41:6**  
T cell development and, **44:209**  
T cell receptor and, **45:117, 118**  
T cell subsets and, **41:74, 91**  
UV-induced, adoptive T cell therapy of tumors and, **49:281, 283–284**
- Tumor-specific transplantation antigens, characteristics, **57:285**
- Tumor transplantation, **49:281–282, 286**
- TUNEL assay, **60:279**  
HIV-1 studies, **63:102, 104–105**
- Tunicamycin  
CD23 antigen and, **49:158, 162**  
complement receptor 1 and, **46:187**  
complement receptor 2 and, **46:201**  
IgE biosynthesis and, **47:18, 19**
- Turner's syndrome, **63:409**
- 12/23 Rule, V(D)J recombination, **64:45, 53, 59**
- Twins studies, RA susceptibility discordance in identical twins, **56:448–449**  
formal genetics, **56:433–435**  
somatic nonidentity, **56:446–449**
- Two-color cytofluorographic analysis, T cell receptor  $\gamma\delta$  proteins, **43:146–147**
- Two-color immunofluorescence analysis, NKH1 antigen and, **42:189**
- Two-signal model, T cell activation, **62:131–132**
- Trk* gene, **59:184**
- Tyk2 Janus kinase, **62:68**  
in IFN- $\alpha/\beta$  response, **60:7–9**
- Tyr385, **62:175, 178, 180**
- Tyrosinase, **62:233–234**
- Tyrosine, **42:97**  
CTL and, **41:135, 148, 162**  
phosphorylation, **48:277–283**  
surface antigens of human leukocytes and, **49:77**
- Tyrosine-containing sequence motifs, **58:127–128, 130**
- Tyrosine kinase, *see* Protein-tyrosine kinase

- Tyrosine phosphorylation, **48:277–283**  
 B cell antigen receptor-induced, targets, **55:233–234**  
 coupled to cytokine binding, **60:4–9**  
 mIg-induced, targets, **55:234–249**  
 protein substrates, and lymphokine production, **53:5–6**  
 protein tyrosine, B cell antigen receptor-induced, **55:231–233**  
 role in signal transduction, **54:418–419**  
 Vav, **60:16**
- U**
- U937 cells, PGHS-2 expression regulation, **62:194–195**  
 U2666 myeloma B cell, **48:182**  
 Ubiquitin  
 conjugation, **65:117**  
 lymphocyte homing and, **44:348**  
 Ubiquitination, **64:6, 107**  
 Ubiquitin–proteasome system, **64:3, 5–8**  
 Ubiquitinylation, **63:396**  
 Ulcerative colitis, *see also* Inflammatory bowel disease  
 antibody secretions and, **42:304**  
 anti-TNF- $\alpha$  therapy, **64:309–310**  
 IgA levels in, **42:298**  
 Ultrastructure, purified tonsillar B cells  
 cultured in CD40 system, **52:210–211**  
 Ultraviolet light, induced tumors, adoptive T cell therapy of tumors and, **49:281, 283–284**  
 Unfolding, **52:2**  
 and proteolysis of antigens, **52:22–78**  
 Ungulate lentiviruses, **52:430–432**  
 bovine immunodeficiency-like virus, **52:432**  
 bovine leukemia virus, **52:432**  
 equine infectious anemia virus, **52:431**  
 Maedi-visna virus, **52:431**  
 Unresponsiveness, specific, hybrid resistance and, **41:384–386**  
 Upper respiratory tract, pulmonary immunity regulation and, **59:372–373**  
 Upstream induction sequence, **65:25**  
 Urea-denatured OVA, IgE biosynthesis and, **47:29, 30, 33**  
 Urine nitrate  
 -NMMA effect, **60:343**  
 production in septic trauma patients, **60:351**  
 Uromodulin, **63:277**  
 U snRNA gene promoters, **43:260, 262**  
 Uterus  
 rodent  
 edema, estrogen-induced eosinophilia and, **39:227–228**  
 estrus cycle, eosinophil infiltration and, **39:227**  
 stromal cells, IL-1ra production, **54:188**  
 UV5C25  
 anterior chamber, **48:213–215**  
 delayed-type hypersensitivity, **48:214**  
 Uveitis  
 autoimmune, *see also* Experimental autoimmune uveitis  
 immune regulation, **48:215–216**  
 pituitary hormones, **63:425**
- V**
- V1-2 segment, **62:18**  
 V1-3 segment, **62:18**  
 V1-8 segment, **62:18**  
 V1-12P pseudogene, **62:23**  
 V1-18 segment, **62:24**  
 V1-24P segment, **62:16**  
 V1-45 segment, **62:17**  
 V1-58P segment, **62:16, 17**  
 V1-69 segment, **62:18, 19**  
 V2-5 segment, **62:18**  
 V3-7 segment, **62:18, 19**  
 V3-9 segment, **62:18, 20**  
 V3-11 segment, **62:18**  
 V3-13 segment, **62:20**  
 V3-15 segment, **62:18, 19**  
 V3-16P segment, **62:16**  
 V3-20 segment, **62:17, 20**  
 V3-21 segment, **62:20**  
 V3-23 segment, **62:19**  
 V3-30 segment, **62:18–19, 20**  
 V3-33 segment, **62:20**  
 V3-35 segment, **62:17**  
 V3-38P segment, **62:16**  
 V3-43 segment, **62:20, 25**  
 V3-47P segment, **62:20**  
 V3-48 segment, **62:19, 20**  
 V3-53 segment, **62:18**

- V3-54P segment, **62:16**  
V3-60P segment, **62:25**  
V3-62P segment, **62:25**  
V3-64 segment, **62:17**  
V3-72 segment, **62:17**  
V3 loop, HIV  
    multiple antigen peptides with, **60:131–134**  
    in octameric multiple antigen peptides,  
    **60:137–138**  
V3 region, **62:24**  
V $\gamma$ 4, expressed in lung, **58:304**  
V4-4 segment, **62:18, 25**  
V4-28 segment, **62:17, 20, 25**  
V4-31, **62:20**  
V4-39, **62:18, 19**  
V4-59, **62:18, 19**  
V4-61, **62:19**  
V5-51, **62:19**  
V6-1 segment, **62:18**  
V7-81 segment, **62:17**  
VI3C segment, **62:24**  
V54 segment, **62:24**  
Vaccination  
    antigen-based strategies, **58:435–437**  
    cancer, strategies, **58:427, 433**  
    efficacy of different clones, **58:430–431**  
    GMS/BCG vaccine, **62:220**  
    HIV infection and, **47:408, 411, 413**  
    MMTV infection, **65:190–191**  
    multiple sclerosis and, **49:374–375**  
    pulmonary diseases, **59:409–412**  
    and tumor-specific antigens, **58:418–420**  
Vaccines, **52:106–107; 65:323**  
    HIV, **65:320–322**  
    immune, autoimmune and  
        immunodeficiency states, **52:106–107**  
    (NANP)<sub>3</sub>-TT, for *P. falciparum*,  
    **60:112–113**  
    and *Neisseria* strain specificity, **60:134–135**  
    neutralizing multiple *Chlamydia* serovars,  
    **60:136**  
    pneumococcal, mutation to, **60:277**  
    SIV, **65:321–322**  
    SIV as model for, **52:451, 452**  
    sporozoite malaria, *see* Sporozoite malaria  
    vaccine  
    subunit, for dental caries, **60:135–136**  
    synthetic T and B cell sites and, **45:195,**  
    **197, 260–264**  
        bacterial antigens, **45:231, 232**  
        candidate synthetic peptide, **45:252–259**  
        globular protein antigens, **45:213**  
        parasitic antigens, **45:228, 230**  
        peptides, **45:239**  
        prediction, **45:251, 252**  
        viral antigens, **45:217–219, 222, 223,**  
        **225, 226**  
        TT-multiple antigen peptides, **60:121–122**  
        virus-induced immunosuppression and,  
        **45:336, 339, 340**  
Vaccinia virus, *see also* Interleukin-2/vaccinia  
    virus  
    cytotoxic T cells and, **38:162–166,**  
    **180–185**  
    regulators of complement activation and,  
    **45:409**  
    responses in MHC class I-deficient mouse,  
    **55:407–408**  
Vaccinia virus complement-control protein,  
    **61:241**  
Valency, antigens, **59:302–305, 308**  
Valerylalicylate, **62:187**  
VAP-1, **64:147, 161–162**  
    and L-VAP-2, **58:377–378**  
    lymphocyte-HEV interaction, **65:365**  
Vap-1, B cell, tyrosine phosphorylation after  
    anti-Ig stimulation, **55:243**  
Variable domain structures, superposition,  
    **43:18–20**  
Variable region, *see also* Heavy chain variable  
    region  
    diversity, **42:95–96, see also** Arsonate  
    idiotypic system, A/J mouse  
    gene expression, *see also* B cell repertoire  
    expression  
    evolutionary selection vs random somatic  
    events in, **42:8–9**  
    age factor, **42:30–32**  
    antigen responsive cell populations,  
    **42:19–22**  
    clonal expansion, **42:32–34**  
    fetal and neonatal development,  
    **42:26–30**  
    junctional diversity, **42:15–18**  
    predominant clonotype expression,  
    **42:22–26**  
    segment selection, **42:18–19**  
    somatic mutations, **42:9–15**  
    mechanics of, **42:2–5**  
    secondary B cell lineage and, **42:69–71**



- Variable region (*continued*)  
 secondary B cells and, **42:72–73**  
 unresolved issues in, **42:5–8**  
 genes, Ig heavy-chain, *see* Heavy chain  
 variable region, genes  
 recombinational mechanisms involved in  
 joining segments of, **40:253–256**  
 T cell receptor, recombination creates  
 diversity, **40:262–264**
- Variant surface glycoprotein, containing  
 diacylglycerol, **60:63–64**
- Variation, somatic, T cell receptors and,  
**38:16**
- Variation pattern  
 germline sequences and, **42:127–128**  
*J558 V<sub>H</sub> gene* and, **42:117, 125–127**
- Varicella Zoster virus, antibodies from  
 combinatorial libraries, **57:221–222**
- Vascular addressins  
 lymphocyte–HEV interaction, **65:361–363, 377**  
 lymphocyte homing and, **44:322, 353**  
 mucosal, lymphocyte–HEV interaction,  
**65:362–363**
- Vascular adhesion protein-1, *see* VAP-1
- Vascular cell adhesion molecule-1, *see*  
 VCAM-1
- Vascular endothelial cells, specific antigen  
 presentation by, **50:261–267**  
 alloantigen presentation, **50:266–267**  
 protein antigen presentation, **50:265–266**  
 regulation of MHC molecule expression,  
**50:262–265**
- Vascular endothelial growth factor,  
**64:319–320**
- Vascular endothelial injury, TNF as cause,  
**56:351**
- Vascular leak syndromes, NO role,  
**60:327–330, 347**
- Vasoactive intestinal peptide, **48:170–172; 61:95**  
 cAMP in lymphocytes and, **39:311**  
 in cerebral artery walls, **39:304**  
 gene, **65:20**  
 Ig production by Peyer's patches and,  
**39:311**  
 lymphocyte adhesion and, **64:153**  
 production by neutrophils and mast cells,  
**39:316**  
 smooth muscle relaxation, **39:303, 306**  
 immediate hypersensitivity and, **39:306**  
 vascular dilatation, **39:302–303, 306**  
 immediate hypersensitivity and, **39:306**
- Vasoactive intestinal peptide receptors  
 kinetics and properties, **39:312–313**  
 on lymphocytes, **39:312**
- Vasodilation  
 early event in inflammation, **60:326–327**  
 NO-induced, **60:347–348**
- Vav, **60:16**
- Vav, **62:42, 45–46**  
 tyrosine phosphorylation, **60:16**
- Vbse, *see* V $\beta$  selective elements
- VCAM-1, **52:363; 62:258, 267; 64:154; 65:359**  
 cell trafficking, **64:317–319**  
 downregulation, **64:172**  
 expression in allergic inflammation,  
**60:172–173**  
 ligand for  $\alpha 4\beta 1$  integrin, **58:374–375**  
 lymphocyte homing and, **64:158, 188**  
 to mucosa, **64:176–177**  
 mAbs, **60:168–171**  
 pregnancy and, **64:194–195**  
 properties, **64:147**  
 recruitment of leukocytes to inflammation  
 site, **58:395**  
 shedding, **64:171**  
 upregulation, **64:165**
- V(D)J joining, antigen receptor genes  
 12/23 rule, **56:32**  
 agents  
 biochemically defined, **56:69–73**  
 cutting, **56:71–72**  
 genetically defined, **56:73–79**  
 hairpin-nicking activity, **56:79**  
 joining signals, binding of, **56:69–71**  
 ligation, **56:72–73**  
 molecular genetics, **56:64–69**  
 properties, **56:64**  
 RAG-1, **56:64–67**  
 RAG-2, **56:66–67**  
 replication role, **56:80–81**  
 severe combined immunodeficiency,  
**56:73–78**  
 terminal deoxynucleotidyl transferase,  
**56:68–69**  
 truncation factors, **56:79–80**  
 end donation, **56:125–126**

- endogenous substrate  
   accessibility, **56:37**, 41–42  
   active cell lines, **56:38–40**  
   chromatin configuration, **56:37**, 41–46  
   DNase I sensitivity, **56:43–44**  
   Ig loci, **56:34–37**  
   methylation, **56:44–46**  
   T cell receptor loci, **56:34–37**  
   transcription, **56:41–43**  
 fidelity, **56:119–127**  
 gene assembly  
   for Igs, **56:28–32**  
   for T cell receptors, **56:28–32**  
 mechanism  
   analysis of process, **56:27–28**, 132  
   cleavage, **56:129–131**  
   end exchange, **56:130–131**  
   hypothesis, **56:127–131**  
   ligation, interim, **56:131**  
   modification, interim, **56:131**  
   synapsis, **56:127–129**  
 model systems, **58:42–43**  
   cell rearrangement, **56:47–50**  
   introduced substrates, **56:50–53**  
   *in vivo*-generated functions, **56:46–47**  
 nonstandard products, **56:32–34**  
   hybrid joint, **56:32–33**  
   open-and-shut joint, **56:32–33**  
 order, origins of  
   12/23 rule, **56:82–86**  
   distance effects, **56:96–98**  
   joining signals, **56:86–90**  
   locus deletion, **56:92–94**  
   mechanisms, **56:81–82**, 118–119  
   orientation, **56:101–104**  
   *pseudo-normal joining*, **56:94–95**  
   rearrangement  
     *cis*, **56:98–99**  
     successive, **56:95–96**  
     *trans*, **56:98–101**  
   recombination outcomes, **56:90–95**  
   recombination recognition sites, **56:86**  
   specificity of end exchange, **56:104–111**  
   three-dimensional signals, **56:111–118**  
   V gene replacement, **56:90–92**  
 pathogenesis, **56:119–127**  
 recombinant structure  
   crossover site location, **56:53–54**  
   germline joining, **56:63–64**  
   homology, **56:60–62**  
   junctional inserts, **56:54–58**  
   N regions, **56:54–55**  
   oligonucleotide capture, **56:62–63**  
   P nucleotides, **56:56–58**  
   terminal deoxynucleotidyl transferase,  
     **56:54–56**  
   truncation, **56:57–60**  
   recombination  
     cryptic site, **56:121–127**  
     interchromosomal, **56:120–121**  
     outcomes, **56:90–95**  
     targets, **56:32**  
   terminology, **56:34**  
 VDJ joints, isolated from chicken thymus,  
   diversity, **50:111**  
 V(D)J junctions  
   encoding CDR3 region, **58:125**  
   and generation of TCR gene diversity,  
     **58:116–117**  
 V(D)J rearrangement, **60:38**, 268  
   precursor B cells, **63:16–19**  
   rabbit  
     antibody repertoire development,  
       **56:195–198**  
     appendix, germinal centers, **56:204**  
     bone marrow, **56:184**  
     GALT model, **56:206–209**  
     mechanism, **56:179**  
     organization, **56:190–192**  
     somatic conversion, **56:198–202**  
     somatic mutation, **56:201**, 203  
   V(D)J recombinase, **64:46**  
 V(D)J recombination, **61:123**, 285, 287–291;  
   **62:1**  
   12/23 Rule, **64:45**, 53, 59  
   assay, **61:124**  
   biochemistry, **64:51**  
     biological consequences, **64:59–61**  
     cleavage at an RSS, **64:51–53**  
     coupled cleavage, **64:53–54**  
     *hairpin formation*, **64:56–59**  
     signal sequence recognition, **64:54–56**  
   broken DNA molecules, **64:43–45**  
   cleavage, **64:52–54**  
   cleavage model, **58:38–39**  
   coding joints, **64:40**, 41–42  
   and DNA repair, and Ku autoantigen,  
     **58:55–60**  
   DSB repair, **58:29–85**; **64:49–51**  
   cell cycle regulation, **58:70–74**

- V(D)J recombination (*continued*)  
 hybrid joints, **64:42**  
 initiation, **58:30–32**  
 joining model, **58:42–43**  
 mechanism, **61:109–110**  
   antigen receptor loci, **61:304–306**  
   DNA double-strand breaks, **61:298–303**  
   lymphocyte-specific proteins, **61:291–298**  
   RAG-1 and RAG-2, **61:291–296**  
   signal binding proteins, **61:303–304**  
   TdT, **61:296–298**  
 open-and-shut joints, **64:42**  
 pathology, **61:285–286, 316–317**  
   ataxia telangiectasia, **61:191, 315**  
   Bloom's syndrome, **61:316**  
   DNA breakage syndromes, **61:314–316**  
   Fanconi's anemia, **61:315**  
   severe combined immunodeficiency,  
     **61:306–311**  
   xeroderma pigmentosum, **61:315–316**  
   X-linked agammaglobulinemia,  
     **61:312–314**  
 properties, **64:39–42**  
 RAG proteins, **64:45–48**  
 relevance of joining activity, **58:45**  
 SCID defect and, **64:49–50**  
 signal joints, **64:40, 41**  
 signal sequence recognition, **64:54–56**  
 stages, **64:40–41**  
 and switch recombination, comparison,  
   **54:235–237**  
 and TCR gene expression, **58:116–117**  
 terminal deoxynucleotidyl transferase,  
   **64:51**
- V(D)J region  
 B cells, shared with germinal centers,  
   **60:272**  
 hypermutation in germinal centers,  
   **60:278–280, 284**
- VDRL antigen, aPL antibodies and,  
**49:227–228, 234–238**
- Vectors  
 episomal, **61:124–128**  
 viral, and gene transfer techniques,  
   **58:422–425**
- VEGF, **64:319–320**
- Veiled cells, **59:60**  
 IBD and, **42:296**
- Venous sinus, B cell formation and, **41:187, 214, 236**
- Venous thrombosis, CD59-negative platelets  
 in, **60:91–92**
- Venules, endothelial, L-selectin association  
 with lymphocyte adhesion, **62:257**
- Vesicles  
 antigen-presenting cells and, **47:68, 87, 89**  
 HIV infection and, **47:393, 396**  
 NK cells and, **47:214, 216, 217, 221**
- Vesicular stomatitis virus, **41:142, 148, 153, 154, 163, 168**  
 NK cells and, **47:286, 287**
- VF1-12P pseudogene, **62:23**
- V gene, **43:252, 255**
- V $\beta$  gene, **43:268–269**
- V gene replacement  
 IgH locus, **64:54**  
 outcome of V(D)J recombination,  
   **56:90–92**
- V gene segment, bursal lymphocyte,  
**48:52–54**
- $\psi$ -V gene segment  
 diversification, **48:58–60**  
 diversification sequences, **48:54–56**  
 gene conversion, **48:58**  
 VL, recombination event, **48:56**
- V gene usage  
 biases in CD5 B cells, **55:319–320**  
 clonal expansions, **55:322–323**  
 human populations, **55:329**  
 neoplasias, **55:322–323**  
 normal cells, **55:320–322**  
 chicken B cell  
 diversification, **57:358–361**  
 recombination models, **57:362–365**
- V<sub>H1</sub>, in rabbit B lymphopoiesis, **56:184**
- V<sub>H2</sub> family, **62:13**
- V<sub>H3</sub> family, **62:18**
- V<sub>H4</sub> family, **62:13, 25**
- V<sub>H5</sub> family, **62:13, 17**
- V<sub>H6</sub>, **60:47**
- V<sub>H6</sub> family, **62:13, 17**
- V<sub>H7</sub> family, **62:14, 15**
- V<sub>H</sub> genes, *see* Heavy chain variable region,  
 genes
- V<sub>H</sub> locus  
 evolution, **62:19–26**  
 physical mapping, **62:4–7**  
 polymorphisms, **62:8–9**  
 repetitive sequences, **62:20, 22**
- V<sub>H</sub> pseudogenes, **62:16–17**

- V<sub>H</sub> segments, **62**:1–2, 7–8, 12–19  
germline, **62**:1–26  
*vif* gene, HIV-1 infectivity, **63**:106  
Vinca alkaloids, in cancer treatment, mAb  
  conjugation procedure, **56**:340–342  
  vinblastine, **56**:341–342  
  vincristine, **56**:340–341  
  vindesine, **56**:340–341  
VIP, *see* Vasoactive intestinal peptide  
Viral antigens, **62**:239–240  
  antigen-presenting cells and, **47**:47, 80, 81  
  synthetic T and B cell sites and,  
    **45**:216–228, 240, 241  
Viral cytokine receptors, **63**:308–310  
Viral determinants, pathogenesis of HIV,  
  analysis using SIV molecular clones,  
    **52**:448–451  
Viral diseases, **60**:128–136  
  multiple antigen peptides as immunogens,  
    **60**:128–134  
Viral genomes, viruses used as animal models  
  for AIDS, organization, **52**:429  
Viral infection  
  and autoimmune diabetes, **51**:308  
  and bacterial, induction of NF- $\kappa$ B, **58**:6  
  cachectin and, **42**:220, 226  
  cytotoxic T cells and  
    adenovirus, **65**:279  
    cytomegalovirus, **65**:278–279  
    Epstein–Barr virus, **65**:279  
    herpes simplex virus, **65**:279  
    HIV, **65**:280–322  
    influenza virus, **65**:278  
  IFN- $\gamma$  and, **62**:77, 95  
  IL-6 and, **54**:37  
  and lymphopenia, **58**:233–237  
  MG and, **42**:272  
  NF-IL6 in, **65**:9–11  
  NK cells and, **42**:182, 183  
  plasmacytomagenesis-induced, **64**:230–232  
  pneumonia, **59**:406–409  
  responses in MHC class I-deficient mouse,  
    **55**:406  
    influenza virus, **55**:406–407  
    lymphocytic choriomeningitis virus,  
      **55**:409–412  
    Sendai virus, **55**:408–409  
    Theiler's virus, **55**:409  
    vaccinia virus, **55**:407–408  
    switch from latency to productivity, role of  
      NF- $\kappa$ B, **58**:16–17  
    X-linked agammaglobulinemia, **59**:145, 150  
Viral inhibition  
  CD8<sup>+</sup> cells, **66**:273–275, 281  
  cell-mediated effects, **66**:286–287  
  cytolysis, **66**:283–286, 287–291  
  HIV-1-specific lytic activity, **66**:275–277,  
    283–286  
  mechanism, **66**:280–291  
  chemokines and, **66**:281–282  
  IL-16, **66**:283  
Viral replication, HIV, CD8<sup>+</sup> and,  
  **65**:281–282  
Viral subterfuges, **52**:74–76  
Viral vectors, and gene transfer techniques,  
  **58**:422–425  
Virulence factors, **63**:308–309  
Virus-dependent cellular cytotoxicity, NK  
  cells and, **47**:286  
Viruses, *see also specific viruses*  
  adoptive T cell therapy of tumors and,  
    **49**:282–283, 323, 334  
    mechanisms, **49**:311, 313–314, 318  
  animal models for AIDS, relationships  
    among, **52**:426–430  
  antibodies, from combinatorial libraries  
    cytomegalovirus, human, **57**:220–221  
    hepatitis B virus, **57**:220  
    herpes simplex virus type 1, **57**:222–227  
    herpes simplex virus type 2, **57**:222–227  
    HIV-1, **57**:211–217  
    measles, **57**:227–228  
    respiratory syncytial virus, **57**:217–219  
    varicella Zoster virus, **57**:221–222  
  autoimmune thyroiditis and  
    cellular immune responses, **46**:297, 298  
    experimental models, **46**:274–276  
    genetic control, **46**:283  
  autoreactive T cells and, **45**:431  
  avian leukosis, in chicken B cell DT40  
    induction, **57**:361–362  
  B cell formation and, **41**:209  
  complement receptor 2 and, **46**:210  
  CTL and, **41**:135, 142, 153, 154, 165  
  cytotoxicity and, **41**:269, 270  
  helper T cell cytokines and, **46**:127, 129,  
    133  
  and host, role in life cycle, **54**:107–108

- Viruses (*continued*)
- humoral immune response and, **45:24, 78, 82, 83**
  - hybrid resistance and, **41:375, 378, 390, 400, 402, 403**
  - Ig heavy-chain variable region genes and, **49:56**
  - infectious
    - exogenous superantigens produced by, **54:115-117**
    - production of exogenous superantigens, **54:115-117**
  - maps of Ig-like loci and, **46:1**
  - NF- $\kappa$ B, strategies to control, **65:127-128**
  - regulators of complement activation and, **45:395, 409**
  - superantigens of, **65:208**
  - surface antigens of human leukocytes and, **49:80, 118**
  - synthetic T and B cell sites and, **45:195, 219, 260, 262**
  - T cell receptor and
    - alloreactivity, **45:156**
    - antigen processing, **45:119, 125, 127**
    - experimental systems, **45:131, 137**
    - structure-function relationships, **45:141**
  - T cell subsets and, **41:54, 56, 57, 74-76, 101**
  - tumor antigen induction by, **57:290-293**
    - Epstein-Barr virus, **57:292**
    - papillomavirus, **57:292-293**
  - Virus-induced immunosuppression, **45:335, 336, 368, 369**
    - HIV, **45:355-363**
      - history of infection, **45:352-355**
      - immune response, **45:363-368**
      - virology, **45:347-352**
    - measles, **45:338-347**
    - virology, **45:336-338**
  - Vitamin A
    - binding to sex steroids, **58:229**
    - proautoimmune potential, **58:278**
  - Vitamin D<sub>3</sub>, binding to sex steroids, **58:229**
  - Vitamin E
    - action of, **65:122, 123**
    - inhibition of HIV lymphocyte death, **58:279**
  - Vitronectin, **61:204, 247-249**
    - leukocyte integrins and, **46:153, 157**
  - V-J joining, **48:46-47**
    - circular episome, **48:47**
    - diversity, **48:47**
    - random nature, **48:47**
  - V-J jointing, embryogenesis, **48:49, 50**
  - V<sub>κ</sub> promoters, **43:238**
  - v-kit*, characteristics, **55:3-6**
  - VLA-4, **62:258; 64:154; 65:359**
    - multiple myeloma, **64:246-248**
  - VLA-5, multiple myeloma, **64:248**
  - VLA-6, multiple myeloma, **64:248**
  - VLA antigens
    - leukocyte integrins and, **46:153, 157**
    - surface antigens of human leukocytes and, **49:83-85, 88**
  - VL gene, diversification sequences, **48:54-56**
  - VL gene segment, **48:41**
    - diversification, **48:56-60**
    - gene conversion, **48:56-60**
    - sequence substitution position, **48:56, 57**
    - sequence substitution size, **48:56, 57**
    - $\psi$ -V gene, recombination event, **48:56**
  - VL pseudogene 5, sequence comparison, **48:55**
  - VL pseudogene 7, sequence comparison, **48:55**
  - V<sub>L</sub>-V<sub>H</sub> interface, **43:103, 110, 112**
    - CDR, **43:125**
  - V<sub>L</sub>-V<sub>L</sub> pairing, **43:112**
  - von Willebrand factor, leukocyte integrins and, **46:158, 159**
  - vpr*, HIV-1 infectivity, **63:86-87**
  - V<sub>preB</sub>, **63:7-8, 29**
    - expression, **63:5-15**
    - gene regulation, **63:4-5**
    - $\mu$  heavy chains, **63:2-3**
    - structure, **63:4**
  - vpu*, HIV-1 infectivity, **63:87, 106**
  - V region, **62:1**
  - V region genes, T cell receptors and, **38:15, 16**
  - V-rel* oncogene, **48:58**
  - V $\beta$  rule, modifications, **54:123-124**
    - specificities of some exogenous bacterial superantigens, **54:109**
  - V $\beta$  selective elements, *see also* T cell receptor, V $\beta$  selective elements
    - cellular basis of action, **50:29-32**
    - responding cells, **50:29-31**
      - CD4 T cells, **50:30**
      - CD8 T cells, **50:30-31**

stimulating cells, **50:31–32**  
 B cells, **50:31**  
 dendritic cells, **50:31**  
 transfer of Vhse among cells, **50:32**  
 general nomenclature, **50:13–14**  
*in vitro* suppression induced by, **50:37**  
 murine, not stimulating primary T cell  
 response, **50:11–13**  
 null alleles, **50:14**  
 role in T cell development and function,  
**50:32–37**  
 in intrathymic development, **50:33**  
 negative selection, **50:34–35**  
 positive selection, **50:34**  
 in periphery, **50:35–37**  
 clonal inactivation by V $\beta$  selective  
 elements, **50:35–36**  
 enhancement of responses to antigen  
 by V $\beta$  selective elements,  
**50:36–37**  
 suppression induced by V $\beta$  selective  
 elements *in vitro*, **50:37**

**W**

Waldenström's macroglobulinemia,  
**64:219–220**  
 aPL antibodies and, **49:227–228**  
 Ig heavy-chain variable region genes and,  
**49:40**

W alleles, and *c-kit* alleles, relationship  
 between, **55:6–7**

WEHI-3 cells  
 chloroleukemia-derived, **39:16**  
 IL-3 production, **39:13, 15–17, 19**  
 rearranged allele and, **39:15–16**

WEHI-3B, **48:77**

WEHI-231 B cell line, growth arrest,  
**50:64–65**

Weibel–Palade bodies, P-selectin stored in,  
**58:356–357; 60:166, 168**

Western blotting, HLA class II, **48:116**

Whitlock–Witte cultures, B cell formation  
 and, **41:209, 216–220, 231**

Wiskott–Aldrich syndrome, **59:159, 248**

*Wnt-1* genes, **65:154, 155**

Woodchuck, chronic hepatitis infection  
 model, **60:346**

Worm burden  
 eosinophil effect, **60:215**  
 reduction, **60:127–128**

Wound healing  
 eosinophil role, **60:228**  
 NO role, **60:350–351**

WT31, CD3, **43:161–163**

## X

Xanthine, genetically engineered antibody  
 molecules and, **44:70**

X-chromosome, mosaicism, **59:159, 195**

Xenograft models  
 HIV-1 disease, **63:79, 89–90, 107**  
 hu-PBL-SCID model, **63:89–98**  
 pathogenesis, **63:90–95, 100**  
 pediatric infection, **63:95**  
 protective immunity, **63:95–98**  
 SCID-hu thy/liv model, **63:89–90,**  
**99–107**  
 hu-PBL-SCID model, **63:79–82**  
 SCID-hu thy/liv model, **63:82–83**

*Xenopus laevis*, antinuclear antibodies and,  
**44:124**

Xenotransplantation, **61:219, 220**  
 models, human-to-mouse, **50:319**

Xeroderma pigmentosum, **61:315**

Xid mutation, **59:174–176**  
 B cells, **59:317–318**  
 mitogenic signaling, **59:328**

XLA, *see* X-linked agammaglobulinemia

X-linked agammaglobulinemia, **59:135–136,**  
**135–197, 317–318, 318; 61:312–314**  
 B cell development, **59:151–162, 317–318**  
 Btk, **59:136, 169–176, 178–196**  
 carrier detection, **59:194–195**  
 clinical manifestations, **59:143–148**  
 defect of B cell development, **60:39–42**  
 diagnosis, prenatal, **59:194–195**  
 in females, **59:149–150, 194**  
 genes  
 cloning, **59:165–169, 165–176**  
 mapping, **59:163–165, 194–195**  
 genetic approach, **59:162–176, 187,**  
**193–194**  
 with growth hormone deficiency, **59:149**  
 and HIGMX-1, immunodeficiency diseases,  
**60:37**

X-linked agammaglobulinemia (*continued*)  
 history, **59**:136–142  
 incidence and prognosis, **59**:142  
 and SCID mice, **50**:308  
 treatment, **59**:150–151

X-linked hyper-IgM syndrome, **59**:248  
 CD40-L role, **61**:1, 18, 41–44, 92–93

X-linked immunodeficiency, *see also* Kid  
 mutation  
 diseases, **59**:248, 317  
 immunology, **63**:51  
 murine, Btk implicated in, **60**:41–42

X-linked lymphoproliferative disorder, NK  
 cells and, **47**:224, 283, 299

X-linked severe combined immunodeficiency,  
**59**:227, 235, 246–247, 318; **61**:152  
 atypical, **59**:252–253  
 IL-2R $\gamma$  mutations, **59**:248–250

X-ray analysis, antibody, **43**:121

X-ray crystallography, **43**:2–3, 8–11

X-ray structures, antibody-antigen interaction,  
**43**:73

XRCC4, V(D)J recombination, **64**:60

XRCC5, **64**:49

## Y

Yeast  
 antinuclear antibodies and, **44**:106  
 cytotoxicity and, **41**:269, 270, 319  
 genetically engineered antibody molecules  
 and, **44**:66, 69  
*SPT14* gene, homolog of *PIG-A*, **60**:72

Yeast artificial chromosomes, maps of Ig-like  
 loci and, **46**:4, 5

Yeast artificial chromosome system, **62**:3

Yeast infections, pneumonia, **59**:402–406

YT cell line, **42**:171, 172

## Z

ZAP70, **63**:138  
 IL-2R coupling, **61**:160

Zinc, cell-mediated killing and, **41**:293, 294

Zinc finger, myeloid, **63**:1, 239

Zinc-finger proteins, BLIMP, **59**:342

Zonal organization, lymph follicles,  
**53**:185–186

Zymogens, **61**:202  
 complement components and, **38**:206, 209,  
 235

Zymosan  
 alternative pathway activation, **38**:386  
 fibronectin, **38**:390  
 $\beta$ -glucan constituent of, **38**:362  
 IBD and, **42**:309  
 ingestion inhibition, **38**:381  
 phagocytosis, human monocyte, **38**:392  
 cellular responses, **38**:373–376, 393  
 composition, **38**:363, 364  
 receptor characterization, **38**:365, 366,  
 368–373  
 phagocytosis, nonelicited murine  
 macrophages  
 cellular responses, **38**:377–380  
 receptor characterization, **38**:376, 377  
 serum-treated, addition to eosinophils,  
**60**:183

## CONTRIBUTOR INDEX

**Boldface numerals indicate volume number**

### A

Abraham, Robert T., **61**:147  
Acha-Orbea, Hans, **65**:139  
Adelman, D. C., **48**:161  
Adolphson, Cheryl R., **39**:177  
Aebischer, Iwan, **61**:341  
Ahearn, Joseph M., **46**:183  
Akira, Shizuo, **54**:1; **65**:1  
Akkaraju, Srinivas, **59**:279  
Altman, Amnon, **48**:227  
Anderson, Steven J., **56**:151  
Andreu, Jose Luis, **50**:147  
Arend, William P., **54**:167  
Arm, Jonathan P., **51**:323  
Asao, Hironobu, **59**:225  
Atkinson, John P., **45**:381; **61**:201  
Austen, K. Frank, **39**:145

### B

Baeuerle, Patrick A., **65**:111  
Baeza, Maria, **50**:237  
Baggiolini, Marco, **55**:97  
Baichwal, Vijay R., **65**:111  
Banchereau, Jacques, **52**:125; **61**:1  
Barbas III, Carlos F., **57**:191  
Bartram, Claus R., **61**:285  
Bassuk, Alexander G., **64**:65  
Bell, Sarah E., **59**:279  
Bennett, Michael, **41**:333  
Bennink, Jack R., **52**:1  
Benoist, Christophe, **55**:424  
Bertocci, Barbara, **57**:353

Bettelheim, Peter, **52**:333  
Beutler, B., **42**:213; **49**:149  
Bevan, Michael J., **59**:99  
Biassoni, Roberto, **55**:341  
Billiau, Alfons, **62**:61  
Bodmer, Helen, **55**:424  
Boehm, T., **50**:119  
Brenner, Michael B., **43**:133  
Brezinschek, Hans Peter, **47**:433  
Bucy, R. Pat, **50**:87  
Burrows, Peter D., **65**:245  
Burton, Dennis R., **51**:1; **57**:191

### C

Calame, Kathryn, **43**:235  
Calvo-Calle, J. Mauricio, **60**:105  
Campbell, R. D., **38**:203  
Capra, J. Donald, **42**:95; **49**:1  
Cardell, Susanna, **55**:424  
Carroll, M. C., **38**:203  
Carson, Dennis A., **38**:275  
Cerami, A., **42**:213  
Chan, Susan, **55**:424  
Charreire, Jeannine, **46**:263  
Charron, Dominique, **48**:107  
Chen, Chen-Lo H., **50**:87  
Chen, Jianzhu, **62**:31  
Cheresh, David A., **40**:323  
Chesnut, Robert W., **39**:51  
Chesterman, Colin N., **49**:193  
Chilton, Paula M., **63**:269  
Ciccione, Ermanno, **55**:341  
Clark, Lisa B., **63**:43



Claverie, Jean-Michel, **45:107**  
 Coffman, Robert L., **46:111; 54:229**  
 Coggeshall, K. Mark, **48:227**  
 Cohen, J. John, **50:55**  
 Cohn, Zanvil A., **41:269**  
 Colman, P. M., **43:99**  
 Cooke, Michael P., **59:279**  
 Cooper, Max D., **50:87; 65:245**  
 Corbi, Angel L., **46:149**  
 Cosgrove, Dominic, **55:424**  
 Cotran, Ramzi S., **50:261**  
 Crane, Mary A., **56:179**  
 Croce, Carlo M., **38:245**  
 Cuende, Eduardo, **53:157**  
 Cyster, Jason G., **59:279**  
 Czop, Joyce K., **38:361**

**D**

Dahan, Auriel, **57:353**  
 Dalloul, A., **49:149**  
 Debre, P., **49:149**  
 DeFranco, Anthony L., **55:221**  
 Delespesse, G., **49:149**  
 Dewald, Beatrice, **55:97**  
 DeWitt, David L., **62:167**  
 Dietrich, Hermann, **47:433**  
 Dinarello, Charles A., **44:153**  
 Dixon, Frank J., **46:61**  
 Dranoff, Glenn, **58:417**  
 Dunon, Dominique, **58:345**  
 Dustin, Michael L., **46:149**

**E**

Eaton, Suzanne, **43:235**  
 Elliott, Michael J., **64:283**  
 Elliott, Tim, **65:47**

**F**

Farries, Timothy C., **61:201**  
 Fathman, C. Garrison, **56:219**  
 Fauci, Anthony S., **47:377**  
 Fearon, Douglas T., **46:183**  
 Feldmann, Marc, **64:283**  
 Fernandez-Botran, Rafael, **45:1; 63:269**

Fink, Pamela J., **59:99**  
 Finn, Olivera J., **62:217**  
 Forman, James, **41:135**  
 Fowlkes, B. J., **44:207**  
 Foy, Teresa M., **63:43**  
 Freimark, Bruce D., **38:275**  
 Fujii, Yoshitaka, **42:233**  
 Fuleihan, Ramsay, **60:37**

**G**

Galli, Stephen J., **55:1**  
 Gaur, Amitabh, **56:219**  
 Gearing, David P., **53:31**  
 Geha, Raif S., **39:255; 60:37**  
 Geissler, Edwin N., **55:1**  
 Cellert, Martin, **64:39**  
 Getzoff, D. Elizabeth, **43:1**  
 Geysen, H. Mario, **43:1**  
 Ghosh, Sankar, **58:1**  
 Gleich, Gerald J., **39:177**  
 Goetzl, E. J., **48:161**  
 Goetzl, Edward J., **39:299**  
 Gold, Michael R., **55:221**  
 Gomez, Javier, **63:127**  
 Gonzalo, Jose Angel, **50:147**  
 Goodnow, Christopher C., **59:279**  
 Greenberg, Philip D., **49:281**  
 Grey, Howard M., **39:51**  
 Gutierrez-Ramos, Jose C., **50:147**

**H**

Hala, Karel, **47:433**  
 Hansen, John A., **40:379**  
 Hansen, Ted H., **64:105**  
 Hardy, Richard R., **55:297**  
 Hartley, Suzanne B., **59:279**  
 Hathcock, Karen S., **62:131**  
 Hayakawa, Kyoko, **55:297**  
 Healy, James L., **59:279**  
 Hedrick, Stephen M., **43:193**  
 Heldin, Carl-Henrik, **55:181**  
 Henderson, Robert A., **62:217**  
 Hercend, Thierry, **42:181**  
 Hirsch, Vanessa M., **52:425**  
 Hitoshi, Yasumichi, **57:145**  
 Hodes, Richard J., **62:131**

Hofstetter, H., **49:149**  
 Hogarth, P. Mark, **57:1**  
 Holers, V. Michael, **45:381**  
 Honjo, Tasuku, **62:1**  
 Hood, Leroy, **44:1; 46:1**  
 Hooghe, Robert, **63:377**  
 Hooghe-Peters, Elisabeth L., **63:377**  
 Horejsi, V., **49:75**  
 Hourcade, Dennis, **45:381**  
 Houssiau, F., **54:79**  
 Hulett, Mark D., **57:1**  
 Hunkapiller, Tim, **44:1**  
 Huston, Marilyn M., **38:313**  
 Hyman, Robert, **54:271**

**I**

Ichijo, Hidenori, **55:181**  
 Igarashi, Hideya, **54:337**  
 Ihle, James N., **39:1; 60:1**  
 Imboden, John B., **41:1**  
 Imhof, Beat A., **58:345**  
 Inoue, Norimitsu, **60:57**  
 Inui, Seiji, **54:337**  
 Ishii, Naoto, **59:225**  
 Ishizaka, Kimishige, **47:1**  
 Ivashkiv, Lionel B., **63:337**

**J**

Jalkanen, Sirpa, **64:139**  
 Janeway, Jr., Charles A., **50:1**  
 Jelinek, Diane F., **40:1**  
 Johnson, Philip R., **52:425**

**K**

Kaplan, Allen P., **50:237**  
 Kappler, John, **38:1; 54:99**  
 Karasuyama, Hajime, **63:1**  
 Karnitz, Larry M., **61:147**  
 Kawasaki, Akemi, **51:215**  
 Kay, A. Barry, **60:151**  
 Kelso, Anne, **48:69**  
 Kelsoe, Garnett, **60:267**  
 Kikutani, Hitoshi, **51:285**  
 Kilcherr, E., **49:149**

Kincade, Paul W., **41:181; 54:271**  
 Kindt, Thomas J., **52:425**  
 Kinoshita, Taroh, **60:57**  
 Kipps, Thomas J., **47:117**  
 Kishimoto, Tadimitsu, **54:1; 64:219; 65:1**  
 Kishimoto, Takashi, **46:149**  
 Kisielow, Pawel, **58:87**  
 Klinman, Norman R., **42:1**  
 Knight, Katherine L., **56:179**  
 Kofler, Reinhard, **46:61**  
 Kojima, Hidefumi, **60:289**  
 Kondo, Motonari, **59:225**  
 Kooijman, Ron, **63:377**  
 Kopp, Elizabeth B., **58:1**  
 Kotzin, Brian, **54:99**  
 Kourilsky, Philippe, **45:107**  
 Kourilsky, Philippe, **57:281**  
 Kraal, Georg, **65:347**  
 Krangel, Michael S., **43:133**  
 Krilis, Steven A., **49:193**  
 Kroemer, Guido, **47:433; 50:147; 53:157; 58:211**  
 Kuna, Piotr, **50:237**  
 Kuwahara, Kazuhiko, **54:337**

**L**

Lai, Eric, **46:1**  
 Larson, Richard S., **46:149**  
 Leberman, Deborah A., **54:229**  
 Lee, David R., **64:105**  
 Lee, Tak H., **39:145; 51:323**  
 Leiden, Jeffrey M., **64:65**  
 Lerner, Richard A., **43:1**  
 Lesley, Jane, **54:271**  
 Leung, Donald Y. M., **54:99**  
 Levin, Steven D., **56:151**  
 Lewis, Susanna M., **56:27**  
 Lindstrom, Jon, **42:233**  
 Linton, Phyllis-Jean, **42:1**  
 Lipscomb, Mary F., **59:369**  
 Lipsky, Peter E., **40:1**  
 Liszewski, M. Kathryn, **61:201**  
 Louahed, J., **54:79**  
 Lublin, Douglas M., **61:201**  
 Lukacs, Nicholas W., **62:257**  
 Luther, Sanjiv A., **65:139**  
 Lynch, Richard C., **40:135**

Lyons, C. Richard, **59:369**  
 Lyons, C. Rick, **60:323**

Mustelin, Tomas, **48:227**  
 Myers, Christopher D., **45:1**

**M**

Ma, Yuhe, **63:269**  
 MacDermott, Richard P., **42:285**  
 Mach, Bernard, **61:327**  
 Mackay, Charles R., **53:217**  
 Maini, Ravinder N., **64:283**  
 Makino, Susumu, **51:285**  
 Marrack, Philippa, **38:1**  
 Marrack, Philippa, **54:99**  
 Martin, Paul J., **40:379**  
 Martinez-A., Carlos, **50:147; 53:157; 63:127**  
 Mathis, Diane, **55:424**  
 Matsuda, Fumihiko, **62:1**  
 Matsuo, Tatsuya, **54:337**  
 McChesney, Michael B., **45:335**  
 McCormack, Wayne T., **48:41**  
 McChee, Jerry R., **40:153**  
 McGillis, Joseph P., **39:299**  
 McKenzie, Ian F. C., **56:301**  
 McMichael, Andrew, **65:277**  
 McNeil, H. Patrick, **49:193**  
 Mebius, Reina E., **65:347**  
 Meek, Katheryn, **42:95**  
 Melchers, Fritiz, **53:123; 63:1**  
 Merckenschlager, Matthias, **55:424**  
 Mestecky, Jiri, **40:153**  
 Metcalf, Donald, **48:69**  
 Metlay, Josua P., **47:45**  
 Metzger, Henry, **43:277**  
 Miceli, M. Carrie, **53:59**  
 Michon, Jean, **42:181**  
 Milich, David R., **45:195**  
 Mingari, Maria Christina, **55:341**  
 Miyazono, Kohei, **55:181**  
 Moore, Jr., Francis D., **56:267**  
 Moqbel, Redwan, **60:151**  
 Moretta, Alessandro, **55:341**  
 Moretta, Lorenzo, **55:341**  
 Morgan, Edward L., **40:61**  
 Morrison, Sherie L., **44:65**  
 Moser, Bernhard, **55:97**  
 Mosier, Donald E., **50:303; 63:79**  
 Mosmann, Tim R., **46:111; 56:1**  
 Mossalayi, D., **49:149**  
 Mulligan, Richard C., **58:417**

**N**

Nadler, Lee Marshall, **51:243**  
 Nagata, Shigekazu, **57:129**  
 Nakamura, Masataka, **59:225**  
 Nakamura, Toshikazu, **59:225**  
 Nakata, Motomi, **51:215**  
 Nardin, Elizabeth H., **60:105**  
 Neiman, Paul E., **56:467**  
 Nezlin, Roald, **48:1**  
 Niederkorn, Jerry Y., **48:191**  
 Nishimoto, Norihiro, **64:219**  
 Noelle, Randolph J., **63:43**  
 Nomura, Jun, **54:337**  
 Nossal, G. J. V., **52:283**  
 Nowell, Peter C., **38:245**  
 Nussenzweig, Ruth S., **45:283; 60:105**  
 Nussenzweig, Victor, **45:283**

**O**

Oi, Vernon T., **44:65**  
 Okumura, Ko, **51:215**  
 Oldstone, Michael B. A., **45:335**  
 Oliveira, Giane A., **60:105**  
 Opstelten, Davina, **63:197**

**P**

Pardoll, Drew M., **44:207**  
 Parkman, Robertson, **49:381**  
 Parnes, Jane R., **44:265; 53:59**  
 Pascual, Virginia, **49:1**  
 Paul, William E., **53:1**  
 Payan, Donald G., **39:299**  
 Perlmutter, Roger M., **56:151**  
 Pietersz, Geoffrey A., **56:301**  
 Plaut, Marshall, **53:1**  
 Pober, Jordan S., **50:261**  
 Pogue, Sarah L., **59:279**  
 Porcelli, Steven A., **59:1**  
 Porter, R. R., **38:203**  
 Pure, Ellen, **47:45**

**R**

Rabbits, T. H., **50:119**  
 Ramesh, Narayanaswamy, **60:37**  
 Rathbun, Gary, **42:95**  
 Rathmell, Jeffrey C., **59:279**  
 Raulet, David H., **55:381**  
 Rehollo, Angelita, **63:127**  
 Reddigari, Sessa, **50:237**  
 Reisfeld, Ralph A., **40:323**  
 Reith, Walter, **61:327**  
 Renauld, J.-C., **54:79**  
 Reynaud, Claude-Agnes, **57:353**  
 Rice, David E., **59:369**  
 Rich, Robert R., **38:313**  
 Ritz, Jerome, **42:181**  
 Rochlitz, Christoph, **57:281**  
 Rodgers, John R., **38:313**  
 Rolink, Antonius, **53:123; 63:1**  
 Rooney, Isabelle A., **61:201**  
 Rosen, Steven D., **44:313**  
 Rosenberg, Zeda F., **47:377**  
 Roth, Claude, **57:281**  
 Rothenberg, Ellen V., **51:85**  
 Rothman, Paul, **54:229**  
 Rousset, Francoise, **52:125**  
 Rowland, April, **56:301**  
 Rowland-Jones, Sarah, **65:277**

**S**

Sakaguchi, Nobuo, **54:337**  
 Salmi, Marko, **64:139**  
 Sanders, Virginia M., **45:1**  
 Sanz, Inaki, **42:95**  
 Sarfati, M., **49:149**  
 Sawasdikosol, Sansana, **52:425**  
 Schlossman, Stuart F., **42:181**  
 Schmidt, Reinhold E., **42:181**  
 Schriever, Folke, **51:243**  
 Schuyler, Mark R., **59:369**  
 Schwartz, Ronald H., **38:31**  
 Schwarz, Klaus, **61:285**  
 Scott, David W., **54:393**  
 Seder, Robert A., **53:1**  
 Shelton, Diane, **42:233**  
 Shimbara, Naoki, **64:1**  
 Shinkai, Yoichi, **51:215**  
 Shinohara, Nobukata, **60:289**

Shokat, Kevan P., **59:279**  
 Sideras, Paschalis, **59:135**  
 Sim, Cek-Kee, **58:297**  
 Singer, Paul A., **46:61**  
 Sklar, Larry A., **39:95**  
 Smith III, Roger, **38:313**  
 Smith, C. I. Edvard, **59:135**  
 Smith, Kendall A., **42:165**  
 Smith, William L., **62:167**  
 Smyth, Mark J., **56:301**  
 Sprent, Jonathan, **41:39**  
 Springer, Timothy A., **46:149**  
 Sreedharan, S. P., **48:161**  
 Stadler, Beda M., **61:341**  
 Stanley, John R., **53:291**  
 Staunton, Donald E., **46:149**  
 Stavnezer, Janet, **61:79**  
 Steimle, Viktor, **61:327**  
 Steinman, Lawrence, **49:357**  
 Steinman, Ralph M., **47:45**  
 Stenson, William F., **42:285**  
 Storb, Rainer, **40:379**  
 Strominger, Jack L., **43:133**  
 Suematsu, Sachiko, **64:219**  
 Sugamura, Kazuo, **59:225**  
 Suter, U., **49:149**

**T**

Taga, Tetsuya, **54:1**  
 Tainer, John A., **43:1**  
 Takaki, Satoshi, **57:145**  
 Takatsu, Kiyoshi, **57:145**  
 Takayama, Hajime, **60:289**  
 Takeda, Junji, **60:57**  
 Tan, Eng M., **44:93**  
 Tan, Rusung, **65:277**  
 Tanahashi, Nobuyuki, **64:1**  
 Tanaka, Keiji, **64:1**  
 Tanaka, Nobuyuki, **52:263**  
 Tanaka, Nobuyuki, **59:225**  
 Taniguchi, Tadatsugu, **52:263**  
 ten Dijke, Peter, **55:181**  
 Theofilopoulos, Argyrios N., **46:61**  
 Thoman, Marilyn L., **46:221**  
 Thomas, E. Donnell, **40:379**  
 Thompson, Craig B., **48:41; 50:87**  
 Trinchieri, Giorgio, **47:187**

Tsurumi, Chizuko, **64**:1  
 Tucker, Philip, **42**:95

**U**

Ulevitch, Richard J., **53**:267  
 Uyttenhove, C., **54**:79

**V**

Valent, Peter, **52**:333  
 van Kooten, Cees, **61**:1  
 Van Snick, J., **54**:79  
 Vink, A., **54**:79  
 Vitetta, Ellen S., **45**:1  
 von Boehmer, Harald, **58**:87

**W**

Waldmann, Thomas A., **40**:247  
 Ward, Peter A., **62**:257  
 Wardlaw, Andrew J., **60**:151  
 Weaver, David T., **58**:29

Webb, Susan R., **41**:39  
 Weigle, William O., **40**:61; **46**:221  
 Weill, Jean-Claude, **57**:353  
 Weinstein, Yacob, **39**:1  
 Weiss, Arthur, **41**:1  
 Wick, George, **47**:433  
 Wilkes, David, **59**:369  
 Wilson, Richard K., **46**:1  
 Winchester, Robert, **56**:389  
 Wolf, Hugo, **47**:433  
 Woody, James N., **64**:283  
 Woof, Jenny M., **51**:1

**Y**

Yagita, Hideo, **51**:215  
 Yednock, Ted A., **44**:313  
 Yewdell, Jonathan W., **52**:1  
 Yokota, Kin-ya, **64**:1  
 Young, John Ding-E, **41**:269

**Z**

Zauderer, Maurice, **45**:417  
 Zsebo, Krisztina M., **55**:1

ISBN 0-12-022467-4

